Final Program

AMERICAN ACADEMY OF DERMATOLOGY
AAD
1938

2017 AAD Annual Meeting

Orlando, Florida • March 3-7, 2017

ORANGE COUNTY CONVENTION CENTER

Final Program

eucrisa™
crisaborole ointment 2%

Now Approved!

EUCRISA™ – the first and only nonsteroidal, topical PDE4 inhibitor for mild-to-moderate atopic dermatitis in patients 2 years of age and older.[1]

INDICATION

EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION

Contraindications

EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.

Warnings and Precautions

Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.

Adverse Reactions

The most common adverse reaction occurring in ≥1% of subjects in clinical trials was application site pain, such as burning or stinging.

Connect•the•dots to booth #2589

Reference: 1. EUCRISA™ (crisaborole) Full Prescribing Information. December 2016.

Please see Brief Summary on adjacent page.

PP-CRI-USA-0199 © 2017 Pfizer Inc. All rights reserved. January 2017

Pfizer

EUCRISA™ (crisaborole) ointment, 2%
Brief Summary of Prescribing Information

INDICATIONS AND USAGE
EUCRISA is indicated for topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.

DOSAGE AND ADMINISTRATION
Apply a thin layer of EUCRISA twice daily to affected areas. EUCRISA is for topical use only and not for ophthalmic, oral, or intravaginal use.

DOSAGE FORMS AND STRENGTHS
Ointment: 20 mg of crisaborole per gram (2%) of white to off-white ointment.

CONTRAINDICATIONS
EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation. [*see Warnings and Precautions*]

WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA. Hypersensitivity should be suspected in the event of severe pruritus, swelling and erythema at the application site or at a distant site. If signs and symptoms of hypersensitivity occur, discontinue EUCRISA immediately and initiate appropriate therapy.

ADVERSE REACTIONS
Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In two double-blind, vehicle-controlled clinical trials (Trial 1 and Trial 2), 1012 subjects 2 to 79 years of age with mild to moderate atopic dermatitis were treated with EUCRISA twice daily for 4 weeks. The adverse reaction reported by ≥1% of EUCRISA-treated subjects is listed in Table 1.

Table 1: Adverse Reaction Occurring in ≥1% of Subjects in Atopic Dermatitis Trials through Week 4

Adverse Reaction	EUCRISA N=1012 n (%)	Vehicle N=499 n (%)
Application site pain[a]	45 (4)	6 (1)

[a] Refers to skin sensations such as burning or stinging.
Less common (<1%) adverse reactions in subjects treated with EUCRISA included contact urticaria [*see Warnings and Precautions*].

USE IN SPECIFIC POPULATIONS
Pregnancy Risk Summary There is no available data with EUCRISA in pregnant women to inform the drug-associated risk for major birth defects and miscarriage. In animal reproduction studies, there were no adverse developmental effects observed with oral administration of crisaborole in pregnant rats and rabbits during organogenesis at doses up to 5 and 3 times, respectively, the maximum recommended human dose (MRHD) [*see Data*]. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies carry some risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects in the U.S. general population is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies. Data *Animal Data* Rat and rabbit embryo-fetal development was assessed after oral administration of crisaborole. Crisaborole did not cause adverse effects to the fetus at oral doses up to 300 mg/kg/day in pregnant rats during the period of organogenesis (5 times the MRHD on an AUC comparison basis). No treatment-related fetal malformations were noted after oral treatment with crisaborole in pregnant rats at doses up to 600 mg/kg/day (18 times the MRHD on an AUC comparison basis) during the period of organogenesis. Maternal toxicity was produced at the high dose of 600 mg/kg/day in pregnant rats and was associated with findings of decreased fetal body weight and delayed skeletal ossification. Crisaborole did not cause adverse effects to the fetus at oral doses up to the highest dose tested of 100 mg/kg/day in pregnant rabbits during the period of organogenesis (3 times the MRHD on an AUC comparison basis). In a prenatal/postnatal development study, pregnant rats were treated with crisaborole at doses of 150, 300, and 600 mg/kg/day by oral gavage during gestation and lactation (from gestation day 7 through day 20 of lactation). Crisaborole did not have any adverse effects on fetal development at doses up to 600 mg/kg/day (18 times the MRHD on an AUC comparison basis). Maternal toxicity was produced at the high dose of 600 mg/kg/day in pregnant rats and was associated with findings of stillbirths, pup mortality, and reduced pup weights.
Lactation Risk Summary There is no information available on the presence of EUCRISA in human milk, the effects of the drug on the breastfed infant or the effects of the drug on milk production after topical application of EUCRISA to women who are breastfeeding. EUCRISA is systemically absorbed. The lack of clinical data during lactation precludes a clear determination of the risk of EUCRISA to a breastfed infant. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EUCRISA and any potential adverse effects on the breastfed infant from EUCRISA or from the underlying maternal condition.
Pediatric Use The safety and effectiveness of EUCRISA have been established in pediatric patients age 2 years and older for topical treatment of mild to moderate atopic dermatitis. Use of EUCRISA in this age group is supported by evidence from two multicenter, randomized, double-blind, parallel-group, vehicle-controlled 28-day trials which included 1,313 pediatric subjects 2 years and older [*see Adverse Reactions and Clinical Studies in Full Prescribing Information*]. The safety and effectiveness of EUCRISA in pediatric patients below the age of 2 years have not been established.
Geriatric Use Clinical studies of EUCRISA did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger subjects.

NONCLINICAL TOXICOLOGY
Carcinogenesis, Mutagenesis, Impairment of Fertility In an oral carcinogenicity study in Sprague-Dawley rats, oral doses of 30, 100, and 300 mg/kg/day crisaborole were administered to rats once daily. A drug-related increased incidence of benign granular cell tumors in the uterus with cervix or vagina (combined) was noted in 300 mg/kg/day crisaborole treated female rats (2 times the MRHD on an AUC comparison basis). The clinical relevance of this finding is unknown. In a dermal carcinogenicity study in CD-1 mice, topical doses of 2%, 5% and 7% crisaborole ointment were administered once daily. No drug-related neoplastic findings were noted at topical doses up to 7% crisaborole ointment (2 times the MRHD on an AUC comparison basis). Crisaborole revealed no evidence of mutagenic or clastogenic potential based on the results of two in vitro genotoxicity tests (Ames assay and human lymphocyte chromosomal aberration assay) and one in vivo genotoxicity test (rat micronucleus assay). No effects on fertility were observed in male or female rats that were administered oral doses up to 600 mg/kg/day crisaborole (18 times the MRHD on an AUC comparison basis) prior to and during early pregnancy.

PATIENT COUNSELING INFORMATION
Advise the patient or caregivers to read the FDA-approved patient labeling (Patient Information). Hypersensitivity Reactions: Advise patients to discontinue EUCRISA and seek medical attention immediately if signs or symptoms of hypersensitivity occur [*see Warnings and Precautions*]. Administration Instructions: Advise patients or caregivers that EUCRISA is for external use only and is not for ophthalmic, oral, or intravaginal use.

Rx only This Brief Summary is based on EUCRISA Prescribing Information, issued December 2016.

© 2017 Pfizer Inc. All rights reserved. January 2017

Based on attendee feedback, the Annual Meeting schedule has been adjusted. Please see below:

SESSION CHANGES

International Day: Select international societies will be holding independent sessions on **Thursday, March 2**.

Focus Sessions: All **focus sessions** are now one hour in length

Courses: **Afternoon courses** will now take place from 1 p.m. to 4 p.m.

Tuesday Sessions: The meeting will now end at 12:30 p.m. on **Tuesday, March 7** with two general sessions taking place that morning.

EXHIBIT HALL HOURS

The exhibit hall will be open new hours and new days!

Friday, March 3 • 10 a.m. – 5 p.m.
Saturday, March 4 • 10 a.m. – 5 p.m.
Sunday, March 5* • 10 a.m. – 3 p.m.

**Guest access to exhibit hall is only allowed on Sunday, March 5th.*

Table of Contents

III-IX	Program Overview
2-10	General Information
11	Program Schedule Key
12-220	Over 375 Expert-led Educational Sessions
221-244	Subject Indices
245-304	Invited Faculty Disclosures/Affiliations

For the most current, up-to-date session information, go to aad.org/AM17 or download the meeting mobile app

FRIDAY–SUNDAY

Hands-on: The Patient Encounter: The Difficult Patient 12
Hands-on: The Patient Encounter: Breaking Bad News 12
Hands-on: The Patient Encounter: Medication Management 13
Hands-on: The Patient Encounter: Total Body Skin Exam 13

FRIDAY

FOCUS SESSIONS • 7:30 TO 8:30 A.M.

U001 • Merkel Cell Carcinoma: Diagnosis, Management and Controversies 16
U002 • Warts 16
U003 • Controversies in Management and Treatment of Cutaneous Lupus and Dermatomyositis Patient 17
U004 • Hospital Dermatology 17
U005 • Lichen Planus and LP Mimickers: Concepts and Controversies 18
U006 • Pain-free Dermatology: Minimizing Discomfort in Procedures for Children and Adults 18
U007 • Sjogren's for the Dermatologist: The Forgotten Autoimmune Connective Tissue Disease 19
U008 • Simple Tricks and Practical Tips to Optimize the Surgical Experience for You and Your Patients 19
U009 • The Truth About Pediatric Contact Dermatitis 20
U010 • Neutrophilic Dermatoses: An Update 20
U011 • Common Complaints Encountered During Dermatologic Surgery: How to Respond and How to Prevent 21
U012 • Help Your Dermatopathologist Work Smarter for You 21
U013 • Recognition and Management of Allergic Skin Reactions in the Athlete 22
U014 • Update: New Modalities in the Diagnosis, Staging and Prognostication of Melanocytic Lesions 22

DISCUSSION GROUP • 9 TO 11 A.M

D001 • How to Create an Unforgettably Positive Patient Experience 23

FORUMS • 9 TO 11 A.M.

F001 • Oral Signs of Systemic Disease 23
F002 • Giving the Best Presentation of Your Life: Every Time! 24
F003 • Coding and Office Management 24
F004 • Management of Patients with Melanocytic and Non-melanocytic Neoplasms 25
F005 • FDA Hot Topics: The Evolving Regulatory Landscape 25
F006 • Invention and Entrepreneurialism in Dermatology: Stories of Success and Reality Check 26
F007 • Hot Topics in Acute and Inpatient Pediatric Dermatology 26
F008 • Controversies in Vitamin D 27
F009 • Skin and Systemic Malignancy 27
F010 • Highlights From the Medical and Pediatric Literature 28
F011 • Malignancy-Associated Dermatomyositis 28
F012 • Challenging Melanocytic Tumors: Test Your Diagnostic and Therapeutic Skills 29
F013 • Caring for the Cancer Patient: Challenging Cases from Inpatient and Outpatient Oncodermatology Consultative Services 29
F014 • Dermatologic Care for a Veteran Patient 30
F015 • Imaging in Dermatology 30

WORKSHOP • 9 TO 11 A.M.

W001 • Self-assessment: Cosmetic Dermatology 31

COURSES • 9 A.M. TO 12 P.M.

C001 • Structure and Function of the Skin: Development, Cell Biology, and Skin Structure 32
C002 • Dermatology Review: General Dermatology and Practice Management 32
C003 • Botulinum Toxin: Video Instruction and Live Panel Discussion 33

SYMPOSIA • 9 A.M. TO 12 P.M.

S001 • New and Emerging Technologies in Dermatology 33
S002 • Advances in Medical Dermatology 34
S003 • Role of Dermatologist in Management of Skin Disease in Solid Organ Transplant Recipients 34
S004 • Therapeutic Hotline 35
S005 • Outbreak! Public Health Threats in Clinical Dermatology 35
S006 • Wounds and Ulcers: The Good, the Bad and the Ugly 36
S007 • Cosmetics 36
S008 • Key Surgical Principles We All Should Know 37

COURSES • 9 A.M. TO 4 P.M.

C004 • Advanced Dermoscopy 37
C005 • Essential Dermatopathology: What You Need to Know for Clinical Practice: Neoplastic 38
C006 • Conquer the Boards: An Experiential Review 38

SYMPOSIA • 9 A.M. TO 5 P.M.

S009 • Gross and Microscopic Symposium 39

FORUMS • 1 TO 3 P.M.

F016 • Emerging Laser and Aesthetic Technology 40
F017 • Managing Melanoma 40

For session types, please refer to page 11

PROGRAM OVERVIEW

F018 • Contact Dermatitis Tips from the American Contact Dermatitis Society 41
F019 • Approaching Severe Inflammatory Skin Disease in Children 41
F020 • Complementary, Natural and Novel Dermatology Therapeutics: An Evidence-based Perspective 42
F021 • The Science of Cosmeceuticals and Nutraceuticals 42
F022 • MACRA, MIPs, and APMs 43
F023 • Dermoscopy for the Non-dermoscopist 43
F024 • What's That? Syndrome Update 44
F025 • Teaching, Coaching, Mentoring and Difficult Conversations 44
F026 • Systemic Medications for the Dermatology Toolbox 45
F027 • Dermatopathology Case Challenge: Recognizing Mimics and Masqueraders 45
F028 • Teledermatology Pearls and Pitfalls from Challenging Cases 46
F029 • Updates in Neutrophilic and Pustular Dermatoses 46
F030 • Dealing with Difficult Patient Encounters 47
F031 • Where Do We Stand? The Pathogenesis and Treatment of Melasma 47

WORKSHOP • 1 TO 3 P.M.

W002 • Practical Approaches to Assessing Psoriasis and Psoriatic Arthritis Patients in Clinic 48

COURSES • 1 TO 4 P.M.

C007 • Structure and Function of the Skin: Pigment, Appendages, Damage & Repair 49
C008 • Dermatology Review: Skin Cancer, Surgical, and Cosmetic 49
C009 • Live Demonstration: The State of the Art of Aesthetic Dermatology 50

SYMPOSIA • 1 TO 4 P.M.

S010 • Pearls from the Posters 50
S011 • Dilemmas and Challenges in Skin Cancer Therapies and Management 51
S012 • Women's Health Therapeutic Hotline 51
S013 • Microscopic Mystery: Dermatopathology with Clinical Correlation 52
S014 • Recent Advances in Bullous Diseases 52
S015 • Common, Challenging and Controversial Short Topics in Patient Management 53
S016 • Hair and Scalp Dermoscopy 53
S017 • Gender Dermatology: Diagnosis and Treatment of Genital Skin Disorders 54

FORUMS • 3:30 TO 5:30 P.M.

F032 • Red Flags and Emergencies in Dermatology 54
F033 • Value in Healthcare: Improving Outcomes and Decreasing Waste 55
F034 • Young Physician Pearls and Pitfalls: A Survival Guide for the First 10 Years 55
F035 • Big Rashes in Little Patients 56
F036 • Skinternal Medicine: An Update on Cutaneous Manifestations of Systemic Disease 56
F037 • The Impact of Drug Pricing on Access to Care: Demystifying the Landscape 57
F038 • Cutaneous Disorders of Pregnancy 57
F039 • Contact Allergens of the Year 58
F040 • Beyond the Tzanck: Bedside Diagnostics for Dermatologists 58
F041 • Translating Evidence into Practice: Atopic Dermatitis Guidelines 59
F042 • Dermatologic Manifestations of HIV and AIDS 59
F043 • Photoprotection 60
F044 • How Would You Reconstruct It? 60
F045 • Practical Management of Atypical Melanocytic Lesions 61
F046 • Challenging Cases in Dermatopathology 61
F047 • How to Quarterback a Championship Team 62

WORKSHOP • 3:30 TO 5:30 P.M.

W003 • Self-assessment: Procedural Dermatology 62

FOCUS SESSIONS • 4:30 TO 5:30 P.M.

U015 • How to Deal with Difficult Patients/People and Look Forward To It! 63
U016 • MOC Changes 63
U017 • Challenging Cases of Dermoscopy: An Interactive Session 64
U018 • Genodermatoses Update 64
U019 • Update of Hair Growth Disorders 65
U020 • Head to Toes: Region-specific Contact Dermatitis 65
U021 • Holy Moly: Religion and the Skin: Cultural Competence 65
U022 • Pigmentary Conundrums: Diagnostic and Therapeutic Pearls 66
U023 • Management of Difficult Wounds 66
U024 • Autoinflammatory Skin Disorders: Clinical Pearls for Diagnosis and Management 67
U025 • New Medical Dermatology Literature that Changed My Approach to Practice 68
U026 • Does the Drug Really Work? Interpreting Clinical Trial Data 69

SATURDAY

FOCUS SESSIONS • 7:30 TO 8:30 A.M.

U027 • The Dermatologist's Role in Meeting the Needs of the Greater Community 70
U028 • Pemphigus and Pemphigoid: Evidence-based Updates 70
U029 • Cutaneous Lymphoma and Mimics: The Importance of Clinical Pathological Correlation 71
U030 • Male Genital Dermatology: Lessons Learned from a Male Genital Skin Disease Clinic 71

U031 • Advanced Use of Systemic Therapies: Rituximab, Thalidomide, and Anti-TNF Alpha Drugs to Manage Complex Dermatoses 72
U032 • A Practical Approach to the Management of Onychomycosis 72
U033 • What is New on Pyoderma Gangrenosum? 73
U034 • Warts and Molluscum: What's New in Treatments, Vaccinations, Immunotherapy and the Sexual Abuse Question 73
U035 • Cold Induced Skin Disease 74
U036 • Dermatologic Findings in the Stem Cell Transplant Patient 74
U037 • Common Geriatric Dermatology Issues that Patients and Their Caregivers May not Recognize or Are Afraid to Talk About 75
U038 • Arthropod-Borne Viruses: What Dermatologists Need to Know 75
U039 • Functional Genomics: From Genes to Drug Targets 76
U040 • Highlights from JAAD 76

COURSE • 7:30 TO 9:30 A.M.

C013 • Basic Self-assessment of Dermatopathology Slide Review 77

DISCUSSION GROUP • 9 TO 11 A.M.

D002 • Child Abuse: Practical Approach and Child Abuse Mimickers 77

FORUMS • 9 TO 11 A.M.

F048 • Translating Evidence into Practice: Acne Guidelines 78
F049 • Skin Signs of Internal Disease: Case-based Challenges 78
F050 • Updates in the Epidemic of Hair Loss in African American Women 79
F051 • Closing the Gender Gap in Academic Dermatology and Dermatology Leadership: Problems and Solutions 79
F052 • Itch 80
F053 • Advanced Dermatopathology 80
F054 • Volunteers Abroad: Beginners 81
F055 • Why Does My Skin "Feel" So Funny? From Dysesthesias to Dysmorphia 81
F056 • Late-breaking Research: Clinical Trials 82
F057 • The Big C's: Children, Cancer, and Cutaneous Complications 82
F058 • Patient Experience, Organizational Culture, and now MACRA: The New Face of Medical Practice 83
F059 • Shedding Light on Controversies in Phototherapy 83
F060 • What's New in Local Wound Care 84
F061 • Lichen Planus and Lichen Planopilaris: An Update 84
F062 • Advanced Melanoma-staging, Mechanisms of Current Therapies, and Update on Future Therapies 85

WORKSHOP • 9 TO 11 A.M.

W004 • Self-assessment: Skin Cancer 85

COURSES • 9 A.M. TO 12 P.M.

C010 • Structure and Function of the Skin: Cancer, Immunity and Inflammation 86
C011 • Dermatology Review: General and Cosmetic 86
C012 • Live Demonstration: Soft Tissue Augmentation and Neuromodulators – Simultaneous Cadaver Prosection and Live Patient Injections 87
C015 • Media Training: Developing and Delivering Key Messages 87

SYMPOSIA • 9 A.M. TO 12 P.M.

S018 • Residents and Fellows Symposium 88
S019 • Acne and Rosacea 88
S020 • Soft Tissue Augmentation: The Nasolabial Fold and Beyond 89
S021 • Disorders of Mucous Membranes 89
S022 • New Emerging Therapies 90

COURSES • 9 A.M. TO 4 P.M.

C016 • Derm Exam Prep Course: Refresher 90
C017 • Pediatric Dermatology 91
C018 • Advanced Practice Management 91

SYMPOSIA • 9 A.M. TO 5 P.M.

S009 • Gross and Microscopic Symposium 92

COURSE • 10 A.M. TO 12 P.M.

C014 • Basic Self-assessment of Dermatopathology Slide Review 93

FORUMS • 1 TO 3 P.M.

F063 • Cutaneous Lupus and Dermatomyositis: Management Pearls and Pitfalls for the General Dermatologist 93
F064 • Controversies and Challenges in Contact Dermatitis 94
F065 • Change is Inevitable - Unlock the Secrets to Manage and Lead It 94
F066 • Management Issues in Cutaneous Lymphoma 95
F067 • Lessons for Dermatology from the Tao Te Ching 95
F068 • Women with Hair Loss 96
F069 • Outpatient Radiotherapy of Skin Cancer: Back to the Future 96
F070 • Biologic Therapy in Dermatology Beyond Psoriasis 97
F071 • To Err is Human: How to Optimize Patient Safety in Your Practice 97
F072 • Late-breaking Research: Clinical Studies/ Pediatric 97
F073 • Late-breaking Research: Procedural Dermatology 98
F074 • The Future of Dermatology: What Changes are Coming and How Can We Prepare? 98

F075 • Practical Guidelines For Using Spironolactone in Acne Patients 99
F076 • Autoimmune Blistering Diseases: What's New 99
F077 • Superficial, Medium, and Deep Chemical Peeling and Relevance in 2017 100
F078 • Wound Closure Design: Basic to Advanced 100

WORKSHOP • 1 TO 3 P.M.

W005 • Self-assessment: Atopic Dermatitis 101

COURSES • 1 TO 4 P.M.

C019 • Live Demonstration: Head and Neck Anatomy – Cadaver Prosection 102
C020 • Basic Self-assessment of Dermatopathology Discussion 102
C021 • Infectious Diseases 103

SYMPOSIA • 1 TO 4 P.M.

S023 • Translating Evidence into Practice: Psoriasis Guidelines 104
S024 • Hot Topics 105
S025 • Chronic Pruritus: Bedside to Bench Perspectives 105
S026 • Tumor Board 106
S027 • Photodynamic Therapy 106
S028 • Acne Treatment Controversies 107
S029 • Rewards and Awards: How to make QI Pay Off 107
S030 • Biologics Promise and Perils 108
S031 • Adventures in Tropical Dermatology 108

DISCUSSION GROUP • 3:30 TO 5:30 P.M.

D003 • Recent Advances in Skin Biology and Skin Disease 109

FORUMS • 3:30 TO 5:30 P.M.

F079 • Journal Watching 109
F080 • The Pregnant Pause: How to Evaluate and Treat Your Pregnant Patients 110
F081 • Practice Gaps in Dermatology: Are We Doing What the Evidence Tells Us We Should? Tips for Your Practice 110
F082 • Hand and Foot Psoriasis, Dermatitis and Other Inflammatory Dermatoses 111
F083 • Phototherapy 111
F084 • Vulvar Disease: What Do You Know? An Overview 112
F085 • Late-breaking Research: Basic Science/ Cutaneous Oncology/Pathology 112
F086 • Herpes Zoster: Controversies and Conundrums in Treatment and Prevention 113
F087 • Lumps and Bumps in Children 113
F088 • Dermatologic Surgery Disasters: A Dissection of Patient Safety Failures 114
F089 • Reconstruction Options for Defects in the Central Face 114
F090 • Botulinum Toxin Applications: Past, Present, and Future 115
F091 • Volunteers Abroad: Advanced 115
F092 • Photosensitivity 116
F093 • Granulomatous Disorders of the Adult Skin 116

WORKSHOP • 3:30 TO 5:30 P.M.

W006 • Self-assessment: Psoriasis 117

FOCUS SESSIONS • 4:30 TO 5:30 P.M.

U041 • Disparities in Dermatology 118
U042 • Melanoma and the Genes: Optimizing Patient Management in the Age of Molecular Testing 118
U043 • Pregnancy Dermatoses: Moving Towards a Better Understanding 119
U044 • Epstein-Barr Virus (EBV) and Its Role in Cutaneous Disease 119
U045 • Avoiding Complications and Maximizing Results in Laser Surgery 120
U046 • Sex, Sores, Science, and Surveillance: Syphilis in the 21st Century 120
U047 • Comorbidities in Psoriasis: What a Dermatologist Needs to Know 121
U048 • Modern Nail Surgery: Aiming on Minimal Trauma and Nail-preservation 121
U049 • Optimal Management of Pediatric Morphea 122
U050 • Do Not Forsake the Love You Had at First: Reflection on Patient Satisfaction Surveys 122
U051 • Hedgehog Inhibitor Therapy for BCC: An Academic and a Private Practice Perspective 123
U052 • Up and Coming Fillers: Experience from Across the Atlantic 123

SUNDAY

FOCUS SESSIONS • 7 TO 8 A.M.

U053 • Light Based Devices: Photomodulation and Hair Growth 124
U054 • Leprosy and Leprosy Reactions 124
U055 • Unmasking Facial Pigmentation 125
U056 • Pearls from the New England Journal of Medicine 125
U057 • Dermatology Business Trends and Practice Opportunities 126
U058 • Measuring and Assessing Derm Surg: Surgical Outcomes and Reimbursement 126
U059 • Dermatologic Management of the Immunosuppressed: From Rapamycin Rash to Wiskott-Aldrich Syndrome (WAS) Dermatitis 127
U060 • The Tongue 127
U061 • My Patient Has Melanoma, Now What Do I Do? 128
U062 • Medical Dermatology Potpourri: Challenges Faced and Lessons Learned 128
U063 • When to Look Deeper: Common Skin Findings as a Harbinger of Genetic Disease 129

U064 • Dermatologist Burnout: How to Spot it and How to Avoid it 129
U065 • Hot Topics in Translational Dermatology 130
U066 • Controversies in Calciphylaxis: An Overview of Pathogenesis, Diagnosis, and Treatment through Case Studies 131

PLENARY • 8 TO 11:30 A.M.

P151 • Plenary Session 132

Clarence S. Livingood, MD, Award and Lectureship
Telemedicine and the Future of Medicine
Carrie L. Kovarik, MD ..... 8:50 a.m.

Eugene J. Van Scott Award for Innovative Therapy of the Skin and Phillip Frost Leadership Lecture Propranolol in Infantile Hemangiomas: A Successful Drug Repurposing
Christine Léauté-Labrèze, MD ..... 9:30 a.m.

Lila and Murray Gruber Memorial Cancer Research Award and Lectureship How Moles Become Cancer
Boris C. Bastian, MD, PhD ..... 10:10 a.m.

Marion B. Sulzberger, MD, Memorial Award and Lectureship
Getting to the Heart (and other Co-morbidities) of Psoriasis
Joel M. Gelfand, MD, MSCE ..... 10:35 a.m.

Guest Speaker: The West African Ebola Epidemic and the Global Health Security Agenda
RADM Jordan W. Tappero, MD, MPH ..... 11:00 a.m.

DISCUSSION GROUP • 1 TO 3 P.M.

D005 • Atopic Dermatitis in Adults: Not Just Big Kids 134

FORUMS • 1 TO 3 P.M.

F094 • Referral Medical Dermatology 134
F095 • Finding Solutions to Challenging Cases 135
F096 • Advances in Lasers and Light Sources: What's the Truth? 135
F097 • Medicolegal Issues 136
F098 • Skin Issues in Latino Patients 136
F099 • Medical Dermatology Challenge: Complex Cases from the Collection of Dr. Samuel Moschella 137
F100 • Stepping Out of the Fry Pan: Tools to Mitigate Burnout 137
F101 • Tackling Challenges in Epidermolysis Bullosa: What Does the Future Hold 138
F102 • Disorders of Pigmentation 138
F103 • Side Effects May Include: Illustrative Cases of Dermatologic Adverse Events 139
F104 • High Yield "Power Hour" for Residents 139
F105 • Dermoscopy: It's Time for a Quiz 140
F106 • A Practical Approach to Adult and Pediatric Autoimmune Connective Tissue Diseases 140
F107 • Dermatologic Side Effects of Anticancer Drugs in 2017: What You Need to Know 141
F108 • Field Cancer and Multiple SCC: Molecular Insights and Clinical Management 141

WORKSHOP • 1 TO 3 P.M.

W007 • Self-assessment: Dermatopathology 142

COURSES • 1 TO 4 P.M.

C022 • Updates in Hair Disorder 142
C023 • Avoiding and Managing Filler Complications 143
C024 • Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management 143

SYMPOSIA • 1 TO 4 P.M.

S032 • Resident Jeopardy 144
S033 • Inflammatory Skin Diseases: The Translational Revolution 144
S034 • Pearls from the Masters of Dermatological Surgery 145
S035 • Cutaneous Lymphomas 145
S036 • Surgical Complications 146
S037 • Vascular Anomalies Symposium: Classification, Clinical Challenges and Management Update 146
S038 • Psoriasis 147
S039 • Managing Tough Real Life Dermatology Cases 147
S040 • Medical Dermatology in Children and Adults: Similarities and Differences in Approach and Management 148
S041 • Melanoma and Mimics: New Diagnostic and Treatment Modalities 148
S042 • Advanced Medical Dermatology 149
S043 • Aging Gracefully 149
S044 • Nails 150

DISCUSSION GROUP • 3:30 TO 5:30 P.M.

D004 • Careers in Academic Dermatology 150

FORUMS • 3:30 TO 5:30 P.M.

F109 • Advanced Dermoscopy 151
F110 • The Skin and the Mind 151
F111 • Dermatology Teachers Exchange Group 152
F112 • Cutaneous T-cell Lymphoma 152
F113 • From Stinging Plants to Fire Ants: Identification, Management and Prevention of Hazardous Plant and Arthropod Exposures 153
F114 • Research Gaps in Psoriasis: Opportunities for Future Studies and Development of New Outcome Measures for Clinical Trials 153
F115 • Acne Boot Camp 154
F116 • Boards and Beyond 154
F117 • Chronic Urticaria and Angioedema: What's New in Pathogenesis and Treatment 155
F118 • Neonatal Dermatology: Case-based Discussions 155
F119 • Approach to Sclerosing Skin Conditions 155
F120 • Treating Tumors and Inflammatory Skin Diseases with Immunomodulators and Biologics 156
F121 • An Evidence-based Approach to Nails: Expert Management of Common Problems 156
F122 • Challenging Cases and Therapeutic Pearls from UVA 157

F123 • Photodocumentation in Dermatology 157

WORKSHOP • 3:30 TO 5:30 P.M.

W008 • Self-assessment: Contact Dermatology 158

FOCUS SESSIONS • 4:30 TO 5:30 P.M.

U067 • Delusional Infestation 158
U068 • Rheumatology for the Dermatologist: Evaluating the Rheumatology Patient in the Dermatology Clinic 159
U069 • PAPA, PASH, and PAPASH-syndromes, SAPHO, and Acne: Skin, Bones, and Inflammation 159
U070 • The Dermatopathology Report: Reading Between the Lines 160
U071 • Photodynamic Therapy in Medical and Aesthetic Dermatology 160
U072 • Intravenous Immunoglobulin (IVIg) in Dermatology 161
U073 • The Human Face as Living and Functional Art 161
U074 • Dermatoses of Infancy 162
U075 • The Red Patient: An Overview of Erythroderma 162
U076 • The ART (Advancement, Rotation, Transposition) of Flaps 163
U077 • Hair Care Practices and Hair Disorders in Skin of Color 164
U078 • LGBT Health: Providing Culturally Competent Care to Patients who are Sexual and Gender Minorities 165

MONDAY

FOCUS SESSIONS • 7:30 TO 8:30 A.M.

U079 • What to do When Patch Testing is Negative 166
U080 • Executing Transposition Flaps Off the Nose 166
U081 • Leading Change in a Changing World 167
U082 • Caring for Vulnerable Patient Populations 167
U083 • Vasculitis 168
U084 • Bureaucracy, Compliance, and Burnout: What it Means to Dermatologists 168
U085 • Developing Effective Multidisciplinary Skin Cancer Care: Driving Better Patient Outcomes and Fulfilling Professional Relationships 169
U086 • Treating Alopecia Areata, Vitiligo and Atopic Dermatitis: JAK Inhibitors, Something New for Dermatology 169
U087 • Update on Cutaneous Reactions to Targeted and Immune Cancer Therapy 170
U088 • Don't Brush it Off: Diagnosis and Management of Hair Loss in Children 170
U089 • Inpatient Dermatology from Horses to Zebras: Lessons Learned at an Academic Hospital 171
U090 • Slap-on/Bug-off: Sunscreen and Insect-Repellent Basics and Controversies 171
U091 • The Science Behind New Devices in Dermatology 172

DISCUSSION GROUP • 9 TO 11 A.M.

D006 • Challenging Pediatric Dermatology Cases 172

FORUMS • 9 TO 11 A.M.

F124 • Adverse Drug Reactions: The Evidence and the Controversies 173
F125 • Redness and Rosacea 173
F126 • Bullous Diseases: Diagnostic and Management Algorithm 174
F127 • Coagulation and Vasculitis 174
F128 • Dermoscopy: Learning From Easy and Difficult Cases 175
F129 • Fractional Laser and Light-based Technologies 175
F130 • M&M for the Medical Dermatologist: Case-based Lessons 176
F131 • Cost-conscious Dermatology 176
F132 • Caring for the Hospitalized Patient: Interesting Cases from the Inpatient Consultative Service 177

WORKSHOP • 9 TO 11 A.M.

W015 • Self-assessment: Acne 177

WORKSHOPS • 9 A.M. TO 12 P.M.

W009 • Hands-on: Lasers 178
W010 • Hands-on: Practical Anatomy for Dermal Fillers 179
W011 • Hands-on: Scar Revision 180
W012 • Hands-on: Nail Surgery 181
W013 • Hands-on: Innovative Suture Techniques Update 182
W014 • Hands-on: Fire and Ice! Electrosurgery and Cryosurgery 183

COURSE • 9 A.M. TO 12 P.M.

C025 • Coding and Documentation 184

SYMPOSIA • 9 A.M. TO 12 P.M.

S045 • Teledermatology Working for You: Customizing Use in the Changing Healthcare Environment 185
S046 • Controversies and Difficult Questions Concerning Biologic Therapeutics 186
S047 • Managing Patients with Melanoma or Other Melanocytic Neoplasms 186
S048 • Alopecia: Work-up and Treatment 187
S049 • Boards Blitz 187
S050 • Dermatologic Surgery: Cosmetic Tips and Pearls 188

S051 • Genetic Disorders: Presentations from Infancy to Adulthood 188
S052 • Systemic Therapies for Dermatologists: A Comprehensive Review and Update 189
S053 • Masters of Dermatology 189
S054 • Dermatitis NEW 190
S055 • Skin of Color Boot Camp: What Every Dermatologist Should Know About the Patient with Darker Skin Tones NEW 190

COURSES • 9 A.M. TO 4 P.M.

C026 • Essential Dermatopathology: What You Need to Know for Clinical Practice: Inflammatory MOC 191
C027 • Fundamentals of Dermoscopy 191
C028 • Advanced Self-assessment of Dermatopathology 192

FORUMS • 1 TO 3 P.M.

F133 • Iatrogenic Injury 192
F134 • AIDS and Sexually Transmitted Diseases (STDs): Hot Topics MOC 193
F135 • Techniques for Flap Success 193
F136 • Pediatric Psoriasis: Systemic Therapy and Beyond 194
F137 • Challenging Diagnostic Cases for Practitioners MOC 194
F138 • Photodynamic Therapy in Medical and Aesthetic Dermatology 195
F139 • Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines 195
F140 • Medical and Surgical Management of Nail Disorders 196

WORKSHOP • 1 TO 3 P.M.

W016 • Self-assessment: Pediatric Dermatology MOC 196

WORKSHOPS • 1 TO 4 P.M.

W017 • Hands-on: Lasers MOC 197
W018 • Hands-on: Practical Anatomy for Dermal Fillers MOC 198
W019 • Hands-on: Wound Closures MOC 199
W020 • Hands-on: Nail Surgery MOC 200
W021 • Hands-on: Varicose and Telangiectatic Veins MOC 201

SYMPOSIA • 1 TO 4 P.M.

S056 • Pearls: Diagnostic and Therapeutic 202
S057 • Skin of Color 202
S058 • Melanoma: The Future is Now MOC 203
S059 • Treating Severe Skin Disease in Children 203
S060 • What's New and What's True in Lasers 204
S061 • Consultative Dermatology for the Hospitalized Patient 204
S062 • Challenging Adult and Pediatric Autoimmune Connective Tissue Disease Cases: Pearls for Diagnosis and Management 205
S063 • Hair Disorders Made Easier 205
S064 • Regional Reconstruction 206
S065 • Cutaneous Oncology 206
S066 • What's New in Dermatopathology 207
S067 • Vitiligo 207

FORUMS • 3:30 TO 5:30 P.M.

F141 • How to be an Effective Clinician Educator 208
F142 • Documentation and Coding: Getting Paid and Passing Audits 208
F143 • Novel Therapies for Cutaneous Malignancies: What's New and What's Ahead 209
F144 • Diagnosis, Treatment and Prevention of Errors in Dermatologic Practice MOC 209
F145 • What's New in Melasma? 210
F146 • Atopic Dermatitis 210
F147 • Point and Counterpoint: Cases in Dermatoethics 211
F148 • Acne, Hair Loss and Hirsutism Evaluation and Management 211
F149 • Psoriasis: Updates in Biologic Therapy, Comorbidities, Genetics, and Biosimilars 212
F150 • Oral Diseases 212

FOCUS SESSIONS • 4:30 TO 5:30 P.M.

U092 • Data-driven Dermatology: Who Will Define our Specialty and How? 213
U093 • Laser and Device-Based Treatment of Scars 213
U094 • Hair Transplantation 214
U095 • Great Cases from Mississippi 214
U096 • Hyperhidrosis: Update on Therapeutics 215
U097 • Relevance of the Human Microbiome in Health and Disease 215
U098 • Non-surgical Skin Cancer Treatments NEW 216
U099 • Take a Pico Under the Hood: Dissecting Picosecond Lasers and Indications NEW 216
U100 • Update on Pediatric Vascular Tumors NEW 217
U101 • Vaccines in Dermatology 217
U102 • About Face: Pearls for Facial Hyperpigmentation Conundrums 218
U103 • Natural Compounds in Addressing Common Dermatologic Problems 219

TUESDAY

SYMPOSIUM • 8 TO 10 A.M.

S068 • Therapeutic and Diagnostic Pearls 220

SYMPOSIUM • 10:30 A.M. TO 12:30 P.M.

S069 • What's New in Dermatology 220

2017 AAD Annual Meeting Session Access, Fees, and Eligibility

REGISTRATION CATEGORY Additional information can be found at **aad.org/AM17**	Standard Registration Rates	Restricted Session Access Be sure to check session designation in the program
Physician members	$800	YES
Applicants for membership (Approved by Nov. 1, 2016)	$800	YES - if dermatologist NO - if non-dermatologist
Adjunct members (research, corporate) (Approved through membership process)	$800	YES
Adjunct members (other) (Approved through membership process)	$800	NO
Life members	$275	YES
Honorary members	$0	YES
Dermatology residents and medical fellows	$260	YES
Non-dermatology residents and medical fellows	$260	NO
Medical students [1]	$130	NO
Non-member physician (treating patients in an office like setting) Day pass for $1,050. Available to only this category, onsite. Can only be purchased on day of use. **One per meeting.**	$2,080	YES - if dermatologist NO - if non-dermatologist
Non-member non-physicians [1] (Non-member corporate individuals, pharmacists, distributors, industry representatives, estheticians, cosmetologists, and scientists/researchers working in the field of dermatology)	$2,220	NO
Derm Care Team [1] (Approved through official AAD processes)	$800	NO
Physician assistants and nurse practitioners [1] (non Derm Care Team) (must be working in an AAD dermatologist member's office. Employing derm does not need to be registered)	$1,020	NO
Nurses (RN/LPN) [1] (non Derm Care Team) (Must be employed by practicing dermatologist. Employing derm does not need to be registered)	$1,020	NO
Dermatology practice staff [1] (non Derm Care Team) (This category is for those who provide patient services and are not a physician, esthetician, or cosmetologist. These individuals may include, but are not limited to, front desk, medical records, referral clerk, insurance billing, coding, office manager, practice administrator, practice manager, and histotechnicians. Must be employed by practicing dermatologist. Employing derm does not need to be registered.)	$580	NO
Guests [2] (Defined as a spouse, significant other, or personal friend who is not an active industry professional. 1 per physician registrant)	$150	
Exhibitors [1 2]		

Seats for (D) Discussion groups, (F) Forums, (U) Focus sessions, (S) Symposia, and (P) Plenary are non-ticketed and are available on a first come, first serve basis for eligible registration categories. Please refer to the grid above for restricted session eligibility. Registration for the scientific portion of the meeting is required in order to attend sessions.

All (C) Courses and (W or WSP) Workshops are ticketed sessions. A tuition and ticket is required for admittance.

[1] This category is not eligible to register a Guest
[2] This category of registration will not be issued a Certificate of Meeting Attendance with registration and is not eligible to claim CME

The sessions types listed below require tuition and ticket for session access.									
Half Day Courses	One Day Courses	Self - Assessment Courses (Basic & Advanced)	Live Demonstration Courses	W002 Practical Approaches to Assessing Psoriasis and Psoriatic Arthritis (tuition for this session has been covered by a grant from Pfizer)	C006 Conquer the Boards	C016 Derm Exam Prep Course	Self - Assessment Workshops	Workshops	Hands on Workshops
$55	$85	$120	$130	$0	$250	$385	$60	$60	$250
$55	$85	$120	$130	$0	$250	$385	$60	$60	$250
$55	$85	$120	$130	$0	$250	$385	$60	$60	$250
$55	$85	$120	NA	$0	$250	$385	$60	$60	$250
$55	$85	$120	$130	$0	$250	$385	$60	$60	$250
$55	$85	$120	$130	$0	$250	$385	$60	$60	$250
$40	$55	$65	$80	$0	$130	$190	$50	$50	$130
$40	$55	$65	NA	$0	$130	$190	$50	$50	$130
$40	$55	$65	NA	$0	$130	$190	$50	$50	$130
$150	$230	$385	$500	$0	$635	$635	$175	$175	$635
$150	$230	$385	NA	$0	$635	$635	$175	$175	$635
$55	$85	$120	NA	$0	$250	$385	$60	$60	$250
$150	$230	$385	NA	$0	$635	$635	$175	$175	$635
$150	$230	$385	NA	$0	$635	$635	$175	$175	$635
$150	$230	This registration category has access to non-restricted (S) Symposia, (P) Plenary session, E-posters, the exhibit hall, and Practice Management designated (C) Courses, (F) Forums, (U) Focus sessions, and (D) Discussion groups.							
Those with a guest badge will only have access to the exhibit hall on Sunday, March 5th. Beginning with the 2017 Annual Meeting, full meeting registration in an alternate appropriate category is required to attend any portion of the scientific program and educational sessions.									
Those with an exhibitor badge will have admittance to the exhibit hall only. Beginning with the 2017 Annual Meeting, full meeting registration in an alternate appropriate category is required to attend any portion of the scientific program and educational sessions.									

For session types, please refer to page 11

CONTINUING MEDICAL EDUCATION INFORMATION

MISSION

The purpose of the American Academy of Dermatology (AAD) CME Program is to provide members with opportunities for life-long learning and assistance in fulfilling their maintenance of certification and licensure requirements, thereby promoting excellence in the provision of dermatologic care.

DEFINITION OF CONTINUING MEDICAL EDUCATION

Continuing medical education consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. The content of CME is that body of knowledge and skills generally recognized and accepted by the profession as within the basic medical sciences, the discipline of clinical medicine, and the provision of health care to the public *Source: www.accme.org*

COMMERCIAL BIAS

A personal judgment in favor of a specific proprietary business interest of a commercial interest. *Source: www.accme.org*

SCIENTIFIC ASSEMBLY COMMITTEE

**As of the April 14-15, 2016 planning meeting.*

Allison Vidimos, MD, RPh; Chair
Robert Brodell, MD
Sheila Friedlander, MD
Jacob Levitt, MD
Erik Stratman, MD
Abel Torres, MD, JD, MBA; President
Henry Lim, MD; President-Elect
Barbara Mathes, MD; Secretary-Treasurer
Marta Van Beek, MD; Assistant Secretary-Treasurer
Amit Garg, MD; Chair, Needs Assessment and Outcomes Committee
M. Laurin Council, MD; Young Physicians Committee Representative
Lawrence Eichenfield, MD; Chair, Named Lectureship Task Force
Lidia Rudnicka, MD; Chair, Poster Exhibits Task Force
Nellie Konnikov, MD; Chair, International Affairs Committee
Arthur Sober, MD; Chair, Council on Education and Maintenance of Certification

LEARNER BILL OF RIGHTS

AAD recognizes that you are a life-long learner who has chosen to engage in continuing medical education to identify or fill a gap in knowledge or skill; and to attain or enhance a desired competency. As part of AAD's duty to you as a learner, you have the right to expect that your continuing medical education experience with AAD includes the following.

Content that:

- *Promotes improvements or quality in healthcare*
- *Is current, valid, reliable, accurate and evidence-based*
- *Addresses the stated objectives or purpose*
- *Is driven and based on independent survey and analysis of learner needs, not commercial interests*
- *Has been reviewed for bias and scientific rigor*
- *Offers balanced presentations that are free of commercial bias*
- *Is vetted through a process that resolves any conflicts of interest of planners and faculty*
- *Is evaluated for its effectiveness in meeting the identified educational need*

A learning environment that:

- *Is based on adult learning principles that support the use of various modalities*
- *Supports learners' abilities to meet their individual needs*
- *Respects and attends to any special needs of the learners*
- *Respects the diversity of groups of learners*
- *Is free of promotional, commercial and/or sales activities*

Disclosure of:

- *Relevant financial relationships that planners, teachers and authors have with commercial interests related to the content of the activity*
- *Commercial support (funding or in-kind resources) of this activity*

For the latest meeting information, please refer to the Annual Meeting Mobile app at **aad.org/mobile**.

American Academy of Dermatology
930 East Woodfield Road, Schaumburg, Illinois 60173
Phone: 847.330.0230 • Fax: 847.330.1090
• Website: aad.org

© 2017 American Academy of Dermatology, Schaumburg, Illinois

No part of this publication may be reproduced without the prior written permission of the American Academy of Dermatology.

2017 AAD ANNUAL MEETING DIRECTLY SPONSORED BY

THE AMERICAN ACADEMY OF DERMATOLOGY

STATEMENT OF NEED

The American Academy of Dermatology's 2017 Annual Meeting is planned to comprehensively address the nine content areas within the Dermatologic Core Curriculum and provide dermatologists and other dermatology health care professionals with high quality educational opportunities for the optimization of dermatologic knowledge, competence and performance.

TARGET AUDIENCE

The primary target audience of the American Academy of Dermatology's 2017 Annual Meeting is its members. Secondary audiences for the Academy's 2017 Annual Meeting include dermatology residents and other dermatology health care professionals.

GLOBAL LEARNING OBJECTIVES

This comprehensive meeting provides learners with opportunities to:

- Review and apply basic knowledge and skills in medical dermatology, dermatologic surgery, pediatric dermatology, and dermatopathology.
- Update their knowledge about recent advances in the diagnosis, management and treatment of diseases of the skin, hair, nails, and mucous membranes.
- Assess the relationship of evidence-based diagnostic approaches and therapies with new dermatologic treatment developments.
- Self assess current practice management skills and develop strategies for improving these skills.
- Develop new skills to improve their everyday practice of dermatology.

NOTE:
Each session has its own specific learning objectives which are included within the Scientific Session listing in the Final Program.

DISCLOSURES

PLANNER DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)

The following Scientific Assembly Committee members reported they have no relationship(s) with commercial interest(s) to disclose relevant to the content of this CME activity:

- Barbara M. Mathes, MD
- Erik Joseph Stratman, MD
- Lidia Rudnicka, MD, PhD
- Marta Jane Van Beek, MD, MPH

The following Scientific Assembly Committee members reported they do have relationship(s) with commercial interest(s) to be disclosed to learners:

PLANNER	COMMERCIAL INTEREST	ROLE
Robert T. Brodell, MD	AbbVie	Speaker / Honoraria
	Galderma Laboratories, L.P.	Consultant / Honoraria
	Galderma Laboratories, L.P.	Speaker / Honoraria
	Galderma Laboratories, L.P.	Speaker / Honoraria
	Genentech, Inc.	Principal Investigator / Honoraria
	Pharmaderm	Speaker / Honoraria
M. Laurin Council, MD	Suneva Medical, Inc.	Advisory Board / Honoraria

For session types, please refer to page 11

PLANNER	COMMERCIAL INTEREST	ROLE
Lawrence Eichenfield, MD	Amgen	Other / Fees
	Anacor Pharmaceuticals, Inc.	Consultant / Honoraria
	Aqua	Consultant / Fees
	Astellas Pharma US, Inc	Principal Investigator / Fees
	Celgene Corporation	Consultant / Fees
	Elsevier Inc.	Other / Patent royalties or other compensation for Intellectual Property Rights
	Galderma Laboratories, L.P.	Consultant / Honoraria
	Galderma Laboratories, L.P.	Principal Investigator / Fees
	Galderma Laboratories, L.P.	Speaker / Honoraria
	Genentech, Inc.	Consultant / Honoraria
	LEO Pharma, US	Consultant / Honoraria
	LEO Pharma, US	Principal Investigator / Fees
	Novan	Principal Investigator / Fees
	Otsuka Pharmaceutical Co., Ltd.	Consultant / Honoraria
	Pierre Fabre Dermatologie	Consultant / Honoraria
	Pierre Fabre Dermatologie	Principal Investigator / Fees
	Regeneron	Principal Investigator / Fees
	Stiefel a GSK company	Principal Investigator / Fees
	Taro Pharm	Consultant / Honoraria
	Tioga Pharmaceuticals, Inc.	Other / Honoraria
	TopMD	Consultant / Stock Options
	Valeant Pharmaceuticals International	Consultant / Honoraria
	Valeant Pharmaceuticals International	Speaker / Honoraria
	Wiley-Blackwell	Other / Honoraria
Sheila Friedlander, MD	Anacor Pharmaceuticals, Inc.	Advisory Board / Honoraria
	Exeltis	Advisory Board / Honoraria
	Leo Pharma Inc	Advisory Board / Honoraria
	Merz Pharmaceuticals, LLC	Advisory Board / Honoraria
	Merz Pharmaceuticals, LLC	Principal Investigator / Grants/ Research Funding
	Sandoz, a Novartis company	Advisory Board / Honoraria
	Sandoz, a Novartis company	Speaker / Honoraria
	Valeant Pharmaceuticals International	Advisory Board / Honoraria
	Valeant Pharmaceuticals International	Other / Grants/Research Funding
Amit Garg, MD	AbbVie	Advisory Board / Honoraria
	Eli Lilly and Company	Advisory Board / Honoraria
	Merck & Co., Inc.	Other / Grants / Research Funding
	Pfizer, Inc.	Advisory Board / Honoraria
Nellie Konnikov, MD	Biofrontera AG	Advisory Board / Honoraria
Jacob Levitt, MD	Amgen	Advisory Board / Honoraria
	Janssen Pharmaceuticals, Inc	Advisory Board / Honoraria
	Medac Pharma, Inc	Advisory Board / Honoraria
	Pfizer Inc.	Advisory Board / Honoraria
	Ranbaxy Laboratories Limited	Ranbaxy Laboratories Limited Advisory Board / Honoraria
	Roche Laboratories	Advisory Board / Fees
	Springer Science & Business Media	Other / Other Financial Benefit

Henry W. Lim, MD	Clinuvel	Principal Investigator / Grant / Research Funding
	Estee Lauder	Principal Investigator / Grants / Research Funding
	Ferndale Laboratories, Inc.	Advisory Board / Honoraria
	Ferndale Laboratories, Inc.	Principal Investigator / Grants / Research Funding
	L'Oréal France	Speaker / Faculty Education / Honoraria
	Mitsubishi Pharma	Consultant / Honoraria
	Pierre Fabre Dermatologie	Speaker / Faculty Education / Honoraria
Arthur Joel Sober, MD	Melasciences	Principal Investigator / Grants / Research Funding
Abel Torres, MD	American Academy of Dermatology Board of Directors	No Compensation Received
	Loma Linda University - LLFMG	No Compensation Received
Allison Therese Vidimos, MD	Genentech, Inc.	Principal Investigator / Grants/ Research Funding

The following Leadership Development Steering Committee members reported they have no relationship(s) with commercial interest(s) to disclose relevant to the content of this CME activity:

- Tammie Ferringer, MD
- Matthew C. Fox, MD
- Kathleen Julie Hectorne, MD
- Sotonye Imadojemu, MD
- Barbara M. Mathes, MD
- Margaret E. Parsons, MD
- Rochelle R. Torgerson, MD, PhD
- Karen Wiss, MD
- Alexandra Y. Zhang, MD

The following Leadership Development Steering Committee members reported they do have relationship(s) with commercial interest(s) to be disclosed to learners:

PLANNER	COMMERCIAL INTEREST	ROLE
Kelly Cordoro, MD	Celgene Corporation	Consultant / Fees
Seemal Desai, MD	AbbVie	Speaker / Honoraria
	AbbVie	Consultant / Fees
	AbbVie	Principal Investigator / Grants/ Research Funding
	Allergan, Inc.	Consultant / Fees
	Anacor Pharmaceuticals, Inc.	Consultant / Fees
	Galderma Laboratories, LP	Advisory Board / Honoraria
	Galderma Laboratories, LP	Consultant / Fees
	Galderma Laboratories, LP	Speaker / Honoraria
	Symbio	Principal Investigator / Grants/ Research Funding
	TKI Research	Principal Investigator / Grants/ Research Funding
	Valeant Pharmaceuticals North America LLC	Consultant / Fees
	Valeant Pharmaceuticals North America LLC	Speaker / Honoraria
Beth Ann Drolet, MD	Pierre Fabre Dermatologie	Other / Grants/Research Funding
Amit Garg, MD	AbbVie	Advisory Board / Honoraria
	Eli Lilly and Company	Advisory Board / Honoraria
	Pfizer Inc.	Advisory Board / Honoraria
Gary Goldenberg, MD	AbbVie	Speaker / Honoraria
	Allergan, Inc	Consultant / Honoraria
	Bayer Pharmaceuticals	Consultant / Honoraria
	Celgene Corporation	Consultant / Honoraria

For session types, please refer to page 11

PLANNER	COMMERCIAL INTEREST	ROLE
Gary Goldenberg, MD (con't)	Celgene Corporation	Speaker / Honoraria
	Dermira	Advisory Board / Honoraria
	Galderma USA	Speaker / Honoraria
	Genentech, Inc.	Consultant / Honoraria
	Janssen Pharmaceuticals, Inc	Consultant / Honoraria
	Leo Pharma A/S	Principal Investigator / Grants/ Research Funding
	LEO Pharma, US	Consultant / Honoraria
	LEO Pharma, US	Speaker / Honoraria
	MelaSciences	Consultant / Honoraria
	Novartis Pharmaceuticals Corp.	Consultant / Honoraria
	Pfizer Inc.	Consultant / Honoraria
	Pharmaderm	Principal Investigator / Grants/ Research Funding
	Pharmaderm	Advisory Board / Honoraria
	Pharmaderm	Speaker / Honoraria
	Ranbaxy Laboratories Limited	Consultant / Honoraria
	Stiefel a GSK company	Consultant / Honoraria
	Stiefel a GSK company	Principal Investigator / Grants/ Research Funding
	Teva Pharmaceuticals USA	Consultant / Fees
	Valeant Pharmaceuticals North America LLC	Consultant / Honoraria
	Valeant Pharmaceuticals North America LLC	Principal Investigator / Grants/ Research Funding
	Valeant Pharmaceuticals North America LLC	Speaker / Honoraria
	Xoft	Consultant / Honoraria
Caroline C. Kim, MD	Castle Biosciences, Inc	Consultant / Fees
	Hoffman-La Roche Ltd.	Principal Investigator / No Compensation Received
	Shape Pharmaceuticals Dermatology	Dermatology Monitoring Safety Board (DSMB)/ Fees

The staff involved with this CME activity and all content validation/peer reviewers of this CME activity have reported no relevant financial relationships with commercial interest(s).

FACULTY DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)

It is the policy of AAD that all faculty participating in a CME-certified activity are required to disclose to AAD and to learners relevant financial relationships that they or their first-degree relatives (spouse, parent, sibling, or child) have with any commercial interest(s). "Relevant financial relationships" include financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Typically, such relationships would be with companies that sell health care products or services that are consumed by or used in the treatment of patients. The intent of this disclosure is not to prevent participation in CME-certified educational activities by individuals with a relevant financial relationship with commercial interest(s), but rather to provide learners with information on which they can make their own determination whether or not said relationship(s) influenced the content of the educational activity.

Session director and faculty disclosure information is located within the Final Program after the scientific schedule. Faculty have been asked to also make a verbal disclosure at the start of their presentations supplemented by a disclosure slide in order to verify the accuracy of the disclosure information printed in the Final Program and ensure their disclosure information is shared with the learners PRIOR to the presentation taking place.

---

[1] **Relevant Financial Relationships:** The ACCME defines "relevant financial relationships" as financial relationships in any amount occurring within the past twelve months that create a conflict of interest. *Source: www.accme.org.*

[2] **Conflict of Interest:** When an individual's interests are aligned with those of a commercial interest the interests of the individual are in "conflict" with the interests of the public. *Source: www.accme.org*

RESOLUTION OF CONFLICTS OF INTEREST
In accordance with the ACCME Standards for Commercial Support of CME, the American Academy of Dermatology has implemented mechanisms, prior to the planning and implementation of this CME activity, to identify and mitigate conflicts of interest for all individuals in a position to control the content of this CME activity.

UNAPPROVED USE DISCLOSURE
The American Academy of Dermatology requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label (not approved for the indications being discussed), unlabeled (not approved for any indications), experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these products/procedures. If you have questions, contact the medical affairs department of the manufacturer for the most recent approval information. Faculty at this meeting will be discussing information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

INDEPENDENCE IN CME
The mission of the Academy's continuing medical education program is to improve patient care and health care outcomes by maintaining, developing and enhancing medical knowledge, patient care, interpersonal and communication skills and professionalism. As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME) and in support of this mission, the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias.

The Academy employs several strategies to ensure these standards will be met. The planning committee members submit and consider their own disclosure information and recuse themselves from planning educational activities should they have conflicts related to the subject area presented. When developing an educational program, the planning committee reviews applications and disclosure of interest forms, along with needs assessment and evaluative data from past activities in order to develop programming. Potential participants are sent detailed guidelines that provide direction on necessary components to ensure independence in continuing medical education activities and to resolve conflict.

CONTENT VALIDATION
Academy-sponsored educational activities are designed to promote improvements or quality in health care and not promote a specific proprietary business interest or a commercial interest. Presentations and related materials must be based on scientific methods generally accepted by the medical community.

Presentations should be evidence-based and discuss the validity of the evidence upon which they base the opinion(s) (see Sackett et al, BMJ 1996;312:71-2). This ensures the audience that the recommendations are supported by the evidence and contributes to management of any potential conflicts of interest. Further, if the presentation includes discussion of unlabeled or investigational use of a commercial product, this also must be disclosed to the participants. CME must give a balanced view of therapeutic options. Use of generic names will contribute to this impartiality.

If CME educational material or content includes trade names, trade names from several companies should be used where available, as opposed to using trade names from just a single company. Educational materials such as slides, abstracts, and handouts cannot contain any advertising or product-group messages.

OUTCOMES MEASUREMENT
Several methods of evaluation are utilized in assessing the educational program. Session directors, speakers, attendees, and formal observers are all given the opportunity to evaluate the educational content and speaker performance. Included in this process are measures to rate the success of the Academy's policies regarding independence in continuing medical education activities with particular focus on the absence of commercial bias.

In addition, the Academy may review speaker presentations stored on the meeting servers to collect aggregate data regarding disclosure. These data are only used to determine effectiveness of the Academy's policies and procedures regarding disclosure. Should it be determined that

For session types, please refer to page 11

a member of the Academy's educational program violated the Academy's "Policy to Ensure Independence in Continuing Medical Education," the individual may not be asked to participate in future educational programs.

DISCLAIMER
The American Academy of Dermatology is not responsible for statements made by faculty. Statements or opinions expressed in this program reflect the views of the faculty and do not reflect the official policy of the American Academy of Dermatology. The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to the diagnostic, management and treatment options of a specific patient's medical condition.

COMMERCIAL SUPPORT DISCLOSURE
The following commercial interests provided in-kind support for the 2017 Annual Meeting at the time of publication:

Bovie Medical Corporation	*Devices for Hands-on Sessions*
Brymill Cryogenic Systems	*Devices for Hands-on Sessions*
Cutera	*Devices for Hands-on Sessions*
Eclipse Aesthetics, LLC	*Devices for Live Demonstration Sessions*
Lumenis	*Devices for Hands-on Sessions*
Midmark Corporation	*Equipment for Live Demonstration Sessions*
Sinclair Pharma USA	*Devices for Live Demonstration Sessions*
ZELTIQ Aesthetics, Inc.	*Devices for Hands-on Sessions*

The following commercial interests provided commercial support for the 2017 Annual Meeting at the time of publication:

Anacor Pharmaceuticals, Inc.	*Translating Evidence to Practice Session: Atopic Dermatitis*
Celegene Corporation	*Audio/Visual, Microscopes, Electrical Support, and Supplies for Scientific Sessions*
Galderma Laboratories, L.P	*Translating Evidence to Practice Session: Acne*
Leo Pharma, Inc.	*Audio/Visual, Microscopes, Electrical Support, and Supplies for Scientific Sessions*
Lilly USA, LLC	*Audio/Visual, Microscopes, Electrical Support, and Supplies for Scientific Sessions*
Pfizer, Inc.	*Audio/Visual, Microscopes, Electrical Support, and Supplies for Scientific Sessions*
Pfizer, Inc.	*Practical Approaches to Assessing Psoriasis and Psoriatic Arthritis Patients in Clinic Session*
The Physicians Foundation	*Leadership Institute Sessions*
Valeant Pharmaceuticals North America, LLC	*Translating Evidence to Practice Session: Acne*

ACCREDITATION
The American Academy of Dermatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA PRA CATEGORY 1 CREDIT™ DESIGNATION
The American Academy of Dermatology designates this live activity for a maximum of ***39.25 AMA PRA Category 1 Credits™.*** Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAD RECOGNIZED CREDIT
The American Academy of Dermatology's Summer Meeting is recognized by the American Academy of Dermatology for *39.25 AAD Recognized Credits* and may be used toward the American Academy of Dermatology's Continuing Medical Education Award.

All Annual Meeting activities, unless otherwise specified, are approved for direct-sponsored *AAD Recognized Credit.*

WHAT YOU NEED TO DO TO RECEIVE CME CREDIT
CME credit is awarded based on participation in the learning activities. CME credits can be claimed online at www.aad.org/evals or in the meeting mobile app. Credit is calculated on a ¼-hour basis and will be reflected on member transcripts within two weeks after the meeting.

NON-MEMBER PHYSICIAN CME CREDIT CERTIFICATE
Non-member physicians who attend the meeting can receive a CME Award Certificate which includes documentation of the total CME credits claimed. If you are a physician and would like to receive a CME Award Certificate, please claim your CME credits and print your CME Award Certificate online at *www.aad.org/evals.*

2017 AAD Annual Meeting Program Guide

PROGRAM SCHEDULE KEY

NOTED SESSIONS

- New Session
- Ticketed Session
- Restricted Session open to dermatologists and adjunct (researcher, corporate) members
- This activity is pending approval by the ABD to satisfy component 2 of MOC
- Audience Response System Session
- Practice Management

SESSION TYPE

D • Discussion Group
U • Focus Session
C • Course
S • Symposium
F • Forum
W • Workshop
WSP • Standardized Patient Workshop

COMPREHENSIVE SCIENTIFIC PROGRAM

For the most current, up-to-date session information (Program Overview) view the searchable program and plan your schedule online through **www.aad.org/AM17.**

Search for sessions, speakers, or topics of interest.

Tuition fee and ticket required for admission

Hands-on: The Patient Encounter: The Difficult Patient

Room: W205A

Director: Kanade Shinkai, MD, PhD

Learning Objectives

Following this session, the attendee should be able to:

1. Practice communication skills in a realistic simulated clinical scenario: difficult conversations.
2. Receive feedback on communication, agenda-setting.
3. Describe personal reflections after the encounter and identify areas for individualized improvement.

Description

This new session will include a one-on-one simulated clinical encounter with an actor patient in which the attendee will face "the difficult patient" – i.e. a patient who presents to the clinic with many demands and requests. The purpose of this session is to get hands-on practice with agenda setting and then to provide the attendee with feedback on their communication skills. A rare opportunity to practice challenging conversations in a safe and realistic setting with feedback, the attendee will be invited to reflect on the encounter and identify areas for individualized improvement.

This activity has been approved by the American Board of Dermatology (ABD) for up to 5 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 0.50 Category 1 CME Credit

Hands-on: The Patient Encounter: Breaking Bad News

Room: W205A

Director: Kanade Shinkai, MD, PhD

Learning Objectives

Following this session, the attendee should be able to:

1. Practice communication skills in a realistic simulated clinical scenario: breaking bad news.
2. Receive feedback on communication and empathy.
3. Describe personal reflections after the encounter and identify areas for individualized improvement.

Description

This new session will include a one-on-one simulated clinical encounter with an actor patient in which the attendee will deliver bad news (medical diagnosis) to the standardized patient. The purpose of this session is to get hands-on practice with delivering bad news and then to provide the attendee with feedback on their counseling and communication skills. A rare opportunity to practice challenging conversations in a safe and realistic setting with feedback, the attendee will be invited to reflect on the encounter and identify areas for individualized improvement.

This activity has been approved by the American Board of Dermatology (ABD) for up to 5 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 0.50 Category 1 CME Credit

Hands-on: The Patient Encounter: Medication Management

Room: W205A

Director: Kanade Shinkai, MD, PhD

Learning Objectives

Following this session, the attendee should be able to:

1. Practice communication skills in a realistic simulated clinical scenario: medication management.
2. Receive feedback on communication and counseling skills.
3. Describe personal reflections after the encounter and identify areas for individualized improvement.

Description

This new session will include a one-on-one simulated clinical encounter with an actor patient in which the attendee will counsel a standardized patient on medication management. The purpose of this session is to get hands-on practice with patient counseling and education and then to provide the attendee with feedback on their counseling and communication skills. A rare opportunity to practice challenging conversations in a safe and realistic setting with feedback, the attendee will be invited to reflect on the encounter and identify areas for individualized improvement.

This activity has been approved by the American Board of Dermatology (ABD) for up to 5 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 0.50 Category 1 CME Credit

Hands-on: The Patient Encounter: Total Body Skin Exam

Room: W205A

Director: Kanade Shinkai, MD, PhD

Learning Objectives

Following this session, the attendee should be able to:

1. Practice bedside manner and communication skills in a realistic simulated clinical scenario: the full body skin exam.
2. Receive feedback on physical exam skills, including gowning/draping, and counseling skills.
3. Describe personal reflections after the encounter and identify areas for individualized improvement.

Description

This new session will include a one-on-one simulated clinical encounter with an actor patient in which the attendee will perform a full body skin exam. The purpose of this session is to get hands-on practice with performing a routine office exam and then to provide the attendee with feedback on their bedside manner and physical exam skills, including gowning/draping and counseling skills. A rare opportunity to practice in a safe and realistic setting with feedback, the attendee will be invited to reflect on the encounter and identify areas for individualized improvement.

This activity has been approved by the American Board of Dermatology (ABD) for up to 5 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 0.50 Category 1 CME Credit

STANDARDIZED PATIENT WORKSHOPS

HANDS-ON: THE PATIENT ENCOUNTER: BREAKING BAD NEWS

FRIDAY, MARCH 3

WSP002	7:30 a.m. - 8:00 a.m.
WSP006	8:15 a.m. - 8:45 a.m.
WSP010	9:00 a.m. - 9:30 a.m.
WSP014	9:45 a.m. - 10:15 a.m.
WSP018	10:30 a.m. - 11:00 a.m.
WSP022	11:15 a.m. - 11:45 a.m.
WSP026	1:00 p.m. - 1:30 p.m.
WSP030	1:45 p.m. - 2:15 p.m.
WSP034	2:30 p.m. - 3:00 p.m
WSP038	3:15 p.m. - 3:45 p.m.
WSP042	4:00 p.m. - 4:30 p.m.
WSP046	4:45 p.m. - 5:15 p.m

SATURDAY, MARCH 4

WSP050	7:30 a.m. - 8:00 a.m.
WSP054	8:15 a.m. - 8:45 a.m.
WSP058	9:00 a.m. - 9:30 a.m.
WSP062	9:45 a.m. - 10:15 a.m.
WSP066	10:30 a.m. - 11:00 a.m.
WSP070	11:15 a.m. - 11:45 a.m.
WSP074	1:00 p.m. - 1:30 p.m.
WSP078	1:45 p.m. - 2:15 p.m.
WSP082	2:30 p.m. - 3:00 p.m
WSP086	3:15 p.m. - 3:45 p.m.
WSP090	4:00 p.m. - 4:30 p.m.
WSP094	4:45 p.m. - 5:15 p.m

SUNDAY, MARCH 5

WSP098	1:00 p.m. - 1:30 p.m.
WSP102	1:45 p.m. - 2:15 p.m.
WSP106	2:30 p.m. - 3:00 p.m
WSP110	3:15 p.m. - 3:45 p.m.
WSP114	4:00 p.m. - 4:30 p.m.
WSP118	4:45 p.m. - 5:15 p.m

HANDS-ON: THE PATIENT ENCOUNTER: MEDICATION MANAGEMENT

FRIDAY, MARCH 3

WSP003	7:30 a.m. - 8:00 a.m.
WSP007	8:15 a.m. - 8:45 a.m.
WSP011	9:00 a.m. - 9:30 a.m.
WSP015	9:45 a.m. - 10:15 a.m.
WSP019	10:30 a.m. - 11:00 a.m.
WSP023	11:15 a.m. - 11:45 a.m.
WSP027	1:00 p.m. - 1:30 p.m.
WSP031	1:45 p.m. - 2:15 p.m.
WSP035	2:30 p.m. - 3:00 p.m
WSP039	3:15 p.m. - 3:45 p.m.
WSP043	4:00 p.m. - 4:30 p.m.
WSP047	4:45 p.m. - 5:15 p.m

SATURDAY, MARCH 4

WSP051	7:30 a.m. - 8:00 a.m.
WSP055	8:15 a.m. - 8:45 a.m.
WSP059	9:00 a.m. - 9:30 a.m.
WSP063	9:45 a.m. - 10:15 a.m.
WSP067	10:30 a.m. - 11:00 a.m.
WSP071	11:15 a.m. - 11:45 a.m.
WSP075	1:00 p.m. - 1:30 p.m.
WSP079	1:45 p.m. - 2:15 p.m.
WSP083	2:30 p.m. - 3:00 p.m
WSP087	3:15 p.m. - 3:45 p.m.
WSP091	4:00 p.m. - 4:30 p.m.
WSP095	4:45 p.m. - 5:15 p.m

SUNDAY, MARCH 5

WSP099	1:00 p.m. - 1:30 p.m.
WSP103	1:45 p.m. - 2:15 p.m.
WSP107	2:30 p.m. - 3:00 p.m
WSP111	3:15 p.m. - 3:45 p.m.
WSP115	4:00 p.m. - 4:30 p.m.
WSP119	4:45 p.m. - 5:15 p.m

HANDS-ON: THE PATIENT ENCOUNTER: THE DIFFICULT PATIENT

FRIDAY, MARCH 3

WSP001	7:30 a.m. - 8:00 a.m.
WSP005	8:15 a.m. - 8:45 a.m.
WSP009	9:00 a.m. - 9:30 a.m.
WSP013	9:45 a.m. - 10:15 a.m.
WSP017	10:30 a.m. - 11:00 a.m.
WSP021	11:15 a.m. - 11:45 a.m.
WSP025	1:00 p.m. - 1:30 p.m.
WSP029	1:45 p.m. - 2:15 p.m.
WSP033	2:30 p.m. - 3:00 p.m
WSP037	3:15 p.m. - 3:45 p.m.
WSP041	4:00 p.m. - 4:30 p.m.
WSP045	4:45 p.m. - 5:15 p.m

SATURDAY, MARCH 4

WSP049	7:30 a.m. - 8:00 a.m.
WSP053	8:15 a.m. - 8:45 a.m.
WSP057	9:00 a.m. - 9:30 a.m.
WSP061	9:45 a.m. - 10:15 a.m.
WSP065	10:30 a.m. - 11:00 a.m.
WSP069	11:15 a.m. - 11:45 a.m.
WSP073	1:00 p.m. - 1:30 p.m.
WSP077	1:45 p.m. - 2:15 p.m.
WSP081	2:30 p.m. - 3:00 p.m
WSP085	3:15 p.m. - 3:45 p.m.
WSP089	4:00 p.m. - 4:30 p.m.
WSP093	4:45 p.m. - 5:15 p.m

SUNDAY, MARCH 5

WSP097	1:00 p.m. - 1:30 p.m.
WSP101	1:45 p.m. - 2:15 p.m.
WSP105	2:30 p.m. - 3:00 p.m
WSP109	3:15 p.m. - 3:45 p.m.
WSP113	4:00 p.m. - 4:30 p.m.
WSP117	4:45 p.m. - 5:15 p.m

HANDS-ON: THE PATIENT ENCOUNTER: TOTAL BODY SKIN EXAM

FRIDAY, MARCH 3

WSP004	7:30 a.m. - 8:00 a.m.
WSP008	8:15 a.m. - 8:45 a.m.
WSP012	9:00 a.m. - 9:30 a.m.
WSP016	9:45 a.m. - 10:15 a.m.
WSP020	10:30 a.m. - 11:00 a.m.
WSP024	11:15 a.m. - 11:45 a.m.
WSP028	1:00 p.m. - 1:30 p.m.
WSP032	1:45 p.m. - 2:15 p.m.
WSP036	2:30 p.m. - 3:00 p.m
WSP040	3:15 p.m. - 3:45 p.m.
WSP044	4:00 p.m. - 4:30 p.m.
WSP048	4:45 p.m. - 5:15 p.m

SATURDAY, MARCH 4

WSP052	7:30 a.m. - 8:00 a.m.
WSP056	8:15 a.m. - 8:45 a.m.
WSP060	9:00 a.m. - 9:30 a.m.
WSP064	9:45 a.m. - 10:15 a.m.
WSP068	10:30 a.m. - 11:00 a.m.
WSP072	11:15 a.m. - 11:45 a.m.
WSP076	1:00 p.m. - 1:30 p.m.
WSP080	1:45 p.m. - 2:15 p.m.
WSP084	2:30 p.m. - 3:00 p.m
WSP088	3:15 p.m. - 3:45 p.m.
WSP092	4:00 p.m. - 4:30 p.m.
WSP096	4:45 p.m. - 5:15 p.m

SUNDAY, MARCH 5

WSP100	1:00 p.m. - 1:30 p.m.
WSP104	1:45 p.m. - 2:15 p.m.
WSP108	2:30 p.m. - 3:00 p.m
WSP112	3:15 p.m. - 3:45 p.m.
WSP116	4:00 p.m. - 4:30 p.m.
WSP120	4:45 p.m. - 5:15 p.m

For session types, please refer to page 11

FOCUS SESSIONS • 7:30 TO 8:30 A.M.

Open admission to eligible categories, no tuition or ticket

U001 • Merkel Cell Carcinoma: Diagnosis, Management, and Controversies

Room: W304G

Director: Kelly L. Harms, MD, PhD

Invited Speaker: Christopher K. Bichakjian, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Utilize the recent developments in clinical management of Merkel cell carcinoma, including sentinel lymph node biopsy, adjuvant therapy, and systemic therapy, to guide multidisciplinary care of patients with MCC.
2. Identify areas of consensus and controversy regarding the clinical and prognostic characteristics of MCC.

Description
Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma with a higher disease-specific mortality than melanoma. MCC is rare, but the incidence of MCC is increasing in the U.S. Clinical management is challenging due to lack of evidence-based data and wide-ranging treatment recommendations in the literature. Multidisciplinary care is frequently indicated and encouraged by the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines. This session will focus on current concepts in the diagnosis and management of MCC.
• *1.00 Category 1 CME Credit*

U002 • Warts

Room: W311G

Director: Angela Yen Moore, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize clinical manifestations of human papillomaviruses.
2. Recognize the oncogenic potential of certain human papillomaviruses.
3. Discuss current therapies for and preventions against human papillomaviruses.

Description
This session will cover the clinical manifestations of human papillomaviruses (HPV) as well as laboratory tests that will confirm the presence and type of HPV. The oncogenic potential of certain HPV types will be discussed, including co-factors that may contribute to cancer development. The available therapies for HPV will be covered and will include antiviral and immunomodulatory treatments. Prevention strategies will be discussed and will include nine-valent, quadrivalent and bivalent vaccines. • *1.00 Category 1 CME Credit*

U003 • Controversies in Management and Treatment of Cutaneous Lupus and Dermatomyositis Patient

Room: W307D

Director: Benjamin F. Chong, MD, MSc

Invited Speaker: David Franklin Fiorentino, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify controversies over management and treatment of patients with cutaneous lupus and dermatomyositis.
2. Summarize literature with differing views on specific topics on management and treatment of patients with cutaneous lupus and dermatomyositis.
3. Provide treatment and management recommendations based on best practice guidelines.

Description
The purpose of this focus session is to identify and discuss management and treatment controversies of cutaneous lupus and dermatomyositis patients. The intended audience is practicing medical dermatologists. Topics/questions to be discussed include: 1) What are the preferred screening modalities for cancers and interstitial lung disease in dermatomyositis patients? 2) Does smoking negatively affect the therapeutic benefit of anti-malarials? 3) How does one define photosensitivity in a lupus patient? 4) Are myositis antibody profiles helpful in the diagnosis and management of dermatomyositis patients? • *1.00 Category 1 CME Credit*

U004 • Hospital Dermatology

Room: W307B

Director: Alina G. Bridges, DO

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize common and complex dermatologic diseases in hospitalized adult and pediatric patients.
2. Review the differential diagnosis of common and complex dermatologic diseases in hospitalized adult and pediatric patients.
3. Diagnose and manage skin diseases in common and complex dermatologic diseases in hospitalized adult and pediatric patients.

Description
We will discuss the important role of the dermatologist as part of the team caring for hospitalized adult and pediatric patients in the inpatient as well as outpatient day hospital settings. We will present common and unusual cases that are encountered in the hospital and on the consultative service. Valuable diagnostic and therapeutic interventions will be reviewed with an emphasis on clinical pathologic correlation. We will review diagnostic and management issues of both common and serious skin conditions in a case-based, interactive format with audience participation. The target audience is dermatologists in a general and pediatric practice.

This activity has been approved by the American Board of Dermatology (ABD) for up to 10 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 1.00 Category 1 CME Credit

U005 • Lichen Planus and LP Mimickers: Concepts and Controversies

Room: W304C

Director: Kevin C. Wang, MD, PhD

Invited Speaker: Adela Rambi G. Cardones, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize and diagnose cutaneous manifestations of lichen planus and properly evaluate the patient for systemic complications and associated conditions.
2. Develop an expanded toolbox for management of lichen planus.
3. Identify and differentiate common lichen planus mimickers.

Description
This focus session is directed at the practicing medical dermatologist and resident physicians. The session will be an interactive case-based discussion of the various cutaneous manifestations of lichen planus, as well as important lichen planus mimickers. Appropriate workup, screening, treatment, and monitoring of patients will be reviewed, with pearls focused on the challenging cases and refractory disease. Selection of optimal therapy and nuances in the use of systemic agents will be reviewed. The session is designed to provide a high-yield review as well as to highlight important knowledge gaps in lichen planus. • *1.00 Category 1 CME Credit*

U006 • Pain-free Dermatology: Minimizing Discomfort in Procedures for Children and Adults

Room: W304A

Director: Peter A. Lio, MD

Invited Speaker: Alisa McQueen, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Evaluate the evidence for different techniques for pain mitigation in children and adults.
2. Discuss the pros and cons of several techniques for dermatology procedures.
3. Utilize appropriate techniques to procedures in daily practice, including skin biopsy, excision, and cryotherapy.

Description
Procedures remain an integral part of dermatology for both adults and children, and many entail some degree of pain or discomfort. In the past decade, there have been a tremendous number of studies demonstrating evidence for managing pain and anxiety in office and emergency department settings, many of which can be directly applied to dermatology procedures. In this session, we will outline several techniques for minimizing pain and discomfort, review the supporting evidence, and discuss practical application in a dermatology office setting. • *1.00 Category 1 CME Credit*

U007 • Sjögren's for the Dermatologist: The Forgotten Autoimmune Connective Tissue Disease

NEW

Room: W303AB

Director: Gideon Smith, MD

Invited Speakers: Maryanne Makredes Senna, MD, Mariko R. Yasuda, MD

Learning Objectives
Following this session, the attendee should be able to:
1. List the Diagnostic Criteria to Diagnose Sjögren's.
2. Recognize Skin Findings and Important History Associated with Sjögren's.
3. Treat the Oral Mucosal, Ocular, Cutaneous and Hair complications of Sjögren's.

Description
Sjögren syndrome is a systemic chronic inflammatory disorder characterized by lymphocytic infiltrates in exocrine organs. Despite being managed primarily by rheumatologists, patients will often first seek out a dermatologist for help with the cutaneous complications such as unexplained hair loss, dry skin, pruritus without rash, dry oral or genital mucosa and erosions, photosensitivity, Raynaud's or vasculitis. This session reviews: the initial workup and basic diagnostic criteria; the classic skin findings in this disease and features on patient history which may help lead to a diagnosis; and the available treatment recommendations for cutaneous or oral features of this disease. • *1.00 Category 1 CME Credit*

U008 • Simple Tricks and Practical Tips to Optimize the Surgical Experience for You and Your Patients

NEW

Room: W207AB

Director: Elizabeth M. Billingsley, MD

Invited Speakers: Marc D. Brown, MD, Charlene Lam, MD, MPH, Allison Therese Vidimos, MD, RPh

Learning Objectives
Following this session, the attendee should be able to:
1. List the differential diagnosis of facial pigmentation.
2. Recognize the clinical features that distinguish melasma from other common causes of facial pigmentation.
3. Describe new advances in the treatment of facial pigmentation.

Description
As the world becomes more diverse, dermatologists are seeing and treating more patients with pigmentary disorders. This session will review the clinical features of melasma, post-inflammatory hyperpigmentation, acquired dermal melanosis and other causes of facial pigmentation. Exciting new developments in treatment such as oral tranexamic acid and picosecond laser technology will be discussed. The format will be interactive with time for audience participation.
• *1.00 Category 1 CME Credit*

U009 • The Truth About Pediatric Contact Dermatitis

NEW

Room: W311E

Director: Sharon E. Jacob, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Outline the approach to a pediatric patient with recalcitrant dermatitis.
2. Identify the top 25 pediatric contact dermatitis allergens.

Description
In the not too distant past, it was believed that allergic contact dermatitis (ACD) in children was uncommon, we now know that is not the case. A recent study by the Pediatric Contact Dermatitis Registry [PCDR] found that 48% of tested children were found to be contact sensitized, with 65% clinical relevance (rates on par with national published adult data). Notably, ten of the top 25 allergens (40%) have the potential to go undetected if custom testing is not performed. Adequate testing is needed to provide the correct confirmatory diagnosis and guide treatment. • *1.00 Category 1 CME Credit*

U010 • Neutrophilic Dermatoses: An Update

NEW

Room: W315A

Director: William Huang, MD

Invited Speakers: Warren W. Piette, MD, Naveed Sami, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify updates to the literature on select neutrophilic dermatoses (Pyoderma Gangrenosum, Sweet's Syndrome, and Cutaneous Small Vessel Vasculitis).
2. Recognize patients at risk for select neutrophilic dermatoses (Pyoderma Gangrenosum, Sweet's Syndrome, and Cutaneous Small Vessel Vasculitis).
3. Manage complex medical patients with select neutrophilic dermatoses (Pyoderma Gangrenosum, Sweet's Syndrome, and Cutaneous Small Vessel Vasculitis).

Description
During this session participants will hear updates on the diagnosis and management of select neutrophilic dermatoses including Pyoderma Gangrenosum, Sweet's Syndrome, and Cutaneous Small Vessel Vasculitis. This session is directed towards dermatologists and dermatologists in training who manage complex medical dermatologic patients. • *1.00 Category 1 CME Credit*

U011 • Common Complaints Encountered During Dermatologic Surgery: How to Respond and How to Prevent

NEW

Room: W203C

Director: Daniel Brian Eisen, MD

Invited Speakers: Omar Ibrahimi, MD, PhD, Erica Lee, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Determine what it is that is bothering the patient regarding their care.
2. Respond appropriately to patient complaint.
3. Devise strategies to avoid future complaints.

Description
Patient complaints are one of the least favorite parts of performing procedures and practicing medicine. Patient complaints are an opportunity to recognize practice problems and improve patient experiences moving forward. This session will discuss why patients complain, how to respond to complaints, and ways to prevent future ones. Common complaints regarding both cutaneous surgery and cosmetic procedures will be addressed. • *1.00 Category 1 CME Credit*

U012 • Help Your Dermatopathologist Work Smarter for You

NEW MOC

Room: W315B

Director: Abel D. Jarell, MD

Invited Speaker: Tammie C. Ferringer, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify and apply the features of a strong and productive relationship between the clinician and dermatopathologist.
2. Determine when, where, and how to perform an adequate biopsy to achieve the most useful diagnosis for the patient in various situations.
3. Outline the steps involved in performing a skin biopsy from the time the specimen is taken from the patient to the time a dermatopathologist renders a diagnosis.

Description
This session is for clinicians, both in training and established at all levels, to understand the essentials and nuances of a strong relationship between the clinician and dermatopathologist in order to achieve the best diagnosis for the patient. The session will describe all of the behind-the-scenes steps in producing a dermatopathological specimen. Various pitfalls will be identified and explained, and specific biopsy techniques will be reviewed. An emphasis will be placed on melanocytic lesions as well as blistering disorders.

This activity has been approved by the American Board of Dermatology (ABD) for up to 10 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 1.00 Category 1 CME Credit

U013 • Recognition and Management of Allergic Skin Reactions in the Athlete

NEW

Room: W308C

Director: Brian Burke Adams, MD, MPH

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize the morphologic features and patterns that should raise suspicion for athletically related cutaneous allergy.
2. Demonstrate numerous prevention strategies to prevent allergic skin reactions in athletes.

Description
An athlete's skin continuously endures exposure to allergens during sporting activities. The athletic venue, protective equipment, sporting implements, medications and even the sport itself induce and foster cutaneous reactions. This brief lecture reviews the epidemiology of various entities especially as they relate to specific sports. This lecture will enable participants to recognize the morphologic features and patterns that should raise suspicion for sports-related cutaneous allergy. Sports-related urticaria, contact dermatitis, and exercise-induced anaphylaxis specifically will be discussed. • *1.00 Category 1 CME Credit*

U014 • Update: New Modalities in the Diagnosis, Staging and Prognostication of Melanocytic Lesions

NEW

Room: W308A

Director: Robert G. Phelps, MD

Invited Speaker: Rajendra Singh, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose and stage difficult melanocytic lesions more accurately.
2. Assess the prognosis and recommend follow up for patients with these difficult melanocytic lesions.

Description
The distinction between benign and malignant melanocytic lesions is difficult. In addition to routine histology, Immunohistochemical markers such as HMB45, melan-A, Ki-67 can help arrive at the correct diagnosis. These same markers can also be used to appropriately stage both primary melanomas and lymph node dissections when performed. New methods using cytogenetics and molecular techniques such as PCR, FISH and comparative genomic hybridization are also now widely available to aid in these assessments. • *1.00 Category 1 CME Credit*

DISCUSSION GROUP • 9 TO 11 A.M.

Open admission to eligible categories, no tuition or ticket

D001 • How to Create an Unforgettably Positive Patient Experience

Room: W304C

Director: Leonard Harry Goldberg, MD

Co-Director: Steven Kenneth Shama, MD, MPH

Learning Objectives
Following this session, the attendee should be able to:
1. Identify features within your office to make the patient encounter positive and unforgettable.
2. Develop methods to make your patients happy and appreciative about their encounter with you and your office.
3. Apply these techniques to cosmetic, academic, and general dermatology practice.

Description
This session will be in a format of brief lectures with questions and discussions with the audience. We will focus on identifying features in the patient-oriented practice, including interpersonal skills, communication techniques, subliminal messages, a friendly office atmosphere, a pleasant clinical experience, that will help attract and keep the many different kinds of patients we see. We will discuss dealing with difficult and high-end patients, including obtaining and maintaining patient trust. • *2.00 Category 1 CME Credits*

FORUMS • 9 TO 11 A.M.

Open admission to eligible categories, no tuition or ticket

F001 • Oral Signs of Systemic Disease

NEW

Room: W202C

Director: Nasim Fazel, MD, DDS

Invited Speakers: Jennifer L. Hand, MD, Ginat W. Mirowski, MD, DMD, Roy Steele Rogers, III, MD, Rochelle R. Torgerson, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize the oral clinical findings associated with genetic, bacterial, nutritional, and gastrointestinal disease.
2. Recognize oral signs of important connective tissue diseases including Sjögren's syndrome, systemic lupus erythematosus and systemic scleroderma.

Description
The prompt detection of oral signs and symptoms that may suggest underlying systemic disease can be invaluable to the clinician in reaching a diagnosis. In this forum, we will discuss the oral manifestations of a broad array of systemic illnesses including genetic, bacterial, nutritional, gastrointestinal, and autoimmune and connective tissue diseases. This will include an overview of associated key signs and salient features to look for on oral mucosal examination and relevant questions in the patient history. • *2.00 Category 1 CME Credits*

F002 • Giving the Best Presentation of Your Life: Every Time!

Room: W304G

Director: Hilary E. Baldwin, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Prepare an exciting and powerful presentation that will captivate, educate and excite your audience.
2. Recognize that each talk is a performance that must be accompanied by careful script writing, rehearsal, costumes and lighting.
3. Apply your knowledge to a personalized, confident presentation that is memorable and retained.

Description
As medical professionals, we are frequently called upon to give presentations to students, residents, colleagues and patients. Often we are asked to deliver material that is not necessarily of our choosing. It is occasionally prepared for us: dull, fact-ridden, locked and unable to be edited. This session is intended for anyone faced with public presentations who desires to make any talk an exciting and memorable performance. Success, measured by audience enjoyment and participation and retention of content upon conclusion of the talk, is achieved through passion, preparation and delivery. We will discuss making the talk your own, preparation and rehearsal of the presentation such that the content delivered is captivating and memorable. The goal is to face every talk with enthusiasm and confidence resulting in the best presentation, every time. • *2.00 Category 1 CME Credits*

F003 • Coding and Office Management

Room: W311E

Director: Alexander Miller, MD

Invited Speakers: Murad Alam, MD, Mark D. Kaufmann, MD, Howard Wooding Rogers, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Appropriately pair CPT procedural codes with corresponding ICD-10 diagnostic codes.
2. Select optimal modifier codes for various coding circumstances.
3. Identify and employ various coding resources.

Description
This session is designed to provide medical professionals with an interactive, audience response system facilitated discussion of various diagnostic and procedural coding challenges. A series of clinical and coding vignettes will be presented.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

F004 • Management of Patients with Melanocytic and Non-melanocytic Neoplasms

NEW

Room: W203C

Director: Harold S. Rabinovitz, MD

Co-Director: Ashfaq A. Marghoob, MD

Invited Speakers: Harald Kittler, MD, Margaret C. Oliviero, NP, MSN

Learning Objectives
Following this session, the attendee should be able to:
1. Formulate management plans for patients with melanoma and other pigmented lesions.
2. Describe how devices incorporate into daily dermatology practice.
3. Identify benefits using newer devices and techniques to aid in diagnosis.

Description
Utilizes visual inspection and diagnostic devices and techniques such as total body photography, dermoscopy, mole mapping, and confocal microscopy. This session will focus on the role of imaging devices in the management of various skin neoplasms. The course will utilize cases to illustrate these points. The session is interactive with a voting system. The session is geared to providing the clinician practical information that can be used in formulating management plans in caring for patients. The targeted audience includes pigmented lesion specialists, dermoscopists, confocalists, and dermatopathologists. • *2.00 Category 1 CME Credits*

F005 • FDA Hot Topics: The Evolving Regulatory Landscape

Room: W311G

Director: Markham C. Luke, MD, PhD

Invited Speakers: Robert Lionberger, Kendall Marcus, MD, Laura Nicole Marquart, MD, Sam Raney

Learning Objectives
Following this session, the attendee should be able to:
1. Summarize key issues that are currently relevant to both FDA and to dermatology as a medical discipline.
2. Recognize the regulatory approaches that FDA is taking to address dermatologically relevant public health concerns.
3. Name some of the regulatory entities within FDA who are relevant to dermatological public health issues.

Description
Current issues relevant to the medical and surgical discipline of dermatology will be discussed by FDA regulators, including representation from both drug product and medical device regulators. A focus this year will be generic topical dermatological drug products. Background on what are generic drugs, factors that affect their approvability and availability, and the development of regulatory approaches to evaluating bio-equivalence for complex drug products will be presented. An update will be given regarding current challenges and novel approaches for evaluation of bio-equivalence for topical drug products. • *2.00 Category 1 CME Credits*

F006 • Invention and Entrepreneurialism in Dermatology: Stories of Success and Reality Check

Room: W307B

Director: Brian D. Zelickson, MD

Invited Speakers: Richard Rox Anderson, MD, Clark C. Otley, MD, Mitchell E. Schwartz, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Examine personal experiences of invention and entrepreneurialism in dermatology.
2. Discuss the potential benefits and pitfalls of invention and entrepreneurialism as a practicing dermatologist.

Description
The presenting dermatologist in this session will share their extensive entrepreneurial experiences with the audience, including the potential pitfalls and ethical considerations of a practicing physician pursing entrepreneurial endeavors. • *2.00 Category 1 CME Credits*

F007 • Hot Topics in Acute and Inpatient Pediatric Dermatology

Room: W311A

Director: Elena B. Hawryluk, MD, PhD

Invited Speakers: Lisa Arkin, MD, Diana H. Lee, MD, Adnan Mir, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Formulate a differential diagnosis for challenging pediatric dermatoses seen in the urgent access, inpatient, or emergency department setting.
2. Recognize the clinical clues including classic findings used to diagnose pediatric dermatoses including the newborn period, and discuss advancements in diagnostic approaches.
3. Select therapeutic and management options based on the best available literature and explore an approach to counseling parents on pediatric dermatoses.

Description
This session will present a case-based overview of common pediatric dermatology emergencies including infections and vascular diseases, and address "hot topics" including the diagnostic workup for blistering diseases in the newborn and the management of severe drug eruptions. The case-based format will create an active learning environment relevant to the dermatology trainee or clinician seeking additional exposure to pediatric dermatology. The session will offer practical tips for evaluation, diagnosis, and management of pediatric dermatoses.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. • 2.00 Category 1 CME Credits

F008 • Controversies in Vitamin D

Room: W415B

Director: Maryam Mandana Asgari, MD

Invited Speakers: Barbara Ann Gilchrest, MD, Henry W. Lim, MD, Martin A. Weinstock, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Counsel patients on vitamin D recommendations, including supplementation and photoprotection.
2. Discuss vitamin D's role in skin health including immunity and carcinogenesis.
3. Examine adverse effects profile of vitamin D supplementation.

Description
Vitamin D remains a hot topic, with possible health benefits continuing to emerge. Controversy has swirled over the conflicting evidence of disease protective relationships and the impact of photoprotection on sufficient vitamin D levels. This forum will discuss controversies in vitamin D, including a discussion of the evidence surrounding benefits, risks, and current recommendations for maintaining sufficient vitamin D. This will include a discussion of the relationship of vitamin D with immunity, skin cancer, hair, and the Institute of Medicine supplement recommendations.
• *2.00 Category 1 CME Credits*

F009 • Skin and Systemic Malignancy

Room: W315B

Director: Vincent Liu, MD

Invited Speakers: April W. Armstrong, MD, MPH, Jonathan A. Dyer, MD, Bernice Kwong, MD, Darrell S. Rigel, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify skin manifestations of systemic malignancy presenting as various paraneoplastic dermatoses, genodermatoses, and skin metastases.
2. Discuss the current state of knowledge of systemic involvement by melanoma in the age of recent diagnostic updates and new therapeutics.
3. Describe the risk of malignancies from dermatologic therapeutics, with particular attention to the biologics.

Description
As "window to the soul," the skin can reveal systemic malignancy via cutaneous metastases, genodermatoses, or paraneoplastic dermatoses. Conversely, therapeutics for skin conditions can increase risk for internal malignancy. As arguably the most significant cutaneous malignancy, melanoma receives specific attention for its metastatic potential, current diagnostic advances, and recent therapeutic breakthroughs. Specific topics discussed in the forum include the following: paraneoplastic dermatoses, genodermatoses, cutaneous metastases, systemic implications of melanoma diagnosis and therapeutics, and systemic malignancy risk of dermatologic medications. The use of patient cases and audience participation will facilitate session attendees' ability to better formulate practical plans for appropriate work-up and therapy in patients with suspected skin signs of systemic malignancy. This forum is designed for both clinicians in practice and those in training. • *2.00 Category 1 CME Credits*

F010 • Highlights From the Medical and Pediatric Literature

Room: W209C

Director: Eric Winfield Hossler, MD

Invited Speakers: Katherine C. Marks, DO, Matthew Lee Palmer, MD, Howard B. Pride, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss relevant Dermatology research and publications from outside the *JAAD* and *JAMA Dermatology*.
2. Utilize new and emerging therapies for Dermatologic disease in both children and adults.
3. Recognize new disease and disease associations.

Description
It is impossible for practitioners to keep up with all the relevant published literature in the field of Dermatology. In this session, we plan to discuss and provide summaries of some of the most important and relevant publications from outside the *JAAD* and *JAMA Dermatology*. Both adult and pediatric Dermatology is discussed. Articles are pulled from journals such as *NEJM, JAMA, Journal of Investigative Dermatology, British Journal of Dermatology, Pediatrics, Pediatric Dermatology, JAMA Pediatrics*, and many others. • *2.00 Category 1 CME Credits*

F011 • Malignancy-Associated Dermatomyositis

NEW

Room: W304E

Director: Anthony Fernandez, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss the association between dermatomyositis and malignancy.
2. Define strategies for malignancy screening in newly diagnosed dermatomyositis patients.
3. Outline treatment strategies for patients with malignancy-associated dermatomyositis.

Description
The association between malignancy and Dermatomyositis (DM) is well-known. Given the increased malignancy risk among DM patients, diagnosis of DM typically triggers malignancy screening. However, malignancy screening protocols often vary from institution-to-institution, department-to-department, and even from clinician-to-clinician within the same department, as do treatment strategies for Malignancy-associated DM (MADM) patients. With ongoing healthcare changes, however, high value and evidence-based malignancy screening and treatment recommendations are important for these patients. Here we review the association between malignancy and DM, discuss strategies for creating an evidence-based malignancy screening protocol for DM patients, and outline treatment strategies specifically for MADM patients. • *2.00 Category 1 CME Credits*

F012 • Challenging Melanocytic Tumors: Test Your Diagnostic and Therapeutic Skills

Room: W206C

Director: Jennifer Y. Lin, MD

Invited Speakers: Carlos Prieto-Granada, Labib Zakka, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize clinicopathologic correlations in challenging melanocytic lesions.
2. Utilize the latest molecular and genetic modalities to aid in the diagnosis of challenging melanocytic tumors.
3. Apply American Joint Committee on Cancer (AJCC) 8th edition guidelines to the treatment of melanoma.

Description
In this highly interactive session, participants will have the opportunity to test their knowledge of challenging melanocytic lesions based on clinical and pathologic images. We utilize this case-based approach to inform the clinician, resident or student on the latest molecular, genetic and epidemiologic data underpinning our understanding of the behavior and prognosis of these difficult lesions. Participants will learn how to recognize, classify and appropriately treat challenging lesions such as Spitz tumors, amelanotic melanomas, and cellular blue nevi. Finally, the AJCC 8th edition guidelines for melanoma will be overviewed and an approach to therapeutics will be discussed. • *2.00 Category 1 CME Credits*

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. • 2.00 Category 1 CME Credits

F013 • Caring for the Cancer Patient: Challenging Cases from Inpatient and Outpatient Oncodermatology Consultative Services

Room: W312A

Director: Jennifer N. Choi, MD

Invited Speakers: Jonathan Cotliar, MD, Mario E. Lacouture, MD, Nicole LeBoeuf, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify possible challenging side effects of chemotherapy and/or radiation and discuss potential management strategies.
2. Discuss possible challenging long-term manifestations of cancer treatment, including graft-versus-host disease after stem cell transplant, and discuss potential management strategies.
3. Identify potential infectious diseases that can occur in the setting of immunosuppression due to cancer therapy, as well as manifestations of cutaneous metastases.

Description
Dermatologic issues are one of the most common complications in patients undergoing cancer therapy. Knowledge of mucocutaneous toxicities to chemotherapy and radiation, neoplasms in cancer patients (particularly cutaneous metastases), paraneoplastic syndromes, complications of stem cell transplant, and infectious diseases of the immunosuppressed is critical in distinguishing the numerous dermatologic conditions that can arise in a patient undergoing cancer treatment. This session will cover these key topics in the field of Oncodermatology through illustrative and challenging cases seen at different academic cancer centers to enhance the knowledge of dermatologists, residents, and other practitioners caring for cancer patients. • *2.00 Category 1 CME Credits*

F014 • Dermatologic Care for a Veteran Patient

NEW

Room: W308A

Director: Jo-Ann Latkowski, MD

Invited Speakers: Ali N. Dana, MD, PhD, Arielle Rachel Nagler, MD, Jessica C. Newman, MD, Mary L. Stevenson, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize unique aspects in the Veterans Affairs (VA) Health Care System.
2. Describe challenging dermatological conditions in veterans.

Description
Veterans make up a unique patient population secondary to their military service and the health care system where they obtain their care. During this forum, participants will learn about the distinct aspects of Veterans Administration (VA) healthcare system including telehealth initiatives, the VA Choice Program and Patient Safety and Quality programs. In addition, we will review and discuss challenges in treating veteran patients with dermatologic conditions from their military service.
• *2.00 Category 1 CME Credits*

F015 • Imaging in Dermatology

NEW

Room: W207A

Director: Anthony Rossi, MD

Invited Speakers: Allan C. Halpern, MD, Kishwer S. Nehal, MD, Milind Rajadhyaksha, PhD, Hilda Stambuk

Learning Objectives
Following this session, the attendee should be able to:
1. Describe the current and future state of digital cutaneous photography and imaging.
2. Compare noninvasive imaging techniques such as confocal microcopy and cutaneous ultrasound.
3. Utilize different radiologic imaging modalities for cutaneous neoplasms and staging.

Description
This session will cover the spectrum of cutaneous imaging. The current state and future of digital photography and mole mapping will be discussed and how it can be integrated into practice. The emerging noninvasive invasive cutaneous imaging tools such as confocal microscopy and ultrasound will be reviewed. In addition, radiological imaging including CT and MRI will be discussed to determine how and when such should be utilized for cutaneous neoplasms.
• *2.00 Category 1 CME Credits*

WORKSHOP • 9 TO 11 A.M.

Tuition fee and ticket required for admission

W001 • Self-assessment: Cosmetic Dermatology

Room: W300

Director: Keyvan Nouri, MD

Invited Speakers: Murad Alam, MD, Kimberly J. Butterwick, MD, Hassan I. Galadari, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Assess the use of neurotoxins, fillers, and lasers.
2. Measure the use of lasers in cosmetic dermatology.

Description
Speakers will present case-based cosmetic dermatology questions and review the answers. A good session for both general and cosmetic dermatologists preparing for the re-certification exam, this session presents 34 case-based questions that apply towards MOC Component 2 self-assessment requirements. Answers are recorded via electronic Audience Response System (ARS), followed by discussion. Immediate, anonymous feedback allows attendees to assess their knowledge and identify areas for further self-directed study. In order to fully participate, it is imperative that participants arrive on time.

This activity has been approved by the American Board of Dermatology for up to 34 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • *2.00 Category 1 CME Credits*

COURSES • 9 A.M. TO 12 P.M.

Tuition fee and ticket required for admission

C001 • Structure and Function of the Skin: Development, Cell Biology, and Skin Structure

Room: W315A

Director: John J. DiGiovanna, MD

Invited Speakers: Radhika Atit, PhD, Andrew P. Kowalczyk, PhD, Jouni J. Uitto, MD, PhD, Kim B. Yancey, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe the embryologic origin, patterning and differentiation of the skin, and the role of keratinocyte differentiation in cornification
2. Recognize the different epidermal cell-cell and cell-matrix adhesion structures and components of the extracellular dermal matrix
3. Predict the diseases resulting from the failure of these skin components

Description
One module of a three-part curriculum discussing the normal structure and function of cells and tissues within the skin, and how their impairment leads to representative diseases. This module focuses on skin embryology, differentiation and patterning; the broad functions and activities of keratinocytes; stratum corneum formation (cornification); epidermal cell-cell and cell-matrix adhesion structures; and the extracellular matrix. Examples will be shown of how skin biology is being translated into patient care. The curriculum is a basic overview of skin biology for residents and dermatologists. Bring a print or electronic copy of the handouts to facilitate following the lectures. • *3.00 Category 1 CME Credits*

C002 • Dermatology Review: General Dermatology and Practice Management

Room: W209AB

Director: Gary Goldenberg, MD

Invited Speakers: Robert T. Brodell, MD, Dirk Michael Elston, MD, Mark D. Kaufmann, MD, Mark Lebwohl, MD, Clifford Warren Lober, MD, JD, Darrell S. Rigel, MD, Daniel M. Siegel, MD, MS, Linda F. Stein Gold, MD, Kenneth J. Tomecki, MD, Marta Jane Van Beek, MD, MPH

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize new developments in medical and surgical dermatology.
2. Evaluate new treatment options for dermatologic conditions, including acne, rosacea, psoriasis, eczema, and infectious diseases.
3. Assess best practices in practice management, including billing, coding, EHR, and new payment models.

Description
This course will comprehensively review new developments in medical, cosmetic and surgical dermatology. Innovation in diagnosis and treatment of common dermatologic conditions, such as skin cancer, actinic keratosis, psoriasis, eczema, acne, contact dermatitis, infectious diseases in dermatology, and rosacea will be reviewed. New developments in cosmetic dermatology and best practices in surgical and cosmetic dermatology will be reviewed. Practice management, including billing, coding, electronic health records, and new payment models. • *3.00 Category 1 CME Credits*

C003 • Botulinum Toxin: Video Instruction and Live Panel Discussion

Room: W314B

Director: David M. Ozog, MD

Invited Speakers: Jean D.A. Carruthers, MD, Suneel Chilukuri, MD, Joel Lee Cohen, MD, Sue Ellen Cox, MD, Dee Anna Glaser, MD, Derek H. Jones, MD, Seth L. Matarasso, MD, Gary D. Monheit, MD, Nowell J. Solish, MD, Susan H. Weinkle, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify nuanced targets for botulinum toxin injection through expert evaluation and analysis.
2. Apply video lessons and pearls to determine optimal treatment sites and doses.
3. Inject safely and manage potential complications.

Description
Master injectors from North America will share video techniques and pearls. Audience members will try and predict injection locations and botulinum toxin doses in this interactive session. Presenters will challenge you with novel approaches which can be used immediately in your practice. Expect to learn several pearls from this expert team.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

---

SYMPOSIA • 9 A.M. TO 12 P.M.

Open admission to eligible categories, no tuition or ticket

S001 • New and Emerging Technologies in Dermatology

Room: W307D

Director: Jane Margaret Grant-Kels, MD

Invited Speakers: David G. Brodland, MD, Justin J. Finch, MD, Pedram Gerami, MD, Allan C. Halpern, MD, Margaret C. Oliviero, NP, MSN, Giovanni Pellacani, MD, Harold S. Rabinovitz, MD, Eric Robert Tkaczyk, MD, MS, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Apply reflectance confocal microscopy in dermatology practice to reduce unnecessary biopsies.
2. Compare the principles and capabilities of multispectral imaging, Raman spectroscopy, photoacoustic imaging, nonlinear imaging, 3 dimensional total body photography, genetic markers, and immunostaining in the diagnosis of malignant diseases in the skin.
3. Describe how cutting edge applications for lasers are available in medical dermatology including laser assisted drug delivery.

Description
The standard of care for skin cancer diagnosis is rapidly evolving. New technologies including reflectance confocal microscopy, new immunostains, techniques to identify genetic markers, 3 dimensional total body photography, multispectral imaging, Ramon spectroscopy, photoacoustic imaging and nonlinear imaging will be reviewed and discussed. Finally, we will discuss cutting edge applications for lasers including laser assisted drug delivery and laser remodeling of scar contractures. Ample opportunity for questions from the audience will be made available.
• 3.00 Category 1 CME Credits

S002 • Advances in Medical Dermatology

Room: W208A

Director: Victoria P. Werth, MD

Co-Director: Kanade Shinkai, MD, PhD

Invited Speakers: Edward W. Cowen, MD, David Franklin Fiorentino, MD, PhD, Robert Micheletti, MD, Eric Lawrence Simpson, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe important developments in complex medical dermatology.
2. Order appropriate diagnostic testing and therapeutic monitoring in patients with complex medical diseases with cutaneous presentations, including those on systemic medications.
3. Formulate therapeutic strategies to manage complex medical dermatology disease, including connective tissue disease, neutrophilic dermatoses, autoinflammatory disease, and atopic dermatitis.

Description
Complex medical dermatology is a field that is evolving at an incredible pace, with many recent developments in diagnostic evaluation and treatments. The focus of this symposium will be on new approaches to evaluating and treating atopic dermatitis, pyoderma gangrenosum, severe drug eruptions, and autoimmune skin diseases. The safe implementation and monitoring of new modes of treatment will also be discussed. The multidisciplinary management of patients with complex medical dermatologic conditions will be presented, including insights learned from the role of dermatology consultants in the inpatient setting. • *3.00 Category 1 CME Credits*

S003 • Role of Dermatologist in Management of Skin Disease in Solid Organ Transplant Recipients

Room: W308C

Director: Nathalie C. Zeitouni, MD

Invited Speakers: Joi B. Carter, MD, Oscar Colegio, MD, PhD, Carrie C Coughlin, MD, Allison Hanlon, MD, PhD, Drew Kurtzman, MD, Stephanie Liu, MD, Paul Nghiem, MD, PhD, Gyorgy Paragh, MD, PhD, Faramarz H. Samie, MD, Amit Sharma, MD, Ally-Khan Somani, MD, PhD, Thomas Stasko, MD, Eric Robert Tkaczyk, MD, MS, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify common and unusual skin disease and skin cancers in organ transplant patients.
2. Discuss the use of chemoprevention measures, field therapy and non invasive imaging in managing solid organ transplant recipients.
3. Develop a management plan for treating certain aggressive skin cancers in solid organ transplant patients.

Description
This session highlights the management of skin disease and skin cancer in adult and pediatric organ transplant recipients and is targeted to the general dermatologist. Medical and surgical options as well as field therapies, chemoprevention and new technologies such as noninvasive imaging will be presented. • *3.00 Category 1 CME Credits*

S004 • Therapeutic Hotline

Room: Chapin Theatre

Director: Seemal Desai, MD

Invited Speakers: Jean L. Bolognia, MD, Boni E. Elewski, MD, Hassan I. Galadari, MD, Pearl E. Grimes, MD, Mark Lebwohl, MD, Darrell S. Rigel, MD, Theodore Rosen, MD, Diane M. Thiboutot, MD, Antonella Tosti, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Utilize new therapeutics in treating patients with psoriasis, actinic keratoses, acne, rosacea, onychomycosis, dyspigmentation, hair disorders and cosmetic concerns.
2. List new therapeutics for melanoma patients and recognize situations when they are required.
3. Identify and analyze newer research paradigms to treat common medical dermatological conditions with new cutting edge therapies.

Description
This session will review new and emerging therapeutics for patients with psoriasis, melanoma, actinic keratoses, acne, rosacea, dyspigmentation, hair loss, onychomycosis and updates in cosmetic dermatology. The newest and what's hot in dermatology ranging from medical to cosmetic to surgical dermatology will be addressed. There will also be a discussion on sunscreens, and selecting the best photoprotection for UVA and UVB coverage. • *3.00 Category 1 CME Credits*

S005 • Outbreak! Public Health Threats in Clinical Dermatology

Room: W303A

Director: Wingfield Ellis Rehmus, MD, MPH

Invited Speakers: Justin P. Bandino, MD, Benjamin Kaffenberger, MD, Kenneth A. Katz, MD, MSc, MSCE, Scott A. Norton, MD, MPH, Misha Rosenbach, MD, Erin M. Warshaw, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize patterns that suggest patient(s) skin conditions may represent a new or emerging disease within a community.
2. Develop a plan for responding to and reporting cases that present as part of an outbreak.
3. Assess risk for development of health challenges among patients due to changes in exposures and the environment.

Description
In this session, participants will examine opportunities for dermatologists to recognize, respond to, and report an index case of a disease outbreak that threatens some aspect of the nation's public health. We review real examples where dermatologists have participated in - or led- the medical and public health response to cases of emerging (and re-emerging) infectious diseases, bioterrorism, food-borne illness, nutritional deficiencies, contact dermatitis, occupational illnesses, and risky fads. Most importantly, we provide the cognitive framework to identify these situations and detail how and when one should notify public health authorities. • *3.00 Category 1 CME Credits*

S006 • Wounds and Ulcers: The Good, the Bad and the Ugly

Room: W415D

Director: Robert S. Kirsner, MD, PhD

Invited Speakers: Afsaneh Alavi, MD, Richard Rox Anderson, MD, Hadar Lev-Tov, MD, David J. Margolis, MD, Gary Sibbald, MD, Marjana Tomic-Canic, PhD, Jill S. Waibel, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify new approaches to treating difficult and non-healing wounds.
2. Assess best treatment options for treating wounds.

Description
This session will cover hot topics in wound healing. The epidemiology and assessment of chronic wounds will be discussed. Established and novel approaches to healing will be highlighted. Special emphasis will be given to use of acellular matrices, new skin grafting tools, miRNA in wound healing, use of systemic medications to speed healing and the potential of better understanding miRNA to improve healing. Difficult wound problems such as pyoderma gangrenosum will also be discussed.
• *3.00 Category 1 CME Credits*

S007 • Cosmetics

Room: W415A

Director: Diane S. Berson, MD

Invited Speakers: Valerie D. Callender, MD, Zoe Diana Draelos, MD, Patricia Farris, MD, Pearl E. Grimes, MD, Arianne Shadi Kourosh, MD, MPH, Nicole Elaine Rogers, MD, Heidi A. Waldorf, MD, Jonathan Zippin, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify different causes of aging of the skin, and choose appropriate skin and hair care for their patients.
2. Recognize cosmetic allergic reactions, and various ways to non-invasively evaluate efficacy of cosmeceuticals including OCT. Finally, hair care and various beauty fads that patients are reading about will be presented

Description
Compare different options for anti-aging, pigmentation/brightening, and cosmetically oriented photo protection, as well as the role of nutritional agents. • *3.00 Category 1 CME Credits*

S008 • Key Surgical Principles We All Should Know

Room: W304A

Director: Sarah T. Arron, MD, PhD

Co-Director: Zaineb Hassan Makhzoumi, MD

Invited Speakers: Conroy Chow, MD, Eva A. Hurst, MD, Shang I. Brian Jiang, MD, Jayne S. Joo, MD, Charlene Lam, MD, MPH

Learning Objectives
Following this session, the attendee should be able to:
1. Identify key anatomical landmarks and danger zones to minimize risk to underlying structures.
2. Apply specific surgical approaches when working on complex sites.
3. Utilize key design and execution techniques to perform skin grafts and flaps.

Description
This session will address key surgical principles that apply to cutaneous procedures. Concepts that are critical to beginning surgeons as well as those with more experience will be covered. Surgical approaches for procedures in specific anatomic areas, important concepts in cosmetic surgery, and key tips for executing skin grafts and flaps will be presented. • *3.00 Category 1 CME Credits*

COURSES • 9 A.M. TO 4 P.M.

Tuition fee and ticket required for admission

C004 • Advanced Dermoscopy

Room: W204C

Director: Orit Markowitz, MD

Invited Speakers: Giuseppe Argenziano, MD, Ralph P. Braun, MD, Horacio Antonio Cabo, MD, Cristina Carrera, MD, PhD, Joel Claveau, MD, Allan C. Halpern, MD, Rainer Hofmann-Wellenhof, MD, Natalia Jaimes, MD, Harald Kittler, MD, Aimilios Lallas, MD, MSc, PhD, Joseph Malvehy, MD, Michael Armando Marchetti, MD, Ashfaq A. Marghoob, MD, Scott Menzies, MBBS, PhD, Nir Nathansohn, MD, Margaret C. Oliviero, NP, MSN, Giovanni Pellacani, MD, Susana Puig, MD, Harold S. Rabinovitz, MD, Alon Scope, MD, H. Peter Soyer, MD, Wilhelm Stolz, MD, Iris Zalaudek, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Analyze and manage difficult situations using dermoscopy.
2. Use diagnostic strategies and integrate dermoscopy into your decisions.

Description
This course is recommended for advanced users of dermoscopy. It will cover many dermoscopy topics as well as attempt to integrate dermoscopy into broader management concepts. Other non-invasive devices and mobile applications will also be covered. • *6.00 Category 1 CME Credits*

C005 • Essential Dermatopathology: What You Need to Know for Clinical Practice: Neoplastic

Room: W305A

Director: Beth S. Ruben, MD

Invited Speakers: John Andrew Carlson, MD, Rosalie Elenitsas, MD, Lynne J. Goldberg, MD, Jacqueline M. Junkins-Hopkins, MD, Hideko Kamino, MD, Jinah Kim, MD, PhD, Philip E. LeBoit, MD, Timothy H. McCalmont, MD, Thaddeus W. Mully, MD, Laura Pincus, MD, Ronald P. Rapini, MD, Omar P. Sangueza, MD, Kevin P. White, MD, Iwei Yeh, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize the best dermatopathologic approach to cutaneous neoplasia.
2. Distinguish benign from malignant neoplasms.
3. Identify the lineage of the neoplasm.

Description
This one day course will cover the common (and some of the more uncommon) neoplasms, both benign and malignant, that have been described in the skin. Clinical pathologic correlation and the algorithmic method using pattern analysis will be reviewed. Various special stains, immunoperoxidase stains and molecular pathology techniques will be reviewed at the onset and applied to each topic where appropriate. At the end of the day the audience should have a good grasp of neoplasms that impact the skin in preparation for certification examinations and clinical practice. • *6.00 Category 1 CME Credits*

C006 • Conquer the Boards: An Experiential Review

Room: W414A

Director: Jennifer Lucas, MD

Invited Speakers: Jennie T. Clarke, MD, Anthony Fernandez, MD, Esteban Fernandez Faith, MD, Natasha Atanaskova Mesinkovska, MD, PhD, Michelle B. Tarbox, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify strengths and weaknesses in one's knowledge base for the dermatopathology and multiple choice sections of the ABD certification exam and make improvements as needed.
2. Familiarize participants with the ABD certification exam format.
3. Practice time management techniques pertinent to a timed exam.

Description
This Board Prep Course will allow attendees a hands-on experience of taking a simulated, shortened version of the ABD certification exam. Attendees will be able to practice their timing, increase their comfort with the exam format, and identify areas of weakness in their knowledge base. The morning session will consist of two sections: dermatopathology glass slides and a multiple choice section which will encompass digital images and written questions. In the afternoon, expert faculty will review the answers of the exam, providing high yield information for the certification exam. Residents attending this course should walk away with a better understanding of the pace and structure of the exam. • *6.00 Category 1 CME Credits*

SYMPOSIA • 9 A.M. TO 5 P.M.

Open admission to eligible categories, no tuition or ticket

S009 • Gross and Microscopic Symposium

Room: W306A

Director: Jose Dario Martinez, MD

Co-Director: Natasha Atanaskova Mesinkovska, MD, PhD

Invited Speakers: Javier Alonso-Llamazares, MD, Adam J. Friedman, MD, Christopher C. Gasbarre, DO, Minerva Gomez, MD, Michelle B. Tarbox, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Review and interpret a broad variety of dermatological conditions through multiple clinical cases, with clinical, surgical, and pathological correlations.
2. Recognize a wide variety of dermatological entities with direct applicability to patient care.
3. Increase their diagnostic and treatment skills.

Description
Two-full day symposium entails 192 presentations, which will cover the gamut of clinical dermatology, predicated on clinical/pathological correlation, with attention to new and interesting observations. Presentations will be grouped into several clinical categories allowing attenders to focus on particular conditions/entities. Each presentation will be five (5) minutes. As such, symposium is lively and fast paced, hopefully "with something for everyone" of the audience. Presentations will be clinically germane and applicable to patient care. Symposium is open to all AAD members, non-members, residents/fellows, and medical students. • *16.00 Category 1 CME Credits*

FORUMS • 1 TO 3 P.M.

Open admission to eligible categories, no tuition or ticket

F016 • Emerging Laser and Aesthetic Technology

Room: W208A

Director: M. Christine Lee, MD, MPH

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss clinical applications of current devices.
2. Recognize the latest cutting-edge technologies.

Description
There has been a rapid proliferation of laser and aesthetic technology over the last several years. Examples include innovations in lasers, light-based, radiofrequency, ultrasound, and combination devices. An overview of the evolution of laser treatments for medical and cosmetic purposes, invasive and noninvasive approaches, high-tech and low-tech techniques will be presented.
New and emerging technologies will be examined and evaluated for their potential roles in the physician's armamentarium, and they will be compared to pre-existing older technology. Special emphasis will be placed on devices used in common cosmetic dermatologic challenges. One of the goals of this session is to help the practitioner approach the decision making process of choosing and utilizing laser and aesthetic technology with greater awareness and knowledge. New and emerging technologies will include a new intraoral laser that treats nasolabial folds, tattoo removal (new picosecond and nanosecond lasers with higher power), skin tightening (new lasers that can tighten any part of the body including mucosal regions which can be used for vaginal rejuvenation, comparing monopolar with unipolar radiofrequency, infrared light sources, ultrasound, needle delivery devices), all types of fractional resurfacing, and comparisons of the newest fractional CO2 lasers, body contouring, and fat melting devices. • *2.00 Category 1 CME Credits*

F017 • Managing Melanoma

Room: W304G

Director: David G. Brodland, MD

Invited Speakers: Emily Y. Chu, MD, PhD, Pedram Gerami, MD, Brent Kirkland, MD, Joy H. Kunishige, MD, Christopher James Miller, MD, John A. Zitelli, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize the importance of educating the patient diagnosed with melanoma and in providing a patient-centered informed consent.
2. Formulate a plan for the first step in therapeutic managing melanoma, surgical removal, and distinguish the advantages of the various forms of excision including wide excision and Mohs micrographic excision with immunostains.
3. Recognize the choices patients have about adjuvant testing and treatment, and discuss sentinel lymph node biopsy from the standpoint of prognosis and its therapeutic value.

Description
The dermatologist serves an important function in the management of melanoma. Even after diagnosis, the role of the dermatologist is critical in designing an appropriate management plan. Providing informed consent and guidance remains an important part of the dermatologist's complete care of the patient. The information provided will enhance the dermatologist's ability to counsel regarding appropriate surgical removal, prognostication using Breslow's thickness, and the prognostic and therapeutic value of sentinel lymph node biopsy relative to the clinical situation. Evidence based approaches for managing atypical nevi will also be discussed. Melanoma follow-up guidelines based on the pathologic stage will be reviewed. • *2.00 Category 1 CME Credits*

F018 • Contact Dermatitis Tips from the American Contact Dermatitis Society

Room: W308A

Director: Heather P. Lampel, MD, MPH

Invited Speakers: Katherine Kristine Brown, MD, Jennifer Chen, MD, Alison Ehrlich, MD, Rajani Katta, MD, Michael P. Sheehan, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Formulate the next steps to take when treating a patch-test negative patient.
2. Summarize patch testing techniques for unique and novel allergens.
3. Determine practical tips for managing patients with steroid allergy or systemic contact dermatitis.

Description
The American Contact Dermatitis Society will be presenting practical high-yield clinical tips. We will outline patch testing and immunosuppressants, as well as how to manage patients with steroid allergy. Since patients with systemic contact dermatitis can have complicated allergen sources, we will discuss diet modification as well as consumer product avoidance. We will address testing unusual allergens, and also discuss next steps when patch testing is negative • *2.00 Category 1 CME Credits*

F019 • Approaching Severe Inflammatory Skin Disease in Children

Room: W307D

Director: Elaine C. Siegfried, MD

Invited Speakers: Andrew Blauvelt, MD, Kelly M. Cordoro, MD, Megha M. Tollefson, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Order an appropriate evaluation for a child with severe inflammatory skin disease.
2. Develop treatment options and strategies for children with severe inflammatory skin disease.
3. Discuss emerging treatments for atopic dermatitis and psoriasis in children.

Description
This session is directed at dermatology providers to take care of children. In this session, severe pediatric atopic dermatitis, psoriasis, and subsets will be discussed. Work-up and evaluation, treatment strategies including systemic options, and the emerging pipeline will be reviewed. At the end of this session, the attendee will gain a greater level of comfort in approaching children with this spectrum of severe inflammatory skin disease. • *2.00 Category 1 CME Credits*

F020 • Complementary, Natural and Novel Dermatology Therapeutics: An Evidence-based Perspective

Room: W304A

Director: Daniel M. Siegel, MD, MS

Invited Speakers: P. Haines Ely, MD, Paul Stamets, DSc, Carl R. Thornfeldt, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss the use of medicinal mushrooms, identify their benefits and dangers, and recognize their value in augmenting conventional therapies.
2. Describe the complex interactions between the human microbiome and how it can be manipulated to manage psoriasis and other diseases.
3. Identify a new approach to manage disorders of pigmentation using a group of novel herbs documented by evidence based medicine to improve efficacy, and prolong remission while improving product safety.

Description
Americans spend $30.2 billion per year on complementary health care (https://nccih.nih.gov/research/results/spotlight/americans-spend-billions). Unfortunately, most practicing dermatologists lack knowledge and information about a host of beneficial therapeutic substances that are available outside the prescription drug realm. This session will be focused on a variety of therapeutic approaches to common skin diseases that involve the use novel plant and fungus derived agents not commonly part of the curriculum in medical school, residency or at most meetings. We encourage you to come with an open mind, listen, learn, ask questions and take back new approaches to help your patients safely and effectively. • *2.00 Category 1 CME Credits*

F021 • The Science of Cosmeceuticals and Nutraceuticals

Room: W415A

Director: Zoe Diana Draelos, MD

Invited Speakers: Patricia Farris, MD, Susan C. Taylor, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Examine the expanding role of cosmeceuticals in dermatology.
2. Recognize the role of diet in optimal health and skin appearance.
3. Describe the role of cosmeceuticals in skin dyspigmentation.

Description
This session will present cutting edge science-based information on cosmeceuticals and nutraceuticals. It will discuss the development of skin care based on new understandings of how aging physiology can be improved through topical intervention. The use of cosmeceuticals for improvement of skin dyspigmentation, both alone and in conjunction with prescription therapies, will be addressed. Finally, a critical look at how diet can negatively and positively impact aging, health, disease, and genetics will be undertaken. At the end of the session, the attendee will have a thorough update of aging science and its impact on appearance and performance.
• *2.00 Category 1 CME Credits*

F022 • MACRA, MIPs, and APMs

Room: W209C

Director: Clifford Warren Lober, MD, JD

Invited Speakers: Murad Alam, MD, Sabra Sullivan, MD, PhD, Marta Jane Van Beek, MD, MPH

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize steps that should be taken to be prepared for the implementation of MIPs and advanced APMs.
2. Describe the criteria for and the benefits of being a qualified participant in an advanced alternative payment model (APM) and distinguish the bonuses and penalties under MIPs and advanced APMs.
3. Distinguish other provisions of MACRA and the AAD's response to this legislation.

Description
MACRA fundamentally alters the basis for paying for physician services. It abolished the SGR, postponed the elimination of global periods, and mandated that beginning in 2019 you will be paid under the merit-based incentive payment system (MIPs) unless you are a qualified provider in an advanced-alternative payment model (advanced-APM). PQRS, value-based modifiers, and meaningful use will be incorporated into MIPs performance categories entitled "quality", "advancing care information", "clinical practice improvement activity", and "resource use". The requirements, advantages, and disadvantages of being in an advanced-APM (vs. MIPs), other MACRA provisions, and the AAD's response to MACRA will be discussed. • *2.00 Category 1 CME Credits*

F023 • Dermoscopy for the Non-dermoscopist

Room: Chapin Theatre

Director: Jennifer A. Stein, MD, PhD

Invited Speakers: Caroline C. Kim, MD, Tracey Liebman, MD, Kelly C. Nelson, MD, David Polsky, MD, PhD, Michelle B. Tarbox, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize characteristic dermoscopic structures of benign and malignant lesions.
2. Use dermoscopy to distinguish benign from suspicious lesions that require biopsy.
3. Formulate a simple pattern recognition system that can be used in general dermatologic practice to minimize unnecessary biopsies and improve detection of malignant lesions.

Description
Novice dermoscopists will be taught recognizable dermoscopic patterns to assist in the diagnosis of pigmented lesions. We will discuss a simple pattern recognition system that can be incorporated into routine dermatologic practice. The session will also include dermoscopy of special sites, including the face and acral surfaces. Participants will be shown unknown cases throughout the session for self-assessment and the approach to diagnosis of these cases will be reviewed. By incorporating dermoscopy into everyday practice, participants will be able to improve their diagnostic accuracy in detecting melanoma and other skin cancers. • *2.00 Category 1 CME Credits*

F024 • What's That? Syndrome Update

Room: W304E

Director: Jennifer L. Hand, MD

Invited Speakers: Jonathan A. Dyer, MD, Amy S. Paller, MD, Virginia Sybert, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose genetic skin disorders with risk of internal cancer.
2. Recognize genetic skin disorders with potential infectious consequences.
3. Distinguish forms of Ichthyosis using clinical characteristics and associated features.

Description
Using clinical examples, this session will focus on genetic syndromes with systemic associations such as risk for infection or malignancy. In addition, the spectrum of disorders associated with Ichthyosis will be explored. • *2.00 Category 1 CME Credits*

F025 • Teaching, Coaching, Mentoring and Difficult Conversations

NEW

Room: W312A

Director: Nicole Fett, MD

Invited Speakers: Tamar Hajar-Serviansky, MD, Karolyn Wanat, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Summarize current data on the most effective learning strategies.
2. Demonstrate an effective coaching interaction.
3. Outline an effective strategy for having difficult conversations.

Description
The session will be divided into three key sections: adult learning theory, mentoring and coaching, and having difficult conversations. The session will be directed to those in leadership positions including, but not limited to clinician educators, program directors, and departmental chairs. Audience response questions will be included in each session for audience engagement. A dermatology resident (or two) will be invited to co-present with faculty during the mentoring and coaching sections, to provide the resident perspective. Coaching, mentoring and difficult conversation vignettes will be acted out by presenting faculty and additional vignettes provided for audience practice. • *2.00 Category 1 CME Credits*

F026 • Systemic Medications for the Dermatology Toolbox

Room: W202C

Director: Taraneh Paravar, MD

Invited Speakers: Carolyn A. Bangert, MD, Cynthia L. Chen, MD, Steven Randolph Mays, MD, Jeremy Adam Schneider, MD, Wynnis L. Tom, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss the mechanism of action of the following medications: azathioprine, mycophenolate mofetil, cyclosporine, dapsone, colchicine, and potassium iodide.
2. Apply recommendations concerning appropriate laboratory evaluations and monitoring of patients on these medications.
3. Review appropriate dosing for each medication.

Description
Despite the long history of use of systemic medications in the treatment of inflammatory diseases of the skin, many dermatologists avoid the use of these medications due to lack of familiarity with such medications and concerns for patient safety. When used appropriately, systemic medications can be an effective treatment option. This session will concisely review a number of these medications, including their mechanism of action, dosing, adverse effects, and monitoring guidelines in adults. The medications to be reviewed include: azathioprine, mycophenolate mofetil, cyclosporine, dapsone, colchicine, potassium iodide. This session is aimed towards general dermatologists and residents. • *2.00 Category 1 CME Credits*

F027 • Dermatopathology Case Challenge: Recognizing Mimics and Masqueraders

NEW

Room: W206C

Director: Soon Bahrami, MD

Invited Speakers: Rosalie Elenitsas, MD, Dirk Michael Elston, MD, Tammie C. Ferringer, MD, Ronald P. Rapini, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify diagnostic entities that present as mimics in dermatopathology.
2. Recognize clinical and histopathologic features that can help avoid diagnostic pitfalls when faced with a dermatopathologic mimic.
3. Utilize ancillary tests when appropriate to enhance diagnostic accuracy in challenging dermatopathologic cases.

Description
Diagnostic mimics in dermatopathology pose a potential pitfall in the provision of accurate diagnostic interpretation of patient biopsies. This session intends to provide dermatopathologists, dermatologists, and those in training with enhanced awareness of both common and novel mimics that may be encountered in dermatopathologic practice. An interactive case-based format will be utilized and speakers will describe glass slide masqueraders that they have faced, ancillary tools employed, and the lessons learned in reaching the correct interpretation. Both inflammatory and neoplastic dermatopathologic cases will be presented. • *2.00 Category 1 CME Credits*

F028 • Teledermatology Pearls and Pitfalls from Challenging Cases

NEW

Room: W312C

Director: Ivy Lee, MD

Invited Speakers: Carrie L. Kovarik, MD, Melissa Muszynski Mauskar, MD, Karen McKoy, MD, MPH, Angela K. Walker, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify regulatory, ethical, and medical challenges and considerations that may arise in teledermatology.
2. Recognize unique considerations for practicing high quality teledermatology in outpatient settings and inpatient settings.
3. Discuss the benefits and challenges in global teledermatology practice.

Description
Teledermatology is increasingly used to deliver care to diverse populations in diverse practice settings. Patient cases from consultative and direct-to-patient practices, from outpatient and inpatient settings, and from domestic and international practices will be shared to highlight medical, ethical, and legal considerations in teledermatology. High-yield educational and practice management resources will be summarized, and proactive quality assessment and improvement programs will be proposed. • *2.00 Category 1 CME Credits*

F029 • Updates in Neutrophilic and Pustular Dermatoses

Room: W307B

Director: Haley Naik, MD

Co-Director: Mital Patel, MD

Invited Speakers: Tina Bhutani, MD, Kieron S. Leslie, MBBS, Laura S. Winterfield, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize complex and monogenic neutrophilic and pustular dermatoses.
2. Choose appropriate testing to evaluate and monitor patients with neutrophilic and pustular dermatoses.
3. Select effective therapies for patients with neutrophilic and pustular dermatoses based on best available evidence from the literature.

Description
Neutrophilic and pustular dermatoses constitute a disease spectrum associated with significant morbidity and mortality. This session will discuss distinguishing morphologic characteristics and significant extracutaneous manifestations of these diseases. Advances in evaluation, monitoring and management of these conditions will be presented. Recently defined neutrophilic and pustular diseases, and their impact on our understanding of neutrophilic disease pathogenesis, will be examined. • *2.00 Category 1 CME Credits*

F030 • Dealing with Difficult Patient Encounters

Room: W315B

Director: Marcelyn K. Coley, MD

Co-Director: Jeannette Rachel Jakus, MD

Invited Speakers: John Y. M. Koo, MD, Neil Prose, MD, Anthony Rossi, MD, Thomas Ziering, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Demonstrate effective and compassionate patient-specific communication.
2. Identify when a patient encounter becomes "difficult".
3. Develop a plan for management of difficult patient encounters.

Description
Challenging patient encounters are stressful for both dermatologists and patients. Examples include undesirable outcomes, delivery of bad news, adjusting to diverse patient populations, managing patient expectations and treating psychocutaneous disease. In these instances, communication requires especially delicate care and it helps to have a game plan. How one deals with difficult encounters is not only important for appropriately managing dermatologic conditions and fostering trusting patient-physician relationships, but can be essential for ethical and medicolegal considerations. This session will use various sample cases to provide tools to best approach and manage these seemingly difficult situations. • *2.00 Category 1 CME Credits*

F031 • Where Do We Stand? The Pathogenesis and Treatment of Melasma

Room: W304C

Director: Pearl E. Grimes, MD

Invited Speakers: Maria Ivonne Arellano-Mendoza, MD, Goh Boon Kee, MBChB, Seemal Desai, MD, Emerson V. A. Lima, PhD, MD, Marta I. Rendon, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss pathogenesis of melasma.
2. Prescribe optimal treatment regimens for patients with melasma.
3. Assess the risk vs benefits of topical agents and resurfacing procedures for this condition.

Description
Melasma is indeed a global pigmentary disorder of major cosmetic significance. It affects millions and profoundly impacts the quality of life of patients. Melasma is inherently difficult to manage and recurrence rates are high. This forum will review global advances in the pathogenesis of melasma. Moreover, evidence-based studies regarding best approaches for managing the disorder will be discussed including sunscreens, antioxidants, topical agents, chemical peels, lasers and microneedling. Current data suggest a tiered multimodality approach is best for managing this condition. • *2.00 Category 1 CME Credits*

WORKSHOP • 1 TO 3 P.M.

Tuition fee and ticket required for admission

W002 • Practical Approaches to Assessing Psoriasis and Psoriatic Arthritis Patients in Clinic

Room: W314B

Director: Joel M. Gelfand, MD, MSCE

Invited Speakers: Alice B. Gottlieb, MD, PhD, Mark Lebwohl, MD, Joseph Merola, MD, MSc, Bruce Elliot Strober, MD, PhD, Abby S. Van Voorhees, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize the importance of assessing patients for psoriasis, psoriatic arthritis.
2. Select tools and scales for the clinical assessment of disease severity and quality of life in patients with psoriasis, psoriatic arthritis for routine clinical use.
3. Use clinical assessment results to select appropriate treatment regimen with the goal of treating to target for patients with psoriasis and/or psoriatic arthritis for better patient outcomes.

Description
The session will be helpful in expanding physician knowledge base and improving clinical confidence and effectiveness in assessing disease severity and quality of life tools in treating patients with psoriasis and psoriatic arthritis. The session will consist of five didactic presentations, interactive patient assessment demonstrations, and virtual patient assessment experiences. Participants will receive implementation tools consisting of laminated pocket cards, reference booklets, score cards, checklists, and apps, as deemed appropriate by expert psoriasis and PsA faculty to ensure practicality in aiding participants in improving their clinical practice. Registration fees for this session have been offset by an educational grant from Pfizer, Inc. Tickets are limited and available on a first come first serve basis. • *2.00 Category 1 CME Credits*

COURSES • 1 TO 4 P.M.

Tuition fee and ticket required for admission

C007 • Structure and Function of the Skin: Pigment, Appendages, Damage & Repair

Room: W315A

Director: John J. DiGiovanna, MD

Invited Speakers: Richard August Clark, MD, George Cotsarelis, MD, Thomas J. Hornyak, MD, PhD, Dennis H. Oh, MD, PhD, John T. Seykora, MD, PhD, Kenneth Howard Kraemer, MD, FAAD

Learning Objectives
Following this session, the attendee should be able to:
1. Distinguish the various skin appendages and describe their functions.
2. Recognize photodermatoses, their underling photobiology, and the contribution of melanocytes, DNA repair and wound healing to skin function.
3. Describe the diseases resulting from the failure of these skin components.

Description
One module of a three-part curriculum discussing the normal structure and function of cells and tissues within the skin, and how their impairment leads to representative diseases. This module will focus on pigmentation, skin appendages, skin damage and repair. Examples will be shown of how skin biology is being translated into patient care. The curriculum is a basic overview of skin biology for residents and dermatologists. Bring a print or electronic copy of the handouts to facilitate following the lectures. • *3.00 Category 1 CME Credits*

C008 • Dermatology Review: Skin Cancer, Surgical, and Cosmetic

Room: W209B

Director: Gary Goldenberg, MD

Invited Speakers: Brian Berman, MD, PhD, Neal D. Bhatia, MD, Andrew Blauvelt, MD, Roger I. Ceilley, MD, Clay J. Cockerell, MD, Joel Lee Cohen, MD, Dee Anna Glaser, MD, Ronald L. Moy, MD, Suzanne Olbricht, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize new developments in medical, surgical and cosmetic dermatology.
2. Evaluate new treatment options for dermatologic conditions, including skin cancer, actinic keratosis, and scars/keloids.
3. Analyze and describe best practices for surgical and cosmetic dermatology.

Description
This course will comprehensively review new developments in medical, cosmetic and surgical dermatology. Innovation in diagnosis and treatment of common dermatologic conditions, such as skin cancer, actinic keratosis, scars and keloids will be reviewed. New developments in cosmetic dermatology and best practices in surgical and cosmetic dermatology will be reviewed.
• *3.00 Category 1 CME Credits*

C009 • Live Demonstration: The State of the Art of Aesthetic Dermatology

Room: W415B

Director: Seth L. Matarasso, MD

Invited Speakers: Tina S. Alster, MD, Allison Arthur, MD, Kenneth R. Beer, MD, Kimberly J. Butterwick, MD, Sue Ellen Cox, MD, Rebecca L. Fitzgerald, MD, Mitchel Paul Goldman, MD, Jeremy Green, MD, Matthew K. Knight, MD, Stephen Howard Mandy, MD, Ronald L. Moy, MD, Mark S. Nestor, MD, PhD, Dimitry Palceski, MD, Nowell J. Solish, MD, Susan H. Weinkle, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Assess the aging face and neck and choose the most appropriate injection techniques.
2. Identify soft tissue fillers and their appropriate uses.
3. Recognize and identify facial and neck anatomy as it relates to the use of cosmetic injections.

Description
This live interactive session will feature experts from around the country demonstrating their techniques and treatment tips with cosmetic injections. Attendees will observe in a live interactive manner precisely how the faculty assess aging faces and go about treating the various areas of the face from brow to neck. Each area will be treated by one of the faculty while another guides the procedure and facilitates dialogue with the audience. There will be discussion and demonstration of the optimal techniques using many of the FDA approved fillers, neuromodulators and deoxycholic acid. • *3.00 Category 1 CME Credits*

SYMPOSIA • 1 TO 4 P.M.

Open admission to eligible categories, no tuition or ticket

S010 • Pearls from the Posters

Room: W308C

Director: Mariya Miteva, MD

Co-Director: Anna Nichols, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Apply new results from research to optimize the clinical practice.
2. Evaluate daily clinical practice in the context of new concepts to enhance patient outcomes.

Description
This session will enable dermatologists, trainees, fellows and students to become familiar with the most recent break-through in dermatological research. The selected posters will include basic, clinical and translational research as well as compelling case reports to cover wide range of topics in clinical dermatology and its subspecialties such as pharmacodermatology, pathophysiology, dermatopathology and dermatosurgery. It will attempt to provide the audience with cutting edge research and novel treatment modalities. • *3.00 Category 1 CME Credits*

S011 • Dilemmas and Challenges in Skin Cancer Therapies and Management

Room: W207A

Director: Darrell S. Rigel, MD

Invited Speakers: M. Shane Chapman, MD, Clay J. Cockerell, MD, Seemal Desai, MD, Laura K. Ferris, MD, PhD, Carrie L. Kovarik, MD, Sancy A. Leachman, MD, PhD, Mark Lebwohl, MD, Mark S. Nestor, MD, PhD, Keyvan Nouri, MD, June K. Robinson, MD, Theodore Rosen, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Assess and manage non-melanoma skin cancer issues.
2. Assess and manage melanoma related issues.

Description
Therapeutic and management Issues related to skin cancer are dealt with on a daily basis by Dermatologists and lack of a comprehensive therapeutic and management issues can lead to increased morbidity and mortality. This course will be designed to present key factors that impact on patient care and how to apply current therapies and management approaches. Spirited questions and answers with active audience participation will be encouraged. This symposium will work toward delivering practical therapeutic and management solutions to these issues that can be immediately incorporated into the attendee's patient care setting.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

S012 • Women's Health Therapeutic Hotline

Room: W311G

Director: Miriam Keltz Pomeranz, MD

Co-Director: Jenny Eileen Murase, MD

Invited Speakers: Brian Alan Ginsberg, MD, Alexandra Boer Kimball, MD, MPH, Lynette J. Margesson, MD, Bethanee Jean Schlosser, MD, PhD, Rochelle R. Torgerson, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Manage hormonal therapy for acne and hair loss in women and psoriasis in pregnant women.
2. Recognize inflammatory vulvar disease and inflammatory breast disease.
3. Utilize increased cultural sensitivity with transgender patients.

Description
This symposium will cover a broad range of topics in women's health. Acne and hair loss, with a focus on hormonal treatments in women, will be explained. Vulvar dermatology, with a focus on how to evaluate and treat patients with inflammatory conditions such as lichen sclerosus, will be discussed. The newest treatments for psoriasis and their safety in pregnancy will be reviewed. Inflammatory conditions of the breast, particularly idiopathic granulomatous mastitis and conditions occurring with lactation, will be elucidated. Issues arising specific to sensitive treatment of our transgender patient population will be expounded upon. • *3.00 Category 1 CME Credits*

S013 • Microscopic Mystery: Dermatopathology with Clinical Correlation

Room: W415D

Director: Melissa Piliang, MD

Invited Speakers: Daniel D. Bennett, MD, Kara M. Braudis, MD, Casey Anderson Carlos, MD, PhD, Jisun Cha, MD, Nicholas Logemann, DO, Palak Kishorkumar Parekh, MD, Adam Rubin, MD, Michi Shinohara, MD, Wendi E. Wohltmann, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Utilize microscopic and clinical clues to diagnose complex skin disease.
2. Develop a differential diagnosis and appropriate work-up plan for challenging dermatopathology cases.
3. Recognize that importance of clinicopathologic correlation in dermatopathology.

Description
Slide clubs allow dermatopathologists to share their most interesting cases and to build broad slide sets for teaching. During this session, slide club members will bring their most interesting and challenging cases to you! Slide club members represent a wide range of practice settings (academic, large multi-specialty groups, military, and private practices of varying size). This will be a fast-paced tour of the complex world of dermatopathology with an emphasis on clinicopathologic correlation. • *3.00 Category 1 CME Credits*

S014 • Recent Advances in Bullous Diseases

Room: W203C

Director: David T. Woodley, MD

Invited Speakers: Frederic Caux, PhD, Janet A. Fairley, MD, Karen Harman, Pascal Joly, MD, PhD, Marcel F. Jonkman, MD, PhD, Michael Kasperkiewicz, MD, Kenneth Yu, MD, Olivia Lai

Learning Objectives
Following this session, the attendee should be able to:
1. Prescribe up-to-date medications for patients with pemphigus, bullous pemphigoid, epidermolysis bullosa acquisita (EBA), dermatitis herpetiformis, linear IgA bullous dermatosis, and mucous membrane pemphigoid.
2. Formulate algorithms for making the diagnosis of autoimmune bullous diseases.
3. Recognize available verified methods to evaluate the severity of bullous diseases.

Description
This session will highlight advances in the diagnosis and treatment of bullous diseases. Evidence-based medicine and basic science data will underpin the diagnostic strategies and therapeutic options for bullous diseases. The diagnostic and therapeutic options available will span an international perspective. • *3.00 Category 1 CME Credits*

S015 • Common, Challenging, and Controversial Short Topics in Patient Management

Room: W311E

Director: April W. Armstrong, MD, MPH

Invited Speakers: Minnelly Luu, MD, Zakia Rahman, MD, Eric Lawrence Simpson, MD, Ashley Wysong, MD, MS

Learning Objectives
Following this session, the attendee should be able to:
1. Manage common yet challenging issues in medical and procedural dermatology.
2. Identify key perspectives in current and controversial management topics in medical and procedural dermatology.

Description
Be a part of this high-yield learning experience in this engaging symposium on common, challenging, and controversial short topics in patient management. Master clinicians from medical and procedural dermatology will speak on a variety of topics affecting in adult and pediatric populations. For example, we will discuss topics that include atopic dermatitis, skin cancers, cosmetic dermatology, pediatric dermatology, and psoriasis.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

S016 • Hair and Scalp Dermoscopy

Room: W414C

Director: Antonella Tosti, MD

Invited Speakers: Alessandra Anzai, MD, Daniel Asz-Sigall, MD, Isabella I. Doche, MD, PhD Gabriella Fabbrocini, MD, Maria Abril Martinez Velasco, MD, Giuseppe A. Micali, MD, Mariya Miteva, MD, Rodrigo Pirmez, MD, Lidia Rudnicka, MD, PhD, Jerry Shapiro, MD, Fernanda Torres, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Utilize dermoscopy in the diagnosis of alopecias and other scalp disorders.
2. Recognize dermoscopic patterns of scarring and non scarring alopecias.
3. Use dermoscopy to identify optimal site for biopsy.

Description
This session is directed to dermatologists and other providers who treat patients with hair and scalp disorders. The session will discuss the dermoscopic features of hair and scalp diseases that benefit from dermoscopic evaluation including non-scarring and scarring alopecias, infections, infestations, inflammatory disorders, and tumors. • *3.00 Category 1 CME Credits*

S017 • Gender Dermatology: Diagnosis and Treatment of Genital Skin Disorders

Room: W303A

Director: Mary Gail Mercurio, MD

Invited Speakers: Catherine Chung, MD, Nananamibia Duffy, MD, Matthew A. Lewis, MD, MPH, Robert Micheletti, MD, Bethanee Jean Schlosser, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Review the clinical spectrum of common vulvar conditions.
2. Recognize systemic disease vulvar presentations.
3. Formulate therapeutic strategies for managing vulvar diseases.

Description
This session will expand physician knowledge in the proper diagnosis and management of vulvar skin conditions. The expert faculty will be discussing infectious and inflammatory processes involving the vulvar skin as well as normal age-related changes. The course is intended to convey practical information and deliver a greater understanding of treatment options. • *3.00 Category 1 CME Credits*

FORUMS • 3:30 TO 5:30 P.M.

Open admission to eligible categories, no tuition or ticket

F032 • Red Flags and Emergencies in Dermatology

Room: W304C

Director: Ronni Wolf, MD

Invited Speakers: Ilona J. Frieden, MD, Lawrence C. Parish, MD, Theodore Rosen, MD, Neil H. Shear, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose and identify critical situations, red flags, and emergencies.
2. Recognize the pathological events and causes of acute life-threatening cutaneous disease.
3. Identify the urgent and appropriate intervention needed and, be well-informed on new and modern treatments of acute life-threatening cutaneous disease.

Description
"Dermatology is the best specialty. The patient never dies -- and never gets well" (anonymous). Many physicians and patients believe that dermatology does not involve life-threatening situations. The fact of the matter is that the dermatologist is frequently the first clinician to examine these patients. The specialist may be responsible for making the initial diagnosis; for differentiating mundane skin ailments from more serious, life-threatening conditions; and for being the first to identify a critical situation. Dermatologists have no choice but to continue to be on the front line of diagnosing and treating all skin diseases, especially the more severe and acute ones. • *2.00 Category 1 CME Credits*

F033 • Value in Health Care: Improving Outcomes and Decreasing Waste

NEW

Room: W314B

Director: Joslyn S. Kirby, MD

Invited Speaker: Adewole Shomari Adamson, MD, MPP

Learning Objectives
Following this session, the attendee should be able to:
1. Compare and contrast types of studies, including studies of health care cost, to guide evidence-based health care.
2. Defining and identify value in health care.
3. Describe guidelines in current and future delivery of health care.

Description
This will be a powerful session that was designed to be high-impact, high-utility and teach skills you can apply right away in your practice. We will define value in healthcare and discuss the methods practitioners can use to improve outcomes and decrease waste for patients. We'll review and apply principles of evidence-based practice, with a special section devoted to 'how to read an economic study'; discussion of behavioral economics and incentivizing behaviors; the power of experience, with a review of when you don't need to test; and discuss the role of guidelines and the new kid on the block -SCAMPs. • *2.00 Category 1 CME Credits*

F034 • Young Physician Pearls and Pitfalls: A Survival Guide for the First 10 Years

Room: W308A

Director: Rahul Narayan Chavan, MD, PhD

Co-Director: Jeremy A. Brauer, MD

Invited Speakers: Carrie L. Davis, MD, Kalyani Marathe, MD, MPH, David Michael Pariser, MD, Marta Jane Van Beek, MD, MPH, David Akio Wada, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe and navigate the daily regulatory hurdles encountered in practice; delineate the organizational structure of the AAD and AADA; and recognize opportunities for young physician involvement.
2. Recognize the interactions between state medical societies and the AAD; and Identify opportunities for involvement in state medical societies.
3. Determine how to incorporate mid-level providers in your practice: examine ways to identify challenges that you may encounter while incorporating mid-level providers in private practice or an academic setting.

Description
The first ten years of practice bring unique challenges in an ever-changing healthcare system. For young physicians, it's not only important to keep up with medical advances, but also to be able to efficiently run their practice. Many also feel the need and desire to give back and continue to advance our great specialty. This session will give young physicians the tools needed to continue to be successful, including, knowledge of regulatory hurdles in a changing practice landscape, involvement in state medical societies, working with mid-level providers and begin an academic career. • *2.00 Category 1 CME Credits*

F035 • Big Rashes in Little Patients

Room: W208A

Director: Julie V. Schaffer, MD

Invited Speakers: Mercedes Gonzalez, MD, Moise L. Levy, MD, Adnan Mir, MD, PhD, Andrea L. Zaenglein, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize the spectrum of cutaneous manifestations of inflammatory disorders and infections in neonates, infants, and children.
2. Identify distinctive cutaneous features and extracutaneous associations of inflammatory dermatoses, reactive eruptions, and infections in children.
3. Formulate appropriate management plans for pediatric rashes.

Description
Rashes with inflammatory and infectious etiologies often have different clinical appearances, time courses, and associated features in infants and children than in adults. This session provides an update on new and under-recognized cutaneous presentations of pediatric infections, reactive eruptions, and inflammatory dermatoses. Case-based scenarios will be utilized to provide clinical pearls, highlight the differential diagnosis, and illustrate strategies for evaluation and management. Topics will range from common but oftentimes frustrating conditions such as acne and atopic dermatitis to unique presentations in neonates to clinical-pathologic correlation.
• *2.00 Category 1 CME Credits*

F036 • Skinternal Medicine: An Update on Cutaneous Manifestations of Systemic Disease

Room: W415A

Director: Jeffrey Phillip Callen, MD

Invited Speakers: Nicole Fett, MD, Amit Garg, MD, Robert S. Kirsner, MD, PhD, Robert Micheletti, MD, Taraneh Paravar, MD, Kanade Shinkai, MD, PhD, Ruth Ann Vleugels, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Formulate a differential diagnosis for patients with complex medical/dermatologic problems.
2. Manage patients with complex medical/dermatology problems more effectively.
3. Discuss the potential adverse reactions of therapies selected to manage patients with systemic diseases.

Description
Using the audience response system, we will present challenging cases for discussion. Each presenter has selected a single case that epitomizes one of their most significant clinical challenges during the past few years. • *2.00 Category 1 CME Credits*

F037 • The Impact of Drug Pricing on Access to Care: Demystifying the Landscape

Room: W312C

Director: Arianne Shadi Kourosh, MD, MPH

Co-Director: Elise A. Olsen, MD

Invited Speaker: John Herr, RPh, Gerald E. Harmon, MD, Martin J. Zagari, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss the current political and regulatory landscape for drug pricing and how it may be addressed by the next Administration.
2. Describe different value frameworks for drugs and the concept of value over cost.
3. Identify common challenges and ways to gain access to necessary medications through compounding.

Description
This presentation will examine the issue of drug pricing and how we can continue to preserve access to necessary medications for our patients. With an evolving political and regulatory landscape to address drug costs, the panel will unravel the current atmosphere. Advocacy efforts at both the state and national level will be discussed. The panel will also explore the recent increased focus on determining the value of a drug and identify current value frameworks. What are some of the pitfalls of today's frameworks and how can they be improved to ensure all stakeholder's voices are heard while remaining transparent. With increasing drug costs other options are emerging to help ensure continued access to drugs; compounding is one of those avenues and the panel will discuss how it can lead to increased access when prices rise.
• *2.00 Category 1 CME Credits*

F038 • Cutaneous Disorders of Pregnancy

Room: W304G

Director: Mark A. Bechtel, MD

Invited Speakers: Lisa K. Pappas-Taffer, MD, Kelly Tyler, MD, Jennifer Villasenor-Park, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize important clinical features of pregnancy specific cutaneous disorders and potential fetal complications.
2. Formulate appropriate and safe topical and systemic therapies for pregnant patients with cutaneous disorders based on recent FDA guidelines and medical literature.
3. Develop appropriate management for pregnant patients with complex medical dermatology issues including cutaneous lupus erythematosus, psoriasis, and cutaneous malignancies based on current medical practice.

Description
The recognition and management of pregnancy related cutaneous disorders can be challenging, along with potential impact on the fetus. Diagnostic clues in the recognition of these disorders, along with better appreciation of fetal compromise will be highlighted. Physiologic skin changes during pregnancy will be reviewed. Diseases with a Th2-immune response, such as lupus erythematosus, often flare during pregnancy and appropriate management will be reviewed. Challenging appropriate evaluation and management issues in the pregnant patient, including psoriasis and serious cutaneous malignancies, will be discussed. An overview of the safety guidelines for topical and systemic dermatologic therapy during pregnancy will be provided.
• *2.00 Category 1 CME Credits*

F039 • Contact Allergens of the Year

Room: W307B

Director: Amber R. Atwater, MD

Invited Speakers: Cory A. Dunnick, MD, Heather P. Lampel, MD, MPH, Margo Reeder, MD, Michael P. Sheehan, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe Contact Allergens of the Year and their clinical relevance.
2. Discuss strategies for allergen avoidance.

Description
We will discuss Contact Allergens of the Year, as determined by the American Contact Dermatitis Society since 2000. This distinction is awarded to allergens regarded as important, clinically relevant, new and emerging, and even no longer relevant. We will discuss each allergen and its importance in the realm of contact dermatitis. • *2.00 Category 1 CME Credits*

F040 • Beyond the Tzanck: Bedside Diagnostics for Dermatologists

Room: W307D

Director: Karolyn Wanat, MD

Invited Speakers: Arturo R. Dominguez, MD, Robert Micheletti, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe diagnostic tests that dermatologists can perform at the bedside.
2. Diagnose dermatologic conditions using common bedside laboratory techniques.
3. Select the appropriate bedside technique for dermatologic conditions using audience response cases.

Description
The use of simple and rapid bedside diagnostic tests by dermatologists can yield quick diagnoses and reduce healthcare costs, improving patient care. These techniques are immensely valuable in resource-limited settings, on the inpatient wards, and in the dermatology office. This session is designed for dermatologists and dermatology residents working in multiple settings to increase the repertoire of bedside diagnostic tests for diagnosis of infectious (including bacterial, viral, fungal, and parasitic) and non-infectious diseases. Appropriate technique will be demonstrated, and images will be provided to help guide learners. Audience response will be in this case-based presentation.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

F041 • Translating Evidence into Practice: Atopic Dermatitis Guidelines

Room: W304AB

Director: Robert Sidbury, MD, MPH

Invited Speakers: Heather Brandling-Bennett, MD, Peter A. Lio, MD, Eric Lawrence Simpson, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Address common patient questions about co-morbidities related to atopic dermatitis.
2. Formulate optimal adjunctive treatment regimens for atopic dermatitis of varying severities.
3. Discuss traditional and emerging topical and systemic therapies.

Description
Atopic dermatitis is a common, chronic inflammatory dermatosis with increasing prevalence. The updated 2014 Guidelines of Care for the Management of Atopic Dermatitis, published as a four parts series in the *JAAD*, present practical, patient-centered, evidence-based recommendations to help the physician make therapeutic decisions. This workshop will present the latest information on the pathogenesis, diagnosis and management of atopic dermatitis in the context of the recently published AAD Guidelines. Emerging treatments for atopic dermatitis will also be discussed. Finally, the AAD guidelines will be contrasted with those from the allergy community.
• *2.00 Category 1 CME Credits*

F042 • Dermatologic Manifestations of HIV and AIDS

Room: W315B

Director: Esther Ellen Freeman, MD, PhD

Invited Speakers: Carrie L. Kovarik, MD, Adam D. Lipworth, MD, Toby A. Maurer, MD, Arturo P. Saavedra, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify cutaneous manifestations of HIV and AIDS.
2. Manage cutaneous manifestations of HIV and AIDS.

Description
HIV and AIDS patients develop unique infectious and non-infectious cutaneous diseases, many of which carry significant morbidity and mortality. The rise of antiretroviral therapy has decreased the prevalence of these complications in the U.S., decreasing familiarity with these diseases among U.S. dermatologists. However, opportunistic infections, HIV-associated malignancies, hypersensitivity reactions to HIV therapies, and severe primary inflammatory dermatoses persist in certain HIV-infected populations in the developed world, and remain common in developing nations. This case-based session will use patient encounters from the U.S., Sub-Saharan Africa, Europe, and Latin America to highlight diagnosis and management of HIV-related skin diseases.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

F043 • Photoprotection

NEW

Room: W209C

Director: Steven Q. Wang, MD

Invited Speakers: Henry W. Lim, MD, Adnan Nasir, MD, PhD, Darrell S. Rigel, MD, Martin A. Weinstock, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify myths in photoprotection and sunscreens.
2. Recognize the need for photoprotection beyond UV radiation.
3. Describe the role of nanotechnology in sunscreens formulation.

Description
Current understanding and novel innovations in photoprotection will be discussed by leading experts in the field. The session will help to debunk common misconceptions and highlight new innovations in sunscreen technology. It will also discuss new research focused on protection beyond UV radiation.
• *2.00 Category 1 CME Credits*

F044 • How Would You Reconstruct It?

MOC

Room: Chapin Theatre

Director: Thomas E. Rohrer, MD

Invited Speakers: John G. Albertini, MD, David G. Brodland, MD, Marc D. Brown, MD, John A. Carucci, MD, PhD, Joel Cook, MD, Andrew J. Kaufman, MD, Naomi Lawrence, MD, Steven M. Rotter, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Analyze a defect and design multiple closure options.
2. Appreciate the multiple options to close any given defect.

Description
In this session, reconstructive masters will present interesting cases from their office and discuss the thought process behind approaching each defect. These are not necessarily the largest or most complicated surgical defects, but a curated selection of cases with multiple reconstructive options and teaching points. The speaker will present a defect to the panel and panel members will comment on how they would approach the reconstruction. The speaker will then show how they repaired the defect and discuss why it did or did not work for that particular patient.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

F045 • Practical Management of Atypical Melanocytic Lesions

Room: W202ABC

Director: Caroline C. Kim, MD

Invited Speakers: Michael E. Ming, MD, Kelly C. Nelson, MD, Jennifer A. Stein, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Implement strategies in clinical practice to accurately monitor atypical nevus patients while avoiding unnecessary biopsies.
2. Recognize clinical features of concerning melanocytic lesions on the scalp/face vs. trunk/extremity vs. acral areas in complex nevus patients.
3. Describe challenges in biopsying pigmented lesions and strategies to improve diagnostic accuracy.

Description
Dermatologists are faced with the difficult task of evaluating and managing patients with atypical melanocytic lesions. This forum will review practical strategies for the evaluation of patients with complex nevus exams and the process of deciding to biopsy a lesion. Clinical case examples utilizing clinical and dermoscopic photos of challenging pigmented lesion patients will be presented by location, including scalp and facial, truncal and extremity, and acral lesions. Challenging biopsy scenarios will also be discussed with strategies to improve diagnostic accuracy. This forum is directed to all general dermatologists.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

F046 • Challenging Cases in Dermatopathology

Room: W206C

Director: Jinah Kim, MD, PhD

Invited Speakers: Brittney Kaufman DeClerck, MD, Jennifer Madison McNiff, MD, Roberto Novoa, MD, Ronald P. Rapini, MD, Beth S. Ruben, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify and evaluate challenging lesions in dermatopathology and utilize ancillary testing and clinical pathologic correlation to promote accurate diagnosis.
2. Distinguish benign and malignant conditions using advanced techniques.

Description
This 2 hour session will cover important benign and malignant disorders that represent common and rare pitfalls in dermatopathology. We will emphasize clinical pathologic correlation in these cases and provide evaluation of mimics of these conditions. Our discussion will also focus on important ancillary testing using immunohistochemical staining, special stains, and molecular techniques for diagnosis. At the completion of the session, the attendees will have a better understanding of challenging cases in dermatopathology. • *2.00 Category 1 CME Credits*

F047 • How to Quarterback a Championship Team

Room: W312A

Director: Alexandra Y. Zhang, MD

Invited Speaker: Marsheila DeVan, MBA

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize Lencioni's Five Dysfunctions of a Team model.
2. Describe ways to combat dysfunction in your team to promote cooperation.
3. Apply the principles of crucial conversations when communicating with your team.

Description
Building your team and managing diverse personalities and skill levels can be challenging for even the most successful leaders. This interactive session will take a deeper look into why teams struggle and even sometimes fail by examining Lencioni's Five Dysfunctions of a Team model, reviewing concepts to combat this dysfunction, and discussing conversation principles to help build your team. Member favorite and communications expert Marsheila DeVan, MBA will facilitate this session.
• *2.00 Category 1 CME Credits*

WORKSHOP • 3:30 TO 5:30 P.M.

Tuition fee and ticket required for admission

W003 • Self-assessment: Procedural Dermatology

Room: W300

Director: David R. Carr, MD

Invited Speakers: Charlene Lam, MD, MPH, Margaret W. Mann, MD, Vineet Mishra, MD, Christine Poblete-Lopez, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify strengths and weaknesses in one's knowledge base of dermatologic surgery through the use of an audience response system (ARS).
2. Demonstrate commitment to lifelong learning and self-assessment via completion of a forum of questions and answers.
3. Integrate and apply concepts in dermatologic surgery to improve patient care.

Description
Concepts in dermatologic surgery that are relevant for the practicing dermatologist will be presented. Answers are recorded via an electronic Audience Response System (ARS), followed by discussion of the case. Immediate, anonymous feedback allows attendees to assess their knowledge and identify areas that require further self-directed study. In order to fully participate, it is imperative that participants arrive on time.

This activity has been approved by the American Board of Dermatology (ABD) for up to 34 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

FOCUS SESSIONS • 4:30 TO 5:30 P.M.

Open admission to eligible categories, no tuition or ticket

U015 • How to Deal with Difficult Patients/People and Look Forward To It!

Room: W305A

Director: Steven Kenneth Shama, MD, MPH

Learning Objectives
Following this session, the attendee should be able to:
1. Describe a difficult person and be able to determine why they bother you.
2. Develop approaches in dealing with these difficult people and discover why you actually can look forward to them.

Description
Difficult Patient/Person elicit emotions in you that you may prefer not to have. Difficult people may include patients, their families, physicians, nurses, and other medical practitioners. We'll find creative ways of dealing with these people and discover what you can learn about yourself and them. Participants will suggest "difficult" scenarios, e.g. the angry, demanding, controlling, or non-compliant person. We will generate many different approaches to solving these frustrating situations. Handouts will be provided giving "answers" to medicine's frustrating interactions, helping solve these challenges in clinical practice and also in risk management. Guaranteed to be memorable, practical, and life/spirit enriching! • *1.00 Category 1 CME Credit*

U016 • MOC Changes

Room: W209B

Director: Julia R. Nunley, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe the important and current concepts of MOC.
2. Name the components of MOC to efficiently and effectively participate in MOC.
3. Manage your personal MOC process.

Description
This session will provide information essential for members to understand, participate in, and manage their own maintenance of certification process. • *1.00 Category 1 CME Credit*

U017 • Challenging Cases of Dermoscopy: An Interactive Session

Room: W311E

Director: Joel Claveau, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Increase the level of confidence in using dermoscopy.
2. Recognize important and new dermoscopic signs of various tumours.

Description
Dermoscopy has become an essential tool for every dermatologist. Over the last 15 years, I had the to chance to teach dermoscopy at various local and international meetings and I find that dermatologists love intercase case sessions. This is helping them to gain confidence in using this diagnostic tool. I expect dermatologists to recognize more than 70% of the tumours presented in this session and increase their use of the dermoscope.

This activity has been approved by the American Board of Dermatology (ABD) for up to 10 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 1.00 Category 1 CME Credit

U018 • Genodermatoses Update

Room: W311GH

Director: Dominique C. Pichard, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Formulate a framework for understanding autoinflammatory skin disease and the rationale for targeted intervention of specific pathways.
2. Recognize the non-infectious cutaneous features that can alert one to a diagnosis of primary immunodeficiency.
3. Identify and diagnose the infections characteristic of newly described immunodeficiencies based on cutaneous manifestations.

Description
This session will provide an overview of new genetic syndromes described in the last several years with an emphasis on skin diseases with important systemic manifestations first identified at the National Institutes of Health. Topics will include new autoinflammatory and immunodeficiency diseases, among others. Recent advances in the monogenic basis of these conditions, as well as the underlying pathophysiologic pathways responsible for the skin phenotypes will be discussed. These mechanisms provide new insight into our understanding of cutaneous infection, autoinflammation, and granuloma formation in both rare and common disease. • *1.00 Category 1 CME Credit*

U019 • Update of Hair Growth Disorders

Room: W414C

Director: Wilma Fowler Bergfeld, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Evaluate hair loss disorders more effectively.
2. Identify clues for evaluation of co-morbidities.
3. Formulate a treatment plan and recognize new innovative therapies.

Description
Hair disorders represent a unique expertise of the dermatologist which has been well established. This session will present common hair disorders, their unique presentations, outline an efficient evaluation, and propose a treatment algorithm based on the diagnosis. Attention will be given to new findings and therapies. • *1.00 Category 1 CME Credit*

U020 • Head to Toes: Region-specific Contact Dermatitis

Room: W207AC

Director: Alison Ehrlich, MD

Invited Speakers: Katherine Kristine Brown, MD, Jennifer Chen, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize region-specific patterns of contact dermatitis.
2. Determine which allergens should be tested given location of dermatitis.
3. Describe best practices in allergen avoidance.

Description
Contact Dermatitis has specific patterns which are clues to determining the culprit allergens. Recognition of these patterns enables clinicians to determine the most relevant patch testing allergens. This session will discuss the use of both standardized allergens and patient products for patch testing patients with region specific dermatitis. In addition, pearls relating to allergen education will be provided. • *1.00 Category 1 CME Credit*

U021 • Holy Moly: Religion and the Skin: Cultural Competence

Room: W315A

Director: Gary J. Brauner, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize dermatitides and traumatic reactive patterns caused by application of garments or religious paraphernalia or preparations.
2. Treat dermatoses with understanding of religious restrictions of use of common dermatologic therapies, both medical and surgical.
3. Explain the reality of stigmata and religious stigmatization of cutaneous disease.

Description
Disparities in delivery of healthcare have made "cultural competency" not merely a helpful but now a legally-required remedy. Ethnicity, race, and language are not the only relevant considerations. Religious practices may cause or prevent cutaneous disease, heavily weigh the social significance of certain diseases, and impact on the delivery of proper dermatologic therapy. This session will highlight such problems; please bring your own as well. • *1.00 Category 1 CME Credit*

U022 • Pigmentary Conundrums: Diagnostic and Therapeutic Pearls

Room: W203C

Director: Nada Elbuluk, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Evaluate various disorders of pigmentation and how they can present in different skin types.
2. Identify tools for appropriately diagnosing pigmentary conditions.
3. Develop appropriate and safe treatment plans for challenging pigmentary conditions.

Description
This session will provide an overview of pigmentary conditions with discussion of conditions caused by hyperpigmentation, hypopigmentation, and/or depigmentation. It will discuss approaches to evaluating and diagnosing pigmentary conditions as well as therapeutic options for these conditions, and how this can be affected by a patient's skin type. The session will be aimed at dermatologists who are interested in expanding their differential of pigmentary disorders as well as their understanding of how to diagnose and treat these conditions in diverse populations.
• *1.00 Category 1 CME Credit*

U023 • Management of Difficult Wounds

Room: W304E

Director: Oliver Fred Miller, III, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Distinguish among ulcers encountered on the legs and feet.
2. Evaluate and treat venous leg ulcers.

Description
Discussion of differential dx of leg ulcers and work up and therapy of ulcers with arterial compromise. In depth discussion of approach to and Rx of venous ulcers with debridement and types of compression. Discussion and Rx of specific leg ulcers including pyoderma gangrenosum and autoimmune disorders. • *1.00 Category 1 CME Credit*

U024 • Autoinflammatory Skin Disorders: Clinical Pearls for Diagnosis and Management

NEW

Room: W303A

Director: Mital Patel, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe the concept for autoinflammation.
2. Identify and manage classic and atypical cutaneous and systemic manifestations of autoinflammatory conditions including: pyoderma gangrenosum, hidradenitis suppurativa, SAPHO, PASH, and PAPASH syndromes, as well as inflammatory bowel disease-related entities.
3. Recognize the role therapeutic agents play in targeting the innate immune system in autoinflammatory disorders.

Description
This session uses clinical vignettes to present classical and atypical cutaneous and systemic manifestations of autoinflammatory diseases of the skin. Additionally, this session will offer practical tips for diagnosis, evaluation, and advanced therapeutic management of patients with autoinflammatory conditions. Cases discussed will include: hidradenitis suppurativa, pyoderma gangrenosum, PASH, PAPASH, Sweet's syndrome, and vasculitis. Special attention will be played to the role that newer therapeutic agents targeting the autoinflammatory innate immune system pathway play in the treatment of these disorders. A case-based approach will be utilized to highlight relevance for the dermatology trainee or experienced clinician. • *1.00 Category 1 CME Credit*

U025 • New Medical Dermatology Literature that Changed My Approach to Practice

NEW

Room: W308C

Director: Warren R. Heymann, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss recent advances in the medical dermatology literature published in "The Heymann File" of SKINMed.
2. Summarize how these advances have changed my approach to practicing dermatology.

Description
I am privileged to write a column in the journal SKINMed titled "The Heymann File" where I comment on new medical and pediatric dermatologic literature. Dermatology is a dynamic discipline - keeping up with the literature is daunting. In this session I will highlight how recent advances reported in the recent dermatology literature have changed my approach to practice. Discussion with attendees to share their experience and perspectives is encouraged.
• *1.00 Category 1 CME Credit*

U026 • Does the Drug Really Work? Interpreting Clinical Trial Data

NEW

Room: W204C

Director: Paul Steven Yamauchi, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss the basic design of conducting clinical trials, the advantages and disadvantages of clinical trials, and to more accurately interpret the data from clinical trials when presented in publications or at conferences.
2. Differentiate the various data analysis of clinical trial endpoints (intent to treat, last observation carried forward, etc) and the basic terminology to assess safety parameters in clinical trials.
3. Assess the impact and clinical relevance of clinical trial data into clinical practice. A hypothetical clinical trial will be presented to serve as an example of analyzing the various endpoints from the data.

Description
Many phase 2 and 3 clinical trial data are published and presented every year for a drug under investigation. The rigidity of the data is dependent on the type of statistical analysis used (intent-to-treat, last-observation-carried-forward, as-observed, etc). It is important for the clinician to understand how conservative the data was analyzed in order to formulate a meaningful clinical assessment. The clinician should also be able to define the various terminology used to assess safety (odds-ratio, hazard-ratio, relative-risk, etc). A hypothetical clinical trial will be presented as an example of analyzing the various endpoints from the data. • *1.00 Category 1 CME Credit*

FOCUS SESSIONS • 7:30 TO 8:30 A.M.

Open admission to eligible categories, no tuition or ticket

U027 • The Dermatologist's Role in Meeting the Needs of the Greater Community

NEW

Room: W307B

Director: Jesse J. Keller, MD

Invited Speakers: David M. Adelson, MD, MS, Oliver J. Wisco, DO

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss the delivery of dermatologic care in the context of a population based model.
2. Utilize strategies such as technology or education that improve efficiency of care delivery while maintaining quality.

Description
The session is directed to dermatologists in urban areas whose patients travel long distances for specialty evaluation. In Oregon we examine the capacity of direct to consumer electronic visits, traditional store and forward outpatient teledermatology, teledermatology in the inpatient setting, and electronic means of empowering a primary care workforce, such as Project Echo. We hypothesize that these interventions will improve the health of a population while significantly lowering direct and indirect costs associated with traditional face to face visits. Finding a local solution is key, and usual barriers to adoption include provider reimbursement and ease of electronic health record interface. • *1.00 Category 1 CME Credits*

U028 • Pemphigus and Pemphigoid: Evidence-based Updates

Room: W311E

Director: Donna Culton, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe relevant pathogenic mechanisms of pemphigus and pemphigoid.
2. Diagnose pemphigus and pemphigoid more effectively.
3. Formulate treatment plans for pemphigus and pemphigoid based on current evidence.

Description
In this session, we will review and evaluate the latest studies on pemphigus and pemphigoid. We will discuss new information regarding mechanisms of disease pathogenesis and how these mechanisms provide rationale for certain therapies. Current thoughts on mechanism of action of new treatment modalities will be presented. Finally, we will discuss the efficacy and safety of both established and newer treatment options including topical steroids, systemic steroids, immunosuppressive agents, intravenous immunoglobulin, and B cell depleting therapies. At the end of this session, the audience will be able to diagnose and treat patients more effectively and confidently.
• *1.00 Category 1 CME Credit*

U029 • Cutaneous Lymphoma and Mimics: The Importance of Clinical Pathological Correlation

Room: W315A

Director: Lyn M. Duncan, MD

Invited Speaker: Joi B. Carter, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Outline a simplified framework for cutaneous T cell and cutaneous B cell lymphomas based on the WHO/EORTC classification.
2. Distinguish the key histopathologic and immunohistochemical features of various cutaneous lymphomas and their mimics.
3. Recognize the importance of clinical and pathological correlation in diagnosing cutaneous lymphomas.

Description
Prompt and accurate diagnosis of cutaneous lymphoma has important clinical implications. The clinical and histopathological features of cutaneous T cell and B cell lymphoma in the skin will be described with an emphasis on clinical pathological correlation and the interpretation of laboratory results. Case based presentations may include pseudolymphomatous folliculitis, measles, cutaneous marginal-zone B cell lymphoma, cutaneous follicle center lymphoma, diffuse large B-cell lymphoma and CD30+ lymphoproliferative diseases including variants of lymphomatoid papulosis, herpes virus induced CD30+ proliferation, anaplastic large cell lymphoma and others.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 1.00 Category 1 CME Credit

U030 • Male Genital Dermatology: Lessons Learned from a Male Genital Skin Disease Clinic

Room: W315B

Director: Anthony P. Hall, MBBS

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose male genital disease more easily.
2. Choose appropriate investigations to aid clinical diagnosis.
3. Select the most appropriate treatment for each disease.

Description
Important common variants and both inflammatory and neoplastic diseases of the male genitalia will be presented. Appropriate investigations will be discussed to aid diagnosis, leading to appropriate management. Emphasis will be placed on important pre-malignant diseases of the male genitalia that should not be missed. *• 1.00 Category 1 CME Credit*

U031 • Advanced Use of Systemic Therapies: Rituximab, Thalidomide, and Anti-TNF Alpha Drugs to Manage Complex Dermatoses

Room: W303A

Director: George F. Cohen, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Formulate alternative treatment plans for patients with severe dermatoses that are recalcitrant to standard therapy with topical or systemic steroids.
2. Recognize the risks, benefits, limitations and alternatives when using anti-TNF medications, rituximab or thalidomide for recalcitrant severe dermatoses.

Description
Rituximab, Thalidomide and the Anti-TNF medications can be useful adjuncts in the management of complex dermatoses such as pyoderma gangrenosum, cutaneous lupus, B-cell disorders and recalcitrant neurodermatoses. The session will describe and illustrate the use of these medications in the aforementioned context. This session is directed to clinicians who treat complex medical dermatology patients as well learners who want to expand their therapeutic acumen.
• 1.00 Category 1 CME Credit

U032 • A Practical Approach to the Management of Onychomycosis

NEW

Room: W209C

Director: Shari Lipner, MD, PhD

Co-Director: Aditya K. Gupta, MD, PhD

Invited Speaker: Molly A. Hinshaw, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Utilize clinicopathologic correlation for improved diagnosis and treatment of onychomycosis.
2. Summarize current and emerging treatments for onychomycosis.

Description
This session is directed towards general dermatologists who are interested in the diagnosis and treatment of nail disorders. Topics to be covered include epidemiology, diagnosis, and treatment of onychomycosis. FDA approved topical and oral therapies will be discussed in detail, as well as, emerging treatments. Faculty include nail experts from around the world. *• 1.00 Category 1 CME Credit*

U033 • What is New on Pyoderma Gangrenosum?

NEW

Room: W305A

Director: Alex Gerardo Ortega-Loayza, MD

Invited Speaker: Kanade Shinkai, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Review updated therapeutic options for patients with pyoderma gangrenosum.
2. Summarize new concepts on the pathophysiology of pyoderma gangrenosum and its associated comorbidities.

Description
This session is directed to medical providers treating patients with pyoderma gangrenosum (PG) in the inpatient and outpatient settings. We will review new alternative medications which have recently emerged as possible targeted therapies in patients with PG. We will also address new associated comorbidities and new concepts on pathogenesis of PG highlighting diagnostic and therapeutic implications. • *1.00 Category 1 CME Credit*

U034 • Warts and Molluscum: What's New in Treatments, Vaccinations, Immunotherapy and the Sexual Abuse Question

NEW

Room: W209B

Director: Tor A. Shwayder, MD

Invited Speaker: Jacob Mashiah, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Assess new treatments for warts and identify why certain warts are more resistant to treatment than others.
2. Apply knowledge of immunotherapy and vaccines in the treatment of warts.
3. Distinguish innocent acquisition of warts versus those spread by sexual abuse.

Description
Warts and Molluscum! They are everywhere. Everyone seems to have a treatment but no one has a cure. Do the common treatments work? Does the HPV vaccine cure warts as well as prevent? Do immunotherapies help in the stubborn cases? Why are some people cured with one session and some just never get better? Why are there so many different treatments for molluscum? Which one really works? Come with us on a one-hour journey to delve into what is new with warts and molluscum, to answer these and many other pressing questions. • *1.00 Category 1 CME Credit*

U035 • Cold Induced Skin Disease

Room: W312C

Director: Lynne H. Morrison, MD

Invited Speaker: Stephanie Mengden, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize clinical features of cold induced skin diseases.
2. Develop an appropriate work up to evaluate patients for underlying systemic disease.
3. Formulate management plans for patients with various forms of cold induced skin disorders.

Description
A variety of skin findings can be precipitated by exposure to cold, including Raynaud's phenomenon and disease, chilblains, cold urticaria, cold panniculitis, cutis marmorata, and cryoglobulinemia. Some of these conditions can be associated with underlying systemic disease. We review the clinical features of these disorders, discuss appropriate evaluation to diagnose and detect associated systemic disease and update knowledge of the pathophysiology and treatment. This session is intended for Dermatologists in practice as well as residents.

This activity has been approved by the American Board of Dermatology (ABD) for up to 10 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 1.00 Category 1 CME Credit

U036 • Dermatologic Findings in the Stem Cell Transplant Patient

Room: W314B

Director: Amy C. Musiek, MD

Invited Speaker: Milan J. Anadkat, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe the basic process of a stem cell transplant.
2. Evaluate the common dermatologic conditions in the stem cell transplant patient.

Description
Stem cell transplants are becoming increasingly common with greater than 8000 performed a year in the United States. Traditionally, they have been used for hematologic malignancies, but the technique has also been used in a variety of autoimmune diseases. Patient receiving stem cell transplants develop a variety of skin conditions including: chemotherapy reactions, engraftment syndrome, graft-vs-host disease, and infections. In this session, we will discuss background on how stem cell transplants are performed and then give an overview of the cutaneous complications.
• 1.00 Category 1 CME Credit

U037 • Common Geriatric Dermatology Issues that Patients and Their Caregivers May not Recognize or Are Afraid to Talk About

Room: W202A

Director: Anne Lynn S. Chang, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe barriers to optimal dermatologic care in older adults.
2. Identify practical interventions to improve detection and management of common dermatologic conditions in older adults that patients and their caregivers may not recognize or be afraid to talk about.

Description
Currently, there is no formal curriculum in postgraduate dermatology training on geriatric dermatology, despite the growing number of patients aged 65 years and older worldwide. Hence, dermatologists need to self-educate to provide optimal care. Because aging is often stigmatized, patients and their caregivers may not recognize or be reluctant to discuss common barriers to treatment, including sub-optimal adherence due to memory impairment, visual problems that preclude self-identification of concerning skin lesions, incontinence-related dermatitis, and under-reporting of elder mistreatment. The audience for this session includes practicing dermatologists, resident physicians, physician assistants, and nurse practitioners. • *1.00 Category 1 CME Credit*

U038 • Arthropod-borne Viruses: What Dermatologists Need to Know

NEW

Room: W203C

Director: Iris Z. Ahronowitz, MD

Co-directors: Kieron S. Leslie, MBBS, Maria Teresa Ochoa, MD

Invited Speaker: David H. Peng, MD, MPH

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize emerging arthropod-borne viruses, newly identified vectors, and patients at highest risk for these diseases.
2. Identify cutaneous findings of the arboviruses, as well as their long term sequelae.
3. Locate helpful resources clinicians can use to learn more about current arboviral threats.

Description
Arthropod-borne viruses (arboviruses) represent a major health burden in both the developing and, increasingly, the developed world, due in part to changes in climate, urbanization and global travel. As a number of these diseases have recognizable skin manifestations, dermatologists can play an important role in diagnosing, managing, and even helping to prevent these infections. We will review the latest updates on several important and timely arboviruses including dengue, chikungunya, West Nile, and Zika viruses. Participants will be equipped to recognize acute and chronic presentations of these diseases and become familiar with the key principles of their diagnosis and management. • *1.00 Category 1 CME Credit*

U039 • Functional Genomics: From Genes to Drug Targets

NEW

Room: W204BC

Director: Lindsey Bordone, MD

Invited Speakers: Angela Christiano, PhD, Ali Jabbari, MD, Julian M. Mackay-Wiggan, MD, Neal S. Walker, DO

Learning Objectives
Following this session, the attendee should be able to:
1. Identify the steps taken from basic science research through drug development and clinical trials.
2. Recognize the importance of janus kinase inhibitors in autoimmune diseases, specifically alopecia areata and vitiligo.

Description
During this session the process of drug development, beginning with basic science research through the steps made toward developing a drug, will be discussed. Specifically, janus kinase inhibitors that are now being used to treat autoimmune conditions such as alopecia areata, and more recently vitiligo, will be featured in explaining this involved process. This talk is directed toward anyone interested in learning about development of, and therapy with, janus kinase inhibitors and future uses of these medications and development of other similar drugs. • *1.00 Category 1 CME Credit*

U040 • Highlights from *JAAD*

Room: W304E

Director: Bruce Harris Thiers, MD

Invited Speaker: Clifford S. Perlis, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Examine key articles recently published in *JAAD*.
2. Recognize new therapeutic approaches to skin disease.
3. Define the requirements for publishing a sound scientific study.

Description
Dr. Thiers, who is Editor of *JAAD*, will present an overview of recent key articles published in that journal. Emphasis will be placed on new data that affect the clinical practice of dermatology. Dr. Perlis is a *JAAD* Associate Editor. He will discuss the requisites for publishing in *JAAD*, and provide tips on how to survive the manuscript review process. • *1.00 Category 1 CME Credit*

COURSE • 7:30 TO 9:30 A.M.

Tuition fee and ticket required for admission

C013 • Basic Self-assessment of Dermatopathology Slide Review

Room: W414A

Director: Christine Ko, MD

Invited Speakers: Alina G. Bridges, DO, Antoanella Calame, MD, Catherine Chung, MD, Whitney A. High, MD, JD, Eleanor Ann Knopp, MD, Kiran Motaparthi, MD, Jeffrey P. North, MD, Benjamin Stoff, MD, Travis W. Vandergriff, MD, Kevin P. White, MD, Jeffrey P. Zwerner, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose histopathologic findings of skin diseases more effectively.
2. Evaluate salient features at the microscope.

Description
This session allows participants to actively evaluate slides at a microscope. 60 cases will be provided, with the discussion centering on the differential diagnosis for each case. The discussion is a separate course, included with the fee for this course, from 1 to 4 pm. *• 2.00 Category 1 CME Credits*

DISCUSSION GROUP • 9 TO 11 A.M.

Open admission to eligible categories, no tuition or ticket

D002 • Child Abuse: Practical Approach and Child Abuse Mimickers

Room: W307CD

Director: Arnold Pieter Oranje, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize specific symptoms and signs indicating child abuse and eliminate specific pattern signs indicating that you have to think of child abuse.
2. Manage these particular suspected cases of child abuse using a system that is well-known in journalism and crime-stories/movies called: Kipling's principle (system of 5Ws and 1H: what, when, where, who, why and how).
3. Identify Child Abuse mimickers and find the concluding diagnoses explained by using tricks and trucs following the Kipling's principle.

CANCELLED

Description
Child abuse has been recognized as a serious problem, of which the awareness in medical discipline but also in the general public has been increased since many years. Child abuse occurs when a child receives a physical or mental injury as a result of acts of commission or omission by other persons. The skin is the most accessible organ of the human being. It is also the most frequently injured organ in child abuse. Therefore, you need specific skills to correctly diagnose skin findings. Diagnostic errors can be prevented through close cooperation between forensic pediatrics, pediatric dermatology and radiology. *• 2.00 Category 1 CME Credit*

FORUMS • 9 TO 11 A.M.

Open admission to eligible categories, no tuition or ticket

F048 • Translating Evidence into Practice: Acne Guidelines

Room: W304A

Director: Bethanee Jean Schlosser, MD, PhD

Co-Director: Andrea L. Zaenglein, MD

Invited Speakers: Emmy M. Graber, MD, MBA, Jonette Elizabeth Keri, MD, PhD, Rachel Victoria Sabbag Reynolds, MD, Megha M. Tollefson, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify current recommendations for the use of topical and oral antibiotics in the management of acne.
2. Utilize hormonal therapies and isotretinoin effectively in appropriately selected patients with acne.
3. Apply the updated AAD Acne Guidelines to the management of acne patients in clinical practice.

Description
The AAD's Guidelines of Care for Acne Management were updated and published in 2016. This session will highlight and emphasize the Guideline's current recommendations for the management of acne. Controversies related to the use of oral antibiotics, hormonal therapies and oral isotretinoin will be discussed. In addition, information on the role of diet in acne will be reviewed. The use of physical modalities in the treatment of acne is also included as a novel component to this year's session. The presentations aim to expand attendees' knowledge and improve clinician confidence and effectiveness in treating acne. Time is allotted for audience questions. *• 2.00 Category 1 CME Credits*

F049 • Skin Signs of Internal Disease: Case-based Challenges

Room: W204C

Director: Courtney Reynolds Schadt, MD

Invited Speakers: Soon Bahrami, MD, Jeffrey Phillip Callen, MD, Cindy Owen, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize skin manifestations of internal disease.
2. Utilize appropriate diagnostic tools and additional testing in the evaluation of internal disease.
3. Treat skin diseases while also coordinating care with appropriate specialists.

Description
This session features case-based challenges utilizing the audience response system. The speakers will present diverse cases of skin manifestations of systemic disease with focus on clinical findings, histopathology, evaluation, diagnosis and treatment.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

F050 • Updates in the Epidemic of Hair Loss in African American Women

Room: W303A

Director: Yolanda M. Lenzy, MD

Invited Speakers: Victoria Holloway Barbosa, MD, Chesahna Kindred, MD, MBA, Kimberly Scott Salkey, MD, Meena Kuimari Singh, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe the results of a large nationwide cohort of African American women examining the prevalence and risk factors for Central Centrifugal Cicatricial Alopecia (CCCA) and Traction Alopecia.
2. Discuss data on genetic link in CCCA.
3. Analyze the state of the science including the latest treatments and explore future directions in CCCA research.

Description
This session will explore the latest research on the epidemic of hair loss among African American women. It is suspected that the current estimates of prevalence are an underestimate and there have been no randomized controlled treatment trials for the most common form of hair loss in this population. We will describe the results of the only large cohort study of 59,000 African American women in the U.S. exploring the prevalence and risk factors for hair loss in this population and our community based research leading to the earlier detection of hair loss by partnering with hair stylists. • *2.00 Category 1 CME Credits*

F051 • Closing the Gender Gap in Academic Dermatology and Dermatology Leadership: Problems and Solutions

Room: W307B

Director: Michi Shinohara, MD

Invited Speakers: Lynn Ann Cornelius, MD, Tammie C. Ferringer, MD, Mary E. Maloney, MD, Sara Samimi, MD, Kanade Shinkai, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify challenges faced in dermatology careers, particularly by women, at home and in the workplace.
2. Discuss strategies for time efficiency and work-life balance.
3. Explore leadership and communication styles, and discuss conflict resolution techniques.

Description
Women are now the majority of dermatology trainees. Although strides have been made, women continue to remain underrepresented in leadership positions in dermatology. Lack of mentorship, lack of leadership training, differing leadership styles, and persistent bias towards gender roles may contribute to these disparities. In this interactive session, a panel of women dermatologists in various career stages will discuss topics including time-management, conflict resolution, and work-life balance. The panel will share tips and pearls for success and balance in any career path in dermatology; audience contribution is encouraged. Although focusing on women, these issues are universal, and participation by all genders is encouraged. • *2.00 Category 1 CME Credits*

F052 • Itch

Room: W208A

Director: Sarina Elmariah, MD

Invited Speakers: Ethan A. Lerner, MD, PhD, Tabi Anika Leslie, MBBS, Gideon Smith, MD, Gil Yosipovitch, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize different types of itch.
2. Evaluate and manage acute and chronic itch.
3. Use new therapeutic options to treat specific types of chronic itch.

Description
Chronic pruritus, arising idiopathically or in association with cutaneous or systemic disease, may be incapacitating. This session is meant for the clinician who wants to understand how itch arises and how best to approach itch management in different clinical scenarios, including but not limited to itch associated with advancing age, systemic and neuropathic disease, scalp itch and allergic disorders. Expert itch clinicians and researches will explain what's new in our understanding of itch prevalence and pathophysiology, and will communicate their experience in the diagnosis and management of challenging itches including scalp, genital, autoimmune-related itches and refractory urticaria. *• 2.00 Category 1 CME Credits*

F053 • Advanced Dermatopathology

Room: W308A

Director: Francisco G. Bravo, MD

Invited Speakers: Lawrence E. Gibson, MD, Beth S. Ruben, MD, Omar P. Sangueza, MD, M. Angelica Selim, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Summarize specific aspects of dermatopathology, either as a matter of anatomical location of the disease (nail or vulvar lesion), the tissue component involved (vascular) or the mechanism of disease (infections or IgG4 deposits).
2. Recognize such pathology on the basis of discussion of specific entities.

Description
During the session the presenters will review specific aspects of dermatopathology , such as vulvar pathology, pigmented lesions on nails, vascular lesions, IgG4 dermatosis and new or under recognized infections affecting the skin.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

F054 • Volunteers Abroad: Beginners

Room: W209C

Director: Casey Anderson Carlos, MD, PhD

Invited Speakers: Aegean Chan, MD, Hayes B. Gladstone, MD, Camille E. Introcaso, MD, Nancy Kelly, Alexia Passe Knapp, MD, Adam D. Lipworth, MD, James J. Nordlund, MD, Scott A. Norton, MD, MPH, Benjamin Stoff, MD, Harvey I. Weinberg, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize the dermatologist's role in international volunteering.
2. Identify steps necessary to participate in dermatologic clinical care and education abroad.
3. Summarize opportunities and challenges that commonly arise for dermatologists volunteering abroad.

Description
Have you ever wanted to volunteer and didn't know how to begin? Did you wonder, is this the right time to volunteer? This course will help you achieve those goals. We will have several speakers from different career points discuss how to incorporate meaningful volunteer experiences into a busy career. We will have representatives from our dermatology volunteer groups to answer your questions about the nuts and bolts of setting up a volunteer project. And we will have a crash course in getting yourself ready for that trip! Join us in this fun, informative and interactive session.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

F055 • Why Does My Skin "Feel" So Funny? From Dysesthesias to Dysmorphia

Room: W315B

Director: Richard G. Fried, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Formulate a comprehensive differential diagnosis of dysesthetic skin sensations.
2. Formulate an appropriate work-up of dysesthetic symptoms.
3. Assess effective and novel treatments for the management of dysesthetic symptoms.

Description
Alteration in skin sensation is commonly encountered in clinical practice. Itch, tingle, burning, pain, hyperesthesia, and formications are but a few of the dysesthetic symptoms that cause patients distress. The possibility of an infectious, inflammatory, autoimmune, metabolic, allergic, or neoplastic etiology needs to be examined. The potential for protean psychiatric reactions to dysesthetic symptoms is understandably huge. In contrast, the role of psychological factors in the etiology or exacerbation of dysesthetic symptoms can be substantial as well. This session will explore the work-up of dysesthetic skin sensations and provide suggestions for the comprehensive management of these difficult patients. *• 2.00 Category 1 CME Credits*

F056 • Late-breaking Research: Clinical Trials

Room: W415D

Director: Hensin Tsao, MD, PhD

Invited Speakers: Andrew Blauvelt, MD, Joel M. Gelfand, MD, MSCE

Learning Objectives
Following this session, the attendee should be able to:
1. Describe ground-breaking scientific developments in dermatologic research.
2. Evaluate and apply information from recent investigations to clinical practice.

Description
These forums will highlight the latest ground-breaking observations in clinical, therapeutics, surgical, pediatric, dermatopathologic and basic research. Researchers are invited to submit abstracts describing their most recent results and the top scoring studies will be invited to discuss their findings in a brief oral presentation during one of the themed Forums. *• 2.00 Category 1 CME Credits*

F057 • The Big C's: Children, Cancer, and Cutaneous Complications

Room: W304G

Director: Jennifer T. Huang, MD

Invited Speakers: Carrie C. Coughlin, MD, Dominique Pichard, MD, Sheilagh M. Maguiness, MD, Patrick J. McMahon, MD, Daniel D. Miller, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose cutaneous reactions to targeted anticancer therapies.
2. Evaluate immunosuppressed patients with suspected opportunistic skin infections.
3. Recognize childhood cancer survivors who are at risk for secondary skin cancer.

Description
Dermatologists can be useful and important in the management of pediatric oncology patients. This session will highlight important cutaneous reactions and sequelae to cancer therapy in children. Topics will include cutaneous reactions to targeted anticancer therapy in children, opportunistic skin infections, graft-versus-host disease, and skin cancer surveillance in childhood cancer survivors. This session is geared towards any practitioner who sees children during or after cancer therapy.
• 2.00 Category 1 CME Credits

F058 • Patient Experience, Organizational Culture, and now MACRA: The New Face of Medical Practice

NEW

Room: W312A

Director: Matthew C. Fox, MD

Co-Director: Seemal Desai, MD

Invited Speaker: Charles N. Ellis, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Define quality and value as it pertains to the care of dermatology patients.
2. Assess the Medicare Access and CHIP Reauthorization Act (MACRA) and how it will affect your dermatology practice; the Merit-Based Incentive Payment System (MIPS) and organized medicine's concept of value based care; and explore defined Clinical Practice Improvement Activities (CPIA).
3. Develop strategies for enhancing the patient experience while delivering high quality dermatologic care.

Description
Providers have long sought to deliver valuable, high quality care to their patients. As healthcare delivery evolves at an organizational level, a clear understanding of how value and quality are being measured and defined is imperative. This session will help you to recognize organizational quality metrics and better understand recent changes in healthcare law and how they will impact care delivery. This session is intended to be interactive, with a heavy emphasis placed on developing strategies for improving patient experience in the brave new world of medical practice.
• *2.00 Category 1 CME Credits*

F059 • Shedding Light on Controversies in Phototherapy

Room: W308CD

Director: Elizabeth A. Buzney, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize the benefits, risks, and limitations of different phototherapy modalities for various dermatologic diseases.
2. Formulate and prescribe a treatment regimen for practice-based and home phototherapy.

Description
This session goes beyond the basic how-to, exploring controversial and evolving areas regarding phototherapy for vitiligo and cutaneous T-cell lymphoma; performance of photopatch testing; and the prescription of home phototherapy. Practical tips for the practitioner will be emphasized.
• *2.00 Category 1 CME Credits*

F060 • What's New in Local Wound Care

Room: W311G

Director: Afsaneh Alavi, MD

Invited Speakers: Robert S. Kirsner, MD, PhD, Severin R. Laeuchli, MD, David J. Margolis, MD, Alina Markova, MD, Marco Romanelli, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss wound bed preparation principles.
2. Summarize new treatments available for local wound management.
3. Formulate an approach to the management of stalled wounds.

Description
Wound healing starts with proper diagnosis and treatment of underlying aetiology of wounds. A holistic approach to wound assessment is required as well as optimizing local wound care. Deeper understandings of wound biology have given rise to many new wound care products. Providing good quality local wound care requires a good knowledge of available products, their cost effectiveness and the principles for the optimal interventions. The aim of this session is to provide a review of the proper dressings and local wound management options for practicing dermatologists. *• 2.00 Category 1 CME Credits*

F061 • Lichen Planus and Lichen Planopilaris: An Update

Room: W203C

Director: Lidia Rudnicka, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Define the clinical spectrum of lichen planus.
2. Diagnose various clinical types of lichen planus.
3. Choose adequate therapy for patients with lichen planus and lichen planopilaris.

Description
The clinical spectrum of lichen planus includes cutaneous lichen planus, mucous membrane lichen planus, lichen planopilaris, frontal fibrosing alopecia and lichen planus of the nails. New clinical manifestations of lichen planus have been described recently. The session is designed to present the clinical spectrum of the disease. New diagnostic approaches (dermoscopy, trichoscopy, SES-ANA) will be discussed. Treatment options will be presented. *• 2.00 Category 1 CME Credits*

F062 • Advanced Melanoma-staging, Mechanisms of Current Therapies, and Update on Future Therapies

Room: W304CD

Director: Delphine J. Lee, MD, PhD

Invited Speakers: Gyorgy Paragh, MD, PhD, Michael K.K. Wong, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Compare stages, prognosis, and new ideas for diagnosis of advanced melanoma.
2. Discuss the role of immunity in melanoma and mechanisms of current therapies, with a focus on immune therapies.
3. Summarize future therapies.

Description
The treatment of melanoma patients with locoregional and distant metastases continues to evolve dramatically with new immune therapies. This session will review the current approaches to advanced disease to provide dermatologists a foundation of knowledge to be more effective in managing melanoma patients with a multidisciplinary team. The discussion will also include currently approved immunotherapies within the NCCN guidelines and their mechanisms of action. Updates on potential future therapies will also be discussed. *• 2.00 Category 1 CME Credits*

WORKSHOP • 9 TO 11 A.M.

Tuition fee and ticket required for admission

W004 • Self-assessment: Skin Cancer

Room: W300

Director: Oscar Colegio, MD, PhD

Invited Speakers: Jerry D. Brewer, MD, Anokhi Jambusaria-Pahlajani, MD, MS, Christine Ko, MD, Daniela Kroshinsky, MD, MPH, Jennifer A. Stein, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose common forms of skin cancer more effectively, clinically, histologically, and dermoscopically.
2. Define aggressive characteristics of common forms of skin cancer, and understand current staging criteria of certain forms of skin cancer.
3. Select the best treatment approach for common forms and challenging presentations of skin cancer.

Description
By the end of this session participants should have a better understanding of the clinical, histologic and dermoscopic features of common forms of skin cancer. In addition, participants should understand the current staging criteria for common forms of skin cancer and how they affect practice guidelines. Furthermore, the audience should understand key aggressive features of common forms of skin cancer, as well as appropriate treatments for different forms of skin cancer. This session presents 34 case-based ABD-approved questions that apply towards MOC Component 2 self-assessment requirements. In order to fully participate, it is imperative that participants arrive on time.

This activity has been approved by the American Board of Dermatology (ABD) for up to 34 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

COURSES • 9 A.M. TO 12 P.M.

Tuition fee and ticket required for admission

C010 • Structure and Function of the Skin: Cancer, Immunity and Inflammation

Room: W315A

Director: John J. DiGiovanna, MD

Invited Speakers: Rachael Clark, MD, PhD, Thomas N. Darling, MD, PhD, Heidi H. Kong, MD, MHS, Kenneth Howard Kraemer, MD, James G. Krueger, MD, PhD, Lloyd S. Miller, MD, PhD, Hensin Tsao, MD, PhD, Mark C. Udey, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify the various mechanisms underlying the development of malignancies.
2. Describe the skin immune system, and the role of inflammation, antimicrobial peptides, and the microbiome.
3. Recognize how alterations in these skin components lead to disease.

Description
One module of a three-part curriculum discussing the normal structure and function of cells and tissues within the skin, and how their impairment leads to representative diseases. This module will focus on mechanisms underlying cancer, and the role of immunity and inflammation in skin disease. Examples will be shown of how skin biology is being translated into patient care. The curriculum is a basic overview of skin biology for residents and dermatologists. Bring a print or electronic copy of the handouts to facilitate following the lectures. • *3.00 Category 1 CME Credits*

C011 • Dermatology Review: General and Cosmetic

Room: W202C

Director: Gary Goldenberg, MD

Invited Speakers: Marc D. Brown, MD, David Eric Cohen, MD, Seemal Desai, MD, Zoe Diana Draelos, MD, Lawrence F. Eichenfield, MD, Boni E. Elewski, MD, George J. Hruza, MD, Joseph L. Jorizzo, MD, Thomas E. Rohrer, MD, Jeffrey M. Sobell, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize new developments in medical, pediatric, and cosmetic dermatology.
2. Evaluate new treatment options for dermatologic conditions, including contact dermatitis, psoriasis, onychomycosis, and vasculitis.
3. Analyze and describe best practices for cosmetic dermatology, including laser surgery.

Description
This course will comprehensively review new developments in medical, cosmetic, and pediatric dermatology. Innovation in diagnosis and treatment of common dermatologic conditions, such as skin cancer, psoriasis, contact dermatitis, and vasculitis will be reviewed. New developments and best practices in cosmetic dermatology will be reviewed. • *3.00 Category 1 CME Credits*

C012 • Live Demonstration: Soft Tissue Augmentation and Neuromodulators – Simultaneous Cadaver Prosection and Live Patient Injections

Room: W415B

Director: Susan H. Weinkle, MD

Invited Speakers: Eric Breisch, PhD, Jean D.A. Carruthers, MD, Sue Ellen Cox, MD, Doris J. Day, MD, Julius Fen, MD, Hassan I. Galadari, MD, David J. Goldberg, MD, JD, Jeremy Green, MD, Joely Kaufman, MD, Seth Matarasso, MD, Mark S. Nestor, MD, PhD, Pierre Nicholai, MD, David M. Ozog, MD, Melanie Palm, MD, Marta I. Rendon, MD, Thomas E. Rohrer, MD, Heidi A. Waldorf, MD, Jackie Yee, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize and identify facial and neck anatomy as it relates to the use of cosmetic injections.
2. Assess and avoid complications injecting at various face and neck locations and depths.
3. Develop a therapeutic rejuvenation plan utilizing a combination of nonsurgical treatments.

Description
This session will include demonstration of newly FDA-approved tools to augment existing nonsurgical rejuvenation. Attendees will have the unique opportunity to see live patient assessment and treatments along-side demonstration of pertinent anatomy on a dissected cadaver - techniques have evolved to require injections at various tissue planes, therefore understanding anatomy is extremely important in order to avoid complications and maximize patient outcomes. Live patient demonstrations will include augmentation with dermal fillers, treatment of submental fullness, and optimal use of neuromodulators. • *3.00 Category 1 CME Credits*

C015 • Media Training: Developing and Delivering Key Messages

Room: W313

Director: Joshua Zeichner, MD

Invited Speaker: Ruth Mugalian, MS

Learning Objectives
Following this session, the attendee should be able to:
1. Prepare compelling and relatable key messages.
2. Communicate key messages clearly, concisely, and effectively.
3. Develop strategies for staying focused on key messages in challenging situations.

Description
The Academy has identified effective communication as a core competency for leadership in dermatology. Learning how to successfully craft and deliver key messages will help you communicate effectively in any situation. Attendees will have the opportunity to practice what they've learned about message development in mock media interviews designed to challenge participants to stay focused while delivering their message. The course director will be assisted by a communications consultant. *This session is open to board-certified dermatologists, graduate members, residents and research fellows only. • *3.00 Category 1 CME Credits*

SYMPOSIA • 9 A.M. TO 12 P.M.

Open admission to eligible categories, no tuition or ticket

S018 • Residents and Fellows Symposium

Room: W305A

Director: Robert Paul Dellavalle, MD, PhD

Invited Speakers: Emily M. Altman, MD, Cory A. Dunnick, MD, Shayla Orton Francis, MD, Mayumi Fujita, MD, PhD, Thomas Casey Gallagher, MD, Christophe F. Hsu, MD, Anne E. Laumann, MBChB, Jason Pelham Lott, MD, David Albert Norris, MD, Amanda Schultz, PA-C, Steven B. Sloan, MD, Bruce Harris Thiers, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify the most significant dermatology laboratory and clinical research performed by residents and fellows.
2. Recognize developing trends in cutaneous biology and clinical dermatology research.

Description
New knowledge about the pathophysiology and treatment of cutaneous disease is crucial for the future of our specialty. In this session, talented resident and fellow investigator finalists for the Everett C. Fox Memorial Award will present their clinical and basic science research discoveries. The founder of the Award, Dr. Fox, was a leading dermatologist in Dallas, Texas, and was active at Baylor and UT Southwestern. He was born in Italy, Texas, in 1902 and graduated from Baylor University College (BUCM) of Medicine in 1928. After specialty training in New York, he returned to Dallas where he practiced until he retired in 1975. He taught clinical dermatology and syphilology at BUCM from 1935 until 1943 and subsequently at UT Southwestern. He was a wonderful teacher and clinician, respected by patients and colleagues alike, and a man of great principle who insisted on punctuality. The Academy is grateful to Dr. Fox for providing the endowment that allows for this Award and encourages research by dermatology residents and fellows. The faculty speakers listed above will serve as the examining and judging panel for the presentations and the Award. *• 3.00 Category 1 CME Credits*

S019 • Acne and Rosacea

Room: Chapin Theatre

Director: Linda F. Stein Gold, MD

Invited Speakers: Hilary E. Baldwin, MD, David Eric Cohen, MD, James Q. Del Rosso, DO, Seemal Desai, MD, Zoe Diana Draelos, MD, Julie Claire Harper, MD, James Joseph Leyden, MD, David M. Ozog, MD, Diane M. Thiboutot, MD, Guy F. Webster, MD, PhD, Jonathan S. Weiss, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Examine current research on the pathophysiology of acne and rosacea.
2. Analyze best clinical practice for the treatment of acne and rosacea.
3. Examine the pipeline of new treatment options for acne and rosacea.

Description
In this session we will examine the current research into the pathophysiology of acne and rosacea. We will look at best treatment approaches for the treatment of these diseases and analyze how these treatments compare. We will also review the drugs on the horizon. *• 3.00 Category 1 CME Credits*

S020 • Soft Tissue Augmentation: The Nasolabial Fold and Beyond

Room: W207AB

Director: Dee Anna Glaser, MD

Invited Speakers: Ada R. Trindade Almeida, MD, Vince Bertucci, MD, Andre Braz, MD, Sue Ellen Cox, MD, Sabrina G. Fabi, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Select the appropriate filler product for the underlying anatomic defect(s).
2. Demonstrate the proper technique(s) for soft-tissue augmentation for facial and body areas, aside from the nasolabial fold.
3. Design an appropriate treatment paradigm to minimize adverse reactions.

Description
Faculty will present innovative approaches to soft tissue augmentation of the face and body, including the forehead, temples, brows, midface, tear trough, lips, lower face, hands, and chest. Videos will demonstrate best practice techniques to maximize outcomes and minimize adverse events. Advanced treatment pearls will be shared to enhance participants' existing techniques. *• 3.00 Category 1 CME Credits*

S021 • Disorders of Mucous Membranes

Room: W304E

Director: Rochelle R. Torgerson, MD, PhD

Invited Speakers: Alison J. Bruce, MBChB, Nasim Fazel, MD, DDS, Jennifer L. Hand, MD, Kalyani Marathe, MD, MPH, Ginat W. Mirowski, MD, DMD, Bethanee Jean Schlosser, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose and manage oral diseases with more ease.
2. Diagnose and manage female, male and pediatric genital disease more effectively.
3. Recognize mucous membrane signs of genodermatoses.

Description
Oral and genital diseases of men, women, and children are under the purview of the dermatologist. Unfortunately, as dermatologists, we often receive limited training in mucosal dermatology. This session will focus on the diagnosis and management of mucous membrane disease in men, women, and children. Complex diseases will be covered, highlighting the key role of the dermatologist in multidisciplinary patient care. *• 3.00 Category 1 CME Credits*

S022 • New Emerging Therapies

Room: W415A

Director: Mark S. Nestor, MD, PhD

Invited Speakers: Glynis R. Ablon, MD, David Eric Cohen, MD, David J. Goldberg, MD, JD, Leon H. Kircik, MD, Theodore Rosen, MD, Guy F. Webster, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify new treatments and therapies that are either available now or will be available in the near future to treat psoriasis, acne, rosacea, hair loss, atopic dermatitis, nonmelanoma skin cancer, as well as infections of the skin.
2. Evaluate present and future therapies for prevention and treatment of scars.
3. Develop treatment algorithms to expand our options for minimally invasive cosmetic dermatology.

Description
This session is designed to present new emerging therapies that are available either now or in the near future for both common dermatologic conditions, including psoriasis, atopic dermatitis, acne, rosacea, infections of the skin and nonmelanoma skin cancer, as well as scar therapy and minimally invasive cosmetic procedures. *• 3.00 Category 1 CME Credits*

COURSES • 9 A.M. TO 4 P.M.

Tuition fee and ticket required for admission

C016 • Derm Exam Prep Course: Refresher

Room: W311A

Director: Nicole M. Burkemper, MD

Co-Director: Michelle B. Tarbox, MD

Invited Speakers: David R. Carr, MD, Lucia Zoraida Diaz, MD, M. Yadira Hurley, MD, Ian A. Maher, MD, Brian L. Swick, MD, Daniel A. West, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose general dermatologic conditions and diseases within the American Board of Dermatology standards for competency.
2. Identify areas needing additional study in preparation for the General Dermatology module of the MOC Recertification examination.
3. Self-assess current knowledge and reflection on clinical practice as stimulated by the dermatologic images, anonymous benchmarking feedback, and discussion at the course.

Description
This course is targeted to dermatologists preparing for the American Board of Dermatology (ABD) Maintenance of Certification (MOC)/Recertification Examination. The course will review the 150 specific disease states provided by the ABD as a study guide for the General Dermatology module of the MOC exam in a format similar to the one used on the exam. The course will provide the audience with an opportunity to identify dermatologic diseases based on images. Note: This course reviews only diagnoses for the General Dermatology module and does NOT include questions from the Subspecialty modules.

This activity has been approved by the American Board of Dermatology (ABD) for up to 141 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 5.75 Category 1 CME Credits

C017 • Pediatric Dermatology

Room: W209B

Director: Patricia M. Witman, MD

Invited Speakers: Laleh Bedocs, DO, Latanya Benjamin, MD, Anna Lee Bruckner, MD, Yvonne Chiu, MD, Dawn M.R. Davis, MD, Jonathan A. Dyer, MD, Esteban Fernandez Faith, MD, Katya Harfmann, MD, Stephanie K. Jacks, MD, Amy J. Nopper, MD, Joyce Teng, MD, Ruth Ann Vleugels, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose skin conditions that occur in newborns and pediatric patients more effectively.
2. Select the most appropriate management strategies for children with skin disease.

Description
Aimed at general dermatologists and dermatology residents, this course is intended to provide the attendee with a comprehensive approach to dermatologic conditions in the neonatal and pediatric age groups. Topics covered will include neonatal dermatology, birthmarks, autoimmune and other inflammatory conditions, developmental anomalies, genodermatoses, and pediatric melanoma. Special considerations when doing procedures and prescribing systemic medications in the pediatric patient will also be discussed.

This activity has been approved by the American Board of Dermatology (ABD) for up to 60 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 6.00 Category 1 CME Creditss

C018 • Advanced Practice Management

Room: W311E

Director: Jeffrey J. Miller, MD

Co-Director: Ninad C. Pendharkar, MD

Invited Speakers: Joseph S. Eastern, MD, Dirk Michael Elston, MD, Emmy M. Graber, MD, MBA, Victor James Marks, MD, Jack S. Resneck, Jr., MD, Bill Southwick

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize the economic trends that impact a dermatology practice.
2. Identify a new practice management change that will benefit your practice.
3. Develop a new leadership skill that will make your practice successful.

Description
This course will delve into the economics, structure, regulatory demands and challenges of today's dermatology practices. It will both touch on the basics as well as deal with advanced concepts of practice management and ways to better understand and enhance your practice. The format will be presentations that will be augmented with audience questions and discussion.
• 6.00 Category 1 CME Credits

SYMPOSIA • 9 A.M. TO 5 P.M.

Open admission to eligible categories, no tuition or ticket

S009 • Gross and Microscopic Symposium

Room: W306A

Director: Jose Dario Martinez, MD

Co-Director: Natasha Atanaskova Mesinkovska, MD, PhD

Invited Speakers: Javier Alonso-Llamazares, MD, Adam J. Friedman, MD, Christopher C. Gasbarre, DO, Minerva Gomez, MD, Michelle B. Tarbox, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Review and interpret a broad variety of dermatological conditions through multiple clinical cases, with clinical, surgical, and pathological correlations.
2. Recognize a wide variety of dermatological entities with direct applicability to patient care.
3. Increase their diagnostic and treatment skills.

Description
Two-full day symposium entails 192 presentations, which will cover the gamut of clinical dermatology, predicated on clinical/pathological correlation, with attention to new and interesting observations. Presentations will be grouped into several clinical categories allowing attenders to focus on particular conditions/entities. Each presentation will be five (5) minutes. As such, symposium is lively and fast paced, hopefully "with something for everyone" of the audience. Presentations will be clinically germane and applicable to patient care. Symposium is open to all AAD members, non-members, residents/fellows, and medical students. • *16.00 Category 1 CME Credits*

COURSE • 10 A.M. TO 12 P.M.

Tuition fee and ticket required for admission

C014 • Basic Self-assessment of Dermatopathology Slide Review

Room: W414A

Director: Christine Ko, MD

Invited Invited Speakers: Alina G. Bridges, DO, Nooshin Ketabchi Brinster, MD, Antoanella Calame, MD, Catherine Chung, MD, Whitney A. High, MD, JD, Eleanor Ann Knopp, MD, Kiran Motaparthi, MD, Jeffrey P. North, MD, Benjamin Stoff, MD, Travis W. Vandergriff, MD, Kevin P. White, MD, Jeffrey P. Zwerner, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose histopathologic findings of skin diseases more effectively.
2. Evaluate salient features at the microscope.

Description
This session allows participants to actively evaluate slides at a microscope. 60 cases will be provided, with the discussion centering on the differential diagnosis for each case. The discussion is a separate course, included with the fee for this course, from 1 PM to 4 PM. • *2.00 Category 1 CME Credits*

FORUMS • 1 TO 3 P.M.

Open admission to eligible categories, no tuition or ticket

F063 • Cutaneous Lupus and Dermatomyositis: Management Pearls and Pitfalls for the General Dermatologist

Room: W203C

Director: Jennie T. Clarke, MD

Co-Director: Alisa Femia, MD

Invited Speakers: Ruth Ann Vleugels, MD, David A. Wetter, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Appropriately diagnose patients with cutaneous lupus erythematosus and dermatomyositis.
2. Develop a treatment algorithm that incorporates modalities including sun protection, topical therapies, and antimalarials.
3. Describe associated systemic complications of lupus and dermatomyositis and screen appropriately for them.

Description
A case-based approach will be utilized to describe practical clinical scenarios that will enable the resident or general dermatologist to appropriately diagnose and manage patients with cutaneous lupus erythematosus and dermatomyositis. Participants will learn to develop treatment algorithms that incorporate modalities such as sun protection, topical therapies, antimalarials, and retinoids. The evidence for the effectiveness of these agents and their safe use in adults and children will be reviewed. Participants will be able to identify when to initiate systemic immunosuppressive therapy and/or refer to other specialists. • *2.00 Category 1 CME Credits*

F064 • Controversies and Challenges in Contact Dermatitis

Room: W315B

Director: Peggy Wu, MD

Invited Speakers: Ponciano D. Cruz, Jr., MD, Brian C. Machler, MD, Christen M. Mowad, MD, David Marc Sheinbein, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Develop an approach to the patch test negative dermatitis.
2. Determine the role of diet in systemic dermatitis.
3. Identify active areas of debate and research within contact dermatitis.

Description
The session will cover common challenges and considerations in contact dermatitis and patch testing. It will encompass the controversy regarding systemic contact dermatitis, update the audience on hot topics from the literature, discuss management of patch test negative dermatitis, and debate the meaning of "hypoallergenic" in the context of personal care products.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

F065 • Change is Inevitable - Unlock the Secrets to Manage and Lead It

Room: W312A

Director: Beth Ann Drolet, MD

Co-Director: Caroline C. Kim, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Develop and empower your team for inevitable change directives.
2. Explore the science of change and learn how to leverage to better navigate and lead change.

Description
Develop and empower your team for inevitable changes that 'happen to you' rather than being generated by you. This session will explore current change research, give you skills to adapt to, influence and lead change directives. *• 2.00 Category 1 CME Credits*

F066 • Management Issues in Cutaneous Lymphoma

Room: W209C

Director: Youn H. Kim, MD

Invited Speakers: Madeleine Duvic, MD, Larisa J. Geskin, MD, Joan Guitart, MD, Laura Pincus, MD, Christiane Querfeld, MD, PhD, Alain H. Rook, MD, Gary S. Wood, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Apply appropriate tools and tests to diagnose challenging cases of cutaneous lymphoma and to distinguish from its mimics.
2. Identify and formulate an optimal management strategy personalized for the patient.
3. Discuss how the prescribed management benefited and potentially harmed the patient and how it can be modified to further improve your clinical practice.

Description
Cutaneous lymphoma is a group of rare disorders with quite heterogeneous presentations, where management should be individualized to optimize the overall benefit. This session will focus on the critical assessment of how we can improve our clinical management by using cases provided by experts. The participants will enjoy the discussions on utilizing cost-effective tools/tests for diagnosis, optimizing diagnosis by appropriate clinical-pathologic interpretation, developing a personalized management program, and evaluating the clinical outcome of the selected management. Each topic discussion will conclude with how the management can be improved to deliver the optimal care for the patient with cutaneous lymphoma. *• 2.00 Category 1 CME Credits*

F067 • Lessons for Dermatology from the Tao Te Ching

Room: W312C

Director: Clay J. Cockerell, MD

Invited Speaker: Steven Kenneth Shama, MD, MPH

Learning Objectives
Following this session, the attendee should be able to:
1. Provide care that is compassionate, appropriate, and effective treatment for health problems and to promote health.
2. Demonstrate a commitment to carrying out professional responsibities, adherence to ethical principles, and sensitivity to diverse patient populations.

Description
Physicians are faced with many stressors today that place them at risk. This is costly as physician's stress can lead to exercise of poor judgement and medical errors. In this session, suggestions are made on to how to deal with these stressors. A Chinese spiritual text, the Tao Te Ching, will be explored in-depth as a tool physicians can use to deal with stress. The text was written by Lao Tzu around 60 B.C.E. and consists of 81 written messages on how to be more effective in many aspects of life. These will be presented and discussed in this interactive forum. *• 2.00 Category 1 CME Credits*

F068 • Women with Hair Loss

Room: W204C

Director: Lynn A. Drake, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Determine the cause of the hair loss in some cases, often in a short time.
2. Diagnose and categorize hair loss in women more effectively.
3. Treat hair loss appropriately.

Description
Women with diffuse hair thinning can often have a significant underlying cause. The physician must frequently be a detective. This session will identity seven key areas that the physician can explore to determine the possible underlying cause of hair thinning, many of which may be serious diseases. Methods to do this in a timely manner (15-minute office workup) will be discussed. Finally, methods of treatment related to the underlying etiology will be identified. *• 2.00 Category 1 CME Credits*

F069 • Outpatient Radiotherapy of Skin Cancer: Back to the Future

Room: W305A

Director: William H. Green, MD

Invited Speakers: Armand B. Cognetta, Jr., MD, David E. Kent, MD, William I. Roth, MD, Christopher Wolfe, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Outline a brief history of superficial radiation therapy underscoring its significance as a therapeutic tool in dermatology over the last century.
2. Define the basics of radiation physics, radiobiology, dosimetry, treatment planning and delivery as they apply to the treatment of nonmelanoma skin cancers.
3. Discuss the basics of setting up and integrating radiotherapy into a dermatologic practice and also the appropriate selection criteria for its usage.

Description
Superficial radiation therapy has played a major role in the treatment of skin cancer by dermatologists for over a century. In recent years, the use of radiotherapy for nonmelanoma skin cancer has declined due to advancement and great success of Mohs surgery. This session highlights the resurgence of superficial radiation therapy by dermatologists for select skin cancers in patients who desire to avoid surgery or who are poor surgical candidates due to various medical co-morbidities or contraindications. We will review the history, physics, dosimetry, efficacy, judicious selection of lesions, and safe practical application of this time honored modality. *• 2.00 Category 1 CME Credits*

F070 • Biologic Therapy in Dermatology Beyond Psoriasis

Room: W311G

Director: Francisco Kerdel, MD

Invited Speakers: Andrew Blauvelt, MD, Madeleine Duvic, MD, Howard Lee Sofen, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Summarize the knowledge of biologics in cutaneous T-cell Lymphoma.
2. Describe the role of new treatments in Hidradenitis Suppurativa.
3. Recognize the need for new treatment (biologics) in Atopic Dermatitis.

Description
This session will summarize the use of biologics in 4 distinct settings. The session will cover the usage of biologics in chronic idiopathic urticarial, atopic dermatitis, cutaneous T-cell Lymphoma, and Hidradenitis Suppurativa. In each session specific data pertinent to the use of biologics in these entities will be reviewed. • *2.00 Category 1 CME Credits*

F071 • To Err is Human: How to Optimize Patient Safety in Your Practice

Room: W314B

Director: Jason Bok Lee, MD

Invited Speakers: Dirk Michael Elston, MD, Sylvia Hsu, MD, Robert Swerlick, MD, Joshua W. Trufant, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify the major categories of patient safety issues in dermatology.
2. Summarize the common medical errors involved in biopsy pathway and procedural dermatology and evaluate strategies to reduce them.
3. Categorize the sources of diagnostic errors.

Description
The session will highlight the important and relevant patient safety issues in dermatology. Recognizing the spectrum of potential medical errors in dermatology practice is the first step in improving patient safety and outcome. A critical review of medical errors specific to biopsy pathway and procedural dermatology will be discussed. The session will also include analyses of diagnostic errors, an important emerging patient safety topic, encountered in dermatology. Best practices and strategies to mitigate the various medical errors will accompany the discussion. • *2.00 Category 1 CME Credits*

F072 • Late-breaking Research: Clinical Studies/Pediatric

Room: W308A

Director: Hensin Tsao, MD, PhD

Invited Speakers: Sewon Kang, MD, Amy S. Paller, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe ground-breaking scientific developments in dermatologic research.
2. Evaluate and apply information from recent investigations to clinical practice.

Description
These forums will highlight the latest ground-breaking observations in clinical, therapeutics, surgical, pediatric, dermatopathologic and basic research. Researchers are invited to submit abstracts describing their most recent results and the top scoring studies will be invited to discuss their findings in a brief oral presentation during one of the themed Forums. • *2.00 Category 1 CME Credits*

F073 • Late-breaking Research: Procedural Dermatology

Room: W304C

Director: Hensin Tsao, MD, PhD

Invited Speakers: Murad Alam, MD, Sandy Sharon Tsao, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe ground-breaking scientific developments in dermatologic research.
2. Evaluate and apply information from recent investigations to clinical practice.

Description
These forums will highlight the latest ground-breaking observations in clinical, therapeutics, surgical, pediatric, dermatopathologic and basic research. Researchers are invited to submit abstracts describing their most recent results and the top scoring studies will be invited to discuss their findings in a brief oral presentation during one of the themed Forums. • *2.00 Category 1 CME Credits*

F074 • The Future of Dermatology: What Changes are Coming and How Can We Prepare?

Room: W304AB

Director: Jack S. Resneck, Jr., MD

Co-Director: Marta Jane Van Beek, MD, MPH

Invited Speakers: Jane Margaret Grant-Kels, MD, Carrie L. Kovarik, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Prepare for major changes in insurance coverage, quality and cost measurement, and payment being implemented by Medicare and private health plans.
2. Examine disruptive technologies that are rapidly affecting the specialty, including telemedicine.
3. Analyze reasons for dermatologists as a specialty to collect our own quality and cost data to demonstrate our value, and to design sustainable payment mechanisms that reward quality care and preserve access (rather than having them designed by others).

Description
Our specialty faces many challenges as we adapt to a health care system in a rapid state of flux. In this session, we will provide updates on healthcare reform, MACRA, insurance exchanges, insurance mergers, narrow networks, and their effects on the specialty. Speakers will also cover the importance of measuring and demonstrating our value, dermatology's efforts to fit in to evolving payment models, the rapid expansion of both high quality and poorly done teldermatology, and threats to our ability to choose our own dermatopathologist. • *2.00 Category 1 CME Credits*

F075 • Practical Guidelines For Using Spironolactone in Acne Patients

Room: W208A

Director: Emmy M. Graber, MD, MBA

Invited Speakers: Shari Marchbein, MD, Bethanee Jean Schlosser, MD, PhD, Raja Sivamani, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Select the best candidates for spironolactone treatment.
2. Counsel patients appropriately on spironolactone side effects.

Description
This session will enable attendees to select the best candidates for spironolactone treatment for acne. Attendees will also gain valuable knowledge about spironolactone side effects and management of patients on this medication. Uses for spironolactone other than for acne treatment will be secondarily discussed. *• 2.00 Category 1 CME Credits*

F076 • Autoimmune Blistering Diseases: What's New

Room: W304G

Director: Dedee F. Murrell, MD

Invited Speakers: Valeria Aoki, MD, Pascal Joly, MD, PhD, Neil J. Korman, MD, PhD, Branka Marinovic, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Order new diagnostic tests available for blistering diseases.
2. Discuss the use of biologics for pemphigus and pemphigoid.
3. Describe how the environment and genetics interact in the generation of pemphigus.

Description
This is an advanced session for those already knowledgeable about the basics of blistering diseases. We will focus on what is new in the field, including some new diagnostic tests which have become available to more rapidly distinguish one form of blistering disease from another. We will also inform attendees about the evidence regarding the use of certain biologics in use or in development and clinical trials, for pemphigus and pemphigoid. Lastly, we will explore the evidence that is known about environmental triggers in susceptible populations which leads to the development of pemphigus, using fogo selvagem as the paradigm. *• 2.00 Category 1 CME Credits*

F077 • Superficial, Medium, and Deep Chemical Peeling and Relevance in 2017

Room: W308CD

Director: Harold J. Brody, MD

Invited Speakers: Dee Anna Glaser, MD, Richard Gordon Glogau, MD, Pearl E. Grimes, MD, Marina Landau, MD, Peter P. Rullan, MD, Seaver Soon, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Apply modified croton oil-phenol chemical peeling techniques to rejuvenate peri-orbital skin, including improvement of infra-orbital dark circles, fine wrinkling, and blepharochalasis.
2. Apply superficial, medium depth and modified croton oil-phenol peeling techniques to rejuvenate facial skin and minimize complications, such as the risk for dyspigmentation.
3. Summarize the clinical and histologic effects of superficial, medium and deep chemical peeling solutions on photo-damaged skin.

Description
In this session, we review scientific and practical information on how to achieve facial rejuvenation using variations on superficial, medium and deep chemical peeling. We will focus on medium depth chemical peeling for facial rejuvenation, and on the following two applications of deep chemical peeling: 1) the use of modified croton oil-phenol solutions to achieve improvements in facial wrinkling while minimizing the risk of hypopigmentation, and 2) the use of modified phenol croton-oil chemical peeling techniques for peri-orbital rejuvenation, including improvement of dark infra-orbital circles, fine wrinkling, and blepharochalasis. *• 2.00 Category 1 CME Credits*

F078 • Wound Closure Design: Basic to Advanced

Room: W307D

Director: Terrence A. Cronin, Jr., MD

Invited Speakers: Terrence A. Cronin, Sr., MD, Jonathan Kantor, MD, Susan H. Weinkle, MD, Andrew Hart Weinstein, MD, MPH

Learning Objectives
Following this session, the attendee should be able to:
1. Perform new and unusual closure designs in unique ways for particular locations.
2. Compare with standard usages, showing tweaks and simplifications for improving outcomes.

Description
Using images of actual patients, showing possible closures; some unusual and unique applications for particular locations. *• 2.00 Category 1 CME Credits*

WORKSHOP • 1 TO 3 P.M.

Tuition fee and ticket required for admission

W005 • Self-assessment: Atopic Dermatitis

Room: W300

Room: W415BC

Director: Zakiya P. Rice, MD

Invited Speakers: Sarah Scott Chisolm, MD, Mercedes Gonzalez, MD, Ali Jabbari, MD, Seema Kini, MD, MSc, Brook Tlougan, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe recent discoveries regarding the epidemiology/pathogenesis/treatment of atopic dermatitis (AD).
2. Appropriately address the pediatric patient with AD.
3. Diagnose underlying syndromes associated with AD.

Description
The following aspects of atopic dermatitis will be covered: 1) epidemiology/pathogenesis; 2) approach to the pediatric patient; 3) associations, specifically genodermatoses and infections; and 4) treatment. 34 case-based ABD approved questions that apply towards MOC Component 2 self-assessment requirements will be presented. Answers are recorded via an electronic Audience Response System (ARS), followed by discussion of the case. Immediate, anonymous feedback allows attendees to assess their knowledge and identify areas that require further self-directed study. In order to fully participate, it is imperative that participants arrive on time.

This activity has been approved by the American Board of Dermatology (ABD) for up to 34 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

COURSES • 1 TO 4 P.M.

Tuition fee and ticket required for admission

C019 • Live Demonstration: Head and Neck Anatomy – Cadaver Prosection

Room: W415BC

Director: Hubert T. Greenway, Jr., MD

Invited Speakers: Eric Breisch, PhD, Gary Lask, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify, differentiate, and locate superficial anatomic structures of the head and neck.
2. Prepare to apply knowledge of superficial facial and neck anatomy to the practice dermatological surgical procedures.
3. Distinguish, detect and manage structures in danger areas in superficial facial and neck surgery.

Description
This fresh cadaver session will provide basic principles in head and neck superficial anatomy as it specifically relates to surgery in dermatology. In addition to lectures, fresh cadaver prosected specimens will be used to visualize via live demonstration important head and neck anatomical structures important for dermatologists and dermatological surgeons. Live demonstrations will be projected on large screens for direct visualization of detained anatomic structures. The focus will be on clinical correlation of the anatomy (pre-op, intraoperative, and post-op) to dermatologic surgical procedures. *• 3.00 Category 1 CME Credits*

C020 • Basic Self-assessment of Dermatopathology Discussion

Room: W414C

Director: Christine Ko, MD

Invited Speakers: Alina G. Bridges, DO, Nooshin Ketabchi Brinster, MD, Antoanella Calame, MD, Catherine Chung, MD, Whitney A. High, MD, JD, Eleanor Ann Knopp, MD, Kiran Motaparthi, MD, Jeffrey P. North, MD, Benjamin Stoff, MD, Travis W. Vandergriff, MD, Kevin P. White, MD, Jeffrey P. Zwerner, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose histopathologic features of skin diseases more effectively.
2. Distinguish key histopathologic features for basic entities.
3. Visually recognize diseases in projected photomicrographs.

Description
This discussion will cover the 60 slides that participants personally examined in CO13 and CO14. Speakers will discuss key features of each case and the pertinent differential diagnosis.
• 3.00 Category 1 CME Credits

C021 • Infectious Diseases

Room: W315A

Director: Ronald P. Rapini, MD

Invited Speakers: Francisco G. Bravo, MD, Tammie C. Ferringer, MD, Whitney A. High, MD, JD, Jose Dario Martinez, MD, Steven Randolph Mays, MD, Theodore Rosen, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize emerging infectious diseases.
2. Order appropriate tests for evaluating infections.
3. Utilize effective therapies for eradication of infections.

Description
We have assembled an excellent group of speakers who will cover a spectrum of infectious diseases, including emerging important agents. • *3.00 Category 1 CME Credits*

SYMPOSIA • 1 TO 4 P.M.

Open admission to eligible categories, no tuition or ticket

S023 • Translating Evidence into Practice: Psoriasis Guidelines

Room: W207A

Director: Alan Menter, MD

Co-Director: Craig A. Elmets, MD

Invited Speakers: Alice B. Gottlieb, MD, PhD, Sewon Kang, MD, Mark Lebwohl, MD, Craig L. Leonardi, MD, Abrar A. Qureshi, MD, MPH

Learning Objectives

Following this session, the attendee should be able to:

1. Develop skills to manage patients with psoriasis and psoriatic arthritis with an emphasis on decision making criteria that will enable the clinician to individualize therapy based upon disease type, extent, response to previous treatments, quality of life issues, and co-morbidities.
2. Recognize and diagnose challenging clinical cases and formulate appropriate evidence-based treatment of patients using the recently published six AAD evidence-based guideline of care for psoriasis, which includes best practices.
3. Address gaps in clinical knowledge and care.

Description

The session will be helpful in expanding physician knowledge base and improving clinical confidence and effectiveness in treating patients with psoriasis and psoriatic arthritis. The session will consist of eight presentations. The session will focus on the various treatment approaches discussed in the guidelines of care and recent advances in systemic treatments for psoriasis and psoriatic arthritis including biosimilars. Studies have shown that high-quality guidelines can make important contributions to improving medical care.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

S024 • Hot Topics

Room: Chapin Theatre

Director: Kenneth J. Tomecki, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss a variety of dermatologic 'hot topics' as identified by registrants at the annual meeting.
2. Recognize the medical/surgical implications of those entities, including diagnosis and treatment, especially emerging and innovative therapies.
3. Apply evolving evidence-based knowledge to patient care.

Description
The symposium will address those 'hot topics' established by registrant consensus, a true reflection of member concerns and interests. The somewhat unstructured session will be a 'potpourri' of medical/surgical topics, including some with social and economic import. Expert speakers will provide 'state of the art' material, highlighting recent trends and developments, and accenting emerging and innovative therapies. Presentations will be derm relevant, clinically germane, and directly applicable to patient care. *• 3.00 Category 1 CME Credits*

S025 • Chronic Pruritus: Bedside to Bench Perspectives

Room: W415D

Director: Ethan A. Lerner, MD, PhD

Co-Director: Michael D. Tharp, MD

Invited Speakers: Jonathan Bonchak, MD, Sarina Elmariah, MD, Erin Gilbert, MD, PhD, Mario E. Lacouture, MD, Sonja Stander, MD, Jill S. Waibel, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Evaluate the patient who has chronic itch.
2. Formulate a treatment plan for the patient with chronic itch.

Description
Chronic pruritus has considerable impact on patient quality of life and successful treatment is a challenge. This session is geared toward the practicing physician. It addresses advances in our understanding of the pathophysiology of itch, workup of the itchy patient, gender differences in chronic itch, guidelines for treatment, and cutting edge approaches to treatment that employ devices and medications.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

S026 • Tumor Board

Room: W304E

Director: Kishwer S. Nehal, MD

Invited Speakers: Christopher Barker, MD, Klaus J. Busam, MD, Karen L. Connolly, MD, Kelly L. Harms, MD, PhD, Vicki J. Levine, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify challenges in management of complex skin cancers.
2. Define characteristics of skin cancers that require a multidisciplinary approach to treatment.

Description
Complex and high risk skin cancers present multiple management dilemmas often requiring a multidisciplinary approach. Role of pathology, imaging, surgery, radiation, and medical oncology will be emphasized with a multidisciplinary faculty. *• 3.00 Category 1 CME Credits*

S027 • Photodynamic Therapy

Room: W307AB

Director: Mollie A. MacCormack, MD

Invited Speakers: Elma D. Baron, MD, Barbara Ann Gilchrest, MD, Michael H. Gold, MD, Colin A. Morton, MD, David Michael Pariser, MD, Fernanda H. Sakamoto, MD, Rolf-Markus Szeimies, MD, PhD, Andrea Willey, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Evaluate the use, limitations and potential of topical PDT for premalignant, malignant, and inflammatory skin conditions.
2. Recognize practical aspects of the therapy and select appropriate patients.
3. Select treatment conditions for particular situations and handle specific therapy-related side effects and complications.

Description
This session is designed for those both new to photodynamic therapy as well as those looking to expand the use of this novel treatment within their practice. Pearls and potential pitfalls will be discussed in the use of photodynamic therapy to treat actinic damage, nonmelanoma skin cancer, acne as well as less common diagnoses. Discussion will include management of side effects and practical practice pointers. *• 3.00 Category 1 CME Credits*

S028 • Acne Treatment Controversies

Room: W202ABC

Director: Julie Claire Harper, MD

Invited Speakers: Hilary E. Baldwin, MD, James Q. Del Rosso, DO, Marco Alexandre Dias da Rocha, MD, Linda F. Stein Gold, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Summarize the current evidence regarding diet and acne.
2. Formulate a safe acne treatment plan for a pregnant or nursing woman.
3. Prescribe antibiotics, oral contraceptives, and isotretinoin for acne safely, effectively and responsibly.

Description
This session will focus on common acne treatment dilemmas that many of us deal with everyday in clinic. How relevant is diet in the development of acne? Do we need to be concerned about antibiotic resistance and how do we prescribe antibiotics responsibly? How do we treat acne in a pregnant or nursing woman? What is the role of hormonal therapy in women with acne? These questions will be analyzed and answered based on up-to-date evidence. *• 3.00 Category 1 CME Credits*

S029 • Rewards and Awards: How to make QI Pay Off

Room: W206C

Director: Hillary Johnson-Jahangir, MD, PhD

Invited Speakers: David M. Adelson, MD, MS, John Barbieri, MD, Seemal Desai, MD, Cerrene Giordano, MD, Michael S. Graves, MD, Lucinda Liu Kohn, MD, Avery H LaChance, MD, MPH, Carole McClanahan, MD, Kevin Richard McMullen, MD, Alyssa Miceli, DO, Jon Klint Peebles, MD, Margo Reeder, MD, Marta Jane Van Beek, MD, MPH, Gil Weintraub, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify and prioritize key quality indicators used for physician payment.
2. Assess self-readiness for a clinical practice improvement activity.
3. Identify how measurement of patient experience impacts dermatology practice.

Description
Changing bipartisan care payment models measure quality and value. Measurements of patient experience will soon factor into physician payment and will be published in the public domain. This highly interactive session aims to bring payment for quality performance to life for anyone interested in preparing for Medicare's new 2017 Quality Payment Program that benchmarks quality performance and clinical practice improvement activities. Wrap-up with rapid-fire real-life practice improvement activities underway by the 2016 "AAD Excellence in Patient Care" award winners.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

S030 • Biologics Promises and Perils

Room: W415A

Director: Bruce Elliot Strober, MD, PhD

Invited Speakers: Joel M. Gelfand, MD, MSCE, Richard G. B. Langley, MD, Craig L. Leonardi, MD, Nehal N. Mehta, MD, Jashin J. Wu, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify co-existing comorbidities in psoriasis patients that potentially may be improved or worsened by the various treatment modalities.
2. Describe the evidence-based data supporting the contention that patients with severe psoriasis are a higher risk for cardiovascular disease.
3. Discuss the evidence-based data supporting the use of novel, pipeline drugs and biosimilars for the treatment of moderate to severe psoriasis.

Description
An overview of what is new and relevant in the treatment of moderate to severe psoriasis. The emphasis will be on new drugs, tough to treat patients, biosimilars, and comorbidities.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

S031 • Adventures in Tropical Dermatology

Room: W303A

Director: Scott A. Norton, MD, MPH

Co-Director: Francisco G. Bravo, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize cutaneous presentations of emerging diseases of the tropics.
2. Recognize cutaneous presentations of non-infectious dermatoses of the tropics.
3. Discuss clinical manifestations of parasitic, fungal, viral, and bacterial infections in the tropics.

Description
Clinical dermatology is an essential component of tropical medicine. In this session, participants will review clinically-important topics in a stimulating, interactive, Jeopardy-style format, accompanied by superb clinical photographs. Each question/answer will be followed by a 2-minute mini-lecture on important diagnostic, therapeutic, and pathophysiologic points. Subjects include Fungal Love, Creepy Crawlies, Equatorial Itch, Don't Go in the Water, etc. *• 3.00 Category 1 CME Credits*

DISCUSSION GROUP • 3:30 TO 5:30 P.M.

Open admission to eligible categories, no tuition or ticket

D003 • Recent Advances in Skin Biology and Skin Disease

Room: W308C

Director: Stephen I. Katz, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize the tremendous advances made in dermatology in the past 10 years.
2. Describe that the advances are reliant on basic science discoveries.
3. Incorporate advances into improved patient care.

Description
Major scientific advances continually inform our approach to patient care. In this session I will describe some phenomenol examples of how basic science discoveries are helping us to better understand the mechanisms involved in and the treatment of human disease. I will describe diseases that, in the past 5-10 years we have come to better understand and will talk about their treatment. I will also describe how the human microbiome may be affecting skin and other human disease. Finally, I will talk about the molecular basis for newer treatments for atopic dermatitis, psoriasis and melanoma. *• 2.00 Category 1 CME Credits*

FORUMS • 3:30 TO 5:30 P.M.

Open admission to eligible categories, no tuition or ticket

F079 • Journal Watching

Room: W311G

Director: Mary Wu Chang, MD

Invited Speakers: Murad Alam, MD, Jeffrey Phillip Callen, MD, Craig A. Elmets, MD, M. Angelica Selim, MD, Hensin Tsao, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe advances in medical and surgical dermatology.
2. Recognize special issues in pediatric dermatology.
3. Evaluate current treatments for psoriasis.

Description
A panel of seven expert faculty analyze, summarize, and teach the significant advances from the most recent literature. The latest news from medical dermatology, surgical dermatology, pediatric dermatology, and dermatopathology will be presented, along with specific sections on psoriasis and melanoma. Time for questions and answers will be provided. *• 2.00 Category 1 CME Credits*

F080 • The Pregnant Pause: How to Evaluate and Treat Your Pregnant Patients

Room: W203C

Director: Marcia S. Driscoll, MD

Invited Speakers: Jane Margaret Grant-Kels, MD, Melissa B. Hoffman, MD, Jonette Elizabeth Keri, MD, PhD, Jenny Eileen Murase, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Develop treatment plans for pregnant patients with common dermatologic diagnoses.
2. Evaluate and manage melanocytic lesions in the pregnant patient.
3. Recognize and treat specific dermatoses of pregnancy.

Description
Dermatologists face multiple challenges when evaluating and treating the pregnant patient. Treatment of psoriasis and acne is difficult; risks to the fetus limit the number of evidence-based studies concerning drug therapy. Concerning melanocytic lesions, do nevi change during pregnancy, and if melanoma is diagnosed, is there a poor prognosis? Infections and infestation in the pregnant patient may present a risk for mother and fetus, and treatment options may be limited. Several dermatoses are specific for pregnancy; early recognition and management may be important to prevent adverse effects on the fetus. This forum will review these topics and provide therapeutic recommendations. *• 2.00 Category 1 CME Credits*

F081 • Practice Gaps in Dermatology: Are We Doing What the Evidence Tells Us We Should? Tips for Your Practice

Room: W315B

Director: Dawn M.R. Davis, MD

Invited Speakers: Mark D.P. Davis, MD, Kristen Irene Lo Sicco, MD, Svetomir Markovic, Patricia M. Witman, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Define an example of a dermatology practice gap related to your practice.
2. Identify ways to overcome dermatology practice gaps you experience.
3. Identify barriers that make overcoming your relevant practice gaps difficult.

Description
Dermatologists strive to provide high quality care to patients. The difference between what is actually done in practice and what should be done in practice based on best available evidence is called a practice gap. Through this interactive session, dermatologists can assess anonymously what they do in practice compared with their peers, and listen to experts talk about some of the more common, pertinent, or important practice gaps encountered in medical, surgical and other aspects of dermatology practice.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

F082 • Hand and Foot Psoriasis, Dermatitis and Other Inflammatory Dermatoses

Room: W304C

Director: Robert Bissonnette, MD, MSc

Invited Speakers: David Eric Cohen, MD, Emma Guttman, MD, PhD, Bruce Elliot Strober, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify and diagnose common inflammatory hand and foot inflammatory dermatoses including psoriasis, irritant and allergic contact dermatitis and palmo-plantar pustulosis.
2. Identify which patients with hand and foot inflammatory dermatoses should be patch tested and use the proper allergens and series.
3. Use evidence-based data to select the best treatment options (including topical, phototherapy and systemic therapy) for hand and foot psoriasis, dermatitis, and palmo-plantar pustulosis.

Description
Common inflammatory dermatoses such as psoriasis, atopic dermatitis and contact dermatitis often involve hands and feet. Unfortunately, the morphology is often different on palms and soles making the diagnosis more challenging. Treatment of these inflammatory skin conditions is also more difficult when palms or soles are involved. This session will review the different clinical presentations of common hand and feet dermatoses and the role of patch testing. The focus will be on the management of hand and foot psoriasis, dermatitis and palmo-plantar pustulosis. Recent data on the efficacy of biological agents and oral systemic agents and will be reviewed and discussed. • *2.00 Category 1 CME Credits*

F083 • Phototherapy

Room: W307D

Director: John Y. M. Koo, MD

Invited Speakers: Tina Bhutani, MD, Ethan Charles Levin, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Examine the role of phototherapy in dermatologic disease.
2. Describe some of the latest advancements in the use of phototherapy to treat skin disease.

Description
This session will start out with a review of phototherapy basics, including narrowband UVB, broadband UVB, PUVA, and Goeckerman regimen. This will be followed by a discussion on advances in phototherapy, including the use of excimer laser to treat generalized psoriasis and other advanced phototherapy strategies such as UVA-1. • *2.00 Category 1 CME Credits*

F084 • Vulvar Disease: What Do You Know? An Overview

Room: W204C

Director: Kristen M. A. Stewart, MD

Invited Speakers: Jill I. Allbritton, MD, Melissa Muszynski Mauskar, MD, Miriam Keltz Pomeranz, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe an organized approach to the vulvar exam.
2. Diagnose and manage classic vulvar diagnoses that present as itch or pain.
3. Identify practical clinical pearls for managing patients with vulvar disorders.

Description
This forum will highlight high yield clinical pearls for Vulvar Dermatology. We will first review an overall approach to the vulvar exam and normal variants. The majority of the session will review cases primarily presenting as itch followed by cases primarily presenting as pain. Finally, high yield pearls will wrap-up the session. This session is directed to all who provide clinical care to patients at all levels of training. • *2.00 Category 1 CME Credits*

F085 • Late-breaking Research: Basic Science/Cutaneous Oncology/Pathology

Room: W304A

Director: Hensin Tsao, MD, PhD

Invited Speaker: Paul Nghiem, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe ground-breaking scientific developments in dermatologic research.
2. Evaluate and apply information from recent investigations to clinical practice.

Description
These forums will highlight the latest ground-breaking observations in clinical, therapeutics, surgical, pediatric, dermatopathologic and basic research. Researchers are invited to submit abstracts describing their most recent results and the top scoring studies will be invited to discuss their findings in a brief oral presentation during one of the themed Forums. • *2.00 Category 1 CME Credits*

F086 • Herpes Zoster: Controversies and Conundrums in Treatment and Prevention

Room: W209C

Director: Lorraine L. Rosamilia, MD

Invited Speakers: Whitney A. High, MD, JD, Kieron S. Leslie, MBBS, Vikash Sudhir Oza, MD, Stephen K. Tyring, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Summarize the pathogenesis and key clinical features of herpes zoster, including unique presentations in special patient populations.
2. Identify the best treatment regimens for herpes zoster based on recent literature, including evidence for and against measures to manage post-herpetic neuralgia.
3. Outline, using case scenarios, systems-based prevention strategies for herpes zoster in health care institutions, including updated vaccination guidelines and hospital isolation policies.

Description
During an inpatient consult for herpes zoster, have you ever been approached by a frantic staff or family member, worried that a pregnant, elderly, or infant contact will be 'infected' if they get too close? Have your patients ever asked you about their risk of having herpes zoster twice? Should they be vaccinated? What are the costs? Risks? In what timeline should antiviral therapy be employed? Is there evidence for prednisone or gabapentin? In case-based form, these and other complex but common scenarios will be examined using viral mechanistic and clinical clues and updated prevention and treatment guidelines. *• 2.00 Category 1 CME Credits*

F087 • Lumps and Bumps in Children

Room: W304G

Director: Hanspaul Makkar, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize common and less common developmental anomalies, and distinguish those which need additional workup from those which can be observed, using a head to toe approach.
2. Diagnose and manage common neoplasms seen in neonates and infants.

Description
Developmental anomalies in the neonatal and infantile period can be challenging to recognize, and sometimes warrant additional investigation. In addition, children can present with skin neoplasms that are unique to this age group, requiring knowledge of their natural history and implications for systemic disease. This session will help the dermatologist by using a head to toe approach in the management of lumps and bumps in the pediatric population.
• 2.00 Category 1 CME Credits

F088 • Dermatologic Surgery Disasters: A Dissection of Patient Safety Failures

Room: W314B

Director: Deborah MacFarlane, MD, MPH

Invited Speakers: Murad Alam, MD, David J. Goldberg, MD, JD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss evidence-based patient safety literature in dermatologic surgery.
2. Examine a series of real-life patient safety scenarios.
3. Reduce risk in their own surgical practice.

Description
Patient safety has an integral role in the strategy to improve U.S. health care. This session will review the evidence-based literature designed to assess the extent and impact of errors in dermatologic surgery. A variety of real-life case scenarios will be presented to illustrate such topics as office surgery safety, patient safety in Mohs surgery and laser safety. Attendees will be encouraged to critically examine their own safety practices and start to plan for their own quality improvements. Forewarned is forearmed. *• 2.00 Category 1 CME Credits*

F089 • Reconstruction Options for Defects in the Central Face

Room: W308A

Director: William G. Stebbins, MD

Invited Speakers: Jeremy S. Bordeaux, MD, MPH, Nathaniel J. Jellinek, MD, Mollie A. MacCormack, MD, Victor Allen Neel, MD, PhD, Andrea Willey, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Select reconstructive options that will ensure optimal aesthetic results for a variety of central facial defects.
2. Identify areas at risk for, and techniques to minimize, distortion of free margins such as the eyelid, eyebrow, nasal ala and lip.
3. Recognize the anatomic and tissue movement principles underlying advanced reconstruction of central facial defects.

Description
Surgical defects involving the central face can be some of the most challenging but also some of the most interesting to repair. This session will focus on the wide range of both single and multiple staged repair options that are available to correct difficult defects involving the mid face area. Attention will be paid to common pitfalls and techniques to correct associated complications.
• 2.00 Category 1 CME Credits

F090 • Botulinum Toxin Applications: Past, Present, and Future

Room: W208A

Director: Joely Anne Kaufman, MD

Invited Speakers: Chytra V. Anand, MBBS, Jean D.A. Carruthers, MD, Jeremy Green, MD, Doris M. Hexsel, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Review the discovery of botulinum toxin and its mechanism of action for dermatologic indications.
2. Differentiate the multiple methods and techniques of botulinum toxin application.
3. Prepare for future toxin introductions and identify the differences between present and future uses.

Description
This forum will address the entire category of botulinum toxins (BTX), from the date of their introduction to the plan for the future of neuromodulator use in dermatology and aesthetic medicine. Topics to be addressed will include a discussion of the various mechanisms of action of botulinum toxins and advances in the clinical use of BTX for both aesthetic and medical indications in dermatology. The differences between male and female injection patterns and result will also be delineated. The forum will finish with an outline of the future of BTX, including new uses, formulations and methods of delivery. *• 2.00 Category 1 CME Creditss*

F091 • Volunteers Abroad: Advanced

Room: W305A

Director: Thanh-Nga Trinh Tran, MD, PhD

Invited Speakers: Casey Anderson Carlos, MD, PhD, Esther Ellen Freeman, MD, PhD, Lilit Garibyan, MD, PhD, Karen McKoy, MD, MPH, Edit B. Olasz, MD, PhD, Amit G. Pandya, MD, Thuy Phung, MD, PhD, Babar K. Rao, MD, Benjamin Stoff, MD, John Strasswimmer, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize the dermatologist's role in development of sustainable dermatology services in developing countries; discuss the diagnosis and management of diseases commonly seen in developing countries.
2. Discuss potential challenges and pitfalls and how to make the project sustainable. Outline potential ways to develop a central resource center that could help provide valuable information, tools, educational materials for the dermatologist doing humanitarian work abroad.
3. Identify key components of providing clinical care including surgical care, working with a limited formulary, teaching, and conducting dermatologic research through international volunteering, establishing and providing pathology services Also, understand the ethical challenges with doing in resources poor settings.

Description
This advanced volunteer abroad course complements the beginners course. Attendees will be presented with discussions including ethics of volunteering, challenges and pitfalls of starting non-profits or starting a new sustainable volunteer effort, conducting research overseas, as well as compiling a volunteering toolbox and engaging in discussion with panelists about their experiences in surgery, pathology, education, clinical care and research. Focus will also be on the challenges of making the effort sustainable. *• 2.00 Category 1 CME Credits*

F092 • Photosensitivity

NEW

Room: W312C

Director: Elma D. Baron, MD

Invited Speakers: Anna Chien, MD, Sewon Kang, MD, Henry W. Lim, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Manage photosensitivity and photodermatoses more effectively.
2. Diagnose photosensitivity in skin of color.
3. Prescribe adequate photoprotective strategies.

Description
This session will equip dermatologists to diagnose and manage patients with photosensitivity. It will provide an update on photodermatoses and photosensitivity disorders, discuss novel concepts regarding photosensitivity in non-Caucasian skin/skin of color. and will enhance a clinician's ability to recommend optimal photo protective strategies for different skin types. The topics are appropriate for anyone providing dermatologic care to patients, as well as trainees in dermatology.
• 2.00 Category 1 CME Credits

F093 • Granulomatous Disorders of the Adult Skin

NEW

Room: W312A

Director: Joseph C. English, III, MD

Invited Speaker: Misha Rosenbach, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Differentiate the common non-infectious versus infectious granulomatous disorders of the adult skin.
2. Recognize the cutaneous, histological and systemic manifestations of granulomatous disorders of the adult skin.
3. Determine the evidence based therapeutic modalities for granulomatous disorders of the adult skin.

Description
Granulomatous disorders represent a unique group of diseases both non-infectious and infectious, that require the utmost clinical pathologic correlation combined with a keen sense of inquiry for underlying systemic disease and immunosuppression. Dermatologists need to be able to differentiate these entities, evaluate patients for specific underlying systemic disease and treat them with a wide range of immunosuppressant to anti-infectious medications. By being aware of the skin manifestations of these abnormal physiologic responses dermatologist can improve patient safety, outcomes and lower healthcare costs. *• 2.00 Category 1 CME Credits*

WORKSHOP • 3:30 TO 5:30 P.M.

Tuition fee and ticket required for admission

W006 • Self-assessment: Psoriasis

Room: W300

Director: Stephen E. Helms, MD

Invited Speakers: Lindsey Brodell Dolohanty, MD, Amy Flischel, MD, Neil J. Korman, MD, PhD

Learning Objectives

Following this session, the attendee should be able to:

1. Review clinical criteria in the diagnosis of psoriasis vulgaris.
2. Analyze the risks and benefits prior to initiation of treatment.
3. Recognize the role of biologic therapy in moderate to severe psoriasis vulgaris which has revolutionized the treatment of this condition in the past decade.

Description

We will cover psoriasis, a common disease that is seen in 2% of the population in the United States and accounts for a significantly greater percentage of dermatologic practice. While the diagnosis of psoriasis vulgaris is usually straightforward, the myriad treatment options must be tailored to the needs of each patient considering risks, benefits, and costs. This session presents 33 case-based ABD approved questions that apply towards MOC Component 2 self-assessment requirements. Answers are recorded via an iPad Audience Response System (ARS), followed by discussion of the case. Immediate, anonymous feedback allows attendees to assess their knowledge and identify areas that require further self-directed study. In order to fully participate, it is imperative that participants arrive on time.

This activity has been approved by the American Board of Dermatology (ABD) for up to 32 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

FOCUS SESSIONS • 4:30 TO 5:30 P.M.

Open admission to eligible categories, no tuition or ticket

U041 • Disparities in Dermatology

NEW

Room: W209AB

Director: Junko Takeshita, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Define and identify health and healthcare disparities.
2. Recognize knowledge gaps and the importance of identifying and understanding disparities in dermatology.
3. Discuss potential patient, provider, and health care systems factors that may contribute to disparities in dermatology.

Description
Disparities in dermatology are under-recognized and largely unaddressed in the educational curriculum, clinical practice, and research. This session will focus on: defining health and healthcare disparities and their impact on health outcomes, reviewing the limited data on dermatologic disparities through disease or population-specific examples, and identifying clinical and research gaps in order to create greater awareness of dermatologic disparities and move towards the provision of equitable dermatologic care. • *1.00 Category 1 CME Credit*

U042 • Melanoma and the Genes: Optimizing Patient Management in the Age of Molecular Testing

Room: W311EF

Director: Emily Y. Chu, MD, PhD

Invited Speaker: Michael Tetzlaff, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify patients who would benefit from germline genetic testing to identify inherited melanoma susceptibility, and distinguish between germline and somatic mutation testing to improve patient counseling.
2. Examine the utility of ancillary testing modalities for the distinction of benign versus malignant melanocytic proliferations in skin biopsies.
3. Recognize the available molecular tests for management of advanced melanoma patients.

Description
An increasing number of genetic and molecular tests are being developed and/or utilized for the management of melanoma patients. Dermatologists should be familiar with scenarios in which such testing would be beneficial. During this session, we will discuss the relevance of clinical testing for cancer susceptibility genes, as well as molecular assays which may aid in establishing melanoma diagnosis, prognosis, and response to therapy (including CGH, FISH, and next generation sequencing panels). This session is intended for a broad audience, from dermatology trainees to established practitioners. • *1.00 Category 1 CME Credit*

U043 • Pregnancy Dermatoses: Moving Towards a Better Understanding

Room: W207A

Director: Samantha A. Vaughan-Jones, MD

Co-Director: Robert Muellegger, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize and differentiate the common and specific pregnancy dermatoses.
2. Identify safe and effective treatments for both mother and fetus.
3. Discuss the effect of pregnancy on other skin diseases.

Description
This session aims to provide clinical clues, diagnostic methods, and adequate treatment options for skin disease in pregnancy. Particular attention will be paid to the classification of the specific dermatoses of pregnancy (which has historically caused much confusion). A simplified classification and algorithm will be presented. Pemphigoid gestationis, polymorphic eruption, atopic eruption and intrahepatic cholestasis of pregnancy will be described in detail, and related fetal risks will be addressed. The effect of pregnancy on other common inflammatory skin diseases such as psoriasis, acne, urticaria as well as some rarer auto-immune disorders (pemphigus, lupus erythematosus) will be discussed. Management advice will be focused on special considerations for these inflammatory dermatoses and skin infections which can arise during pregnancy. • *1.00 Category 1 CME Credit*

U044 • Epstein-Barr Virus (EBV) and Its Role in Cutaneous Disease

Room: W206C

Director: Emily Keimig, MD, MS

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize the clinical dermatologic manifestations of EBV infection.
2. Assess the value of laboratory tests used in detecting EBV infection.
3. Discuss the role of EBV as it relates to the immunologic status of the patient.

Description
Epstein-Barr virus (EBV) is a ubiquitous virus worldwide that has a wide range of mucocutaneous manifiestations. These presentations vary from self-resolving, benign conditions to potentially life threatening lymphoproliferative disorders. This session provides an overview of the epidemiology, pathophysiology, and diagnostic testing in EBV infection. The mucocutaneous and lymphoproliferative presentations of EBV infection will be discussed as well as factors that may pre-dispose to their development. • *1.00 Category 1 CME Credit*

U045 • Avoiding Complications and Maximizing Results in Laser Surgery

Room: W202C

Director: Eric F. Bernstein, MD

Co-Director: Roy G. Geronemus, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify and avoid common complications in laser surgery.
2. Implement and apply strategies for managing laser complications.
3. Discuss some basics of laser physics and skin biology as it pertains to laser surgery, and apply this knowledge to diagnose which conditions are amenable to laser treatment.

Description
A comprehensive overview of lasers and other energy-based devices will be covered. An introduction to the physics and biology behind laser-tissue interactions will be presented to enable avoiding common complications and maximizing results of laser surgery. The presenters have extensive experience with a very wide range of devices and can offer their individual pearls and approaches to using modern lasers and energy-based devices. At the completion of the course, attendees should have a better understanding of lasers and energy-based devices, how to use them more safely, and apply this knowledge to manage complications more effectively when they occur.
• 1.00 Category 1 CME Credit

U046 • Sex, Sores, Science, and Surveillance: Syphilis in the 21st Century

Room: W315A

Director: Erin H. Amerson, MD

Invited Speakers: Adriana Cruz, MD, Kenneth A. Katz, MD, MSc, MSCE

Learning Objectives
Following this session, the attendee should be able to:
1. Describe current local and global epidemiologic trends in syphilis and congenital syphilis.
2. Summarize testing and treatment recommendations for syphilis, including changes to recommendations for screening and testing.
3. Recognize novel syphilis testing methods being used in the developing world.

Description
This session will review common and uncommon clinical presentations of adult and congenital syphilis, discuss syphilis epidemiology and its implications for public health locally and globally, and update the audience on new screening and testing recommendations. This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. *• 1.00 Category 1 CME Credit*

U047 • Comorbidities in Psoriasis: What a Dermatologist Needs to Know

Room: W414C

Director: Ronald B. Prussick, MD

Invited Speaker: Nehal N. Mehta, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Examine the known comorbidities associated with psoriasis.
2. Discuss the pathophysiology and epidemiology that underlies the comorbidities.
3. Determine if treatments or lifestyle changes can modify comorbidities.

Description
Moderate to severe psoriasis has been associated with a number of comorbidities which will be discussed. Dr. N. Mehta will review the ongoing cardiometabolic research involving psoriasis patients at the National Institutes of Health (NIH). We will look at the role of systemic inflammation and whether treatment of the skin or lifestyle changes will help modify underlying comorbidities.
• *1.00 Category 1 CME Credit*

U048 • Modern Nail Surgery: Aiming on Minimal Trauma and Nail-preservation

Room: W415D

Director: Christoph R. Loeser, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Evaluate specific nail problems and localize the anatomic site(s) of the pathology (e.g. nail-plate, proximal or lateral nail folds, matrix, nail-bed, bone, joint).
2. Identify appropriate measures for treatment, including nail-surgery.
3. Develop strategies for planning and executing nail-surgery with focus on nail-preservation and minimal trauma.

Description
At least in Dermatology, diagnosis and treatment of nail diseases or nail problems have finally moved from severe traumatizing surgery to delicate nail-preserving and minimal invasive techniques. This session guides the audience from localizing the problem in the anatomic (sub-) unit to planning an individual approach on the basis of instructive cases. Attendants will familiarize themselves with minimal invasive techniques. Useful instruments and methods are presented. The audience is encouraged to share their own experience and tricks of the trade.
• *1.00 Category 1 CME Credit*

U049 • Optimal Management of Pediatric Morphea

Room: W304E

Director: Yvonne Chiu, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize patients at increased risk of extracutaneous manifestations and select appropriate diagnostic workup.
2. Confidently treat severe pediatric morphea with systemic therapy.

Description
Recent research in pediatric morphea has expanded understanding of this disorder. This session will highlight new literature and provide guidance on optimal management based on current evidence. Linear morphea is the most common subtype present in children and is associated with the highest morbidity. A suggested algorithm for workup and monitoring of extracutaneous manifestations will be presented. Selection of optimal therapy and nuances in the use of systemic agents such as methotrexate will be reviewed. • *1.00 Category 1 CME Credit*

U050 • Do Not Forsake the Love You Had at First: Reflection on Patient Satisfaction Surveys

NEW

Room: W303A

Director: Yaohui Gloria Xu, MD

Invited Speaker: Mark Eliason, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize the inevitable trend that doctors are evaluated by random patients and the transparency of survey results.
2. Analyze the potential impact of these surveys on both physicians and patients.
3. Identify positive ways to re-enforce patient-doctor relationships.

Description
Doctors have been evaluated by patients for ages but there has never been a time like today when our acts are scrutinized and our scores are displayed against each other. Have we forsaken the love of medicine that we had at first? What is our reaction? What is our reflection? What is the evidence that patient surveys improve the outcome of patient care? This interactive session is designed to help physicians develop a positive attitude and identify positive ways to re-enforce patient-doctor relationships. • *1.00 Category 1 CME Credit*

U051 • Hedgehog Inhibitor Therapy for BCC: An Academic and a Private Practice Perspective

NEW

Room: W307B

Director: John Strasswimmer, MD, PhD

Invited Speaker: Anne Lynn S. Chang, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Summarize the peer reviewed literature of the use of Hedgehog pathway inhibitors.
2. Identify practice gaps to implementation of Hedgehog therapy.
3. Recognize important side effect management.

Description
Hedgehog (Hh) pathway inhibitors, also called smoothened inhibitors, include vismodegib and sonidegib. They have an important role in complicated BCC tumors. We will review relevant literature and share the perspective and experience of our patient care in both a private practice and academics settings. • *1.00 Category 1 CME Credit*

U052 • Up and Coming Fillers: Experience from Across the Atlantic

NEW

Room: W311A

Director: Hassan I. Galadari, MD

Invited Speakers: Andre Braz, MD, Travis W. Vandergriff, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Utilize sound anatomic understanding to identify areas to correctly inject fillers.
2. Choose the right filler for the right indication on the right patient.
3. Recognize filler complications from histopathologic examination.

Description
This unique session will shed light on different aspects in the field of soft tissue augmentation using fillers. The first part will discuss the physical properties of fillers and their specific uses. The second part will look into anatomic considerations when it comes to injecting the materials. The final part will look into the ability to identify filler elements on histopathology in the event of complication occurrence. The audience will be able to learn how to and where to inject materials that will soon be approved in the U.S. and avoid common pitfalls that may potentially occur. • *1.00 Category 1 CME Credit*

FOCUS SESSIONS • 7 TO 8 A.M.

Open admission to eligible categories, no tuition or ticket

U053 • Light Based Devices: Photomodulation and Hair Growth

NEW

Room: W311A

Director: Maria K. Hordinsky, MD

Invited Speakers: Richard Rox Anderson, MD, Ronda S. Farah, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss the basic science behind light based devices used for hair growth.
2. Identify the light based devices available on the market for hair growth including photobiomodulation (low level light therapy).
3. Select light based devices for management of the patient with alopecia.

Description
Dr. Rox Anderson will open the session with an overview of the basic science behind light based devices and hair growth. He will review the theory behind photobiomodulation (low level laser therapy) and also review recent research on other light based devices resulting in hair growth. Dr. Ronda Farah will provide a detailed overview of the FDA-cleared photobiomodulation devices and other light based devices available for hair growth. Dr. Maria Hordinsky will close the session with a discussion of her clinical and research experience with light based devices for hair loss in the outpatient setting. • *1.00 Category 1 CME Credit*

U054 • Leprosy and Leprosy Reactions

NEW

Room: W206C

Director: Mohammad Rafiqul Mowla, MD, MBBS

Invited Speakers: AQM Serajul Islam, Prof. Ben Naafs

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose and categorize leprosy.
2. Recognize and differentiate leprosy reactions.
3. Manage leprosy and leprosy reactions.

Description
The speakers will highlight the review and updates on 'Leprosy' and 'Leprosy reactions'. The topics will encompass current diagnosis and treatment of 'Leprosy' and 'Leprosy reactions' (LRs). It will help us in early detection and management of Leprosy to prevent disability and deformity. The lectures will be stimulating to develop reinforced new therapies to curb LRs for improving leprosy health care services. • *1.00 Category 1 CME Credit*

U055 • Unmasking Facial Pigmentation

Room: W203C

Director: Michelle Rodrigues, MBBS

Learning Objectives
Following this session, the attendee should be able to:
1. List the differential diagnosis of facial pigmentation.
2. Recognize the clinical features that distinguish melasma from other common causes of facial pigmentation.
3. Describe new advances in the treatment of facial pigmentation.

Description
As the world becomes more diverse, dermatologists are seeing and treating more patients with pigmentary disorders. This session will review the clinical features of melasma, post-inflammatory hyperpigmentation, acquired dermal melanosis and other causes of facial pigmentation. Exciting new developments in treatment such as oral tranexamic acid and picosecond laser technology will be discussed. The format will be interactive with time for audience participation.
• *1.00 Category 1 CME Credit*

U056 • Pearls from the *New England Journal of Medicine*

Room: W304G

Director: Amy Yuntzu-Yen Chen, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe and discuss recent original articles relating to dermatology from the *New England Journal of Medicine.*
2. Utilize the newly described treatments and/or diagnostic tools when caring for dermatologic patients.

Description
This session will focus on presenting selected original articles relating to dermatology from the *New England Journal of Medicine* over the last few years. Audiences will be kept up to date regarding the latest therapy, genetic testing and/or molecular biology to improve patient care.
• *1.00 Category 1 CME Credit*

U057 • Dermatology Business Trends and Practice Opportunities

Room: W304A

Director: Marc A. Darst, MD

Invited Speakers: Richard S. Cooper, JD, Thomas J. Ferkovic, Matt L. Leavitt, DO, Patrick McElgunn, MD, Andrea Tesvich Murina, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Review and discuss evolving dermatology practice trends and the various market factors that influence a decision to align with other physicians/practices, addressing both macro factors (general market factors) and micro factors (factors that are specific to the individual group).
2. Explore clinical processes and alignment options to best fit your practice model.
3. Implement preliminary overhaul and enhancements to your practice before deciding what business alignment to pursue. Critically assess examples of successful practice transitions and alignments.

Description
The business of medical practice is evolving into more complex and integrated networked arrangements that seek to drive greater quality improvements and enhance care coordination through cost savings and clinical process efficiencies. This session will help dermatologists position their practices for survival and success amid a changing health care delivery and finance environment. It will explore a number of business models, clinical arrangements and practice pathways designed to help dermatologists in solo, group and multispecialty practice settings.
• 1.00 Category 1 CME Credit

U058 • Measuring and Assessing Derm Surgery: Surgical Outcomes and Reimbursement

Room: W312C

Director: Ian A. Maher, MD

Invited Speakers: Howard Wooding Rogers, MD, Oliver J. Wisco, DO

Learning Objectives
Following this session, the attendee should be able to:
1. Define the necessary steps for measure development in dermatologic surgery.
2. Discuss how quality measures and other metrics play into the evaluation of dermatologic surgical procedures by payors and regulators.
3. Examine the role of registries and core outcome sets in improving care quality as well as preparing dermatologic surgery for payor evaluation.

Description
This session will educate attendees on the ways that "quality of care" is determined by regulators and payors. The definitions and development process for Quality Measures will be discussed. Payor evaluation processes of dermatologic surgery will be reviewed. Finally, we will discuss the use of registries and core outcome sets in helping provide evidence of quality and value in dermatologic surgical care. *• 1.00 Category 1 CME Credit*

U059 • Dermatologic Management of the Immunosuppressed: From Rapamycin Rash to Wiskott-Aldrich Syndrome (WAS) Dermatitis

Room: W305A

Director: Jerry D. Brewer, MD

Invited Speakers: Anthony A. Gaspari, MD, Julia S. Lehman, MD, Arturo P. Saavedra, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Assess patients that are immunosuppressed in an efficient and comprehensive fashion regarding dermatologic needs and skin cancer detection.
2. Apply appropriate information for triaging and managing high risk skin cancer in the setting of immunosuppression.
3. Define risk factors for dermatologic conditions in the setting of immunosuppression including risk factors for skin cancer misbehavior and how those risk factors affect the management approach.

Description
This session will look at acquired as well as iatrogenic forms of immunodeficiency as it relates to the skin. The session will also discuss the complicated factors of stem cell transplantation and how that impacts dermatology. Finally this session will look at skin cancer in the setting of immunosuppression, risk factor stratification, and proper triage and management approaches to the patient with skin cancer in the setting of immunosuppression. • *1.00 Category 1 CME Credit*

U060 • The Tongue

Room: W202C

Director: Janellen Smith, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe normal variations of tongue anatomy and presentation.
2. Develop a reasonable differential diagnosis for diseases involving the tongue.
3. Formulate a treatment plan for common conditions of the tongue.

Description
Everything you wanted to know about the tongue and more. One of the largest collections of clinical slides devoted specifically to the body's most unruly organ. A comprehensive overview of diseases that may involve the tongue. • *1.00 Category 1 CME Credit*

U061 • My Patient Has Melanoma, Now What Do I Do?

Room: W204C

Director: David Polsky, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Formulate a strategy for the evaluation and management of the newly diagnosed melanoma patient.
2. Develop a plan for the follow up of melanoma patients.

Description
This session will cover the management of patients after their initial diagnosis of melanoma. We will review the evidence supporting clinical staging, surgical management, sentinel lymph node biopsy, and molecular tests. We will also discuss follow up strategies including the identification and management of patients at increased risk for additional primary melanomas. *• 1.00 Category 1 CME Credit*

U062 • Medical Dermatology Potpourri: Challenges Faced and Lessons Learned

Room: W303A

Director: Christina Lam, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Use a case-based approach to the diagnosis of autoimmune connective tissue and other complex medical dermatology diseases.
2. Develop a practical and algorithmic approach to treating the skin manifestations of patients with these systemic diseases.

Description
Inflammatory disorders of the skin can present in a myriad of ways and it is important that dermatologists are able to distinguish between benign conditions and cutaneous manifestations of more serious systemic diseases. Using a case-based approach emphasizing audience participation, this session will highlight clinical pearls for recognizing cutaneous signs important in the diagnosis of select connective tissue diseases. Treatment strategies based on the latest available data in the literature will be discussed, concentrating on an algorithmic approach in the use of systemic medications. This session is geared toward general dermatologists and residents in training.
• 1.00 Category 1 CME Credit

U063 • When to Look Deeper: Common Skin Findings as a Harbinger of Genetic Disease

NEW

Room: W209B

Director: Evelyn Lilly, MD

Invited Speaker: Brittany Gareth Craiglow, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize skin findings that prompt further examination to determine whether genetic testing would be beneficial.
2. Choose among the types of genetic testing available and their advantages and disadvantages.
3. Identify the preventative screening necessary and optimized treatment regimens for particular genetic diseases.

Description
This session will identify the common skin findings that can be signs for systemic genetic diseases. Additionally, we will summarize the localized skin diseases that appear to be the result of post-zygotic mutations which still have potential to affect the patient's children. We will then assess the clinical situations in which genetic testing is appropriate and how to choose the type of genetic testing that would be optimal. Once a diagnosis is rendered, we will discuss the ways in which we can still help patients with incurable diseases. • *1.00 Category 1 CME Credit*

U064 • Dermatologist Burnout: How to Spot it and How to Avoid it

NEW MOC

Room: W315B

Director: Andrea Tesvich Murina, MD

Invited Speaker: William L. Waller, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify factors that lead to physician burnout.
2. Promote early recognition of burnout.
3. Discuss strategies and action plans to combat burnout.

Description
Burnout is becoming and increasingly bigger problem among physicians, and dermatologists are not immune. Burnout leads to emotional exhaustion, loss of meaning in work, and feelings of ineffectiveness. It decreases productivity, morale, and quality of care. Solving the problem of physician burnout requires system wide changes, but there are several steps that dermatologists can take to improve their own wellness.

This activity has been approved by the American Board of Dermatology (ABD) for up to 10 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 1.00 Category 1 CME Credit

U065 • Hot Topics in Translational Dermatology

NEW

Room: W304E

Director: Rachael Clark, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Explore how alterations in the immune system can contribute to inflammatory skin diseases.
2. Discuss novel therapies targeting specific immunologic pathways in skin.
3. Discuss how tissues and analytic technologies available through the Human Skin Disease Resource Center can help translational researchers.

Description
This session is designed to update the audience on new developments in translational immunology, especially those that are of most interest to clinical practitioners. The session will touch on general immunology of the skin, with an emphasis on understanding the pathogenesis and treatments of inflammatory skin diseases. We will also highlight the resources available through the Human Skin Disease Resource Center that can help clinicians carry out translational research projects.
• *1.00 Category 1 CME Credit*

U066 • Controversies in Calciphylaxis: An Overview of Pathogenesis, Diagnosis, and Treatment through Case Studies

NEW

Room: W314B

Director: Christine Baran Warren, MD, MS

Invited Speaker: Anthony Fernandez, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify risk factors for developing uremic and non-uremic calciphylaxis.
2. Describe cutaneous manifestations of calciphylaxis and recognize the utility of various histologic features in making the diagnosis.
3. Discuss the differential diagnosis of calciphylaxis, as well as challenges in rendering the correct diagnosis, and formulate multidisciplinary treatment strategies.

Description
Calciphylaxis, or calcific uremic arteriolopathy, is considered a rare disease with poor prognosis. It is characterized by vascular calcification with accompanying intimal hypertrophy and small vessel thrombosis, resulting in skin ulceration and necrosis. Calciphylaxis may be more common than previously recognized with an increasing number of individuals, with and without end stage renal disease, being diagnosed with this disorder. This session will use an audience-response and case-based format to review current knowledge surrounding the pathophysiology, risk factors, clinical and diagnostic features, and management options for this challenging disease.
• 1.00 Category 1 CME Credit

Dermatology's Leading Experts

AAD/A ANNUAL BUSINESS MEETING

SUNDAY, MARCH 5 • 8:00 A.M. • CHAPIN THEATRE

Start your morning at the AAD Business Meeting!
The vitality of our organization is more important than ever. Hear from Dr. Torres and Dr. Mathes as they discuss the priorities and initiatives of the organization, and deliver the annual financial report. While there, get to know the president-elect candidates so you can make an informed decision for the AAD elections.

Carrie L. Kovarik, MD, FAAD*

Clarence S. Livingood, MD, Award and Lectureship
Telemedicine and the Future of Medicine
8:50 a.m.

Dermatology will continue to face challenges as new models for health care delivery systems evolve and value based care becomes implemented on a wider scale. Teledermatology has the potential to improve access for patient care within these health care systems and provide an efficient, patient-centered experience. Teledermatology can be used to improve patient care, access, and outcomes in a variety of ways, including triage, urgent care, inpatient consultation, direct follow-up with patients, and patient monitoring, when integrated into the patients' overall medical care. Recommendations for standard ethical practices in teledermatology are essential in order to ensure consistent coordinated, high-quality care. We are currently at a crossroads where technology, medical care, patient needs, business success, and free market competition are in occasional opposition and imbalance. The position of our specialty and future of medicine will be determined by how the advocates of these opposing forces work together.

Christine Léauté-Labrèze, MD*

Eugene J. Van Scott Award for Innovative Therapy of the Skin and Phillip Frost Leadership Lecture
Propranolol in Infantile Hemangiomas: A Successful Drug Repurposing
9:30 a.m.

In 2014, propranolol was the first treatment approved to treat complicated infantile hemangiomas. The effect was first observed in an infant treated with propranolol for corticosteroid induced myocardiopathy. The step from a serendipitous observation of the therapeutic effect to the voluntary administration to ensure the reproducibility was easy to make because there was no satisfactory treatment for infantile hemangiomas. I will explain how a well-known molecule used in cardiology for 50 years has been developed with success in an unexpected indication.

*These lectures are approved for 2.25 Category 1 CME Credits.

to deliver Plenary Lectures

Boris C. Bastian, MD, PhD*

Lila and Murray Gruber Memorial Cancer Research Award and Lectureship

How Moles Become Cancer

10:10 a.m.

The lecture will cover recent research on the molecular evolution of melanomas from their corresponding precursor lesions and provide a summary of the molecular taxonomy of melanocytic neoplasms.

Joel M. Gelfand, MD, MSCE, FAAD*

Marion B. Sulzberger, MD, Memorial Award and Lectureship

Getting to the Heart (and other Co-morbidities) of Psoriasis

10:35 a.m.

Psoriasis is a chronic Th1, Th17 inflammatory disease of the skin and joints. Emerging research ranging from large, broadly representative population-based studies, to smaller, deeply phenotyped, specialty clinic-based studies, to experimental animal models, indicate that psoriasis is associated with major cardiovascular events, disorders of metabolism, diabetes, end stage renal disease and mortality. It ultimately culminates in approximately five years of life lost among patients with more severe skin disease. Emerging observational and experimental studies in humans are better defining the impact of systemic treatment of psoriasis on major health outcomes such as major cardiovascular events. These scientific advances have important clinical implications for the care of patients with psoriasis and have resulted in changes to standard of care recommendations.

RADM Jordan W. Tappero, MD, MPH*

Guest Speaker

The West African Ebola Epidemic and the Global Health Security Agenda

11:00 a.m.

As Senior Advisor for Global Health, Center for Global Health (CGH), Centers for Disease Control and Prevention (CDC), he provides strategic scientific and programmatic contributions to the Office of the Director's (CGH/OD) management and oversight of a more than $3 billion annual budget. He also leads and executes CGH/OD's efforts to institutionalize the Global Health Security Agenda at CDC. Dr. Tappero brings 24 years of extensive global experience to this key leadership position, including 11 years residing overseas.

DISCUSSION GROUP • 1 TO 3 P.M.

Open admission to eligible categories, no tuition or ticket

D005 • Atopic Dermatitis in Adults: Not Just Big Kids

NEW

Room: W208A

Director: Jonathan I. Silverberg, MD, PhD, MPH

Learning Objectives
Following this session, the attendee should be able to:
1. Describe the various presentations of atopic dermatitis in adults.
2. Identify key differences between atopic dermatitis in children and adults.
3. Discuss treatment considerations for atopic dermatitis in adults.

Description
This session will review the diagnosis and unique aspects of atopic dermatitis in adults. Key subjects to be covered include differences of phenotype, comorbidities, clinical course and response to topical and systemic treatment of atopic dermatitis in adults as compared with children.
• 2.00 Category 1 CME Credits

FORUMS • 1 TO 3 P.M.

Open admission to eligible categories, no tuition or ticket

F094 • Referral Medical Dermatology

Room: W209C

Director: Joseph L. Jorizzo, MD

Invited Speakers: Joanna L. Harp, MD, Rita O. Pichardo, MD, Lindsay Chaney Strowd, MD, George Varghese, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Examine different aspects of approaching referral patients with complex medical dermatology programs.
2. Evaluate referral patients with neutrophilic dermatoses, hidradenitis suppurativa and related dermatoses, hair issues and vulvar dermatoses, and conditions that require exclusion of cutaneous lymphoma.
3. Choosing treatment strategies for general medical dermatology referral patients and patients with the issues raised above.

Description
A general discussion outlining key problem areas in patient evaluation and therapy for referral patients with complex medical dermatology problems with examples from rheumatologic dermatology will start the session. This will be followed with practical talks discussing patient evaluation and therapy for the following disease categories: neutrophilic dermatoses, hidradenitis suppurativa and related syndromes, hair disorders, vulvar dermatoses, and dermatoses requiring evaluation for lymphoma. A panel discussion at the end will allow for interaction with faculty on these and other issues. *• 2.00 Category 1 CME Credits*

F095 • Finding Solutions to Challenging Cases

Room: W305A

Director: Milan J. Anadkat, MD

Invited Speakers: Heather Ciliberto, MD, Martha Laurin Council, MD, Lindsey Brodell Dolohanty, MD, Benjamin Kaffenberger, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize challenging diagnostic and therapeutic dermatologic dilemmas.
2. Formulate a logical clinical approach to conquer these dermatologic challenging scenarios.

Description
Clinical practice offers the potential to become stumped every now and again, regardless of your level of expertise. This session will present unique scenarios encountered in clinical practice (medical, surgical, pediatric) that have posed a diagnostic or therapeutic challenge. The ensuing discussion will then focus on how these dilemmas were tackled. Each invited lecturer is a junior academic faculty that routinely manages such patients across the country. These lecturers are the stars of tomorrow. Audience members will actively interact with lecturers during the forum through the Audience Response System.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

F096 • Advances in Lasers and Light Sources: What's the Truth?

Room: W304A

Director: Jill S. Waibel, MD

Invited Speakers: Richard Rox Anderson, MD, Paul M. Friedman, MD, Arielle N.B. Kauvar, MD, Kristen Marie Kelly, MD, Suzanne L. Kilmer, MD, E. Victor Ross, Jr., MD, Peter Randall Shumaker, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss the most current indications and advanced treatment protocols for laser and light treatments.
2. Identify the most appropriate candidates for laser and device treatments and gain treatment pearls to take back to your office.
3. Review of cutting edge research and emerging laser, light and other devices for use in both medical and aesthetic dermatology.

Description
This course is designed for dermatologists with a solid foundation of laser-tissue interaction. The expert civilian, academic, and military faculty will present information for the experienced laser surgeon to improve clinical outcomes and patient satisfaction. The most popular laser devices and indications will be discussed as well as an extensive review of laser/light clinical trials from 2015. The course will cover vascular, pigment, tattoo, fractional laser, resurfacing and ultrasound devices, and take a look into the future of lasers, light, and microneedles. This educational session will offer pearls to improve patient outcomes and pitfalls to avoid complications. *• 2.00 Category 1 CME Credits*

F097 • Medicolegal Issues

Room: W206C

Director: David J. Goldberg, MD, JD

Co-Director: Whitney A. High, MD, JD

Invited Speakers: Mathew M. Avram, MD, JD, Clifford Warren Lober, MD, JD, Abel Torres, MD, JD

Learning Objectives
Following this session, the attendee should be able to:
1. Analyze and examine medicolegal issues in Dermatology.
2. Summarize medicolegal issues is medical, surgical and cosmetic dermatology and dermatopatholgy.

Description
This session will look at medicolegal issues as they relate to all aspects of dermatology. The goal of the session is to teach attendees how to avoid litigation in medical, cosmetic, and surgical dermatology as well as dermatopathology. *• 2.00 Category 1 CME Credits*

F098 • Skin Issues in Latino Patients

Room: W306A

Director: Marta I. Rendon, MD

Invited Speakers: Maria Ivonne Arellano-Mendoza, MD, Mercedes Florez, MD, Maritza I. Perez, MD, Bret Ribotsky, DPM, Eduardo Tomas Weiss, MD, Qian Zheng, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize and examine the perception of skin color in Latin American descendants, and review the importance of a new classification scale.
2. Define and summarize the most common hypo and hyper pigmentation disorders in Latino populations in 2017.
3. Discuss common dermatologic conditions such as acne and skin cancer and distinguish special considerations in relation to Latin skin types.

Description
This session will outline the current leading research regarding Latin American skin. We will examine the need of developing a new skin classification scale to better define Latin skin types. Common skin conditions such as hypo and hyper pigmentation disorders will be discussed and new treatment protocols will be analyzed. Acne treatment and special considerations in this patient population will be discussed. Latinos are more likely to be diagnosed with late-stage skin cancer. This session will cover a thorough review on early detection and current treatment guidelines.
• 2.00 Category 1 CME Credits

F099 • Medical Dermatology Challenge: Complex Cases from the Collection of Dr. Samuel Moschella

Room: W311E

Director: Jennifer Tan, MD

Co-Director: Arturo P. Saavedra, MD, PhD

Invited Speakers: Allireza Alloo, MD, Samuel Leonard Moschella, MD, Ruth Ann Vleugels, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Visually identify and diagnose classic and atypical presentations of cutaneous manifestations of systemic disease.
2. Select management options for complex medical dermatologic disease based on the best available evidence from the literature.
3. Discuss the use of advanced systemic therapies for the management of refractory dermatologic conditions.

Description
After following patients with complex medical dermatologic disease for over fifty years, Dr. Samuel Moschella, along with several colleagues, will share medical dermatology images and discuss clinical clues for identifying complex skin conditions. This session will offer practical tips for diagnosis, appropriate evaluation, and advanced therapeutic management of patients with systemic diseases affecting the skin. Audience self-assessment will be encouraged through kodachrome review, and a case-based approach will be utilized to highlight relevance for the dermatology trainee or experienced clinician. Cases discussed will include those focusing on granulomatous, lymphoproliferative, and connective tissue diseases as well as pediatric and tropical dermatology.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

F100 • Stepping Out of the Fry Pan: Tools to Mitigate Burnout

Room: W312A

Director: Kathleen Julie Hectorne, MD

Co-Director: Rochelle R. Torgerson, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify specific signs of burnout in yourself and your team.
2. Develop strategies to avoid burnout for yourself and your team.
3. Implement strategies to work within your organization to reduce incidents of burnout.

Description
Burnout among physicians is on the rise. As the practice of medicine continues to change, physicians are often busier than ever before and feel less in control of their practices. In this session, we will look at the factors that cause burnout in dermatologists in various practice settings. Participants will be able to identify signs of burnout in themselves and others, leaving this session with strategies for reducing personal burnout as well as strategies for working within the larger organization to minimize the stressors that cause burnout. *• 2.00 Category 1 CME Credits*

F101 • Tackling Challenges in Epidermolysis Bullosa: What Does the Future Hold

Room: W315A

Director: Anna Lee Bruckner, MD

Invited Speakers: Marcel F. Jonkman, MD, PhD, Anne W. Lucky, MD, M. Peter Marinkovich, MD, Dedee F. Murrell, MD, Jean Tang, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Assess the pros and cons of biopsies versus genetic testing in the diagnosis of epidermolysis bullosa (EB).
2. Identify manifestations and complications of EB in which inflammation plays a role.
3. Discuss the complex nature of EB and summarize new and emerging therapies for EB.

Description
Epidermolysis Bullosa (EB) is a group of rare inherited disorders characterized by blistering and erosions of the skin and mucosa in areas of minor trauma. Both children and adults with EB present diagnostic and therapeutic challenges. This session will review advances in the diagnosis and management of EB and an interdisciplinary approach to care. The roles of skin biopsy and genetic testing will be discussed. Challenges in designing good clinical studies, emerging treatments, and the role of inflammation in severe forms of EB will be presented. • *2.00 Category 1 CME Credits*

F102 • Disorders of Pigmentation

Room: W414C

Director: Andrew F. Alexis, MD

Invited Speakers: Jean L. Bolognia, MD, Paul M. Friedman, MD, Pearl E. Grimes, MD, Amit G. Pandya, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss current approaches to the management of melasma and postinflammatory hyperpigmentation.
2. Summarize laser and light-based modalities that can be utilized in the treatment of disorders of pigmentation.
3. Recognize common disorders of hypopigmentation.

Description
Disorders of pigmentation, including melasma, postinflammatory hyperpigmentation, and vitiligo are highly prevalent, yet therapeutically challenging. This session will feature practical approaches to the management of pigmentary disorders, including the use of topical, laser, and light-based therapies. Clinical pearls to assist in the diagnosis of disorders of hypopigmentation will also be discussed. • *2.00 Category 1 CME Credits*

F103 • Side Effects May Include: Illustrative Cases of Dermatologic Adverse Events

Room: W308A

Director: Cindy Owen, MD

Invited Speakers: Nicole Fett, MD, Raegan D. Hunt, MD, PhD, Neil H. Shear, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize different forms of cutaneous adverse reactions and uncommon side effects of dermatologic medications.
2. Manage patients with dermatologic adverse reactions and develop evaluation and treatment plans based on reaction type.
3. Determine the most likely causative medications for specific cutaneous adverse reactions.

Description
Dermatologists are frequently called upon to diagnose and manage patients with suspected drug rashes. With the pace of new medication development, it is important but difficult to keep up with the spectrum of side effects relevant to dermatology. This case-based interactive session will explore dermatologic adverse events. This will include cutaneous adverse reactions of non-dermatologic medications, as well as rare potential side effects of medications commonly prescribed by dermatologists. Cases will be selected that illustrate the clinical presentation, differential diagnosis, workup, and management of a variety of cutaneous adverse reactions and dermatologic drug side effects.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

F104 • High Yield "Power Hour" for Residents

Room: W415B

Director: Harley A. Haynes, MD

Co-Director: Ruth Ann Vleugels, MD

Invited Speakers: Elizabeth A. Buzney, MD, Adam D. Lipworth, MD, Manisha Thakuria, MD, Fei-Shiuann Clarissa Yang, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Examine pearls and measure competency in high-yield topics.
2. Discuss key topics in dermatology, including drugs used in dermatology, infectious disease dermatology, allergic contact dermatitis, basement membrane disorders, and pediatric dermatology.
3. Demonstrate comprehension through multiple choice questions.

Description
This forum is designed for dermatology residents who seek to achieve a comfort level with five high-yield topics encountered during training. Image-based learning will focus on: 1) mechanisms of action and side effects of systemic dermatologic therapies, 2) infectious disease dermatology, 3) allergens associated with contact dermatitis, 4) inherited and immunobullous disorders of the epidermal basement membrane, and 5) key concepts in pediatric and neonatal dermatology. Multiple choice questions will highlight take-home pearls. These sessions are popular among residents at our institution. • *2.00 Category 1 CME Credits*

F105 • Dermoscopy: It's Time for a Quiz

Room: W311G

Director: Robert H. Johr, MD

Invited Speakers: Giuseppe Argenziano, MD, Wilhelm Stolz, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Accurately identify all of the relevant dermoscopic criteria in melanocytic, non-melanocytic, benign and malignant lesions.
2. Create a dermoscopic differential diagnosis for the important global patterns and local criteria.
3. Determine if a lesion is low, intermediate or high risk; decide the disposition of a lesion; decide whether to ignore, follow-up or make a histopathologic diagnosis.

Description
This session will cover all of the essential information you need to know to have a practical, clinically oriented understanding of dermoscopy. There will be a review of the two step algorithm, global patterns and local criteria needed to diagnose melanocytic, non-melanocytic, benign and malignant skin lesions. An interactive self-assessment quiz will include both clinical and dermoscopic images. *• 2.00 Category 1 CME Credits*

F106 • A Practical Approach to Adult and Pediatric Autoimmune Connective Tissue Diseases

Room: W308C

Director: Alisa Femia, MD

Invited Speakers: Drew Kurtzman, MD, Julie V. Schaffer, MD, Nicole Seminara, MD, Ruth Ann Vleugels, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Utilize clinical examination to aid in accurate diagnosis of autoimmune connective tissue disease.
2. Formulate an algorithm for appropriate work-up of autoimmune connective tissue diseases.
3. Develop management strategies for autoimmune connective tissue diseases.

Description
Autoimmune connective tissue diseases can have devastating consequences on morbidity and mortality in both the pediatric and adult population. Due to the rarity of many of these conditions, the paucity of Level 1 evidence guiding work-up and management, and the frequent need for chronic immunosuppressive therapy, many challenges exist when managing these conditions. This session will focus on diagnosis, work-up, and management of challenging adult and pediatric autoimmune connective tissue diseases seen in dermatology-rheumatology clinics, and will include an interactive discussion of sclerosing disorders, lupus erythematosus, dermatomyositis, as well as other conditions in the dermatology-rheumatology domain. *• 2.00 Category 1 CME Credits*

F107 • Dermatologic Side Effects of Anticancer Drugs in 2017: What You Need to Know

Room: W307B

Director: Mario E. Lacouture, MD

Invited Speakers: Jennifer N. Choi, MD, Jae Jung, MD, PhD, Nicole LeBoeuf, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize impact on quality of life and clinical characteristics of dermatologic adverse events to therapies in cancer.
2. Describe the mechanisms involved in dermatologic adverse events to therapies in cancer.
3. Discuss mechanistically-based interventions to improve quality of life and decrease toxicity in cancer patients.

Description
Systemic therapies (cytotoxic/targeted agents, immune checkpoint inhibitors) have resulted in remarkable improvements in patient survival across all cancers. Despite this remarkable success, the majority of patients treated with these drugs will develop dermatologic adverse events, which lead to decreased quality of life and inconsistent antineoplastic therapy, both of which may affect clinical outcome. This session will provide up-to-date information on dermatologic adverse event incidence, mechanisms, clinical presentation, and preventive/therapeutic interventions which are essential for optimal dermatologic care of people living with cancer. *• 2.00 Category 1 CME Credits*

F108 • Field Cancer and Multiple SCC: Molecular Insights and Clinical Management

Room: W307D

Director: Sean Christensen, MD, PhD

Invited Speakers: John A. Carucci, MD, PhD, Oscar Colegio, MD, PhD, Gary Goldenberg, MD, Andrea Willey, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify patients at risk for multiple SCC development.
2. Recognize the contribution of ultraviolet light and genetic mutations to SCC development within a field of actinic damage.
3. Select and prescribe appropriate field treatment to decrease the incidence and progression of SCC.

Description
Development of multiple SCCs within areas of actinic damage is common and is best described by the field cancerization paradigm. This session, designed for general dermatologists and dermatologic surgeons, will discuss how ultraviolet light and acquired genetic mutations promote multiple SCC development within a damaged field of skin. Prevention, topical treatments, photodynamic therapy, and systemic treatments for field cancerization will be reviewed, along with the evidence to support their use. Participants will learn how to select the optimal field treatment strategy for individual patients, including combination treatment and management of high-risk populations such as organ transplant recipients. *• 2.00 Category 1 CME Credits*

WORKSHOP • 1 TO 3 P.M.

Tuition fee and ticket required for admission

W007 • Self-assessment: Dermatopathology

Room: W300

Director: Brian L. Swick, MD

Invited Speakers: Nicole M. Burkemper, MD, Arni K. Kristjansson, MD, Karolyn Wanat, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose common and uncommon dermatologic histopathologic disease.
2. Recognize the importance of clinico-pathologic correlation in histopathology.
3. Identify areas for improvement in knowledge of histopathologic diagnosis using self-assessment.

Description
Attendees will be presented with a wide range of virtual histopathologic specimens for diagnosis and self-assessment. Clinical information may also be provided to aid in diagnosis. For each case presented, anonymous answers will be recorded via self-response computerized system, followed immediately by discussion of the case. In order to fully participate, it is imperative that participants arrive on time.

This activity has been approved by the American Board of Dermatology (ABD) for up to 34 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

COURSES • 1 TO 4 P.M.

Tuition fee and ticket required for admission

C022 • Updates in Hair Disorder

Room: W203C

Director: Leonard C. Sperling, MD

Invited Speakers: Eleanor Ann Knopp, MD, Yolanda M. Lenzy, MD, Paradi Mirmirani, MD, Jerry Shapiro, MD, Rodney Daniel Sinclair, MD, Antonella Tosti, MD, Ken Washenik, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Use up to date and evidence-based information to assess, treat, and counsel patients with hair disorders.
2. Discuss basic follicular biology and pathophysiology of common hair diseases.

Description
This session will present new and noteworthy findings and approaches in the world of hair disorders. Cutting edge research in androgenetic alopecia, alopecia areata, and cicatricial alopecia is leading to a better understanding of the pathogenesis of these disorders, and promises new therapeutic options for our patients. *• 3.00 Category 1 CME Credits*

C023 • Avoiding and Managing Filler Complications

Room: W415A

Director: Joel Lee Cohen, MD

Invited Speakers: Mathew M. Avram, MD, JD, Katie Beleznay, MD, Lisa M. Donofrio, MD, Michael H. Gold, MD, Jeremy Green, MD, Shannon Humphrey, MD, Mark S. Nestor, MD, PhD, Arisa Ortiz, MD, David M. Ozog, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Review types of complications that can be seen with the use of filler soft-tissue augmentation agents.
2. Discuss methods of treatment for each of these filler complications.
3. Identify anatomic considerations as well as pearls and pitfalls for select regions of filler use.

Description
This session will review the spectrum of potential filler complications from superficial bumps and swelling, to nodules, to granulomas and to vascular compromise and necrosis. An emphasis will be placed on reviewing treatment algorithms for these types of issues. Regional anatomic considerations and pearls will be discussed. And new this year, data from the FDA will be presented as well. • *3.00 Category 1 CME Credits*

C024 • Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management

NEW

Room: W312C

Director: Michelle Anne Lowes, MBBS, PhD

Invited Speakers: Afsaneh Alavi, MD, Iltefat H. Hamzavi, MD, Paul Gregory Hazen, MD, Gregor B.E. Jemec, MD, Alexandra Boer Kimball, MD, MPH, Abrar A. Qureshi, MD, MPH, Christopher John Sayed, MD, Noah S. Scheinfeld, MD, JD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize the physical lesions that constitute hidradenitis suppurativa/acne inversa, their characteristic distribution, and their tendency to recur over time.
2. Select appropriate preventive, medical and surgical therapies based on the patient's lifestyle, sex, body type, and lesions present.

Description
This session will begin with a review of the epidemiology and comorbidities of HS, diagnosis of HS and phenotypes, and current concepts of HS pathogenesis. Medical treatment options to be discussed include topical, intralesional, and oral treatments, as well as biologics. Surgical treatment options will be presented by a dermatologic and plastic surgeon. The importance of a multi-specialty approach, lifestyle modifications, support groups, and recommendations for wound care will also be covered. The implementation of the European Guidelines for HS will also be discussed. There will be a Q&A session at the end of the Course with the Faculty. • *3.00 Category 1 CME Credits*

SYMPOSIA • 1 TO 4 P.M.

Open admission to eligible categories, no tuition or ticket

S032 • Resident Jeopardy

Room: W304C

Director: David H. Peng, MD, MPH

Invited Speakers: Milan J. Anadkat, MD, Brittney Kaufman DeClerck, MD, Roopal Vashi Kundu, MD, Victoria Rose Sharon, MD, Michelle B. Tarbox, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Self-assess core competencies across numerous domains in dermatology.
2. Identify gaps in medical knowledge.
3. Interact and network with colleagues at similar career levels from various institutions across the country.

Description
Join your colleagues for self-assessment through this popular, fun and engaging game show format. Contestants representing various residency training programs will face Jeopardy-style queries and image based inquiries encompassing the breadth of dermatology in a friendly competition. Audience members are invited to play along and test their own Jeopardy prowess. Which institution will emerge as the 2017 AAD Resident Jeopardy champion? A trophy will be awarded to the deserving program. *• 3.00 Category 1 CME Credits*

S033 • Inflammatory Skin Diseases: The Translational Revolution

Room: W304E

Director: Emma Guttman, MD, PhD

Invited Speakers: Kevin D. Cooper, MD, John Harris, MD, PhD, James G. Krueger, MD, PhD, Mark Lebwohl, MD, David Albert Norris, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Distinguish the immune axes that are characteristic of various Inflammatory skin diseases.
2. Apply treatment novel treatment approaches to inflammatory skin diseases based on their immune skewing.
3. Identify molecular targets and relevant targeted or broad therapeutics for inflammatory skin diseases.

Description
Inflammatory skin diseases have recently undergone a translational revolution, with many approved or currently tested therapies. Psoriasis has been a model disease for translational medicine. Within this model, targeted therapeutics have not only provided great therapeutic benefit, but also allowed a better understanding of the underlying inflammatory pathogenic circuits, cementing psoriasis as a Th17/IL-23 driven disease. This opened the door to similar approaches for other common inflammatory skin diseases, such as atopic dermatitis. Through targeted therapeutics we are able to understand disease mechanisms and differentiate different disease phenotypes. This revolution is now extending to alopecia areata, vitiligo, and contact dermatitis. *• 3.00 Category 1 CME Credits*

S034 • Pearls from the Masters of Dermatological Surgery

Room: W209B

Director: Christopher B. Zachary, MD

Invited Speakers: Murad Alam, MD, Marc D. Brown, MD, Jean D.A. Carruthers, MD, Daniel Brian Eisen, MD, Hubert T. Greenway, Jr., MD, C. William Hanke, MD, Christopher B. Harmon, MD, George J. Hruza, MD, Andrew J. Kaufman, MD, Suzanne L. Kilmer, MD, Gary Lask, MD, Patrick K. Lee, MD, E. Victor Ross, Jr., MD

Learning Objectives
Following this session, the attendee should be able to:
1. Evaluate the various Pearls presented and assess their relative potential benefits to your own practice.
2. Select the top three ideas that will improve your clinical outcomes in surgical practice.
3. Predict how the discussions might assist you in helping you to make your practice more efficient.

Description
This year's Pearls from the Masters of Dermatologic Surgery will have more conventional dermatologic surgery and fewer aesthetic pearls. While some of the most fascinating changes in technology are indeed happening with devices, there remain a great many tips and techniques used in our specialty that will be aired by our world class faculty. We look forward to sharing what we have gleaned by trial and error and from what our teachers taught us. But in truth, given that we never stop learning, you will find the majority of the faculty sitting at the front row all taking notes! • *3.00 Category 1 CME Credits*

S035 • Cutaneous Lymphomas

Room: W303A

Director: Laura Pincus, MD

Invited Speakers: Wei Ai, MD, Yann Charli-Joseph, MD, Joan Guitart, MD, Youn H. Kim, MD, Timothy H. McCalmont, MD, Christiane Querfeld, MD, PhD, Maarten H. Vermeer, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Evaluate, work-up, diagnose and design a treatment course for patients with different forms of cutaneous lymphomas (including B- and T-cell types).
2. Analyze a descriptively written pathology report regarding a diagnosis of cutaneous lymphoma and design a treatment plan for such a patient.
3. Recognize molecular advances in cutaneous lymphomas.

Description
This session will provide an in-depth and comprehensive review of the classic clinical and histopathologic presentations of different forms of cutaneous T-cell and B-cell lymphoma. In addition, management of both early and advanced stage cutaneous lymphoma will be reviewed. How to interpret a pathology report that is descriptively written (i.e. a specific diagnosis is not given) and then how to treat such a patient will be discussed as well. The session will also cover molecular advances in cutaneous lymphoma. • *3.00 Category 1 CME Credits*

S036 • Surgical Complications

Room: W202C

Director: Eva A. Hurst, MD

Invited Speakers: Mariah C. Brown, MD, Joel Lee Cohen, MD, Martha Laurin Council, MD, Emily J. Fisher, MD, Dee Anna Glaser, MD, Roy C. Grekin, MD, Thomas E. Rohrer, MD, Valencia D. Thomas, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify complications in dermatologic surgery, laser, and cosmetic procedures.
2. Develop an approach to minimize and prevent surgical complications.
3. Design a strategy to manage surgical complications should they arise.

Description
Surgical complications are unavoidable, even in the most experienced hands. Physicians who perform cutaneous surgery should engage in practices that seek to prevent such complications from arising. However, dermatologic surgeons must be prepared to recognize and treat surgical complications in the event that they arise. Having a strategy to minimize the risk of suboptimal results stemming from complications is key. Experienced cutaneous surgeons will discuss the prevention, diagnosis, and management of complications that may occur when performing dermatologic surgery, laser surgery, and cosmetic procedures. *• 3.00 Category 1 CME Credits*

S037 • Vascular Anomalies Symposium: Classification, Clinical Challenges and Management Update

Room: W204C

Director: Maria Cecilia Garzon, MD

Invited Speakers: Eulalia Baselga, MD, Beth Ann Drolet, MD, Ilona J. Frieden, MD, Anita N. Haggstrom, MD, Erin F. Mathes, MD, Katherine B. Puttgen, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Formulate an approach to common vascular anomalies.
2. Identify problematic hemangiomas and recognize when treatment is required.
3. Examine potential pitfalls associated with the diagnosis and management of vascular anomalies.

Description
Dermatologists play a primary role in diagnosing and directing the management of vascular anomalies. This session will provide an overview of new information pertaining to the vascular anomalies most commonly encountered by the dermatologist. Understanding this updated information may lead to modifications in care and have a significant impact on patient outcomes

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

S038 • Psoriasis

Room: Chapin Theatre

Director: Boni E. Elewski, MD

Invited Speakers: Andrew Blauvelt, MD, Seemal Desai, MD, Kenneth B. Gordon, MD, Primal Kaur, MD, MBA, Alexandra Boer Kimball, MD, MPH, Richard G. B. Langley, MD, Mark Lebwohl, MD, Alan Menter, MD, David Michael Pariser, MD, Carlos A. Sattler, MD, Bruce Elliot Strober, MD, PhD, Paul W. Tebbey, PhD, MBA

Learning Objectives
Following this session, the attendee should be able to:
1. Select the best systemic therapy or biologic for each psoriasis patient depending on extent of disease and comorbidities.
2. Recognize safety profile of available systemic therapies. Select the best treatment for pregnant patients.
3. Discuss the interchangeability, safety and immunogenicity of biosimilars.

Description
New topical, oral and biologic therapies are available to treat psoriasis patients. Selection of the best agent to treat each patient can be difficult. Irrespective of insurance should TNF blockers or IL-17/IL-23 blockers be first line therapy for moderate to severe disease? Do comorbidities affect treatment decisions? Psoriasis treatment in pregnancy will also be highlighted as will treatment of genital psoriasis. New data on prevalence of psoriasis in different populations will also be addressed. Biosimilars are here but what do we know about their interchangeability, safety and immunogenicity? What should be do to protect our patients? This session is geared for the practicing dermatologist.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

S039 • Managing Tough Real Life Dermatology Cases

Room: W304G

Director: Dirk Michael Elston, MD

Invited Speakers: Robert T. Brodell, MD, Jeffrey Phillip Callen, MD, Anthony Fernandez, MD, M. Yadira Hurley, MD, Alexander Miller, MD, Stanley J. Miller, MD, Joseph C. Pierson, MD, Kathryn Schwarzenberger, MD, Kanade Shinkai, MD, PhD, Elaine C. Siegfried, MD, Thomas Stasko, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Manage common but tricky medical dermatology problems.
2. Manage common but tricky surgical dermatology problems.
3. Manage common but tricky pediatric dermatology problems.

Description
The faculty will present common but difficult real life cases representing medical, surgical and pediatric dermatology. The session will include an audience response system to benchmark how other members of the audience would manage the patient. The faculty presenter and panel will discuss their approaches. • *3.00 Category 1 CME Credits*

S040 • Medical Dermatology in Children and Adults: Similarities and Differences in Approach and Management

NEW

Room: W314B

Director: Kelly M. Cordoro, MD

Invited Speakers: Lindy Peta Fox, MD, Warren R. Heymann, MD, Joslyn S. Kirby, MD, Erin F. Mathes, MD, Vikash Sudhir Oza, MD, Elena Pope, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose skin diseases in children and adults more effectively.
2. Compare evaluations and treatments for skin diseases in children and adults.
3. Distinguish pediatric from adult care needs as patients transition from pediatric to adult clinics.

Description
The practice of "complex medical dermatology" applies to the care of both adults and children. This new session is designed to highlight a selection of hot topics and modern day challenges of managing pediatric and adult patients with complex issues. Some approaches overlap while others differ in important ways. Join this stellar line-up of pediatric, adult and general dermatologists as they share their passion, experience and expertise. *• 3.00 Category 1 CME Credits*

S041 • Melanoma and Mimics: New Diagnostic and Treatment Modalities

NEW

Room: W315B

Director: Martin Charles Mihm, Jr., MD

Invited Speakers: Mai Hoang, MD, Adriano Piris, MD, Tobias Schatton, PhD, Ryan Sullivan, MD, Labib Zakka, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize the morphology and molecular pathology of different melanoma sub-types and borderline lesions.
2. Determine the appropriate patient management algorithm based on the combination of clinico-pathological correlation and, if necessary, molecular findings.
3. Discuss the newly available molecular tests and the new treatment options for metastatic melanoma such as targeted therapy, immunotherapy, and combination therapies.

Description
The session will consist of a combination of formal lectures and interactive presentations. Different melanoma types and borderline melanocytic lesions will be discussed with emphasis on a combined approach spanning from clinico-pathological presentation to new molecular techniques available for diagnosis. New treatment options will also be discussed including targeted therapy and immunotherapy. The session will be directed to general Dermatologists, Dermato-oncologists, and Dermatopathologists. The participants will be actively engaged through ARS.
• 3.00 Category 1 CME Credits

S042 • Advanced Medical Dermatology

Room: W311A

Director: Misha Rosenbach, MD

Invited Speakers: Nicole Fett, MD, Galen Toye Foulke, MD, Joanna L. Harp, MD, John Harris, MD, PhD, Daniela Kroshinsky, MD, M.P.H., Robert Micheletti, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose complex medical dermatological diseases with the most up-to-date tests.
2. Manage patients with severe or recalcitrant medical-dermatological diseases.
3. Recognize novel and emerging phenotypes of med-derm diseases.

Description
This session will focus on cutting-edge concepts in the pathogenesis, diagnosis and management of complex dermatologic disorders. The speakers will present the most current updates on challenging dermatologic diseases. This year will cover chemotherapy reactions, vasculitis, graft-versus-host disease, emerging issues in infectious diseases and dermatology, pyoderma gangrenosum, connective tissue disease, and more. Although this session will also cover exciting new information that is not yet published in the literature, the speakers will highlight practical approaches and algorithms to patient care that will be useful and relevant to attendees' clinical practice. *• 3.00 Category 1 CME Credits*

S043 • Aging Gracefully

Room: W415D

Director: Heidi A. Waldorf, MD

Invited Speakers: Andrew F. Alexis, MD, Sabrina G. Fabi, MD, Michael H. Gold, MD, Shannon Humphrey, MD, Terrence Keaney, MD, Susan H. Weinkle, MD, Sabine Zenker, MD, Qian Zheng, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Define the parameters of 'graceful aging' from a consumer versus a medical perspective.
2. Predict the progression of aging and anticipate the interventions that may be helpful.
3. Formulate a therapeutic plan appropriate for prevention, rejuvenation and maintenance.

Description
'Aging gracefully' is often used to describe those who defer cosmetic interventions. However, patients frequently use the phrase to describe using noninvasive cosmetic procedures to look attractive and well rested but also age-appropriate. This session will explore what aging well means to the consumer versus the cosmetic dermatologist. Speakers will address how to predict a patient's ongoing needs given intrinsic and extrinsic factors including age, race, gender, lifestyle and environment. Choice and timing of cosmeceutical regimens, injectable neuromodulators, soft tissue fillers and various devices commonly used for noninvasive rejuvenation will be stressed. *• 3.00 Category 1 CME Credits*

S044 • Nails

Room: W207A

Director: Adam Rubin, MD

Invited Speakers: Robert L. Baran, MD, Jane S. Bellet, MD, C. Ralph Daniel, MD, Judith Dominguez-Cherit, MD, Daniela Gutierrez Mendoza, MD, Nathaniel J. Jellinek, MD, Christopher James Miller, MD, Bianca Maria Piraccini, MD, Phoebe Rich, MD, Dimitris Rigopoulos, MD, Avner Shemer, MD, Michela Starace, MD, PhD, Antonella Tosti, MD, Tracey C. Vlahovic, DPM

Learning Objectives
Following this session, the attendee should be able to:
1. Describe state-of-the-art treatments for onychomycosis.
2. Discuss up to date information regarding the diagnosis and treatment of nail unit melanoma.
3. Discuss up to date information regarding the relationship between nail psoriasis and psoriatic arthritis.

Description
This session is directed towards general dermatologists and those with an interest in nail disorders. Expert faculty from around the world will provide updates and their personal experiences with key topics in nail disorders. Major areas of nail disease will be emphasized, including inflammatory and neoplastic disorders affecting the nail unit. Updates on onychomycosis will be provided. Multiple surgical talks are included which will cover treatment of chronic paronychia and nail surgery in children. *• 3.00 Category 1 CME Credits*

DISCUSSION GROUP • 3:30 TO 5:30 P.M.

Open admission to eligible categories, no tuition or ticket

D004 • Careers in Academic Dermatology

Room: W308CD

Director: Daniela Kroshinsky, MD, MPH

Co-Director: Jeffrey Phillip Callen, MD

Invited Speakers: April W. Armstrong, MD, MPH., Jeremy S. Bordeaux, MD, MPH, Oscar Colegio, MD, PhD, Luis A. Diaz, MD, Lawrence F. Eichenfield, MD, Brett Andrew King, MD, PhD, Gideon Smith, MD, Erik Joseph Stratman, MD, Gary S. Wood, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify the many roles that physicians may take in an academic setting and the paths to these roles.
2. Recognize the routes toward a successful career in academia and to promotion within the academic setting.
3. Prepare for job selection and identify future challenges that academic leaders will face.

Description
This session is intended medical students, residents and young physicians interested in academic medicine. During this symposium, we will explore the many different types of careers in academic dermatology through short presentations from successful academicians, including their shared career development pearls and pitfalls. The session will also review how one might prepare for a rewarding career in academia, how to approach negotiating a position, and how success is defined in the academic setting. Following the presentations, the group will divide into small, rotating, interactive focus groups for question and answers on specific topics of interest to attendees.
• 2.00 Category 1 CME Credits

FORUMS • 3:30 TO 5:30 P.M.

Open admission to eligible categories, no tuition or ticket

F109 • Advanced Dermoscopy

Room: W415B

Director: Iris Zalaudek, MD

Invited Speaker: Aimilios Lallas, MD, MSc, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize specific patterns of keratinocyte skin cancer.
2. Recognize specific patterns associated with inflammatory skin diseases.
3. Diagnose and manage pigmented and non-pigmented skin lesions in the daily routine.

Description
This session provides clues for the dermoscopic diagnosis and management of skin lesions in dermato-oncology and general dermatology. • *2.00 Category 1 CME Credits*

F110 • The Skin and the Mind

Room: W312A

Director: Francisco A. Tausk, MD

Invited Speakers: Richard G. Fried, MD, PhD, Richard D. Granstein, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize how stressors modify the evolution of psoriasis and why some patients worsen under stress.
2. Describe how peripheral nerves and their products can regulate the immunity and inflammation of the skin.
3. Develop effective treatment plans to decrease or eliminate skin manipulation/picking.

Description
The mind affects the skin in various ways. This session will approach the subject from the perspective of psychoneuroirnmunology as well as the practical daily treatment of patients. We will: 1) Discuss novel regulatory functions of nerve products such as neuropeptides and neurotransmitters on inflammation and skin immunity. The interplay of stressors and signals from nerves may prove to be amenable to new therapeutic interventions. 2) Review mechanisms of stress and how they modulate the evolution of psoriasis, presenting this disease as a model of psychosomatics in dermatological diseases. 3) Examine types of skin manipulation, etiologic factors, and management strategies. • *2.00 Category 1 CME Credits*

F111 • Dermatology Teachers Exchange Group

Room: W206C

Director: Roy Mitchell Colven, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss new teaching initiatives developed by various residency programs.
2. Assess current and novel teaching methods and curriculum for generalizability and efficacy.

Description
The Dermatology Teachers Exchange Group (DTEG) convenes semiannually at the Association of Professors of Dermatology and AAD Annual Meetings. Teaching methods, curriculum, and evaluation mechanisms and platforms for residents, medical students, faculty, and patients will be presented in abstract form and discussed. The meeting also serves as a forum for networking and exchange of ideas among teachers in dermatology. *• 2.00 Category 1 CME Credits*

F112 • Cutaneous T-cell Lymphoma

Room: W209C

Director: Alain H. Rook, MD

Invited Speakers: Rachael Clark, MD, PhD, Paul Haun, MD, MS, Youn H. Kim, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnosis of CTCL will be presented using the latest data.
2. Treat CTCL will be presented using the latest therapies.

Description
This session will be dedicated to new issues in the diagnosis and treatment of cutaneous T-cell lymphomas. *• 2.00 Category 1 CME Credits*

F113 • From Stinging Plants to Fire Ants: Identification, Management and Prevention of Hazardous Plant and Arthropod Exposures

Room: W315A

Director: Julian J. Trevino, MD

Invited Speaker: Amy Yuntzu-Yen Chen, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify the plants and arthropods discussed and recognize the cutaneous manifestations associated with the plant and arthropod exposures.
2. Select the most appropriate therapy and/or preventative measures for the various plant/arthropod exposures presented.
3. Discuss the effectiveness, mechanism of action and safety of insect repellents.

Description
Cutaneous manifestations resulting from exposures to plants and arthropods are commonly encountered in medical dermatology practice. These have consequences ranging from minor annoyances to serious medical conditions. A broad range of arthropod and plant exposures with dermatological manifestations will be reviewed. The epidemiology, pathogenesis and clinical manifestations of the selected plant and arthropod exposures will be presented. Prevention and management of these adverse cutaneous reactions will be discussed. Updated information on the Zika virus will be included. Insect repellents will be extensively reviewed, emphasizing the efficacy, mechanisms of action and safety of these agents.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

F114 • Research Gaps in Psoriasis: Opportunities for Future Studies and Development of New Outcome Measures for Clinical Trials

Room: W311E

Director: Alice B. Gottlieb, MD, PhD

Invited Speakers: Kristina Patrice Callis-Duffin, MD, Mark Lebwohl, MD, Kendall Marcus, MD, Joseph Merola, MD, MSc, Vibeke Strand, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify gaps in research and clinical knowledge.
2. Suggest studies that can be conducted to fill the gaps.
3. Discuss the development of new outcome measures in dermatology.

Description
This session will be helpful in expanding physician knowledge base in the field of psoriasis. Despite important advances, substantial deficits remain in the understanding of psoriasis and its treatment, necessitating further research in many areas. In this session the most important gaps in research that exist currently and suggestions for studies that should be performed to address these deficits will be discussed. The session will also address the efforts of International Dermatology Outcomes Measures (IDEOM) Committee to develop outcome measures that accurately and reliably measure the impact of treatments on patients' disease severity and quality of life using the Delphi method.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

F115 • Acne Boot Camp

Room: W414CD

Director: James Q. Del Rosso, DO

Co-Director: Joshua Zeichner, MD

Invited Speakers: Hilary E. Baldwin, MD, Julie Claire Harper, MD, Linda F. Stein Gold, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Develop a management plan that incorporates educational objectives for the patient, proper skin care, factors that impact on treatment selection, and follow-up to evaluate progress, and assess compliance.
2. Summarize major adverse reactions associated with acne therapies, including medical and physical modalities, with a suggested plan for monitoring for potential side effects and how to manage them.

Description
This session provides a thorough, practical overview designed to assist clinicians in optimizing the care of acne patients during office visits. Emphasis will be placed on rational selection and implementation of acne therapies. Beyond these topics, session will cover how to (1) optimize compliance, (2) explain acne to patients and assess improvement, (3) determine follow up-plans with explanations to patient, (4) explain potential side effects without creating fears that induce poor compliance, (5) monitor for potentially significant adverse reactions. • *2.00 Category 1 CME Credits*

F116 • Boards and Beyond

Room: W307AB

Director: Justin P. Bandino, MD

Co-director: Faranak Kamangar, MD

Invited Speakers: Thomas D. Horn, MD, Kachiu Cecilia Lee, MD, MPH, Vineet Mishra, MD, Arthur Joel Sober, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe the structure, format, and process for the American Board of Dermatology examination from the perspective of ABD administrators as well as dermatologists who recently took the examination.
2. Recognize the challenges of launching a career in dermatology as seen through community practice, academics, and alternative career paths.
3. Describe steps taken by new graduates to begin Maintenance of Certification requirements, involvement with local/national professional societies, and leadership opportunities after residency.

Description
After spending many years in training, residents find themselves with major hurdles to pass as they become successful dermatologists. These include taking the boards, deciding on a career path, starting Maintenance of Certification and becoming active members of the dermatology community. This session will provide information about the structure, format, and process of taking the American Board of Dermatology examination. We will discuss and define the many opportunities available to young dermatologists from academic dermatology to private practice to industry and more unconventional paths. We will also give advice on how to become active participants within the field of dermatology. • *2.00 Category 1 CME Credits*

F117 • Chronic Urticaria and Angioedema: What's New in Pathogenesis and Treatment

Room: W208A

Director: Amit Garg, MD

Invited Speakers: Adam J. Friedman, MD, Michael D. Tharp, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize urticaria and angioedema phenotypes and formulate appropriate workups.
2. Select evidence based therapeutic strategies involving antihistamines, anti-inflammatory agents, and immunomodulators.

Description
This session will offer evidence- and experience-based commentary from experts on clinical queries and dilemmas related to the evaluation and longitudinal management of urticaria subtypes. Case challenges will also be reviewed. • *2.00 Category 1 CME Credits*

F118 • Neonatal Dermatology: Case-based Discussions

Room: W311G

Director: Paula Carolina Luna, MD

Co-Director: Margarita M. Larralde, MD

Invited Speakers: Sadaf Hussain, MD, Catherine C. McCuaig, MD, Lara Wine Lee, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Evaluate and recognize common and uncommon neonatal dermatoses.
2. Select the best complementary studies and treatments for neonatal conditions.

Description
This session will be divided into two parts. The first will show interesting neonatal cases and the second part will be an interactive session, trough case base modality, challenging the audience to think about common and uncommon neonatal dermatoses. • *2.00 Category 1 CME Credits*

F119 • Approach to Sclerosing Skin Conditions

Room: W306A

Director: Anna Haemel, MD

Invited Speakers: Nicole Fett, MD, Heidi Tewich Jacobe, MD, Emily Keimig, MD, MS

Learning Objectives
Following this session, the attendee should be able to:
1. Utilize a rational framework for the evaluation of patients with sclerosing skin disease.
2. Describe key updates from the morphea literature over the last several years.
3. Identify the complications of systemic sclerosis and initial evaluation/management strategies.

Description
We will take a practical approach to sclerosing skin disease. A series of photos will be used to illustrate the morphological spectrum of these conditions and some potential mimickers. Key updates from the morphea literature will be highlighted. The complications and internal manifestations associated with systemic sclerosis will be discussed, with a focus on strategies for screening and initial management. Challenging cases and pearls will be presented. • *2.00 Category 1 CME Credits*

F120 • Treating Tumors and Inflammatory Skin Diseases with Immunomodulators and Biologics

Room: W307D

Director: Neal D. Bhatia, MD

Co-Director: Adam J. Friedman, MD

Invited Speakers: Emma Guttman, MD, PhD, Dedee F. Murrell, MD, Theodore Rosen, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Categorize and differentiate dermatoses based on their inflammatory versus neoplastic origin and their potential responses to topical and systemic immunotherapies.
2. Recognize potential applications of immune-based therapies outside of conventional uses.
3. Select therapeutic options to modify a disease process in addition to alleviate symptoms based on the immune mechanisms that create them.

Description
As the understanding of the immune system pathways continues to expand, so must the potential applications of immunomodulators that can impact the process of diseases instead of just symptoms. Our current therapeutic regimens are as efficacious as our comfort with their mechanisms of action. This begins with matching appropriate immune processes as "building blocks" of diseases to those counteracted and modified by the therapies. The goals of this session are to dissect various immune system functions that create inflammatory dermatoses and explore applications of topical and systemic therapies that could potentially serve as standards of care.
• 2.00 Category 1 CME Credits

F121 • An Evidence-based Approach to Nails: Expert Management of Common Problems

Room: W304AB

Director: Chris Adigun, MD

Invited Speakers: Nathaniel J. Jellinek, MD, Michela Starace, MD, PhD, Dana W.K. Stern, MD, Curtis T. Thompson, MD, John Yost, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Evaluation and management of common nail tumors and conditions.
2. Utilize dermoscopy for evaluation of common nail abnormalities.
3. Demonstrate understanding of current safety data of UV nail lamps.

Description
This session is designed to assist dermatologists that do not specialize in nails, but want to expand their knowledge of current evaluation and management strategies for common nail conditions. We will cover practical management of brittle nails, common nail tumors, and dermoscopy of nail conditions. We will also address how to properly submit a nail specimen to the dermatopathologist. Finally, we will cover the most current data we have regarding the safety of the widely utilized UV nail lamps. *• 2.00 Category 1 CME Credits*

F122 • Challenging Cases and Therapeutic Pearls from UVA

Room: W308A

Director: Kenneth E. Greer, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose uncommon manifestations of common diseases.
2. Diagnose common manifestations of uncommon diseases.
3. Discuss treatment where appropriate.

Description
Through clinical slides show common manifestations of unusual diseases and uncommon manifestations of common disease and discuss treatment where appropriate.
• 2.00 Category 1 CME Credits

F123 • Photodocumentation in Dermatology

Room: W305A

Director: Allan C. Halpern, MD

Invited Speakers: Jane Margaret Grant-Kels, MD, Whitney A. High, MD, JD, Anthony Rossi, MD, Daniel M. Siegel, MD, MS

Learning Objectives
Following this session, the attendee should be able to:
1. Examine the changing clinical, technical, and regulatory environment for using digital images in Dermatology.
2. Examine practical considerations for successful implementation of digital photography in clinical practice.

Description
While "a picture is worth a thousand words," most dermatology documentation is still text based despite the current ubiquity of digital photography. In this session, we will review the opportunities presented by the newest generation of digital cameras, smartphones, and cloud computing for improving dermatology documentation. Among the topics to be covered will be the integration of photography in the dermatology EMR and recent advances in total body photography and digital dermoscopy for skin cancer diagnosis and surveillance. We will also discuss the specific use case of photographic documentation to avoid wrong site surgery. Lastly we will address the ethical and medicolegal challenges associated with image privacy and with the current lack of imaging standards for dermatology.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

WORKSHOP • 3:30 TO 5:30 P.M.

Tuition fee and ticket required for admission

W008 • Self-assessment: Contact Dermatology

Room: W300

Director: Vincent Anthony DeLeo, MD

Invited Speakers: Tamara Lazic, MD, Jonathan Zippin, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose allergic contact dermatitis more effectively.
2. Design a personal approach to patch testing that fits their practice setting.
3. Identify the most relevant exposure pattern for common allergens.

Description
A group of diverse case studies which are common in the clinical practice will be presented. For each case a number of possible etiologic allergens will be presented in a multiple choice fashion. Each correct and incorrect choice will be discussed in detail.

This activity has been approved by the American Board of Dermatology (ABD) for up to 34 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • *2.00 Category 1 CME Credits*

FOCUS SESSIONS • 4:30 TO 5:30 P.M.

Open admission to eligible categories, no tuition or ticket

U067 • Delusional Infestation

Room: W304G

Director: Anthony Paul Bewley, MBChB

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize the associations and causes of delusional infestation.
2. Diagnose and manage patients with delusional infestation.
3. Differentiate the different types of presentation of patients with delusional infestation.

Description
Delusional infestation is a primarily psychiatric disease wherein patients presents to dermatologists and dermatology health care professionals rather than to psychiatry professionals. Dermatologists often struggle with the management of patients with delusional infestation. Research has demonstrated that effective management of patients with delusional infestation is best with management of the skin together with management of the delusional beliefs. In this presentation, I will outline the causes, diagnosis, investigation and management of patients with delusional infestation. I will present best practice (such as is available from evidence based medicine), and will discuss ways in which management can be facilitated. • *1.00 Category 1 CME Credit*

U068 • Rheumatology for the Dermatologist: Evaluating the Rheumatology Patient in the Dermatology Clinic

Room: W207ABC

Director: Joseph Merola, MD, MSc

Learning Objectives
Following this session, the attendee should be able to:
1. Define the relationship between cutaneous and systemic lupus, describe dermatomyositis as defined by autoantibody profiles, distinguish inflammatory and non-inflammatory arthritis.
2. Appropriately order and interpret autoimmune serologic testing.
3. Develop a helpful review of systems to approach systemic rheumatologic disease.

Description
We will review the relationship between cutaneous lupus subsets and systemic lupus as well as current understanding of prognostic implications of CLE with regard to systemic disease. We will review dermatomyositis clinical findings (skin and systemic) as they relate to autoantibody profiles. We will review appropriate rheumatology review of systems and approach to inflammatory arthritis for the dermatologist. Other topics will include brief review of systemic sclerosis screening and monitoring. • *1.00 Category 1 CME Credit*

U069 • PAPA, PASH, and PAPASH-syndromes, SAPHO, and Acne: Skin, Bones, and Inflammation

Room: W203ABC

Director: Gerd Plewig, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize how auto-inflammatory diseases, acne, arthritis, acne inversa (hidradenitis suppurativa), and pyoderma gangrenosum interact.
2. Describe how interleukin-1 receptor antagonists immediately improve pyoderma.
3. Identify which laboratory tests are appropriate and which treatment options are available.

Description
Hereditary and acquired inflammatory signs and symptoms affecting skin, joints, bones, lungs, and gut may be seen in PAPA syndrome (pyogenic arthritis, pyoderma gangrenosum, and acne), PASH (pyoderma gangrenosum, acne and suppurative hidradenitis/acne inversa), and PAPASH (pyogenic arthritis, pyoderma gangrenosum, acne and suppurative hidradenitis/ acne inversa), SAPHO (synovitis, acne, pustulosis palmoplantaris, hyperostosis, and osteitis), cryopyrinopathies, and other auto-inflammatory syndromes. This session focuses on important knowledge of proteins interacting with pyrin. Furthermore, acne inversa/hidradenitis suppurativa is associated with Crohn´s disease and ulcerative colitis. • *1.00 Category 1 CME Credit*

U070 • The Dermatopathology Report: Reading Between the Lines

Room: W312C

Director: M. Yadira Hurley, MD

Invited Speakers: Kevin P. Boyd, MD, Nicole M. Burkemper, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Assess the validity of margins and adequacy of biopsy sample for evaluation of specific diagnoses: neoplastic and inflammatory.
2. Recognize when tissue for direct immunofluorescence will aid in determining a specific diagnosis and identify where to choose the biopsy sample.
3. Examine a pathology report and determine points of discussion with the pathologist that will help optimize patient care.

Description
Approximately 30% of patients in a Dermatology practice are biopsied. Dermatopathology reports often incorporate language that is uncommon and not easily translated into clinical practice. This session is directed towards general dermatologists who aim to understand tissue processing and pathology reports and apply the information to optimize patient care. Topics will include sensitivity and specificity of margins, utility of direct immunofluorescence, and the importance of biopsy site and technique. Suggestions for efficient and directed discussion with the diagnostician will be outlined and discussed in an interactive format. • *1.00 Category 1 CME Credit*

U071 • Photodynamic Therapy in Medical and Aesthetic Dermatology

Room: W202A

Director: Maria M. Tsoukas, MD, PhD

Invited Speaker: Nellie Konnikov, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Assess photodynamic therapy as a useful method for field cancerization in elderly and high risk immunosuppressed patients.
2. Evaluate the modalities that can be combined to potentiate and optimize PDT for treating AKs, nonmelanoma skin cancer, acne and aged skin.
3. Select PDT candidates and set therapeutic goals.

Description
Photodynamic therapy is a useful modality for field cancerization in elderly and high risk immunosuppressed patients. PDT achieves eradication of actinic keratosis and superficial nonmelanoma skin cancers, however, several serial treatments are required to achieve lesion clearance and recurrence control. This session will explore the aspect of potentiating and optimizing PDT by utilizing sequential application of various field therapies with PDT. New insights into conventional and daylight PDT protocols for AKs, acne and photorejuvenation will be discussed. • *1.00 Category 1 CME Credit*

U072 • Intravenous Immunoglobulin (IVIg) in Dermatology

Room: W314AB

Director: Sergei A. Grando, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify dermatological indications for IVIg.
2. Identify the mechanism of therapeutic action of IVIg in dermatoses.

Description
High-dose IVIg therapies have immunomodulatory capacity and have been shown to be effective in treating severe autoimmune diseases. In dermatology, autoimmune blistering diseases and some connective tissue diseases are the main diseases treated with IVIg after failure of standard immunosuppressive therapy. The high efficacy of IVIg is not hampered by severe side-effects, as is the case for systemic corticosteroid and immunosuppressive therapies. However, IVIg is underutilized by dermatologists. The problem stems from lack of knowledge about its efficacy and cost-effectiveness, compared to conventional immunosuppressive treatments, unwarranted concerns about its unsafely as well as difficulties with approval by insurance companies. • *1.00 Category 1 CME Credit*

U073 • The Human Face as Living and Functional Art

Room: W204C

Director: Cyndi Jill Yag-Howard, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Examine the works of famous artists in order to understand their perceptions of a beautiful face.
2. Recognize facial structure and anatomy as they relate to contour and expression in both static and dynamic dimensions.
3. Assess the psychological impact of an individual's facial appearance and facial expressions on the individual and on those who visualize him/her, as well as the impactful positive role the dermatologist can play through facial sculpting.

Description
The director will utilize anatomic structures and various forms of art from well-known and lesser-known artists to study facial structure and anatomy, as well as the concept of beauty. She will cite literature on the psychological impact of physical appearance. She will also discuss the unique role dermatologists play as facial sculpting artists working with living medium. • *1.00 Category 1 CME Credit*

U074 • Dermatoses of Infancy

NEW

Room: W303A

Director: Victoria R. Barrio, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify common and uncommon dermatoses that affect infants and neonates.
2. Select the best treatments for skin disease in infants.
3. Discuss current literature regarding skin disease in babies.

Description
Infancy is a unique period of life that involves the transition from the womb to the everyday environment. Patients in the first year of life can present with dermatoses unique to this period of life. This session will explore several of the more common and uncommon diseases that may present at this age. This case-based session will include discussion of the differential diagnosis for this age group, as well as therapeutic considerations. There will also be brief discussion of tips to improve the visit for the patients and their families. • *1.00 Category 1 CME Credit*

U075 • The Red Patient: An Overview of Erythroderma

NEW

Room: W209

Director: Farah R. Abdulla, MD

Co-Director: Jaehyuk Choi, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Develop a differential diagnosis of the causes of erythroderma.
2. Formulate an evaluation for a patient with erythroderma.
3. Recognize the systemic complications of erythroderma.

Description
This session on erythroderma will focus on dermatologic conditions that present both chronically in the office and acutely in the emergency room. Erythroderma is the clinical presentation of a wide range of cutaneous and systemic diseases including psoriasis, atopic dermatitis, drug hypersensitivity reactions, and more rarely Sézary syndrome. After a review of the differential diagnosis of erythroderma as well as its systemic complications, cases will be presented as a basis to further the discussion on workup and therapeutic options. Participation will be encouraged through the use of the audience response system. • *1.00 Category 1 CME Credit*

U076 • The ART (Advancement, Rotation, Transposition) of Flaps

NEW

Room: W304E

Director: Christine Poblete-Lopez, MD

Invited Speakers: David R. Carr, MD, Charlene Lam, MD, MPH, Christie Travelute, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss the application of regional flaps including principal design concepts.
2. Identify vital steps to each flap to optimize outcomes.
3. Effectively utilize these flaps given a certain defect and understand their limitations.

Description
The geometry and science behind flaps can be learned in a textbook. However, with the combination of tissue dynamics and unique facial features, precise execution of flaps is the "art" of dermatologic surgery. Each flap contains small nuances and tricks that are often not presented in the literature but key to flap movement and optimizing the aesthetic outcome. In the ART of Flaps, our aim is to demonstrate these finer points and ways the audience can finesse their own flaps including flap design, flap movement characteristics and perioperative technique. • *1.00 Category 1 CME Credit*

U077 • Hair Care Practices and Hair Disorders in Skin of Color

NEW

Room: W311A

Director: Nkanyezi Ngwenyama Ferguson, MD

Invited Speakers: Andrew F. Alexis, MD, Yolanda M. Lenzy, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify and understand the unique hair care practices used among patients of color.
2. Assess and diagnose hair disorders commonly seen in patients of color.
3. Identify preventative measures and treatment options for hair disorders in patients of color.

Description
The session will include an in depth discussion detailing the unique hair care practices among patients of color. Hair disorders commonly encountered by men and women in this population will be discussed along with approaches to diagnosis and practical management. The session will include discussion of approaches to counseling patients regarding optimization of hair care practices. The audience for this session is the general dermatologist who may encounter diverse patient populations and who would like to better understand the unique hair care practices and hair disorders in this population. • *1.00 Category 1 CME Credit*

U078 • LGBT Health: Providing Culturally Competent Care to Patients who are Sexual and Gender Minorities

NEW

Room: W315B

Director: Kenneth A. Katz, MD, MSc, MSCE

Invited Speakers: Brian Alan Ginsberg, MD, Patrick E. McCleskey, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Summarize demographics and terminology important in providing culturally competent care to LGBT persons.
2. Recognize dermatologically relevant infectious and non-infectious diseases and conditions important in caring for LGBT persons.
3. Apply best practices in taking a sexual history and recognizing gender identification and gender history.

Description
Lesbian, gay, bisexual and transgender (LGBT) persons face unique health challenges and disparities. Contributing to those disparities is a shortage of physicians with cultural competence in providing care to LGBT persons, according to the U.S. government's Healthy People 2020 plan. Healthy People 2020 specifically prioritizes improving LGBT health. This session aims to improve dermatologists' ability to provide culturally competent care to LGBT persons. Topics include demographics; terminology; epidemiology of dermatologically relevant infectious and non-infectious diseases; public health recommendations regarding HIV and STD testing, sexual health-related vaccinations, and HIV prophylaxis (PrEP and PEP); and taking a sexual and gender-identity history. • *1.00 Category 1 CME Credit*

FOCUS SESSIONS • 7:30 TO 8:30 A.M.

Open admission to eligible categories, no tuition or ticket

U079 • What to do when Patch Testing is Negative

Room: W306A

Director: Christen M. Mowad, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Evaluate the patient suspected of allergic contact dermatitis.
2. Assess the patient who is patch test negative and formulate a plan.
3. Manage the patient who is patch test negative.

Description
Patients with chronic dermatitis are often referred for patch testing. Performing patch testing is an important part of the work up and should be conducted. However, sometimes patch testing is negative and the clinician is faced with what should be done next. This session reviews patch testing addressing potential pitfalls and proceeds to discuss appropriate next steps in the management and work up of these challenging patients. • *1.00 Category 1 CME Credit*

U080 • Executing Transposition Flaps Off the Nose

Room: W206C

Director: Jeremy Robert Etzkorn, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Select defects appropriate for transposition flaps off the nose.
2. Design and execute single and multi-lobed extranasal transposition flaps.
3. Describe anatomy relevant to lifting and tacking transposition flaps off the nose.

Description
This practical session will use case examples and videos to illustrate key principles to execute single and multi-lobed transposition flaps for extranasal defects. While literature often focuses on using these flaps for nasal reconstruction, this session will focus on using transposition flaps to repair extranasal defects (e.g., periocular and perioral). Topics will include: selection of appropriate defects and tissue reservoirs, principles of transposition flap design, and anatomy relevant to lifting and tacking these flaps to produce reliable results and ideal contour. This session is directed toward dermatologic surgeons of all levels. • *1.00 Category 1 CME Credit*

U081 • Leading Change in a Changing World

Room: W312A

Director: Felisa S. Lewis, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Summarize the organizational change management process and identify key elements in the process.
2. Recognize the obstacles to change in an organization and develop strategies to overcome resistance to change.
3. Apply strategies to encourage orderly change processes in your organization.

Description
What makes change so difficult? Change can be a challenge for any organization, whether it's internally or externally driven. Drawing on the fields of business, psychology, and education, this session will educate participants about the organizational change process, and the key factors to accomplish change in an orderly manner. Of course, resistance to change is a frequent obstacle, and strategies to overcome resistance and encourage change will also be presented. Audience members will also be invited to share tips with the group. • *1.00 Category 1 CME Credit*

U082 • Caring for Vulnerable Patient Populations

Room: W305A

Director: Vikash Sudhir Oza, MD

Invited Invited Speakers: Brian Alan Ginsberg, MD, Toby A. Maurer, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize challenges and opportunities in the dermatologic care of certain vulnerable patient groups with an emphasis on patients with developmental disabilities, transgender patients and the undocumented patient.
2. Utilize core principles of empathy, respect, and curiosity to improve and build therapeutic alliances across diverse vulnerable patient groups.

Description
We are going to discuss three diverse patient care groups — patients with developmental disabilities, transgender patients and undocumented patients — to illustrate principles and strategies needed to build therapeutic alliances with vulnerable patient groups. We will discuss how developmental disability, and in particular autism spectrum disorder, can influence skin disease, management and the dermatologic visit. We will raise awareness to the dermatologic needs of the transgender community. Lastly, we will review challenges in caring for undocumented patients and ways dermatologists can bridge the care gap. • *1.00 Category 1 CME Credit*

U083 • Vasculitis

Room: W307B

Director: Robert Micheletti, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize and diagnose cutaneous manifestations of vasculitis.
2. Properly evaluate the vasculitis patient for systemic complications and associated conditions.
3. Effectively treat cutaneous manifestations of vasculitis and coordinate care with colleagues from other medical subspecialties.

Description
This session is directed at the practicing medical dermatologist, the dermatologist who sees inpatient consults, and resident physicians. The session will be a case-based discussion of the cutaneous manifestations of various dermatology-relevant vasculitides, the appropriate work-up for systemic manifestations of vasculitis, and the coordination of care with colleagues in internal medicine. Appropriate screening, treatment, and monitoring of patients will be reviewed, with treatment pearls focused on treatment of the cutaneous manifestations of vasculitis. The presenter is board-certified in internal medicine and dermatology with clinical focuses in inpatient dermatology consults and vasculitis. • *1.00 Category 1 CME Credit*

U084 • Bureaucracy, Compliance, and Burnout: What it Means to Dermatologists

Room: W315A

Director: J. Matthew Knight, MD

Invited Speakers: Neal D. Bhatia, MD, Mark D. Kaufmann, MD, Suzanne Olbricht, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Examine the social, economic, and bureaucratic forces shaping the practice of dermatology in America.
2. Identify the factors contributing to anxiety, frustration, and even hopelessness for dermatologists.
3. Formulate lifelong strategies to identify, prevent, and combat burnout in our specialty.

Description
This panel discussion/Q&A will analyze the factors (regulatory, social, and economic) contributing to heightened feelings of frustration and anxiety for dermatologists, whether employed or in private practice. We will analyze the silent epidemic of physician burnout among American physicians, and discuss strategies to prevent, identify, and mitigate burnout for dermatologists. • *1.00 Category 1 CME Credit*

U085 • Developing Effective Multidisciplinary Skin Cancer Care: Driving Better Patient Outcomes and Fulfilling Professional Relationships

NEW

Room: W209C

Director: Scott W. Fosko, MD

Invited Invited Speaker: Paul H. Bowman, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe effective multidisciplinary collaborations.
2. Recognize how a multidisciplinary approach benefits patient care.
3. Describe how a multidisciplinary approach to patient care can assist with your professional development and fulfillment.

Description
Skin cancer is a broad and complex condition. Dermatologists can take a leadership role in coordinating multidisciplinary care. We have the necessary clinical, pathologic, and both medical and procedural therapeutic perspectives. Yet, the need for additional specialty input is often needed in select patients. This session will highlight the role of dermatologists as cutaneous oncologists, and how they can partner with colleagues across many specialties. Case presentations will be provided that demonstrate multidisciplinary care's role with enhancing patient outcomes and driving innovation. The personal and professional benefits of collegial interactions will be discussed. • *1.00 Category 1 CME Credit*

U086 • Treating Alopecia Areata, Vitiligo and Atopic Dermatitis: JAK Inhibitors, Something New for Dermatology

Room: W304E

Director: Brett Andrew King, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify and describe a new drug class that will be useful in dermatology.
2. Utilize JAK inhibitors for the treatment of alopecia areata, vitiligo, and atopic dermatitis.
3. Summarize the potential adverse effects of JAK inhibitors.

Description
Effective treatments for alopecia areata, vitiligo, and atopic dermatitis are limited. The recent development of Janus kinase (JAK) inhibitors has led to new therapeutic options in dermatology. The application of JAK inhibitors to three common dermatologic diseases will be presented, including the results of clinical trials and case series. Basic science and safety will be discussed. The audience for this session will be dermatologists whose practice involves the care of patients with these common dermatoses. • *1.00 Category 1 CME Credit*

U087 • Update on Cutaneous Reactions to Targeted and Immune Cancer Therapy

Room: W315B

Director: Anisha Patel, MD

Invited Speaker: Stavonnie Patterson, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose, prevent, and manage cutaneous side effects of novel chemotherapies including BRAF inhibitors, MEK inhibitors, and EGFR inhibitors, while focusing on newer drugs such as second generation TKIs, second generation mTOR inhibitors, RET inhibitors, anti-PD1 therapy, and anti-CTLA4 therapy.
2. Describe associations between the above cutaneous side effects and cancer prognosis.
3. Formulate team-based treatment plans with ancillary services, such as podiatry and physical therapy, and the primary oncologist.

Description
This session provides an update on novel cancer therapies, expected cutaneous reactions, and prevention and management of these reactions. Emphasis will be placed on practical, team-based management strategies. Particular focus will be placed on the toxicities from immune checkpoint inhibitors and the associations between cutaneous side effects and cancer outcomes. This topic is applicable to both community-based and academic dermatologists as these drugs are being used more widely with recent FDA approvals.

This activity has been approved by the American Board of Dermatology (ABD) for up to 10 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 1.00 Category 1 CME Credit

U088 • Don't Brush it Off: Diagnosis and Management of Hair Loss in Children

Room: W304A

Director: Brittany Gareth Craiglow, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Develop a differential diagnosis for children presenting with hair loss.
2. Identify patients for whom additional diagnostic workup is warranted.
3. Formulate treatment plans for a variety of diagnoses, from basic to complex.

Description
Hair loss in children is often straightforward, caused by conditions such as tinea capitis or alopecia areata that typically present with fairly classic clinical features. In some cases, however, hair loss results from a variety of less common conditions and diagnosis and management can be more challenging. This session will use a case-based approach to review both common and rare causes of alopecia in children, with special focus paid to clinical findings and diagnostic workup, including utility of scalp biopsy, hair mount, and laboratory and/or genetic testing. Management algorithms for a variety of diagnoses will be presented. *• 1.00 Category 1 CME Credit*

U089 • Inpatient Dermatology from Horses to Zebras: Lessons Learned at an Academic Hospital

NEW

Room: W209B

Director: Victoria Rose Sharon, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose and evaluate inpatient dermatologic emergencies.
2. Formulate a differential diagnosis for challenging inpatient consultations.
3. Coordinate multidisciplinary management and collaborate with inpatient medical and surgical specialties.

Description
Inpatient dermatology consultations are challenging as patients often have multiple medical problems, are on many medications, and have the potential to develop severe systemic sequelae. The role of the astute dermatologist in recognizing cutaneous signs in the hospitalized patient and coordinating interdisciplinary care makes a significant difference in prognosis and management. In an interactive case-based format, we will review a subset of dermatologic emergencies and routine and unusual inpatient consultations. This session is targeted to dermatology residents, general dermatologists, and dermatologists that see hospital consults. • *1.00 Category 1 CME Credit*

U090 • Slap-on/Bug-off: Sunscreen and Insect-repellent Basics and Controversies

NEW

Room: W304C

Director: Sophia Lindsay Delano, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Differentiate products for sun protection and insect-avoidance based on efficacy and potential adverse effects.
2. Recognize current controversies regarding sun protection and insect-repellents that may prevent patient compliance.

Description
This session will review the basics of sun protection and insect-repellent products including available products, SPF labeling standards, adverse side effects and controversies regarding their use. This session is for providers of all levels who discuss sun and insect exposure protection with patients. • *1.00 Category 1 CME Credit*

U091 • The Science Behind New Devices in Dermatology

Room: W312C

Director: Jennifer MacGregor, MD

Co-Director: Anne M. Chapas, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Examine the basic scientific principles behind the latest radiofrequency, ultrasound, microwave and laser devices.
2. Analyze the evidence (or lack of evidence) supporting the use of devices for specific clinical applications.
3. Identify trends and evaluate evolving technology that may be relevant to clinical practice in the future.

Description
Over the past decade there has been an explosion of new energy devices that promise to tighten skin, reduce fat, stop sweating, eliminate tattoos and smooth the signs of aging. Some of these procedures are based on preclinical scientific studies with clinical evidence supporting their efficacy; however, some devices continue to be marketed with minimal scientific literature. Dermatologists will be inundated with the 'latest' devices they need for their practice and a solid understanding of the concepts and evidence underlying their efficacy (or lack thereof) is essential. This session will review the science, preclinical and clinical research behind the most popular energy devices on the market and help participants evaluate new and evolving technology in the future. • *1.00 Category 1 CME Credit*

DISCUSSION GROUP • 9 TO 11 A.M.

Open admission to eligible categories, no tuition or ticket

D006 • Challenging Pediatric Dermatology Cases

Room: W308C

Director: Joan E. Tamburro, DO

Learning Objectives
Following this session, the attendee should be able to:
1. Assess infants and children with difficult to diagnose and/or treat skin eruptions.
2. Synthesize a differential diagnosis and working diagnosis for infants and children with difficult to diagnose and/or treat skin eruptions.
3. Identify issues to discuss with patients, families, and primary care providers of patients with difficult to diagnose and/or treat skin eruptions.

Description
This session on pediatric dermatology emergencies will focus on dermatologic conditions that present acutely in the nursery, office and emergency room, and require the immediate development of an evaluation and treatment plan. After a brief introduction to review variable expression of emergent disorders in different pediatric age groups, seasons, and geographic locations, the session will challenge the participants to develop a differential diagnosis for blistering, palpable purpuric and nodular disorders in an emergent setting. This will include infections and infestations, cutaneous findings in child maltreatment syndrome, autoimmune disorders, as well as benign and malignant tumors of childhood. • *2.00 Category 1 CME Credits*

FORUMS • 9 TO 11 A.M.

Open admission to eligible categories, no tuition or ticket

F124 • Adverse Drug Reactions: The Evidence and the Controversies

Room: W306AB

Director: Neil H. Shear, MD

Invited Speaker: Erik Joseph Stratman, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Distinguish between the pros and cons regarding genetic testing for certain drugs and reactions.
2. Evaluate the steps that can help reduce risks to patients when informing them about therapy.
3. Recognize the risk and risk perception in pregnancy.

Description
Prescribing medications is a very skilled task that is uniquely in the hands of physicians. Dermatologists may face changing science, exploding amounts of data, and skeptical patients. Legal risks also abound. In this sea of turmoil, it is important to share strategies to mitigate risks and learn from each other about lessons learned.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

F125 • Redness and Rosacea

Room: W206C

Director: Yolanda Rosi Helfrich, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe clinical features of rosacea.
2. Recognize skin diseases other than rosacea that can produce facial redness.
3. Develop an appropriate plan to manage facial redness.

Description
Rosacea is a common inflammatory skin disease. Various subtypes of rosacea will be discussed and compared to other dermatologic processes that can produce facial redness. A large part of the session involves case-based presentation. Established and emerging treatments for rosacea and facial erythema will be presented. *• 2.00 Category 1 CME Credits*

F126 • Bullous Diseases: Diagnostic and Management Algorithm

Room: W304E

Director: Luca Borradori, MD

Invited Speakers: Lawrence F. Eichenfield, MD, Russell P. Hall, III, MD, Michael Hertl, MD, Kim B. Yancey, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize the common and misleading presentations of bullous dermatoses in childhood and adulthood with a clear diagnostic algorithm.
2. Evaluate, diagnose and properly manage autoimmune bullous diseases of the skin and mucosae in your daily practice.
3. Discuss the most recent practical advances in the field which change the practical approach of this group of diseases.

Description
The session will review the broad spectrum of presentations of blistering diseases with a specific attention for autoimmune mediated conditions. We will summarize the current diagnostic algorithm, remind the place and limits of the various diagnostic tests, and finally, discuss guidelines and the evidence-based principles of management. The overall goal is to gain new knowledge useful for your daily practice. USA and international experts will share their experience in this fascinating and challenging area. • *2.00 Category 1 CME Credits*

F127 • Coagulation and Vasculitis

Room: W303A

Director: Warren W. Piette, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize distinct morphologic subsets of purpura that are useful diagnostically.
2. Categorize occlusive syndromes into distinct pathophysiologic categories, leading to appropriate treatment.
3. Distinguish vasculitis syndromes from those of simple hemorrhage or coagulopathic vascular occlusion.

Description
This session will be divided into thirds, with time for questions between each section. The sections are as follows: 1) Practical Morphologic Approach to Purpura, Vasculitis, and Coagulation, 2) Focus on Coagulopathies and the Skin; and 3) Selected Complex Cases/Syndromes. Each section will be 20-25 minutes, with 5-10 minutes for questions after each section. • *2.00 Category 1 CME Credits*

F128 • Dermoscopy: Learning From Easy and Difficult Cases

Room: W304G

Director: Horacio Antonio Cabo, MD

Co-Director: Wilhelm Stolz, MD

Invited Speakers: Zoe Apalla, MD, Gabriella Brancaccio, MD, Aimilios Lallas, MD, MSc, PhD, Caterina Longo, MD, PhD, Renato Marchiori Bakos, MD, PhD, Orit Markowitz, MD, Elvira Moscarella, MD, Gabriel Esteban Salerni, MD, Philipp Tschandl, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize the different dermoscopy structures and criteria for melanocytic and non-melanocytic lesions.
2. Analyze dermoscopic cases of different complexity (from easy to difficult cases).
3. Discuss the different approaches to arrive at correct diagnosis.

Description
The purpose of this session is to increase knowledge in dermoscopy with the help of clinical cases. We will show cases of different complexity and sometimes the same type of lesion (melanocytic or non-melanocytic), emphasizing the presence of less common dermoscopic criteria in the most difficult case. Audience participation is very important. *• 2.00 Category 1 CME Credits*

F129 • Fractional Laser and Light-based Technologies

Room: W415A

Director: Roy G. Geronemus, MD

Invited Speakers: Tina S. Alster, MD, Henry H.L. Chan, MD, PhD, Jeremy Green, MD, Dieter Manstein, MD, PhD, Elizabeth Tanzi, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss the current indications, limitations, and potential for fractional laser, light-based and energy-based devices in dermatology.
2. Identify possible side effects and complications of fractionated skin resurfacing and rejuvenation procedures and develop strategies to prevent and treat them.
3. Develop a working algorithm for the clinical use of fractionated devices, including preoperative assessment, intraoperative treatment protocol, and postoperative follow-up.

Description
This session is appropriate for experienced and potential users of fractional laser and light technologies. Specific treatment protocols will be outlined and tips to optimize clinical outcomes will be shared. The expert faculty will use evidence-based approaches to examine the strengths and weaknesses of current fractional technology. A review of fractionated laser skin resurfacing and rejuvenation in varying skin tones and conditions as well as a discussion of future technologic applications will provide the attendee with the latest advancements in the fields.
• 2.00 Category 1 CME Credits

F130 • M&M for the Medical Dermatologist: Case-based Lessons

NEW

Room: W305A

Director: Daniel D. Miller, MD

Invited Speakers: Dirk Michael Elston, MD, Lindy Peta Fox, MD, Misha Rosenbach, MD, Kanade Shinkai, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Examine complex presentations of challenging medical dermatology cases.
2. Discuss complications, medical errors, ethical dilemmas and sources of morbidity/mortality in an open, constructive learning environment.
3. Recognize pitfalls in the diagnosis and management of severe skin diseases.

Description
This session is designed to provide an open forum for the discussion of challenging medical dermatology cases in the style of a Morbidity and Mortality conference. Difficult cases with complications such as delayed diagnoses, adverse medication reactions and ethical dilemmas will be presented to a panel of medical dermatology and dermatopathology experts in a "no judgement" atmosphere to facilitate learning from complex cases. • *2.00 Category 1 CME Credits*

F131 • Cost-conscious Dermatology

Room: W307B

Director: Kevin Kia, MD

Invited Speaker: Adewole Shomari Adamson, MD, MPP

Learning Objectives
Following this session, the attendee should be able to:
1. Compare the cost to benefit ratio of commonly prescribed therapeutics.
2. Assess the necessity for laboratory and radiologic tests for skin diseases.
3. Treat the un- and under-insured more effectively.

Description
The cost of medicine is escalating dramatically. Laboratory tests, imaging, and prescription drugs represent a significant portion of healthcare expenditures. This session will examine the cost to benefit ratio for both the evaluation and management of several commonly encountered conditions. This session is applicable to all dermatologists who practice medical dermatology. Specific attention will be made on understanding how best to evaluate and treat patients that are under- or uninsured and how to navigate the rapidly changing costs of generic drugs. • *2.00 Category 1 CME Credits*

F132 • Caring for the Hospitalized Patient: Interesting Cases from the Inpatient Consultative Service

Room: W308A

Director: Lauren C. Hughey, MD

Invited Speakers: Adela Rambi G. Cardones, MD, Jeremy Jackson, MD, Arash Mostaghimi, MD, MPH, Karolyn Wanat, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize morphology and distribution of skin findings in hospitalized patients in order to develop broad differentials.
2. Choose appropriate work-up for hospitalized patient with skin disease.
3. Prepare optimal treatment plan for hospitalized patient with skin disease.

Description
Four hospital dermatologists will present challenging cases from the wards of their institution. Each speaker will present their case in detail allowing both audience participation and comments from a panel of experienced dermatology hospitalists. Each case is chosen to stimulate conversation and be instructive in how to approach similar patients on the wards. *• 2.00 Category 1 CME Credits*

WORKSHOP • 9 TO 11 A.M.

Tuition fee and ticket required for admission

W015 • Self-assessment: Acne

Room: W300

Director: Ninad C. Pendharkar, MD

Invited Speakers: Bryan Erik Anderson, MD, Joslyn S. Kirby, MD, Nicholas Sebes, MD, Morgan Wilson, MD

Learning Objectives

Following this session, the attendee should be able to:
1. Diagnose clinical presentations of acne variants and understand the potential for systemic complications.
2. Assess and compare various treatment modalities for acne vulgaris.
3. Identify and appropriately treat common side effects from medications used to treat acne.

Description
Topics will include medications used to treat acne, side effects of these medications, acne variants, and pathogenesis. The session presents 34 case-based ABD approved questions that apply towards MOC Component 2 self-assessment requirements. Answers are recorded via an iPad Audience Response System (ARS), followed by discussion of the case. Immediate, anonymous feedback allows attendees to assess their knowledge and identify areas that require further self-directed study. In order to fully participate, it is imperative that participants arrive on time.

This activity has been approved by the American Board of Dermatology (ABD) for up to 34 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

WORKSHOPS • 9 A.M. TO 12 P.M.

Tuition fee and ticket required for admission

W009 • Hands-on: Lasers

Room: W205A

Director: Mathew M. Avram, MD, JD

Co-Director: Arisa Ortiz, MD

Invited Speakers: Eric F. Bernstein, MD, Ashish Bhatia, MD, Catherine M. DiGiorgio, MS, MD, Jeremy Green, MD, Omar Ibrahimi, MD, PhD, Suzanne L. Kilmer, MD, Kachiu Cecilia Lee, MD, MPH, Yakir S. Levin, MD, Andrew A. Nelson, MD, Ogechukwu C. Onwudiwe, MD, Melanie Palm, MD, Nazanin A. Saedi, MD, Kelly J. Stankiewicz, MD, Anne Marie Tremaine, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss current indications and treatment protocols for laser and light treatments including vascular, tattoo, pigment, acne, nonablative, fractional, and ablative lasers.
2. Identify appropriate patients and gain treatment pearls for skin tightening, fat melting, and body contouring procedures.
3. Utilize proper laser techniques, and treat a variety of dermatologic conditions with laser and light devices.

Description
This session is geared toward all levels of dermatologists, from beginner and intermediate to advanced levels. It offers small groups, hands-on experience practicing a variety of laser skills and techniques. Approaches to patient assessment and selection, treatment planning, equipment selection, laser safety, and proper application of devices will be covered. Small groups will rotate between stations demonstrating ablative resurfacing, nonablative rejuvenation, tattoo and pigment removal, acne and vascular lesions, skin tightening, fat melting, and body contouring. Participants will complete a pre- and post-assessment of procedural skills covered in this session.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

W010 • Hands-on: Practical Anatomy for Dermal Fillers

Room: W204B

Director: Sue Ellen Cox, MD

Co-Director: Derek H. Jones, MD

Invited Speakers: Katie Beleznay, MD, Vince Bertucci, MD, Andre Braz, MD, Sabrina G. Fabi, MD, Jeremy Green, MD, Seth Matarasso, MD, Vic A. Narurkar, MD, Marina Peredo, MD, Anthony Rossi, MD, Kathleen M. Welsh, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify structural and functional facial anatomy relevant to filler injections.
2. Utilize proper techniques for soft tissue augmentation pan-facially.
3. Implement peri-procedural assessment and strategies for avoidance and management of complications.

Description
This hands-on training session for dermal fillers will begin with a video review of anatomy presented by Dr. Braz. Participants will then break into groups of five beginner/intermediate or five intermediate/advanced injectors, and circulate through each of five tables focused on a specific anatomical region of the face. Each demonstration table will be staffed by an instructor and equipped with high fidelity cutaneous surgical training models for practice injections using both needles and cannulas.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

W011 • Hands-on: Scar Revision

Room: W203C

Director: Jeremy S. Bordeaux, MD, MPH

Co-Director: Ian A. Maher, MD

Invited Speakers: Jerry D. Brewer, MD, Mariah C. Brown, MD, David R. Carr, MD, John A. Carucci, MD, PhD, Daniel Brian Eisen, MD, Todd E. Holmes, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize when a z-plasty, geometric broken line closure, or w-plasty can be utilized to improve scar outcome.
2. Design and execute repair of ectropion, eclabion, alar notching, melolabial fold distortion, vermillion border distortion, brow distortion, and tenting/webbing.

Description
This session is geared toward advanced dermatologic surgeons. It offers small group, hands-on experience practicing a variety of surgical scar revision techniques, with faculty engaged in teaching at each table. Z-plasty, geometric broken line closure, and W-plasty will be discussed and performed. Design and execution for repair of ectropion, eclabion, alar notching, melolabial fold distortion, vermillion border distortion, brow distortion and tenting/webbing will be performed. Participants will have the opportunity for realistic hands-on practice with cadaveric arms and high quality synthetic head models.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • *3.00 Category 1 CME Credits*

W012 • Hands-on: Nail Surgery

Room: W203B

Director: Nathaniel J. Jellinek, MD

Co-Director: Elizabeth M. Billingsley, MD

Invited Speakers: Chris Adigun, MD, Jane S. Bellet, MD, Todd Cartee, MD, Siobhan Coulter Collins, MD, Molly A. Hinshaw, MD, Aleksandar L. J. Krunic, MD, PhD, Christopher James Miller, MD, Phoebe Rich, MD, Ellen K. Roh, MD, Adam Rubin, MD, Faramarz H. Samie, MD, Dana W.K. Stern, MD, John Yost, MD, Martin N. Zaiac, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Establish a solid foundation of principles that will guide nail surgery, from simple to advanced procedures.
2. Treat a variety of nail conditions with surgical techniques including punch biopsy, shave (tangential biopsy), longitudinal biopsy, and a variety of nail plate avulsion techniques.
3. Perform advanced nail procedures, including en bloc excision of all nail tissues and nail flaps, for advanced level participants.

Description
This session is geared toward all levels of nail surgeons, from beginner and intermediate to advanced levels. It offers small group, hands-on experience practicing a variety of nail surgery techniques. Participants will be instructed on how to avulse the nail in several fashions (partial and complete), perform multiple different nail procedures (including punch, shave, longitudinal techniques), and for those with more advanced background, treat nail melanoma with en bloc excision of all nail tissues and perform nail flaps. Approaches to patient assessment, including surgical planning, equipment/suture selection, and anatomical considerations to optimize outcomes will be covered. Anatomy as it relates to safe surgical technique will be stressed. Fresh frozen cadaveric hands that allow for realistic hands-on practice will be utilized.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

W013 • Hands-on: Innovative Suture Techniques Update

Room: W204C

Director: Andrew Hart Weinstein, MD, MPH

Co-Director: Cyndi Jill Yag-Howard, MD

Invited Speakers: Murad Alam, MD, Jonathan Kantor, MD, Arianne Shadi Kourosh, MD, MPH, Kavita Mariwalla, MD, Alexander Miller, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Utilize deep tension relieving sutures.
2. Apply new methods for suturing.
3. Utilize novel variations of existing suture techniques.

Description
This session combines an extensive lecture/video presentation with hands on instruction and practice sessions. Learn how to perform novel closure techniques that you did not know you could not live without. You will see a drawing and high quality video of these techniques that allow you to close wounds using minimal tension and therefore improve cosmetics. Next, you will practice these techniques with our expert faculty.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

W014 • Hands-on: Fire and Ice! Electrosurgery and Cryosurgery

NEW MOC

Room: W202C

Director: Paola Pasquali, MD

Co-Director: Arash Taheri, MD

Invited Speakers: Lucia Achell, MD, Kamran Balighi, MD, Emad El Gamal, MD, Azael D. Freites-Martinez, MD, Courtney S. Green, MD, Sima Kavand, Razieh Soltani Arabshahi, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss the principles of cryobiology and electrosurgery and its practical applications.
2. Treat common benign skin conditions with cryosurgery, applying different available techniques.
3. Treat benign and malignant skin lesions with electrosurgery, applying different available techniques.

Description
This session is geared toward all levels of surgeons, from beginner and intermediate to advanced levels. It offers small group, hands-on experience practicing a variety of cryosurgical and electrosurgical techniques. Participants will be instructed on how to select patients and lesions, and proper techniques (for cryosurgery: open, close, tweezer, semi-open, semi-closed and intralesional; for electrosurgery: deep vs superficial coagulation, fulguration, and clean vs blend cutting). Pig feet and ears and gelatin molds will allow realistic hands-on practice. Electrosurgery on beef (red meat) will allow us to have a better understanding of depth of tissue damage during electrosurgery.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

COURSE • 9 A.M. TO 12 P.M.

Open admission to eligible categories, no tuition or ticket

C025 • Coding and Documentation

Room: W311A

Director: Murad Alam, MD

Invited Speakers: Clifford Warren Lober, MD, JD, Mollie A. MacCormack, MD, Alexander Miller, MD, Melissa Piliang, MD, Howard Wooding Rogers, MD, Daniel M. Siegel, MD, MS

Learning Objectives
Following this session, the attendee should be able to:
1. Evaluate pending changes to the coding and documentation environment to better ensure adherence with latest recommendations.
2. Recognize specific coding conventions pertaining to subject areas like surgery and dermatopathology.
3. Identify operationally significant legal and regulatory constraints that impinge on medical record description and documentation.

Description
CPT coding, appropriate chart documentation, specific issues relevant to dermatopathology and dermatologic surgery, and relevant legal and regulatory implications will be discussed. Coming changes and recent additions will be emphasized. Time will be available for questions from the audience.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

SYMPOSIA • 9 A.M. TO 12 P.M.

Open admission to eligible categories, no tuition or ticket

S045 • Teledermatology Working for You: Customizing Use in the Changing Health Care Environment

Room: W209B

Director: Carrie L. Kovarik, MD

Invited Speakers: Bruce A. Brod, MD, Arturo R. Dominguez, MD, Karen E. Edison, MD, Jules Lipoff, MD, Mark Patrick Seraly, MD, Jonathan Winter, MD, Peter C. Young, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe how teledermatology may be an integral part of a changing health care landscape in your practice.
2. Examine how teledermatology can be used in different practice settings and consider issues that impact implementation, including reimbursement, licensure, and contracts in your practice.
3. Discuss how different teledermatology workflows may be beneficial in improving the care and satisfaction of dermatology patients in a variety of settings.

Description
Dermatology will continue to face challenges as new models for health care delivery systems evolve and government policies change. Teledermatology has the potential to improve access for patient care within these health care systems and individual practices, as well as provide an efficient, patient-centered experience. Teledermatology can be used to improve patient care, access, and outcomes in a variety of ways, including triage, urgent care, inpatient consultation, direct patient follow-up, and patient monitoring. Attendees will engage in discussions on how to evaluate the uses of teledermatology and determine how it may fit into their practice. Panel discussions with practicing dermatologists that use teledermatology in a variety of settings will be engaged to allow participants to develop a plan for teledermatology utilization.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

S046 • Controversies and Difficult Questions Concerning Biologic Therapeutics

Room: W312C

Director: Stephen E. Wolverton, MD

Invited Speakers: Kenneth B. Gordon, MD, Michael P. Heffernan, MD, Megan H. Noe, MD, MPH, Bruce Elliot Strober, MD, PhD, Junko Takeshita, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize important risk factors for biologics complications including severe infections and potential malignancies.
2. Utilize information presented to understand unequal utilization of biologics, at least in part due to significant cost barriers.
3. Evaluate the role of emerging biologics studied for atopic dermatitis in the overall armamentarium for this dermatosis.

Description
The spectrum of biologic therapeutics in dermatology is rapidly evolving. There are a number of controversies and difficult questions concerning drug safety issues that need clarification. In this symposium we will address both malignancy risk and serious infection risk due to biologic therapeutics as a whole. As subsets of infection risk, monitoring for tuberculosis and hepatitis B reactivation along with unique vaccine risks will be addressed. Additional topics include (a) clinical response and related drug costs for biologics, (b) possible unequal access for patients to biologics, and (c) newer biologic therapeutic options for atopic dermatitis. *• 3.00 Category 1 CME Credits*

S047 • Managing Patients with Melanoma or Other Melanocytic Neoplasms

Room: W415B

Director: Michael E. Ming, MD

Invited Speakers: Emily Y. Chu, MD, PhD, Timothy M. Johnson, MD, Sancy A. Leachman, MD, PhD, Ashfaq A. Marghoob, MD, Beth S. Ruben, MD, Jennifer A. Stein, MD, PhD, Susan M. Swetter, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize points to consider when developing a management plan for acral pigmented lesions, melanonychia, and dysplastic nevi.
2. Identify which patients would benefit from genetic testing and/or sentinel lymph node mapping.
3. Evaluate aids for early detection of melanoma, describe national staging guidelines for melanoma, and describe options for treatment of metastatic melanoma.

Description
This session will aid dermatologists in creating appropriate management plans for patients with melanoma or other melanocytic neoplasms. Topics covered are ones encountered in daily practice, including issues regarding re-excision of dysplastic nevi, how to approach acral pigmented lesions or melanonychia, aids for early detection of melanoma, the role of genetic testing and sentinel lymph node mapping, a discussion of national guidelines for melanoma patients, and an overview of new treatments for metastatic disease. This session is geared towards giving the working clinician practical information to assist in formulating management plans.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

S048 • Alopecia: Work-up and Treatment

Room: W207A

Director: Nicole Elaine Rogers, MD

Invited Speakers: Carolyn Goh, MD, Yolanda M. Lenzy, MD, Melissa Piliang, MD, Adriana N. Schmidt, MD, Rodney Daniel Sinclair, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Compare the different types of hair loss across demographic groups.
2. Analyze the different needs of patients with various types of hair loss.
3. Recognize the similarities in treating all patients with hair loss.

Description
This session will cover the many different presentations of hair loss including male and female pattern hair loss, alopecia areata, cicatrial alopecias, and will provide an interesting overview of treatment algorithms for each. • *3.00 Category 1 CME Credits*

S049 • Boards Blitz

Room: W208A

Director: Adam J. Friedman, MD

Co-Director: Jennifer Lucas, MD

Invited Speakers: Anna Yasmine Kirkorian, MD, Bonnie Anne Lee, MD, Kalyani Marathe, MD, MPH

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize and/or diagnose commonly tested images related to medical dermatology, pediatric dermatology, surgical dermatology, and clinical pathologic correlates.
2. Identify strengths and weaknesses in one's fund of knowledge to better prepare for the ABD certification exam and/or in-training exam and make improvements as needed.

Description
The in-training exam and board certification in Dermatology all require a continued mastery of a broad breadth of information as dictated by the American Board of Dermatology (ABD) – overwhelmed yet? This interactive session will provide key point/ tips for identifying and answering questions on the digital image portion of the certification exam. Attendees will have the opportunity to view digital images with associated questions preparing them for the image portion of the exam. High-yield study material will also be covered as images are reviewed. The session will benefit any dermatologist preparing for the ABD certification, recertification, or in-training exam. • *3.00 Category 1 CME Credits*

S050 • Dermatologic Surgery: Cosmetic Tips and Pearls

Room: W414C

Director: Gary D. Monheit, MD

Co-Director: Rhoda S. Narins, MD

Invited Speakers: Macrene Alexiades-Armenakas, MD, PhD, Tina S. Alster, MD, Mathew M. Avram, MD, JD, Derek H. Jones, MD, Suzanne L. Kilmer, MD, Kavita Mariwalla, MD, Girish S. Munavalli, MD, MHS, Jason K. Rivers, MD, Ava T. Shamban, MD, Elizabeth Tanzi, MD, Jill S. Waibel, MD, Susan H. Weinkle, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Evaluate the present cosmetic tips as related to your practice.
2. Assess the objectivity of the pearls presented.
3. Incorporate the best suggestions with your present procedures.

Description
The core procedures for a cosmetic surgery practice are presented with new techniques, procedures and studies to improve the attendees understanding of the field. Experts in each area will present their most important findings over the past year. • *3.00 Category 1 CME Credits*

S051 • Genetic Disorders: Presentations from Infancy to Adulthood

Room: W311E

Director: Jonathan A. Dyer, MD

Invited Speakers: Brittany Gareth Craiglow, MD, Jennifer L. Hand, MD, Sibel Ersoy-Evans, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Differentiate and identify primary immunodeficiencies with dermatologic findings.
2. Categorize and evaluate genodermatoses with cafe au lait macules (CALM).

Description
This session will review several hot topics in inherited skin disease. Primary immunodeficiencies may present with subtle skin findings which only a dermatologist would recognize. Cafe au lait macules (CALM) are common skin lesions but can also hint at genetic disease. • *3.00 Category 1 CME Credits*

S052 • Systemic Therapies for Dermatologists: A Comprehensive Review and Update

Room: W415D

Director: J. Mark Jackson, MD

Invited Speakers: M. Shane Chapman, MD, Lawrence F. Eichenfield, MD, Anthony Fernandez, MD, Craig L. Leonardi, MD, Guy F. Webster, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Use the current and new systemic therapies appropriately.
2. Monitor and manage patients on these systemic therapies.
3. Utilize practical pearls and new information for each therapy to improve patient outcomes.

Description
This session is directed toward medical dermatologists and residents interested in learning to best utilize, manage, monitor and administer the current systemic therapies available to treat dermatologic diseases, as well as for dermatologists looking to refresh and update their knowledge of systemic therapies. The session will cover chemotherapies, immunosuppressives immunomodulators, anti-inflammatories, systemic retinoids, antibiotics and the biologic agents. The goal will be to learn practical pearls as well as important scientific information for each therapy. The presenters are known for their expertise in the agents discussed. • *3.00 Category 1 CME Credits*

S053 • Masters of Dermatology

Room: W307D

Director: William D. James, MD

Invited Speakers: Timothy G. Berger, MD, Jean L. Bolognia, MD, Jeffrey Phillip Callen, MD, Dirk Michael Elston, MD, Ilona J. Frieden, MD, Kenneth E. Greer, MD, Warren R. Heymann, MD, Howard Ira Maibach, MD, Oliver Fred Miller, III, MD, Amy S. Paller, MD, Susan C. Taylor, MD, Kim B. Yancey, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe seminal clinical observations in dermatology, their genesis, and subsequent impact on the practice of dermatology.
2. Identify and explain how leaders of our specialty first determined and subsequently developed their areas of interest.
3. Describe the directions for future advancement of the Masters' focus areas.

Description
A series of presentations by master clinicians will highlight their most important contributions to our specialty. They will emphasize unsolved challenges that remain. • *3.00 Category 1 CME Credits*

S054 • Dermatitis

NEW

Room: W304A

Director: Charles N. Ellis, MD

Invited Speakers: David Eric Cohen, MD, Lawrence F. Eichenfield, MD, Adelaide A. Hebert, MD, Margaret S. Lee, MD, PhD, Seth J. Orlow, MD, PhD, Jonathan I. Silverberg, MD, PhD, MPH, Eric Lawrence Simpson, MD, Gil Yosipovitch, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Advise patients and their families on prevention and non-pharmacologic approaches to dermatitis and itching using material from this session.
2. Implement new therapeutics in patients with atopic dermatitis according to labeling and expert opinion.
3. Assess likelihood of certain contactants as causing a patient's dermatitis based on current prevalence of various antigens.

Description
Dermatitis is arguably the most common skin malady. This session will highlight atopic dermatitis and consider other dermatitides. We can help our patients by advising on: prevention; non-pharmacologic approaches to treatment; engaging other health professionals; and risks (co-morbidities) to consider. Atopic dermatitis is like psoriasis 5-10 years ago – in an explosion of new treatments. We will discuss both topical and systemic therapies. We will also contemplate itch and contact allergens. The speakers endeavor to make each topic practical and immediately useful. Send questions about speakers' topics in advance of the meeting to dermquestion@gmail.com.
• 3.00 Category 1 CME Credits

S055 • Skin of Color Boot Camp: What Every Dermatologist Should Know About the Patient with Darker Skin Tones

NEW

Room: W304C

Director: Susan C. Taylor, MD

Invited Speakers: Victoria Holloway Barbosa, MD, Cheryl M. Burgess, MD, Valerie D. Callender, MD, Candrice R Heath, MD, Amy J. McMichael, MD, Temitayo Ogunleye, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Improve clinician confidence with medical management for disorders common in patients with darker skin tones.
2. Provide a quick and accurate assessment approach.
3. Provide treatment algorithms.

Description
This session provides a practical and comprehensive overview to assist clinicians in optimizing the care of the skin of color patient. Diagnostic and treatment algorithms will be provided. Topics will include hyperpigmentation, acne, cosmetic enhancement, keloids, acne keloidalis nuchae, pseudofolliculitis barbae, scalp disorders and alopecia. *• 3.00 Category 1 CME Credits*

COURSES • 9 A.M. TO 4 P.M.

Tuition fee and ticket required for admission

C026 • Essential Dermatopathology: What You Need to Know for Clinical Practice: Inflammatory

Room: W209C

Director: Catherine Chung, MD

Invited Speakers: Carrie Ann R. Cusack, MD, Dirk Michael Elston, MD, Anthony Fernandez, MD, Tammie C. Ferringer, MD, Paul Haun, MD, MS, Michael D. Ioffreda, MD, Michael C. Lynch, MD, Darius R. Mehregan, MD, Margot S. Peters, MD, Melissa Piliang, MD, Beth S. Ruben, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Develop a differential diagnosis for basic histopathologic patterns of inflammatory diseases.
2. Diagnose by histopathology common inflammatory disorders.
3. Utilize various approaches to pattern recognition used in the histopathologic diagnosis of inflammatory conditions.

Description
This course is presented by multiple experts in dermatopathology and presents their approaches to the histopathologic diagnosis of inflammatory conditions and differential diagnoses. This course will cover the spectrum of inflammatory disorders including: spongiotic and psoriasiform dermatitis, interface dermatitis, granulomatous and histiocytic disorders, metabolic and depositional diseases, genodermatoses, vasculitides, vesiculobullous disorders, infections, nail pathology, and alopecia. This course utilizes the Audience Response System to allow attendees to test knowledge and this year will include a self-assessment review session. • *6.00 Category 1 CME Credits*

C027 • Fundamentals of Dermoscopy

Room: W311G

Director: Mary C. Martini, MD

Invited Speakers: Ana M. Ciurea, MD, Pedram Gerami, MD, Claudia Hernandez, MD, Jason Bok Lee, MD, Ashfaq A. Marghoob, MD, Margaret C. Oliviero, NP, MSN, Harold S. Rabinovitz, MD, Jennifer A. Stein, MD, PhD, Xiaolong Alan Zhou, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify melanocytic and non-melanocytic patterns on dermoscopy.
2. Recognize and identify major dermoscopic findings in melanoma.
3. Differentiate between benign and malignant non-melanocytic and melanocytic neoplasms.

Description
This introductory course is for the dermatologist who is new to dermoscopy or needs a refresher course. The two step mechanism will be presented and images from a wide array of melanocytic and non-melanocytic lesions will be presented in the morning session. There will be a series of unknown dermoscopy cases presentations throughout the course allowing the attendees to test their knowledge. The afternoon session includes dermoscopy path correlates and lectures on specific issues in dermoscopy including spitz tumors, anatomic variations, and mimickers in dermoscopy. • *6.00 Category 1 CME Credits*

C028 • Advanced Self-assessment of Dermatopathology

Room: W414A

Director: Whitney A. High, MD, JD

Invited Speakers: Antoanella Calame, MD, Clay J. Cockerell, MD, Brittney Kaufman DeClerck, MD, Dirk Michael Elston, MD, Jinah Kim, MD, PhD, Timothy H. McCalmont, MD, Ronald P. Rapini, MD, Omar P. Sangueza, MD. Christopher R. Shea, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Analyze 50 unknown dermatopathology cases of advanced complexity via independent microscopic exam.
2. Formulate an appropriate differential diagnosis.
3. Select the most appropriate diagnosis based upon the histopathologic features and clinical situation.

Description
This self-assessment course in dermatopathology is designed to allow participants to test their skills and knowledge base using actual examination of glass slides containing unknowns. The faculty is not able to give an all-inclusive review in this session, but important points in the microscopic differential diagnosis will be highlighted with regard to some advanced dermatopathology cases. This activity has been approved by the American Board of Dermatology (ABD) for up to 60 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • *6.00 Category 1 CME Credits*

FORUMS • 1 TO 3 P.M.

Open admission to eligible categories, no tuition or ticket

F133 • Iatrogenic Injury

Room: W206C

Director: Eve Judith Lowenstein, MD, PhD

Co-Director: George Kroumpouzos, MD, PhD

Invited Speakers: Jerry D. Brewer, MD, John J. DiGiovanna, MD, Daniela Kroshinsky, MD, MPH, Mario E. Lacouture, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Provide an update on the adverse skin effects of anti-cancer agents, immunosuppression and systemic retinoids.
2. Review iatrogenic injuries incurred in the hospitalized patient.
3. Survey pigmentary skin disorders secondary to medication exposure.

Description
As new targeted therapies are introduced, skin complications secondary to medications grow in number, variety and complexity. This session focuses on several areas where recent therapeutic advances have introduced new and unusual skin changes induced iatrogenically in the hospital and outpatient setting. We will focus on iatrogenic injury secondary to immunosuppression, chemotherapy and melanoma medications. An update on controversies relevant to isotretinoin risks will be included. Iatrogenic skin injury of the hospitalized patient has received little attention in the dermatology literature and will be discussed. Finally, pigmentary skin disorders secondary to medication exposure will be addressed. • *2.00 Category 1 CME Credits*

F134 • AIDS and Sexually Transmitted Diseases (STDs): Hot Topics

Room: W307B

Director: Kieron S. Leslie, MBBS

Invited Speakers: Erin H. Amerson, MD, Esther Ellen Freeman, MD, PhD, Margot J. Whitfeld, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Manage skin diseases associated with HIV infection.
2. Evaluate patients with sexually transmitted infections.
3. Recognize global challenges in Kaposi's Sarcoma management.

Description
This session will review existing and new emerging skin problems in patients with HIV infection. Specific areas that will be focused on include skin diseases associated with hepatitis C, Kaposi's sarcoma and HPV related disease and treatment options. Challenges and opportunities in development of HIV vaccines will also be presented.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

F135 • Techniques for Flap Success

Room: W303A

Director: Jonathan L. Cook, MD

Co-Director: Juan-Carlos Martinez, MD

Invited Speakers: Anna A. Bar, MD, Joel Cook, MD, Walayat Hussain, MBChB, Ian A. Maher, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Compare flap designs for the repair of common Mohs surgical defects.
2. Recognize flap modifications that can improve surgical results.

Description
This session is designed to improve the surgical skills of the intermediate to advanced dermatologic surgeon. Attention will be directed to proper flap design and execution.
• 2.00 Category 1 CME Credits

F136 • Pediatric Psoriasis: Systemic Therapy and Beyond

Room: W208A

Director: Megha M. Tollefson, MD

Invited Speakers: Kelly M. Cordoro, MD, Wilson Liao, MD, Amy S. Paller, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe clinically relevant aspects of the genetics of pediatric psoriasis.
2. Recognize and address the potential comorbidities of pediatric psoriasis.
3. Choose appropriately among the available systemic, biologic and light-based treatments for various clinical presentations of severe pediatric psoriasis, considering benefits and limitations of each treatment.

Description
Management of moderate to severe pediatric psoriasis is challenging and requires understanding of potential comorbidities as well as proper use of systemic and biologic therapies for this age group, including those that are emerging. This session will provide updates on clinical, comorbidity, quality of life, and therapeutics and will focus on the basic principles and advanced practices necessary to manage challenging pediatric psoriasis cases. An expert panel will discuss each of these areas and cases will be used to emphasize learning points. The session is directed towards clinicians and trainees and is intended to be immediately applicable to your practice. *• 2.00 Category 1 CME Credits*

F137 • Challenging Diagnostic Cases for Practitioners

Room: W308C

Director: Brooks Albert Bahr, MD

Invited Speakers: Elizabeth E. Bailey, MD, MPH, David Syngyu Lee, MD, Eric Austin Millican, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe challenging diagnostic dilemmas encountered by dermatology practitioners, and determine appropriate therapies based on available evidence.
2. Recognize potential practice gaps and identify areas of improvement to be implemented in future practice.

Description
This course is directed to Nurse Practitioners and Physician Assistants practicing in dermatology and will discuss challenging diagnostic cases encountered in hospital-based, academic, and private practice settings. Cases will be presented on topics ranging from dermatologic surgical cases, dermatopathology, nail diseases, general dermatology, hospital-based dermatology and more.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

F138 • Photodynamic Therapy in Medical and Aesthetic Dermatology

Room: W307CD

Director: Nellie Konnikov, MD

Invited Speakers: Rolf-Markus Szeimies, MD, PhD, Maria M. Tsoukas, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Update the principles and mechanism of action of Photodynamic Therapy (PDT) to empower your clinical expertise.
2. Summarize the evidence based data on the efficacy and safety of ALA-PDT in clinical practice.
3. Discuss the evolving role and implementation of topical ALA-PDT in the management of your patients in current medical and aesthetic practices.

Description
This session is directed to physicians looking to expand utilization of topical PDT in their busy medical and aesthetic practice. The discussion will focus on relevant principles of PDT, practical application and current data on safety and efficacy in Dermatology. Highlights will include practical application of PDT in U.S. and abroad, including updates on current research and development in Photodynamic Therapy. • *2.00 Category 1 CME Credits*

F139 • Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines

Room: W305A

Director: Susan M. Swetter, MD

Invited Speakers: Christopher K. Bichakjian, MD, Alison Bates Durham, MD, James M. Grichnik, MD, PhD, Pascale Guitera, MD, PhD, Jinah Kim, MD, PhD, Bernice Kwong, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Apply current national guidelines for cutaneous melanoma to clinical practice, including biopsy technique, pathology evaluation, baseline/surveillance studies, and surgical management.
2. Describe the most recent AJCC melanoma staging system and its application to clinical practice, with special attention to patient selection for sentinel node biopsy.
3. Recognize and manage dermatologic side effects of the newer systemic treatments for advanced melanoma.

Description
This session will provide an overview of current recommendations for the diagnosis and management of cutaneous melanoma (AJCC stages 0-II), utilizing the recent AAD and current NCCN clinical practice guidelines. Members of the AAD and NCCN melanoma guidelines panels will address biopsy techniques, pathology assessment, baseline/surveillance studies, sentinel lymph node biopsy staging, surgery, and adjuvant therapy for primary melanoma. Treatment of dermatologic side effects related to newer systemic therapies for advanced melanoma will be covered in this session. We will also provide a comparison of international melanoma guidelines, focusing on those employed in Australia and New Zealand. • *2.00 Category 1 CME Credits*

F140 • Medical and Surgical Management of Nail Disorders

Room: W311E

Director: Molly A. Hinshaw, MD

Invited Speakers: Boni E. Elewski, MD, Shari Lipner, MD, PhD, Bianca Maria Piraccini, MD, Phoebe Rich, MD, Dimitris Rigopoulos, MD, Antonella Tosti, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize clinical settings in which nail biopsy or evaluation of nail clippings guide medical and/or surgical management.
2. Outline at least one strategy for the medical management of various nail disorders including nail psoriasis, lichen planus, and onychomycosis.
3. Describe various surgical and procedural approaches to the management of nail disorders including tangential shave biopsy/removal and intralesional injections with corticosteroid.

Description
We will discuss practical approaches to nail disorders affecting patients of all ages. Detailed medical, surgical and procedural approaches will be provided by world experts in nail diseases. Attendees should expect to learn skills that can be readily incorporated into practice.
• 2.00 Category 1 CME Credits

WORKSHOP • 1 P.M. TO 3 P.M.

Tuition fee and ticket required for admission

W016 • Self-assessment: Pediatric Dermatology

Room: W300

Director: Teresa S. Wright, MD

Invited Speakers: Bernard Cohen, MD, Katherine B. Puttgen, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify features of neurofibromatosis type 1 in the pediatric population.
2. Differentiate among treatment options for function threatening infantile hemangiomas.
3. Discuss causes of and therapies for tinea capitis.

Description
Attendees will review clinical findings of important genodermatoses in children including tuberous sclerosis, neurofibromatosis type 1, and Rothmund-Thomson. An update on vascular anomalies in children, including infantile hemangiomas and congenital hemangiomas, will be reviewed. Epidemiology of important pediatric dermatology infections and infestations will be discussed. This session presents 33 case-based ABD approved questions that apply towards MOC Component 2 self-assessment requirements. Answers are recorded via an electronic Audience Response System (ARS), followed by discussion of the case. Immediate, anonymous feedback allows attendees to assess their knowledge and identify areas that require further self-directed study. In order to fully participate, it is imperative that participants arrive on time.

This activity has been approved by the American Board of Dermatology (ABD) for up to 33 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

WORKSHOPS • 1 TO 4 P.M.

Tuition fee and ticket required for admission

W017 • Hands-on: Lasers

Room: W205A

Director: Mathew M. Avram, MD, JD

Co-Director: Arisa Ortiz, MD

Invited Speakers: Eric F. Bernstein, MD, Ashish Bhatia, MD, Catherine M. DiGiorgio, MS, MD, Jeremy Green, MD, Omar Ibrahimi, MD, PhD, Suzanne L. Kilmer, MD, Kachiu Cecilia Lee, MD, MPH, Yakir S. Levin, MD, Andrew A. Nelson, MD, Ogechukwu C. Onwudiwe, MD, Melanie Palm, MD, Nazanin A. Saedi, MD, Kelly J. Stankiewicz, MD, Anne Marie Tremaine, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss current indications and treatment protocols for laser and light treatments including vascular, tattoo, pigment, acne, nonablative, fractional, and ablative lasers.
2. Identify appropriate patients and gain treatment pearls for skin tightening, fat melting, and body contouring procedures.
3. Utilize proper laser techniques, and treat a variety of dermatologic conditions with laser and light devices.

Description
This session is geared toward all levels of dermatologists, from beginner and intermediate to advanced levels. It offers small groups, hands-on experience practicing a variety of laser skills and techniques. Approaches to patient assessment and selection, treatment planning, equipment selection, laser safety, and proper application of devices will be covered. Small groups will rotate between stations demonstrating ablative resurfacing, nonablative rejuvenation, tattoo and pigment removal, acne and vascular lesions, skin tightening, fat melting, and body contouring. Participants will complete a pre- and post-assessment of procedural skills covered in this session.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

W018 • Hands-on: Practical Anatomy for Dermal Fillers

Room: W204B

Director: Sue Ellen Cox, MD

Co-Director: Derek H. Jones, MD

Invited Speakers: Andre Braz, MD, Kimberly J. Butterwick, MD, Suneel Chilukuri, MD, Rebecca L. Fitzgerald, MD, Kavita Mariwalla, MD, Melanie Palm, MD, Marina Peredo, MD, Kristel Polder, MD, Anthony Rossi, MD, Susan H. Weinkle, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify structural and functional facial anatomy relevant to filler injections.
2. Utilize proper techniques for soft tissue augmentation pan-facially.
3. Implement peri-procedural assessment and strategies for avoidance and management of complications.

Description
This hands-on training session for dermal fillers will begin with a video review of anatomy presented by Dr. Braz. Participants will then break into groups of five beginner/intermediate or five intermediate/advanced injectors, and circulate through each of five tables focused on a specific anatomical region of the face. Each demonstration table will be staffed by an instructor and equipped with high fidelity cutaneous surgical training models for practice injections using both needles and cannulas.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

W019 • Hands-on: Wound Closures

Room: W203B

Director: Siegrid S. Yu, MD

Co-director: Eva A. Hurst, MD

Invited Speakers: Martha Laurin Council, MD, Shayna Gordon, MD, Seaver Soon, MD, Simon S. Yoo, MD, Zaineb Makhzoumi, MD, FAAD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize anatomic considerations of wound closures on the head and neck to optimize outcomes and avoid complications.
2. Describe design and execution pearls and pitfalls for linear closures and advancement, rotation, and transposition flaps.
3. Perform complex linear repairs and the various types of local flap closures, depending on participant skill.

Description
This session is geared toward beginner and intermediate levels. It offers small group, hands-on experience practicing a variety of wound closure techniques, with faculty engaged in teaching at each table. Relevant anatomy and the fundamentals of wound closures will be discussed in brief didactic format. Complex layered linear repairs and local flaps including all types of advancement, rotation, and transposition flaps will be reviewed. Participants will then have opportunity for realistic hands-on practice with cadaveric arms and artificial heads. Anatomic considerations, suture technique pearls, and safe techniques for optimizing outcome and minimizing complications will be emphasized.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

W020 • Hands-on: Nail Surgery

Room: W203C

Director: Nathaniel J. Jellinek, MD

Co-Director: Elizabeth M. Billingsley, MD

Invited Speakers: Chris Adigun, MD, Jane S. Bellet, MD, Siobhan Coulter Collins, MD, Aleksandar L. J. Krunic, MD, PhD, Ellen K. Roh, MD, John Yost, MD, Martin N. Zaiac, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Establish a solid foundation of principles that will guide nail surgery, from simple to advanced procedures.
2. Treat a variety of nail conditions with surgical techniques including punch biopsy, shave (tangential biopsy), longitudinal biopsy, and a variety of nail plate avulsion techniques.
3. Perform advanced nail procedures, including en bloc excision of all nail tissues and nail flaps, for advanced level participants.

Description
This session is geared toward all levels of nail surgeons, from beginner and intermediate to advanced levels. It offers small group, hands-on experience practicing a variety of nail surgery techniques. Participants will be instructed on how to avulse the nail in several fashions (partial and complete), perform multiple different nail procedures (including punch, shave, longitudinal techniques), and for those with more advanced background, treat nail melanoma with en bloc excision of all nail tissues and perform nail flaps. Approaches to patient assessment, including surgical planning, equipment/suture selection, and anatomical considerations to optimize outcomes will be covered. Anatomy as it relates to safe surgical technique will be stressed. Fresh frozen cadaveric hands that allow for realistic hands-on practice will be utilized.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

W021 • Hands-on: Varicose and Telangiectatic Veins

Room: W202C

Director: Margaret W. Mann, MD

Co-Director: Todd Cartee, MD

Invited Speakers: Daniel Pablo Friedmann, MD, Mitchel Paul Goldman, MD, Julie K. Karen, MD, Vineet Mishra, MD, Girish S. Munavalli, MD, MHS, Robert A. Weiss, MD, Ashley Wysong, MD, MS

Learning Objectives
Following this session, the attendee should be able to:
1. Describe the anatomy of the lower extremity venous system and identify patient characteristics that warrant noninvasive imaging prior to initiating treatment.
2. Formulate an appropriate treatment plan for leg veins ranging from spider veins to truncal varicosities.
3. Determine the appropriate use of sclerotherapy, lasers, and more advanced venous techniques and recite the advantages and disadvantages of each treatment modality.

Description
This hands-on training session will focus on how to manage lower extremity venous disease, with an emphasis on treating cosmetically undesirably spider and reticular veins of the legs. Faculty will describe the anatomy of the lower extremity venous system; identify patient characteristics that warrant noninvasive imaging; formulate an appropriate treatment plan for leg veins ranging from spider veins to truncal varicosities; determine the appropriate use of sclerotherapy, lasers, and more advanced venous techniques; and recite the advantages and disadvantages of each treatment modality. Following the didactic portion, participants will break into small groups and circulate through hands-on stations staffed by instructors, where they will practice patient examination with ultrasound and perform sclerotherapy on multiple simulation training devices.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

SYMPOSIA • 1 TO 4 P.M.

Open admission to eligible categories, no tuition or ticket

S056 • Pearls: Diagnostic and Therapeutic

Room: W311A

Director: Stephen P. Stone, MD

Invited Speakers: Robert T. Brodell, MD, Gary Goldenberg, MD, Aimilios Lallas, MD, MSc, PhD, Mark Lebwohl, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Use innovative therapies for patients with complicated conditions, or common maladies unresponsive to commonly effective approaches.
2. Safely and effectively utilize established medications for off-label uses.

Description
Faculty will present innovative approaches to some treatment-resistant dermatologic problems, some using newer drugs and treatments, others reaching back to therapies that worked in the past but may have been forgotten. Off-label and ABM (anecdote-based management) will predominate, with a few evidence-based pearls as well. Target audience is the office-based dermatologist. Participants are urged to e-mail challenging cases to drspstone@gmail.com in advance of the meeting for discussion by the faculty. The more audience participation, the merrier!
• 3.00 Category 1 CME Credits

S057 • Skin of Color

Room: W209A

Director: Diane M. Jackson-Richards, MD

Invited Speakers: Benjamin F. Chong, MD, MSc, Seemal Desai, MD, Raechele Cochran Gathers, MD, Ellen Pritchett, MD, Michelle Rodrigues, MBBS

Learning Objectives
Following this session, the attendee should be able to:
1. Examine various skin conditions unique to persons with skin of color and better diagnose these skin conditions.
2. Diagnose, treat, and manage the skin conditions covered.

Description
This session will provide attendees with insight into skin conditions more commonly seen in skin of color and provide ways to better diagnose and manage these conditions. Disorders of pigmentation, connective tissue and hair and scalp will be covered. *• 3.00 Category 1 CME Credits*

S058 • Melanoma: The Future is Now

Room: W312C

Director: Sancy A. Leachman, MD, PhD

Invited Speakers: Suephy C. Chen, MD, Melissa Gill, MD, Allan C. Halpern, MD, Michael E. Ming, MD, Jeffrey P. North, MD, Tracy Petrie, Susan M. Swetter, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize cutting-edge methods and technologies for prevention, detection, diagnosis and multidisciplinary treatment of melanoma.
2. Evaluate which new methods and technologies are important and appropriate to incorporate into your dermatology practice.

Description
Dramatic progress has been made in melanoma management over the past 5 years, including creation of a staggering number of new phone apps, imaging devices, diagnostic and prognostic laboratory tests, and combination therapies. It is essential that dermatologists evaluate and incorporate new methods and technologies into their practices, but which are ready for "prime time?" In this session, dermatology innovators will describe, explain, and assess data with respect to the most promising new methods and technologies available for melanoma. Liberal question and answer periods and panel discussions are included to encourage audience engagement and to ensure exploration of controversial topics.

This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 3.00 Category 1 CME Credits

S059 • Treating Severe Skin Disease in Children

Room: W308A

Director: Erin F. Mathes, MD

Invited Speakers: Brittany Gareth Craiglow, MD, Jennifer T. Huang, MD, Christine T. Lauren, MD, Sheilagh M. Maguiness, MD, Paradi Mirmirani, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose inherited, inflammatory, infectious, and oncologic dermatologic diseases in children.
2. Select systemic, topical and other therapies for severe skin disease in children.
3. Develop an approach to hospitalized children with skin disease.

Description
This session is will use a case-based approach designed to tackle therapeutic challenges that confront clinicians who take care of children. Cutting edge as well as tried and true therapies will be presented with special attention to how they can be safely and effectively used for pediatric patients. We will cover: pediatric dermatology emergencies, oncology topics, atopic dermatitis, alopecia, vascular anomalies, and disorders of keratinization. • *3.00 Category 1 CME Credits*

S060 • What's New and What's True in Lasers

Room: W207A

Director: Kristen Marie Kelly, MD

Invited Speakers: Macrene Alexiades-Armenakas, MD, PhD, Mathew M. Avram, MD, JD, Roy G. Geronemus, MD, Arielle N.B. Kauvar, MD, Suzanne L. Kilmer, MD, Keyvan Nouri, MD, Arisa Ortiz, MD, Jill S. Waibel, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify new light and energy based devices and techniques available to dermatologic surgeons.
2. Evaluate the benefits of traditional new devices and techniques.
3. Describe limitations of traditional and new devices and techniques.

Description
What's New and What's True in Lasers will explore evaluation of new devices as well as innovative uses of devices that have been available. Speakers with both clinical and research experience will share their expertise on topics including: the newest vascular targeting devices, light based acne treatments, skin tightening, light based treatments for pre-cancers and skin cancers, scar therapy, dermatologic devices adapted for women's health and an update on laser safety. The topics will be traditional laser surgery indications but novel cutting edge approaches will be highlighted and discussion will be encouraged. • *3.00 Category 1 CME Credits*

S061 • Consultative Dermatology for the Hospitalized Patient

Room: W304C

Director: Lindy Peta Fox, MD

Invited Speakers: Jonathan Cotliar, MD, Joanna L. Harp, MD, Daniela Kroshinsky, MD, MPH, Daniel D. Miller, MD, Misha Rosenbach, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify common and uncommon cutaneous manifestations of systemic diseases and infections as they present in the hospitalized patient with skin disease.
2. Develop a working differential diagnosis, management plan, and treatment algorithm for hospitalized patients with skin disease.
3. Recognize histopathologic patterns of skin diseases that affect the hospitalized patient.

Description
In this session, attendees will learn about common and uncommon cutaneous manifestations of inflammatory, infectious and neoplastic diseases in the hospitalized patient. Information will be delivered in a case-based format, with an emphasis on high-yield learning and practice points that are not necessarily available in the literature or textbooks. The ultimate goal of this session is to empower the audience with the knowledge and tools to more effectively and confidently manage cutaneous diseases in hospitalized patients. • *3.00 Category 1 CME Credits*

S062 • Challenging Adult and Pediatric Autoimmune Connective Tissue Disease Cases: Pearls for Diagnosis and Management

Room: W304E

Director: Ruth Ann Vleugels, MD

Invited Speakers: Alisa Femia, MD, Drew Kurtzman, MD, Christina Lam, MD, Mital Patel, MD, Joanie Pinard, MD, Natalie Ann Wright, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify and diagnose classic and atypical presentations of cutaneous manifestations of autoimmune connective tissue diseases in both adults and children.
2. Select management options for skin involvement in complex connective tissue diseases based on the best available evidence from the literature.

Description
Using clinical cases, classic and atypical presentations of cutaneous manifestations of autoimmune connective tissue diseases will be emphasized. This session will offer practical tips for diagnosis, appropriate evaluation, and advanced therapeutic management of both adult and pediatric patients with connective tissue diseases affecting the skin. Audience self-assessment will be encouraged through image review, and a case-based approach will be utilized to highlight relevance for the dermatology trainee or experienced clinician. Cases discussed will include those focusing on dermatomyositis, cutaneous lupus erythematosus, vasculitis, systemic sclerosis, eosinophilic fasciitis, and morphea, amongst others. • *3.00 Category 1 CME Credits*

S063 • Hair Disorders Made Easier

Room: W306A

Director: Lynne J. Goldberg, MD

Invited Speakers: Yolanda M. Lenzy, MD, Paradi Mirmirani, MD, Melissa Piliang, MD, Nicole Elaine Rogers, MD, Jerry Shapiro, MD, Antonella Tosti, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Demonstrate increased comfort in evaluating hair loss patients.
2. Diagnose patients with hair loss accurately.
3. Treat and counsel alopecia patients.

Description
This session will cover the basics of the patient evaluation for hair loss, including diagnostic tips, treatment pearls, ethnic hairstyling, evaluation for surgery, and clinicopathologic correlation. It is directed at all practitioners who see alopecia patients including dermatologists, mid-level dermatology providers, and dermatology residents. • *3.00 Category 1 CME Credits*

S064 • Regional Reconstruction

Room: W304AB

Director: Christopher James Miller, MD

Invited Speakers: Jeremy S. Bordeaux, MD, MPH, Jeremy Robert Etzkorn, MD, Eduardo Moioli, MD, PhD, Thuzar Shin, MD, PhD, Joseph Sobanko, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Apply principles of effective surgical design and technique to achieve reproducibly excellent results for flap reconstruction of the central face.
2. Discuss the tissue mechanics and relative indications for sliding flaps, lifting flaps, and interpolation flaps of the central face.
3. Identify wound characteristics that require modification, combination, or supplementation of flaps to preserve free margins and contour.

Description
This practical session will illustrate with photos and videos workhorse reconstruction options for cutaneous defects around the eyes, nose, and mouth. Relevant anatomy will be reviewed to provide a basis for assessing cutaneous defects and to help design and execute reconstructions that recreate normal contour. The session will focus on classic reconstruction designs and demonstrate when modification is necessary to avoid complications and to attain aesthetic results. This survey course includes ample time for questions and audience interaction. • *3.00 Category 1 CME Credits*

S065 • Cutaneous Oncology

Room: W315A

Director: Fiona O'Reilly Zwald, MD

Invited Speakers: Mathew M. Avram, MD, JD, Anna A. Bar, MD, Jerry D. Brewer, MD, John Y. M. Koo, MD, Mio Nakamura, MD, Thuzar Shin, MD, PhD, Seaver Soon, MD, Teresa Tabora Soriano, MD, Susan M. Swetter, MD, Ashley Wysong, MD, MS

Learning Objectives
Following this session, the attendee should be able to:
1. Apply non surgical management strategies for the treatment of skin cancer.
2. Evaluate high risk skin cancer in immunosuppressed patients.
3. Define baseline and surveillance strategies and current management of malignant melanoma.

Description
This session is directed towards general and surgical dermatologists. The session will address current management, baseline and surveillance studies for malignant melanoma. Non surgical therapies for treatment of skin cancer will be discussed. The management and treatment of high risk skin cancer in immunosuppressed patients will be discussed. • *3.00 Category 1 CME Credits*

S066 • What's New in Dermatopathology

Room: W315B

Director: Nooshin Ketabchi Brinster, MD

Invited Speakers: Tammie C. Ferringer, MD, Whitney A. High, MD, JD, Richard Jordan, MD, Jacqueline M. Junkins-Hopkins, MD, Shane A. Meehan, MD, Beth S. Ruben, MD, Leonard C. Sperling, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Apply histological criteria to diagnose recently described cutaneous disorders.
2. Diagnose dermatologic conditions using the latest histochemical and immunohistochemical techniques.
3. Recognize the importance of clinco-pathological correlation in the diagnosis of cutaneous disease.

Description
This session with provide an update in the field of dermatopathology, with an excellent group of speakers who will cover a range of topics including disorders of hair and nails, cutaneous lymphoma, oral pathology with a focus on HPV related lesions, melanocytic lesions, inflammatory diseases, infectious disease and the latest in immunohistochemistry. *• 3.00 Category 1 CME Credits*

S067 • Vitiligo

Room: W414C

Director: John Harris, MD, PhD

Invited Speakers: Seemal Desai, MD, Khaled Ezzedine, MD, Pearl E. Grimes, MD, Iltefat H. Hamzavi, MD, Amit G. Pandya, MD, Thierry Passeron, Michelle Rodrigues, MBBS

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize a variety of presentations of vitiligo in both children and adults, and their implications for prognosis and treatment.
2. Describe current therapies, their relative efficacy, and limitations.
3. Discuss emerging treatments in the context of disease pathogenesis.

Description
Recent discoveries in the pathogenesis, risk factors, and features of disease activity have influenced the way that we diagnose and manage vitiligo patients. Patterns of depigmentation in children and adults will be discussed, as well as their differential diagnoses and implications for prognosis and treatment. Current approaches to management and their comparative efficacy will be outlined, and emerging targeted therapies will be characterized. The goal is to empower attendees to approach vitiligo in a way that will lead to improved outcomes for their patients. *• 3.00 Category 1 CME Credits*

FORUMS • 3:30 TO 5:30 P.M.

Open admission to eligible categories, no tuition or ticket

F141 • How to be an Effective Clinician Educator

Room: W305A

Director: Patrick E. McCleskey, MD

Co-Director: Susan Burgin, MD

Invited Speakers: Joslyn S. Kirby, MD, Heather Woodworth Wickless, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe efficient techniques for teaching students, residents, or new mid-level providers in a busy clinic.
2. Identify new ideas for group teaching, case discussion, lectures for adult learners, and feedback for the teacher.
3. Discuss how to overcome challenges in your teaching practice.

Description
We are all teachers, whether it's our colleagues who refer to us, our own physician extender staff, nurses, medical assistants, or our community's medical students and residents. Our most precious resource is our time, and when we're asked to teach, we have to figure out how to balance our professional responsibility with the practicality of time constraints. This session will help stimulate ideas about how you might incorporate more teaching into your practice as effortlessly as possible. Teaching is community service — get involved! • *2.00 Category 1 CME Credits*

F142 • Documentation and Coding: Getting Paid and Passing Audits

Room: W303ABC

Director: Howard Wooding Rogers, MD

Invited Speakers: Murad Alam, MD, Scott M. Dinehart, MD, Mollie A. MacCormack, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe the performance and documentation requirements for surgical services.
2. Properly use modifier 25.
3. Prepare for and avoid insurer / Medicare audits and identify the audit triggers.

Description
You've done the work, now you'd like to get paid, and not worry about audits. You and your staff must complete multiple steps for this to occur promptly. Our session will focus on appropriate documentation for the most common levels of service, accurate use of CPT codes and modifiers for different clinical scenarios, and simplified use of ICD-10. The program will also include responses to questions frequently posed to coding experts and will provide ample time to answer your coding questions. • *2.00 Category 1 CME Credits*

F143 • Novel Therapies for Cutaneous Malignancies: What's New and What's Ahead

Room: W308C

Director: Debjani Sahni, MBBS, MD

Invited Speakers: Rhoda Myra Alani, MD, Sarah T. Arron, MD, PhD, Ervin H. Epstein, Jr., MD, Susan M. Swetter, MD, Manisha Thakuria, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Distinguish appropriate use of current and novel therapies in cutaneous malignancies.
2. Recognize and manage known common side effects of therapies utilized in cutaneous malignancies.
3. Recognize the correct clinical setting in which these therapies are best indicated.

Description
Several recent advances in the molecular biology of cutaneous oncology have culminated in the development of multiple targeted therapies. As cutaneous oncology moves towards a more personalized approach, dermatologists should be aware of the multitude of therapies that exist and where current ongoing research is heading, to ensure that patients are provided with the most appropriate treatments. Knowledge of the biological mechanisms of the drugs and their effects will improve patient counseling and quality of care. *• 2.00 Category 1 CME Credits*

F144 • Diagnosis, Treatment and Prevention of Errors in Dermatologic Practice

Room: W307D

Director: Eliot N. Mostow, MD

Invited Speakers: Stephen E. Helms, MD, Kelly C. Nelson, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify examples of iatrogenic problems in a medical dermatology clinic including diagnostic errors.
2. Develop systems within the practice to reduce iatrogenic problems.

Description
Experts agree that physicians and practices make errors, some more serious than others. This frames the basis of the gap that we plan to reduce/close using lecture and discussion to identify potential errors (diagnosis) and at least one thing that can be done to reduce (treatment) or prevent (prevention) errors in your practice. The intent is to be practical with the goal of improving patient outcomes. We cover cognitive and technical errors with an ultimate focus on methods to reduce both. We encourage interaction.

This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org. • 2.00 Category 1 CME Credits

F145 • What's New in Melasma?

Room: W415A

Director: Amit G. Pandya, MD

Invited Speakers: Eunice Chavez Del Rosario, MD, MS, Thierry Passeron, Michelle Rodrigues, MBBS

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize the clinical presentation of melasma as well as its mimics.
2. Describe the dermoscopic features of melasma.
3. List the indications and contraindications for treatment of melasma with tranexamic acid and lasers.

Description
Melasma continues to be common throughout the world. Treatment of melasma is often difficult and prolonged. Many patients do not achieve complete remission, even with combination treatment. This session will present new findings regarding the pathogenesis of melasma that may be helpful in developing treatment regimens in the future. It will also present new findings on the use of dermoscopy for melasma, as well as oral tranexamic acid and lasers for the treatment of melasma. • *2.00 Category 1 CME Credits*

F146 • Atopic Dermatitis

Room: W304G

Director: Eric Lawrence Simpson, MD

Co-Director: Lawrence F. Eichenfield, MD

Invited Speakers: Emma Guttman, MD, PhD, Peter A. Lio, MD, Amy S. Paller, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Recognize advances in understanding of pathogenesis of atopic dermatitis.
2. Formulate best practices in patient and family education and counseling.
3. Improve knowledge of traditional and emerging topic and systemic therapies.

Description
Effectively treating patients with atopic dermatitis yields great rewards for patients, families and providers. This session reviews advances in our understanding of the pathobiology of the disease, reviews treatment guidelines and informs providers of the emerging systemic therapies on the horizon. Discussions of therapeutics will extend beyond treatment guidelines as experienced clinicians will share their treatment pearls they find useful in their toughest pediatric and adult patients. • *2.00 Category 1 CME Credits*

F147 • Point and Counterpoint: Cases in Dermatoethics

Room: W206C

Director: Lionel Gordon Bercovitch, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Analyze the ethical and professional issues regarding whether skin cancer screenings are serving a meaningful purpose.
2. Discuss the ethical and professional obligations of physicians confronted with racist or bigoted patients.
3. Evaluate whether the putative benefits of the current system of recertification justify the burdens placed on practicing dermatologists.

Description
The session will take the form of debates of 4 contemporary ethical and professional dilemmas facing dermatology today. Is the time, effort and manpower devoted to free skin cancer screenings justified by the health outcomes achieved? Does a dermatologist have a moral or professional obligation to continue treating a patient who expresses racist or bigoted views? In this era of high deductibles, must a dermatologist agree to suboptimal care requested by a patient because of cost concerns? Are there limits to patient autonomy to dictate care? The FDA is considering banning artificial tanning for minors. Should it also be banned for everyone including adults? There will be ample time for audience participation and discussion.
• 2.00 Category 1 CME Credits

F148 • Acne, Hair Loss and Hirsutism Evaluation and Management

Room: W415B

Director: Kanade Shinkai, MD, PhD

Invited Speakers: Jennifer Fu, MD, Rachel Victoria Sabbag Reynolds, MD, Bethanee Jean Schlosser, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Select and safely prescribe oral contraceptive pills and spironolactone for the treatment of acne in adult female patients.
2. Order appropriate, focused diagnostic evaluation for female patients with cutaneous manifestations of hyperandrogenism.
3. Describe key features and essential management principles of patients with Polycystic Ovary Syndrome.

Description
Acne, hirsutism, and androgenetic alopecia are common reasons why women present to dermatologists and are often challenging to treat. Management of these conditions in an adult female patient may require distinct diagnostic and therapeutic considerations, including workup for endocrine disorders and use of hormonal therapy. In this session, speakers will present current evidence-based recommendations for management of patients with cutaneous manifestations of hyperandrogenism, including updated information on what every dermatologist should know about Polycystic Ovary Syndrome. This session highlights the practical approach to managing these conditions and is relevant to the clinical practice of any dermatology provider.
• 2.00 Category 1 CME Credits

F149 • Psoriasis: Updates in Biologic Therapy, Comorbidities, Genetics, and Biosimilars

Room: W208A

Director: Jashin J. Wu, MD

Invited Speakers: Andrew Blauvelt, MD, John Y. M. Koo, MD, Wilson Liao, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Examine updates in genetics of psoriasis and how they may apply to clinical practice.
2. Assess recent data that examines the relationship between biologic therapy and comorbidities.
3. Discuss updates in biologic therapy and biosimilars for patients with severe psoriasis.

Description
Psoriasis is a common, chronic disease that has many therapeutic options with different risk/benefit profiles and monitoring guidelines. We will examine updates in the genetics of psoriasis and how they may apply to clinical practice. We will discuss recent data that examines the relationship between biologic therapy and comorbidities. We will review updates about the biologic therapies and discuss the future with biosimilars. • *2.00 Category 1 CME Credits*

F150 • Oral Diseases

Room: W307B

Director: Ginat W. Mirowski, MD, DMD

Invited Speakers: Nasim Fazel, MD, DDS, Roy Steele Rogers, III, MD, Rochelle R. Torgerson, MD, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose normal oral findings in individuals with premalignant or paraneoplastic disorders.
2. Distinguish the signs and symptoms of worrisome oral lesions.
3. Determine the best techniques for biopsying suspicious lesions and treating ulcers of Behçet of the oral cavity.

Description
This session will focus on oral diseases that are associated with premalignant or paraneoplastic disorders and patients with Behçet. A focus on the approach, evaluation and treatment of these challenging cases will be presented. • *2.00 Category 1 CME Credits*

FOCUS SESSIONS • 4:30 TO 5:30 P.M.

Open admission to eligible categories, no tuition or ticket

U092 • Data-driven Dermatology: Who Will Define our Specialty and How?

Room: W312C

Director: Daniel D. Bennett, MD

Invited Speakers: Robert Swerlick, MD, Marta Jane Van Beek, MD, MPH

Learning Objectives
Following this session, the attendee should be able to:
1. Summarize the sources of data used by physicians, hospitals, payers, regulators and patients to assess clinical practice.
2. Identify and develop tools to collect clinical data.
3. Apply data to patient care and quality improvement.

Description
Those with data will define "quality patient care," yet most physicians are poorly prepared to understand sources of data, assess their validity and, more importantly, direct the development of tools to improve patient care, practice efficiency and physician satisfaction. This session will: 1) Define sources of data generated by clinical practice, 2) Show how dermatologists can generate data to define high quality care, and 3) Propose mechanisms to utilize data in clinical practice.
• *1.00 Category 1 CME Credit*

U093 • Laser and Device-Based Treatment of Scars

Room: W308A

Director: Arielle N.B. Kauvar, MD

Invited Speakers: Paul M. Friedman, MD, Mitchel Paul Goldman, MD, Jill S. Waibel, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Categorize scar types.
2. Assess patient's scarring and prescribe the most appropriate treatment.
3. Identify new devices and techniques for treating scars.

Description
This session will explore the different type of scars and the use of lasers and device-based treatments to correct them. Traditional as well as novel, cutting-edge treatments and techniques will be explored for erythematous, pigmented, hypertrophic and atrophic scars, acne scars, burn scars, surgical scars and complex scars from trauma. • *1.00 Category 1 CME Credit*

U094 • Hair Transplantation

Room: W315B

Director: Marc R. Avram, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Integrate hair transplants into a busy dermatology practice.
2. Review the role of medical therapy, including LLLT and PRP, in hair transplantation.
3. Recognize appropriate candidate selection for follicular unit extraction vs. elliptical strip surgery.

Description
The session will cover all aspects of hair transplantation from the role of medical therapy to candidate selection, the role of robotic FUE vs. non-robotic FUE vs. donor elliptical harvesting, hairline design for men, and pre-and post-operative patient care. In addition, instrumentation, anesthesia, and staff training will be reviewed. *• 1.00 Category 1 CME Credit*

U095 • Great Cases from Mississippi

Room: W311G

Director: Jeremy Jackson, MD

Invited Speaker: Stephanie K Jacks, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss the clinical characteristics of challenging cases seen at the University of Mississippi Medical Center.
2. Describe management strategies for challenging cases seen at the University of Mississippi Medical Center.

Description
In this session, interesting and challenging cases seen at the University of Mississippi Medical Center will be discussed. Both pediatric and adult cases will be discussed. This session is directed to all dermatologists with a particular focus toward dermatologists early in their careers.
• 1.00 Category 1 CME Credit

U096 • Hyperhidrosis: Update on Therapeutics

Room: W209B

Director: Martha Laurin Council, MD

Invited Speakers: Dee Anna Glaser, MD, Adelaide A. Hebert, MD, David Michael Pariser, MD, Jennifer D. Peterson, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe various therapeutic modalities utilized for hyperhidrosis including topical therapies, systemic therapies, iontophoresis, botulinum toxin, and use of devices.
2. Discuss the nuances of the approach to hyperhidrosis in the pediatric patient.
3. Identify the variable presentations of hyperhidrosis, and tailor a treatment algorithm to individual patients.

Description
In this session, the dermatologist will learn how to diagnose and manage hyperhidrosis, or excessive sweating. Various treatment modalities, including topical therapy, systemic therapy, iontophoresis, botulinum toxin therapy, and the use of devices will be discussed. New this year, the session will include the approach to the pediatric patient. After attending the session, the dermatologist should understand the variable presentations of hyperhidrosis, and should be able to tailor a treatment plan to his/her individual patients. • *1.00 Category 1 CME Credit*

U097 • Relevance of the Human Microbiome in Health and Disease

Room: W315A

Director: Heidi H. Kong, MD, MHS

Invited Speaker: Mahmoud A. Ghannoum, PhD

Learning Objectives
Following this session, the attendee should be able to:
1. Discuss current literature on human skin microbiome research.
2. Recognize potential clinical relevance of skin microbiome research to human health and disease.

Description
Bacteria, fungi, and viruses reside in and on us and are important in dermatology. Scientific advances in genomics have expanded the research on our abundant microbial communities, or the human microbiome. This session will review the basic concepts of the microbiome, summarize recent research on the human skin microbiome, and discuss potential clinical relevance to human health and disease. • *1.00 Category 1 CME Credit*

U098 • Non-surgical Skin Cancer Treatments

NEW

Room: W304A

Director: Allison Hanlon, MD, PhD

Invited Speakers: Faramarz H. Samie, MD, Nathalie C. Zeitouni, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Identify clinical factors when surgical treatment is not advisable.
2. Identify non-surgical treatments for cutaneous malignancies.
3. Outline therapeutic options for skin cancers not suitable for surgical treatment.

Description
Skin cancer can be treated with different therapies. Tumor and patient factors can dictate the appropriate treatment. In this session, we will discuss patient and tumor factors that influence the treatment approach. We will review evidence based, non-surgical treatments for skin cancer; including topical medications, radiotherapy, and photodynamic therapy. • *1.00 Category 1 CME Credit*

U099 • Take a Pico Under the Hood: Dissecting Picosecond Lasers and Indications

NEW

Room: W304C

Director: Jeremy A. Brauer, MD

Invited Speakers: Eric F. Bernstein, MD, Robert A. Weiss, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Differentiate between picosecond technology and available lasers and other pulse durations and lasers used for similar indications.
2. Utilize the knowledge gained in this session in the appropriate determination and selection of picosecond device/wavelength/method of delivery in the treatment of its various indications.

Description
In this session we will review the theory, technology, development, and clinical use of picosecond lasers in dermatology. • *1.00 Category 1 CME Credit*

U100 • Update on Pediatric Vascular Tumors

NEW

Room: W311E

Director: Heather Ciliberto, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Describe infantile hemangioma classification and recognize facial segmental patterns.
2. Define RICH, PICH, NICH, KHE and TA.
3. Recognize features of Kasabach-Merritt phenomenon.

Description
Do vascular birthmarks on infants make you feel uncomfortable? Are you ever concerned you are making the correct diagnosis and initiating appropriate work-up when evaluating infants with vascular tumors? This session will provide an in-depth review of different forms of hemangiomas including identifying the differences between infantile hemangiomas, congenital hemangiomas and other pediatric vascular tumors including kaposiform hemangioendothelioma, and tufted angioma. Information will be targeted for general dermatologists and those in training. • *1.00 Category 1 CME Credit*

U101 • Vaccines in Dermatology

Room: W304E

Director: Misha Matongo Mutizwa, MD

Invited Speaker: Lacy Louise Sommer, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Outline current recommendations for vaccination in immunocompetent and immunocompromised (including iatrogenically immunocompromised) adult and pediatric dermatology patients.
2. Summarize the current evidence supporting the use of vaccines for dermatologic indications (e.g., HPV, VZV).
3. Discuss future directions for vaccines in dermatology.

Description
While primary care providers have historically borne the responsibility for vaccination, vaccines are directly relevant to dermatologists for a variety of reasons. Many of the currently available vaccines are for diseases with predominant or prominent cutaneous signs and symptoms. Moreover, as dermatologists often iatrogenically immunosuppress patients in treating inflammatory or autoimmune dermatoses, an awareness of recommendations for vaccination in these patients is increasingly important. This session is intended to serve as a concise, evidence-based summary of the subject of vaccination as it relates to the field of dermatology. • *1.00 Category 1 CME Credit*

U102 • About Face: Pearls for Facial Hyperpigmentation Conundrums

Room: W209C

Director: Roopal Vashi Kundu, MD

Invited Speaker: Neelam Vashi, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Analyze different diagnostic clues to facial hyperpigmentation.
2. Recognize key characteristics of unique causes of facial hyperpigmentation.
3. Manage facial hyperpigmentation using safe and effective treatments.

Description
Review pearls for the diagnosis and therapy of facial hyperpigmentation with a focus on skin of color patients. Structural and functional differences in the skin, as well as the influence of cultural practices, produce variances in skin disease and presentation based on skin type. Especially in the skin of color population, dyschromia is a growing concern, and a top chief complaint when presenting to the dermatologist. A thorough understanding of the etiology and management strategies of facial hyperpigmentation is of great importance in caring for those afflicted. • *1.00 Category 1 CME Credit*

U103 • Natural Compounds in Addressing Common Dermatologic Problems

Room: W306A

Director: Reena N. Rupani, MD

Invited Speakers: Hilary E. Baldwin, MD, Matthew S. Goldberg, MD, Peter A. Lio, MD, Nicole Elaine Rogers, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Formulate a treatment plan for several common dermatologic diseases that includes integrative therapies.
2. Summarize key takeaways on nutrition and skin health.

Description
Integrative dermatology is a growing field. This session will highlight the role for botanicals, herbs, and nutrition in common dermatologic illnesses including hair loss, acne/rosacea, eczema, and other inflammatory dermatoses. • *1.00 Category 1 CME Credit*

SYMPOSIUM • 8 TO 10 A.M.

Open admission to eligible categories, no tuition or ticket

S068 • Therapeutic and Diagnostic Pearls

Room: W415A

Director: Theodore Rosen, MD

Invited Speakers: Seemal Desai, MD, Ashfaq A. Marghoob, MD, Neil S. Sadick, MD, Daniel M. Siegel, MD, MS, Gil Yosipovitch, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Manage select problems more efficiently, such as dyschromia, pruritus, cutaneous infections and hair loss.
2. Apply surgical pearls to daily practice.
3. Utilize the dermatoscope more effectively in the diagnosis of various lesions.

Description
This session is directed toward both novice and experienced clinicians. The symposium is designed to present pragmatic pearls which can be adopted immediately. Medical, surgical and diagnostic dermatological topics will be covered by recognized experts in their areas of interest. Information conveyed will be based upon both peer-reviewed literature and the result of personal experience.
• *3.00 Category 1 CME Credits*

SYMPOSIUM • 10:30 A.M. TO 12:30 P.M.

Open admission to eligible categories, no tuition or ticket

S069 • What's New in Dermatology

Room: W415A

Director: Mark Lebwohl, MD

Invited Speakers: Brett M. Coldiron, MD, Sheila Fallon Friedlander, MD, Darrell S. Rigel, MD, Theodore Rosen, MD, Linda F. Stein Gold, MD, Susan H. Weinkle, MD

Learning Objectives
Following this session, the attendee should be able to:
1. Diagnose new infectious diseases more effectively.
2. Precribe optimal topical and systemic therapies for dermatologic conditions.
3. Utilize appropriate tools to diagnose malignant melanoma and predict prognosis.

Description
This session will summarize important new developments covering the entire field of dermatology. The symposium will start with breakthroughs in the diagnosis and treatment of melanoma, followed by a review of new developments in infectious disease, dermatologic surgery, pediatric dermatology, and cosmetic dermatology. The session will close with a review of new topical therapies and new systemic therapies in dermatology. • *3.00 Category 1 CME Credits*

HOW TO USE THE SUBJECT INDEX The subject index is designed to help attendees better plan their educational activities. The index is divided into nine different primary topics with subtopics listed alphabetically under these primary topics:

- Basic Science
- Dermatopathology
- Interpersonal and Communication Skills
- Medical Dermatology
- Pediatric Dermatology
- Practice-Based Learning and Improvement
- Procedural Dermatology
- Professionalism and Maintenance of Certification
- Systems-Based Practice

BASIC SCIENCE

Basic SciencePhotophysics and Photobiology, Including Lasers

C007 Structure and Function of the Skin: Pigment, Appendages, Damage & Repair, 49
C011 Dermatology Review: General and Cosmetic, 86
F005 FDA Hot Topics: The Evolving Regulatory Landscape, 25
F043 Photoprotection, 60
F069 Outpatient Radiotherapy of Skin Cancer: Back to the Future, 96
F081 Practice Gaps in Dermatology: Are We Doing What the Evidence Tells Us We Should? Tips for Your Practice, 110
S023 Translating Evidence into Practice: Psoriasis Guidelines, 104
U071 Photodynamic Therapy in Medical and Aesthetic Dermatology, 160

Basic Methodologies in Skin Research, Including Epidemiology, Biostatistics and Animal Models

F005 FDA Hot Topics: The Evolving Regulatory Landscape, 25
F006 Invention and Entrepreneurialism in Dermatology: Stories of Success and Reality Check, 26
S018 Residents and Fellows Symposium, 88
S023 Translating Evidence into Practice: Psoriasis Guidelines, 104
U026 Does the Drug Really Work? Interpreting Clinical Trial Data, 68
U039 Functional Genomics: From Genes to Drug Targets, 76
U065 Hot Topics in Translational Dermatology, 130
U097 Relevance of the Human Microbiome in Health and Disease, 215

Cutaneous Physiology, Including Wound Healing, Immunology, Cancer Biology, Itch, Pigmentation, and Angiogenesis

C001 Structure and Function of the Skin: Development, Cell Biology, and Skin Structure, 32
C007 Structure and Function of the Skin: Pigment, Appendages, Damage & Repair, 49
C010 Structure and Function of the Skin: Cancer, Immunity and Inflammation, 86
C019 Live Demonstration: Head and Neck Anatomy – Cadaver Prosection, 102
D003 Recent Advances in Skin Biology and Skin Disease, 109
D005 Atopic Dermatitis in Adults: Not Just Big Kids, 134
F081 Practice Gaps in Dermatology: Are We Doing What the Evidence Tells Us We Should? Tips for Your Practice, 110
F110 The Skin and the Mind, 151
F112 Cutaneous T-cell Lymphoma, 152
S009 Gross and Microscopic Symposium, 39, 92
S023 Translating Evidence into Practice: Psoriasis Guidelines, 104
S025 Chronic Pruritus: Bedside to Bench Perspectives, 105
U013 Recognition and Management of Allergic Skin Reactions in the Athlete, 22
U065 Hot Topics in Translational Dermatology, 130
U086 Treating Alopecia Areata, Vitiligo and Atopic Dermatitis: JAK Inhibitors, Something New for Dermatology, 169
W004 Self-assessment: Skin Cancer, 85

Embryology

C001 Structure and Function of the Skin: Development, Cell Biology, and Skin Structure, 32

General Cellular Biology, Including Apoptosis, Cell Cycle and Cell Cycle Regulation, Second Messenger Systems, Receptor Biology, Stem Cells

C001 Structure and Function of the Skin: Development, Cell Biology, and Skin Structure, 32
C007 Structure and Function of the Skin: Pigment, Appendages, Damage & Repair, 49
C010 Structure and Function of the Skin: Cancer, Immunity and Inflammation, 86
D003 Recent Advances in Skin Biology and Skin Disease, 109
F009 Skin and Systemic Malignancy, 27
S009 Gross and Microscopic Symposium, 39, 92
U039 Functional Genomics: From Genes to Drug Targets, 76
U065 Hot Topics in Translational Dermatology, 130

Genetics and Biochemistry, Including Basic Principles of Genetics, DNA, Transcription, Translation, and Proteins

C001 Structure and Function of the Skin: Development, Cell Biology, and Skin Structure, 32
C007 Structure and Function of the Skin: Pigment, Appendages, Damage & Repair, 49
C010 Structure and Function of the Skin: Cancer, Immunity and Inflammation, 86

D003 Recent Advances in Skin Biology and Skin Disease, 109
F009 Skin and Systemic Malignancy, 27
F024 What's That? Syndrome Update, 44
F076 Autoimmune Blistering Diseases: What's New, 99
F101 Tackling Challenges in Epidermolysis Bullosa: What Does the Future Hold, 138
F108 Field Cancer and Multiple SCC: Molecular Insights and Clinical Management, 141
S009 Gross and Microscopic Symposium, 39, 92
U039 Functional Genomics: From Genes to Drug Targets, 76

Microbiology

C002 Dermatology Review: General Dermatology and Practice Management, 32
C010 Structure and Function of the Skin: Cancer, Immunity and Inflammation, 86
D003 Recent Advances in Skin Biology and Skin Disease, 109
F086 Herpes Zoster: Controversies and Conundrums in Treatment and Prevention, 113
S009 Gross and Microscopic Symposium, 39, 92
S031 Adventures in Tropical Dermatology, 108
U034 Warts and Molluscum: What's New in Treatments, Vaccinations, Immunotherapy and the Sexual Abuse Question, 73
U065 Hot Topics in Translational Dermatology, 130
U097 Relevance of the Human Microbiome in Health and Disease, 215

Pharmacology

D003 Recent Advances in Skin Biology and Skin Disease, 109
D005 Atopic Dermatitis in Adults: Not Just Big Kids, 134
F005 FDA Hot Topics: The Evolving Regulatory Landscape, 25
F009 Skin and Systemic Malignancy, 27
F010 Highlights From the Medical and Pediatric Literature, 28
F081 Practice Gaps in Dermatology: Are We Doing What the Evidence Tells Us We Should? Tips for Your Practice, 110
F104 High Yield "Power Hour" for Residents, 139
F120 Treating Tumors and Inflammatory Skin Diseases with Immunomodulators and Biologics, 156
S010 Pearls from the Posters, 50
U034 Warts and Molluscum: What's New in Treatments, Vaccinations, Immunotherapy and the Sexual Abuse Question, 73
U039 Functional Genomics: From Genes to Drug Targets, 76
U072 Intravenous Immunoglobulin (IVIg) in Dermatology, 161
W015 Self-assessment: Acne, 177

Structure and Function of Skin, Including Basement Membrane Zone

C001 Structure and Function of the Skin: Development, Cell Biology, and Skin Structure, 32
C007 Structure and Function of the Skin: Pigment, Appendages, Damage & Repair, 49
C010 Structure and Function of the Skin: Cancer, Immunity and Inflammation, 86
C024 Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management, 143
F104 High Yield "Power Hour" for Residents, 139
S049 Boards Blitz, 187
U097 Relevance of the Human Microbiome in Health and Disease, 215
U102 About Face: Pearls for Facial Hyperpigmentation Conundrums, 218
W015 Self-assessment: Acne, 177

DERMATOPATHOLOGY

Dermatopathologic Findings in the Perforating Disorders, Atrophies, and Other Disorders of Dermal Connective Tissue (Includes Degenerative Disorders)

C028 Advanced Self-assessment of Dermatopathology, 192
S009 Gross and Microscopic Symposium, 39, 92

Dermatopathologic Findings in Various Benign and Malignant Cutaneous Neoplasms and Neoplastic Diseases, Including Cutaneous Lymphomas

C005 Essential Dermatopathology: What You Need to Know for Clinical Practice: Neoplastic, 38
C008 Dermatology Review: Skin Cancer, Surgical, and Cosmetic, 49
C013 Basic Self-assessment of Dermatopathology Slide Review, 77
C014 Basic Self-assessment of Dermatopathology Slide Review, 93
C020 Basic Self-assessment of Dermatopathology Discussion, 102
C028 Advanced Self-assessment of Dermatopathology, 192
F009 Skin and Systemic Malignancy, 27
F027 Dermatopathology Case Challenge: Recognizing Mimics and Masqueraders, 45
F046 Challenging Cases in Dermatopathology, 61
F053 Advanced Dermatopathology, 80
F057 The Big C's: Children, Cancer, and Cutaneous Complications, 82
F079 Journal Watching, 109
F112 Cutaneous T-cell Lymphoma, 152
F139 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines, 195
S001 New and Emerging Technologies in Dermatology, 33
S009 Gross and Microscopic Symposium, 39, 92
S013 Microscopic Mystery: Dermatopathology with Clinical Correlation, 52
S035 Cutaneous Lymphomas, 145
S066 What's New in Dermatopathology, 207
U012 Help Your Dermatopathologist Work Smarter for You, 21
U014 Update: New Modalities in the Diagnosis, Staging and Prognostication of Melanocytic Lesions, 22
U029 Cutaneous Lymphoma and Mimics: The Importance of Clinical Pathological Correlation, 71

U042 Melanoma and the Genes: Optimizing Patient Management in the Age of Molecular Testing, 118
W004 Self-assessment: Skin Cancer, 85
W007 Self-assessment: Dermatopathology, 142

Dermatopathologic Findings in Various Connective Tissue Diseases and Other Rheumatologic Disease

C013 Basic Self-assessment of Dermatopathology Slide Review, 77
C014 Basic Self-assessment of Dermatopathology Slide Review, 93
C020 Basic Self-assessment of Dermatopathology Discussion, 102
C026 Essential Dermatopathology: What You Need to Know for Clinical Practice: Inflammatory, 191
C028 Advanced Self-assessment of Dermatopathology, 192
F046 Challenging Cases in Dermatopathology, 61
F049 Skin Signs of Internal Disease: Case-based Challenges, 78
F053 Advanced Dermatopathology, 80
S009 Gross and Microscopic Symposium, 39, 92
013 Microscopic Mystery: Dermatopathology with Clinical Correlation, 52
S066 What's New in Dermatopathology, 207
W007 Self-assessment: Dermatopathology, 142

Dermatopathologic Findings in Various Cutaneous Drug Reactions

F009 Skin and Systemic Malignancy, 27
F046 Challenging Cases in Dermatopathology, 61
F057 The Big C's: Children, Cancer, and Cutaneous Complications, 82
S009 Gross and Microscopic Symposium, 39, 92
S066 What's New in Dermatopathology, 207
U087 Update on Cutaneous Reactions to Targeted and Immune Cancer Therapy, 170

Dermatopathologic Findings in Various Developmental Cysts And Other Malformations

C005 Essential Dermatopathology: What You Need to Know for Clinical Practice: Neoplastic, 38
S009 Gross and Microscopic Symposium, 39, 92
W007 Self-assessment: Dermatopathology, 142

Dermatopathologic Findings in Various Genodermatoses

C026 Essential Dermatopathology: What You Need to Know for Clinical Practice: Inflammatory, 191
C028 Advanced Self-assessment of Dermatopathology, 192
F009 Skin and Systemic Malignancy, 27
F046 Challenging Cases in Dermatopathology, 61
F101 Tackling Challenges in Epidermolysis Bullosa: What Does the Future Hold, 138
S009 Gross and Microscopic Symposium, 39, 92
W007 Self-assessment: Dermatopathology, 142

Dermatopathologic Findings in Various Infections, Infestations, and Bites

C013 Basic Self-assessment of Dermatopathology Slide Review, 77
C014 Basic Self-assessment of Dermatopathology Slide Review, 93
C020 Basic Self-assessment of Dermatopathology Discussion, 102
C021 Infectious Diseases, 103
C026 Essential Dermatopathology: What You Need to Know for Clinical Practice: Inflammatory, 191
C028 Advanced Self-assessment of Dermatopathology, 192
F035 Big Rashes in Little Patients, 56
F046 Challenging Cases in Dermatopathology, 61
F053 Advanced Dermatopathology, 80
F057 The Big C's: Children, Cancer, and Cutaneous Complications, 82
F086 Herpes Zoster: Controversies and Conundrums in Treatment and Prevention, 113
S009 Gross and Microscopic Symposium, 39, 92
S013 Microscopic Mystery: Dermatopathology with Clinical Correlation, 52
S031 Adventures in Tropical Dermatology, 108
S066 What's New in Dermatopathology, 207
U032 A Practical Approach to the Management of Onychomycosis, 72
W007 Self-assessment: Dermatopathology, 142

Dermatopathologic Findings in Various Metabolic and Systemic Diseases, Including the Mucinoses

C028 Advanced Self-assessment of Dermatopathology, 192
F046 Challenging Cases in Dermatopathology, 61
F049 Skin Signs of Internal Disease: Case-based Challenges, 78
S009 Gross and Microscopic Symposium, 39, 92
S013 Microscopic Mystery: Dermatopathology with Clinical Correlation, 52
W007 Self-assessment: Dermatopathology, 142

Dermatopathologic Findings in Various Non-infectious Ulcerative Diseases

S009 Gross and Microscopic Symposium, 39, 92
W007 Self-assessment: Dermatopathology, 142

Dermatopathologic Findings in Various Non-neoplastic Adnexal Diseases

C024 Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management, 143
S009 Gross and Microscopic Symposium, 39, 92

Dermatopathologic Findings in Various Papulosquamous Disorders

C013 Basic Self-assessment of Dermatopathology Slide Review, 77
C014 Basic Self-assessment of Dermatopathology Slide Review, 93
C020 Basic Self-assessment of Dermatopathology Discussion, 102
F009 Skin and Systemic Malignancy, 27
F035 Big Rashes in Little Patients, 56

F137 Challenging Diagnostic Cases for Practitioners, 194
S009 Gross and Microscopic Symposium, 39, 92
S066 What's New in Dermatopathology, 207
U075 The Red Patient: An Overview of Erythroderma, 162
W007 Self-assessment: Dermatopathology, 142

Dermatopathologic Findings in Various Types of Panniculitis and Disorders of the Subcutaneous Fat
C026 Essential Dermatopathology: What You Need to Know for Clinical Practice: Inflammatory, 191
C028 Advanced Self-assessment of Dermatopathology, 192
S009 Gross and Microscopic Symposium, 39, 92
S066 What's New in Dermatopathology, 207
W007 Self-assessment: Dermatopathology, 142

Dermatopathologic Findings in Various Types of Vasculitis, Vasculopathy, and Purpura
C026 Essential Dermatopathology: What You Need to Know for Clinical Practice: Inflammatory, 191
C028 Advanced Self-assessment of Dermatopathology, 192
F009 Skin and Systemic Malignancy, 27
F046 Challenging Cases in Dermatopathology, 61
S009 Gross and Microscopic Symposium, 39, 92
S066 What's New in Dermatopathology, 207
W007 Self-assessment: Dermatopathology, 142

Dermatopathologic Findings in Various Vesicobullous Disorders
C013 Basic Self-assessment of Dermatopathology Slide Review, 77
C014 Basic Self-assessment of Dermatopathology Slide Review, 93
C020 Basic Self-assessment of Dermatopathology Discussion, 102
C026 Essential Dermatopathology: What You Need to Know for Clinical Practice: Inflammatory, 191
C028 Advanced Self-assessment of Dermatopathology, 192
S009 Gross and Microscopic Symposium, 39, 92
S013 Microscopic Mystery: Dermatopathology with Clinical Correlation, 52
S066 What's New in Dermatopathology, 207
U012 Help Your Dermatopathologist Work Smarter for You, 21
W007 Self-assessment: Dermatopathology, 142

Dermatopathologic Findings of Hair and Nails, Including Alopecia
C022 Updates in Hair Disorders, 142
C026 Essential Dermatopathology: What You Need to Know for Clinical Practice: Inflammatory, 191
C028 Advanced Self-assessment of Dermatopathology, 192
F053 Advanced Dermatopathology, 80
S009 Gross and Microscopic Symposium, 39, 92
S013 Microscopic Mystery: Dermatopathology with Clinical Correlation, 52
S044 Nails, 150
S066 What's New in Dermatopathology, 207
U032 A Practical Approach to the Management of Onychomycosis, 72
U048 Modern Nail Surgery: Aiming on Minimal Trauma and Nail-preservation, 121
W007 Self-assessment: Dermatopathology, 142

Dermatopathologic Findings of Oral and Anogenital Diseases
F053 Advanced Dermatopathology, 80
S009 Gross and Microscopic Symposium, 39, 92
S013 Microscopic Mystery: Dermatopathology with Clinical Correlation, 52
S066 What's New in Dermatopathology, 207

Dermatopathology Artifacts
F027 Dermatopathology Case Challenge: Recognizing Mimics and Masqueraders, 45
U012 Help Your Dermatopathologist Work Smarter for You, 21
U052 Up and Coming Fillers: Experience from Across the Atlantic, 123
U070 The Dermatopathology Report: Reading Between the Lines, 160

Dermatopathology Differential Diagnosis: "Invisible" Dermatoses
F046 Challenging Cases in Dermatopathology, 61
S049 Boards Blitz, 187

Dermatopathology Differential Diagnosis: Dermatologic Diseases with Diffuse Infiltrates
C026 Essential Dermatopathology: What You Need to Know for Clinical Practice: Inflammatory, 191
F046 Challenging Cases in Dermatopathology, 61
S049 Boards Blitz, 187
S066 What's New in Dermatopathology, 207
W007 Self-assessment: Dermatopathology, 142

Dermatopathology Differential Diagnosis: Dermatologic Diseases with Interface Dermatitis
C013 Basic Self-assessment of Dermatopathology Slide Review, 77
C014 Basic Self-assessment of Dermatopathology Slide Review, 93
C026 Essential Dermatopathology: What You Need to Know for Clinical Practice: Inflammatory, 191
F009 Skin and Systemic Malignancy, 27
F046 Challenging Cases in Dermatopathology, 61
S013 Microscopic Mystery: Dermatopathology with Clinical Correlation, 52
S049 Boards Blitz, 187
S066 What's New in Dermatopathology, 207
W007 Self-assessment: Dermatopathology, 142

Dermatopathology Differential Diagnosis: Dermatologic Diseases with Nodular Inflammation or Infiltrates
C026 Essential Dermatopathology: What You Need to Know for Clinical Practice: Inflammatory, 191
F009 Skin and Systemic Malignancy, 27
F046 Challenging Cases in Dermatopathology, 61
S049 Boards Blitz, 187

S066 What's New in Dermatopathology, 207
U029 Cutaneous Lymphoma and Mimics: The Importance of Clinical Pathological Correlation, 71
W007 Self-assessment: Dermatopathology, 142

Dermatopathology Differential Diagnosis: Dermatologic Diseases with Perivascular Infiltrates
C026 Essential Dermatopathology: What You Need to Know for Clinical Practice: Inflammatory, 191
F009 Skin and Systemic Malignancy, 27
F046 Challenging Cases in Dermatopathology, 61
S049 Boards Blitz, 187
S066 What's New in Dermatopathology, 207
W007 Self-assessment: Dermatopathology, 142

Dermatopathology Stains, Including Histochemistry, Immunohistochemistry, and Immunofluorescence
C005 Essential Dermatopathology: What You Need to Know for Clinical Practice: Neoplastic, 38
F009 Skin and Systemic Malignancy, 27
F046 Challenging Cases in Dermatopathology, 61
S013 Microscopic Mystery: Dermatopathology with Clinical Correlation, 52
S049 Boards Blitz, 187
S066 What's New in Dermatopathology, 207
U029 Cutaneous Lymphoma and Mimics: The Importance of Clinical Pathological Correlation, 71
U042 Melanoma and the Genes: Optimizing Patient Management in the Age of Molecular Testing, 118
U070 The Dermatopathology Report: Reading Between the Lines, 160
W007 Self-assessment: Dermatopathology, 142

Disorders of Pigmentation
F053 Advanced Dermatopathology, 80
S009 Gross and Microscopic Symposium, 39, 92
U102 About Face: Pearls for Facial Hyperpigmentation Conundrums, 218

Normal Histology of The Skin
U012 Help Your Dermatopathologist Work Smarter for You, 21
U065 Hot Topics in Translational Dermatology, 130

Patient Care and the Dermatopathologist: Patient Safety Issues
F027 Dermatopathology Case Challenge: Recognizing Mimics and Masqueraders, 45
F046 Challenging Cases in Dermatopathology, 61
F071 To Err is Human: How to Optimize Patient Safety in Your Practice, 97
F088 Dermatologic Surgery Disasters: A Dissection of Patient Safety Failures, 114
U012 Help Your Dermatopathologist Work Smarter for You, 21
U070 The Dermatopathology Report: Reading Between the Lines, 160

INTERPERSONAL AND COMMUNICATION SKILLS

Non-Patient Communication, Including Advocacy and Staff, Colleague, Consultant, and Health Care System Communications
C018 Advanced Practice Management, 91
F002 Giving the Best Presentation of Your Life: Every Time!, 24
F022 MACRA, MIPs, and APMs, 43
F025 Teaching, Coaching, Mentoring and Difficult Conversations, 44
F028 Teledermatology Pearls and Pitfalls from Challenging Cases, 46
F034 Young Physician Pearls and Pitfalls: A Survival Guide for the First 10 Years, 55
F047 How to Quarterback a Championship Team, 62
F051 Closing the Gender Gap in Academic Dermatology and Dermatology Leadership: Problems and Solutions, 79
F058 Patient Experience, Organizational Culture, and now MACRA: The New Face of Medical Practice, 83
F086 Herpes Zoster: Controversies and Conundrums in Treatment and Prevention, 113
F088 Dermatologic Surgery Disasters: A Dissection of Patient Safety Failures, 114
F100 Stepping Out of the Fry Pan: Tools to Mitigate Burnout, 137
F110 The Skin and the Mind, 151
F111 Dermatology Teachers Exchange Group, 152
F141 How to be an Effective Clinician Educator, 208
F144 Diagnosis, Treatment and Prevention of Errors in Dermatologic Practice, 209
U012 Help Your Dermatopathologist Work Smarter for You, 21
U013 Recognition and Management of Allergic Skin Reactions in the Athlete, 22
U015 How to Deal with Difficult Patients/People and Look Forward To It!, 63
U064 Dermatologist Burnout: How to Spot it and How to Avoid it, 129
U070 The Dermatopathology Report: Reading Between the Lines, 160
U081 Leading Change in a Changing World, 167
U082 Caring for Vulnerable Patient Populations, 167
U085 Developing Effective Multidisciplinary Skin Cancer Care: Driving Better Patient Outcomes and Fulfilling Professional Relationships, 169
U086 Treating Alopecia Areata, Vitiligo and Atopic Dermatitis: JAK Inhibitors, Something New for Dermatology, 169
U102 About Face: Pearls for Facial Hyperpigmentation Conundrums, 218

Patient Communication and Service Excellence
C015 Media Training: Developing and Delivering Key Messages, 87
C018 Advanced Practice Management, 91
D001 How to Create an Unforgettably Positive Patient Experience, 23
D002 CANCELLED: Child Abuse: Practical Approach nd Child Abuse Mimickers, 77

SUBJECT INDEX

F010 Highlights From the Medical and Pediatric Literature, 28
F022 MACRA, MIPs, and APMs, 43
F028 Teledermatology Pearls and Pitfalls from Challenging Cases, 46
F030 Dealing with Difficult Patient Encounters, 47
F058 Patient Experience, Organizational Culture, and now MACRA: The New Face of Medical Practice, 83
F086 Herpes Zoster: Controversies and Conundrums in Treatment and Prevention, 113
F088 Dermatologic Surgery Disasters: A Dissection of Patient Safety Failures, 114
F100 Stepping Out of the Fry Pan: Tools to Mitigate Burnout, 137
F110 The Skin and the Mind, 151
F144 Diagnosis, Treatment and Prevention of Errors in Dermatologic Practice, 209
S048 Alopecia: Work-up and Treatment, 187
S053 Masters of Dermatology, 189
U011 Common Complaints Encountered During Dermatologic Surgery: How to Respond and How to Prevent, 21
U015 How to Deal with Difficult Patients/People and Look Forward To It!, 63
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U042 Melanoma and the Genes: Optimizing Patient Management in the Age of Molecular Testing, 118
U050 Do Not Forsake the Love You Had at First: Reflection on Patient Satisfaction Surveys, 122
U071 Photodynamic Therapy in Medical and Aesthetic Dermatology, 160
U073 The Human Face as Living and Functional Art, 161
U078 LGBT Health: Providing Culturally Competent Care to Patients who are Sexual and Gender Minorities, 164
U081 Leading Change in a Changing World, 167
U082 Caring for Vulnerable Patient Populations, 167
U102 About Face: Pearls for Facial Hyperpigmentation Conundrums, 218

MEDICAL DERMATOLOGY

Acne, Rosacea and Other Adult Adnexal Diseases

C002 Dermatology Review: General Dermatology and Practice Management, 32
C024 Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management, 143
F098 Skin Issues in Latino Patients, 136
F115 Acne Boot Camp, 154
F125 Redness and Rosacea, 173
F131 Cost-conscious Dermatology, 176
F148 Acne, Hair Loss and Hirsutism Evaluation and Management, 211
S003 Role of Dermatologist in Management of Skin Disease in Solid Organ Transplant Recipients, 34
S004 Therapeutic Hotline, 35
S009 Gross and Microscopic Symposium, 39, 92
S012 Women's Health Therapeutic Hotline, 51
S019 Acne and Rosacea, 88
S022 New Emerging Therapies, 90
S028 Acne Treatment Controversies, 107
S055 Skin of Color Boot Camp: What Every Dermatologist Should Know About the Patient with Darker Skin Tones, 190
U040 Highlights from JAAD, 76
U069 PAPA, PASH, and PAPASH-syndromes, SAPHO, and Acne: Skin, Bones, and Inflammation, 159
U071 Photodynamic Therapy in Medical and Aesthetic Dermatology, 160
U103 Natural Compounds in Addressing Common Dermatologic Problems, 219
W015 Self-assessment: Acne, 177

Adult Patient Care: Assessment Skills, Plan Formulation, and Patient Recommendations

C004 Advanced Dermoscopy, 37
D005 Atopic Dermatitis in Adults: Not Just Big Kids, 134
F013 Caring for the Cancer Patient: Challenging Cases from Inpatient and Outpatient Oncodermatology Consultative Services, 29
F017 Managing Melanoma, 40
F018 Contact Dermatitis Tips from the American Contact Dermatitis Society, 41
F023 Dermoscopy for the Non-dermoscopist, 43
F032 Red Flags and Emergencies in Dermatology, 54
F036 Skinternal Medicine: An Update on Cutaneous Manifestations of Systemic Disease, 56
F068 Women with Hair Loss, 96
F092 Photosensitivity, 116
F094 Referral Medical Dermatology, 134
F098 Skin Issues in Latino Patients, 136
F119 Approach to Sclerosing Skin Conditions, 155
F120 Treating Tumors and Inflammatory Skin Diseases with Immunomodulators and Biologics, 156
F125 Redness and Rosacea, 173
F130 M&M for the Medical Dermatologist: Case-based Lessons, 176
F137 Challenging Diagnostic Cases for Practitioners, 194
F139 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines, 195
F148 Acne, Hair Loss and Hirsutism Evaluation and Management, 211
S004 Therapeutic Hotline, 35
S010 Pearls from the Posters, 50
S025 Chronic Pruritus: Bedside to Bench Perspectives, 105
S039 Managing Tough Real Life Dermatology Cases, 147
S047 Managing Patients with Melanoma or Other Melanocytic Neoplasms, 186
S053 Masters of Dermatology, 189
S056 Pearls: Diagnostic and Therapeutic, 202
U010 Neutrophilic Dermatoses: An Update, 20
U030 Male Genital Dermatology: Lessons Learned from a Male Genital Skin Disease Clinic, 71
U036 Dermatologic Findings in the Stem Cell Transplant Patient, 74
U042 Melanoma and the Genes: Optimizing Patient Management in the Age of Molecular Testing, 118
U044 Epstein-Barr Virus (EBV) and Its Role in Cutaneous Disease, 119
U061 My Patient Has Melanoma, Now What Do I Do?, 128
U063 When to Look Deeper: Common Skin Findings as a Harbinger of Genetic Disease, 129
U096 Hyperhidrosis: Update on Therapeutics, 215

Adult Patient Care: History Taking and Physical Diagnosis

D005 Atopic Dermatitis in Adults: Not Just Big Kids, 134
F032 Red Flags and Emergencies in Dermatology, 54
F068 Women with Hair Loss, 96
F094 Referral Medical Dermatology, 134
F103 Side Effects May Include: Illustrative Cases of Dermatologic Adverse Events, 139
F119 Approach to Sclerosing Skin Conditions, 155
F132 Caring for the Hospitalized Patient: Interesting Cases from the Inpatient Consultative Service, 177
U013 Recognition and Management of Allergic Skin Reactions in the Athlete, 22
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U063 When to Look Deeper: Common Skin Findings as a Harbinger of Genetic Disease, 129
U095 Great Cases from Mississippi, 214

Adult Patient Care: In-office and Ancillary Diagnostics, including KOH, Tzanck, and Patch Testing

C027 Fundamentals of Dermoscopy, 191
F017 Managing Melanoma, 40
F018 Contact Dermatitis Tips from the American Contact Dermatitis Society, 41
F023 Dermoscopy for the Non-dermoscopist, 43
F068 Women with Hair Loss, 96
F144 Diagnosis, Treatment and Prevention of Errors in Dermatologic Practice, 209

Adult Patient Care: Non-surgical Office-based Procedures Including Cryotherapy

F060 What's New in Local Wound Care, 84
F068 Women with Hair Loss, 96
F069 Outpatient Radiotherapy of Skin Cancer: Back to the Future, 96
F105 Dermoscopy: It's Time for a Quiz, 140
F108 Field Cancer and Multiple SCC: Molecular Insights and Clinical Management, 141
U006 Pain-free Dermatology: Minimizing Discomfort in Procedures for Children and Adults, 18
U071 Photodynamic Therapy in Medical and Aesthetic Dermatology, 160
U098 Non-surgical Skin Cancer Treatments, 216

Adult Patient Care: Patient Safety Issues

D005 Atopic Dermatitis in Adults: Not Just Big Kids, 134
F014 Dermatologic Care for a Veteran Patient, 30
F038 Cutaneous Disorders of Pregnancy, 57
F088 Dermatologic Surgery Disasters: A Dissection of Patient Safety Failures, 114
F107 Dermatologic Side Effects of Anticancer Drugs in 2017: What You Need to Know, 141
F114 Research Gaps in Psoriasis: Opportunities for Future Studies and Development of New Outcome Measures for Clinical Trials, 153
F130 M&M for the Medical Dermatologist: Case-based Lessons, 176
F133 Iatrogenic Injury, 192
F148 Acne, Hair Loss and Hirsutism Evaluation and Management, 211
U069 PAPA, PASH, and PAPASH-syndromes, SAPHO, and Acne: Skin, Bones, and Inflammation, 159
U101 Vaccines in Dermatology, 217

Adult Patient Care: Population Health and Preventive Care

D005 Atopic Dermatitis in Adults: Not Just Big Kids, 134
F010 Highlights From the Medical and Pediatric Literature, 28
F054 Volunteers Abroad: Beginners, 81
F098 Skin Issues in Latino Patients, 136
S031 Adventures in Tropical Dermatology, 108
U013 Recognition and Management of Allergic Skin Reactions in the Athlete, 22
U038 Arthropod-Borne Viruses: What Dermatologists Need to Know, 75
U041 Disparities in Dermatology, 118
U078 LGBT Health: Providing Culturally Competent Care to Patients who are Sexual and Gender Minorities, 164
U090 Slap-on/Bug-off: Sunscreen and Insect-Repellent Basics and Controversies, 171
U101 Vaccines in Dermatology, 217

Adult Psychocutaneous Disease

S025 Chronic Pruritus: Bedside to Bench Perspectives, 105

Aging/Geriatrics

C011 Dermatology Review: General and Cosmetic, 86
F021 The Science of Cosmeceuticals and Nutraceuticals, 42
F068 Women with Hair Loss, 96
F109 Advanced Dermoscopy, 151
S007 Cosmetics, 36
S009 Gross and Microscopic Symposium, 39, 92
U037 Common Geriatric Dermatology Issues that Patients and Their Caregivers May not Recognize or Are Afraid to Talk About, 75
U071 Photodynamic Therapy in Medical and Aesthetic Dermatology, 160

Atrophies, Perforating Disorders, and Disorders of Dermal Connective Tissue

F094 Referral Medical Dermatology, 134

Cutaneous Lymphomas

F014 Dermatologic Care for a Veteran Patient, 30
F066 Management Issues in Cutaneous Lymphoma, 95
F070 Biologic Therapy in Dermatology Beyond Psoriasis, 97
F094 Referral Medical Dermatology, 134
F099 Medical Dermatology Challenge: Complex Cases from the Collection of Dr. Samuel Moschella, 137
F112 Cutaneous T-cell Lymphoma, 152
F122 Challenging Cases and Therapeutic Pearls from UVA, 157
S003 Role of Dermatologist in Management of Skin Disease in Solid Organ Transplant Recipients, 34
S009 Gross and Microscopic Symposium, 39, 92
S035 Cutaneous Lymphomas, 145

SUBJECT INDEX

S040 Medical Dermatology in Children and Adults: Similarities and Differences in Approach and Management, 148
S059 Treating Severe Skin Disease in Children, 203
S066 What's New in Dermatopathology, 207
U029 Cutaneous Lymphoma and Mimics: The Importance of Clinical Pathological Correlation, 71
U044 Epstein-Barr Virus (EBV) and Its Role in Cutaneous Disease, 119
U075 The Red Patient: An Overview of Erythroderma, 162

Disorders of Hair and Nails
C004 Advanced Dermoscopy, 37
C022 Updates in Hair Disorders, 142
F024 What's That? Syndrome Update, 44
F050 Updates in the Epidemic of Hair Loss in African American Women, 79
F053 Advanced Dermatopathology, 80
F068 Women with Hair Loss, 96
F094 Referral Medical Dermatology, 134
F107 Dermatologic Side Effects of Anticancer Drugs in 2017: What You Need to Know, 141
F121 An Evidence-based Approach to Nails: Expert Management of Common Problems, 156
F140 Medical and Surgical Management of Nail Disorders, 196
F148 Acne, Hair Loss and Hirsutism Evaluation and Management, 211
S004 Therapeutic Hotline, 35
S009 Gross and Microscopic Symposium, 39, 92
S012 Women's Health Therapeutic Hotline, 51
S016 Hair and Scalp Dermoscopy, 53
S022 New Emerging Therapies, 90
S044 Nails, 150
S048 Alopecia: Work-up and Treatment, 187
S049 Boards Blitz, 187
S055 Skin of Color Boot Camp: What Every Dermatologist Should Know About the Patient with Darker Skin Tones, 190
S063 Hair Disorders Made Easier, 205
S066 What's New in Dermatopathology, 207
S068 Therapeutic and Diagnostic Pearls, 220
U005 Lichen Planus and LP Mimickers: Concepts and Controversies, 18
U007 Sjogren's for the Dermatologist: The Forgotten Autoimmune Connective Tissue Disease, 19
U019 Update of Hair Growth Disorders, 65
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U032 A Practical Approach to the Management of Onychomycosis, 72
U039 Functional Genomics: From Genes to Drug Targets, 76
U040 Highlights from JAAD, 76
U048 Modern Nail Surgery: Aiming on Minimal Trauma and Nail-preservation, 121
U053 Light Based Devices: Photomodulation and Hair Growth, 124
U077 Hair Care Practices and Hair Disorders in Skin of Color, 163
U086 Treating Alopecia Areata, Vitiligo and Atopic Dermatitis: JAK Inhibitors, Something New for Dermatology, 169
U103 Natural Compounds in Addressing Common Dermatologic Problems, 219

Drug Reactions
F009 Skin and Systemic Malignancy, 27
F013 Caring for the Cancer Patient: Challenging Cases from Inpatient and Outpatient Oncodermatology Consultative Services, 29
F032 Red Flags and Emergencies in Dermatology, 54
F057 The Big C's: Children, Cancer, and Cutaneous Complications, 82
F064 Controversies and Challenges in Contact Dermatitis, 94
F103 Side Effects May Include: Illustrative Cases of Dermatologic Adverse Events, 139
F107 Dermatologic Side Effects of Anticancer Drugs in 2017: What You Need to Know, 141
F122 Challenging Cases and Therapeutic Pearls from UVA, 157
F130 M&M for the Medical Dermatologist: Case-based Lessons, 176
F133 Iatrogenic Injury, 192
F139 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines, 195
S009 Gross and Microscopic Symposium, 39, 92
S010 Pearls from the Posters, 50
S025 Chronic Pruritus: Bedside to Bench Perspectives, 105
S042 Advanced Medical Dermatology, 149
S049 Boards Blitz, 187
S059 Treating Severe Skin Disease in Children, 203
S061 Consultative Dermatology for the Hospitalized Patient, 204
S066 What's New in Dermatopathology, 207
U004 Hospital Dermatology, 17
U005 Lichen Planus and LP Mimickers: Concepts and Controversies, 18
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U036 Dermatologic Findings in the Stem Cell Transplant Patient, 74
U087 Update on Cutaneous Reactions to Targeted and Immune Cancer Therapy, 170
U089 Inpatient Dermatology from Horses to Zebras: Lessons Learned at an Academic Hospital, 171

Drugs and Medical Therapy, Including Topical, Oral, Injectable, and Infused
C002 Dermatology Review: General Dermatology and Practice Management, 32
F009 Skin and Systemic Malignancy, 27
F010 Highlights From the Medical and Pediatric Literature, 28
F013 Caring for the Cancer Patient: Challenging Cases from Inpatient and Outpatient Oncodermatology Consultative Services, 29
F020 Complementary, Natural and Novel Dermatology Therapeutics: An Evidence-based Perspective, 42
F026 Systemic Medications for the Dermatology Toolbox, 45
F032 Red Flags and Emergencies in Dermatology, 54
F038 Cutaneous Disorders of Pregnancy, 57
F070 Biologic Therapy in Dermatology Beyond Psoriasis, 97

F076 Autoimmune Blistering Diseases: What's New, 99
F079 Journal Watching, 109
F103 Side Effects May Include: Illustrative Cases of Dermatologic Adverse Events, 139
F104 High Yield "Power Hour" for Residents, 139
F107 Dermatologic Side Effects of Anticancer Drugs in 2017: What You Need to Know, 141
F108 Field Cancer and Multiple SCC: Molecular Insights and Clinical Management, 141
F120 Treating Tumors and Inflammatory Skin Diseases with Immunomodulators and Biologics, 156
F122 Challenging Cases and Therapeutic Pearls from UVA, 157
F126 Bullous Diseases: Diagnostic and Management Algorithm, 174
F130 M&M for the Medical Dermatologist: Case-based Lessons, 176
F140 Medical and Surgical Management of Nail Disorders, 196
F149 Psoriasis: Updates in Biologic Therapy, Comorbidities, Genetics, and Biosimilars, 212
S003 Role of Dermatologist in Management of Skin Disease in Solid Organ Transplant Recipients, 34
S004 Therapeutic Hotline, 35
S009 Gross and Microscopic Symposium, 39, 92
S010 Pearls from the Posters, 50
S012 Women's Health Therapeutic Hotline, 51
S022 New Emerging Therapies, 90
S025 Chronic Pruritus: Bedside to Bench Perspectives, 105
S033 Inflammatory Skin Diseases: The Translational Revolution, 144
S038 Psoriasis, 147
S040 Medical Dermatology in Children and Adults: Similarities and Differences in Approach and Management, 148
S046 Controversies and Difficult Questions Concerning Biologic Therapeutics, 186
S052 Systemic Therapies for Dermatologists: A Comprehensive Review and Update, 189
S056 Pearls: Diagnostic and Therapeutic, 202
S059 Treating Severe Skin Disease in Children, 203
U005 Lichen Planus and LP Mimickers: Concepts and Controversies, 18
U024 Autoinflammatory Skin Disorders: Clinical Pearls for Diagnosis and Management, 67
U026 Does the Drug Really Work? Interpreting Clinical Trial Data, 68
U031 Advanced Use of Systemic Therapies: Rituximab, Thalidomide, and Anti-TNF Alpha Drugs to Manage Complex Dermatoses, 72
U039 Functional Genomics: From Genes to Drug Targets, 76
U040 Highlights from JAAD, 76
U051 Hedgehog Inhibitor Therapy for BCC: An Academic and a Private Practice Perspective, 123
U056 Pearls from the New England Journal of Medicine, 125
U062 Medical Dermatology Potpourri: Challenges Faced and Lessons Learned, 128
U072 Intravenous Immunoglobulin (IVIg) in Dermatology, 161
U101 Vaccines in Dermatology, 217

Eczematous Dermatoses, Including Atopic and Contact Dermatitis

C002 Dermatology Review: General Dermatology and Practice Management, 32
C008 Dermatology Review: Skin Cancer, Surgical, and Cosmetic, 49
D005 Atopic Dermatitis in Adults: Not Just Big Kids, 134
F010 Highlights From the Medical and Pediatric Literature, 28
F018 Contact Dermatitis Tips from the American Contact Dermatitis Society, 41
F039 Contact Allergens of the Year, 58
F041 Translating Evidence into Practice: Atopic Dermatitis Guidelines, 59
F052 Itch, 80
F064 Controversies and Challenges in Contact Dermatitis, 94
F070 Biologic Therapy in Dermatology Beyond Psoriasis, 97
F082 Hand and Foot Psoriasis, Dermatitis and Other Inflammatory Dermatoses, 111
F104 High Yield "Power Hour" for Residents, 139
F113 From Stinging Plants to Fire Ants: Identification, Management and Prevention of Hazardous Plant and Arthropod Exposures, 153
F131 Cost-conscious Dermatology, 176
F146 Atopic Dermatitis, 210
S005 Outbreak! Public Health Threats in Clinical Dermatology, 35
S015 Common, Challenging and Controversial Short Topics in Patient Management, 53
S022 New Emerging Therapies, 90
S025 Chronic Pruritus: Bedside to Bench Perspectives, 105
S033 Inflammatory Skin Diseases: The Translational Revolution, 144
S046 Controversies and Difficult Questions Concerning Biologic Therapeutics, 186
S049 Boards Blitz, 187
S054 Dermatitis, 190
S069 What's New in Dermatology, 220
U020 Head to Toes: Region-specific Contact Dermatitis, 65
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U041 Disparities in Dermatology, 118
U075 The Red Patient: An Overview of Erythroderma, 162
U086 Treating Alopecia Areata, Vitiligo and Atopic Dermatitis: JAK Inhibitors, Something New for Dermatology, 169
W008 Self-assessment: Contact Dermatology, 158

Emergency Care

F032 Red Flags and Emergencies in Dermatology, 54
S042 Advanced Medical Dermatology, 149
S061 Consultative Dermatology for the Hospitalized Patient, 204
U004 Hospital Dermatology, 17
U075 The Red Patient: An Overview of Erythroderma, 162
U089 Inpatient Dermatology from Horses to Zebras: Lessons Learned at an Academic Hospital, 171

Immunobullous Diseases
F076 Autoimmune Blistering Diseases: What's New, 99
F099 Medical Dermatology Challenge: Complex Cases from the Collection of Dr. Samuel Moschella, 137
F103 Side Effects May Include: Illustrative Cases of Dermatologic Adverse Events, 139
F122 Challenging Cases and Therapeutic Pearls from UVA, 157
F126 Bullous Diseases: Diagnostic and Management Algorithm, 174
S009 Gross and Microscopic Symposium, 39, 92
S014 Recent Advances in Bullous Diseases, 52
S049 Boards Blitz, 187
U004 Hospital Dermatology, 17
U028 Pemphigus and Pemphigoid: Evidence-based Updates, 70
U072 Intravenous Immunoglobulin (IVIg) in Dermatology, 161

Infections (Bacterial, Fungal, Viral, and Other), Infestations and Bites
C002 Dermatology Review: General Dermatology and Practice Management, 32
C011 Dermatology Review: General and Cosmetic, 86
C021 Infectious Diseases, 103
F010 Highlights From the Medical and Pediatric Literature, 28
F020 Complementary, Natural and Novel Dermatology Therapeutics: An Evidence-based Perspective, 42
F032 Red Flags and Emergencies in Dermatology, 54
F053 Advanced Dermatopathology, 80
F054 Volunteers Abroad: Beginners, 81
F060 What's New in Local Wound Care, 84
F086 Herpes Zoster: Controversies and Conundrums in Treatment and Prevention, 113
F093 Granulomatous Disorders of the Adult Skin, 116
F099 Medical Dermatology Challenge: Complex Cases from the Collection of Dr. Samuel Moschella, 137
F104 High Yield "Power Hour" for Residents, 139
F113 From Stinging Plants to Fire Ants: Identification, Management and Prevention of Hazardous Plant and Arthropod Exposures, 153
F126 Bullous Diseases: Diagnostic and Management Algorithm, 174
F134 AIDS and Sexually Transmitted Diseases (STDs): Hot Topics, 193
F140 Medical and Surgical Management of Nail Disorders, 196
S005 Outbreak! Public Health Threats in Clinical Dermatology, 35
S009 Gross and Microscopic Symposium, 39, 92
S022 New Emerging Therapies, 90
S025 Chronic Pruritus: Bedside to Bench Perspectives, 105
S031 Adventures in Tropical Dermatology, 108
S040 Medical Dermatology in Children and Adults: Similarities and Differences in Approach and Management, 148
S046 Controversies and Difficult Questions Concerning Biologic Therapeutics, 186
S049 Boards Blitz, 187
S054 Dermatitis, 190
S059 Treating Severe Skin Disease in Children, 203
S061 Consultative Dermatology for the Hospitalized Patient, 204
S066 What's New in Dermatopathology, 207
S068 Therapeutic and Diagnostic Pearls, 220
S069 What's New in Dermatology, 220
U004 Hospital Dermatology, 17
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U036 Dermatologic Findings in the Stem Cell Transplant Patient, 74
U038 Arthropod-Borne Viruses: What Dermatologists Need to Know, 75
U044 Epstein-Barr Virus (EBV) and Its Role in Cutaneous Disease, 119
U046 Sex, Sores, Science, and Surveillance: Syphilis in the 21st Century, 120
U054 Leprosy and Leprosy Reactions, 124
U089 Inpatient Dermatology from Horses to Zebras: Lessons Learned at an Academic Hospital, 171
U090 Slap-on/Bug-off: Sunscreen and Insect-Repellent Basics and Controversies, 171
U101 Vaccines in Dermatology, 217

Lupus, Dermatomyositis, Scleroderma and Other Adult Collagen Vascular Disorders and Rheumatologic Disease
F011 Malignancy-Associated Dermatomyositis, 28
F036 Skinternal Medicine: An Update on Cutaneous Manifestations of Systemic Disease, 56
F049 Skin Signs of Internal Disease: Case-based Challenges, 78
F053 Advanced Dermatopathology, 80
F094 Referral Medical Dermatology, 134
F099 Medical Dermatology Challenge: Complex Cases from the Collection of Dr. Samuel Moschella, 137
F103 Side Effects May Include: Illustrative Cases of Dermatologic Adverse Events, 139
F106 A Practical Approach to Adult and Pediatric Autoimmune Connective Tissue Diseases, 140
F119 Approach to Sclerosing Skin Conditions, 155
F122 Challenging Cases and Therapeutic Pearls from UVA, 157
S009 Gross and Microscopic Symposium, 39, 92
S042 Advanced Medical Dermatology, 149
S049 Boards Blitz, 187
S062 Challenging Adult and Pediatric Autoimmune Connective Tissue Disease Cases: Pearls for Diagnosis and Management, 205
S066 What's New in Dermatopathology, 207
U003 Controversies in Management and Treatment of Cutaneous Lupus and Dermatomyositis Patient, 17
U007 Sjogren's for the Dermatologist: The Forgotten Autoimmune Connective Tissue Disease, 19
U025 New Medical Dermatology Literature that Changed My Approach to Practice, 67
U033 What is New on Pyoderma Gangrenosum?, 73
U062 Medical Dermatology Potpourri: Challenges Faced and Lessons Learned, 128
U068 Rheumatology for the Dermatologist: Evaluating the Rheumatology Patient in the Dermatology Clinic, 159
U072 Intravenous Immunoglobulin (IVIg) in Dermatology, 161

Nevi, Seborrheic Keratoses, and other Benign Skin Lesions

C002 Dermatology Review: General Dermatology and Practice Management, 32
C004 Advanced Dermoscopy, 37
C027 Fundamentals of Dermoscopy, 191
F015 Imaging in Dermatology, 30
F017 Managing Melanoma, 40
F023 Dermoscopy for the Non-dermoscopist, 43
F045 Practical Management of Atypical Melanocytic Lesions, 61
F105 Dermoscopy: It's Time for a Quiz, 140
F128 Dermoscopy: Learning From Easy and Difficult Cases, 175
F144 Diagnosis, Treatment and Prevention of Errors in Dermatologic Practice, 209
S004 Therapeutic Hotline, 35
S047 Managing Patients with Melanoma or Other Melanocytic Neoplasms, 186
S066 What's New in Dermatopathology, 207
U017 Challenging Cases of Dermoscopy: An Interactive Session, 64
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U025 New Medical Dermatology Literature that Changed My Approach to Practice, 67

Occupational Dermatology

C011 Dermatology Review: General and Cosmetic, 86
F018 Contact Dermatitis Tips from the American Contact Dermatitis Society, 41
F039 Contact Allergens of the Year, 58
F113 From Stinging Plants to Fire Ants: Identification, Management and Prevention of Hazardous Plant and Arthropod Exposures, 153
S031 Adventures in Tropical Dermatology, 108
S054 Dermatitis, 190
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65

Oral and Anogenital Diseases, Including Sexually Transmitted Diseases

F001 Oral Signs of Systemic Disease, 23
F053 Advanced Dermatopathology, 80
F084 Vulvar Disease: What Do You Know? An Overview, 112
F094 Referral Medical Dermatology, 134
F150 Oral Diseases, 212
S012 Women's Health Therapeutic Hotline, 51
S017 Gender Dermatology: Diagnosis and Treatment of Genital Skin Disorders, 54
S021 Disorders of Mucous Membranes, 89
S066 What's New in Dermatopathology, 207
U005 Lichen Planus and LP Mimickers: Concepts and Controversies, 18
U030 Male Genital Dermatology: Lessons Learned from a Male Genital Skin Disease Clinic, 71
U060 The Tongue, 127
U078 LGBT Health: Providing Culturally Competent Care to Patients who are Sexual and Gender Minorities, 164

Panniculitis and Other Disorders of Subcutaneous Fat

S049 Boards Blitz, 187

Photodermatoses and Other Disorders Due to Light, Trauma, and Other Physical Agents

F043 Photoprotection, 60
F092 Photosensitivity, 116
F103 Side Effects May Include: Illustrative Cases of Dermatologic Adverse Events, 139
S004 Therapeutic Hotline, 35
S005 Outbreak! Public Health Threats in Clinical Dermatology, 35
S023 Translating Evidence into Practice: Psoriasis Guidelines, 104
S031 Adventures in Tropical Dermatology, 108
U035 Cold Induced Skin Disease, 74

PREGNANCY

F038 Cutaneous Disorders of Pregnancy, 57
S012 Women's Health Therapeutic Hotline, 51
S038 Psoriasis, 147
U043 Pregnancy Dermatoses: Moving Towards a Better Understanding, 119

PRURITUS

F052 Itch, 80
F137 Challenging Diagnostic Cases for Practitioners, 194
S023 Translating Evidence into Practice: Psoriasis Guidelines, 104
S025 Chronic Pruritus: Bedside to Bench Perspectives, 105
S033 Inflammatory Skin Diseases: The Translational Revolution, 144
S054 Dermatitis, 190
S068 Therapeutic and Diagnostic Pearls, 220
U005 Lichen Planus and LP Mimickers: Concepts and Controversies, 18
U086 Treating Alopecia Areata, Vitiligo and Atopic Dermatitis: JAK Inhibitors, Something New for Dermatology, 169

Psoriasis and Other Papulosquamous Dermatoses

C002 Dermatology Review: General Dermatology and Practice Management, 32
C011 Dermatology Review: General and Cosmetic, 86
F010 Highlights From the Medical and Pediatric Literature, 28
F020 Complementary, Natural and Novel Dermatology Therapeutics: An Evidence-based Perspective, 42
F029 Updates in Neutrophilic and Pustular Dermatoses, 46
F079 Journal Watching, 109
F082 Hand and Foot Psoriasis, Dermatitis and Other Inflammatory Dermatoses, 111
F083 Phototherapy, 111
F109 Advanced Dermoscopy, 151
F110 The Skin and the Mind, 151
F114 Research Gaps in Psoriasis: Opportunities for Future Studies and Development of New Outcome Measures for Clinical Trials, 153

F137 Challenging Diagnostic Cases for Practitioners, 194
F140 Medical and Surgical Management of Nail Disorders, 196
F149 Psoriasis: Updates in Biologic Therapy, Comorbidities, Genetics, and Biosimilars, 212
S003 Role of Dermatologist in Management of Skin Disease in Solid Organ Transplant Recipients, 34
S004 Therapeutic Hotline, 35
S009 Gross and Microscopic Symposium, 39, 92
S015 Common, Challenging and Controversial Short Topics in Patient Management, 53
S022 New Emerging Therapies, 90
S023 Translating Evidence into Practice: Psoriasis Guidelines, 104
S030 Biologics Promise and Perils, 108
S033 Inflammatory Skin Diseases: The Translational Revolution, 144
S038 Psoriasis, 147
S046 Controversies and Difficult Questions Concerning Biologic Therapeutics, 186
S049 Boards Blitz, 187
S069 What's New in Dermatology, 220
U040 Highlights from JAAD, 76
U041 Disparities in Dermatology, 118
U047 Comorbidities in Psoriasis: What a Dermatologist Needs to Know, 121
U075 The Red Patient: An Overview of Erythroderma, 162

Sarcoidosis and Other Non-Infectious Disorders of Macrophages and Langerhans Cells

F093 Granulomatous Disorders of the Adult Skin, 116
S009 Gross and Microscopic Symposium, 39, 92
S042 Advanced Medical Dermatology, 149
S049 Boards Blitz, 187

SKIN OF COLOR

C011 Dermatology Review: General and Cosmetic, 86
F031 Where Do We Stand? The Pathogenesis and Treatment of Melasma, 47
F050 Updates in the Epidemic of Hair Loss in African American Women, 79
F054 Volunteers Abroad: Beginners, 81
F092 Photosensitivity, 116
F098 Skin Issues in Latino Patients, 136
F102 Disorders of Pigmentation, 138
F145 What's New in Melasma?, 210
S004 Therapeutic Hotline, 35
S031 Adventures in Tropical Dermatology, 108
S053 Masters of Dermatology, 189
S055 Skin of Color Boot Camp: What Every Dermatologist Should Know About the Patient with Darker Skin Tones, 190
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U022 Pigmentary Conundrums: Diagnostic and Therapeutic Pearls, 66
U041 Disparities in Dermatology, 118
U055 Unmasking Facial Pigmentation, 125
U077 Hair Care Practices and Hair Disorders in Skin of Color, 163
U102 About Face: Pearls for Facial Hyperpigmentation Conundrums, 218

Skin Signs of Adult Endocrine, Metabolic and Systemic Diseases

F009 Skin and Systemic Malignancy, 27
F011 Malignancy-Associated Dermatomyositis, 28
F024 What's That? Syndrome Update, 44
F036 Skinternal Medicine: An Update on Cutaneous Manifestations of Systemic Disease, 56
F049 Skin Signs of Internal Disease: Case-based Challenges, 78
F060 What's New in Local Wound Care, 84
F099 Medical Dermatology Challenge: Complex Cases from the Collection of Dr. Samuel Moschella, 137
F127 Coagulation and Vasculitis, 174
F148 Acne, Hair Loss and Hirsutism Evaluation and Management, 211
S009 Gross and Microscopic Symposium, 39, 92
S021 Disorders of Mucous Membranes, 89
S061 Consultative Dermatology for the Hospitalized Patient, 204
U010 Neutrophilic Dermatoses: An Update, 20
U035 Cold Induced Skin Disease, 74
U062 Medical Dermatology Potpourri: Challenges Faced and Lessons Learned, 128
U063 When to Look Deeper: Common Skin Findings as a Harbinger of Genetic Disease, 129

Ulcers and Ulcerating Dermatoses

F029 Updates in Neutrophilic and Pustular Dermatoses, 46
F060 What's New in Local Wound Care, 84
F122 Challenging Cases and Therapeutic Pearls from UVA, 157
S006 Wounds and Ulcers: The Good, the Bad and the Ugly, 36
S009 Gross and Microscopic Symposium, 39, 92
S023 Translating Evidence into Practice: Psoriasis Guidelines, 104
S031 Adventures in Tropical Dermatology, 108
U004 Hospital Dermatology, 17
U010 Neutrophilic Dermatoses: An Update, 20
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U023 Management of Difficult Wounds, 66
U024 Autoinflammatory Skin Disorders: Clinical Pearls for Diagnosis and Management, 67
U066 Controversies in Calciphylaxis: An Overview of Pathogenesis, Diagnosis, and Treatment through Case Studies, 131

Ultraviolet Light Therapy and Other Physical Treatment Modalities

F098 Skin Issues in Latino Patients, 136
S004 Therapeutic Hotline, 35
S023 Translating Evidence into Practice: Psoriasis Guidelines, 104
U071 Photodynamic Therapy in Medical and Aesthetic Dermatology, 160

Urticarial Dermatoses and Erythemas
F029 Updates in Neutrophilic and Pustular Dermatoses, 46
F117 Chronic Urticaria and Angioedema: What's New in Pathogenesis and Treatment, 155
S025 Chronic Pruritus: Bedside to Bench Perspectives, 105
S040 Medical Dermatology in Children and Adults: Similarities and Differences in Approach and Management, 148
S049 Boards Blitz, 187
U013 Recognition and Management of Allergic Skin Reactions in the Athlete, 22

Vasculitis, Vasculopathy and Purpura
C011 Dermatology Review: General and Cosmetic, 86
F036 Skinternal Medicine: An Update on Cutaneous Manifestations of Systemic Disease, 56
F094 Referral Medical Dermatology, 134
F099 Medical Dermatology Challenge: Complex Cases from the Collection of Dr. Samuel Moschella, 137
F103 Side Effects May Include: Illustrative Cases of Dermatologic Adverse Events, 139
F127 Coagulation and Vasculitis, 174
S009 Gross and Microscopic Symposium, 39, 92
S042 Advanced Medical Dermatology, 149
S049 Boards Blitz, 187
S059 Treating Severe Skin Disease in Children, 203
S061 Consultative Dermatology for the Hospitalized Patient, 204
S062 Challenging Adult and Pediatric Autoimmune Connective Tissue Disease Cases: Pearls for Diagnosis and Management, 205
U007 Sjogren's for the Dermatologist: The Forgotten Autoimmune Connective Tissue Disease, 19
U010 Neutrophilic Dermatoses: An Update, 20
U024 Autoinflammatory Skin Disorders: Clinical Pearls for Diagnosis and Management, 67
U062 Medical Dermatology Potpourri: Challenges Faced and Lessons Learned, 128
U066 Controversies in Calciphylaxis: An Overview of Pathogenesis, Diagnosis, and Treatment through Case Studies, 131
U083 Vasculitis, 168

Vitiligo, Melasma, and Other Disorders of Pigmentation
C011 Dermatology Review: General and Cosmetic, 86
F020 Complementary, Natural and Novel Dermatology Therapeutics: An Evidence-based Perspective, 42
F031 Where Do We Stand? The Pathogenesis and Treatment of Melasma, 47
F098 Skin Issues in Latino Patients, 136
F102 Disorders of Pigmentation, 138
F103 Side Effects May Include: Illustrative Cases of Dermatologic Adverse Events, 139
F133 Iatrogenic Injury, 192
F145 What's New in Melasma?, 210
S004 Therapeutic Hotline, 35
S033 Inflammatory Skin Diseases: The Translational Revolution, 144
S049 Boards Blitz, 187
S055 Skin of Color Boot Camp: What Every Dermatologist Should Know About the Patient with Darker Skin Tones, 190
S067 Vitiligo, 207
S068 Therapeutic and Diagnostic Pearls, 220
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U022 Pigmentary Conundrums: Diagnostic and Therapeutic Pearls, 66
U039 Functional Genomics: From Genes to Drug Targets, 76
U055 Unmasking Facial Pigmentation, 125
U086 Treating Alopecia Areata, Vitiligo and Atopic Dermatitis: JAK Inhibitors, Something New for Dermatology, 169
U102 About Face: Pearls for Facial Hyperpigmentation Conundrums, 218

Xerosis, Ichthyosis, and Other Adult Disorders of Cornification and Keratinization
F024 What's That? Syndrome Update, 44
F098 Skin Issues in Latino Patients, 136
S025 Chronic Pruritus: Bedside to Bench Perspectives, 105
U007 Sjogren's for the Dermatologist: The Forgotten Autoimmune Connective Tissue Disease, 19
U063 When to Look Deeper: Common Skin Findings as a Harbinger of Genetic Disease, 129

PEDIATRIC DERMATOLOGY

Cutaneous Disorders of the Newborn
C011 Dermatology Review: General and Cosmetic, 86
C017 Pediatric Dermatology, 91
F010 Highlights From the Medical and Pediatric Literature, 28
F024 What's That? Syndrome Update, 44
F035 Big Rashes in Little Patients, 56
F118 Neonatal Dermatology: Case-based Discussions, 155
F122 Challenging Cases and Therapeutic Pearls from UVA, 157
S009 Gross and Microscopic Symposium, 39, 92
S049 Boards Blitz, 187
U063 When to Look Deeper: Common Skin Findings as a Harbinger of Genetic Disease, 129
U074 Dermatoses of Infancy, 162

Ectodermal Dysplasia
U063 When to Look Deeper: Common Skin Findings as a Harbinger of Genetic Disease, 129

Epidermolysis Bullosa and Other Vesicobullous Disorders of Childhood
C017 Pediatric Dermatology, 91
F007 Hot Topics in Acute and Inpatient Pediatric Dermatology, 26
F101 Tackling Challenges in Epidermolysis Bullosa: What Does the Future Hold, 138
F126 Bullous Diseases: Diagnostic and Management Algorithm, 174
S009 Gross and Microscopic Symposium, 39, 92
U063 When to Look Deeper: Common Skin Findings as a Harbinger of Genetic Disease, 129

Hereditary Disorders of the Dermis, Including Atrophies
F024 What's That? Syndrome Update, 44

Medical Therapy Issues in the Pediatric Patient
C011 Dermatology Review: General and Cosmetic, 86
C017 Pediatric Dermatology, 91
F010 Highlights From the Medical and Pediatric Literature, 28
F019 Approaching Severe Inflammatory Skin Disease in Children, 41
F024 What's That? Syndrome Update, 44
F035 Big Rashes in Little Patients, 56
F140 Medical and Surgical Management of Nail Disorders, 196
S040 Medical Dermatology in Children and Adults: Similarities and Differences in Approach and Management, 148
S053 Masters of Dermatology, 189
S054 Dermatitis, 190
S056 Pearls: Diagnostic and Therapeutic, 202
S059 Treating Severe Skin Disease in Children, 203
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U088 Don't Brush it Off: Diagnosis and Management of Hair Loss in Children, 170
W016 Self-assessment: Pediatric Dermatology, 196

Normal Skin Variants and Developmental Anomalies
C017 Pediatric Dermatology, 91
S049 Boards Blitz, 187
U074 Dermatoses of Infancy, 162

Pediatric Adnexal Diseases
C024 Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management, 143
S049 Boards Blitz, 187
W015 Self-assessment: Acne, 177

Pediatric Benign and Malignant Skin Neoplasms, Including Tumor Syndromes of Childhood
F009 Skin and Systemic Malignancy, 27
F010 Highlights From the Medical and Pediatric Literature, 28
F057 The Big C's: Children, Cancer, and Cutaneous Complications, 82
F105 Dermoscopy: It's Time for a Quiz, 140
S003 Role of Dermatologist in Management of Skin Disease in Solid Organ Transplant Recipients, 34
S049 Boards Blitz, 187
S059 Treating Severe Skin Disease in Children, 203
U025 New Medical Dermatology Literature that Changed My Approach to Practice, 67
U063 When to Look Deeper: Common Skin Findings as a Harbinger of Genetic Disease, 129

Pediatric Collagen Vascular Disorders and Other Rheumatologic Disease
C017 Pediatric Dermatology, 91
F007 Hot Topics in Acute and Inpatient Pediatric Dermatology, 26
F035 Big Rashes in Little Patients, 56
F106 A Practical Approach to Adult and Pediatric Autoimmune Connective Tissue Diseases, 140
F122 Challenging Cases and Therapeutic Pearls from UVA, 157
S009 Gross and Microscopic Symposium, 39, 92
S049 Boards Blitz, 187
S062 Challenging Adult and Pediatric Autoimmune Connective Tissue Disease Cases: Pearls for Diagnosis and Management, 205
U049 Optimal Management of Pediatric Morphea, 122

Pediatric Disorders Due to Light, Trauma, and Other Physical Agents
F035 Big Rashes in Little Patients, 56
F092 Photosensitivity, 116

Pediatric Disorders of Hair and Nails
C017 Pediatric Dermatology, 91
F024 What's That? Syndrome Update, 44
F105 Dermoscopy: It's Time for a Quiz, 140
F140 Medical and Surgical Management of Nail Disorders, 196
S044 Nails, 150
S048 Alopecia: Work-up and Treatment, 187
S049 Boards Blitz, 187
S055 Skin of Color Boot Camp: What Every Dermatologist Should Know About the Patient with Darker Skin Tones, 190
S059 Treating Severe Skin Disease in Children, 203
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U048 Modern Nail Surgery: Aiming on Minimal Trauma and Nail-preservation, 121
U086 Treating Alopecia Areata, Vitiligo and Atopic Dermatitis: JAK Inhibitors, Something New for Dermatology, 169
U088 Don't Brush it Off: Diagnosis and Management of Hair Loss in Children, 170
W016 Self-assessment: Pediatric Dermatology, 196

Pediatric Disorders of Non-Infectious Macrophages and Langerhans Cells
S049 Boards Blitz, 187

Pediatric Disorders of Pigmentation
C011 Dermatology Review: General and Cosmetic, 86
C017 Pediatric Dermatology, 91
S049 Boards Blitz, 187
S067 Vitiligo, 207
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65

Pediatric Eczematous Eruptions
F007 Hot Topics in Acute and Inpatient Pediatric Dermatology, 26
F010 Highlights From the Medical and Pediatric Literature, 28
F019 Approaching Severe Inflammatory Skin Disease in Children, 41
F035 Big Rashes in Little Patients, 56

F041 Translating Evidence into Practice: Atopic Dermatitis Guidelines, 59
S009 Gross and Microscopic Symposium, 39, 92
S015 Common, Challenging and Controversial Short Topics in Patient Management, 53
S049 Boards Blitz, 187
S054 Dermatitis, 190
S059 Treating Severe Skin Disease in Children, 203
S069 What's New in Dermatology, 220
U009 The Truth About Pediatric Contact Dermatitis, 20
U103 Natural Compounds in Addressing Common Dermatologic Problems, 219

Pediatric Exanthematous Diseases and Hypersensitivity Syndromes
F010 Highlights From the Medical and Pediatric Literature, 28
F035 Big Rashes in Little Patients, 56
S009 Gross and Microscopic Symposium, 39, 92
S049 Boards Blitz, 187
S059 Treating Severe Skin Disease in Children, 203

Pediatric Infections, Infestations, and Bites
C017 Pediatric Dermatology, 91
C021 Infectious Diseases, 103
F007 Hot Topics in Acute and Inpatient Pediatric Dermatology, 26
F010 Highlights From the Medical and Pediatric Literature, 28
F035 Big Rashes in Little Patients, 56
F057 The Big C's: Children, Cancer, and Cutaneous Complications, 82
F086 Herpes Zoster: Controversies and Conundrums in Treatment and Prevention, 113
S009 Gross and Microscopic Symposium, 39, 92
S031 Adventures in Tropical Dermatology, 108
S039 Managing Tough Real Life Dermatology Cases, 147
S040 Medical Dermatology in Children and Adults: Similarities and Differences in Approach and Management, 148
S049 Boards Blitz, 187
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U034 Warts and Molluscum: What's New in Treatments, Vaccinations, Immunotherapy and the Sexual Abuse Question, 73
U090 Slap-on/Bug-off: Sunscreen and Insect-Repellent Basics and Controversies, 171
U101 Vaccines in Dermatology, 217
W016 Self-assessment: Pediatric Dermatology, 196

Pediatric Metabolic and Systemic Diseases (Includes Endocrine Disorders and the Skin)
C017 Pediatric Dermatology, 91
S009 Gross and Microscopic Symposium, 39, 92
S049 Boards Blitz, 187
U025 New Medical Dermatology Literature that Changed My Approach to Practice, 67

Pediatric Oral and Anogenital Dermatoses
F122 Challenging Cases and Therapeutic Pearls from UVA, 157
S021 Disorders of Mucous Membranes, 89
S049 Boards Blitz, 187
U034 Warts and Molluscum: What's New in Treatments, Vaccinations, Immunotherapy and the Sexual Abuse Question, 73

Pediatric Panniculitis and Other Subcutaneous Fat Disorders
S009 Gross and Microscopic Symposium, 39, 92
S049 Boards Blitz, 187

Pediatric Papulosquamous Disorders
F019 Approaching Severe Inflammatory Skin Disease in Children, 41
F035 Big Rashes in Little Patients, 56
F136 Pediatric Psoriasis: Systemic Therapy and Beyond, 194
S015 Common, Challenging and Controversial Short Topics in Patient Management, 53
S049 Boards Blitz, 187

Pediatric Patient Care: Assessment Skills, Plan Formulation, and Patient/Family Recommendations
C017 Pediatric Dermatology, 91
D002 CANCELLED: Child Abuse: Practical Approach and Child Abuse Mimickers, 77
F024 What's That? Syndrome Update, 44
F035 Big Rashes in Little Patients, 56
F079 Journal Watching, 109
F140 Medical and Surgical Management of Nail Disorders, 196
S040 Medical Dermatology in Children and Adults: Similarities and Differences in Approach and Management, 148
S054 Dermatitis, 190
U063 When to Look Deeper: Common Skin Findings as a Harbinger of Genetic Disease, 129
U095 Great Cases from Mississippi, 214

Pediatric Patient Care: History Taking and Physical Diagnosis
D002 CANCELLED: Child Abuse: Practical Approach and Child Abuse Mimickers, 77
F019 Approaching Severe Inflammatory Skin Disease in Children, 41
F035 Big Rashes in Little Patients, 56
F126 Bullous Diseases: Diagnostic and Management Algorithm, 174
F140 Medical and Surgical Management of Nail Disorders, 196
S040 Medical Dermatology in Children and Adults: Similarities and Differences in Approach and Management, 148
U013 Recognition and Management of Allergic Skin Reactions in the Athlete, 22
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U063 When to Look Deeper: Common Skin Findings as a Harbinger of Genetic Disease, 129
U095 Great Cases from Mississippi, 214

Pediatric Patient Care: In-office and Ancillary Diagnostics
U034 Warts and Molluscum: What's New in Treatments, Vaccinations, Immunotherapy and the Sexual Abuse Question, 73
W016 Self-assessment: Pediatric Dermatology, 196

Pediatric Patient Care: Non-surgical Office-based Procedures
F105 Dermoscopy: It's Time for a Quiz, 140
S039 Managing Tough Real Life Dermatology Cases, 147
U006 Pain-free Dermatology: Minimizing Discomfort in Procedures for Children and Adults, 18
U034 Warts and Molluscum: What's New in Treatments, Vaccinations, Immunotherapy and the Sexual Abuse Question, 73

Pediatric Patient Care: Patient Safety Issues
D002 CANCELLED: Child Abuse: Practical Approach and Child Abuse Mimickers, 77
F019 Approaching Severe Inflammatory Skin Disease in Children, 41
S053 Masters of Dermatology, 189
S059 Treating Severe Skin Disease in Children, 203
U006 Pain-free Dermatology: Minimizing Discomfort in Procedures for Children and Adults, 18
U101 Vaccines in Dermatology, 217

Pediatric Patient Care: Population Health and Preventive Care
C017 Pediatric Dermatology, 91
D004 Careers in Academic Dermatology, 150
S031 Adventures in Tropical Dermatology, 108
U013 Recognition and Management of Allergic Skin Reactions in the Athlete, 22
U090 Slap-on/Bug-off: Sunscreen and Insect-Repellent Basics and Controversies, 171
U101 Vaccines in Dermatology, 217

Pediatric Psychocutaneous Disease
U082 Caring for Vulnerable Patient Populations, 167

Vascular Disorders of Infancy and Childhood, Including Hemangiomas and Malformations
C017 Pediatric Dermatology, 91
F079 Journal Watching, 109
F122 Challenging Cases and Therapeutic Pearls from UVA, 157
S009 Gross and Microscopic Symposium, 39, 92
S037 Vascular Anomalies Symposium: Classification, Clinical Challenges and Management Update, 146
S049 Boards Blitz, 187
S059 Treating Severe Skin Disease in Children, 203
U040 Highlights from JAAD, 76
U100 Update on Pediatric Vascular Tumors, 217
W016 Self-assessment: Pediatric Dermatology, 196

Vasculitic Disorders of Childhood
F035 Big Rashes in Little Patients, 56
S009 Gross and Microscopic Symposium, 39, 92
S049 Boards Blitz, 187

Xerosis, Ichthyosis, and Other Hereditary Disorders of Cornification and Keratinization
C011 Dermatology Review: General and Cosmetic, 86
F024 What's That? Syndrome Update, 44
S049 Boards Blitz, 187
S059 Treating Severe Skin Disease in Children, 203
U063 When to Look Deeper: Common Skin Findings as a Harbinger of Genetic Disease, 129

PRACTICE-BASED LEARNING AND IMPROVEMENT

Literature Reviews, Evidence-Based Medicine, and How to Access, Assess and Incorporate Evidence-Based Resources to Improve Practice
F010 Highlights From the Medical and Pediatric Literature, 28
F017 Managing Melanoma, 40
F031 Where Do We Stand? The Pathogenesis and Treatment of Melasma, 47
F033 Value in Healthcare: Improving Outcomes and Decreasing Waste *****
F086 Herpes Zoster: Controversies and Conundrums in Treatment and Prevention, 113
F088 Dermatologic Surgery Disasters: A Dissection of Patient Safety Failures, 114
F090 Botulinum Toxin Applications: Past, Present, and Future, 115
F114 Research Gaps in Psoriasis: Opportunities for Future Studies and Development of New Outcome Measures for Clinical Trials, 153
S010 Pearls from the Posters, 50
S032 Resident Jeopardy, 144
S059 Treating Severe Skin Disease in Children, 203
S067 Vitiligo, 207
U028 Pemphigus and Pemphigoid: Evidence-based Updates, 70
U071 Photodynamic Therapy in Medical and Aesthetic Dermatology, 160
U095 Great Cases from Mississippi, 214

Participate in Activities to Assess and Improve Quality Practice
C018 Advanced Practice Management, 91
F014 Dermatologic Care for a Veteran Patient, 30
F022 MACRA, MIPs, and APMs, 43
F058 Patient Experience, Organizational Culture, and now MACRA: The New Face of Medical Practice, 83
F098 Skin Issues in Latino Patients, 136
F111 Dermatology Teachers Exchange Group, 152
F114 Research Gaps in Psoriasis: Opportunities for Future Studies and Development of New Outcome Measures for Clinical Trials, 153
F130 M&M for the Medical Dermatologist: Case-based Lessons, 176
F140 Medical and Surgical Management of Nail Disorders, 196
F144 Diagnosis, Treatment and Prevention of Errors in Dermatologic Practice, 209
S029 Rewards and Awards: How to make QI Pay Off, 107
S032 Resident Jeopardy, 144
S045 Teledermatology Working for You: Customizing

Use in the Changing Healthcare Environment

S053 Masters of Dermatology, 189
U012 Help Your Dermatopathologist Work Smarter for You, 21
U015 How to Deal with Difficult Patients/People and Look Forward To It!, 63
U058 Measuring and Assessing Derm Surg: Surgical Outcomes and Reimbursement, 126
U064 Dermatologist Burnout: How to Spot it and How to Avoid it, 129
U081 Leading Change in a Changing World, 167
U085 Developing Effective Multidisciplinary Skin Cancer Care: Driving Better Patient Outcomes and Fulfilling Professional Relationships, 169
U092 Data-driven Dermatology: Who Will Define our Specialty and How?, 213

Teach and Facilitate Learning of Others

C018 Advanced Practice Management, 91
D001 How to Create an Unforgettably Positive Patient Experience, 23
D004 Careers in Academic Dermatology, 150
F006 Invention and Entrepreneurialism in Dermatology: Stories of Success and Reality Check, 26
F028 Teledermatology Pearls and Pitfalls from Challenging Cases, 46
F031 Where Do We Stand? The Pathogenesis and Treatment of Melasma, 47
F050 Updates in the Epidemic of Hair Loss in African American Women, 79
F111 Dermatology Teachers Exchange Group, 152
F130 M&M for the Medical Dermatologist: Case-based Lessons, 176
F140 Medical and Surgical Management of Nail Disorders, 196
F141 How to be an Effective Clinician Educator, 208
F144 Diagnosis, Treatment and Prevention of Errors in Dermatologic Practice, 209
S032 Resident Jeopardy, 144
S053 Masters of Dermatology, 189
U012 Help Your Dermatopathologist Work Smarter for You, 21
U015 How to Deal with Difficult Patients/People and Look Forward To It!, 63
U073 The Human Face as Living and Functional Art, 161

Use Technology to Improve Practice

C004 Advanced Dermoscopy, 37
F004 Management of Patients with Melanocytic and Non-melanocytic Neoplasms, 25
F006 Invention and Entrepreneurialism in Dermatology: Stories of Success and Reality Check, 26
F015 Imaging in Dermatology, 30
F022 MACRA, MIPs, and APMs, 43
F023 Dermoscopy for the Non-dermoscopist, 43
F028 Teledermatology Pearls and Pitfalls from Challenging Cases, 46
F031 Where Do We Stand? The Pathogenesis and Treatment of Melasma, 47
F058 Patient Experience, Organizational Culture, and now MACRA: The New Face of Medical Practice, 83
F109 Advanced Dermoscopy, 151
F111 Dermatology Teachers Exchange Group, 152
F114 Research Gaps in Psoriasis: Opportunities for Future Studies and Development of New Outcome Measures for Clinical Trials, 153
F123 Photodocumentation in Dermatology, 157
F141 How to be an Effective Clinician Educator, 208
F144 Diagnosis, Treatment and Prevention of Errors in Dermatologic Practice, 209
S045 Teledermatology Working for You: Customizing Use in the Changing Healthcare Environment
S068 Therapeutic and Diagnostic Pearls, 220
U009 The Truth About Pediatric Contact Dermatitis, 20
U058 Measuring and Assessing Derm Surg: Surgical Outcomes and Reimbursement, 126
U069 PAPA, PASH, and PAPASH-syndromes, SAPHO, and Acne: Skin, Bones, and Inflammation, 159
U092 Data-driven Dermatology: Who Will Define our Specialty and How?, 213

PROCEDURAL DERMATOLOGY

Wound Healing and Wound Care

C008 Dermatology Review: Skin Cancer, Surgical, and Cosmetic, 49
C024 Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management, 143
F005 FDA Hot Topics: The Evolving Regulatory Landscape, 25
F081 Practice Gaps in Dermatology: Are We Doing What the Evidence Tells Us We Should? Tips for Your Practice, 110
S006 Wounds and Ulcers: The Good, the Bad and the Ugly, 36
S036 Surgical Complications, 146
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U093 Laser and Device-Based Treatment of Scars, 213

Anesthesia (Topical, Local, and Systemic) and Patient Monitoring During Procedures

C024 Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management, 143
F088 Dermatologic Surgery Disasters: A Dissection of Patient Safety Failures, 114
S008 Key Surgical Principles We All Should Know, 37
U006 Pain-free Dermatology: Minimizing Discomfort in Procedures for Children and Adults, 18

Basic Surgical Skills, Biopsy, Techniques and Excisional Surgery

C008 Dermatology Review: Skin Cancer, Surgical, and Cosmetic, 49
C019 Live Demonstration: Head and Neck Anatomy – Cadaver Prosection, 102
F017 Managing Melanoma, 40
F045 Practical Management of Atypical Melanocytic Lesions, 61
F078 Wound Closure Design: Basic to Advanced, 100
F122 Challenging Cases and Therapeutic Pearls from UVA, 157
F140 Medical and Surgical Management of Nail Disorders, 196

SUBJECT INDEX

S008 Key Surgical Principles We All Should Know, 37
S034 Pearls from the Masters of Dermatological Surgery, 145
U008 Simple Tricks and Practical Tips to Optimize the Surgical Experience for You and Your Patients, 19
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
W013 Hands-on: Innovative Suture Techniques Update, 182

Botulinum Toxin and Chemodenervation
C003 Botulinum Toxin: Video Instruction and Live Panel Discussion, 33
C008 Dermatology Review: Skin Cancer, Surgical, and Cosmetic, 49
F090 Botulinum Toxin Applications: Past, Present, and Future, 115
S004 Therapeutic Hotline, 35
S015 Common, Challenging and Controversial Short Topics in Patient Management, 53
S022 New Emerging Therapies, 90
S025 Chronic Pruritus: Bedside to Bench Perspectives, 105
S034 Pearls from the Masters of Dermatological Surgery, 145
S036 Surgical Complications, 146
S050 Dermatologic Surgery: Cosmetic Tips and Pearls, 188
S069 What's New in Dermatology, 220
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U096 Hyperhidrosis: Update on Therapeutics, 215
W001 Self-assessment: Cosmetic Dermatology, 31

Chemical Peeling
F031 Where Do We Stand? The Pathogenesis and Treatment of Melasma, 47
F077 Superficial, Medium, and Deep Chemical Peeling and Relevance in 2017, 100
F098 Skin Issues in Latino Patients, 136
S004 Therapeutic Hotline, 35
S050 Dermatologic Surgery: Cosmetic Tips and Pearls, 188
055 Skin of Color Boot Camp: What Every Dermatologist Should Know About the Patient with Darker Skin Tones, 190
U102 About Face: Pearls for Facial Hyperpigmentation Conundrums, 218
W001 Self-assessment: Cosmetic Dermatology, 31

Cryosurgery
C008 Dermatology Review: Skin Cancer, Surgical, and Cosmetic, 49
C024 Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management, 143
W014 Hands-on: Fire and Ice! Electrosurgery and Cryosurgery, 183

Dermabrasion and Microdermabrasion
S050 Dermatologic Surgery: Cosmetic Tips and Pearls, 188
S055 Skin of Color Boot Camp: What Every Dermatologist Should Know About the Patient with Darker Skin Tones, 190

Dressings and Postoperative Care, Including Management of Complications
D001 How to Create an Unforgettably Positive Patient Experience, 23
F088 Dermatologic Surgery Disasters: A Dissection of Patient Safety Failures, 114
F135 Techniques for Flap Success, 193
S006 Wounds and Ulcers: The Good, the Bad and the Ugly, 36
S008 Key Surgical Principles We All Should Know, 37
U008 Simple Tricks and Practical Tips to Optimize the Surgical Experience for You and Your Patients, 19
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65

Electrosurgery
C024 Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management, 143
F088 Dermatologic Surgery Disasters: A Dissection of Patient Safety Failures, 114
W014 Hands-on: Fire and Ice! Electrosurgery and Cryosurgery, 183

Flap Reconstruction
C024 Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management, 143
F044 How Would You Reconstruct It?, 60
F089 Reconstruction Options for Defects in the Central Face, 114
F135 Techniques for Flap Success, 193
S003 Role of Dermatologist in Management of Skin Disease in Solid Organ Transplant Recipients, 34
S034 Pearls from the Masters of Dermatological Surgery, 145
S064 Regional Reconstruction, 206
U076 The ART (Advancement, Rotation, Transposition) of Flaps, 163
U080 Executing Transposition Flaps Off the Nose, 166
W019 Hands-on: Wound Closures, 199

Graft Reconstruction
C024 Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management, 143
F044 How Would You Reconstruct It?, 60
F089 Reconstruction Options for Defects in the Central Face, 114
F135 Techniques for Flap Success, 193
S003 Role of Dermatologist in Management of Skin Disease in Solid Organ Transplant Recipients, 34
S034 Pearls from the Masters of Dermatological Surgery, 145
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65

Hair Transplantation and Scalp Reduction
C022 Updates in Hair Disorders, 142
S048 Alopecia: Work-up and Treatment, 187
U094 Hair Transplantation, 214

Instrumentation Used in Procedural Dermatology
C024 Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management, 143
W012 Hands-on: Nail Surgery, 181
W013 Hands-on: Innovative Suture Techniques Update, 182

W014 Hands-on: Fire and Ice! Electrosurgery and Cryosurgery, 183
W020 Hands-on: Nail Surgery, 200

Lasers and Intense Pulsed Ligh

C011 Dermatology Review: General and Cosmetic, 86
C024 Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management, 143
F005 FDA Hot Topics: The Evolving Regulatory Landscape, 25
F016 Emerging Laser and Aesthetic Technology, 40
F031 Where Do We Stand? The Pathogenesis and Treatment of Melasma, 47
F079 Journal Watching, 109
F081 Practice Gaps in Dermatology: Are We Doing What the Evidence Tells Us We Should? Tips for Your Practice, 110
F145 What's New in Melasma?, 210
S015 Common, Challenging and Controversial Short Topics in Patient Management, 53
S022 New Emerging Therapies, 90
S025 Chronic Pruritus: Bedside to Bench Perspectives, 105
S034 Pearls from the Masters of Dermatological Surgery, 145
S036 Surgical Complications, 146
S050 Dermatologic Surgery: Cosmetic Tips and Pearls, 188
S059 Treating Severe Skin Disease in Children, 203
S060 What's New and What's True in Lasers, 204
S069 What's New in Dermatology, 220
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U045 Avoiding Complications and Maximizing Results in Laser Surgery, 120
U055 Unmasking Facial Pigmentation, 125
U071 Photodynamic Therapy in Medical and Aesthetic Dermatology, 160
U073 The Human Face as Living and Functional Art, 161
U091 The Science Behind New Devices in Dermatology, 172
U093 Laser and Device-Based Treatment of Scars, 213
U099 Take a Pico Under the Hood: Dissecting Picosecond Lasers and Indications, 216
W001 Self-assessment: Cosmetic Dermatology, 31
W021 Hands-on: Varicose and Telangiectatic Veins, 201

MELANOMA

C002 Dermatology Review: General Dermatology and Practice Management, 32
C004 Advanced Dermoscopy, 37
C008 Dermatology Review: Skin Cancer, Surgical, and Cosmetic, 49
F004 Management of Patients with Melanocytic and Non-melanocytic Neoplasms, 25
F009 Skin and Systemic Malignancy, 27
F015 Imaging in Dermatology, 30
F017 Managing Melanoma, 40
F023 Dermoscopy for the Non-dermoscopist, 43
F045 Practical Management of Atypical Melanocytic Lesions, 61
F081 Practice Gaps in Dermatology: Are We Doing What the Evidence Tells Us We Should? Tips for Your Practice, 110
F105 Dermoscopy: It's Time for a Quiz, 140
F128 Dermoscopy: Learning From Easy and Difficult Cases, 175
F139 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines, 195
S001 New and Emerging Technologies in Dermatology, 33
S003 Role of Dermatologist in Management of Skin Disease in Solid Organ Transplant Recipients, 34
S011 Dilemmas and Challenges in Skin Cancer Therapies and Management, 51
S015 Common, Challenging and Controversial Short Topics in Patient Management, 53
S047 Managing Patients with Melanoma or Other Melanocytic Neoplasms, 186
S058 Melanoma: The Future is Now, 203
S065 Cutaneous Oncology, 206
S069 What's New in Dermatology, 220
U017 Challenging Cases of Dermoscopy: An Interactive Session, 64
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U040 Highlights from JAAD, 76
U059 Dermatologic Management of the Immunosuppressed: From Rapamycin Rash to Wiskott-Aldrich Syndrome (WAS) Dermatitis, 127
U061 My Patient Has Melanoma, Now What Do I Do?, 128
U085 Developing Effective Multidisciplinary Skin Cancer Care: Driving Better Patient Outcomes and Fulfilling Professional Relationships, 169
U098 Non-surgical Skin Cancer Treatments, 216
W004 Self-assessment: Skin Cancer, 85

Mohs Micrographic Surgery

C008 Dermatology Review: Skin Cancer, Surgical, and Cosmetic, 49
D004 Careers in Academic Dermatology, 150
F014 Dermatologic Care for a Veteran Patient, 30
F017 Managing Melanoma, 40
F044 How Would You Reconstruct It?, 60
F079 Journal Watching, 109
F088 Dermatologic Surgery Disasters: A Dissection of Patient Safety Failures, 114
F089 Reconstruction Options for Defects in the Central Face, 114
F135 Techniques for Flap Success, 193
F137 Challenging Diagnostic Cases for Practitioners, 194
F139 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines, 195
S001 New and Emerging Technologies in Dermatology, 33
S003 Role of Dermatologist in Management of Skin Disease in Solid Organ Transplant Recipients, 34
S034 Pearls from the Masters of Dermatological Surgery, 145
S065 Cutaneous Oncology, 206
S068 Therapeutic and Diagnostic Pearls, 220
S069 What's New in Dermatology, 220
U058 Measuring and Assessing Derm Surg: Surgical Outcomes and Reimbursement, 126

U059 Dermatologic Management of the Immunosuppressed: From Rapamycin Rash to Wiskott-Aldrich Syndrome (WAS) Dermatitis, 127
U076 The ART (Advancement, Rotation, Transposition) of Flaps, 163

NAIL SURGERY

F121 An Evidence-based Approach to Nails: Expert Management of Common Problems, 156
F140 Medical and Surgical Management of Nail Disorders, 196
S036 Surgical Complications, 146
S044 Nails, 150
U008 Simple Tricks and Practical Tips to Optimize the Surgical Experience for You and Your Patients, 19
U048 Modern Nail Surgery: Aiming on Minimal Trauma and Nail-preservation, 121
W012 Hands-on: Nail Surgery, 181
W020 Hands-on: Nail Surgery, 200

Non-Melanoma Skin Cancer, Including Basal Cell and Squamous Cell Carcinomas

C004 Advanced Dermoscopy, 37
C008 Dermatology Review: Skin Cancer, Surgical, and Cosmetic, 49
C011 Dermatology Review: General and Cosmetic, 86
F014 Dermatologic Care for a Veteran Patient, 30
F015 Imaging in Dermatology, 30
F023 Dermoscopy for the Non-dermoscopist, 43
F069 Outpatient Radiotherapy of Skin Cancer: Back to the Future, 96
F105 Dermoscopy: It's Time for a Quiz, 140
F108 Field Cancer and Multiple SCC: Molecular Insights and Clinical Management, 141
F109 Advanced Dermoscopy, 151
F128 Dermoscopy: Learning From Easy and Difficult Cases, 175
F135 Techniques for Flap Success, 193
S001 New and Emerging Technologies in Dermatology, 33
S003 Role of Dermatologist in Management of Skin Disease in Solid Organ Transplant Recipients, 34
S011 Dilemmas and Challenges in Skin Cancer Therapies and Management, 51
S015 Common, Challenging and Controversial Short Topics in Patient Management, 53
S022 New Emerging Therapies, 90
S065 Cutaneous Oncology, 206
U001 Merkel Cell Carcinoma: Diagnosis, Management and Controversies, 16
U017 Challenging Cases of Dermoscopy: An Interactive Session, 64
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U040 Highlights from JAAD, 76
U051 Hedgehog Inhibitor Therapy for BCC: An Academic and a Private Practice Perspective, 123
U059 Dermatologic Management of the Immunosuppressed: From Rapamycin Rash to Wiskott-Aldrich Syndrome (WAS) Dermatitis, 127
U071 Photodynamic Therapy in Medical and Aesthetic Dermatology, 160
U085 Developing Effective Multidisciplinary Skin Cancer Care: Driving Better Patient Outcomes and Fulfilling Professional Relationships, 169
U098 Non-surgical Skin Cancer Treatments, 216
W004 Self-assessment: Skin Cancer, 85
W014 Hands-on: Fire and Ice! Electrosurgery and Cryosurgery, 183

Phlebology

W021 Hands-on: Varicose and Telangiectatic Veins, 201

PHOTODYNAMIC THERAPY

C024 Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management, 143
F005 FDA Hot Topics: The Evolving Regulatory Landscape, 25
F108 Field Cancer and Multiple SCC: Molecular Insights and Clinical Management, 141
S003 Role of Dermatologist in Management of Skin Disease in Solid Organ Transplant Recipients, 34
S027 Photodynamic Therapy, 106
U071 Photodynamic Therapy in Medical and Aesthetic Dermatology, 160
U098 Non-surgical Skin Cancer Treatments, 216
W004 Self-assessment: Skin Cancer, 85

Pre-Operative Patient Evaluation and Documentation

D001 How to Create an Unforgettably Positive Patient Experience, 23
F015 Imaging in Dermatology, 30
F017 Managing Melanoma, 40
F088 Dermatologic Surgery Disasters: A Dissection of Patient Safety Failures, 114
F098 Skin Issues in Latino Patients, 136
S008 Key Surgical Principles We All Should Know, 37
S039 Managing Tough Real Life Dermatology Cases, 147
S065 Cutaneous Oncology, 206
021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U073 The Human Face as Living and Functional Art, 161

Procedural Management of Benign Subcutaneous Lesions

S034 Pearls from the Masters of Dermatological Surgery, 145
S039 Managing Tough Real Life Dermatology Cases, 147

Scar Revision

C008 Dermatology Review: Skin Cancer, Surgical, and Cosmetic, 49
F098 Skin Issues in Latino Patients, 136
S034 Pearls from the Masters of Dermatological Surgery, 145
S036 Surgical Complications, 146
U011 Common Complaints Encountered During Dermatologic Surgery: How to Respond and How to Prevent, 21
U093 Laser and Device-Based Treatment of Scars, 213
U099 Take a Pico Under the Hood: Dissecting Picosecond Lasers and Indications, 216

Skin Cancer in the Organ Transplant Recipient

D004 Careers in Academic Dermatology, 150
F137 Challenging Diagnostic Cases for Practitioners, 194
S003 Role of Dermatologist in Management of Skin Disease in Solid Organ Transplant Recipients, 34
S065 Cutaneous Oncology, 206
U051 Hedgehog Inhibitor Therapy for BCC: An Academic and a Private Practice Perspective, 123
U059 Dermatologic Management of the Immunosuppressed: From Rapamycin Rash to Wiskott-Aldrich Syndrome (WAS) Dermatitis, 127
U071 Photodynamic Therapy in Medical and Aesthetic Dermatology, 160
U085 Developing Effective Multidisciplinary Skin Cancer Care: Driving Better Patient Outcomes and Fulfilling Professional Relationships, 169
U098 Non-surgical Skin Cancer Treatments, 216
W004 Self-assessment: Skin Cancer, 85

Skin Structure and Surgical Anatomy

C019 Live Demonstration: Head and Neck Anatomy – Cadaver Prosection, 102
C024 Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management, 143
F104 High Yield "Power Hour" for Residents, 139
F140 Medical and Surgical Management of Nail Disorders, 196
S064 Regional Reconstruction, 206
U052 Up and Coming Fillers: Experience from Across the Atlantic, 123
W019 Hands-on: Wound Closures, 199

Tissue Augmentation (Fillers and Fat Transplant)

S020 Soft Tissue Augmentation: The Nasolabial Fold and Beyond, 89
S034 Pearls from the Masters of Dermatological Surgery, 145
S036 Surgical Complications, 146
S050 Dermatologic Surgery: Cosmetic Tips and Pearls, 188
S055 Skin of Color Boot Camp: What Every Dermatologist Should Know About the Patient with Darker Skin Tones, 190
S069 What's New in Dermatology, 220
U021 Holy Moly: Religion and the Skin: Cultural Competence, 65
U052 Up and Coming Fillers: Experience from Across the Atlantic, 123
U073 The Human Face as Living and Functional Art, 161
W001 Self-assessment: Cosmetic Dermatology, 31

PROFESSIONALISM AND MAINTENANCE OF CERTIFICATION

Ethics and Ethical Conduct*

D001 How to Create an Unforgettably Positive Patient Experience, 23
F006 Invention and Entrepreneurialism in Dermatology: Stories of Success and Reality Check, 26
F028 Teledermatology Pearls and Pitfalls from Challenging Cases, 46
F051 Closing the Gender Gap in Academic Dermatology and Dermatology Leadership: Problems and Solutions, 79
F054 Volunteers Abroad: Beginners, 81
F067 Lessons for Dermatology from the Tao Te Ching, 95
F074 The Future of Dermatology: What Changes are Coming and How Can We Prepare?, 98
F088 Dermatologic Surgery Disasters: A Dissection of Patient Safety Failures, 114
F097 Medicolegal Issues, 136
S053 Masters of Dermatology, 189
U015 How to Deal with Difficult Patients/People and Look Forward To It!, 63
U058 Measuring and Assessing Derm Surg: Surgical Outcomes and Reimbursement, 126
U084 Bureaucracy, Compliance, and Burnout: What it Means to Dermatologists, 168

LEADERSHIP

C002 Dermatology Review: General Dermatology and Practice Management, 32
C018 Advanced Practice Management, 91
D001 How to Create an Unforgettably Positive Patient Experience, 23
D004 Careers in Academic Dermatology, 150
F006 Invention and Entrepreneurialism in Dermatology: Stories of Success and Reality Check, 26
F025 Teaching, Coaching, Mentoring and Difficult Conversations, 44
F034 Young Physician Pearls and Pitfalls: A Survival Guide for the First 10 Years, 55
F047 How to Quarterback a Championship Team, 62
F051 Closing the Gender Gap in Academic Dermatology and Dermatology Leadership: Problems and Solutions, 79
F074 The Future of Dermatology: What Changes are Coming and How Can We Prepare?, 98
F111 Dermatology Teachers Exchange Group, 152
F116 Boards and Beyond, 154
F141 How to be an Effective Clinician Educator, 208
F144 Diagnosis, Treatment and Prevention of Errors in Dermatologic Practice, 209
S053 Masters of Dermatology, 189
U015 How to Deal with Difficult Patients/People and Look Forward To It!, 63
U081 Leading Change in a Changing World, 167
U085 Developing Effective Multidisciplinary Skin Cancer Care: Driving Better Patient Outcomes and Fulfilling Professional Relationships, 169

Participation in MOC Program

F011 Malignancy-Associated Dermatomyositis, 28
F116 Boards and Beyond, 154
S025 Chronic Pruritus: Bedside to Bench Perspectives, 105
S049 Boards Blitz, 187
U016 MOC Changes, 63
W001 Self-assessment: Cosmetic Dermatology, 31
W005 Self-assessment: Atopic Dermatitis, 101
W015 Self-assessment: Acne, 177

SUBJECT INDEX

Professional Development
C018 Advanced Practice Management, 91
D001 How to Create an Unforgettably Positive Patient Experience, 23
D004 Careers in Academic Dermatology, 150
F006 Invention and Entrepreneurialism in Dermatology: Stories of Success and Reality Check, 26
F025 Teaching, Coaching, Mentoring and Difficult Conversations, 44
F028 Teledermatology Pearls and Pitfalls from Challenging Cases, 46
F034 Young Physician Pearls and Pitfalls: A Survival Guide for the First 10 Years, 55
F051 Closing the Gender Gap in Academic Dermatology and Dermatology Leadership: Problems and Solutions, 79
F058 Patient Experience, Organizational Culture, and now MACRA: The New Face of Medical Practice, 83
F097 Medicolegal Issues, 136
F116 Boards and Beyond, 154
F141 How to be an Effective Clinician Educator, 208
S034 Pearls from the Masters of Dermatological Surgery, 145
S053 Masters of Dermatology, 189
U011 Common Complaints Encountered During Dermatologic Surgery: How to Respond and How to Prevent, 21
U015 How to Deal with Difficult Patients/People and Look Forward To It!, 63
U050 Do Not Forsake the Love You Had at First: Reflection on Patient Satisfaction Surveys, 122
U064 Dermatologist Burnout: How to Spot it and How to Avoid it, 129
U081 Leading Change in a Changing World, 167
U084 Bureaucracy, Compliance, and Burnout: What it Means to Dermatologists, 168
U085 Developing Effective Multidisciplinary Skin Cancer Care: Driving Better Patient Outcomes and Fulfilling Professional Relationships, 169

Sensitivity to a Diverse Patient Population
D001 How to Create an Unforgettably Positive Patient Experience, 23
F028 Teledermatology Pearls and Pitfalls from Challenging Cases, 46
F030 Dealing with Difficult Patient Encounters, 47
F054 Volunteers Abroad: Beginners, 81
F098 Skin Issues in Latino Patients, 136
S025 Chronic Pruritus: Bedside to Bench Perspectives, 105
S031 Adventures in Tropical Dermatology, 108
S034 Pearls from the Masters of Dermatological Surgery, 145
S040 Medical Dermatology in Children and Adults: Similarities and Differences in Approach and Management, 148
S048 Alopecia: Work-up and Treatment, 187
S053 Masters of Dermatology, 189
S059 Treating Severe Skin Disease in Children, 203
U011 Common Complaints Encountered During Dermatologic Surgery: How to Respond and How to Prevent, 21
U015 How to Deal with Difficult Patients/People and Look Forward To It!, 63
U041 Disparities in Dermatology, 118
U050 Do Not Forsake the Love You Had at First: Reflection on Patient Satisfaction Surveys, 122
U078 LGBT Health: Providing Culturally Competent Care to Patients who are Sexual and Gender Minorities, 164
U082 Caring for Vulnerable Patient Populations, 167
U102 About Face: Pearls for Facial Hyperpigmentation Conundrums, 218

Teamwork
C018 Advanced Practice Management, 91
D001 How to Create an Unforgettably Positive Patient Experience, 23
F006 Invention and Entrepreneurialism in Dermatology: Stories of Success and Reality Check, 26
F022 MACRA, MIPs, and APMs, 43
F025 Teaching, Coaching, Mentoring and Difficult Conversations, 44
F028 Teledermatology Pearls and Pitfalls from Challenging Cases, 46
F051 Closing the Gender Gap in Academic Dermatology and Dermatology Leadership: Problems and Solutions, 79
F058 Patient Experience, Organizational Culture, and now MACRA: The New Face of Medical Practice, 83
F088 Dermatologic Surgery Disasters: A Dissection of Patient Safety Failures, 114
F111 Dermatology Teachers Exchange Group, 152
F141 How to be an Effective Clinician Educator, 208
F144 Diagnosis, Treatment and Prevention of Errors in Dermatologic Practice, 209
S034 Pearls from the Masters of Dermatological Surgery, 145
S053 Masters of Dermatology, 189
U013 Recognition and Management of Allergic Skin Reactions in the Athlete, 22
U015 How to Deal with Difficult Patients/People and Look Forward To It!, 63
U071 Photodynamic Therapy in Medical and Aesthetic Dermatology, 160
U081 Leading Change in a Changing World, 167
U085 Developing Effective Multidisciplinary Skin Cancer Care: Driving Better Patient Outcomes and Fulfilling Professional Relationships, 169

Volunteerism and Social Consciousness
F028 Teledermatology Pearls and Pitfalls from Challenging Cases, 46
F054 Volunteers Abroad: Beginners, 81
F116 Boards and Beyond, 154
F141 How to be an Effective Clinician Educator, 208
S031 Adventures in Tropical Dermatology, 108
S053 Masters of Dermatology, 189
U013 Recognition and Management of Allergic Skin Reactions in the Athlete, 22
U015 How to Deal with Difficult Patients/People and Look Forward To It!, 63

SYSTEMS-BASED PRACTICE

Accessing Non-Physician Patient Services Outside of Your Field to Benefit Your Patients, Including Advocacy

D005 Atopic Dermatitis in Adults: Not Just Big Kids, 134
S005 Outbreak! Public Health Threats in Clinical Dermatology, 35
U078 LGBT Health: Providing Culturally Competent Care to Patients who are Sexual and Gender Minorities, 164
U087 Update on Cutaneous Reactions to Targeted and Immune Cancer Therapy, 170

Electronic Health Records, Computer Technology, Photography and other Practice Services to Improve Your Practice

C002 Dermatology Review: General Dermatology and Practice Management, 32
C025 Coding and Documentation, 184
D005 Atopic Dermatitis in Adults: Not Just Big Kids, 134
F015 Imaging in Dermatology, 30
F022 MACRA, MIPs, and APMs, 43
F028 Teledermatology Pearls and Pitfalls from Challenging Cases, 46
F058 Patient Experience, Organizational Culture, and now MACRA: The New Face of Medical Practice, 83
F088 Dermatologic Surgery Disasters: A Dissection of Patient Safety Failures, 114
F111 Dermatology Teachers Exchange Group, 152
F123 Photodocumentation in Dermatology, 157
S045 Teledermatology Working for You: Customizing Use in the Changing Healthcare Environment
U027 The Dermatologist's Role in Meeting the Needs of the Greater Community, 70

Practice Management and the Business of Dermatology, Including Coding, Office Regulation, Accreditation, Managed Care, Government Regulation, and Cost Containment

C018 Advanced Practice Management, 91
C025 Coding and Documentation, 184
F003 Coding and Office Management, 24
F005 FDA Hot Topics: The Evolving Regulatory Landscape, 25
F022 MACRA, MIPs, and APMs, 43
F034 Young Physician Pearls and Pitfalls: A Survival Guide for the First 10 Years, 55
F037 The Impact of Drug Pricing on Access to Care: Demystifying the Landscape, 57
F058 Patient Experience, Organizational Culture, and now MACRA: The New Face of Medical Practice, 83
F071 To Err is Human: How to Optimize Patient Safety in Your Practice, 97
F074 The Future of Dermatology: What Changes are Coming and How Can We Prepare?, 98
F142 Documentation and Coding: Getting Paid and Passing Audits, 208
S029 Rewards and Awards: How to make QI Pay Off, 107
S034 Pearls from the Masters of Dermatological Surgery, 145
U057 Dermatology Business Trends and Practice Opportunities, 126
U058 Measuring and Assessing Derm Surg: Surgical Outcomes and Reimbursement, 126
U064 Dermatologist Burnout: How to Spot it and How to Avoid it, 129
U084 Bureaucracy, Compliance, and Burnout: What it Means to Dermatologists, 168
U092 Data-driven Dermatology: Who Will Define our Specialty and How?, 213

Responsibility for Population Health, Including Reporting Requirements

F005 FDA Hot Topics: The Evolving Regulatory Landscape, 25
F011 Malignancy-Associated Dermatomyositis, 28
F022 MACRA, MIPs, and APMs, 43
F028 Teledermatology Pearls and Pitfalls from Challenging Cases, 46
F074 The Future of Dermatology: What Changes are Coming and How Can We Prepare?, 98
F086 Herpes Zoster: Controversies and Conundrums in Treatment and Prevention, 113
S005 Outbreak! Public Health Threats in Clinical Dermatology, 35
S029 Rewards and Awards: How to make QI Pay Off, 107
U027 The Dermatologist's Role in Meeting the Needs of the Greater Community, 70
U058 Measuring and Assessing Derm Surg: Surgical Outcomes and Reimbursement, 126
U078 LGBT Health: Providing Culturally Competent Care to Patients who are Sexual and Gender Minorities, 164
U092 Data-driven Dermatology: Who Will Define our Specialty and How?, 213
U101 Vaccines in Dermatology, 217

Risk Management/Malpractice

C018 Advanced Practice Management, 91
C025 Coding and Documentation, 184
F071 To Err is Human: How to Optimize Patient Safety in Your Practice, 97
F088 Dermatologic Surgery Disasters: A Dissection of Patient Safety Failures, 114
F142 Documentation and Coding: Getting Paid and Passing Audits, 208
F144 Diagnosis, Treatment and Prevention of Errors in Dermatologic Practice, 209
U011 Common Complaints Encountered During Dermatologic Surgery: How to Respond and How to Prevent, 21

Teaming with Other Providers of Care to Benefit Your Patients

C002 Dermatology Review: General Dermatology and Practice Management, 32
C018 Advanced Practice Management, 91
D005 Atopic Dermatitis in Adults: Not Just Big Kids, 134
F011 Malignancy-Associated Dermatomyositis, 28
F015 Imaging in Dermatology, 30
F017 Managing Melanoma, 40
F022 MACRA, MIPs, and APMs, 43

SUBJECT INDEX

F028 Teledermatology Pearls and Pitfalls from Challenging Cases, 46
F034 Young Physician Pearls and Pitfalls: A Survival Guide for the First 10 Years, 55
F050 Updates in the Epidemic of Hair Loss in African American Women, 79
F098 Skin Issues in Latino Patients, 136
F107 Dermatologic Side Effects of Anticancer Drugs in 2017: What You Need to Know, 141
F111 Dermatology Teachers Exchange Group, 152
F139 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines, 195
F141 How to be an Effective Clinician Educator, 208
F144 Diagnosis, Treatment and Prevention of Errors in Dermatologic Practice, 209
S001 New and Emerging Technologies in Dermatology, 33
S007 Cosmetics, 36
S034 Pearls from the Masters of Dermatological Surgery, 145
S053 Masters of Dermatology, 189
S054 Dermatitis, 190
S059 Treating Severe Skin Disease in Children, 203
S062 Challenging Adult and Pediatric Autoimmune Connective Tissue Disease Cases: Pearls for Diagnosis and Management, 205
U001 Merkel Cell Carcinoma: Diagnosis, Management and Controversies, 16
U011 Common Complaints Encountered During Dermatologic Surgery: How to Respond and How to Prevent, 21
U012 Help Your Dermatopathologist Work Smarter for You, 21
U013 Recognition and Management of Allergic Skin Reactions in the Athlete, 22
U027 The Dermatologist's Role in Meeting the Needs of the Greater Community, 70
U070 The Dermatopathology Report: Reading Between the Lines, 160
U071 Photodynamic Therapy in Medical and Aesthetic Dermatology, 160
U078 LGBT Health: Providing Culturally Competent Care to Patients who are Sexual and Gender Minorities, 164
U081 Leading Change in a Changing World, 167
U085 Developing Effective Multidisciplinary Skin Cancer Care: Driving Better Patient Outcomes and Fulfilling Professional Relationships, 169
U087 Update on Cutaneous Reactions to Targeted and Immune Cancer Therapy, 170
U095 Great Cases from Mississippi, 214

A

Abdulla, Farah R., MD, University of Chicago, no financial relationships exist with commercial interests.

Ablon, Glynis R., MD, Asst Clin Prof, U CA, Los Angeles, CA, Eclipse Medical – Speaker/Faculty Education(H); EndyMed Medical Inc. USA – Speaker/Faculty Education(H); Galderma Laboratories, L.P. – A(H); Lifes2Good – I(Grants/Research Funding); Neothetics – I(Grants/Research Funding); ThermiAesthetics – Speaker/Faculty Education(H); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding).

Achell, Lucia, MD, Lucia Achell Dermatologist México City, no financial relationships exist with commercial interests.

Adams, Brian Burke, MD, MPH,Prof & Chair, Dept Derm, U Cincinnati, Cincinnati, OH; Chief, Section Derm, VAMC-Cincinnati, Galderma Laboratories, LP – C(Fees); Mission – A(SO).

Adamson, Adewole Shomari, MD, MPP,Adewole Adamson, MD, MPP, Assistant Professor, University of North Carolina - Chapel Hill, no financial relationships exist with commercial interests.

Adelson, David M., MD, MS,Associate Professor of Dermatology, Oregon Health Science University, no financial relationships exist with commercial interests.

Adigun, Chris, MD, Dermatology & Laser Center of Chapel Hill, Chapel Hill, NC, Celgene Corporation – Speaker/Faculty Education(H); Cipher Pharmaceuticals – A(H); Klara/Goderma, Inc. – C(Fees); Miramar Labs – C(Fees); Sandoz, a Novartis company – A(H).

Ahronowitz, Iris Z, MD, Assistant Professor of Clinical Dermatology, University of Southern California, Los Angeles, CA, no financial relationships exist with commercial interests.

Ai, Wei, MD, MD, PhD, Associate Clinical Professor of Medicine, Univsersity of California, San Francisco, CA, no financial relationships exist with commercial interests.

Alam, Murad, MD, Professor of Dermatology, Otolaryngology, and Surgery, Northwestern University, Chicago, Illinois, Amway Corporation – C(H).

Alani, Rhoda Myra, MD, Herbert Mescon Endowed Professor and Chair, Department of Dermatology, Boston University, Boston, MA, Acylin Therapeutics, Inc – F(Fees); LabCorp, Inc. – C(Fees), I(Grants/Research Funding).

Alavi, Afsaneh, MD, Assistant Professor, University of Toronto, Toronto, ON,Canada, AbbVie – A(H), I(Grants/Research Funding), Speaker/Faculty Education(Grants/Research Funding); Galderma Canada, Inc – A(H); Janssen Pharmaceuticals, Inc – A(H); Regeneron – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – A(H); XOMA (US) LLC – I(Grants/Research Funding).

Albertini, John G., MD, The Skin Surgery Center, Winston-Salem, NC, Genentech, Inc. – I(Grants/Research Funding).

Alexiades-Armenakas, Macrene, MD, PhD,Associate Clinical Professor Yale University School of Medicine, Dermatology and Laser Surgery Cente, Allergan, Inc – A(H); Alma Lasers – I(Grants/Research Funding); DEKA – I(Grants/Research Funding); DUSA Pharmaceuticals – I(Grants/Research Funding); Lancome – I(Grants/Research Funding); Syneron Candela – I(Grants/Research Funding).

Alexis, Andrew F., MD, Assoc Prof, Icahn School of Medicine at Mount Sinai, New York, NY, Aclaris Therapeutics, Inc. – A(H); Allergan, Inc – I(Grants/Research Funding); Allergan, Inc. – A(H), C(Fees); Amgen – A(H), C(Fees); Anacor Pharmaceuticals, Inc. – A(H); Derma Instruments USA L.P. – I(Grants/Research Funding); Ferndale Laboratories, Inc. – A(H); Galderma Laboratories, L.P. – A(H), C(Fees); L'Oreal USA Inc. – A(H), C(-Fees); Leo Pharma Inc. – A(H); Mitsibushi Pharma – C(Fees); Novan – I(Grants/Research Funding); Novartis – A(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Roche Laboratories – C(Fees); Sandoz, a Novartis company – A(H); Sanova Works – SP(H); Solta Medical – O(EQ); Springer Science & Business Media – O(OB); Suneva Medical, Inc. – A(H); Trevi Therapeutics – I(Grants/Research Funding); Unilever – A(H); Valeant Pharmaceuticals North America LLC – A(H); Wiley-Blackwell – O(OB).

Allbritton, Jill I., MD, Instructor Johns Hopkins Medical Institute, no financial relationships exist with commercial interests.

Alloo, Allireza, MD, Assistant Professor of Dermatology, Hofstra Northwell School of Medicine, Hempstead, NY, no financial relationships exist with commercial interests.

Almeida, Ada R. Trindade, MD, Dermatologist at Hospital do Servidor Publico Municipal de Sao Paulo, Brazil. Director of Cosmiatry, Allergan, Inc. – C(H); Galderma Laboratories, L.P. – C(H).

Alonso-Llamazares, Javier, MD, Voluntary Associate Professor of Clinical Dermatology. University of Miami, Celgene Corporation – SP(H).

Alster, Tina S., MD, Dir, Washington Inst Derm Laser Surg, Clin Prof,Georgetown U, Washington, DC, Home Skinovations – C(ST); L'Oreal USA Inc. – C(OB); Revance Therapeutics, Inc. – I(Grants/Research Funding).

Altman, Emily M., MD, Summit Medical Group, Berkeley Heights, NJ, no financial relationships exist with commercial interests.
Amerson, Erin H., MD, Associate Clinical Professor of Dermatology, University of California-San Francisco, CA, no financial relationships exist with commercial interests.
Anadkat, Milan J., MD, Associate Professor, Dermatology, Washington University School of Medicine, St. Louis, MO, BestDoctors – C(H); Biogen – C(H); Clinical Assistance Programs – C(Fees); XOMA (US) LLC – I(Fees).
Anand, Chytra V., MBBS,Senior Consultant Cosmetic Dermatologist, Kosmoderma Clinics, Bangalore, India, Allergan, Inc – A(H), Speaker/Faculty Education(H); Alma Lasers – SP(H); Galderma Laboratories, L.P. – C(H); Merz Aesthetics – A(H).
Anderson, Bryan Erik, MD, Professor, Dept Derm, Penn State Univ, Hershey, PA, Elsevier Inc. – O(IP).
Anderson, Richard Rox, MD, Prof Derm, Harvard Med Sch, Boston, MA, Cytrellis Biosystems, Inc – C(SO); Living Proof, Inc. – C(SO); Massachusetts General Hospital – E(IP); MOE Medical Devices LLC – C(H); Photomedex – C(H); Seven Oaks – C(IP); Seventh Sense BioSystems – C(SO); Sofregen Medical, Inc. – C(SO); Strata Skin Sciences – C(H).
Anzai, Alessandra, MD, Reasearch Fellow of Dermatology, Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil, no financial relationships exist with commercial interests.
Aoki, Valeria, MD, Associate Professor of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil, no financial relationships exist with commercial interests.
Apalla, Zoe, MD, PhD, First Department of Dermatology, Aristotle University of Thessaloniki, Greece, no financial relationships exist with commercial interests.
Arellano-Mendoza, Maria Ivonne, MD, Dermatologist, Hospital General de Mexico Dr. Eduardo Liceaga, Mexico City, Mexico, Bioderma – SP(H); Galderma Laboratories, LP – A(H); Pierre Fabre Dermo Cosmetique France – A(H); Sanfer, S.L. – SP(H).
Argenziano, Giuseppe, MD, Dermatology Unit, Second University of Naples, Naples, Italy, no financial relationships exist with commercial interests.
Arkin, Lisa, MD, MD, Asst Prof of Dermatology and Pediatrics, University of Wisconsin School of Medicine, Madison, Wi, no financial relationships exist with commercial interests.
Armstrong, April W., MD, MPH,Associate Dean, University of Southern California, AbbVie – A(H), SP(H); Celgene Corporation – C(H); Eli Lilly and Company – I(Grants/Research Funding), SP(H); Janssen-Ortho Inc. – A(H), I(Grants/Research Funding); Modernizing Medicine – C(H); National Institutes of Health – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H), I(Grants/Research Funding); Pfizer Inc. – A(H); Regeneron – I(Grants/Research Funding).
Arron, Sarah T., MD, PhD,Associate Professor, University of California, San Francisco, CA, Amyris, Inc. – C(Fees); Genentech, Inc. – E(S), I(S); LEO Pharma, US – I(S); Navigant – I(S); Portola Pharmaceuticals, Inc. – C(Fees); Zebra Medical Technologies – C(Fees).
Asgari, Maryam Mandana, MD, Massachusetts General Hospital and Harvard Medical School, Boston MA, Pfizer Inc. – I(Grants/Research Funding); Valeant Pharmaceuticals International – I(Grants/Research Funding).
Asz-Sigall, Daniel, MD, Dermatologist, ABC medical center and Dermalomas Clinic, no financial relationships exist with commercial interests.
Atit, Radhika, PhD,Associate Professor, Departments of Biology, Genetics, Dermatology, CWRU, no financial relationships exist with commercial interests.
Atwater, Amber R., MD, Associate Professor, Duke University Department of Dermatology, Durham, NC, Biosense Webster – C(Fees); Medtronics – C(Fees); St. Jude Medical – C(Fees).
Avram, Marc R., MD, Clinical Professor of Dermatology, Cornell Medical Ctr, New York, N.Y., Restoration Robotics, Inc – C(NC).
Avram, Mathew M., MD, JD,Dir, Massachusetts Gen Hosp Laser & Cosm Ctr, Associate Professor, Harvard Med Sch, Boston, MA, Allergan, Inc – C(Fees); Cytrellis Biosystems, Inc – C(ST); Invasix – C(Fees); Masters of Aesthetics, Inc. – F(Fees); Sciton Inc. – A(Fees); Zalea, LLC – C(Fees); Zeltiq Aesthetics – C(Fees).

B

Bahr, Brooks Albert, MD, Assistant Professor, University of Utah Dermatology, Salt Lake City, UT, no financial relationships exist with commercial interests.
Bahrami, Soon, MD, Assistant Professor Division of Dermatoloy, University of Louisville, Louisville, KY, no financial relationships exist with commercial interests.
Bailey, Elizabeth E, MD, MPH,Clinical Assistant Professor of Dermatology, Stanford University School of Medicine, Stanford, CA, no financial relationships exist with commercial interests.
Baldwin, Hilary E., MD, Assoc Prof Clin Derm, SUNY, Brooklyn, NY, Allergan, Inc. – A(H);

Bayer – SP(NC); Galderma Laboratories, L.P. – SP(H); Novan – I(Grants/Research Funding); Ranbaxy Laboratories Limited – SP(H); Valeant Pharmaceuticals International – SP(H).

Balighi, Kamran, MD, Tehran University of Medical Sciences, Tehran, Iran, no disclosure available at time of printing.

Bandino, Justin P, MD, Dermatopathology Fellow, Medical University of South Carolina, Charleston, SC, no financial relationships exist with commercial interests.

Bangert, Carolyn A., MD, Associated Dermatologists, PC, Tucson, Arizona, no financial relationships exist with commercial interests.

Bar, Anna A., MD, Assistant Professor of Dermatology, Oregon Health & Science University, Portland OR, no financial relationships exist with commercial interests.

Baran, Robert L., MD, Prof, Nail Disease Center, Cannes, France, no financial relationships exist with commercial interests.

Barbieri, John, MD, Dermatology Resident, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, no financial relationships exist with commercial interests.

Barbosa, Victoria Holloway, MD, Clinical Assistant Professor, Rush University Department of Dermatology, Chicago, IL, no financial relationships exist with commercial interests.

Barker, Christopher, MD, Asst. Attending, Dept. of Radiation Oncology, Memorial Sloan Kettering Cancer Ctr., New York, NY, American Academy of Dermatology – Speaker/Faculty Education(NC); American College of Mohs Surgery – Speaker/Faculty Education(H); American Society for Radiation Oncology – I(Grants/Research Funding), O(OB); Amgen – I(Grants/Research Funding); Esaote – I(EQ); Genentech, Inc. – I(Grants/Research Funding); Menssana Research, Inc. – I(Grants/Research Funding); Multinational Association for Supportive Care in Cancer – SP(NC); Novartis – A(H); Nucletron B.V. – C(H), I(EQ), I(Grants/Research Funding); Patient Resource, LLC – A(NC); RP Pharmaceuticals – C(Fees); Trans Tasman Radiation Oncology Group – I(Grants/Research Funding).

Baron, Elma D., MD, Prof, Dept Derm, Case W Reserve U, Chf, VA Med Ctr, Cleveland, OH, Biofrontera AG – A(H); Elorac, Inc. – I(Grants/Research Funding); Solgenix LLC – I(Grants/Research Funding).

Barrio, Victoria R., MD, Clinical Associate Professor of Dermatology and Pediatrics, U.C.S.D. San Diego, CA, no financial relationships exist with commercial interests.

Baselga, Eulalia, MD, Associate Professor; Director Pediatric Dermatology. Hospital S.Creu i S. Pau Barcelona, Spain, Almirall – SP(H); Astellas Pharma US, Inc – SP(H); Intendis, Inc. – SP(H); ISDIN – C(H); Pierre Fabre Dermo-Cosmétique US – I(H).

Bastian, Boris C., MD, Departments of Dermatology and Pathology, University of California, San Francisco, no financial relationships exist with commercial interests.

Baumann, Leslie, MD, Baumann Cosmetic and Research Institute, Miami, FL, Allergan, Inc. – PI((Grants/Research Funding)), Avon Products, Inc. –PI ((Grants/Research Funding)), Coria Laboratories - AB(H), Dermworx – PI ((Grants/Research Funding)), Galderma Laboratories, L.P. – PI ((Grants/Research Funding)), Genzyme Corporation – PI((Grants/Research Funding)), GlaxoSmithKline – PI((Grants/Research Funding)), Johnson & Johnson (Consumer Products Company) – PI(Equipment), L'Oreal USA Inc. – PI(Equipment), Medicis Pharmaceutical Corporation – PI((Grants/Research Funding)), sanofi-aventis – PI((Grants/Research Funding)), Schick – PI((Grants/Research Funding)), Skin Type Solutions, LLC. – Founder(No Compensation Received), Topix Pharmaceuticals,Inc. - AB(H), Ulthera – PI((Grants/Research Funding)), Unilever Home & Personal Care USA-PI((Grants/Research Funding)), Vicept Therapeutics, Inc. – PI((Grants/Research Funding)), Vichy Laboratoires - AB(H).

Bechtel, Mark A., MD, Clinical Professor of Dermatology, Division of Dermatology, University of Pennsylvania, Philadelphia, no financial relationships exist with commercial interests.

Bedocs, Laleh, DO,Dermatology Partners, Inc, no financial relationships exist with commercial interests.

Beer, Kenneth R., MD, Kenneth Beer MD PA, General, Surgical and Esthetic Dermatology, West Palm Beach and Jupiter, FL,N/A.

Beleznay, Katie, MD, Clinical Instructor, Department of Dermatology and Skin Science, Vancouver, British Columbia, AbbVie – C(H); Allergan, Inc. – I(Fees); Amgen – O(H); Celgene Corporation – SP(H); Cipher Pharmaceuticals – A(H); Cutanea Life Sciences – I(Fees); Evolus, Inc. – I(Fees); Galderma Canada, Inc – A(H), SP(H); Johnson & Johnson Consumer Products Company – A(H); LEO Laboratories Ltd (LEO Pharma) – I(Fees), SP(H); Novartis – SP(H); Revance Therapeutics, Inc. – I(Fees); Valeant Pharmaceuticals International – SP(-Fees); Valeant Pharmaceuticals North America LLC – A(H); Zeltiq Aesthetics – I(Fees).

Bellet, Jane S., MD, Associate Professor, Pediatrics and Dermatology, Duke University School of Medicine, Durham, NC, Merck & Co., Inc. – SH(NC).

Benjamin, Latanya, MD, Director Pediatric Dermatology Joe DiMaggio Children's Hospital Hollywood, FL, no financial relationships exist with commercial interests.
Bennett, Daniel D., MD, Associate Professor, University of Wisconsin School of Medicine and Public Health, Madison, WI, no financial relationships exist with commercial interests.
Bercovitch, Lionel Gordon, MD, Prof Derm,Warren Alpert Sch Med Brown U, Providence,RI, no financial relationships exist with commercial interests.
Berger, Timothy G., MD, Prof Clin Derm, UCSF, San Francisco, CA, Anacor Pharmaceuticals, Inc. – A(H); OptumRx – C(H).
Bergfeld, Wilma Fowler, MD, Emeritus Director Dermpath, Director DP Fellowsh, Depts Derm and Path, Cleveland Clin, Cleveland, OH, Incyte Corporation – I(NC); Johnson and Johnson Consumer Products Company – A(H); Kythera – A(H), I(NC); Procter & Gamble Company – A(H); Samumed, LLC – A(H), I(NC).
Berman, Brian, MD, PhD,Emeritus Prof Derm U Miami, Miami, FL, Aclaris Therapeutics, Inc. – A(H), C(H); Actavis – I(Grants/Research Funding); AiViva BioPharma, Inc. – C(H); Allergan, Inc. – I(Grants/Research Funding); Allos – A(H); Almirall – A(H); Amira Pharmaceuticals – C(H); Anacor Pharmaceuticals, Inc. – A(H), I(Grants/Research Funding); Bayer Pharmaceuticals – SP(H); Berg Pharma, LLC – A(ST), C(H); Biofrontera AG – C(H); C & H Scientific, LLC – A(H); Capstone Therapeutics Corp. – C(H); Celumigen Pharmaceuticals, Inc. – B(SO), C(H), C(SO); Centocor Ortho Biotech Inc. – C(H), SP(H); CHS Pharma – A(ST); Clark Pharmaceuticals, LLC – C(H); Crescita Therapeutics Inc. – C(H); Dermira – A(H), A(SO); Doak – A(H); Dr. Tattoff – A(H), A(SO); DUSA Pharmaceuticals, Inc – A(H); DUSA Pharmaceuticals, Inc. – C(H), I(Grants/Research Funding); Excaliard Pharmaceuticals, Inc. – C(H); Exeltis – C(H), I(Grants/Research Funding); Ferndale Laboratories, Inc. – C(H); Foamix – A(H); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding), SP(H); GlaxoSmithKline – C(H); Graceway Pharmaceuticals, LLC – SP(H); Halscion – A(H); Klara/Goderma, Inc. – C(SO); Leo Pharma A/S – I(Grants/Research Funding); LEO Pharma, US – A(H), SP(H); Liquidia Technologies, Inc. – C(H); Medicis Pharmaceutical Corporation – A(H), SP(H); Medimetriks Pharmaceuticals, Inc. – C(H); MediWound – C(H); Merz Pharmaceuticals, LLC – A(H), Speaker/Faculty Education(H); Novan – C(H); Novartis Pharmaceuticals Corp. – SP(H); Oculus innovative Sciences, Inc. – C(SO); Onset Therapeutics – A(H), SP(H); Peplin Inc. – A(H), C(H); Pharmaderm – A(H); Pulse Biosciences – C(H); RXi Pharmaceuticals Corporation – I(NC); sanofi-aventis – A(H), SP(H); Sensus Healthcare – A(H); Smith & Nephew – A(H); Sol-Gel Technologies – C(H); Stiefel a GSK company – A(H), SP(H); Tigercat Pharma, Inc – I(Grants/Research Funding); TopMD – A(ST), C(H); Valeant Pharmaceuticals International – SP(H).
Bernstein, Eric F., MD, Clinical Professor, Department of Dermatology, University of Pennsylvania, Philadelphia, PA, Candela Corporation – A(Fees); Syneron, Inc. – I(Grants/Research Funding); Zeltiq Aesthetics – A(H), I(Grants/Research Funding).
Berson, Diane S., MD, Assoc Prof Derm, Weill Med Col of Cornell U, NY, NY, Allergan, Inc – C(H); Galderma Laboratories, L.P. – A(H); La Roche-Posay Laboratoire Pharmaceutique – A(H); Medicis Pharmaceutical Corporation – A(H); Procter & Gamble Company – C(H).
Bertucci, Vince, MD, Co-Director, Cosmetic Dermatology & Laser Fellowship, University of Toronto, Canada, Allergan, Inc – C(Fees); Allergan, Inc. – A(Fees), I(Fees), SP(H); Evolus, Inc. – I(Fees); Galderma Canada, Inc – A(Fees), SP(H); Galderma Laboratories, L.P. – A(Fees); Galderma USA – I(Fees); La Roche-Posay Laboratorie Pharmaceutique – A(Fees); Leo Pharma Inc – SP(H); Leo Pharma Inc. – A(Fees); Merz Aesthetics – A(Fees), C(Fees), I(Fees); Revance Therapeutics, Inc. – C(Fees), I(Fees), SP(Fees); Valeant Pharmaceuticals International – C(Fees).
Bewley, Anthony Paul, MBChB,Dr Anthony Bewley, Consultant Dermatologist, The Royal London Hospital, London, UK., AbbVie – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding); Janssen-Cilag – A(H); Leo Pharma A/S – A(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding), Speaker/Faculty Education(H); Stiefel a GSK company – Speaker/Faculty Education(H); Unilever – I(Grants/Research Funding).
Bhatia, Neal D., MD, Director of Clinical Dermatology, Therapeutics Clinical Research, Aclaris Therapeutics, Inc. – C(H); Actavis – I(NC); Allergan, Inc – C(H); Almirall – C(H); Anacor Pharmaceuticals, Inc. – C(H); Aqua – C(H); Bayer Pharmaceuticals – C(H); Biofrontera AG – C(H); Brickell Biotech, Inc. – I(NC); Cipher Pharmaceuticals – C(H); Dermira – I(NC); DUSA Pharmaceuticals, Inc. – A(H); Exeltis – C(H); Ferndale Laboratories, Inc. – C(H); Galderma Laboratories, L.P. – SP(H); Glenmark Generics Inc. – I(NC); IntraDerm Pharmaceuticals – C(H); ISDIN – C(NC); LEO Pharma, US – C(H); Novartis Pharmaceuticals Corp. – C(H);

Pharmaderm – C(H); Promius Pharma, LLC – A(H); Regeneron – I(NC); Sandoz, a Novartis company – C(H); Sanofi/Regeneron – I(NC); Sun Pharmaceutical Industries Ltd. – C(H); Valeant Pharmaceuticals International – C(H); Viamet Pharmaceuticals, Inc – I(NC).

Bhutani, Tina, MD, Assistant Professor, UCSF Department of Dermatology, San Francisco, CA, AbbVie – A(H); Cutanea Life Sciences – A(H); Genentech, Inc. – I(Grants/Research Funding); Janssen Research & Development, LLC – I(Grants/Research Funding); Leo Pharma Inc – I(Grants/Research Funding); MelaSciences – I(Grants/Research Funding); Merck & Co., Inc – I(Grants/Research Funding); Novartis – I(Grants/Research Funding).

Bichakjian, Christopher K., MD, Professor, U of Michigan, Ann Arbor, MI, no financial relationships exist with commercial interests.

Billingsley, Elizabeth M., MD, Prof Derm, Dir Mohs Surgery, Penn St Hershey Med Ctr PSU Coll of Med, Hershey, PA," Genentech, Inc. – I(Grants/Research Funding); Hedgepath Pharmaceutic,*HedgePath Pharmaceuticals, Inc. – I(Grants/Research Funding)."*

Bissonnette, Robert, MD, MSc,Innovaderm Research, Montreal, Quebec, AbbVie – A(H), C(H), I(Grants/Research Funding), SP(H); Amgen – C(H), I(Grants/Research Funding), SP(H); Boehringer Ingelheim – A(H), I(Grants/Research Funding); Celgene Corporation – A(H), I(Grants/Research Funding); Eli Lilly and Company – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – C(H), I(Grants/Research Funding); Glenmark Generics Inc. – I(Grants/Research Funding); Janssen-Ortho Inc. – C(H), I(Grants/Research Funding), SP(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – A(H), I(Grants/Research Funding); Stiefel a GSK company – C(H); Vitae Pharmaceuticals – I(Grants/Research Funding).

Blauvelt, Andrew, MD, President and Investigator, Oregon Medical Research Center, Portland, OR, AbbVie – C(H), I(Fees); Amgen – C(H), I(Fees); Boehringer Ingelheim – A(H), C(H), I(Fees); Dermira – A(H), C(H), I(Fees); Eli Lilly and Company – A(H), C(H), I(Fees), SP(H); Genentech, Inc. – I(Fees); Genzyme Corporation – C(H); GlaxoSmithKline – I(Fees); Janssen-Ortho Inc. – A(H), C(H), I(Fees); Merck & Co., Inc – A(H), C(H), I(Fees); Novartis Pharmaceuticals Corp. – A(H), C(H), I(Fees); Regeneron – A(H), C(H), I(Fees); Sandoz, a Novartis company – A(H), C(H), I(Fees); Sun Pharmaceutical Industries Ltd. – C(H); UCB – C(H), I(Fees); Valeant Pharmaceuticals International – A(H), C(H), I(Fees).

Bohnert, Krista, no financial relationships.

Bolognia, Jean L., MD, Prof, Dept Derm, Yale U, New Haven, CT, Elsevier Inc. – O(IP).

Bonchak, Jonathan, MD, Resident, Emory University, Department of Dermatology, no financial relationships exist with commercial interests.

Boon Kee, Goh, MBChB,Consultant Dermatologist, Skin Physicians Private Limited, Mount Elizabeth Medical Centre, Singapore, no financial relationships exist with commercial interests.

Bordeaux, Jeremy S., MD, MPH,Associate Prof, Dept of Derm, Case Western Reserve University, Univ Hosp Case Med Ctr, Cleveland, OH, no financial relationships exist with commercial interests.

Bordone, Lindsey, MD, Assistant Professor of Dermatology, Columbia University Medical Center, New York, NY, no financial relationships exist with commercial interests.

Borradori, Luca, MD, Professor , Department of Dermatology, University Hospital, Inselspital, 3010 Bern, Switzerland, no financial relationships exist with commercial interests.

Bowman, Paul H., MD, Tampa, FL,no disclosure available at time of printing.

Boyd, Kevin P., MD, Dermatology Associates of Colorado; Denver, Colorado, no financial relationships exist with commercial interests.

Brancaccio, Gabriella, MD, Second University of Naples, Naples, Italy, no financial relationships exist with commercial interests.

Brandling-Bennett, Heather, MD, Associate Professor, Seattle Children's Hopsital, University of Washington, Seattle, WA, Galderma Research & Development, LLC – I(Grants/Research Funding); Scioderm – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – A(H).

Braudis, Kara M., MD, Assistant Professor; Director of Dermatopathology U. of Missouri Dept of Dermatology; Columbia MO, no financial relationships exist with commercial interests.

Brauer, Jeremy A., MD, Clinical Assistant Professor, Department of Dermatology NYU SOM, New York, NY, Cynosure – SP(H); Cynosure, Inc – A(H); Miramar Labs – A(NC), C(H); ON Light Sciences, Inc. – SP(H).

Braun, Ralph P., MD, Dept Derm, U Hosp Zürich, Zürich, Switzerland, no financial relationships exist with commercial interests.

Brauner, Gary J., MD, Assoc Clin Prof Derm, Icahn School of Medicine at Mt Sinai, New York, NY, no financial relationships exist with commercial interests.

Bravo, Francisco G., MD, Prof Derm & Path, Cayetano Heredia U, Lima, Peru, no financial relationships exist with commercial interests.

Braz, Andre, MD, Professor of Cosmiatry, Dermatology Division of the Policlínica Geral do Rio

de Janeiro, Brazil, Allergan, Inc – A(H), SP(H); Merz Pharmaceuticals, LLC – SP(Fees).
Breisch, Eric, PhD,Adjunct Clinical Professor of Anatomy, UCSD School of Medicine, La Jolla, CA, Allergan, Inc – C(H).
Brewer, Jerry D., MD, Associate Professor of Dermatology, Mayo Clinic, Rochester, MN, no financial relationships exist with commercial interests.
Bridges, Alina G., DO,Associate Prof, Dept Derm, Mayo Clinic, Rochester, MN, no financial relationships exist with commercial interests.
Brinster, Nooshin Ketabchi, MD, New York University, New York, NY, no financial relationships exist with commercial interests.
Brod, Bruce A., MD, Clinical Prof of Dermatology, Univ of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, no financial relationships exist with commercial interests.
Brodell, Robert T., MD, Instructor Derm, U Rochester, Prof & Chair Dept of Derm, & Prof of Path, University of Mississippi, AbbVie – SP(H); Galderma Laboratories, L.P. – C(H), I(H), SP(H); Genentech, Inc. – I(H); Pharmaderm – SP(H).
Brodland, David G., MD, Asst Clin Prof, Dept Derm/Otolaryngol/Plastic Surgery, U Pittsburgh, Pittsburgh,PA, no financial relationships exist with commercial interests.
Brody, Harold J., MD, Clin Prof, Dept Derm, Sch Med, Emory U, Atlanta, GA, Allergan, Inc. – SP(H); Galderma Laboratories, LP – SP(H); Kythera Biopharmaceuticals – SP(H); Merz Aesthetics – SP(H).
Brown, Katherine Kristine, MD, Assistant Professor of Clinical Dermatology, University of Pennsylvania, Philadelphia, PA, no financial relationships exist with commercial interests.
Brown, Marc D., MD, Prof, Derm and Oncology, Sch Med, U Rochester, Rochester, NY, no financial relationships exist with commercial interests.
Brown, Mariah C., MD, Assistant Professor, Department of Dermatology, University of Colorado, Aurora, CO, no financial relationships exist with commercial interests.
Bruce, Alison J., MBChB,Associate Professor of Dermatology, Derm, Mayo Clin, Jacksonville, FL, no financial relationships exist with commercial interests.
Bruckner, Anna Lee, MD, MD, Associate Professor of Dermatology & Pediatrics, University of Colorado, Aurora, CO, Anacor Pharmaceuticals, Inc. – A(H); Scioderm – I(Grants/Research Funding).
Burgess, Cheryl M., MD, Asst Clin Prof, Dept Derm, Georgetown Univ. Washington, DC, Allergan, Inc. – A(H), I(Grants/Research Funding), SH(ST); Galderma USA – A(H); Kythera – I(Grants/Research Funding); Merz Aesthetics – A(H).
Burgin, Susan, MD, Asst Prof, Dept. of Derm, Beth Israel Med Ctr, Harvard Med Sch, Boston, MA,VisualDx, C(H).
Burkemper, Nicole M., MD, Associate Professor of Dermatology and Pathology; Saint Louis University; Saint Louis, MO, no financial relationships exist with commercial interests.
Busam, Klaus J., MD, Professor, Cornell University; Director of Dermpath, Memorial Sloan-Kettering Canc Ctr, New York, NY, no financial relationships exist with commercial interests.
Butterwick, Kimberly J., MD, Priv Pract Derm, San Diego, CA, Allergan, Inc – I(Grants/Research Funding); Allergan, Inc. – A(H); Colorescience – A(H); Galderma Laboratories, L.P. – A(H); Merz Pharmaceuticals, LLC – A(H); Suneva Medical, Inc. – A(H); ThermiAesthetics – C(H); Valeant Pharmaceuticals International – C(H).
Buzney, Elizabeth A., MD, Assistant Professor in Dermatology, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, no financial relationships exist with commercial interests.

C

Cabo, Horacio Antonio, MD, Professor of Clinical Dermatology, University of Buenos Aires, Argentina, no financial relationships exist with commercial interests.
Calame, Antoanella, MD, Director, Compass Dermatopathology, San Diego, CA, Volunteer Clinical Professor of Dermatology, UCSD, Castle Biosciences – A(H); Compass Dermatopathology, Inc. – F(S).
Callen, Jeffrey Phillip, MD, Prof Med (Derm), Div Derm, Scho Med, U Louisville, Louisville, KY, arGEN-X – A(H); Biogen – A(H), Speaker/Faculty Education(H); Eli Lilly and Company – C(H); JAMA – B(H); UpToDate, Inc. – B(H).
Callender, Valerie D., MD, Prof, Dept Derm, Howard U Col Med, Washington, DC, Aclaris Therapeutics, Inc. – I(Grants/Research Funding); Aerolase – A(NC); Allergan, Inc – I(Grants/Research Funding), SP(H); Allergan, Inc. – C(H); Anacor Pharmaceuticals, Inc. – A(H); Avon Products, Inc. – A(H); Bayer – C(NC); Cassiopea SpA – A(H); Galderma Laboratories, L.P. – C(H); Galderma USA – I(Grants/Research Funding); Novan – I(Grants/Research Funding); PCA SKIN – A(H); Samumed, LLC – A(H); Unilever Home & Personal Care USA – A(H).
Callis-Duffin, Kristina Patrice, MD, Assocate Professor, Dept of Derm, U of Utah, Salt Lake City, UT, AbbVie – I(Grants/Research Funding), SP(H); Amgen – A(H), C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(Fees); Celgene Corporation – A(H), I(Grants/Research Funding); Eli Lilly and Company – C(H), I(Grants/

Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); Novartis – C(H), I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); Xenoport, Inc – I(Grants/Research Funding).

Cardones, Adela Rambi G., MD, Assistant Professor, Department of Dermatology, Duke University, Durham NC, no financial relationships exist with commercial interests.

Carlos, Casey Anderson, MD, PhD,Dermatology Arts, Bellevue, WA & Univ of Washington, Div of Dermatology, Seattle, WA, no financial relationships exist with commercial interests.

Carlson, John Andrew, MD, Professor, Albany Medical College, Albany, NY, no financial relationships exist with commercial interests.

Carr, David R., MD, The Ohio State University, Assistant Professor, Columbus, OH, no financial relationships exist with commercial interests.

Carrera, Cristina, MD, PhD,Dermatologist, Associate Professor, Hospital Clinic, University of Barcelona, Spain, no financial relationships exist with commercial interests.

Carruthers, Jean D.A., MD, Clin Prof, Dept Ophth, U BC, Vancouver, British Columbia, Canada, Allergan, Inc. – C(H), I(Grants/Research Funding); Alphaeon – I(Grants/Research Funding); Kythera – C(H); Kythera Biopharmaceuticals – I(H); Merz Aesthetics – C(H), I(H); Revance Therapeutics, Inc. – I(H).

Cartee, Todd, MD, Asst Professor of Dermatology, Penn State Hershey Medical Center, Hershey, PA, no financial relationships exist with commercial interests.

Carter, Joi B., MD, Assistant Professor, Dartmouth Hitchcock Medical Center, Lebanon NH, Millennium Pharmaceuticals – Independent Contractor(Fees); Soligenix, Inc – I(Fees).

Carucci, John A., MD, PhD,Chf, Mohs Surg, NYU-Langone Medical Center, New York, NY, GlaxoSmithKline – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(NC); Pfizer Inc. – I(NC).

Castelo-Soccio, Leslie, MD, PhD,Assistant Professor Pediatrics and Dermatology, The Children's Hospital of Philadelphia, Phila, PA, no financial relationships exist with commercial interests.

Caux, Frederic, PhD,Pr Frédéric Caux, Reference Center for Bullous Diseases, Avicenne Hospital, Bobigny, France, LEO Laboratories Ltd (LEO Pharma) – I(Fees); Roche Laboratories – I(Fees).

Ceilley, Roger I., MD, Clinical Professor of Dermatology , The Univ. of IA, West Des Moines, IA, Ferndale Laboratories, Inc. – Speaker/Faculty Education(H); Genentech, Inc. – Speaker/Faculty Education(H); Medicis Pharmaceutical Corporation – C(H).

Cha, Jisun, MD, Assistant Professor, Rutgers-Robert Wood Johnson Medical School, New Brunswick NJ, no financial relationships exist with commercial interests.

Chan, Aegean, MD, Mark P. Seraly, MD, PC & Associates, Dermatologist, McMurray, PA, no financial relationships exist with commercial interests.

Chan, Henry H.L., MD, PhD,Hon Clin Prof, Dept of Medicine, HKU; Visiting Scientist, Wellman Ctr for Photomedicine, MGH, USA, Access Business Group International LLC – C(Fees); Basis Medical Technologies Inc – A(OB); Cutera, Inc. – I(Grants/Research Funding); Cynosure, Inc. – C(Fees), I(Grants/Research Funding); Cytrellis Biosystems, Inc – SH(ST); Lumenis – O(EQ); McGraw-Hill Companies – O(IP); Merz Asia Pacific Pte Ltd – O(H); Quanta System S.p.A – I(Grants/Research Funding), O(EQ); Syneron, Inc. – A(H), C(OB), SH(SO); Venus Concept – I(EQ).

Chang, Anne Lynn S., MD, MD, Associate Professor of Dermatology, Stanford University School of Medicine, Stanford, CA, Galderma Laboratories, L.P. – I(Grants/Research Funding); Genentech, Inc. – I(Grants/Research Funding); Merck & Co., Inc – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Nuskin – I(Grants/Research Funding).

Chang, Mary Wu, MD, Clin Prof, Dept Derm & Ped, U CT, & Dir Pediatric Dermatology of New England, West Hartford, CT, Anacor Pharmaceuticals, Inc. – A(H); Journal Watch Dermatology – E(H); Kimberly Clark – C(NC); Pierre Fabre Dermatologie – SP(H); Procter & Gamble Company – O(H); Valeant Pharmaceuticals North America LLC – A(H).

Chang, Timothy Warren, MD, Micrographic Surgery & Dermatologic Oncology Fellow, University of California, San Francisco, no financial relationships exist with commercial interests.

Chapas, Anne M., MD, Instructor of Dermatology, Mount Sinai Medical School, NY NY, Actavis – I(Grants/Research Funding), Speaker/Faculty Education(H); Alastin Skincare, Inc – I(Grants/Research Funding); Cutera, Inc. – C(H); DUSA Pharmaceuticals, Inc. – SP(H); Galderma USA – C(H); Merz Aesthetics – C(H); Restorsea LLC – I(Grants/Research Funding); Solta Medical – I(EQ), SP(H); Syneron Candela – A(H); Syneron, Inc. – C(EQ); Valeant Pharmaceuticals North America LLC – A(H).

Chapman, M. Shane, MD, Associate Professor, Section Chief, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, Celgene Corporation – I(Grants/Research Funding); Genentech, Inc. – A(H); Pfizer Inc. – I(Grants/Research Funding).

Charli-Joseph, Yann, MD, Director of the Cutaneous Hematopathology Clinic, National Institute of Health Sciences & Nutrition, no financial relationships exist with commercial interests.
Chavan, Rahul Narayan, MD, PhD,Sacred Heart Medical Group, Pensacola, FL, no financial relationships exist with commercial interests.
Chen, Amy Yuntzu-Yen, MD, Asst Prof, Dept of Dermatology, University of Connecticut School of Medicine, Farmington, CT, UpToDate, Inc – O(H).
Chen, Cynthia L., MD, Associate Physician, The Permanente Medical Group, Pleasanton, California, no financial relationships exist with commercial interests.
Chen, Jennifer, MD, Clinical Assistant Professor, Stanford Hospital and Clinics, Redwood City, CA, no financial relationships exist with commercial interests.
Chen, Suephy C., MD, Associate Professor, Dept Derm, Emory U and Atlanta VAMC, Atlanta, GA, Astellas Pharma US, Inc – A(H).
Chien, Anna, MD, , no financial relationships exist with commercial interests.
Chilukuri, Suneel, MD, Director, Refresh Dermatology; Volunteer Clinical Faculty, Baylor College of Medicine; Houston, TX, Allergan, Inc – Speaker/Faculty Education(H); BTL Industries – Speaker/Faculty Education(H); Cynosure, Inc – Speaker/Faculty Education(H); Galderma USA – Speaker/Faculty Education(H); PCA SKIN – Speaker/Faculty Education(H); SkinMedica, Inc. – I(Grants/Research Funding); Suneva Medical, Inc. – Speaker/Faculty Education(H); Theravant Corporation – Speaker/Faculty Education(H).
Chisolm, Sarah Scott, MD, Assistant Professor, Emory University, Atlanta, GA, no financial relationships exist with commercial interests.
Chiu, Yvonne, MD, Associate Professor of Dermatology and Pediatrics; Medical College of Wisconsin; Milwaukee, WI, no financial relationships exist with commercial interests.
Choi, Jaehyuk, MD, PhD,Assistant Professor, Department of Dermatology, Northwestern University, Chicago, IL, no financial relationships exist with commercial interests.
Choi, Jennifer N., MD, Associate Professor of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, Biogen – A(H); Biotest Laboratories, Inc. – A(H); Bristol-Myers Squibb – A(H); Onyx – SP(H).
Chong, Benjamin F., MD, MSc,Assistant Professor, University of Texas Southwestern Medical Center, Dallas, TX, Biogen – I(Grants/Research Funding); Daavlin Company – I(Grants/Research Funding).
Chow, Conroy, MD, Assistant Professor, Loma Linda University, Loma Linda, California, no financial relationships exist with commercial interests.
Christensen, Sean, MD, PhD,Assistant Professor of Dermatology, Yale University School of Medicine, New Haven, CT, Novartis – I(Grants/Research Funding).
Christiano, Angela, PhD,Prof Derm & Genetics, Columbia Univ, New York, NY, no financial relationships exist with commercial interests.
Chu, Emily Y., MD, PhD,Assistant Professor of Dermatology, University of Pennsylvania, Philadelphia, PA, no financial relationships exist with commercial interests.
Chung, Catherine, MD, Assistant Professor of Dermatology and Pathology, Penn State Hershey Medical Center, Hershey, PA, no financial relationships exist with commercial interests.
Ciliberto, Heather, MD, Clinical Assistant Professor, University of Iowa Hospitals and Clinics, Iowa City, IA, no financial relationships exist with commercial interests.
Ciurea, Ana M., MD, Associate Professor, The University of Texas, M D Anderson Cancer Center, Houston, TX, no financial relationships exist with commercial interests.
Clark, Rachael, MD, PhD,Associate Prof. of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, Adaptive Biotechnologies Corporation – C(H); Dermira – C(H); Janssen Biotech – C(H).
Clark, Richard August, MD, Vice-Chair for Research and Prof, Dept Derm, Sch Med, Stony Brook Univer, NeoMatrix Formulations, Inc. – F(ST).
Clarke, Jennie T., MD, M.D. Associate Professor of Dermatology, University of Utah, Myriad Genetics Inc – E(S).
Claveau, Joel, MD, Assoc Prof Derm, Melanoma and Skin Cancer Clinic, CHUQ, Hôtel-Dieu de Québec, Canada, 3Gen, LLC – Speaker/Faculty Education(NC); MetaOptima – C(EQ).
Cockerell, Clay J., MD, Director of Dermatopathology, University of Texas Southwestern Medical Center Dallas, Castle Biosciences, Inc – C(H); Celgene Corporation – SP(H); Cockerell Dermatology Management, LLC – F(NC); Myriad Genetic Laboratories – C(H); PTV – A(NC); Sensus Healthcare – C(NC); TopMD – F(NC).
Cognetta, Armand B., MD, Chief of the Division of Dermatology, Florida State University College of Medicine, Tallahassee FL, DUSA Pharmaceuticals, Inc – SP(H); Genentech, Inc. – SP(H); MDSolarSciences Corporation – SH(ST); Melafind – I(Grants/Research Funding); Sensus Healthcare – SH(ST); XBiotech – I(Grants/Research Funding).
Cohen, Bernard, MD, Professor of Pediatrics and Dermatology, Johns Hopkins School of Medicine, sanofi-aventis – A(H).

Cohen, David Eric, MD, Professor and Vice Chair Dept of Derm, NYU School of Medicine, New York, NY, Almirall – A(H); Bickel Biotechnology – B(SO); Dermira – B(Fees), B(ST); Facilitation of International Dermatology Education – C(H); Ferndale Laboratories, Inc. – C(H); Medimetriks Pharmaceuticals, Inc. – C(H), C(SO); Novartis – C(H); Topica – B(H), B(SO).
Cohen, George F., MD, Associate Clinical Professor and Dermatology Residency program Director, Florida State University, no financial relationships exist with commercial interests.
Cohen, Joel Lee, MD, Director, AboutSkin Dermatology and DermSurgery. (Greenwood Village and Lone Tree, CO)., Allergan, Inc. – C(H), I(Grants/Research Funding); Galderma USA – C(H), I(Grants/Research Funding); LEO Pharma, US – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – C(H); Sciton Inc. – C(H).
Coldiron, Brett M., MD, Clin Assoc Prof Derm, U Cincinnati, Cincinnati, OH, no financial relationships exist with commercial interests.
Colegio, Oscar, MD, PhD,Associate Professor of Dermatology, Pathology and Surgery, Yale University, New Haven, CT, no financial relationships exist with commercial interests.
Coley, Marcelyn K., MD, Summit Medical Group, Berkeley Heights, NJ, Catalent Pharma Solutions – E(S).
Colven, Roy Mitchell, MD, Prof, Div Derm, Univ Washington, Seattle, WA, no financial relationships exist with commercial interests.
Connolly, Karen L, MD, Visiting Investigator, Memorial Sloan Kettering Cancer Center Dermatology Service, New York, NY, no financial relationships exist with commercial interests.
Cook, Joel, MD, Professor of Dermatology, Med Univ SC, no financial relationships exist with commercial interests.
Cook, Jonathan L., MD, Prof, Derm, Duke U, Durham, NC, no financial relationships exist with commercial interests.
Cooper, Kevin D., MD, Professor & Chair, Dept Derm, University Hospitals & Case Western Reserve University, Cleveland, OH, Avon Products, Inc. – C(S); BioMotiv, LLC – C(Fees); Fluence Therapeutics – O(NC); L'Oreal USA Inc. – I(Grants/Research Funding); Pfizer Inc. – C(S); Thesan Pharmaceuticals – C(S).
Cooper, Richard S., JD,McDonald Hopkins Law Firm, Cleveland, OH, American Academy of Dermatology – O(Fees); hc1.com – A(SO); Vermillion – A(SO).
Cordoro, Kelly M., MD, Assoc Prof of Derm and Peds, UCSF, San Francisco, CA, Anacor Pharmaceuticals, Inc. – A(H); Valeant Pharmaceuticals North America LLC – C(H).
Cornelius, Lynn Ann, MD, Chf Div Derm, WA U Sch of Med, St Louis, MO, Genentech, Inc. – I(Grants/Research Funding).
Cotliar, Jonathan, MD, Chief & Clinical Associate Professor, Division of Dermatology, City of Hope National Medical Center, Science 37, Inc. – C(NC); Xcovery – C(NC).
Cotsarelis, George, MD, Professor and Chair, Dept Derm, Sch Med, U PA, Philadelphia, PA, Allergan, Inc – I(Grants/Research Funding); Follica – A(H), F(SO); Johnson & Johnson Consumer Products Company – C(Fees), I(Grants/Research Funding).
Coughlin, Carrie C, MD, Assistant Professor, Division of Dermatology, Washington University School of Medicine, St. Louis MO, no financial relationships exist with commercial interests.
Council, Martha Laurin, MD, Assistant Professor of Dermatology, Washington University, St. Louis, MO, no financial relationships exist with commercial interests.
Cowen, Edward W., MD, Senior Clinician, Dermatology Branch, Natl Canc Inst, NIH, Bethesda, MD, UpToDate, Inc – O(OB).
Cox, Sue Ellen, MD, President, Aesthetic Solutions, Chapel Hill, NC; Assoc Clinical Professor UNC; Affiliate Duke Derm, Allergan, Inc. – A(H), I(OB); Bayer Pharmaceuticals – I(OB); Candesant Biomedical, Inc. – SH(ST); Cearna, Inc – A(SO); Croma-Pharma GmbH Austria – I(OB); Evolus, Inc. – I(OB); Galderma Laboratories, L.P. – Speaker/Faculty Education(H); Merz Aesthetics – SP(H); Neothetics – I(OB); Revance Therapeutics, Inc. – I(OB); TEOXANE Laboratories – I(OB); TruInject Medical Corporation – SH(ST); Valeant Pharmaceuticals North America LLC – C(H).
Craiglow, Brittany Gareth, MD, Assistant Professor, Dermatology & Pediatrics, Yale University School of Medicine, Pfizer Inc. – C(H).
Cronin, Terrence A., MD, Clin Prof, U Miami, Miami, FL, no financial relationships exist with commercial interests.
Cronin, Terrence A., MD, Asst Voluntary Prof Derm, Sch Med, U of Miami, Melbourne, FL, no financial relationships exist with commercial interests.
Cruz, Adriana, MD, Research Associate, CIDEIM, Cali, Valle del Cauca, Colombia, no financial relationships exist with commercial interests.
Cruz, Ponciano D., MD, Prof & Vice Chmn, Dept Derm, U TX SW, Dallas, TX, Galderma Laboratories, L.P. – I(Grants/Research Funding); Mary Kay Inc. – C(H); RCTS – C(H).
Culton, Donna, MD, PhD,Assistant Professor, University of North Carolina at Chapel Hill, Chapel Hill, NC, Stiefel a GSK company – O(Grants/Research Funding).

Cusack, Carrie Ann R., MD, Associate Professor, Drexel University College of Medicine,Dept of Dermatology, Philadelphia, PA, no financial relationships exist with commercial interests.

D

Dana, Ali N, MD, PhD,James J. Peters Bronx Veterans Affairs Medical Center, Bronx, New York: Director of Resident Clinic, no financial relationships exist with commercial interests.

Daniel, C. Ralph, MD, Clin Prof Derm, U MS, Jackson, Ms, Clin Prof Derm, U AL, Birminham, AL, Anacor Pharmaceuticals, Inc. – C(H); Elsevier Inc. – O(IP); Gerson Lehrman Group – A(H), C(OB); IVREA Pharmaceuticals – C(H); Kikaku – C(H); Medicis Pharmaceutical Corporation – C(H); Medimetriks Pharmaceuticals, Inc. – A(SO), C(H), I(H); Mediquest – A(H), C(OB); Meiji Seika Pharma Co., Ltd – A(H); Navigant – C(H); Novobiotics Pharmaceuticals, LLC – C(H); Nycomed Amersham – C(H); Perrigo Company – C(Fees); Polichem SA – C(H); Scisive Consulting LP – C(H); Springer Science & Business Media – O(Fees); Talima Therapeutics – C(H); Valeant Pharmaceuticals International – C(H); Visiting Professor – SP(H).

Darling, Thomas N., MD, PhD,Prof and Chair, Dept Derm, USUHS, Bethesda, MD, no financial relationships exist with commercial interests.

Darst, Marc A., MD, Darst Dermatology, Charlotte Dermatopathology, Marc Darst MD, FAAD, Private Practice, Charlotte NC,, Boehringer Ingelheim – I(Grants/Research Funding); Taro Pharm – A(H).

Davis, Carrie L., MD, Volunteer Clinical Assistant Professor of Dermatology, IU School of Medicine, Bloomington, IN, Celgene Corporation – SP(H).

Davis, Dawn M.R., MD, Associate Professor of Dermatology and Pediatrics, Mayo Clinic, Rochester, MN, no financial relationships exist with commercial interests.

Davis, Mark D.P., MD, Prof, Dept Derm, Mayo Clin, Rochester, MN, no financial relationships exist with commercial interests.

Day, Doris J., MD, Clinical Associate Professor, Dermatology, NYU Medical Center, New York, NY, Allergan, Inc - AB(H), Galderma USA - AB(H), isdin - AB(H), Lumenis – SP/Faculty Education(H), Merz Aesthetics - AB(H), MyoScience - AB(H), Neocutis - AB(H), Neothetics - AB(H), Olay - AB(H) – Solta - Medical Speaker/Faculty Education(H), Valeant Pharmaceuticals North America LLC – AB(H).

DeClerck, Brittney Kaufman, MD, Asst Professor, Pathology and Dermatology, University of Southern California, Los Angeles, CA, no financial relationships exist with commercial interests.

Del Rosario, Eunice Chavez, MD, MS,,N/A.

Del Rosso, James Q., DO,Clincal Professor Dermatology, Adjunct Faculty Touro Univ COM, Henderson, Nevada, Aclaris Therapeutics Inc. – C(H), I(Grants/Research Funding); Allergan, Inc – SP(H); Allergan, Inc. – SP(H); Anacor Pharmaceuticals, Inc. – C(H); Aqua – C(H), SP(H); Bayer – C(H), I(Grants/Research Funding), SP(H); Celgene Corporation – C(H), I(Grants/Research Funding), SP(H); Dermira – C(H); Ferndale Laboratories, Inc. – C(H); Galderma Laboratories, L.P. – C(H), I(Grants/Research Funding), SP(H); Genentech, Inc. – SP(H); Innocutis – C(H); Leo Pharma Inc. – C(H), I(Grants/Research Funding); LEO Pharma, US – SP(H); Novan – C(H), I(Grants/Research Funding); Novartis – SP(H); Novartis Pharmaceuticals Corp. – E(S); Pharmaderm – C(H), SP(H); Promius Pharma, LLC – C(H); Ranbaxy Laboratories Limited – C(H), I(Grants/Research Funding); Sebacia, Inc. – I(Grants/Research Funding); Taro Pharm – C(H); Unilever Home & Personal Care USA – A(H); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding), SP(H).

Delano, Sophia Lindsay, MD, Boston Children's Hospital, Instructor Harvard Medical School, Boston MA, no financial relationships exist with commercial interests.

DeLeo, Vincent Anthony, MD, Clinical Professor, USC, Los Angeles, Ca & Professor Emeritus, Mt. Sinai, New York, NY, The Estée Lauder Companies, Inc. – C(Fees).

Dellavalle, Robert Paul, MD, PhD,Prof, Derm Dept, U CO School of Medicine, Denver, CO, Department. of Veterans Affairs – E(S), I(Grants/Research Funding); Journal of Investigative Dermatology – Independent Contractor(OB); Journal of the American Academy of Dermatology – O(OB); Pfizer Inc. – I(Grants/Research Funding); University of Colorado – E(S); UpToDate, Inc – Independent Contractor(IP).

Desai, Seemal, MD, Clinical Assistant Professor of Dermatology, University of Texas Southwestern Medical Ctr, Dallas,TX, AbbVie – C(Fees), I(Grants/Research Funding), SP(H); Allergan, Inc – C(Fees); Anacor Pharmaceuticals, Inc. – C(Fees); Dermira – I(Grants/Research Funding); Ferndale Laboratories, Inc. – A(Fees); Foamix – I(Grants/Research Funding); Galderma Laboratories, LP – C(Fees), SP(H); Innovaderm Research Inc. – I(Grants/Research Funding); Novan – I(Grants/Research Funding); Perrigo Company – I(Grants/Research Funding); Symbio – I(Grants/Research Funding); Teva – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – C(Fees), SP(H); Watson Laboratories, Inc. – I(Grants/Research Funding).

DeVan, Marsheila, MBA,Marsheila holds a BA in Political Science from the University of California, Los Angeles a MA of Bus, no financial relationships exist with commercial interests.
Dias da Rocha, Marco Alexandre, MD, Marco Alexandre Dias da Rocha, MD, PhD - (UNIFESP/EPM São Paulo/SP - Dermatologist), Bayer – A(-Fees), SP(Fees); Galderma Brasil Ltda – SP(Fees).
Diaz, Lucia Zoraida, MD, MD, Assistant Professor of Pediatrics, University of Texas Dell Medical School, Austin, TX., no financial relationships exist with commercial interests.
Diaz, Luis A., MD, Professor, Dept Derm, U NC, Chapel Hill, NC, no financial relationships exist with commercial interests.
DiGiorgio, Catherine M, MS, MD, Laser Fellow, Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, no financial relationships exist with commercial interests.
DiGiovanna, John J., MD, Senior Research Physician, Dermatology Branch, National Cancer Institute, NIH, Bethesda, MD, no financial relationships exist with commercial interests.
Dinehart, Scott M., MD, Director, Arkansas Skin Cancer Center, Little Rock, AR, Genentech, Inc. – A(H), SP(H); Spire Learning – SP(H); Valeant Pharmaceuticals North America LLC – O(H).
Doche, Isabella I, MD, PhD,MD University of São Paulo - Sao Paulo, Brazil, no financial relationships exist with commercial interests.
Dolohanty, Lindsey Brodell, MD, Assistant Professor of Dermatology, University of Rochester Rochester, New York, no financial relationships exist with commercial interests.
Dominguez, Arturo R, MD, UT Southwestern Medical Center at Dallas,Assistant Professor, Dept. of Dermatology; Dallas, TX, no financial relationships exist with commercial interests.
Dominguez-Cherit, Judith, MD, Chief of department of dermatology Instituto Nacional de Ciencias Medicas y Nutricion Mexico, no financial relationships exist with commercial interests.
Donofrio, Lisa M., MD, AsocClinProf, DeptDerm, YaleU SchMed, NewHaven, CT, AsstClinProf, DeptDerm, Tulane U, New Orleans,LA, Allergan, Inc. – A(H), I(OB); American Society of Dermatologic Surgery – B(None Chosen); Canfield Scientific, Inc. – O(H); Fotofinder – I(H); Galderma Laboratories, L.P. – I(None Chosen); Galderma USA – C(H); Journal of Dermatologic Surgery – O(None Chosen); Kythera – I(H); Mentor Corporation – I(H), I(OB); Merz Pharmaceuticals, LLC – I(OB); Revance Therapeutics, Inc. – I(OB).
Draelos, Zoe Diana, MD, Consulting Professor, Department of Dermatology, Duke University School of Medicine, Durham, NC, Abbott Laboratories – I(Grants/Research Funding); Actavis – I(Grants/Research Funding); AGI Dermatics – I(Grants/Research Funding); Allergan, Inc. – I(Grants/Research Funding); Alphaeon – I(Grants/Research Funding); Altana – I(Grants/Research Funding); AmDerma Pharmaceuticals, LLC – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Amneal Pharmaceuticals, LLC – I(Grants/Research Funding); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); Anterios Inc. – I(Grants/Research Funding); AstraZeneca – I(Grants/Research Funding); Avon Products, Inc. – I(Grants/Research Funding); Bayer – I(Grants/Research Funding); Bayer Consumer Healthcare Pharmaceuticals – I(Grants/Research Funding); Beiersdorf, Inc. – I(Grants/Research Funding); Biorasi, LLC – I(Grants/Research Funding); Boots – C(Grants/Research Funding); Botaneco – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Chattem, Inc. – I(Grants/Research Funding); Colgate-Palmolive – I(Grants/Research Funding); Dermira – I(Grants/Research Funding); Dial Corporation – I(Grants/Research Funding); DSE Pharmaceuticals – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Elizabeth Arden – I(Grants/Research Funding); Estee Lauder – C(Grants/Research Funding); Exeltis – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding); GlaxoSmithKline – I(Grants/Research Funding); Glenmark Generics Inc. – I(Grants/Research Funding); Guthy-Renker – I(Grants/Research Funding); Helix BioMedix – I(Grants/Research Funding); Johnson & Johnson Consumer Products Company – I(Grants/Research Funding); Kao Brands – I(Grants/Research Funding); Kimberly Clark – I(Grants/Research Funding); Kythera – I(Grants/Research Funding); L'Oreal USA Inc. – I(Grants/Research Funding); La Roche-Posay Laboratoire Pharmaceutique – I(Grants/Research Funding); Lexington International LLC – I(Grants/Research Funding); Living Proof, Inc – I(Grants/Research Funding); Lumity – I(Grants/Research Funding); MakuCell, Inc. – I(Grants/Research Funding); Maruho Co., Ltd – I(Grants/Research Funding); Medicis Pharmaceutical Corporation – I(Grants/Research Funding); Merck & Co., Inc. – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); Mimetica Pty. Limited – I(Grants/Research Funding); Neocutis – I(Grants/Research Funding); Neutrogena Corporation – I(Grants/Research Funding); Niadyne

– I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Nuskin – I(Grants/Research Funding); Nycomed Amersham – I(Grants/Research Funding); Oculus – I(Grants/Research Funding); Onset Therapeutics – I(Grants/Research Funding); Otsuka Pharmaceutical Co., Ltd. – I(Grants/Research Funding); Pacific Biosciences – I(Grants/Research Funding); Paddock – I(Grants/Research Funding); Perrigo Company – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Pharmaderm – I(Grants/Research Funding); Procter & Gamble Company – I(Grants/Research Funding); Promius Pharma, LLC – I(Grants/Research Funding); Quinnova Pharmaceuticals, Inc. – I(Grants/Research Funding); Ranbaxy Laboratories Limited – I(Grants/Research Funding); RECKITT BENCKISER (ESPAÑA), S.L. – I(Grants/Research Funding); Revance Therapeutics, Inc. – I(Grants/Research Funding); Revision Skincare – I(Grants/Research Funding); Signum Biosciences, Inc. – I(Grants/Research Funding); SkinMedica, Inc. – I(Grants/Research Funding); Stiefel a GSK company – I(Grants/Research Funding); Sun Products Corporation – I(Grants/Research Funding); Suneva Medical, Inc. – I(Grants/Research Funding); Symrise – I(Grants/Research Funding); Syneron, Inc. – I(Grants/Research Funding); Taro Pharm – I(Grants/Research Funding); Teva Pharmaceuticals USA – I(Grants/Research Funding); Tolmar – I(Grants/Research Funding); TriaBeauty – I(Grants/Research Funding); Valeant Pharmaceuticals International – I(Grants/Research Funding); Vichy Laboratoires – I(Grants/Research Funding); Xenoport, Inc. – I(Grants/Research Funding); XOMA (US) LLC – I(Grants/Research Funding).

Drake, Lynn A., MD, Lect, Dept Derm, Harvard Med Sch, Boston, MA, no financial relationships exist with commercial interests.

Driscoll, Marcia S., MD, M.D., Pharm.D., Clinical Associate Professor of Dermatology, University of Maryland, Baltimore, MD, UpToDate, Inc – O(H).

Drolet, Beth Ann, MD, Prof, Derm Ped, Med Col WI, Milwaukee, WI, Pierre Fabre Dermatologie – O(Grants/Research Funding).

Duffy, Nananamibia, MD, Instructor of Dermatology, University of Rochester, Rochester NY, no financial relationships exist with commercial interests.

Duncan, Lyn M., MD, Professor of Pathology, Harvard Medical School, Chief, MGH Dermatopathology, Boston, MA, no financial relationships exist with commercial interests.

Dunnick, Cory A., MD, Cory A. Dunnick, MD. Associate Prof. of Dermatology, Univ. of Colorado and Denver VAMC, Denver, CO, Genentech, Inc. – I(Grants/Research Funding).

Durham, Alison Bates, MD, University of Michigan Health System, no financial relationships exist with commercial interests.

Duvic, Madeleine, MD, Prof Med & Derm, Derm Dept, UT - MD Anderson Cancer Ctr, Houston, TX, Allos – A(H), I(Grants/Research Funding); Angimmune LLC – I(Grants/Research Funding); Eisai Pharmaceuticals – C(H), I(Grants/Research Funding), SP(H); Innate Pharma S.A. – I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – C(H), I(Grants/Research Funding); Millennium Pharmaceuticals – C(H); Millennium Pharmaceuticals, Inc. – Data Safety Monitoring Board(H); miRagen Therapeutics, Inc. – C(H), I(Grants/Research Funding); NAAF – I(Grants/Research Funding); Seattle Genetics – A(H), I(Grants/Research Funding); Solgenix, Inc. – I(Grants/Research Funding); TetraLogic Pharmaceuticals – I(Grants/Research Funding); Therakos, Inc. – I(Grants/Research Funding).

Dyer, Jonathan A., MD, Associate Professor of Dermatology and Child Health Columbia, MO, Scioderm – I(NC).

E

Eastern, Joseph S., MD, Former Clin Asst Prof, UMDNJ; Clin Asst Prof, Seton Hall U, Newark, NJ, AbbVie – A(H), I(Grants/Research Funding), SP(H); Aqua – A(H), SP(H); Celgene Corporation – SP(H); Eli Lilly and Company – A(H), SP(H); Galderma Laboratories, L.P. – A(H), SP(H); Genentech, Inc. – A(H), SP(H); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Janssen-Ortho Inc. – A(H); Leo Pharma Inc – A(H); LEO Pharma, US – SP(H); Medimetriks Pharmaceuticals, Inc. – A(H); Novartis Pharmaceuticals Corp. – A(H), SP(H); Quinnova Pharmaceuticals, Inc. – A(H), SP(H); sanofi-aventis – SP(H); Taro Pharm – SP(H); Valeant Pharmaceuticals International – A(H), SP(H).

Edison, Karen E., MD, Prof & Chmn,Dept Derm, U Missouri, Columbia, MO, no financial relationships exist with commercial interests.

Ehrlich, Alison, MD, Professor and Chair, Dept Derm, George Washington U, Washington DC., AbbVie – I(Grants/Research Funding), SP(H); Amgen – A(H); Celgene Corporation – I(Grants/Research Funding), SP(H); Dermira – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); GlaxoSmithKline – A(H); Janssen-Ortho Inc. – I(Grants/Research Funding); Leo Pharma Inc – I(Grants/Research Funding); Merck & Co., Inc. – I(Grants/Research Funding); Regeneron – I(Grants/Research Funding).

Eichenfield, Lawrence F., MD, Chf Ped & Adol Derm, Prof Derm and Ped, U CA, Rady Child Hosp, San Diego, CA, Amgen – O(Fees); Anacor Pharmaceuticals, Inc. – C(H); Aqua – C(Fees); Astellas Pharma US, Inc – I(Fees); Celgene Corporation – C(Fees); Dermata – C(ST); Elsevier Inc. – O(IP); Galderma Laboratories, L.P. – C(H), I(Fees), SP(H); Genentech, Inc. – C(H); Kimberly Clark – I(Fees); LEO Pharma, US – C(H), I(Fees); Novan – I(Fees); Otsuka Pharmaceutical Co., Ltd. – C(H); Pierre Fabre Dermatologie – C(H), I(Fees); Ranbaxy Laboratories Limited – C(Fees); Regeneron – I(Fees); Stiefel a GSK company – I(Fees); Taro Pharm – C(H); Tioga Pharmaceuticals, Inc. – O(H); TopMD – C(SO); Valeant Pharmaceuticals International – C(H), SP(H); Wiley-Blackwell – O(H).

Eisen, Daniel Brian, MD, Professor of Clinical Dermatology, University of California Davis, Sacramento, CA, no financial relationships exist with commercial interests.

El Gamal, Emad, MD, Professor of Dermatology, Damietta Faculty of Medicine, Al-Azhar University. Egypt, no financial relationships exist with commercial interests.

Elbuluk, Nada, MD, Assistant Professor, Department of Dermatology, NYU Langone Medical Center, New York, NY, Aclaris Therapeutics Inc. – A(H).

Elenitsas, Rosalie, MD, Prof Derm, Dept Derm, U PA, Philadelphia, PA, Lippincott Williams & Wilkins – O(IP); Myriad Genetics Inc – C(Fees).

Elewski, Boni E., MD, Prof Derm, U AL, Birmingham, AL, abbvie – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Boehringer Ingelheim – I(Grants/Research Funding); Celgene Corporation – C(H), I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Hoffman-La Roche Ltd. – O(Fees); Incyte Corporation – I(Grants/Research Funding); Intendis GmbH – C(H); Janssen-Ortho Inc. – I(Grants/Research Funding); Lilly ICOS LLC – C(H); Merck & Co., Inc – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – C(H); Novan – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding); Viomet – I(Grants/Research Funding).

Eliason, Mark, MD, Associate Professor, Department of Dermatology University of Utah, Salt Lake City, Utah, Myriad Genetic Laboratories – SH(ST).

Ellis, Charles N., MD, WB Taylor Prof, Dept Derm, U MI Sch Med, Ann Arbor, MI, Celgene Corporation – C(Fees); Ferndale Laboratories, Inc. – C(H); Gilead Sciences, Inc. – C(Fees); GlaxoSmithKline – C(Fees); Lattice System – F(IP); Medimetriks Pharmaceuticals, Inc. – C(Fees); Otsuka Pharmaceutical Co., Ltd. – C(H); VisualDx – C(H), C(SO).

Elmariah, Sarina, MD, Assistant Dermatologist, Massachusetts General Hospital, Boston, MA, no financial relationships exist with commercial interests.

Elmets, Craig A., MD, Prof, Chmn, Dept Derm, U AL at Birmingham, Birmingham, AL, California Association of Winegrape Growers – I(Grants/Research Funding); Ferndale Laboratories, Inc. – C(H); Idera Pharmaceuticals, Inc. – I(Grants/Research Funding); Kyowa Hakko USA – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – Data Safety Monitoring Board(Fees); Medgenics, Inc. – SH(NC); Solgenix LLC – I(Grants/Research Funding); Vaxin – C(SO).

Elston, Dirk Michael, MD, Professor and Chair, Department of Dermatology, Medical University of South Carolina, Charleston, SC, no financial relationships exist with commercial interests.

Ely, P. Haines, MD, Clin Prof Derm, UC, Davis, CA, no financial relationships exist with commercial interests.

English, Joseph C., MD, Prof Derm, Dept Derm, U Pittsburgh, Pittsburgh, PA, no financial relationships exist with commercial interests.

Epstein, Ervin H., MD, Senior Scientist, Children's Hospital of Oakland Research Institute,no financial relationships exist with commercial interests.

Ersoy-Evans, Sibel, Prof of Derm, Hacettepe University School of Medicine, no financial relationships exist with commercial interests.

Etzkorn, Jeremy Robert, MD, Assistant Professor, Department of Dermatology, University of Pennsylvania, Philadelphia, PA, no financial relationships exist with commercial interests.

Ezzedine, Khaled, MD, Professor Khaled EZZEDINE, Department of Dermatology Hôpital Henri Mondor, 94010 Crétei FRANCE, no financial relationships exist with commercial interests.

F

Fabbrocini, Gabriella, MD, Associate Professor of Dermatology-Section of Dermatology-University Federico II-Naples-Italy, no financial relationships exist with commercial interests.

Fabi, Sabrina G., MD, Volunteer, Assistant Clinical Professor, Department of Dermatology, Univ. of California San Diego, Alastin Skincare, Inc – A(H); Allergan, Inc – Speaker/Faculty Educa-

tion(H); Kythera – I(Grants/Research Funding); Lumenis – SP(H); Merz Aesthetics – Speaker/Faculty Education(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Ulthera – Speaker/Faculty Education(H); Valeant Pharmaceuticals North America LLC – A(H); Zeltiq Aesthetics – Speaker/Faculty Education(H).

Fairley, Janet A., MD, Prof and Chair, Dept Derm, University of Iowa, and VA Medical Center, Iowa City IA,no financial relationships exist with commercial interests.

Farah, Ronda S, MD, Assistant Professor, University of Minnesota, Minneapolis, Minnesota, Inovio Pharmaceuticals, Inc – SH(NC); Pfizer Inc. – SH(NC).

Farris, Patricia, MD, Metairie, LA, Allergan, Inc. – Speaker/Faculty Education(H); ISDIN – A(H); Kythera – Speaker/Faculty Education(H); L'Oreal USA Inc. – A(H); Regimen MD – F(ST); SkinCeauticals LLC – A(H).

Fazel, Nasim, MD, DDS,Assoc Prof, University of California, Davis, Sacramento, CA, Celgene Corporation – I(Grants/Research Funding).

Femia, Alisa, MD, Assistant Professor, New York University School of Medicine, New York, NY, no financial relationships exist with commercial interests.

Ferguson, Nkanyezi Ngwenyama, MD, Clinical Assistant Professor, Department of Dermatology, University of Iowa, Iowa City, Iowa, no financial relationships exist with commercial interests.

Ferkovic, Thomas J.,Managing Partner, Medic Management Group, LLC., Akron, Ohio, Medic Management Group, LLC – F(S).

Fernandez, Anthony, MD, Staff, Depts. of Dermatology & Pathology, Cleveland Clinic, Cleveland, OH, AbbVie – I(H), SP(H); Mallinckrodt Pharmaceuticals – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H); Roche Laboratories – I(Grants/Research Funding).

Fernandez Faith, Esteban, MD, Assistant Professor, The Ohio State University College of Medicine, Columbus, OH, no financial relationships exist with commercial interests.

Ferringer, Tammie C., MD, Section Head and Fellowship Director, Dermatopathology, Geisinger Med Ctr, Danville, PA, no financial relationships exist with commercial interests.

Ferris, Laura K., MD, PhD,Associate Professor, University of Pittsburgh, Department of Dermatology, Pittsburgh, PA, Abbott Laboratories – I(OB); Amgen – I(OB); Boehringer Ingelheim – I(OB); Castle Biosciences, Inc – C(H), I(OB); Celgene Corporation – I(OB); Centocor Ortho Biotech Inc. – I(OB); DermTech International – C(H), I(OB); Eli Lilly and Company – I(OB); Janssen Pharmaceuticals, Inc – C(H); LEO Pharma, US – I(OB); Medimmune – I(OB); Pfizer Inc. – I(OB); Regeneron – I(OB).

Fett, Nicole, MD, Associate Professor, Oregon Health and Science University, Portland, Oregon, no financial relationships exist with commercial interests.

Finch, Justin J., MD, Assistant Professor, University of Connecticut Health Center, Dept of Dermatology, Farmington, CT, no financial relationships exist with commercial interests.

Fiorentino, David Franklin, MD, PhD,Professor, Dept Dermatology, Stanford University Sch Med, Stanford, CA, Idera Pharmaceuticals, Inc. – I(Fees); Johnson & Johnson Pharmaceutical Research & Development – C(H).

Fisher, Emily J., MD, Director Mohs Surgery, Kenwood Mohs, Mercy Health Physicians, Cincinnati, Ohio, no financial relationships exist with commercial interests.

Fitzgerald, Rebecca L., MD, Clinical Instructor of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA,Allergan, Inc., C(H), S(H), Galderma USA - C(H), Merz Aesthetics - C(H), S(H), Valeant Pharmaceuticals International, C(H), S(H).

Flischel, Amy, MD, Clinical Instructor of Dermatology, University of Illinois, College of Medicine, Chicago, IL, no financial relationships exist with commercial interests.

Florez, Mercedes, MD, Associate Professor, Dermatology, Herbert Wertheim College of Medicine, FIU, MIami FL, no financial relationships exist with commercial interests.

Fosko, Scott W., MD, Chair, Department of Dermatology, Mayo Clinic Florida, Jacksonville, Florida, Genentech, Inc. – A(H), C(Fees), I(Grants/Research Funding), SP(Fees).

Foulke, Galen Toye, MD, Assistant Professor, Penn State Hershey College of Medicine, PSU, Hershey PA, no financial relationships exist with commercial interests.

Fox, Lindy Peta, MD, Assoc Prof Derm, UCSF, San Francisco, CA, no financial relationships exist with commercial interests.

Fox, Matthew C., MD, Assistant Professor, Division of Dermatology, Dell Medical School, Univeristy of Texas at Austin, no financial relationships exist with commercial interests.

Francis, Shayla Orton, MD, Francis Skin Surgery and Dermatology, Centennial, co, no financial relationships exist with commercial interests.

Freeman, Esther Ellen, MD, PhD,Director MGH Global Health Dermatology, Massachusetts General Hospital, Harvard Medical School, MA, no financial relationships exist with commercial interests.

Freites-Martinez, Azael D., MD, Dermatology Service. Memorial Sloan Kettering Cancer Center New York, NY, no financial relationships exist with commercial interests.

Fried, Richard G., MD, PhD,Clin Dir, Yardley Derm and Yardley Clinical Research Associates,

Yardley, PA, Allergan, Inc. – SP(H); Centocor Ortho Biotech Inc. – SP(H); Eli Lilly and Company – I(Fees); Galderma Laboratories, L.P. – SP(H); Janssen Pharmaceuticals, Inc – I(Fees); Johnson and Johnson Consumer Products Company – A(H); Merz Aesthetics – I(EQ); Valeant Pharmaceuticals North America LLC – Speaker/Faculty Education(H).

Frieden, Ilona J., MD, Prof Derm Peds, University of California, San Francisco, CA, Pierre Fabre Dermo-Cosmétique US – C(H).

Friedlander, Sheila Fallon, MD, Professor of Dermatology & Pediatrics, UCSD/Rady Children's Hosp, San Diego,CA, Anacor Pharmaceuticals, Inc. – A(H); Exeltis – A(H); Leo Pharma Inc – A(H); Merz Pharmaceuticals, LLC – A(H), I(Grants/Research Funding); Sandoz, a Novartis company – A(H), SP(H); Valeant Pharmaceuticals International – A(H), I(H), O(Grants/Research Funding).

Friedman, Adam J., MD, Associate Professor of Dermatology, George Washington School of Medicine, Washington, D.C., Amgen – A(H), Speaker/Faculty Education(H); Biogen – A(H); Dematology Foundation – I(Grants/Research Funding); Encore Dermatology, Inc. – C(H); Exeltis – C(H); Galderma USA – C(H); GlaxoSmithKline – C(H); IntraDerm Pharmaceuticals – C(H); Janssen-Ortho Inc. – I(Grants/Research Funding); Johnson and Johnson Consumer Products Company – C(H); La Roche-Posay Laboratorie Pharmaceutique – A(H); Liquidia Technologies, Inc. – C(H); Nerium International – A(H); Novartis – A(H); Oculus innovative Sciences, Inc. – C(H); Onset Dermatologics – Speaker/Faculty Education(H); Onset Therapeutics – C(H); Orlando Dermatology Aesthetic & Clinical (ODAC) – SP(H); Pfizer Inc. – C(H); Promius Pharma, LLC – A(H), SP(H); Salvona Technologies LLC – A(H); Sanova Works – C(H); Valeant Pharmaceuticals International – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – A(H), SP(H).

Friedman, Paul M., MD, Clin Assist Prof of Derm, U TX Houston Med School, Houston, TX, Allergan, Inc – SP(H); Kybella – SP(H); Solta Medical – I(EQ).

Friedmann, Daniel Pablo, MD, Westlake Dermatology Clinical Research Center; Westlake Dermatology & Cosmetic Surgery; Austin, TX, Aclaris Therapeutics, Inc. – A(H); Allergan, Inc. – I(Fees), Speaker/Faculty Education(H); Galderma Laboratories, LP – I(Fees); Lumenis – I(EQ), I(Grants/Research Funding); Merz Aesthetics – C(H), I(Fees), Speaker/Faculty Education(H); Zeltiq Aesthetics – I(Grants/Research Funding).

Fu, Jennifer, MD, Clnical Instructor, University of California, San Francisco, San Francisco, CA, no financial relationships exist with commercial interests.

Fujita, Mayumi, MD, PhD,Professor, Dermatology, University of Colorado Anschutz Medical Campus, Aurora CO, Maruho Co., Ltd – C(-Fees); Olatec Industries LLC – C(Fees).

G

Galadari, Hassan I., MD, Assistant Professor of Dermatology, College of Medicine, UAE University, Al Ain, UAE, Allergan, Inc. – SP(H); Aqtis Medical – I(Grants/Research Funding); Merz Aesthetics – SP(H); TEOXANE Laboratories – Speaker/Faculty Education(H).

Gallagher, Thomas Casey, MD, Clinical Attending, VA Hospital, University of Colorado, Denver, CO, no financial relationships exist with commercial interests.

Garfein, Evan,Associate Professor of Surgery, Chief, Division of Plastic Surgery, Montefiore Medical Center, SIGMA Surgical – F(NC); Stryker Corporation – C(Fees).

Garg, Amit, MD, Assoc Prof and Chair, Dept of Dermatology, Hofstra Northwell School of Medicine, Lake Success, NY, AbbVie – A(H); Bristol-Myers Squibb – A(H); Eli Lilly and Company – A(H); Merck & Co., Inc – O(Grants/Research Funding); Pfizer Inc. – A(H); Valeant Pharmaceuticals North America LLC – A(H).

Garibyan, Lilit, MD, PhD,Instructor Harvard Medical School, Wellmen Center for Photomedicine, MGH Department of Dermatology, no financial relationships exist with commercial interests.

Garzon, Maria Cecilia, MD, Prof Derm & Peds at CUMC Columbia U, New York, NY, Astellas Pharma US, Inc – I(NC).

Gasbarre, Christopher C., DO,Regional Health, Spearfish, SD, no financial relationships exist with commercial interests.

Gaspari, Anthony A., MD, Prof, Dept Derm, Sch Med, U MD, Baltimore, MD, no financial relationships exist with commercial interests.

Gathers, Raechele Cochran, MD, Raechele Cochran Gathers, MD, Senior Staff Physician, Henry Ford Hospital, Detroit, Mi., no financial relationships exist with commercial interests.

Gelfand, Joel M., MD, MSCE,Professor of Dermatology and Epidemiology, Univeristy of Pennsylvania, Philadelphia, PA, AbbVie – C(H), I(Grants/Research Funding); Coherus Biosciences – Data Safety Monitoring Board(H); Eli Lilly and Company – I(Grants/Research Funding), Speaker/Faculty Education(Fees); Elsevier Inc. – O(NC); Janssen Pharmaceuticals, Inc – C(H), I(Grants/Research Funding); Merck & Co., Inc –

Data Safety Monitoring Board(H); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); Regeneron – I(Grants/Research Funding); Sanofi US Services – A(H); Valeant Pharmaceuticals North America LLC – C(H).

Gerami, Pedram, MD, Professor Derm/Dermpath Northwestern Univ Feinberg School of Med, Chicago, IL, Castle Biosciences, Inc – C(H); DermTech International – C(H); Myriad Genetics Inc – C(H).

Geronemus, Roy G., MD, Clin Prof Derm, NYU Med Ctr, Director of Laser&Skin Surgery Center of NY,New York, NY, Allergan, Inc – I(Grants/Research Funding); Allergan, Inc. – A(Grants/Research Funding); Cutera, Inc. – I(Grants/Research Funding); Cynosure, Inc – A(Grants/Research Funding), I(Grants/Research Funding); Cytrellis Biosystems, Inc – I(ST), SH(ST); Merz Aesthetics – I(Grants/Research Funding); Miramar Labs – I(Grants/Research Funding); Syneron Candela – A(Grants/Research Funding), I(Grants/Research Funding); Zeltiq Aesthetics – A(Grants/Research Funding), I(Grants/Research Funding), SH(ST).

Geskin, Larisa J., MD, Associate Professor, Dept Dermatology, Columbia University, New York, Actelion – Speaker/Faculty Education(H); Mallinckrodt Pharmaceuticals – C(H).

Ghannoum, Mahmoud A., PhD,MSc PhD, Prof Mycology, Dir, Ctr for Med Mycol, Derm Dept, Case Med Sch, U Hosp, Anacor Pharmaceuticals, Inc. – C(Fees); Astellas Pharma US, Inc – C(Fees).

Gibson, Lawrence E., MD, Prof, Dept Derm, Mayo Clin, Mayo Fndtn, Rochester, MN,no financial relationships exist with commercial interests.

Gilbert, Erin, MD, PhD,Founder and Director, Gilbert Dermatology, Brooklyn, New York, Allergan, Inc – C(H); Glowbiotics – C(Fees); Johnson and Johnson Consumer Products Company – O(Fees); Merz Aesthetics – C(H); mybody, LLC – A(H).

Gilchrest, Barbara Ann, MD, Consultant, Massachusetts General Hospital, Boston, MA and Harvard Medical School, ChromaDerm – F(IP); Living Proof, Inc – A(H).

Gill, Melissa, MD, Medical Director, SkinMedical Research and Diagnostics, Dobbs Ferry, NY, Bostwick Laboratories, Dermatocor Division – Independent Contractor(Fees); Castle Biosciences, Inc – A(Fees); Edimer Pharmaceuticals – C(Fees); Park Madison Laboratories, Inc. – C(Fees).

Ginsberg, Brian Alan, MD, Assitant Professor, The Mount Sinai Hospital, New York, NY, no financial relationships exist with commercial interests.

Giordano, Cerrene, MD, Dermatologic Surgery Fellow, Memorial Sloan Kettering Cancer Center, New York, NY, no financial relationships exist with commercial interests.

Gladstone, Hayes B., MD, President, Gladstone Clinic, San Ramon, CA, Syneron Candela – Speaker/Faculty Education(H).

Glaser, Dee Anna, MD, Prof, Interim Chair Dept Derm, St. Louis U, St. Louis, MO, Allergan, Inc. – I(Grants/Research Funding), O(H); Brickell Biotech, Inc. – I(Grants/Research Funding); Dermira – A(H), I(Grants/Research Funding); Forest Laboratories – C(NC); Galderma Laboratories, L.P. – A(H); Galderma Research & Development, LLC – I(Grants/Research Funding); Merz Aesthetics – I(Grants/Research Funding); Miramar Labs – C(H); Strathspey Crown – I(Grants/Research Funding); Unilever Home & Personal Care USA – A(H).

Glogau, Richard Gordon, MD, Clin Prof Derm, UCSF, San Francisco, CA, Allergan, Inc. – A(H), C(OB), I(Grants/Research Funding); Galderma USA – C(H); Gerson Lehrman Group – C(-Fees); Kythera Biopharmaceuticals – A(H), I(Grants/Research Funding); Merz Aesthetics – C(OB); Q-Med – Data Safety Monitoring Board(Fees); Revance Therapeutics, Inc. – C(OB), I(OB).

Goh, Carolyn, MD, Assistant Clinical Professor of Dermatology, David Geffen School of Medicine - UCLA, Los Angeles, CA, no financial relationships exist with commercial interests.

Gold, Michael H., MD, Gold Skin Care Center, TN Clin Rsch Ctr, Nashville, TN, Aerolase – SH(H); Alma Lasers – SP(H); Clarisonic – A(ST), SP(H); DermTech International – SH(-SO); EndyMed Medical Inc. USA – I(Grants/Research Funding), SP(H); Home Skinovations – I(OB); Invasix – SP(H); Kythera – SP(H); Lumenis – SP(H); Medimetriks Pharmaceuticals, Inc. – A(SO); Merz Pharmaceuticals, LLC – SP(H); Neothetics – I(Grants/Research Funding), SP(H); Syneron, Inc. – SP(H); Venus Concept – C(SO), SP(H).

Goldberg, David J., MD, JD,Clin Prof, Derm, Icahn Sch of Med at Mt. Sinai; Adjunct Prof, Law, Fordham Law School, New York, NY, Allergan, Inc. – I(Grants/Research Funding); Alma Lasers – I(Grants/Research Funding); Almirall – C(S); Aquavit Pharmaceuticals – E(SO); Cutera, Inc. – I(Grants/Research Funding); EndyMed Medical Inc. USA – Speaker/Faculty Education(S); Foamix – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding); InMode MD Ltd – C(Grants/Research Funding); LaLumiere, LLC – A(S); Leo Pharma Inc – I(Grants/Research Funding);

Neothetics – I(Grants/Research Funding); Novan – I(Grants/Research Funding); Sebcaia, Inc – I(Grants/Research Funding); Sensus Healthcare – C(Fees); Sienna Biopharmaceuticals – I(Grants/Research Funding); Stratapharma – I(Grants/Research Funding); Syneron, Inc. – I(Grants/Research Funding), SP(H).

Goldberg, Leonard Harry, MD, DermSurg Associates Director, Houston, TX; Clin Prof of Dermatology UT Houston, TX, no financial relationships exist with commercial interests.

Goldberg, Lynne J., MD, Professor of Dermatology and Pathology, Boston University School of Medicine, Boston, MA, Living Proof, Inc – C(Fees).

Goldberg, Matthew S, MD, MedStar Georgetown University Hospital/Washington Hospital Center Dermatology, Washington, DC, no financial relationships exist with commercial interests.

Goldenberg, Gary, MD, Assistant Clinical Prof of Dermatology, Mt Sinai School of Medicine, AbbVie – SP(H); Allergan, Inc – C(H); Anacor Pharmaceuticals, Inc. – C(H); Bayer – SP(H); Bayer Pharmaceuticals – C(H); Castle Biosciences – SP(H); Celgene Corporation – C(H), SP(H); Dermira – A(H); Eli Lilly and Company – C(Fees), SP(H); Galderma USA – SP(H); Genentech, Inc. – C(H); Janssen Pharmaceuticals, Inc – C(H); Leo Pharma A/S – I(Grants/Research Funding); LEO Pharma, US – C(H), SP(H); MelaSciences – C(H); Novartis Pharmaceuticals Corp. – C(H), SP(H); Pfizer Inc. – C(H); Pharmaderm – A(H), I(Grants/Research Funding), SP(H); Ranbaxy Laboratories Limited – C(H); Stiefel a GSK company – C(H), I(Grants/Research Funding); Taro Pharm – C(Fees); Teva Pharmaceuticals USA – C(Fees); Valeant Pharmaceuticals North America LLC – C(H), I(Grants/Research Funding), SP(H); Xoft – C(H).

Goldman, Mitchel Paul, MD, Vol Clin Prof, Derm, UC, San Diego, CA, Allergan, Inc. – A(Grants/Research Funding), I(Grants/Research Funding); DUSA Pharmaceuticals, Inc – I(Grants/Research Funding); Galderma USA – C(H), I(Grants/Research Funding); Lumenis – C(Fees), I(EQ); Merz Aesthetics – C(Grants/Research Funding), I(Grants/Research Funding); Sienna Biopharmaceuticals – C(Fees), I(Grants/Research Funding); SkinMedica, Inc. – C(H); SkinMedica, Inc. – I(Grants/Research Funding); Solta Medical – I(Grants/Research Funding); Syneron, Inc. – I(EQ); Valeant Pharmaceuticals International – C(H).

Gomez, Minerva, MD, Professor, Dermatology Department University Hospital, UANL, Monterrey NL Mexico, no financial relationships exist with commercial interests.

Gonzalez, Mercedes, MD, Clinical Assistant Professor, Department of Dermatology, University of Miami, Miami, FL, Encore Dermatology, Inc. – SP(H); Pierre Fabre Dermatologie – C(H).

Gordon, Kenneth B., MD, Professor and Chair, Medical College of Wisconsin, AbbVie – C(H), I(Grants/Research Funding); Amgen – C(H), I(Grants/Research Funding); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Celgene Corporation – A(H), I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); Lilly ICOS LLC – A(H); Merck & Co., Inc. – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H); Pfizer Inc. – A(H); Sun Pharmaceutical Industries Ltd. – C(H).

Gordon, Shayna, MD, Mohs Fellow, Washington University in St. Louis, MO, no financial relationships exist with commercial interests.

Gottlieb, Alice B., MD, PhD,Professor of Dermatology, New York Medical College, Valhalla, NY, Abbott Laboratories – A(H), C(H), I(Grants/Research Funding); AbbVie – C(H), I(Grants/Research Funding), SP(H); Aclaris Therapeutics, Inc. – C(NC); Actelion – A(H); Akros Pharma, Inc. – C(H); Amgen – A(H), C(H), I(Grants/Research Funding), O(Grants/Research Funding); Amicus Therapeutics – C(H); Astellas Pharma US, Inc – A(H); Baxalta Incorporated – C(H); Beiersdorf, Inc. – A(H); BMS – A(H); Canfite – C(H); Catabasis Pharmaceuticals, Inc – Data Safety Monitoring Board(H); Celgene Corporation – A(H), C(H), I(Grants/Research Funding); Coronado Biosciences – A(H), I(Grants/Research Funding); Crescendo Bioscience, Inc. – C(NC); CSL Behring – C(H); DermiPsor – O(H); Dr. Reddy – C(H); DUSA Pharmaceuticals, Inc – C(H); Genentech, Inc. – A(H); GlaxoSmithKline – C(H); Immune Control – I(Grants/Research Funding); Incyte Corporation – C(H); Janssen-Ortho Inc. – A(H), I(H); Karyopharm Therapeutics – O(NC); KPI Therapeutics, Inc. – C(H); Lerner Medical Devices, Inc. – I(Grants/Research Funding); Lilly ICOS LLC – C(H), I(Grants/Research Funding); Meiji Seika Pharma Co., Ltd – C(H); Merck & Co., Inc – I(Grants/Research Funding); Merck & Co., Inc. – C(NC); Mitsibushi Pharma – C(H); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Novo Nordisk A/S – A(H), I(Grants/Research Funding); Pfizer Inc. – A(H), I(Grants/Research Funding); sanofi-aventis – C(H); Seiji Seika Pharma Co., Ltd – C(H); Sun Pharmaceutical Industries Ltd. – C(H); Takeda Pharmaceuticals

USA Inc – C(H); Teva – C(H); UCB – A(H), I(Grants/Research Funding); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – C(H); Vertex Pharmaceuticals, Inc. – C(H); Xenoport, Inc – I(Grants/Research Funding); Xenoport, Inc. – C(H).

Graber, Emmy M., MD, MBA,Boston, MA, Allergan, Inc – A(H).

Grando, Sergei A., MD, PhD,UC Irvine, CA, no financial relationships exist with commercial interests.

Granstein, Richard D., MD, Chmn, Dept Derm, Weill Cornell Medicine, New York, NY, Castle Biosciences, Inc – A(Fees); Elysium Health, Inc. – A(SO); Galderma Laboratories, LP – A(SO); Velius, LLC – A(SO).

Grant-Kels, Jane Margaret, MD, Prof Derm, Peds, Path;, Chair Emeritus, Derm Dept; Dir Cut Onc Ctr ,Sch Med, U CT, Farmington, CT, Melafind – O(ST).

Graves, Michael S, MD, Southwest Skin Cancer & Vein Clinic, Austin, TX, no financial relationships exist with commercial interests.

Green, Courtney S, MD, Mohs Surgery/General Dermatology, Kansas City Skin & Cancer Center, Kansas City, Missouri, no financial relationships exist with commercial interests.

Green, Jeremy, MD, MD Skin Associates of South Florida & Clinical Assistant Professor UMiami Dermatology, Miami, FL, Allergan, Inc – A(H), I(Grants/Research Funding), SP(H); BioPharmX – I(Grants/Research Funding); Brickell Biotech, Inc. – I(Grants/Research Funding); Cutera, Inc. – I(Grants/Research Funding), SP(H); Cynosure, Inc – SP(H); Galderma Laboratories, L.P. – I(Grants/Research Funding); Galderma USA – A(H); Lutronics, Inc. – A(H); Merz Aesthetics – A(H), I(Grants/Research Funding), SP(H); Neothetics – I(Grants/Research Funding); Revance Therapeutics, Inc. – O(Grants/Research Funding); Sienna Labs, Inc. – A(H), I(Grants/Research Funding); Valeant Pharmaceuticals International – I(Grants/Research Funding), SP(H).

Green, William H., MD, Assistant Prof of Derm, Proc. Derm Fellowship Co-Dir @ FSUCOM; Dermatology Associates of Tallahassee, no financial relationships exist with commercial interests.

Greenway, Hubert T., MD, Chmn Derm Surg/Mohs, CEO Emeritus, Scripps Clinic, La Jolla, CA, Consortium for Global Education – A(NC), SP(NC); Superfoods RX – F(ST); UCSD, Anat/Surg CME Course – F(H), SP(NC).

Greer, Kenneth E., MD, Former Chair and Professor of dermatology at the university , Dept Derm, U VA, Charlottesville, VA, no financial relationships exist with commercial interests.

Grekin, Roy C., MD, Prof, Dept Derm, UCSF, San Francisco, CA, no financial relationships exist with commercial interests.

Grichnik, James M., MD, PhD,Director, Scully-Welsh Cancer Center, Clearview Diagnostics – A(H); Digital Derm, Inc – F(ST); Galileo Group – C(ST); Novartis – C(Fees).

Griffith, James L, MD, MSc, resident, physician, Henry Ford Health System, Detroit, MI.

Grimes, Pearl E., MD, Clin Prof, Div Derm, UCLA, Los Angeles, CA, Allergan, Inc. – C(H), I(Grants/Research Funding); Clinuvel – I(H); Galderma Laboratories, L.P. – C(Grants/Research Funding), C(H); Kythera – I(H); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); Obagi Medical Products – I(H); Procter & Gamble Company – C(H); Suneva Medical, Inc. – I(H).

Guevara, Bryan, MD, Dept of Derm; Southern Philippines Medical Center, Davao, Philippines. no financial relationships exist with commercial interests.

Guitart, Joan, MD, Prof of Derm and Path, Northwestern U, Chicago, IL, Actelion – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – A(Fees); Soligenix, Inc – I(Grants/Research Funding); Tetralogic Pharmaceuticals – I(Grants/Research Funding).

Guitera, Pascale, MD, PhD,A/Pr Sydney Uni, Fellow Australasian College and French Society of Derm., PhD., Caliber Imaging and Diagnostics Inc. – Speaker/Faculty Education(Grants/Research Funding).

Gulbasaran, Fatmagul,Celal Bayar Uni ,Dept of Derm, Manisa, Turkey, no financial relationships.

Gupta, Aditya K., MD, PhD,Mediprobe Research Inc., London, ON, Canada, Moberg Derma – C(Fees); MOE Medical Devices LLC – I(Grants/Research Funding); NuvoLase, Inc – I(Grants/Research Funding); Sandoz, a Novartis company – A(Fees); Valeant Pharmaceuticals International – I(Grants/Research Funding).

Gutierrez Mendoza, Daniela, MD, Talapan, Mexico, no financial relationships exist with commercial interests.

Guttman, Emma, MD, PhD,Professor, Dermatology Department, Mount Sinai School of Medicine, NY, NY, AbbVie – C(H); Almirall – C(H); Anacor Pharmaceuticals, Inc. – C(H); Asana Biosciences, LLC – C(H); Celgene Corporation – A(H), C(H), I(Grants/Research Funding); Dermira – A(H), C(H); Eli Lilly and Company – C(H), I(Grants/Research Funding); Galderma Research & Development, LLC – A(H), C(H); Glenmark Generics Inc. – B(H), C(H), I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – C(H); Leo Pharma Inc – C(H), I(Grants/Research Funding); Medimmune – A(H), C(H), I(Grants/Research Funding); Mitsibushi Pharma – C(H); Novartis – A(H), C(H), I(Grants/Research Funding); Pfizer Inc. – A(H), C(H); Regeneron – A(H), C(H); Regeneron Pharmaceuticals, Inc. – I(Grants/Research Fund-

ing); sanofi-aventis – C(H); Sanofi/Regeneron – B(H); Stiefel a GSK company – C(H); Vitae Pharmaceuticals – C(H), I(Grants/Research Funding).

H

Haemel, Anna, MD, Assistant Professor, UCSF Dermatology, San Francisco, CA, no financial relationships exist with commercial interests.

Haggstrom, Anita N., MD, Associate Professor, Dermatology and Pediatrics, Indiana University, Indianapolis, IN, no financial relationships exist with commercial interests.

Hajar-Serviansky, Tamar, MD, Dermatology resident Oregon Health & Science University, Portland OR, no financial relationships exist with commercial interests.

Hall, Anthony P., MBBS,Associate Professor, School of Medicine, Deakin University. Skin and Cancer Foundation (Inc), no financial relationships exist with commercial interests.

Hall, Russell P., MD, Prof Derm, Duke U Med Ctr, Durham, NC, Dermatology Foundation- S(H), Genentech, Inc. - C(H), Novan - C(H) , Roche Laboratories Data Safety - Monitoring Board(H), Society for Investigative Dermatology - Other(H), Stiefel a GSK company - PI(Grants/ Research Funding), Syntimmune, Inc. - C(H), Centocor Ortho Biotech Inc. - PI(Grants/Research Funding), National Institutes of Health - PI(Grants/Research Funding).

Halpern, Allan C., MD, Chief, Dermatology Service, MSKCC, New York, NY, Caliber Imaging and Diagnostics Inc. – A(OB); Canfield Scientific, Inc. – C(OB); DermTech International – C(OB); Janssen Research & Development, LLC – C(OB); Quintiles Pharma – Data Safety Monitoring Board(OB); SciBASE – C(OB).

Hamzavi, Iltefat H., MD, Senior Staff Physician, Henry Ford Hospital, Detroit, MI AND Hamzavi Dermatology, Abbott Laboratories – I(Fees); AbbVie – A(NC); Allergan, Inc. – I(Grants/Research Funding); Amgen – I(Fees); ChromaDerm – C(Fees); Clinuvel – I(Fees); Daavlin Company – I(EQ); Dow Pharmaceutical Sciences, Inc. – I(Fees); Estee Lauder – I(Fees); Ferndale Laboratories, Inc. – I(Fees); Galderma Laboratories, L.P. – I(Fees); Microdermis Corporation – I(Fees), I(Grants/Research Funding); Pfizer Inc. – I(Fees).

Hand, Jennifer L., MD, Assistant Professor of Dermatology, Pediatrics and Medical Genetics, Mayo Clinic, Rochester, MN, UpToDate, Inc – C(IP).

Hanke, C. William, MD, Clin Prof, Sch Med, IN U, Indianapolis, IN, Allergan, Inc. – A(H), I(Grants/Research Funding); Dermavance – I(Grants/Research Funding); Educational Testing and Assessment Systems, Inc. (ETAS) – O(H); Elsevier Inc. – O(IP); Genentech, Inc. – I(Grants/Research Funding), SP(H); Informa HealthCare – O(IP); Kythera – I(Grants/Research Funding); LEO Pharma, US – I(Grants/ Research Funding), SP(H); Neothetics – I(Grants/Research Funding); Orlando Dermatology Aesthetic & Clinical (ODAC) – C(H); Sanova Works – O(H); Springer Science & Business Media – O(IP).

Hanlon, Allison, MD, PhD,Vanderbilt Dermatology, Nashville, TN, Merck & Co., Inc – C(Fees).

Harfmann, Katya, MD, Clinical Assistant Professor of Pediatric Dermatology, Nationwide Children's Hospital, Columbus, OH, no financial relationships exist with commercial interests.

Harman, Karen,Consultant Dermatologist, University Hospitals Leicester, Leicester Royal Infirmary, Leicester, Uk, no financial relationships exist with commercial interests.

Harmon, Christopher B., MD, Surgical Dermatology Group, Birmingham, Alabama, no financial relationships exist with commercial interests.

Harmon, Gerald E.,American Medical Association,no financial relationships exist with commercial interests.

Harms, Kelly L, MD, PhD,Assistant Professor, Department of Dermatology, University of Michigan, Ann Arbor, MI, no financial relationships exist with commercial interests.

Harp, Joanna L., MD, Assistant Professor of Dermatology, Weill Cornell Medical College, New York, New York, no financial relationships exist with commercial interests.

Harper, Julie Claire, MD, Clin Assoc Prof, Dept Derm, U AL Med Ctr, Birmingham, AL, Allergan, Inc – SP(H); Bayer Pharmaceuticals – I(Fees), O(H); BioPharmX – A(H); Dermira – A(H); Galderma Laboratories, L.P. – C(H); Galderma USA – SP(H); La Roche-Posay Laboratoire Pharmaceutique – SP(H); Novan – A(H); Promius Pharma, LLC – SP(H); Valeant Pharmaceuticals North America LLC – SP(H).

Harris, John, MD, PhD,Associate Professor of Dermatology, UMass Medical School, Worcester, MA, AbbVie – C(H), I(Grants/Research Funding); Aclaris Therapeutics, Inc. – C(Fees); Celgene Corporation – I(Grants/Research Funding); Combe Incorporated – C(Fees); Concert Pharmaceuticals – A(H); Genzyme Corporation – I(Grants/Research Funding); Mitsibushi Pharma – C(H); Novartis – C(Fees); Pfizer Inc. – C(H), I(Grants/Research Funding); Stiefel a GSK company – I(Grants/Research Funding).

Hartman, Rebecca, MD, MPH, Harvard Combined Dermatology Residency Training

Program, no financial relationships exist with commercial interests.

Haun, Paul, MD, MS,Assistant Professor, University of Pennsylvania, Philadelphia, PA, no financial relationships exist with commercial interests.

Hawryluk, Elena B., MD, PhD,Assistant Professor of Dermatology, Harvard Medical School, Boston, MA, Foundation Medicine, Inc – E(SO); Gritstone Oncology – E(S); UpToDate, Inc – O(OB).

Haynes, Harley A., MD, Vice Chairman Emeritus, Dept of Dermatology, BWH, Prof Derm, Harvard Med Sch, Boston, MA, no financial relationships exist with commercial interests.

Hazen, Paul Gregory, MD, Clinical Professor of Dermatology, Case-Western Reserve University, Cleveland, OH,N/A.

Heath, Candrice R, MD, Premier Derm and Cosmetic Surgery, Newark, DE, no financial relationships exist with commercial interests.

Hebert, Adelaide A., MD, Prof Derm & Ped, U TX, Houston, TX, Allergan, Inc. – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Anacor Pharmaceuticals, Inc. – A(H); Astellas Pharma US, Inc – I(Grants/Research Funding); Bayer – SP(H); Cassiopia – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Chugai Pharma – I(Grants/Research Funding); Department of DEFENSE – O(Grants/Research Funding); Dermira – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), SP(H); GlaxoSmithKline – A(H), Data Safety Monitoring Board(H), I(Grants/Research Funding); Healthpoint – I(Grants/Research Funding); Intendis, Inc. – SP(H); Medimetriks Pharmaceuticals, Inc. – I(Grants/Research Funding); Menarini Group – SP(H); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); NIH – I(Grants/Research Funding); Novan – I(H); Novartis Pharmaceuticals Corp. – O(H); Onset Therapeutics – SP(H); Pharmaderm – A(H); PPD Inc. – I(Grants/Research Funding); Prim-Med – SP(H); Promius Pharma, LLC – A(H); Promius Pharmaceuticals – A(H), I(Grants/Research Funding); Regeneron – Data Safety Monitoring Board(H); Shionogi USA – A(IP); Sinclair Pharma – SP(H); Stiefel a GSK company – A(H); TopMD – I(Grants/Research Funding); Valeant Pharmaceuticals International – A(H), SP(H); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding).

Hectorne, Kathleen Julie, MD, Mayo Clinic and Mayo Health System, Clinical Instructor , Rochester and Austin, MN, no financial relationships exist with commercial interests.

Heffernan, Michael P., MD, San Luis Dermatology, AbbVie – C(H), I(Grants/Research Funding); Eli Lilly and Company – C(H), Speaker/Faculty Education(H); Innovaderm Research Inc. – I(Grants/Research Funding); Merck Serono – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding).

Helfrich, Yolanda Rosi, MD, Associate Professor, University of Michigan Department of Dermatology, Ann Arbor, Michigan, Amgen – I(Grants/Research Funding); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); Boehringer Ingelheim – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding); Novartis – I(Grants/Research Funding).

Helms, Stephen E., MD, Professor Department of Dermatology University of Mississippi Medical Center, Jackson, Mississippi, no financial relationships exist with commercial interests.

Hernandez, Claudia, MD, Associate Professor Dermatology, Rush University Medical Center, Chicago, IL, no financial relationships exist with commercial interests.

Hertl, Michael, MD, Michael Hertl, MD, Professor and Chairman, Department of Dermatology, University of Marburg, Germany, Biotest Laboratories, Inc. – I(Grants/Research Funding); Fresenius Medical Care – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Roche Laboratories – A(H).

Hexsel, Doris M., MD, Dermatologist, Medical Director of Brazilian Center for Studies in Dermatology (Porto Alegre,Brazil), Galderma Laboratories, L.P. – A(Fees); Galderma Research & Development, LLC – I(Grants/Research Funding); Merz Aesthetics – C(Fees).

Heymann, Warren R., MD, Hd, Div Derm, Prof Med and Ped, Cooper Medical School of Rowan University, Camden, NJ, no financial relationships exist with commercial interests.

High, Whitney A., MD, JD,Assoc Prof, Director, Depts of Derm & Path , U of Colorado, Denver, CO, no financial relationships exist with commercial interests.

Hinshaw, Molly A., MD, Associate Professor, UWSMPH, Madison, WI, Accure Medical, LLC – F(ST).

Ho, Allen Wayne, MD, PhD, Harvard Combined Dermatology Residency program, no financial relationships exist with commercial interests.

Hoang, Mai, MD, Associate Professor of Pathology, Harvard Medical School and Massachusetts General Hospital, Boston, no financial relationships exist with commercial interests.

Hoffman, Melissa B, MD, Dermatology resident, Winston Salem, NC, no financial relationships exist with commercial interests.
Hofmann-Wellenhof, Rainer, MD, Assoc. Professor, Dept. of Dermatology, Medical University Graz, Graz, Austria, Derm Tech International – O(OB); e-derm-consult GmbH – F(OB); Elsevier Inc. – O(H); Fotofinder – O(EQ); GlaxoSmithKline – I(OB); Janssen-Cilag – I(OB); La Roche-Posay Laboratorie Pharmaceutique – O(H); Melafind – C(OB); SciBASE – I(OB); Springer Science & Business Media – O(H).
Holmes, Todd E., MD, Associate Professor, University of Vermont Medical Center, Burlington, VT, no financial relationships exist with commercial interests.
Hordinsky, Maria K., MD, Prof & Hd, Dept Derm, U MN, Minneapolis, MN, Allergan, Inc. – I(Grants/Research Funding); Astellas Pharma US, Inc – I(Grants/Research Funding); Concert Pharmaceuticals – C(Fees); Incyte Corporation – O(Grants/Research Funding); Procter & Gamble Company – C(H); UpToDate, Inc – I(Grants/Research Funding).
Horn, Thomas D., MD, Massachusetts General Hospital Dermatology, Harvard Medical School, American Board of Dermatology – B(S); Squarex – B(S); Type IV Technologies – F(ST).
Hornyak, Thomas J., MD, PhD,Chief, Derm, VA Maryland HCS;Assoc Prof Derm&Biochem/Mol Biol, U Maryland Sch of Med, Baltimore, MD, N/A.
Hossler, Eric Winfield, MD, Program Director, Dermatology; Associate, Dermatopathology, Geisinger Medical Ctr, Danville, PA, no financial relationships exist with commercial interests.
Hruza, George J., MD, Clin Prof Derm/Otolaryngol, St Louis U, St Louis, MO, Amgen – SH(NC); Express Scripts (formerly Medco Health Solutions) – SH(NC); Johnson & Johnson Consumer Products Company – SH(NC); MD Complete – SH(NC); Merck & Co., Inc. – SH(NC); Pfizer Inc. – SH(NC); Procter & Gamble Company – SH(NC); Pulse Biosciences – A(H); Teva – SH(NC); Unilever – SH(NC).
Hsu, Christophe F., MD, Global Dermatology Information Portal - Geneva, Switzerland, Dermatologica Helvetica – E(S); Journal of the American Academy of Dermatology – O(NC).
Hsu, Sylvia, MD, Professor and Chair, Dept Derm, Temple University School of Medicine, AbbVie – A(H); Amgen – A(H); Centocor Ortho Biotech Inc. – I(Fees); Eli Lilly and Company – A(H); Janssen-Ortho Inc. – A(H); Novartis – A(H); Promius Pharma, LLC – A(H); Ranbaxy Laboratories Limited – A(H); Valeant Pharmaceuticals North America LLC – A(H).
Huang, Jennifer T., MD, Assistant Professor of Dermatology, Boston Children's Hospital, Harvard Medical School, Boston, MA, no financial relationships exist with commercial interests.
Huang, William, MD, Assistant Professor and Residency Program Director, Wake Forest University Department of Dermatology, Galderma Laboratories, LP – SP(H); Merz Pharmaceuticals, LLC – I(NC); Roche Laboratories – I(NC); XOMA (US) LLC – I(NC).
Hughey, Lauren C., MD, Village Dermatology; Clinical Assoc Prof, Dept Derm, U of AL, Birmingham, AL, Actelion – C(Fees).
Humphrey, Shannon, MD, MD FRCPC FAAD, Clinical Assistant Professor, Department of Dermatology & Skin Science UBC Vancouver, Allergan, Inc. – I(Grants/Research Funding); Cutanea Life Sciences – I(H); Evolus, Inc. – I(H); Galderma Laboratories, L.P. – SP(H); Galderma Laboratories, LP – A(H); GlaxoSmithKline – C(H); Johnson & Johnson Consumer Products Company – C(H); Kythera Biopharmaceuticals – I(Grants/Research Funding); L'Oréal France – SP(H); Merz Aesthetics – C(H); Revance Therapeutics, Inc. – C(H), SP(H); Sienna Biopharmaceuticals – C(H); Zeltiq Aesthetics – I(Grants/Research Funding).
Hunt, Raegan D., MD, PhD,Assistant Professor of Dermatology and Pediatrics, Baylor College of Medicine, Houston, TX, no financial relationships exist with commercial interests.
Hurley, M. Yadira, MD, Prof, Dir Dermpath Fellowship, Dir Div Dermpath, Dept Derm, St. Louis U, St. Louis, MO, Abbott Laboratories – I(Grants/Research Funding); AbbVie – I(Grants/Research Funding); Actelion – C(H), I(Grants/Research Funding), SP(H), Speaker/Faculty Education(H); Amgen – I(Grants/Research Funding); Anacor Pharmaceuticals, Inc. – O(Grants/Research Funding); AstraZeneca – I(Grants/Research Funding); Castle Biosciences – A(H); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); Genentech, Inc. – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Regeneron – I(Grants/Research Funding); XOMA (US) LLC – I(Grants/Research Funding).
Hurst, Eva A., MD, Associate Professor, Washington University School of Medicine, St. Louis, MO, no financial relationships exist with commercial interests.
Hussain, Sadaf, MD, Boston Children's Hospital/Harvard Medical School, Attending Dermatologist, Boston, MA, no financial relationships exist with commercial interests.

Hussain, Walayat, MBChB,Consultant Dermatologic Surgeon, Leeds Teaching Hospitals NHS Trust, Leeds, UK, no financial relationships exist with commercial interests.

I

Ibrahimi, Omar, MD, PhD,Founding Medical Director, Connecticut Skin Institute, Stamford, CT, Cutera, Inc. – SH(ST), SP(H); kythera – SH(ST); Living Proof, Inc – I(Grants/Research Funding); Lumenis – I(Grants/Research Funding); Lutronics, Inc. – I(Grants/Research Funding); Merz Aesthetics – SP(H); Neothetics – SH(ST); Procter & Gamble Company – SH(ST); Zeltiq Aesthetics – SH(NC).

Introcaso, Camille E., MD, Dermatologist, Pennsylvania Center for Dermatology, Philadelphia PA, no financial relationships exist with commercial interests.

Ioffreda, Michael D., MD, Prof, Dept Derm, Col Med, PA St, Hershey, PA, no financial relationships exist with commercial interests.

Islam, AQM Serajul,Professor of Dermatology, Chittagong Medical College; President, Bangladesh Dermatological Soceity., no financial relationships exist with commercial interests.

J

Jabbari, Ali, MD, Florence Irving Assistant Professor of Dermatology at CUMC, Columbia University, no financial relationships exist with commercial interests.

Jacks, Stephanie K, MD, Assistant Professor, Departments of Dermatology/Pediatrics, University of Mississippi Medical Center, Galderma Laboratories, L.P. – O(OB).

Jackson, J. Mark, MD, Clinical Professor of Medicine and Dermatology, University of Louisville Div of Derm, Louisville, KY, AbbVie – C(H), I(Grants/Research Funding); Amgen – C(H), I(Grants/Research Funding); Celgene Corporation – C(Fees), I(Grants/Research Funding); Galderma Laboratories, L.P. – C(H), I(Grants/Research Funding); Genentech, Inc. – C(H); Janssen-Ortho Inc. – A(H), I(Grants/Research Funding); Johnson & Johnson Pharmaceutical Research & Development – C(H), I(Grants/Research Funding); Lilly ICOS LLC – C(H), I(Grants/Research Funding); Medimetriks Pharmaceuticals, Inc. – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Promius Pharmaceuticals – A(H), C(H); Quinnova Pharmaceuticals, Inc. – A(H); Topica – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – C(H).

Jackson, Jeremy, MD, Assistant Professor of Dermatology, University of Mississippi Medical Center, Jackson, MS, AbbVie – I(H); Actelion – I(Grants/Research Funding), SP(H); Celgene Corporation – SP(H); DUSA Pharmaceuticals, Inc – SP(H).

Jackson-Richards, Diane M., MD, Senior Staff Dermatologist, Henry Ford Health Systems, no financial relationships exist with commercial interests.

Jacob, Sharon E., MD, Professor, Dermatology Loma Linda University and Section Chief Dermatology VA-LL, American Academy of Allergy Asthma Immunology – SP(H); Dermatitis Academy – F(Grants/Research Funding); HMP Communications – SP(H); Johnson and Johnson Consumer Products Company – C(Fees); Skintifique – C(NC).

Jacobe, Heidi Tewich, MD, Associate Prof, UT Southwestern Med Ctr, Dallas, TX, Intrexon Corporation – C(Fees).

Jaimes, Natalia, MD, Department of Dermatology & Cutaneous Surgery, University of Miami, Miami, FL, UpToDate, Inc – O(IP).

Jakus, Jeannette Rachel, MD, Director of Clinical Research, Department of Dermatology, SUNY Downstate Medical Center Brooklyn, NY, Galderma Research & Development, LLC – C(H).

Jambusaria-Pahlajani, Anokhi, MD, MS,Senior Staff Physician, Baylor Scott and White, Round Rock, TX, no financial relationships exist with commercial interests.

James, William D., MD, Prof, Dept Derm, U PA, Philadelphia, PA, Elsevier Inc. – O(OB); Naked Biome, Inc. – A(NC); Statpearls Publishing – O(NC); WebMD – O(H).

Janette, Joely,,N/A.

Jarell, Abel D., MD, Dermatologist and Dermatopathologist, Northeast Dermatology Associates, Portsmouth, NH, Castle Biosciences, Inc – SP(H); Vivex Biomedical, Inc. – I(Grants/Research Funding).

Jellinek, Nathaniel J., MD, Asst Prof, Dept Derm, Brown Med Sch, Providence, RI; Adj Asst Prof, Div Derm, UMass Med Sch, Wor, MA, no financial relationships exist with commercial interests.

Jemec, Gregor B.E., MD, Prof., Dept. of Dermatology, Roskilde; Health Sciences Faculty, U. of Copenhagen, Denmark,N/A.

Jiang, Shang I. Brian, MD, Clinical Professor of Dermatology, University of California, San Diego, La Jolla, CA, DUSA Pharmaceuticals, Inc. – I(EQ), I(Fees).

Johnson, Timothy M., MD, Professor Dermatology, Otolaryngology, and Surgery. University of Michigan, Ann Arbor, MI, no financial relationships exist with commercial interests.

Johnson-Jahangir, Hillary, MD, PhD,MD, PhD, Clinical Assistant Professor, University of Iowa, Iowa City, Iowa, no financial relationships exist with commercial interests.
Johr, Robert H., MD, Voluntary Prof Emeritus Derm, Associate Voluntary Prof Emeritus Peds, U Miami, Miami, FL, 3Gen, LLC – SP(Grants/Research Funding), SP(H).
Joly, Pascal, MD, PhD,Pascal Joly,MD, PhD, Professor, Head Dermatology department, Rouen University Hospital, France, Almirall – C(H); GlaxoSmithKline – C(H); Lilly ICOS LLC – C(H); Novartis Pharmaceuticals Corp. – C(H); Principia Biopharma Inc – C(H); Roche Laboratories – C(H); sanofi-aventis – C(H).
Jones, Derek H., MD, Assoc Clin Prof, Div Derm, David Geffen Sch Med, UCLA, Los Angeles, CA,N/A.
Jonkman, Marcel F., MD, PhD,Prof, Dept Derm, U Med Ctr, Groningen, Netherlands, Philae Pharmaceuticals – F(ST).
Joo, Jayne S, MD, Attending physician, Dept of Dermatology University of California, Davis, VA Sacramento Medical Ctr, no financial relationships exist with commercial interests.
Jordan, Richard, MD, Professor of Oral Pathology, Pathology & Radiation Oncology, University of California San Francisco, no financial relationships exist with commercial interests.
Jorizzo, Joseph L., MD, Prof Frmr Founding Chair, Derm ,WFUSM;Prof of Clin Derm , Weill Cornell Medical College ,NY,NY, Amgen – A(H); LEO Pharma, US – A(H).
Jung, Jae, MD, PhD,Assistant Professor, City of Hope National Medical Center, Los Angeles, CA, no financial relationships exist with commercial interests.
Junkins-Hopkins, Jacqueline M., MD, Ackerman Academy of Dermatopathology, New York, NY, USA, no financial relationships exist with commercial interests.

K

Kaffenberger, Benjamin, MD, Assistant Professor of Dermatology, Ohio State University Wexner Medical Center, Columbus OH, Biogen – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); XBiotech – I(Grants/Research Funding); XOMA (US) LLC – I(Grants/Research Funding).
Kamino, Hideko, MD, Professor Derm & Path, NYU Langone Med Ctr, NY, NY, no financial relationships exist with commercial interests.
Kang, Sewon, MD, Professor & Chairman, Dpt. of Dermatology, Johns Hopkins School of Medicine, Anacor Pharmaceuticals, Inc. – C(H); Dermira – SH(ST); Galderma Laboratories, L.P. – A(H); L'Oreal USA Inc. – C(H); Unilever Home & Personal Care USA – A(H).
Kantor, Jonathan, MD, Adj Asst Prof, Univ of Pennsylvania School of Med & Fl Center for Derm, Abbott Laboratories – I(OB); Allergan, Inc – I(OB); Asubio Pharmaceuticals, Inc. – I(OB); Celgene Corporation – I(OB); Idera Pharmaceuticals, Inc. – I(OB); Janssen-Ortho Inc. – I(OB); Kythera – I(OB); LEO Pharma, US – I(OB); McGraw-Hill Companies – O(IP); Pfizer Inc. – I(OB); Taro Pharm – I(OB); Tolmar – I(OB).
Karen, Julie K., MD, Assistant Clinical Professor of Dermatology, NYU Langone Medical Center, New York, NY, Allergan, Inc – C(Fees); Energizer Holdings, Inc – C(Fees); Procter & Gamble Company – C(Fees).
Kasperkiewicz, Michael, MD, Dr. Michael Kasperkiewicz, Department of Dermatology, University of Lübeck, Lübeck, Germany, no financial relationships exist with commercial interests.
Katta, Rajani, MD, Houston Methodist Hospital, Department of Dermatology, Houston, TX, no financial relationships exist with commercial interests.
Katz, Kenneth A., MD, MSc, MSCE,Dept. of Dermatology, Kaiser Permanente, San Francisco, CA, Arrowhead Research Corporation – SH(NC); Madrigal Pharmaceuticals – SH(ST); Prevention Health Labs, Inc. – F(ST); Synta Pharmaceuticals Corp – SH(NC).
Katz, Stephen I., MD, PhD,Director, NIAMS, NIH, Bethesda, MD, no financial relationships exist with commercial interests.
Kaufman, Andrew J., MD, Clinical Associate Professor, USC Keck School of Medicine, no financial relationships exist with commercial interests.
Kaufman, Joely Anne, MD, Associate Professor of Clinical Dermatology University of Miami Miller School of Medicine; Miami, FL, Alphaeon – SH(NC); Cutera, Inc. – SP(H); Elizabeth Arden – A(Fees); Endo International plc – I(Grants/Research Funding); Energizer Holdings, Inc – C(Fees); Galderma USA – A(H), I(Fees); Kythera Biopharmaceuticals – Speaker/Faculty Education(Fees); Lutronics, Inc. – A(H); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); Neothetics – I(Fees); Revance Therapeutics, Inc. – I(Fees); TEOXANE Laboratories – I(Fees); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding).
Kaufmann, Mark D., MD, Assoc Clin Prof, Dept Derm, Icahn School of Med at Mt Sinai , New York, NY, Aclaris Therapeutics, Inc. – C(H); Anacor Pharmaceuticals, Inc. – A(H); Castle Biosciences, Inc – A(H); Dermira – C(H); DUSA Pharmaceuticals – A(H); Encore Dermatology, Inc. – C(Fees); Exeltis – A(H); Ferndale

Laboratories, Inc. – A(H); Klara/Goderma, Inc. – C(SO); Modernizing Medicine – A(SO); Promius Pharma, LLC – A(H); Sun Pharmaceutical Industries Ltd. – A(H); Valeant Pharmaceuticals North America LLC – A(H).

Kaur, Primal, MD, MBA,Amgen, Thousand Oaks, California, Amgen – E(S).

Kauvar, Arielle N.B., MD, Clin Prof Derm, NYU Sch Med, New York, NY; Director, NY Laser & Skin Care, New York, NY, Allergan, Inc – A(NC); Lumenis – C(Fees); Sebcaia, Inc – C(Fees); Syneron, Inc. – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – C(Fees).

Kavand, Sima, resident physician, Presence St.Francis Hospital, Evanston, IL, no financial relationships exist with commercial interests.

Keaney, Terrence, MD, Assistant Clinical Professor, George Washington University, Department of Dermatology, Aclaris Therapeutics Inc. – A(H); Allergan, Inc – A(H), SP(H); Eclipse Medical – SP(H); Merz Aesthetics – A(H); SkinCeauticals LLC – I(H); Syneron Candela – SP(H); Unilever – C(H).

Keimig, Emily, MD, MS,Assistant Professor; Northwestern University, Chicago, IL, no financial relationships exist with commercial interests.

Keller, Jesse J, MD, Assistant Professor, Oregon Health & Science University, Portland, OR., no financial relationships exist with commercial interests.

Kelly, Kristen Marie, MD, Prof Derm & Surg U CA Irvine, CA, Asclepion Laser Technologies GmbH – O(EQ); Candela Corporation – O(EQ); Light Sciences Oncology – I(EQ); New Star Lasers – I(EQ); Nitto Denko Avecia, Inc – I(EQ); Pierre Fabre Dermatologie – C(H); Reliant Technologies, Inc. – O(EQ); Thermage – O(EQ).

Kelly, Nancy,Executive Director, Health Volunteers Overseas, Washington DC, no financial relationships exist with commercial interests.

Kent, David E., MD, Clin Inst, Div Derm, Derm Med, Med Col GA, Augusta, GA,no financial relationships exist with commercial interests.

Kerdel, Francisco, MD, Larkin Community Hospital, Abbott Laboratories – SP(H); Amgen – SP(H); Astellas Pharma US, Inc – A(H); Celgene Corporation – I(Grants/Research Funding); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); Eisai Pharmaceuticals – SP(H); Pfizer Inc. – SP(H); Stiefel a GSK company – I(Grants/Research Funding), SP(H).

Keri, Jonette Elizabeth, MD, PhD,Associate Prof of Dermatology, Univ of Miami, & Chief of Derm Service, Miami VA, Miami, FL, Hoffman-La Roche Ltd. – C(Fees).

Kia, Kevin, MD, Clinical Assistant Professor, UT-Southwestern, Dallas, TX, Castle Biosciences, Inc – C(H).

Kilmer, Suzanne L., MD, Clin Prof, UC Davis Med Ctr, Sacramento, CA, Allergan, Inc – I(Grants/Research Funding); Cutera, Inc. – I(Grants/Research Funding); Cynosure, Inc. – I(Grants/Research Funding); Cytrellis Biosystems, Inc – A(Grants/Research Funding); Galderma USA – A(H); Lumenis – I(Grants/Research Funding); Lutronics, Inc. – I(Grants/Research Funding); Merz Aesthetics – I(Grants/Research Funding); Miramar Labs – A(H); Sebacia, Inc. – I(Grants/Research Funding); Sienna Labs, Inc. – A(H); Solta Medical – I(Grants/Research Funding); Syneron Candela – A(Grants/Research Funding); Ulthera – I(Grants/Research Funding); Zarin Medical – A(H); Zeltiq Aesthetics – A(H); Zift Medical – A(H).

Kim, Caroline C., MD, Assistant Professor, Harvard Medical School; Director, PLC, Dept. of Derm, BIDMC; Boston, MA, Castle Biosciences, Inc – C(Fees); DAMAE Medical – C(Fees); Hoffman-La Roche Ltd. – I(NC).

Kim, Jinah, MD, PhD,Assistant Professor of Pathology and Dermatology, Stanford University, Stanford, CA, Kyowa Hakko Kirin Pharma, Inc. – C(Grants/Research Funding); Myriad Genetics Inc – C(Fees).

Kim, Youn H., MD, Prof, Derm Dept, Stanford U Med Sch, Stanford, CA, Eisai Pharmaceuticals – A(H), I(Grants/Research Funding); Forty Seven Inc. – A(H); Horizon Pharma, Inc. – C(H); Infinity Pharmaceuticals, Inc. – I(Grants/Research Funding); Innate Pharma, S.A. – I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – A(H), I(OB); Merck & Co., Inc. – I(Grants/Research Funding); Millennium Pharmaceuticals – A(H), I(OB); miRagen Therapeutics, Inc. – I(Grants/Research Funding); Neumedicine, Inc. – I(Grants/Research Funding); Portola Pharmaceuticals, Inc. – C(H); Seattle Genetics – C(H), I(Grants/Research Funding); Soligenix, Inc – I(Grants/Research Funding); Tetralogic Pharmaceuticals – I(Grants/Research Funding).

Kimball, Alexandra Boer, MD, MPH,Prof, Harvard Med Sch and Beth Israel Deaconess, Boston, MA, AbbVie – C(H), I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Dermira – C(H), I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding), I(Residency/Fellowship Program Funding); Lilly ICOS LLC – C(H); Merck & Co., Inc – C(H), I(Grants/Research Funding); Novartis – C(H), I(Grants/Research Funding); Procter & Gamble Company – C(H), I(Grants/Research Funding); Sanofi/Regeneron – C(H), I(Grants/Research Funding); Unilever Home & Personal Care USA – C(H).

Kindred, Chesahna, MD, MBA,MedStar Health, Baltimore, MD, no financial relationships exist with commercial interests.

King, Brett Andrew, MD, PhD,Assistant Professor of Dermatology, Yale School of Medicine, New Haven, CT, Aclaris Therapeutics Inc. – A(H); Concert Pharmaceuticals – C(Fees); Eli Lilly and Company – C(Fees); Pfizer Inc. – A(H); Regeneron – A(H).

Kini, Seema, MD, MSc,Assistant Professor, Emory University. Atlanta, GA, no financial relationships exist with commercial interests.

Kirby, Joslyn S., MD, Penn State Hershey, Milton S. Hershey Medical Center, no financial relationships exist with commercial interests.

Kircik, Leon H., MD, Clincial Associate Professor, Icahn School of Medicine, Mount Sinai, NY, 3M Pharmaceuticals – I(Grants/Research Funding), SP(H); Abbott Laboratories – SP(H); Ablynx – I(Grants/Research Funding); Acambis – I(Grants/Research Funding); Allergan, Inc – A(H), C(H), I(H), SP(H); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding), SP(H); Astellas Pharma US, Inc – I(Grants/Research Funding), SP(H); Asubio Pharmaceuticals, Inc. – I(Grants/Research Funding); Bayer Consumer Healthcare Pharmaceuticals – I(Grants/Research Funding); Biogen – A(H); Biolife – I(Grants/Research Funding); Biopelle, Inc. – I(Grants/Research Funding); Breckinridge Pharma – I(Grants/Research Funding); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); ColBar LifeScience Ltd. – A(H), C(H); CollaGenex Pharmaceuticals, Inc. – C(H), I(Grants/Research Funding), SP(H); Connetics Corporation – A(H), C(H), I(Grants/Research Funding); Coria Laboratories – I(Grants/Research Funding); Dermik Laboratories, a business of sanofi-aventis U.S. LLC – SP(H); Dow Pharmaceutical Sciences, Inc. – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Embil Pharmaceuticals, Co., Ltd – SP(H); EOS – A(H); Ferndale Laboratories, Inc. – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), C(H), I(Grants/Research Funding), SP(H); Genentech, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); GlaxoSmithKline – I(Grants/Research Funding); Healthpoint – I(Grants/Research Funding); Intendis, Inc. – A(H), C(H), I(Grants/Research Funding); Isdin – A(H); Johnson & Johnson Consumer Products Company – A(H), C(H), I(Grants/Research Funding), SH(ST), SP(H); Laboratory Skin Care, Inc. – C(H); Leo Pharma Inc – C(H), I(Grants/Research Funding), SP(H); Medical International Technologies – C(H); Medicis Pharmaceutical Corporation – I(Grants/Research Funding); Merck & Co., Inc – C(H); Merck Serono – SP(H); Merz Pharmaceuticals, LLC – C(H); NanoBio Corporation – A(H), I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Nucryst – I(Grants/Research Funding); Obagi Medical Products – I(Grants/Research Funding); Onset Dermatologics – I(Grants/Research Funding), SP(H); Othro Dermatologics – A(H), C(H), I(Grants/Research Funding), SP(H); Pfizer Inc. – I(Grants/Research Funding); Pharmaderm – I(Grants/Research Funding), SP(H); Promius Pharma, LLC – A(H), C(H), I(Grants/Research Funding); PuraCap Pharmaceutical – C(H); QLT Inc. – I(H); SkinMedica, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); Stiefel a GSK company – A(H), C(H), I(Grants/Research Funding), SP(H); Sun Pharmaceutical Industries Ltd. – A(H); TolerRx – I(Grants/Research Funding); Triax Pharmaceuticals, LLC – C(H), I(Grants/Research Funding), SP(H); Valeant Pharmaceuticals International – A(H), C(H), I(Grants/Research Funding), SP(H); Warner Chilcott – A(H), I(Grants/Research Funding), SP(H); Xenoport, Inc. – I(Grants/Research Funding); Zalicus – I(Grants/Research Funding).

Kirkland, Brent, MD, Mohs Surgeon, Dermatologists of Southwest Ohio, Cincinnati, OH and Dayton, OH, no financial relationships exist with commercial interests.

Kirkorian, Anna Yasmine, MD, Assistant Professor of Dermatology & Pediatrics, Children's National Health Network, Washington, DC, no financial relationships exist with commercial interests.

Kirsner, Robert S., MD, PhD,Chairman & Harvey Blank Professor, University of Miami Miller School of Medicine, FL, AbbVie – C(Grants/Research Funding); Acelity – C(H); Almirall – A(H); Cardinal Health – A(H); Castle Biosciences, Inc – O(H); Harbor MedTech, Inc. – C(H); Keraderm – C(H); Kerecis Limited – A(H); Macrocure Ltd. – C(H); Molynecke – A(H); National Healing Corp – A(H); Smith & Nephew – A(H), I(Grants/Research Funding); Tissue Repair Company – I(Grants/Research Funding); XOMA Corporation – I(Grants/Research Funding).

Kittler, Harald, MD, Assoc Prof, Derm, Med U Vienna, Vienna, Austria, no financial relationships exist with commercial interests.

Knapp, Alexia Passe, MD, HealthPartners, St. Paul, Minnesota, no financial relationships exist with commercial interests.

Knight, J. Matthew, MD, Chief of Dermatology, Orlando Health/Arnold Palmer Hospital for Children, Lumenis – I(Grants/Research Funding), SP(H).

Knopp, Eleanor Ann, MD, Clinical Asst Professor, University of Washington; Group Health Permanente, Seattle, WA, no financial relationships exist with commercial interests.

Ko, Christine, MD, Prof, Dept Derm, Yale U, New Haven, CT, Elsevier Inc. – O(IP); Wiley-Blackwell – O(IP).

Kohn, Lucinda Liu, MD, Resident Physician, University of California, San Francisco, San Francisco, California, no financial relationships exist with commercial interests.
Kohorst, John Jacob, MD, Mayo Clinic, Dept of Derm, Rochester, MN, no financial relationships exist with commercial interests.
Kong, Heidi H., MD, MHS,MD, MHSc, Investigator, Derm Br, Natl Inst Hlth, Bethesda, MD, no financial relationships exist with commercial interests.
Konnikov, Nellie, MD, Clinical Prof Derm, BU School of Medicine , Boston, MA, Biofrontera AG – A(H).
Koo, John Y. M., MD, Prof, Derm, UCSF, San Francisco, CA Board Certified in Psychiatry and Dermatology, AbbVie – SP(H); Celgene Corporation – SP(H); Eli Lilly and Company – C(Fees); Leo Pharma Inc. – SP(H); Novartis Pharmaceuticals Corp. – SP(H); Pfizer Inc. – C(Fees).
Korman, Neil J., MD, PhD,Prof Derm, CWRU, U Hosp Case Medical Center, Cleveland, OH, AbbVie – I(Grants/Research Funding), SP(H); Amgen – A(H), I(Grants/Research Funding); Celgene Corporation – A(H), I(Grants/Research Funding); Eli Lilly and Company – A(H), I(Grants/Research Funding); Immune Pharmaceuticals – A(Fees); Janssen Pharmaceuticals, Inc – A(H), O(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H), C(H); Pfizer Inc. – A(H), I(Grants/Research Funding).
Kourosh, Arianne Shadi, MD, MPH,MD, Faculty, Dept of Dermatology, Massachusetts General Hospital & Harvard Medical School, Boston, no financial relationships exist with commercial interests.
Kovarik, Carrie L., MD, Associate Prof, Dept Derm, U Penn, Philadelphia PA, no financial relationships exist with commercial interests.
Kowalczyk, Andrew P., PhD,Professor of Cell Biology and Dermatology, Emory University, Atlanta, GA, no financial relationships exist with commercial interests.
Kraemer, Kenneth Howard, MD, Chf, DNA Repair Sect, Derm Branch, NCI, Bethesda, MD, no financial relationships exist with commercial interests.
Kristjansson, Arni K., MD, Assistant Professor. University of Connnecticut, Framington, CT, no financial relationships exist with commercial interests.
Kroshinsky, Daniela, MD, MPH,Associate Professor, Massachusetts General Hospital, Harvard Medical School, Boston, MA, no financial relationships exist with commercial interests.
Kroumpouzos, George, MD, PhD,Clinical Associate Professor of Dermatology, Alpert Med School of Brown University, Providence, RI, no financial relationships exist with commercial interests.
Krueger, James G., MD, PhD,Prof & Lab Hd Invest Derm, Rockefeller U, New York, NY, AbbVie – C(H); Amgen – I(Grants/Research Funding); Baxter – C(H); Biogen – C(H); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H), I(Grants/Research Funding); Delenex Therapeutics AG – C(H); Dermira – C(H), I(Grants/Research Funding); Eli Lilly and Company – C(H), I(Grants/Research Funding); EMD Serono – C(H); Innovaderm Research Inc. – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); Kadmon Corporation, LLC – C(H), I(Grants/Research Funding); Kineta, Inc. – C(H), I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – I(Grants/Research Funding); Leo Pharma Inc – I(Grants/Research Funding); Merck & Co., Inc. – C(H); Novartis – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H); Parexel – I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); Provectus Pharmaceuticals – I(Grants/Research Funding); Regeneron – I(Grants/Research Funding); Sanofi US Services – C(H); Vitae Pharmaceuticals – I(Grants/Research Funding); Xenoport, Inc. – C(H).
Krunic, Aleksandar L. J., MD, PhD,Adjunct Associate Professor Northwestern Univeresity Chicago, no financial relationships exist with commercial interests.
Kundu, Roopal Vashi, MD, Associate Professor, Department of Dermatology, Northwestern University Feinberg SOM, Chicago,IL, no financial relationships exist with commercial interests.
Kunishige, Joy H., MD, University of Pittsburgh Medical Center, no financial relationships exist with commercial interests.
Kuo, Karen, MD, Stanford University, no financial relationships exist with commercial interests.
Kurtzman, Drew, MD, Assistant Professor, The University of Arizona, Tucson, Arizona, no financial relationships exist with commercial interests.
Kwong, Bernice, MD, Clinical Associate Professor of Dermatology. Stanford University. California, no financial relationships exist with commercial interests.

L

LaChance, Avery H, MD, MPH,Dermatology Resident, Harvard Combined Dermatology Residency, Boston, MA, no financial relationships exist with commercial interests.

Lacouture, Mario E., MD, Member, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, Berg Pharma, LLC – I(Grants/Research Funding); Boehringer Ingelheim – C(H); Bristol-Myers Squibb – SP(Grants/Research Funding); Genentech, Inc. – C(H); Novartis – C(H); Quintiles Pharma – C(H).
Laeuchli, Severin R., MD, University Hospital, Zurich, Switzerland, AbbVie – A(H); ebi-pharm ag – SP(H); Galderma Laboratories, LP – SP(H); Meda Pharmaceuticals Inc. – A(H); MiMedx Group, Inc – A(H); Urgo Group – A(H).
Lai, Olivia,Preliminary Medicine Resident, Eisenhower Medical Center, Rancho Mirage, CA, no financial relationships exist with commercial interests.
Lallas, Aimilios, MD, MSc, PhD,Dr Aimilios Lallas, First Department of Dermatology, Aristotle University, Thessaloniki, Greece, no financial relationships exist with commercial interests.
Lam, Charlene, MD, MPH,Assistant Professor, Department of Dermatology, Penn State Hershey, Hershey, PA, no financial relationships exist with commercial interests.
Lam, Christina, MD, Assistant Professor of Dermatology, Boston University School of Medicine, Boston, MA, Biogen – I(Fees).
Lampel, Heather P., MD, MPH,Cary, NC, no financial relationships exist with commercial interests.
Landau, Marina, MD, Dept Derm, Wolfson Med Ctr, Holon, Israel, Croma-Pharma GmbH Austria – AB(H), Merz Aesthetics – AB(H), Q-Med - S(H).
Langley, Richard G. B., MD, Prof Dir Rsch Dalhousie Med Sch, Halifax, Nova Scotia, Canada, no disclosure available at time of printing.
Larralde, Margarita M., MD, Prof. Dermatology UBA; MhD; Director Dermatology & Pediatric Dermatology Hosp. Aleman, Argentina, Galderma Argentina, S.A. – SP(Fees); Genzyme Corporation – SP(Fees); La Roche-Posay Laboratorie Pharmaceutique – SP(Fees); Pierre Fabre Dermatologie – SP(Fees).
Lask, Gary, MD, Clin Prof, Div Derm, David Geffen Sch of Med UCLA, Los Angeles, CA,N/A.
Latkowski, Jo-Ann, MD, Associate Professor of Dermatology, NYU SOM, no financial relationships exist with commercial interests.
Laumann, Anne E., MBChB,Professor of Dermatology, MBChB,MRCP(UK), Northwestern University, Chicago, Illinois, AbbVie – I(NC); Celgene Corporation – I(NC); Centocor Ortho Biotech Inc. – I(NC); Idera Pharmaceuticals, Inc. – I(NC); Janssen Pharmaceuticals, Inc – I(NC); Johnson & Johnson Consumer Products Company – I(NC); Parexel – I(NC); Regeneron – I(NC); XOMA (US) LLC – I(NC), I(OB).
Lauren, Christine T., MD, Assistant Prof of Dermatology and Pediatrics at CUMC, Columbia Univ Medical Center, New York, NY, LeoPharma-AB(H).
Lawrence, Naomi, MD, Professor of Medicine, Director of Dermatolog Cooper Medical School of Rowan University, Marlton, NJ, no financial relationships exist with commercial interests.
Lazic, Tamara, MD, Assistant Clinical Professor of Dermatology, Mount Sinai School of Medicine, Valeant Pharmaceuticals North America LLC – A(H).
Leachman, Sancy A., MD, PhD,Professor & Chair, Dermatology; Knight Melanoma Program Director, OHSU, Portland, OR, Castle Biosciences, Inc – A(H); Myriad Genetics Inc – A(H), C(Fees).
Leaute-Labreze, Christine, MD, MD, CHU of Bordeaux, Pediatric Dermatology Unit, Bordeaux, FRANCE, Pierre Fabre Dermatologie – C(H).
Leavitt, Matt L., DO, KCU-GMEC/Dermatology Residency of Orlando, no disclosure available at time of printing.
LeBoeuf, Nicole, MD, Assistant Professo of Dermatology Brigham and Women's/Dana-Farber, Harvard Medical School Boston, MA, no financial relationships exist with commercial interests.
LeBoit, Philip E., MD, Prof, Depts Path & Derm, Univ. of California, San Francisco, CA,Elsevier Inc.-IC(F).
Lebwohl, Mark, MD, Prof & Chmn, Dept Derm, Icahn Sch Med at Mount Sinai , New York, NY, AbbVie – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); Boehringer Ingelheim – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Corrona, Inc. – O(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Janssen Research & Development, LLC – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); Medimmune – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Vidac Pharma – I(Grants/Research Funding).
Lee, Bonnie Anne, MD, Bonnie Lee, M.D. Assistant Professor of Dermatology, Albert Einstein College of Medicine, Bronx, NY, no financial relationships exist with commercial interests.
Lee, David Syngyu, MD, Asst.Prof, Clinical Derm, University of Southern California, no financial relationships exist with commercial interests.
Lee, Delphine J., MD, PhD,Chief of Dermatol-

ogy, Harbor UCLA Medical Center, Torrance, CA; Director, JWCI, Santa Monica, CA;, Biogen – SH(NC); Providence Partners for Health LLC – SH(NC).

Lee, Diana H., MD, Assistant Professor of Dermatology and Pediatrics, Albert Einstein College of Medicine, Bronx, NY, no financial relationships exist with commercial interests.

Lee, Erica, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center, New York, NY, no financial relationships exist with commercial interests.

Lee, Ivy, MD, Assistant Clinical Professor and Director of Telemedicine, UCLA Olive View, no financial relationships exist with commercial interests.

Lee, Jason Bok, MD, Professor, Thomas Jefferson University, Philadelphia, PA, no financial relationships exist with commercial interests.

Lee, Kachiu Cecilia, MD, MPH,Assistant Professor of Dermatology, Brown University, Providence, RI, no financial relationships exist with commercial interests.

Lee, M. Christine, MD, MPH,Asst Clin Prof, Dept Derm Surg, UCSF; Dir, Skin and Laser Treatment Institute, Walnut Creek, CA, BTL Industries – A(EQ); Cutera, Inc. – C(H); Cynosure – C(H); Fotona, LLC – C(H); Lumenis – SP(H); Solta Medical – C(Fees); Syneron, Inc. – C(NC); Ulthera – SP(H).

Lee, Margaret S., MD, PhD,Assistant Professor of Dermatology and Pediatrics, BU School of Medicine, Boston MA, Pierre Fabre Dermatologie – C(H).

Lee, Patrick K., MD, Clinical Professor of Dermatology, University of California Irvine Department of Dermatology, no financial relationships exist with commercial interests.

Lehman, Julia S., MD, Associate Professor, Department of Dermatology, Mayo Clinic, Rochester, MN, no financial relationships exist with commercial interests.

Lenzy, Yolanda M., MD, Medical Director, Lenzy Dermatology & Hair Loss Center, Chicopee, MA, no financial relationships exist with commercial interests.

Leonardi, Craig L., MD, Adjunct Prof, Dept Derm, St. Louis U, St Louis, MO, AbbVie – A(H), SP(H); Actavis – I(OB); Amgen – A(H), I(OB); Boehringer Ingelheim – A(H), I(OB); Celgene Corporation – I(OB), SP(H); Coherus Biosciences – I(OB); Corrona, Inc. – I(OB); Dermira – C(H), I(OB); Eli Lilly and Company – A(H), I(OB), SP(H); Galderma Laboratories, L.P. – I(OB); Glenmark Generics Inc. – I(OB); Janssen Pharmaceuticals, Inc – A(H), I(OB); Leo Pharma A/S – A(H); Leo Pharma Inc – I(OB); Novartis – SP(H); Novartis Pharmaceuticals Corp. – I(OB); Novella – I(OB); Pfizer Inc. – A(H), I(OB); Sandoz, a Novartis company – A(H), I(OB); Stiefel a GSK company – I(OB); UCB – A(H); Warner Chilcott – I(OB).

Lerner, Ethan A., MD, PhD,Assoc Prof Derm, Harvard Med Sch, Boston, MA, Dermira – C(Fees); Lerner Medical Devices, Inc. – F(NC); Procter & Gamble Company – SP(Fees); Tioga Pharmaceuticals, Inc. – C(NC); Toray Industries, Inc. – C(Fees).

Leslie, Kieron S., MBBS,Professor of Clinical Dermatology, University of California, San Francisco, no financial relationships exist with commercial interests.

Leslie, Tabi Anika, MBBS,Consultant Dermatologist, Royal Free Hospital, London, UK., no financial relationships exist with commercial interests.

Levin, Ethan Charles, MD, UCSF Department of Dermatology, San Francisco, CA, no financial relationships exist with commercial interests.

Levin, Yakir S, MD, PhD,Yakir Levin, MD, PhD, Clinical and Research Fellow, Massachusetts General Hospital Dermatology, no financial relationships exist with commercial interests.

Levine, Vicki J., MD, Clinical Assistant Professor of Dermatoloty, NYU School of Medicine, New York, NY, no financial relationships exist with commercial interests.

Lev-Tov, Hadar, MD, Assistant Professor, University of Miami, Miami, FL, DermVeda – F(SO).

Levy, Moise L., MD, Dell Children's Medical Center, Austin; Prof, Pediatrics & Med (Derm), Dell Med School, UT Austin, Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); Castle Creek Pharmaceuticals – C(NC); Scioderm – I(Grants/Research Funding); UpToDate, Inc. – O(S).

Lewis, Felisa S., MD, Chief, Dermatology, Ft. Belvoir Community Hospital, no financial relationships exist with commercial interests.

Lewis, Matthew A, MD, MPH,Clinical Assistant Professor, Stanford Dermatology, Palo Alto, CA, no financial relationships exist with commercial interests.

Leyden, James Joseph, MD, Emer Prof, Dept Derm, U PA, Philadelphia, PA, Aclaris Therapeutics, Inc. – C(H); Allergan, Inc. – C(H); Avon Products, Inc. – C(H); Cutanea Life Sciences – C(H); Foamix – C(H); Galderma Laboratories, L.P. – C(H); Photosonix – C(H); Sienna Labs, Inc. – C(H); Sol-Gel Technologies – C(H); Unilever Home & Personal Care USA – C(H); Valeant Pharmaceuticals North America LLC – B(H).

Liao, Wilson, MD, Associate Professor of Dermatology, University of California San Francisco, San Francisco, CA, Abbott Laboratories – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Novartis Pharma-

ceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding).

Liebman, Tracey, MD, Instructor of Dermatology, Ronald O. Perelman Department of Dermatology, NYU School of Medicine, no financial relationships exist with commercial interests.

Lilly, Evelyn, MD, Clinical Instructor, Harvard Medical School, Massachusetts General Hospital; Boston, MA, Eli Lilly and Company – E(S), E(SO).

Lim, Henry W., MD, Chairman & C.S. Livingood Chr, Dept of Dermatology, Henry Ford Hosp, Detroit, MI, Allergan, Inc. – I(Grants/Research Funding); Estee Lauder – I(Grants/Research Funding); Ferndale Laboratories, Inc. – I(Grants/Research Funding).

Lima, Emerson V. A., PhD, MD, PhD in Dermatology - USP, Brazil ; Post- doc -UFPE, Recife - Brazil,, no financial relationships exist with commercial interests.

Lin, Jennifer Y., MD, Assistant Professor in Dermatology, Brigham and Women's Hospital, Boston, MA, no financial relationships exist with commercial interests.

Ling, Yuting, Nanjing Med Univ, no financial relationships exist with commercial interests.

Lio, Peter A., MD, Assistant Professor of Clinical Dermatology, Northwestern University, Chicago, IL, Anacor Pharmaceuticals, Inc. – A(H); AOBiome, LLC – I(Grants/Research Funding); DermTap, Inc. – A(SO); Exeltis – C(Fees); Ferndale Laboratories, Inc. – SP(H); Galderma Laboratories, L.P. – SP(Fees); Galderma Laboratories, LP – C(Fees); Heel (Biologische Heilmittel Heel GmbH) – C(Fees); IntraDerm Pharmaceuticals – A(H); Johnson & Johnson Consumer Products Company – A(H), C(Fees), SP(Fees); La Fondation pour la Dermatite Atopique (Foundation for Atopic Dermatitis – I(Grants/Research Funding); Mission – Speaker/Faculty Education(H); Modernizing Medicine – A(NC), SH(SO); National Eczema Assocaition – A(NC); Odeza LLC – C(SO); Pierre Fabre Dermatologie – SP(H); Regeneron – A(Fees), SP(Fees); Sanofi US Services – A(H); Theraplex – C(Fees); Valeant Pharmaceuticals International – C(Fees); Valeant Pharmaceuticals North America LLC – SP(H).

Lionberger, Robert,Director, Office of Research and Standards, OGD/CDER/FDA Silver Spring, MD, no financial relationships exist with commercial interests.

Lipner, Shari, MD, PhD,Assistant Professor of Dermatology, Weill Cornell Medicine, Department of Dermatology, NY, NY, MOE Medical Devices LLC – I(Grants/Research Funding); Sandoz, a Novartis company – A(H).

Lipoff, Jules, MD, Assistant Professor, Department of Dermatology, University of Pennsylvania, Philadelphia, PA, Blue Cross/Blue Shield – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Springer Science & Business Media – O(IP).

Lipworth, Adam D., MD, Director, Program for Infectious Diseases of the Skin, Brigham and Women's Hospital, Boston, MA, Modernizing Medicine – SH(ST).

Liszewski, Walter, MD, Dept of Derm, University of Minnesota, no financial relationships exist with commercial interests.

Liu, Stephanie, MD, Instructor of Dermatology, Harvard Medical School/Brigham and Women's Hospital, Boston MA, no financial relationships exist with commercial interests.

Liu, Vincent, MD, Clinical Professor, Departments of Dermatology & Pathology, University of Iowa, Iowa City, IA, no financial relationships exist with commercial interests.

Lo Sicco, Kristen Irene, MD, The Ronald O. Perelman Department of Dermatology, NYU School of Medicine, no financial relationships exist with commercial interests.

Lober, Clifford Warren, MD, JD,Adjunct Assoc Prof, Derm & Derm. Surgery, U So FL, Tampa, FL, no financial relationships exist with commercial interests.

Loeser, Christoph R., MD, Senior Consultant, Deputy Director Skin Hospital, Skin Cancer Center, Ludwigshafen, Germany, no financial relationships exist with commercial interests.

Logemann, Nicholas, DO,Dermatologist/Dermatopathologist, Walter Reed National Military Medical Center, Bethesda, MD, no financial relationships exist with commercial interests.

Longo, Caterina, MD, PhD,University of Modena and Reggio Emilia, Italy, no financial relationships exist with commercial interests.

Lott, Jason Pelham, MD, US Deputy Director of Medical Affairs, Dermatology, Bayer HealthCare AG, Bayer HealthCare – E(OB), E(S), E(ST).

Lowenstein, Eve Judith, MD, PhD,Cheif Medical Dermatology, Dept Derm, Suny Downstate, Brooklyn, NY and Kings County Hospital, AlphaImpact RX – C(H); Anacor Pharmaceuticals, Inc. – A(H); Brand Institute Inc – C(H); Celgene Corporation – A(H); COM.DAT – C(H); ConsultantLive publications by UBM LLC – Independent Contractor(H); Curizon – C(H); e-Rewards – C(H); Gerson Lehrman Group's Council of Advisors (GLG) – C(H); J Reckner Associates – C(H); M3 Global Research – C(H); MDLinx – C(H); Medical Liability Mutual Insurance Co - MLMIC – I(Fees); MedSurvey – C(H).

Lowes, Michelle Anne, MBBS, PhD,, no financial relationships exist with commercial interests.

Lucas, Jennifer, MD, Staff, Cleveland Clinic,

Cleveland, Ohio, no financial relationships exist with commercial interests.
Lucky, Anne W., MD, Adjunct Prof Derm & Peds, Cincinnati Children's Hospital, Cincinnati OH, Amicus Therapeutics – C(Grants/Research Funding); Castle Creek Pharmaceuticals – I(NC); Fibrocell Science – C(Fees); Shire – I(Grants/Research Funding).
Luke, Markham C., MD, PhD,Director, Division of Therapeutic Performance, OGD, CDER, FDA, Silver Spring, MD, no financial relationships exist with commercial interests.
Luna, Paula Carolina, MD, Dermatologist/ Pediatric Dermatologist. Hospital Alemán and Hospital R Mejía. Buenos Aires Argentina, AbbVie – Speaker/Faculty Education(H); Genzyme Corporation – Speaker/Faculty Education(H); La Roche-Posay Laboratorie Pharmaceutique – Speaker/Faculty Education(H); Novartis – I(Fees), Speaker/Faculty Education(H); Pierre Fabre Dermatologie – SP(H).
Luu, Minnelly, MD, Assistant Professor of Dermatology, Keck School of Medicine of USC, Los Angeles, CA,N/A.
Lynch, Michael C, MD, Assistant Professor of Pathology, West Virginia University, Morgantown, WV, no financial relationships exist with commercial interests.

M

MacCormack, Mollie A., MD, Foundation Medical Partners, Nashua, NH, no financial relationships exist with commercial interests.
MacFarlane, Deborah, MD, MPH,Prof Derm and Head and Neck Surgery, M D Anderson Cancer Center, Houston, TX, no financial relationships exist with commercial interests.
MacGregor, Jennifer, MD, Union Square Laser Dermatology, Columbia University Medical Center, New York, NY, Allergan, Inc. – C(H).
Machler, Brian C., MD, Assoc Asst Prof, Dept Derm, Sch Med, NYU, New York, NY, U Miami, Miami, FL, no financial relationships exist with commercial interests.
Mackay-Wiggan, Julian M., MD, Associate Professor of Dermatology at CUMC, Columbia University Dept. of Dermatology, New York, NY, BiologicsMD, Inc. – A(NC); Bristol-Myers Squibb – I(Grants/Research Funding); Concert Pharmaceuticals – C(Fees).
Maguiness, Sheilagh M., MD, Assistant Professor, Dermatology and Pediatrics, University of Minnesota, Minneapolis, MN, no financial relationships exist with commercial interests.
Maher, Ian A., MD, Assistant Professor of Dermatology, Saint Louis University, St. Louis, MO, Roche Laboratories – I(Grants/Research Funding).
Maibach, Howard Ira, MD, Professor, UCSF, Sch of Medicine, Dept of Dermatology, San Francisco, CA,N/A.
Makhzoumi, Zaineb Hassan, MD, Assistant Professor, University of Maryland School of Medicine Baltimore, MD, Genentech, Inc. – Speaker/Faculty Education(H).
Makkar, Hanspaul, MD, Associate Professor of Dermatology, University of Connecticut School of Medicine, Farmington CT,N/A.
Makredes Senna, Maryanne, MD, Instructor of Dermatology, Director of H.A.I.R. Unit, Massachusetts General Hospital, Boston, MA, Concert Pharmaceuticals – C(Fees).
Maloney, Mary E., MD, Prof, Med Sch, U MA, Worcester, MA, Celgene Corporation – C(H).
Malvehy, Joseph, MD, Director of the Melanoma Unit, Dermatology Department. Hosp Clin, Barcelona, SPAIN, Cedilp – F(S); Taylor & Francis – O(IP).
Mandy, Stephen Howard, MD, Volunteer Prof,Dept Derm, Sch Med, U Miami, Miami, Fl, Almirall – C(S); Galderma USA – A(H); Merz Aesthetics – A(H); Procter & Gamble Company – C(S); Sinclair Pharma – A(H); Valeant Pharmaceuticals International – Speaker/Faculty Education(H).
Mann, Margaret W., MD, Associate Professor, Director of Aesthetic Dermatology, Case Western University, Cleveland, OH, no financial relationships exist with commercial interests.
Manstein, Dieter, MD, PhD,Assistant Professor of Dermatology, Harvard Medical School, Boston, MA, Blossom Innovations, LLC – SH(ST); Cynosure, Inc. – O(IP); Everbloom LLC – F(ST); GME German Medical Engineering GmbH – SH(ST); Lumenis – A(H), I(Grants/Research Funding); Neutrogena Corporation – C(H); R2 Dermatology, Inc. – C(Fees); Syneron Candela – O(IP); Zalea, LLC – SH(ST); Zeltiq Aesthetics – A(Fees), C(Fees), O(IP).
Marathe, Kalyani, MD, MPH,Assistant professor of dermatology and pediatrics, GWU school of medicine and health sciences, Sanova Works – Independent Contractor(H).
Marchbein, Shari, MD, , Allergan, Inc – A(H).
Marchetti, Michael Armando, MD, Assistant Attending, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, Ignyta, Inc, – C(S).
Marchiori Bakos, Renato, MD, PhD,Renato M. Bakos, MD, PhD. Federal University of Rio Grande do Sul, Porto Alegre, RS Brazil, no financial relationships exist with commercial interests.
Marcus, Kendall, MD, Food and Drug Administration,N/A.
Margesson, Lynette J., MD, Asst Prof ObGyn & Surgery (Dermatology), Geisel School of Med-

icine at Dartmouth, Hanover, NH, UpToDate, Inc – Independent Contractor(H).

Marghoob, Ashfaq A., MD, Attending Physician, Memorial Sloan-Kettering, New York, NY, no financial relationships exist with commercial interests.

Margolis, David J., MD, Prof, Sch Med, U PA, Philadelphia, PA, Astellas Pharma US, Inc – A(-Fees); Derma Sciences Inc. – Data Safety Monitoring Board(Fees); Kerecis Limited – A(Fees); Macrocure Ltd. – Data Safety Monitoring Board(-Fees); PuriCore, Inc. – Data Safety Monitoring Board(NC); Sanofi/Regeneron – Data Safety Monitoring Board(Fees); Valeant Pharmaceuticals International – I(Grants/Research Funding).

Marinkovich, M. Peter, MD, Associate Prof, Dept Derm, Stanford U Sch Med, Stanford, CA,N/A.

Marinovic, Branka, MD, PhD,Prof, Head, Dept of Dermatoogyl and Venereology, Univ Hosp Center, Zagreb, Croatia, no financial relationships exist with commercial interests.

Mariwalla, Kavita, MD, Director, Mariwalla Dermatology, West Islip, NY, no financial relationships exist with commercial interests.

Markova, Alina, MD, Assistant Attending of Dermatology, Memorial Sloan Kettering Cancer Center, New York, NY, no financial relationships exist with commercial interests.

Markovic, Svetomir,Professor of Medicine and Oncology, Rocheter, MN, no financial relationships exist with commercial interests.

Markowitz, Orit, MD, Mt Sinai Medical Center,NY,NY: Asst Prof, Derm; Downstate Medical, Bklyn,NY: Adjunct Asst Prof, Derm, 3Gen, LLC – SP(H); Amgen – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc – I(OB); Elsevier Inc. – Speaker/Faculty Education(H); Galderma Laboratories, L.P. – I(OB); Leo Pharma Inc – C(H), I(Grants/Research Funding); Lippincott Williams & Wilkins – O(Fees); Lucid, Inc. – I(EQ); MDSolarSciences Corporation – A(NC); MelaSciences – Speaker/Faculty Education(H); Michelson Diagnostics Ltd. – I(EQ).

Marks, Katherine C., DO,Pediatric Dermatologist, Geisinger Medical Center, Danville, PA, no financial relationships exist with commercial interests.

Marks, Victor James, MD, Associate, Department of Dermatology, Geisinger Health System, Danville, PA, no financial relationships exist with commercial interests.

Marquart, Laura Nicole, MD, FDA, no financial relationships exist with commercial interests.

Martinez, Jose Dario, MD, Internal Medicine and Dermatology Professor, University Hospital, UANL, Monterrey, Mexico, no financial relationships exist with commercial interests.

Martinez, Juan-Carlos, MD, Assistant Professor of Dermatology, Mayo Clinic College of Medicine, Jacksonville, FL, no financial relationships exist with commercial interests.

Martinez Velasco, Maria Abril, MD, MD, Medica Sur, Mexico D.F, no financial relationships exist with commercial interests.

Martini, Mary C., MD, Division Head of Dermatology, Allegheny Health Network, Pittsburgh, Pa, Dove/Unilever – A(H).

Maruthappu, Thiviyani, MBBS, MD, Buzaro Institute, Queen Mary University of London, no financial relationships exist with commercial interests.

Mashiah, Jacob, MD, Dr jacob Mashiah, Pediatric Dermatolog, Dana children's hospital, Tel -aviv Medical center Israel, no financial relationships exist with commercial interests.

Matarasso, Seth L., MD, Clin Prof Derm, UCSF, San Francisco, CA, Allergan, Inc – C(H).

Mathes, Erin F., MD, Associate Professor of Dermatology and Pediatrics, UCSF, San Francisco, CA, Rodan and Fields – SP(H); Zosano Pharma – C(H).

Maurer, Toby A., MD, Prof, UCSF, Chief, Derm, San Francisco Gen Hosp, San Francisco, CA, no financial relationships exist with commercial interests.

Mauskar, Melissa Muszynski, MD, Assistant Professor, University of Texas Southwestern Medical Center, Dallas Tx, no financial relationships exist with commercial interests.

Mays, Steven Randolph, MD, Assoc Prof, Dept Derm, UT Medical School,Houston, Houston, TX, no financial relationships exist with commercial interests.

McCalmont, Timothy H., MD, Prof Derm & Path, U CA, San Francisco, CA, no financial relationships exist with commercial interests.

McClanahan, Carole, MD, Resident, University of Iowa Dermatology, Iowa City, Iowa, no financial relationships exist with commercial interests.

McCleskey, Patrick E., MD, Dept of Dermatology, Kaiser Permanente, Oakland CA, and US Air Force Reserves, Travis AFB, CA, no financial relationships exist with commercial interests.

McCuaig, Catherine C., MD, Associate Clinical Professor of Pediatric Dermatology, CHU Sainte Justine, University of Montreal, no financial relationships exist with commercial interests.

McElgunn, Patrick, MD, , AbbVie – A(H), SP(H); Allergan, Inc – A(H), SP(H); Celgene Corporation – SP(H); Galderma USA – SP(H); LEO Pharma, US – SP(H); Promius Pharmaceuticals – SP(H); Valeant Pharmaceuticals North America LLC – SP(H).

McKoy, Karen, MD, MPH,Asst Clin Prof in Derm, Harvard Med Sch, Lahey Clin, Burlington, MA, Merck & Co., Inc – O(S); Parexel – C(-Fees).

McMahon, Patrick J., MD, Assistant Professor of Pediatrics and Dermatology, The Children's Hospital of Philadelphia, no financial relationships exist with commercial interests.

McMichael, Amy J., MD, Prof, Dept Derm, Wake Forest Baptist Med Ctr, Winston-Salem, NC, Abbott Laboratories – I(OB); Aclaris Therapeutics Inc. – A(H); Allergan, Inc. – C(H), I(OB); Amgen – C(OB); Anacor Pharmaceuticals, Inc. – A(H); Astellas Pharma US, Inc – C(H); Cassiopea S.p.A. – I(Grants/Research Funding); Galderma Laboratories, L.P. – C(OB); Guthy-Renker – C(H); Healthwise (Boise ID) – C(H); Incyte Corporation – C(H); Informa – O(OB); Intendis, Inc. – I(OB); Johnson & Johnson Consumer Products Company – C(H); Merz Pharmaceuticals, LLC – A(H); NAAF – A(NC); North American Hair Research Society – B(NC); Procter & Gamble Company – C(H), I(OB); Samumed, LLC – C(H), I(Grants/Research Funding); Stiefel a GSK company – C(H); UpToDate, Inc – Speaker/Faculty Education(H).

McMullen, Kevin Richard, MD, Resident, UCSF Department of Dermatology, no financial relationships exist with commercial interests.

McNiff, Jennifer Madison, MD, Prof Dept Derm & Path, Yale U, New Haven, CT, no financial relationships exist with commercial interests.

McQueen, Alisa, MD, Associate Professor of Pediatrics, The University of Chicago Comer Children's Hospital, Chicago IL, Anacor Pharmaceuticals, Inc. – A(H); DermTap, Inc. – A(SO); Ferndale Laboratories, Inc. – SP(H); Galderma Laboratories, L.P. – SP(Fees); Galderma Laboratories, LP – C(Fees); IntraDerm Pharmaceuticals – A(H); Johnson & Johnson Consumer Products Company – SP(Fees); Johnson and Johnson Consumer Products Company – A(H), C(Fees); La Fondation pour la Dermatite Atopique (Foundation for Atopic Dermatitis – I(Grants/Research Funding); Mission – Speaker/Faculty Education(H); Modernizing Medicine – A(NC); National Eczema Assocaition – A(NC).

Meehan, Shane A., MD, Associate Prof of Dermatology and Pathology, New York University School of Medicine, New York, NY, no financial relationships exist with commercial interests.

Mehregan, Darius R., MD, Professor and Hermann Pinkus Chair, Dept. Dermatology, Wayne State University, Detroit MI., no financial relationships exist with commercial interests.

Mehta, Nehal N., MD, Chief, Section of Inflammation and Cardiometabolic Diseases, NHLBI, Bethesda, MD, no financial relationships exist with commercial interests.

Mengden, Stephanie, MD, Assistant Professor, Dept of Dermatology, Oregon Health & Science University, Portland, OR, no financial relationships exist with commercial interests.

Menter, Alan, MD, MD, Chief of Dermatology, Director of Derm Residency Program, Baylor Univ Medical Center, Dallas, TX, AbbVie – A(H), C(H), I(Grants/Research Funding), SP(H); Amgen – A(Grants/Research Funding), C(H), I(Grants/Research Funding), SP(H); Boehringer Ingelheim – A(H), I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Eli Lilly and Company – A(H), C(H), I(Grants/Research Funding), I(H); Galderma USA – C(H); Janssen Biotech – SP(H); Janssen Pharmaceuticals, Inc – A(H), C(H), I(Grants/Research Funding); LEO Pharma, US – A(H), C(H), SP(H); Medimetriks Pharmaceuticals, Inc. – I(Grants/Research Funding); Merck & Co., Inc – I(Grants/Research Funding); Novartis – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding), SP(H); Wyeth Labs – C(H), SP(H).

Menzies, Scott, MBBS, PhD,Professor, Sydney Medical School, Univ of Sydney, Sydney, Australia, SciBASE – A(Fees).

Mercurio, Mary Gail, MD, Prof Derm, U Rochester, Rochester, NY, no financial relationships exist with commercial interests.

Merola, Joseph, MD, MSc,Assistant Professor, Harvard Medical School, Brigham and Women's Hospital - Dermatology/Rheumatology, AbbVie – A(H), SP(H); Amgen – A(H), I(NC); Biogen – C(Fees), I(Grants/Research Funding); Eli Lilly and Company – A(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H); Momenta Pharmaceuticals, Inc. – C(H); Novartis – A(H); Pfizer Inc. – I(NC).

Mesinkovska, Natasha Atanaskova, MD, PhD,Department of Dermatology, University of California, Irvine, CA, no financial relationships exist with commercial interests.

Micali, Giuseppe A., MD, Chmn, Dept Derm, Catania Univ, Catania, Italy, no financial relationships exist with commercial interests.

Miceli, Alyssa, DO,Resident, OMNEE/Park Avenue Dermatology, Orange Park, FL, no financial relationships exist with commercial interests.

Micheletti, Robert, MD, Assistant Professor of Dermatology and Medicine, University of Pennsylvania, Philadelphia, PA, no financial relationships exist with commercial interests.

Mihm, Martin Charles, MD, Co-Director Melanoma Program, BWH; Prof of Pathology & Dermatology, HMS, Boston; Co-Director, MCPCS,

Alnylam – C(IP); Caliber Imaging and Diagnostics Inc. – A(NC); MelaSciences – A(NC); Novartis – C(IP); Wiley & Sons, Inc. – C(IP).
Miletta, Nathanial R, MD, Assistant Professor, Uniformed Services University of the Health Sciences, no financial relationships exist with commercial interests.
Miller, Alexander, MD, Clin Prof, Dept Derm, U CA, Irvine, CA, no financial relationships exist with commercial interests.
Miller, Christopher James, MD, Dept Derm, U of Pennsylvania, Philadelphia, PA, no financial relationships exist with commercial interests.
Miller, Daniel D., MD, Assistant Professor, University of Minnesota Department of Dermatology, Minneapolis, MN., no financial relationships exist with commercial interests.
Miller, Jeffrey J., MD, Prof, Chair, Dept Derm, Penn State Col Med, Hershey, PA, no financial relationships exist with commercial interests.
Miller, Lloyd S., MD, PhD,Associate Professor, Johns Hopkins Department of Dermatology, Baltimore, Maryland, Chan Soon-Shiong Institute for Advanced Health – C(Fees), I(Grants/Research Funding); Medimmune – I(Grants/Research Funding); Nantworks – C(Fees); Noveome Biotherapeutics – SH(ST); Pfizer Inc. – I(Grants/Research Funding); Stemnion, Inc. – C(Fees), SH(ST).
Miller, Oliver Fred, MD, Emer, Chmn, Dept Derm, Geisinger Clin, Danville, PA, no financial relationships exist with commercial interests.
Miller, Stanley J., MD, Lecturer, Johns Hopkins Hospital, Baltimore, MD, UpToDate, Inc – E(IP).
Millican, Eric Austin, MD, Assistant Professor, Department of Dermatology, University of Utah, Salt Lake City, UT, no financial relationships exist with commercial interests.
Ming, Michael E., MD, Assoc Prof, Dept Derm, U PA, Philadelphia, PA, no financial relationships exist with commercial interests.
Mir, Adnan, MD, PhD,Assistant Professor, University of Texas Southwestern Medical Center, Dallas, Texas, Pierre Fabre Dermatologie – A(H).
Mirmirani, Paradi, MD, The Permanente Medical Group, Vallejo, CA, Cicatricial Alopecia Research Foundation – A(NC); Samumed, LLC – A(H); Springer Science & Business Media – O(IP); UpToDate, Inc – O(IP).
Mirowski, Ginat W., MD, DMD, Adj Assoc Prof, Oral Path, Medicine, Radiology, Indiana Univ Schl of Dentistry, Indianapolis, IN, UpToDate, Inc. – O(H).
Mishra, Vineet, MD, Director of Mohs Surgery and Procedural Dermatology; University of Texas HSC - San Antonio, no financial relationships exist with commercial interests.
Miteva, Mariya, MD, Assistant Professor, Department of Dermatology, University of Miami, FL, Novartis – I(Grants/Research Funding).
Moioli, Eduardo, MD, PhD,Mohs Micrographic Surgery Fellow, University of Pennsylvania, no financial relationships exist with commercial interests.
Monheit, Gary D., MD, Private Practice, Total Skin & Beauty Dermatology/Ass. Clinical Professor, U of AL, Birmingham, AL, Allergan, Inc. – C(H), I(Grants/Research Funding); Croma-Pharma GmbH Austria – I(Grants/Research Funding); Evolus, Inc. – I(Grants/Research Funding); Galderma Laboratories, L.P. – C(H), I(Grants/Research Funding); Genentech, Inc. – SP(H); Kythera – C(H), I(Grants/Research Funding); Merz Pharmaceuticals, LLC – C(H); Revance Therapeutics, Inc. – C(H), I(Grants/Research Funding); Suneva Medical, Inc. – C(NC), I(Grants/Research Funding); TEOXANE Laboratories – I(Grants/Research Funding).
Moore, Angela Yen, MD, Dept Derm, UTMB Galveston, TX -- Dept Derm, Baylor Medical Dallas, TX, AbbVie – A(H), I(Grants/Research Funding), SP(H); Allergan, Inc. – I(Grants/Research Funding), SP(H); Amgen – I(Grants/Research Funding); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); Aqua – A(H), SP(H); Astellas Pharma US, Inc – I(Grants/Research Funding); Centocor Ortho Biotech Inc. – I(H); Coherus Biosciences – I(H); DUSA Pharmaceuticals, Inc. – A(H); Eli Lilly and Company – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); Johnson & Johnson Pharmaceutical Research & Development – I(Grants/Research Funding); LEO Pharma, US – I(Grants/Research Funding), SP(H); Merz Pharmaceuticals, LLC – A(H), SP(H); Novan – I(Grants/Research Funding); Novartis – A(H), C(H), I(Grants/Research Funding); Parexel – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Prestium Pharma, Inc – SP(H); Ranbaxy Laboratories Limited – I(Grants/Research Funding); Regeneron – I(Grants/Research Funding); Therapeutics – I(Grants/Research Funding); TKL Research – I(Grants/Research Funding); Tolmar – I(Grants/Research Funding); XOMA (US) LLC – I(Grants/Research Funding).
Morrison, Lynne H., MD, Assoc Prof, Dermatology Dept, Oregon Health Sciences University, Portland, OR, no financial relationships exist with commercial interests.
Morton, Colin A., MD, MD, MBChB, FRCP(UK), Cons, Dept. of Derm, Stirling, Scotland, UK, AbbVie – SP(H); Almirall – A(H); Biofrontera AG – I(Grants/Research Funding); Galderma

Research & Development, LLC – I(Grants/Research Funding); Leo Pharma Inc. – I(Grants/Research Funding).

Moscarella, Elvira, MD, Arcispedale Santa Maria Nuova-IRCCS, Viale Risorgimento 80 42100 Reggio Emilia, no financial relationships exist with commercial interests.

Moschella, Samuel Leonard, MD, Sr. Consult, Lahey Clin, Burlington, MA, Clinical Prof Derm, Emeritus, Harv Med Schl, no financial relationships exist with commercial interests.

Mostaghimi, Arash, MD, MPH,Assistant Prof, Dept of Dermatology, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, no financial relationships exist with commercial interests.

Mostow, Eliot N., MD, Prof/Chair, NEOMED, Akron, OH; Assoc Clin Prof, Case Western Reserve U, Cleveland, OH, Elsevier Inc. – C(S); Vivacare – A(OB).

Motaparthi, Kiran, MD, Dermatopathologist, Miraca Life Sciences, Irving, TX, no financial relationships exist with commercial interests.

Mowad, Christen M., MD, Professor, Geisinger Medical Center, Danville, PA, Elsevier Inc. – B(H); Takeda Pharmaceuticals USA Inc – E(S); UpToDate, Inc – O(IP).

Mowla, Mohammad Rafiqul, MD, MBBS,Assistant Professor, Dept. of Dermatology & Venereology, Chittagong Medical College, Bangladesh., no financial relationships exist with commercial interests.

Moy, Ronald L., MD, Cllinical Professor, Keck School of Medicine at USC, Los Angelesl, California, MD, DNA EGF Renewal – F(NC).

Mozafarpoor, Samaneh, Resident of Derm, Skin Diseases and Leishmaniasis Research Center, Dept of Derm, Isfahan Univ of Medical Sciences, Isfahan, Iran, no financial relationships exist with commercial interest.

Muellegger, Robert, MD, Professor, Department of Dermatology, State Hospital , AT-2700 Wiener Neustadt,N/A.

Mugalian, Ruth, MS,Vice President, Public Communications Inc., Chicago, IL, no financial relationships exist with commercial interests.

Mully, Thaddeus W., MD, Thaddeus Mully MD Professor, University of California, San Francisco, no financial relationships exist with commercial interests.

Munavalli, Girish S., MD, MHS,Clin Asst Professor, Dept of Derm, Sch Med, Wake Forest University, Winston Salem, NC, BTG PLC – A(H); Covidien – C(H); Fibrocell Sciences – A(H); Lumenis – I(EQ); Merz Aesthetics – A(H).

Murase, Jenny Eileen, MD, Asst Clin Prof UCSF & PAFMG, San Francisco & Mountain View, CA, no financial relationships exist with commercial interests.

Murina, Andrea Tesvich, MD, Assistant Professor Dermatology, Tulane University School of Medicine, New Orleans, LA, AbbVie – SP(H); Celgene Corporation – SP(H); Janssen Pharmaceuticals, Inc – A(H); Regeneron – O(Grants/Research Funding); Suneva Medical, Inc. – A(H).

Murrell, Dedee F., MD, Prof & Hd, Dept Derm, St George Hosp, U NSW, Sydney, Australia, 3M Pharmaceuticals – C(Grants/Research Funding); Abbott Laboratories – A(H), SP(H); AbbVie – I(Grants/Research Funding); Actavis – Speaker/Faculty Education(H); Almirall – C(H); Amgen – I(Fees); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); Ascent Pharmaceuticals – SP(H); CSL – SP(Grants/Research Funding), SP(H); Delfin Technology – I(EQ); Eli Lilly and Company – A(H); Galderma Laboratories, L.P. – I(Grants/Research Funding), I(OB); Janssen-Ortho Inc. – O(Grants/Research Funding); Leo Pharma Inc – Speaker/Faculty Education(H); Medimmune – I(Grants/Research Funding); Merck Serono – I(Fees), I(Grants/Research Funding); Molynlycke – SP(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H), I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Pierre Fabre Dermo-Cosmétique US – SP(H); Principia Biopharma Inc – C(H); Roche Laboratories – A(H), I(Grants/Research Funding); Samumed, LLC – I(Grants/Research Funding); Schering-Plough Corporation – I(Grants/Research Funding), SP(OB); Shire – A(H), I(Grants/Research Funding); Stiefel a GSK company – SP(H); XOMA (US) LLC – I(Grants/Research Funding).

Musiek, Amy C., MD, Associate Professor of Medicine (Dermatology), Washington University in St. Louis, St. Louis, MO, Actelion – SP(H).

Mutizwa, Misha Matongo, MD, Assistant Professor of Dermatology, Temple University School of Medicine, Philadelphia, PA, Biota – C(NC).

N

Naafs, Ben,Retired Professor & Head of the Department, Munnekeburen. Netherlands. Stichting Global Dermatology, no financial relationships exist with commercial interests.

Nagler, Arielle Rachel, MD, Assistant Professor, The Ronald O. Perelman Department of Dermatology at NYU School of Medicine, no financial relationships exist with commercial interest.

Naik, Haley, MD, Assistant Professor, Department of Dermatology, University of California San Francisco, no financial relationships exist with commercial interests.

Nakamura, Mio, MD, Clinical Research Fellow, University of California San Francisco, San Fran-

cisco, CA, no financial relationships exist with commercial interests.

Narins, Rhoda S., MD, Clin Prof Dept Derm, NYU Med Ctr, and Medical Dir.off the Dermatology Surg & Laser Center, New York,, Allergan, Inc. – C(H); Galderma USA – I(Grants/Research Funding); Merz Aesthetics – C(H); Revance Therapeutics, Inc. – A(H); Suneva Medical, Inc. – I(Grants/Research Funding).

Narurkar, Vic A., MD, Chairman, Dermatology, California Pacific Medical Center, San Francisco, CA, Allergan, Inc. – A(Grants/Research Funding), I(Fees); Medicis Pharmaceutical Corporation – C(H); Merz Aesthetics – C(H); MyoScience – I(SO); Palomar Medical Technologies – I(Grants/Research Funding); Revance Therapeutics, Inc. – A(SO); Solta Medical – I(Grants/Research Funding).

Nasir, Adnan, MD, PhD,Clin Prof, Dept Derm, UNC, Chapel Hill, NC, Amgen – I(OB).

Nathansohn, Nir, MD, Director, Pigmented Lesions Clinic, C. Sheba Medical Center, Tel Hashomer, Israel, no financial relationships exist with commercial interests.

Neel, Victor Allen, MD, PhD,Dermatologic Surgery Division, Massachusetts General Hospital, Boston, MA, no financial relationships exist with commercial interests.

Nehal, Kishwer S., MD, Attending Physican Memorial Sloan-Kettering Cancer Center, New York, NY, no financial relationships exist with commercial interests.

Nelson, Andrew A., MD, Clinical Assistant Professor, Tufts University, Boston, MA; Nelson Dermatology, St. Petersburg, FL, InMode MD Ltd, C(Stock Options and Equipment), S(No Compensation Received).

Nelson, Kelly C., MD, Associate Professor, Division of Dermatology, MD Anderson Cancer Center, Houston TX, no financial relationships exist with commercial interests.

Nestor, Mark S., MD, PhD,Assoc Voluntary Prof, Department of Dermatology and Plastic Surgery, University of Miami, Miami, FL, Actavis – I(Grants/Research Funding); Allergan, Inc – A(H), I(Grants/Research Funding); Almirall – A(H), C(H); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); Bayer HealthCare – A(H), C(H); Brickell Biotech, Inc. – I(Grants/Research Funding); Castle Biosciences, Inc – A(H); Cosmederm Biosciences, Inc – I(Grants/Research Funding); Croma-Pharma GmbH Austria – I(Grants/Research Funding); Cynova Laboratories – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Erchonia Corporation – C(H), I(Grants/Research Funding); Evolus, Inc. – I(Grants/Research Funding); Exeltis – I(Grants/Research Funding); Ferndale Laboratories, Inc. – A(H), C(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), C(H), I(Grants/Research Funding); I.F.C., S.A. – I(Grants/Research Funding); LaLumiere, LLC – A(H), C(H), I(Grants/Research Funding); Leo Pharma Inc – I(Grants/Research Funding); Leo Pharma Inc. – A(H); Neothetics – A(H), C(H), I(Grants/Research Funding); Sensus Healthcare – A(H), C(H); Sinclair Pharma – A(H), C(H), I(Grants/Research Funding); Strathspey Crown – SH(NC); ThermiAesthetics – A(H), C(H), SP(H); Ulthera – C(H), I(Grants/Research Funding).

Newman, Jessica C., MD, Columbia university college of physicians and surgeons, Assistant Clinical Professor of Dermatology, no financial relationships exist with commercial interests.

Nghiem, Paul, MD, PhD,George F. Odland Professor & Head, U of Washington Dermatology; Fred Hutchinson Cancer Ctr Seattle, Bristol-Myers Squibb – I(Grants/Research Funding); EMD Serono – C(Fees); Merck & Co., Inc – A(H).

Nichols, Anna, MD, PhD,Instructor, University of Miami Department of Dermatology and Cutaneous Surgery, Miami, FL, Berg Pharma, LLC – I(Grants/Research Funding); Medimetriks Pharmaceuticals, Inc. – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Scioderm – I(Grants/Research Funding).

Noe, Megan H, MD, MPH,Clinical Instructor and Post-Doctoral Research Fellow, University of Pennsylvania, Philadelphia, PA, no financial relationships exist with commercial interests.

Nopper, Amy J., MD, Prof Pediatrics Univ MO-Kansas City; Div.Director Pediatric Derm, Children's Mercy, Kansas City, MO, no financial relationships exist with commercial interests.

Norris, David Albert, MD, Prof & Chrm, Dept Derm, U CO School of Medicine, Anschutz Medical Campus, Aurora, CO, Western States Biopharmaceuticals Inc – A(ST).

North, Jeffrey P., MD, Assistant Professor of Dermatology and Pathology, UCSF, San Francisco, CA, no financial relationships exist with commercial interests.

Norton, Scott A., MD, MPH,Chief of Derm, Children's Nat'l Med Ctr; Prof of Derm & Peds, George Washington Univ, Washington, DC, no financial relationships exist with commercial interests.

Nouri, Keyvan, MD, Prof of Dermatology, Ophthalmology, and Otolaryngology; Dir. of Derm Surgery; U Miami; Miami, FL, Genentech, Inc. – I(NC).

Novoa, Roberto, MD, Clinical Assistant Professor, Depts. of Pathology & Dermatology, Stanford University, Palo Alto, CA, Novan – SH(ST); Zebra Medical Technologies, Inc. – C(Fees).

Nunley, Julia R., MD, Professor, Dept Derm, VA Commonwealth U, Richmond, VA, no financial relationships exist with commercial interests.

O

Ochoa, Maria Teresa, MD, Assoc Clin Prof., Dept Derm, Keck Sch Med, USC, Los Angeles, CA, no financial relationships exist with commercial interests.

Ogunleye, Temitayo, MD, Assistant Professor, Department of Dermatology, University of Pennsylvania, Philadelphia, PA, no financial relationships exist with commercial interests.

Oh, Dennis H., MD, PhD,Associate Professor, University of California, San Francisco, CA, no financial relationships exist with commercial interests.

Olasz, Edit B., MD, PhD,Associate Professor, Medical College of Wisconsin, Milwaukee, WI, no financial relationships exist with commercial interests.

Olbricht, Suzanne, MD, Chf Derm, Lahey HospClin, Assoc Prof Derm, Harvard MS, Boston, MA, no financial relationships exist with commercial interests.

Oliviero, Margaret C., NP, MSN,Advanced Registered Nurse Practioner. Skin & Cancer Assoc, Plantation, FL. & U of Miami, Miami FL., 3Gen, LLC – SP(H); Caliber Imaging and Diagnostics Inc. – C(NC); Canfield Scientific, Inc. – C(NC); Genentech, Inc. – I(NC).

Olsen, Elise A., MD, Prof Dermatology and Medicine, Duke U Med Ctr, Durham, NC, Aclaris Therapeutics, Inc. – C(H); Advanced Consultative Services – F(H); Allergan, Inc. – O(IP); Concert Pharmaceuticals – C(H); Helsinn Healthcare – O(H); Huron Consulting Group – C(H); Incyte Corporation – C(H); Leirion Foundation – F(NC); NA Hair Research Society – I(Grants/Research Funding); UpToDate, Inc – O(H).

Onwudiwe, Ogechukwu C., MD, Oge C Onwudiwe, MD Wellman Center for Photomedicine/Massachusetts General Hospital Boston, MA, no financial relationships exist with commercial interests.

Oranje, Arnold Pieter, MD, Kinderhuid.nl, Rotterdam, Dermicis, Dermatology, Alkmaar, the Netherlands, Pierre Fabre Dermo Cosmetique France – A(H); Procter & Gamble Company – C(Fees); Stiefel a GSK company – A(H).

Orlow, Seth J., MD, PhD,Prof Derm & Ped, Chmn, Derm, NYU Sch Med, New York, NY, Almirall – B(H); Dermira – A(H); Provectus Pharmaceuticals – C(Fees); Unilever – A(H).

Ortega-Loayza, Alex Gerardo, MD, Assistant Professor, Department of Dermatology, Oregon Health Sciences and University, Portland, OR, no financial relationships exist with commercial interests.

Ortiz, Arisa, MD, Director, Laser & Cosmetic Dermatology, Assistant Professor, Dpt of Dermatology, UCSD, San Diego, CA, Alastin Skincare, Inc – A(H), C(H); Allergan, Inc – SH(NC); BTL Industries – O(EQ); Cutera, Inc. – I(EQ); InMode MD Ltd – A(H), SP(H); Neothetics – SH(NC); Sciton Inc. – A(H), SP(H); Ulthera – Data Safety Monitoring Board(H); Zeltiq Aesthetics – O(EQ).

Otley, Clark C., MD, Professor, Dermatology Dept, Mayo Clinic and Mayo Clinic College of Medicine; Rochester, MN, no financial relationships exist with commercial interests.

Owen, Cindy, MD, Assistant Clinical Professor of Dermatology, University of Louisville, Louisville, KY, no financial relationships exist with commercial interests.

Oza, Vikash Sudhir, MD, Assistant Professor, Dept. of Dermatology and Pediatrics, New York University, NYC, NY, no financial relationships exist with commercial interests.

Ozog, David M., MD, Henry Ford Hospital, Vice Chair Dermatology, Director of Cosmetic Dermatology, Detroit Michigan, no financial relationships exist with commercial interests.

P

Paller, Amy S., MD, Chair/Prof Derm Dept.; Prof, Peds; Feinberg School of Medicine, Northwestern U, Chicago, IL, AbbVie – I(NC); Amgen – C(H), I(NC); Amicus Therapeutics – C(H); Celgene Corporation – I(NC); Dermira – C(H); Eli Lilly and Company – C(H); Galderma Laboratories, L.P. – C(H); Genentech, Inc. – C(H); Janssen Pharmaceuticals, Inc – I(NC); Novartis Pharmaceuticals Corp. – C(H); Pfizer Inc. – C(H); Procter & Gamble Company – A(H); Regeneron – C(H); Stiefel a GSK company – C(H); Valeant Pharmaceuticals North America LLC – C(H); Vitae Pharmaceuticals – A(H).

Palm, Melanie, MD, Founder/Medical Director, Art of Skin MD, Solana Beach, CA, Allergan, Inc – A(H); BTL Industries – Speaker/Faculty Education(H); Galderma Laboratories, L.P. – C(H); Kythera – Speaker/Faculty Education(H); Lumenis – SP(H); Lutronics, Inc. – C(OB); Merz Aesthetics – Speaker/Faculty Education(H); Valeant Pharmaceuticals International – C(H).

Palmer, Matthew Lee, MD, General Dermatologist, Geisinger Health System, Danville, PA, no financial relationships exist with commercial interests.

Pandya, Amit G., MD, Prof, Dept Derm, U TX SW Med Ctr, Dallas, TX, no financial relationships exist with commercial interests.

Pappas-Taffer, Lisa K., MD, Assistant Professor of Clinical Dermatology, The University of

Pennsylvania, Philadelphia, PA, no disclosure available at time of printing.
Paragh, Gyorgy, MD, PhD,Assistant Professor of Oncology, Department of Dermatology, Roswell Park Cancer Institute,Buffalo,NY, no financial relationships exist with commercial interests.
Paravar, Taraneh, MD, Assistant Professor, Department of Dermatology; University of California, San Diego; San Diego, CA, no financial relationships exist with commercial interests.
Parekh, Palak Kishorkumar, MD, Associate Professor, Baylor Scott & White Health/Texas A&M Medical Center, Temple, TX, no financial relationships exist with commercial interests.
Pariser, David Michael, MD, Prof, Dept Derm, E VA Med Sch, Norfolk, VA, Abbott Laboratories – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Bickel Biotechnology – C(H), I(Grants/Research Funding); Biofrontera AG – C(H); Celgene Corporation – C(H), I(Grants/Research Funding); Dermira – C(H); DUSA Pharmaceuticals, Inc. – C(H); Eli Lilly and Company – I(Grants/Research Funding); LEO Pharma, US – C(H), I(Grants/Research Funding), I(H); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Novo Nordisk A/S – I(Grants/Research Funding); Ortho Dermatologics – I(Grants/Research Funding); Peplin Inc. – I(Grants/Research Funding); Pfizer Inc. – A(H), I(H); Photocure ASA – I(Grants/Research Funding); Promius Pharmaceuticals – C(H), I(Grants/Research Funding); Regeneron – C(H), I(Grants/Research Funding); Stiefel a GSK company – I(Grants/Research Funding); TheraVida – C(H); Valeant Pharmaceuticals International – C(H), I(Grants/Research Funding).
Parish, Lawrence C., MD, Clin Prof Derm/Cut Biol, Sidney Kimmel Medical College at Thomas Jefferson Univers, Philadelphia, PA, Actavis – I(Grants/Research Funding); Allergan, Inc. – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Boehringer Ingelheim – I(Grants/Research Funding); Derma Sciences Inc. – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Galderma USA – I(Grants/Research Funding); Glenmark Generics Inc. – C(H); Novartis – I(Grants/Research Funding); Perrigo Company – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding); Vitae Pharmaceuticals – I(Grants/Research Funding).
Pasquali, Paola, MD, Dermatologist, Coordinator Dermatology Department, Pius Hospital de Valls (Tarragona), Spain, Almirall – O(H); Leo Pharma Inc – O(H); Springer Science & Business Media – O(IP).
Passeron, Thierry,University Hospital of Nice, France & INSERM U1065, team 12, C3M, Nice, France, AbbVie – A(H); Astellas Pharma US, Inc – I(Grants/Research Funding); Bioderma – Speaker/Faculty Education(H); Celgene Corporation – I(Grants/Research Funding); Galderma Research & Development, LLC – A(H); GlaxoSmithKline – Speaker/Faculty Education(H); Janssen-Cilag – A(H); L'Oréal Research and Innovation – Speaker/Faculty Education(H); La Roche-Posay Laboratorie Pharmaceutique – Speaker/Faculty Education(H); Lancome – C(H); MSD – A(H); Novartis – SP(H); Pfizer Inc. – A(H); Symrise – A(H); Syneron Candela – Speaker/Faculty Education(H).
Patel, Anisha, MD, Assistant Professor, UT MD Anderson Cancer Center and UT Houston Medical School, Houston, TX, no financial relationships exist with commercial interests.
Patel, Mital, MD, Harvard Medical School Instructor in Dermatology, Brigham and Women's Hospital, Boston, MA, no financial relationships exist with commercial interests.
Patterson, Stavonnie, MD, MD, Assistant Professor, Northwestern University, Department of Dermatology, Chicago, IL, no financial relationships exist with commercial interests.
Peebles, Jon Klint, MD, Klint Peebles, University of Wisconsin, Madison, Wisconsin, no financial relationships exist with commercial interests.
Pellacani, Giovanni, MD, Prof, Department of Dermatology, University of Modena and Reggio Emilia, Italy, Mavig – SP(H).
Pendharkar, Ninad C., MD, Associate, Geisinger Health System, State College, PA, no financial relationships exist with commercial interests.
Peng, David H., MD, MPH,Chair, Department of Dermatology, Keck School of Medicine, University of Southern California, no financial relationships exist with commercial interests.
Peredo, Marina, MD, Associate Clinical Professor, Mount Sinai Hospital of New York, no financial relationships exist with commercial interests.
Perez, Maritza I., MD, Cin Prof Derm, Mt. Sinai Icahn School of Medicine, New York, NY, Allergan, Inc – C(H); Cutera, Inc. – SP(H); Procter & Gamble Company – C(H).
Perlis, Clifford S., MD, Private Practice, Abington, PA, no financial relationships exist with commercial interests.
Peters, Margot S., MD, Professor of Dermatology and Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN, no financial relationships exist with commercial interests.
Peterson, Jennifer D., MD, Suzanne Bruce & Associates, Houston, TX,N/A.
Petrie, Tracy,MoleMapper Product Manager, Oregon Health & Science University, Portland, Oregon, no financial relationships exist with

commercial interests.
Phelps, Robert G., MD, Dir Dermpath, Mt. Sinai Sch Med, New York, NY, sanofi-aventis – C(Fees).
Phung, Thuy, MD, PhD,Department of Pathology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, no financial relationships exist with commercial interests.
Pichard, Dominique C, MD, Clinical Research Fellow, National Institutes of Health/CCR/NCI, Bethesda, MD, no financial relationships exist with commercial interests.
Pichardo, Rita O., MD, Associate Professor. Dermatology department. Wake Forest School of Medicine. Winston-Salem, NC, no financial relationships exist with commercial interests.
Pierson, Joseph C., MD, Associate Professor, Residency Program Director, Univ of Vermont Medical Center, Burlington, VT, no financial relationships exist with commercial interests.
Piette, Warren W., MD, Chr, Div Derm, Cook Cty Hosp, Prof, Dept Derm, RUSH Medical Center, Chicago, IL, no financial relationships exist with commercial interests.
Piliang, Melissa, MD, Cleveland Clinic, Cleveland, OH, Castle Biosciences – A(H); Incyte Corporation – I(NC); Kythera – I(NC); Samumed, LLC – A(H).
Pinard, Joanie, MD, Brigham & Women's Hospital, no diclosure availble at time of printing.
Pincus, Laura, MD, Associate Professor of Dermatology and Pathology, UCSF, San Francisco, CA, no financial relationships exist with commercial interests.
Piraccini, Bianca Maria, MD, Associate Professor, MD, PhD, University of Bologna, Italy, no financial relationships exist with commercial interests.
Piris, Adriano, MD, Co-Director, Mihm Cutaneous Pathology Consultative Service, BWH. Boston, MA., no financial relationships exist with commercial interests.
Pirmez, Rodrigo, MD, Dermatologist, Santa Casa da Misericórdia do Rio de Janeiro, Rio de Janeiro, Brazil, no financial relationships exist with commercial interests.
Plewig, Gerd, MD, Prof, Dept Derm, U Munich, Munich, Germany, no financial relationships exist with commercial interests.
Poblete-Lopez, Christine, MD, Staff, Dermatology; Dermatology & Plastic Surgery Institute, Cleveland Clinic, Cleveland, OH, no financial relationships exist with commercial interests.
Polder, Kristel, MD, Clinical Assistant Professor, University of Texas Southwestern Department of Dermatology, Dallas, TX, Allergan, Inc. – A(H); Galderma Laboratories, L.P. – SP(H); L'Oreal USA Inc. – SP(H); Solta Medical – I(H), SP(H).
Polsky, David, MD, PhD,Professor, The Ronald O. Perelman Dept of Dermatology, NYU School of Medicine, New York, NY, Celgene Corporation – A(H); Derm Tech International – C(Fees); MolecularMD – C(Fees); Novartis – A(H).
Pomeranz, Miriam Keltz, MD, Associate Prof, clinical, The Ronald O. Perelman Dept Derm, NYU & Bellevue, New York, NY, Procter & Gamble Company – A(Fees); UpToDate, Inc – O(IP).
Pope, Elena, MD, Professor of Paediatrics, University of Toronto, Canada; Head, Section of Paediatric Dermatology, AbbVie – A(Fees); Amgen – I(NC); Centocor Ortho Biotech Inc. – I(NC); Galderma Canada, Inc – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(Fees); Pierre Fabre Dermo-Cosmétique US – I(NC).
Pride, Howard B., MD, Director, Dept Derm, Geisinger Med Ctr, Danville, PA, no financial relationships exist with commercial interests.
Prieto-Granada, Carlos,Carlos N. Prieto-Granada, Assistant Professor, UAB Pathology Department, Birmingham, AL, no financial relationships exist with commercial interests.
Pritchett, Ellen, MD, Senior Staff Physician, Henry Ford Dermatology, Detroit, MI, no financial relationships exist with commercial interests.
Prose, Neil, MD, Prof Derm, Ped, Duke U Med Ctr, Durham, NC, Johnson and Johnson Consumer Products Company – C(Fees).
Prussick, Ronald B., MD, Assistant Clinical Professor, Department of Dermatology, George Washington University, Washington DC, AbbVie – SP(Fees); Celgene Corporation – SP(H); Galderma USA – SP(Fees); Immunotec, Inc – C(Fees); Janssen-Ortho Inc. – SP(H); LEO Pharma, US – SP(H); Medimetriks Pharmaceuticals, Inc. – A(SO).
Puig, Susana, MD, Prof., Dermatologist, Melanoma Unit, Dermatology Dep., Hosital Clinic, Barcelona, Spain,N/A.
Puttgen, Katherine B., MD, Assistant Professor, Dermatology & Pediatrics, Johns Hopkins SOM, Baltimore, MD, Anacor Pharmaceuticals, Inc. – A(H); Pierre Fabre Dermatologie – A(H).

Q

Querfeld, Christiane, MD, PhD,Assistant Professor; City of Hope Cancer Center, Los Angeles-Duarte, CA, Actelion – A(H); Celgene Corporation – A(H); miRagen Therapeutics, Inc. – B(H).
Qureshi, Abrar A., MD, MPH,Prof & Chair, Dept of Dermatology, Rhode Island Hospital, Brown Med School, Providence, RI, Abbott Laboratories – C(H); AbbVie – C(H); Amgen – C(H), I(Grants/Research Funding); Janssen Pharmaceuticals, Inc

– C(H); Merck & Co., Inc – C(H); Merck & Co., Inc. – I(IP); Novartis – C(H); Novartis Pharmaceuticals Corp. – C(H); Pfizer Inc. – C(H), I(IP); Regeneron – I(NC); Sanofi/Regeneron – I(NC).

R

Rabinovitz, Harold S., MD, Voluntary Clinical Professor, Dept Derm, School of Medicine, U Miami, Miami. FL, 3Gen, LLC – SP(EQ); Caliber Imaging and Diagnostics Inc. – I(EQ); Canfield Scientific, Inc. – C(EQ); FotoFinder – C(NC); Heine – C(EQ); Nantworks – C(EQ).

Rahman, Zakia, MD, Clinical Associate Professor of Dermatology, Stanford University, Palo Alto, CA, Cutera, Inc. – C(OB); Lexington International LLC – A(OB); MyoScience – C(OB); TriaBeauty – C(OB); Zeltiq Aesthetics – C(OB).

Rajadhyaksha, Milind, PhD,Associate Member, Memorial Sloan Kettering Cancer Center, New York, NY, Caliber Imaging and Diagnostics Inc. – SH(SO).

Raney, Sam,Scientific Lead, Division of Therapeutic Performance, no financial relationships exist with commercial interests.

Rao, Babar K., MD, Acting Chairman, Clinical Prof. Dept of Derm, Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ, Celgene Corporation – SP(H); CureMD, Inc. – C(OB); Lucid, Inc. – C(SO).

Rapini, Ronald P., MD, Chernosky Prof & Chmn, Dept Derm, U TX, Houston, TX, Elsevier Inc. – O(IP).

Redenius, Rachel Ann, MD, no financial relationships exist with commercial interests.

Reeder, Margo, MD, Assistant Professor, University of Wisconsin School of Medicine and Public Health, Madison, WI, Epic systems - dermatology steering board – A(NC).

Rehmus, Wingfield Ellis, MD, MPH,Asst Clin Prof Pediatrics, Assoc Member Dermatology, Univ. British Columbia, Vancouver BC, AbbVie – A(H), SP(H); CeraVe/Valeante – A(H), SP(H); Pierre Fabre Dermatologie – A(H).

Rendon, Marta I., MD, Medical director, The Rendon Center for Dermatology & Aesthetic Medicine, Boca Raton, Fl,, Allergan, Inc – A(H), Speaker/Faculty Education(H); Allergan, Inc. – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Galderma Research & Development, LLC – I(Grants/Research Funding); Galderma USA – A(H), Speaker/Faculty Education(H); L'Oreal USA Inc. – A(H); Leo Pharma Inc – I(Grants/Research Funding); Merck & Co., Inc – I(Grants/Research Funding); Merz Aesthetics – A(H), Speaker/Faculty Education(H); Pierre Fabre Dermo-Cosmétique US – C(H); Sensus Healthcare – A(NC); Valeant Pharmaceuticals International – A(H).

Resneck, Jack S., MD, Professor and Vice-Chair of Dermatology, UCSF Sch of Med, San Francisco, CA, no financial relationships exist with commercial interests.

Reynolds, Rachel Victoria Sabbag, MD, Asst. Prof, Harvard Med, Beth Israel Deaconess Med Center, Boston, MA, Biosense Webster – C(-Fees); Medtronics – C(Fees).

Ribotsky, Bret, DPM,Founder, Podiatric Success, Boca Raton, FL, Merz Pharmaceuticals, LLC – C(Fees).

Rice, Zakiya P., MD, Assistant Professor, Emory University Departments of Dermatology and Pediatrics, Atlanta, GA, Celgene Corporation – I(OB); International hyperhidrosis society – Speaker/Faculty Education(H); Pierre Fabre Dermatologie – C(H); Regeneron – I(OB).

Rich, Phoebe, MD, Adjunct Professor, Dept of Dermatology, Oregon Health and Science University, Portland, OR, AbbVie – I(Grants/Research Funding); Allergan, Inc – I(Grants/Research Funding); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); Boehringer Ingelheim – I(Grants/Research Funding); Cassiopea SpA – I(Grants/Research Funding); Dermira – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Foamix – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding); Janssen-Ortho Inc. – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – I(Grants/Research Funding); Merck & Co., Inc – I(Grants/Research Funding); Moberg Derma – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Ranbaxy Laboratories Limited – I(Grants/Research Funding); Sandoz, a Novartis company – I(Grants/Research Funding); Valeant Pharmaceuticals International – I(Grants/Research Funding); Viomet – I(Grants/Research Funding).

Rigel, Darrell S., MD, Clin Prof Derm, New York Univ Med Ctr, New York, NY, Beiersdorf, Inc. – A(H); Foamix – B(H); Johnson and Johnson Consumer Products Company – I(H); Neutrogena Corporation – I(H); Novartis – A(H); Sensus Healthcare – B(Fees); Valeant Pharmaceuticals International – A(H).

Rigopoulos, Dimitris, MD, Professor, Medical School Athens University, Athens, Greece, no financial relationships exist with commercial interests.

Rivers, Jason K., MD, Clinical Professor, Department of Dermatology and Skin Sci-

ence, UBC, Vancouver, BC, Canada, Acne and Rosacea Society of Canada – B(NC); Allergan, Inc. – C(H), I(Grants/Research Funding), SP(H); American Society of Dermatologic Surgery – O(NC); Canadian Dermatology Association – O(S); Canadian Society for Dermatologic Surgery – B(NC); Canfield Scientific, Inc. – I(H); Cipher Pharmaceuticals – C(Fees); Galderma Canada, Inc – C(H), SP(H); Leo Pharma Inc. – C(H), I(Grants/Research Funding), SP(H); Medscape – O(H); Merz Pharmaceuticals, LLC – I(Fees); MetaOptima – A(ST), C(SO), Independent Contractor(Fees); Regeneron – I(Grants/Research Funding); Riversol Skincare Solutions Inc – F(ST); Valeant Pharmaceuticals North America LLC – A(H); Xenon Pharmaceuticals – I(Grants/Research Funding); Zeltiq Aesthetics – I(Grants/Research Funding).

Robinson, Elizabeth, MD, George Washington University, no financial relationships exist with commercial interests.

Robinson, June K., MD, Research Prof Derm, NW U Feinberg Schl of Medicine, Chicago, IL, no financial relationships exist with commercial interests.

Rodrigues, Michelle, MBBS,MBBS (Hons) FACD St. Vincent's Hospital, Melbourne, Australia, La Roche-Posay Laboratorie Pharmaceutique – Speaker/Faculty Education(H).

Rogers, Howard Wooding, MD, Advanced Dermatology, Norwich, CT, no financial relationships exist with commercial interests.

Rogers, Nicole Elaine, MD, Assistant Clinical Professor, Tulane Dept. of Dermatology, New Orleans, LA, Johnson & Johnson Consumer Products Company – C(Fees); ParaPRO LLC – SP(H); Redken – C(Fees); Regimen MD – SH(NC).

Rogers, Roy Steele, MD, Prof Derm, Mayo Clin , Phoenix, AZ, no financial relationships exist with commercial interests.

Roh, Ellen K., MD, Assistant in Dermatology, Massachusetts General Hospital, Boston, MA, no financial relationships exist with commercial interests.

Rohrer, Thomas E., MD, Skincare Physicians, Chestnut Hill, MA Brown U, Providence, RI, Allergan, Inc. – I(Grants/Research Funding); Candela Corporation – A(H), SP(H); Medicis Pharmaceutical Corporation – SP(H); Merz Pharmaceuticals, LLC – I(H); Ulthera – I(H).

Romanelli, Marco, MD, PhD,Chairman Dept. of Dermatology, University of Pisa, AbbVie – A(H); Acelity – A(H); Leo Pharma Inc – A(H); Novartis – A(H).

Rook, Alain H., MD, U Penn, Dept Derm, Prof, Philadelphia, PA, Galderma USA – I(IP).

Rosamilia, Lorraine L., MD, Staff Dermatologist, Geisinger Health System, State College, PA, no financial relationships exist with commercial interests.

Rosen, Theodore, MD, Prof, Dept Derm, Baylor Col Med, Houston, TX, Medimetriks Pharmaceuticals, Inc. – C(H); Valeant Pharmaceuticals International – C(H).

Rosenbach, Misha, MD, Assistant Professor, Dermatology and Internal Medicine, University of Pennsylvania, Philadelphia, PA, Celgene Corporation – A(H); Centocor Ortho Biotech Inc. – I(NC); Gilead Sciences, Inc – I(Grants/Research Funding).

Ross, E. Victor, MD, Dir Cosm & Laser Derm Scripps Clin, San Diego, CA, Alma Lasers – I(Grants/Research Funding); Candela Corporation – A(Grants/Research Funding), I(H); Cutera, Inc. – I(EQ), I(Grants/Research Funding); Cynosure, Inc – C(H), I(Grants/Research Funding); Lumenis – I(EQ), I(H); Palomar Medical Technologies – SP(H); Syneron, Inc. – I(Grants/Research Funding).

Ross, Nicholas,MD, Jefferson Dermatology Associates of Thomas Jefferson University Hospital, no financial relationships exist with commercial interests.

Rossi, Anthony, MD, Assistant Attending, Memorial Sloan Kettering Cancer Center; Asst Prof, Weill Cornell, New York, NY, Allergan, Inc – A(H); EBSCO Industries, Inc. – C(Fees); Elekta – A(H); Merz Aesthetics – C(Fees); Novartis – A(Fees).

Roth, William I., MD, Clinical Professor, Univ of Miami School of Medicine, Department of Dermatology, Elekta – C(H); Sensus Healthcare – A(OB), SP(H).

Rotter, Steven M., MD, Founder & Director the Center for Skin Surgery, PLLC, no financial relationships exist with commercial interests.

Ruben, Beth S., MD, Professor, Depts. of Derm and Path, UC San Francisco, CA; Palo Alto Medical Foundation, no financial relationships exist with commercial interests.

Rubin, Adam, MD, Assistant Prof of Dermatology, Dept of Dermatology, University of Pennsylvania, Philadelphia, PA, Lippincott Williams & Wilkins – O(OB); United Health Care – A(H); University of Pennsylvania – E(S).

Rudnicka, Lidia, MD, PhD,Chairman Department of Dermatology, Medical University of Warsaw, Warsaw, Poland, Johnson & Johnson Pharmaceutical Research & Development – I(Grants/Research Funding); Lilly ICOS LLC – SP(Fees); Pierre Fabre Dermo Cosmetique France – Speaker/Faculty Education(OB); Stiefel a GSK company – A(Fees).

Rullan, Peter P., MD, Volunteer Clinical Faculty,

Dept. of Dermatology, U. of California, San Diego, CA, no financial relationships exist with commercial interests.
Rupani, Reena N., MD, Assistant Professor of Dermatology, Mt Sinai School of Medicine, New York, NY, no financial relationships exist with commercial interests.

S

Saavedra, Arturo P., MD, PhD,Massachusetts General Hospital, Harvard Medical School, Boston, MA, no financial relationships exist with commercial interests.
Sabbah, Laura, MD, University of Montreal, no financial relationships exist with commercial interests.
Sadick, Neil S., MD, Clin Prof, Dept Derm, Weill Med College Cornell, New York, NY, Actavis – I(Grants/Research Funding); Allergan, Inc. – C(H), O(H); Almirall – C(H); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); Auxilium Pharmaceuticals, Inc. – C(H); Bayer – I(Grants/Research Funding); Biorasi, LLC – I(Grants/Research Funding); BTG PLC – C(H); Carma Laboratories, Inc – O(H); Cassiopea SpA – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding), SP(H); Cutera, Inc. – SP(H); Cynosure, Inc. – C(H), I(Grants/Research Funding); DUSA Pharmaceuticals, Inc – I(Grants/Research Funding); Eclipse Medical – O(H); Eli Lilly and Company – I(Grants/Research Funding); Endo International plc – C(H), I(Grants/Research Funding); EndyMed Medical Inc. USA – SP(H); Eternogen – C(SO); Ferndale Laboratories, Inc. – C(H); Galderma Laboratories, L.P. – A(H), O(H); Galderma USA – C(Fees), I(Grants/Research Funding); Gerson Lehrman Group – C(H); Hydropeptide, LLC – I(Grants/Research Funding); Merz Aesthetics – A(H), C(H); Neostrata – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Nutraceutical Wellness, LLC. – I(Grants/Research Funding); Palomar Medical Technologies – I(Grants/Research Funding); Prescriber's Choice – O(H); Regeneron – I(Grants/Research Funding); Roche Laboratories – I(Grants/Research Funding); Samumed, LLC – I(Grants/Research Funding); Slender Medical Ltd. – A(SO); Solta Medical – O(H), SP(H); Storz Medical AG – SP(H); Suneva Medical, Inc. – A(H), C(H), O(H); Valeant Pharmaceuticals International – C(H), I(Grants/Research Funding), O(H); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding); Vascular Insights, LLC – SH(SO); Venus Concept – C(SO), SP(H).
Sahni, Debjani, MBBS, MD, Assistant Professor in Dermatology, Boston University Medical School, Boston, MA, no financial relationships exist with commercial interests.
Sakamoto, Fernanda H., MD, Assistant Professor, Dermatology, Wellman Ctr Photomedicine, MGH, Harvard Medical School, Boston, MA, Living Proof, Inc – C(Fees); Olivio Laboratories, LLC – C(SO); Ouanta Aesthetic Lasers USA, LLC – A(NC); Seven Oaks – O(IP).
Salerni, Gabriel Esteban, MD, Hospital Provincial del Centenario de Rosario & Universidad Nacional de Rosario, Argentina, no financial relationships exist with commercial interests.
Salkey, Kimberly Scott, MD, Associate Professor, Eastern Virginia Medical School, Norfolk, VA, no financial relationships exist with commercial interests.
Sami, Naveed, MD, Associate Professor, Dermatology, University of Alabama-Birmingham, Birmingham, Alabama, no financial relationships exist with commercial interests.
Samie, Faramarz H., MD, Associate Professor of Surgery - Dermatology, Dartmouth-Hichcock Medical Center, Lebanon, NH, no financial relationships exist with commercial interests.
Samimi, Sara, MD, Assistant Professor, University of Pennsylvania, Philadelphia PA, no financial relationships exist with commercial interests.
Sangueza, Omar P., MD, Prof Dir Derm Path, Wake Forest Univ Sch of Med, Winston Salem, NC, no financial relationships exist with commercial interests.
Sattler, Carlos A., MD, VP, US Clinical Development and Medical Affairs, Sandoz Inc., no financial relationships exist with commercial interests.
Sayed, Christopher John, MD, Assistant Professor. University of North Carolina Department of Dermatology. Chapel Hill, NC., AbbVie – A(Fees), I(Fees), SP(Fees).
Schadt, Courtney Reynolds, MD, Assistant Professor, Division of Dermatology, University of Louisville, Louisville, KY, no financial relationships exist with commercial interests.
Schaffer, Julie V., MD, Div of Peds Derm , Hackensack Univ Med Ctr, Hackensack, NJ, no financial relationships exist with commercial interests.
Schatton, Tobias, PhD,Assistant Professor of Dermatology, Harvard Medical School/Brigham and Women's Hospital, Boston, MA, no financial relationships exist with commercial interests.
Scheinfeld, Noah S., MD, JD,Asst Clin Prof, Weil Cornell Medical College, New York, NY, Abbott Laboratories – I(OB); AbbVie – SP(H); Astellas Pharma US, Inc – I(OB); Celgene Corporation – I(OB); Optigenex Inc. – C(OB); Promius Pharma, LLC – I(OB); Ranbaxy Laboratories Limited – C(H); Stiefel a GSK company – A(H), SP(H).
Schlosser, Bethanee Jean, MD, PhD,Associate Prof, Dept of Dermatology, Northwestern University, Chicago, IL, Decision Support in

Medicine, LLC – O(H); Elorac, Inc. – I(Fees); Galderma Research & Development, LLC – I(-Fees); Novan – I(Fees); UpToDate, Inc – O(H).
Schmidt, Adriana N., MD, Adriana N. Schmidt, Santa Monica Dermatology Medical Group, Santa Monica, California, no financial relationships exist with commercial interests.
Schneider, Jeremy Adam, MD, Assistant Clinical Professor, UC San Diego, Department of Dermatology, no financial relationships exist with commercial interests.
Schultz, Amanda, PA-C,Veterans Affairs Hospital, Denver, CO, no financial relationships exist with commercial interests.
Schwartz, Mitchell E., MD, Affiliate Member, University of Vermont Medical Center, Burlington, Vermont, ProCell Therapies – F(OB).
Schwarzenberger, Kathryn, MD, Professor , Dept. of Dermatology, Univ. of Tennessee Health Science Center, Memphis, TN, Pretel, Inc. – F(NC).
Scope, Alon, MD, Director, Pigmented lesion clinic, Sheba MC and Senior lecturer, Tel Aviv University, Israel, Roche Laboratories – Speaker/Faculty Education(Fees).
Scott, Jeffrey Futterleib, MD, Chief Resident, Department of Dermatology, University Hospitals Case Medical Center, no financial relationships exist with commercial interest.
Sebes, Nicholas, MD, Associate Dermatologist Geisinger Health System, Danville, PA, no financial relationships exist with commercial interests.
Selim, M. Angelica, MD, Professor of Pathology at Duke University Medical Center, Durham, NC, no disclosure available at time of printing.
Semenov, Yevgeniy, MD, Washington University of St.Louis, School of Medicine, no financial relationships exist with commercial interests.
Seminara, Nicole, MD, Assistant Professor. The Ronald O. Perelman Department of Dermatology, NYU Schoold of Medicine, no financial relationships exist with commercial interests.
Seraly, Mark Patrick, MD, Clinical Assistant Professor of Dermatology-University of Pittsburgh; Chief Medical Officer Iagnosis, Iagnosis Inc – F(ST).
Seykora, John T., MD, PhD,Associate Prof, Dept Derm, Perelman School of Medicine, Univ. PA, Philadelphia, PA, no financial relationships exist with commercial interests.
Shama, Steven Kenneth, MD, MPH,Professional Speaker/Consultant, Brookline, MA, Delphin Global – F(NC).
Shapiro, Jerry, MD, Professor, Department of Dermatology, New York University School of Medicine, New York, New York, Aclaris Therapeutics Inc. – A(H); Allergan, Inc. – A(H); Applied Biology – C(H); Bayer Consumer Healthcare Pharmaceuticals – C(NC); Cassiopea SpA – A(NC); Incyte Corporation – C(NC); Johnson & Johnson Consumer Products Company – C(H); L'Oréal France – C(H); RepliCel Life Sciences – F(ST); Samumed, LLC – A(H).
Sharma, Amit, MD, Senior Associate Consultant. Mayo Clinic, Scottsdale AZ, no financial relationships exist with commercial interests.
Sharon, Victoria Rose, MD, Assistant Prof, Director of Dermatologic Surgery, Northwell Hofstra School of Medicine, New York, NY, no financial relationships exist with commercial interests.
Shea, Christopher R., MD, Eugene J. Van Scott Professor in Dermatology, University of Chicago, Chicago, IL, no financial relationships exist with commercial interests.
Shear, Neil H., MD, Prof & Chair, Dept Derm, U Toronto, Toronto, Ontario, CANADA, AbbVie – A(H); Actelion – SP(H); Amgen – A(Grants/Research Funding); Biogen – A(H); Celgene Corporation – SP(H); Eli Lilly and Company – A(H); Janssen Pharmaceuticals, Inc – Data Safety Monitoring Board(H); Janssen-Ortho Inc. – C(H), SP(H); Leo Pharma Inc – C(H); Novartis Pharmaceuticals Corp. – A(H), C(H); Pfizer Inc. – SP(H); Sanofi/Regeneron – A(H); Takeda Pharmaceuticals USA Inc – SP(H); Valeant Pharmaceuticals International – A(H).
Sheehan, Michael P., MD, Indiana University School of Medicine, Department of Dermatology, no financial relationships exist with commercial interests.
Sheinbein, David Marc, MD, Associate Professor, Washington University School of Medicine, St. Louis, MO, no financial relationships exist with commercial interests.
Shemer, Avner, MD, Associate Professor, Tel Ha'Shomer Medical Centre, Affiliated to Tel Aviv University, Israel., no financial relationships exist with commercial interests.
Shin, Thuzar, MD, PhD,Assistant Professor, Department of Dermatology, University of Pennsylvania, Philadelphia, PA, no financial relationships exist with commercial interests.
Shinkai, Kanade, MD, PhD,Associate Professor of Dermatology, University of California, San Francisco, CA, no financial relationships exist with commercial interests.
Shinohara, Michi, MD, Clinical Assistant Professor, University of Washington Dermatology and Dermatopathology, Seattle, WA, Solgenix, Inc. – I(S).
Shumaker, Peter Randall, MD, Chairman, Dermatology Department, Naval Medical Center San Diego, CA, no financial relationships exist with commercial interests.

Shwayder, Tor A., MD, Dir, Ped Derm, Henry Ford Hosp, Detroit, MI, no financial relationships exist with commercial interests.

Sibbald, Gary, MD, BSc, MD, M.Ed., D.Sc. (Hon),FRCPC (Med) (Derm), Prof of Med and Public Health, UofT, Toronto, Canada, 3M Pharmaceuticals – A(H), I(Grants/Research Funding), SP(H); Abbott Laboratories – I(Grants/Research Funding); AbbVie – I(Grants/Research Funding); Axcelon Biopolymers Corporation – I(Grants/Research Funding); BSN medical GmbH – A(H), I(Grants/Research Funding), SP(H); CCAC – I(Grants/Research Funding); CIDA, Inc. – I(Grants/Research Funding); Coloplast – A(H), I(Grants/Research Funding), SP(H); Exciton Technologies Inc. – I(Grants/Research Funding); Galderma Laboratories, LP – SP(H); Galderma USA – SP(H); Gaymar Industries, Inc. acquired by Stryker – A(H), SP(H); Government of Ontario, Canada – I(Grants/Research Funding); Healthpoint – A(H), I(Grants/Research Funding); Hollister, Co. – A(H), I(Grants/Research Funding), SP(H); Johnson & Johnson Pharmaceutical Research & Development – I(Grants/Research Funding); KCI – A(H), I(Grants/Research Funding), SP(H); Leo Pharma Inc – SP(H); Molynlycke – A(H), I(Grants/Research Funding), SP(H); Registered Nurses' Association of Ontario – A(H), I(Grants/Research Funding); Shire – I(Grants/Research Funding); Stiefel a GSK company – SP(H); Systagenix – A(H), I(Grants/Research Funding), SP(H); Valeant Pharmaceuticals International – I(Grants/Research Funding), SP(H).

Sidbury, Robert, MD, MPH,Professor, Dept of Ped, Seattle Childrens Hospital, Anacor Pharmaceuticals, Inc. – I(NC); Galderma USA – A(H); Pierre Fabre Dermatologie – I(Grants/Research Funding); Quinnova Pharmaceuticals, Inc. – A(H); Roche Laboratories – C(Fees).

Siegel, Daniel M., MD, MS,Clin Prof, Dept Derm, Sch Med, SUNY Downstate, Brooklyn, NY, Actavis – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Biofrontera AG – C(H); Caliber Imaging and Diagnostics Inc. – B(SO); Castle Biosciences, Inc – A(H); Clearpath Solutions Group – A(H), A(NC); Dantech Systems – F(IP); DUSA Pharmaceuticals, Inc. – A(H), C(H); Elsevier Inc. – O(IP); Ferndale Laboratories, Inc. – A(H); Foamix – A(H); Galderma Laboratories, L.P. – A(H); Genentech, Inc. – A(H), SP(H); Gerson Lehrman Group – C(Fees); Kamedis Limited – C(ST); Klara/Goderma, Inc. – A(SO); Leerink Swann – C(H); LEO Pharma, US – A(H), C(H), SP(H); Logical Images – C(SO); MakuCell, Inc. – C(H); Meda Pharmaceuticals Inc. – C(H); MelaSciences – C(H); Michelson Diagnostics Ltd. – A(Grants/Research Funding), I(EQ); MIM Labs – A(H); Modernizing Medicine – A(SO); Novartis – C(Fees); Pfizer Inc. – A(H); Photomedex – A(ST); Quinnova Pharmaceuticals, Inc. – A(SO); Regeneron – I(Grants/Research Funding); Remote Derm – A(SO); Sanova Works – O(H); Smith & Nephew – A(H); Surgical Media Inc. – A(OB), A(SO); Tetros Group – A(NC); Valeant Pharmaceuticals International – C(Fees); Vivacare – A(NC).

Siegfried, Elaine C., MD, Prof Ped & Derm, St. Louis University, St. Louis, MO, Amgen – I(OB); Anacor Pharmaceuticals, Inc. – I(Fees); Celgene Corporation – A(H); Eli Lilly and Company – C(Fees); Galderma Laboratories, LP – A(H); GlaxoSmithKline – Data Safety Monitoring Board(Fees); Pierre Fabre Dermo-Cosmétique US – I(Fees); Regeneron – I(Fees); Stiefel a GSK company – I(Fees); Valeant Pharmaceuticals North America LLC – C(Fees); Verrica Pharmaceuticals Inc – A(Fees).

Silverberg, Jonathan I., MD, PhD, MPH,Assistant Professor, Dept of Dermatology, Northwestern Univ Feinberg School of Medicine, Chicago, IL, AbbVie – C(H), I(NC); Anacor Pharmaceuticals, Inc. – C(H); Celgene Corporation – I(NC); Eli Lilly and Company – C(H), I(NC); Galderma Research & Development, LLC – C(H); GlaxoSmithKline – C(H), I(NC); Hoffman-La Roche Ltd. – I(NC); Medimmune – C(H); Procter & Gamble Company – C(H); PuriCore, Inc. – C(H); Regeneron – C(H), I(NC).

Simpson, Eric Lawrence, MD, Professor of Dermatology, Oregon Health & Science University, Portland, OR, AbbVie – C(Fees); Anacor Pharmaceuticals, Inc. – C(Fees), I(Grants/Research Funding); Celgene Corporation – C(Fees), I(Grants/Research Funding); Chugai Pharma – I(Grants/Research Funding); Dermira – C(Fees); Eli Lilly and Company – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding); Genentech, Inc. – C(Fees), I(Grants/Research Funding); GlaxoSmithKline – C(Fees); Medimmune – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Pfizer Inc. – C(Fees); Regeneron – C(Fees), I(Grants/Research Funding); Tioga Pharmaceuticals, Inc. – I(Grants/Research Funding).

Sinclair, Rodney Daniel, MD, Professor and Chairman, Deptartment Dermatology, Epworth Hospital, Melbourne, Australia, Amgen – I(Fees); Ascend Pharmaceuticals, Inc. – B(Fees); Bayer – Speaker/Faculty Education(H); Boehringer Ingelheim – I(Grants/Research Funding); Celgene Corporation – I(Fees); Coherus Biosciences – I(Fees); CSL – C(Fees); GlaxoSmithKline – I(Fees); inVentiv Health – I(Fees); Janssen Pharmaceuticals, Inc – O(Fees); Johnson & Johnson Pharmaceutical Research

& Development – I(Fees); Leo Pharma Inc – A(Fees); Medimmune – I(Fees); Medpace – I(Fees); Merck & Co., Inc – I(Fees); Novartis – I(Fees); Pfizer Inc. – I(Fees); Principia Biopharma Inc – I(Fees); Regeneron Pharmaceuticals, Inc. – I(Fees); Samson Clinical – F(IP).

Singh, Meena Kuimari, MD, Attending Physician, KMC Dermatology, Shawnee, KS, no disclosure available at time of printing.

Singh, Rajendra, MD, Associate Professor, Dept. of Dermatology and Pathology, Icahn School of Medicine, Mt. Sinai, NY, no financial relationships exist with commercial interests.

Sivamani, Raja, MD, Assistant Professor of Clinical Dermatology, UC Davis, Sacramento, CA, Valeant Pharmaceuticals North America LLC – C(Fees).

Sloan, Steven B., MD, Associate Professor of Dermatology University of Connecticut School of Medicine, Farmington, CT, Journal of the American Academy of Dermatology – O(Fees); Medical Review Institute of America – Independent Contractor(Fees); Medscape – A(H).

Smith, Gideon, MD, Director Connective Tissue Diseases Clinic, Dept of Dermatology, Mass General Hospital, Boston, MA, Allergan, Inc. – I(Grants/Research Funding); Cipher Pharmaceuticals – C(S); National Rosacea Society – I(S).

Smith, Janellen, MD, Professor, University of California, Irvine Irvine, California, Merck & Co., Inc. – SH(ST).

Sobanko, Joseph, MD, Assistant Professor of Dermatology, University of Pennsylvania, Philadelphia, PA,N/A.

Sobell, Jeffrey M., MD, Asst Prof Derm, Tufts U Sch Med, Boston, MA, abbvie – A(H); AbbVie – I(Grants/Research Funding), SP(H); Amgen – A(H), I(Grants/Research Funding), SP(H); Celgene Corporation – A(H), I(Grants/Research Funding), SP(H); Eli Lilly and Company – A(H), I(Grants/Research Funding), SP(H); Janssen-Ortho Inc. – A(H), I(Grants/Research Funding), SP(H); Merck & Co., Inc – I(Grants/Research Funding); Novartis – C(H), I(Grants/Research Funding), SP(H); Regeneron – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – A(H).

Sober, Arthur Joel, MD, Prof, Dept Derm, Harvard Med Sch, Boston, MA, MelaSciences – I(Grants/Research Funding).

Sofen, Howard Lee, MD, Associate Clinical Professor of Medicine/Dermatology UCLA School of Medicine, Genentech, Inc. – I(Grants/Research Funding), Speaker/Faculty Education(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding), SP(H).

Solish, Nowell J., MD, Asst Prof Derm, U Toronto, Toronto, Canada, Allergan, Inc – A(H); Allergan, Inc. – SP(H); Galderma USA – SP(H); International hyperhidrosis society – B(H); Revance Therapeutics, Inc. – A(H).

Solky, Benjamin Arthur, MD, Winchester and Westford, MA, no financial relationships exist with commercial interests.

Soltani Arabshahi, Razieh, MD, Associate Staff, Cleveland Clinic Foundation, Cleveland, OH, no financial relationships exist with commercial interests.

Somani, Ally-Khan, MD, PhD,Assistant Professor, Dept. of Dermatology, Indiana University School of Medicine, Indianapolis, IN, Aviragen Therapeutics Inc. – C(S); Castle Biosciences, Inc – C(H); Cook Biotech Inc. – A(S).

Sommer, Lacy Louise, MD, Assistant Professor of Medicine; Cooper Medical School of Rowan University; Camden, New Jersey, no financial relationships exist with commercial interests.

Soon, Seaver, MD, Division of Dermatology & Dermatologic Surgery, Scripps Clinic, La Jolla, CA, Genentech, Inc. – I(Grants/Research Funding).

Soriano, Teresa Tabora, MD, Clinical Professor of Medicine, UCLA Division of Dermatology, Los Angeles, CA, no financial relationships exist with commercial interests.

Southwick, Bill,Chief Executive Officer of QualDerm Partners, Brentwood, TN, no financial relationships exist with commercial interests.

Soyer, H. Peter, MD, Prof & Chmn, DRC, The University of Queensland, Diamantina Institute, TRI, Brisbane, Australia, e-derm-consult GmbH – F(NC); Molemap Australia – C(ST); Tele Diagnostic Systems Inc. – C(Fees).

Spengane, Zandile,DR NEZ Spengane, MBChB (UCT), Mphil (HIV&AIDS Management) Stellenbosch University, no financial relationships exist with commercial interests.

Sperling, Leonard C., MD, Prof, Dept Derm, Uniformed Svc U, Bethesda, MD, no financial relationships exist with commercial interests.

Stambuk, Hilda,, no financial relationships exist with commercial interests.

Stamets, Paul, DSc,Director of Research, Fungi Perfecti Laborotories, Fungi Perfecti LLC – F(OB).

Stander, Sonja, MD, Professor of Dermatology and Neurodermatology, University Hospital Muenster, Germany, Tigercat Pharma, Inc. – A(H); Trevi Therapeutics – C(H).

Stankiewicz, Kelly J., MD, Laser, Cosmetic, and Dermatologic Surgeon, The Dermatology Institute, Naperville, IL, Cutera, Inc. – C(H), SP(H).

Starace, Michela, MD, PhD,Department of Experimental, Diagnostic and Specialty Medicine Dermatology University of Bologna, no financial relationships exist with commercial interests.

Stasko, Thomas, MD, Prof and Chair Derma-

tology, U of Oklahoma, Oklahoma City, OK, no financial relationships exist with commercial interests.

Stebbins, William G., MD, Assistant Professor, Division of Dermatology, Vanderbilt University, Nashville, TN, DUSA Pharmaceuticals, Inc. – SP(H).

Stein, Jennifer A., MD, PhD,Associate Professor, Dept Derm, NYU School of Medicine, New York, NY, no financial relationships exist with commercial interests.

Stein Gold, Linda F., MD, Dir Derm Research, Henry Ford Hosp, Detroit, MI, AbbVie – A(H); Actavis – SP(H); Allergan, Inc – A(H); Allergan, Inc. – I(Grants/Research Funding); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); Aqua – A(H); Ferndale Laboratories, Inc. – C(H); Foamix – A(H); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding); Leo Pharma Inc. – I(Grants/Research Funding); LEO Pharma, US – A(H); Lilly ICOS LLC – A(H); Medicis Pharmaceutical Corporation – A(H); Merz Pharmaceuticals, LLC – A(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – A(H); Promius Pharmaceuticals – A(H); Roche Laboratories – O(H); Stiefel a GSK company – A(H), I(Grants/Research Funding); Taro Pharm – A(H); Topica – I(Grants/Research Funding); Valeant Pharmaceuticals International – A(H), I(Grants/Research Funding).

Stern, Dana WK, MD, Assistant Clinical Professor, Mount Sinai Medical School, NYC, NY, no financial relationships exist with commercial interests.

Stevenson, Mary L, MD, Assistant Professor, Mohs Micrographic Surgery and Dermatologic Surgery, no financial relationships exist with commercial interests.

Stewart, Kristen M. A., MD, Total Dermatology Care Center, Jacksonville, FL, Procter & Gamble Company – C(Fees).

Stoff, Benjamin, MD, Assistant Professor of Dermatology, Emory University School of Medicine, no financial relationships exist with commercial interests.

Stolz, Wilhelm, MD, Prof, Hd, Dept Derm II, Clin Muenchen-Thalkirchen, Munich, Germany, Almirall – SP(H); La Roche-Posay Laboratorie Pharmaceutique – SP(H); Leo Pharma Inc – SP(H); McGraw-Hill Companies – O(IP); MSD – SP(H).

Stone, Rivka, MD, Department of Dermatology and Cutaneous Surgery, University of Miami-Miller School of Medicine, no financial relationships exist with commercial interest.

Stone, Stephen P., MD, Prof Clin Med, Dir Clin Research, Div Derm, SIU Sch Med, Springfield, IL, Abbott Laboratories – SH(OB); Acuderm, Inc. – SH(NC); Celgene Corporation – A(H), I(Grants/Research Funding); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); Johnson & Johnson Consumer Products Company – SH(OB); OPKO Health, Inc – SH(OB); Pfizer Inc. – SH(OB); Polynoma LLC – I(Grants/Research Funding); Teva – SH(OB); XOMA Corporation – I(Grants/Research Funding).

Strand, Vibeke, MD, Adjunct Clinical Professor, Division Immunology/Rheumatology, Stanford University School of Medicine, AbbVie – C(H); Amgen – C(H); AstraZeneca – C(H); Bayer – C(H); Boehringer Ingelheim – C(H); Bristol-Myers Squibb – C(H); Celgene Corporation – C(H); Celltrion – C(H); EMD Serono – C(H); Genentech, Inc. – C(H); GlaxoSmithKline – C(H); Horizon Pharma, Inc. – C(H); Janssen Biotech – C(H); Merck & Co., Inc – C(H); Novartis – C(H); Pfizer Inc. – C(H); Regeneron – C(H); Samsung – C(H); Samumed, LLC – C(H); Sandoz, a Novartis company – C(H); sanofi-aventis – C(H); UCB – C(H).

Strasswimmer, John, MD, PhD,Professor of Surgery (Dermatology) and Biochemistry, Florida Atlantic University Boca Raton, FL, Novartis – C(H).

Stratman, Erik Joseph, MD, Chairman, Program Director, Dept of Derm, Marshfield Clin, Marshfield, WI, no financial relationships exist with commercial interests.

Strober, Bruce Elliot, MD, PhD,Professor and Chair, Dept Derm, University of Connecticut, Farmington, CT, AbbVie – A(H), C(H), I(NC), O(NC), SP(H); Amgen – A(H), C(H), I(NC); Boehringer Ingelheim – C(H), I(NC); Celgene Corporation – A(H), C(H), I(NC); Dermira – C(H); Eli Lilly and Company – A(H), C(H), I(NC); Janssen-Ortho Inc. – A(H), C(H), I(NC), O(NC); Leo Pharma Inc – C(H); Maruho Co., Ltd – C(H); Novartis Pharmaceuticals Corp. – A(H), C(H); Pfizer Inc. – A(H), C(H), I(NC); Sun Pharmaceutical Industries Ltd. – C(H), I(NC); UCB – A(H).

Strowd, Lindsay Chaney, MD, Assistant Professor of Dermatology Wake Forest Baptist Health Winston-Salem NC, no financial relationships exist with commercial interests.

Suggs, Amanda Kristine, MD, University Hospitals, Cleveland Medical Center, no financial relationships exist with commercial interests.

Sullivan, Ryan, MD, Massachusetts General Hospital Cancer Center, Array BioPharma – C(Fees); Biodesix, Inc. – A(Fees); Boehringer Ingelheim – O(Fees); WorldCare Clinical LLC – C(Fees).

Sullivan, Sabra, MD, PhD,Dermatology Associates, LLC, Jackson, MS, Candela Corporation – SP(H).

Swerlick, Robert, MD, Alicia Leizman Stonecipher Chair, Dept Derm, Emory U, Atlanta VA

Hosp, Atlanta, GA, AbbVie – SH(NC); Amgen – SH(NC); Biogen – SH(NC); Bristol-Myers Squibb – SH(NC); Gilead Sciences – SH(NC); InVivo Therapeutics Corporation – SH(NC); Ionis Pharmaceuticals, Inc. – SH(NC); Pfizer Inc. – SH(NC); Vertex Pharmaceuticals Incorporated – SH(NC).

Swetter, Susan M., MD, Prof, Dept Derm, Stanford U Sch Med, Stanford, CA, no financial relationships exist with commercial interests.

Swick, Brian L., MD, Clinical Associate Professor, University of Iowa, Iowa City VAMC, Iowa City, IA, no financial relationships exist with commercial interests.

Sybert, Virginia, MD, Clinical Professor, Div of Medical Genetics, UNiversity of washington. Locum tenens GH Permanente, no financial relationships exist with commercial interests.

Szeimies, Rolf-Markus, MD, PhD,Prof & Head of Dept. of Dermatol, Klinikum Vest Acad. Teaching Hosp., Ruhr-Univ. Bochum, Almirall – A(H), I(Fees), SP(H); Biofrontera AG – A(H), I(Fees); Desitin Arzneimittel GmbH – SP(H); Galderma Laboratories, L.P. – A(H), I(Fees), SP(H); ISDIN – A(H); Janssen Pharmaceuticals, Inc – SP(H); Leo Pharma A/S – A(H), I(Fees); photonamic GmbH & Co. KG – I(Fees); Pierre Fabre Dermo Cosmetique France – A(H), SP(H).

T

Taheri, Arash, MD, Department of Dermatology and Department of Internal Medicine, Wake Forest School of Medicine, no financial relationships exist with commercial interests.

Takeshita, Junko, MD, PhD,Assistant Professory, Department of Dermatology, University of Pennsylvania, Philadelphia, PA, Pfizer Inc. – I(Grants/Research Funding).

Tamburro, Joan E., DO,Cleveland Clinic Institute of dermatology and Plastic Surgery, Director of Pediatric Dermatology, OH, no financial relationships exist with commercial interests.

Tan, Jennifer, MD, Northstar Dermatology, Keller, Texas, no financial relationships exist with commercial interests.

Tang, Jean, MD, PhD,M.D., Ph.D., Assistant Professor, Department of Dermatology, Stanford University, Stanford, CA, Genentech, Inc. – C(H).

Tanzi, Elizabeth, MD, Associate Professor of Dermatology, George Washington Medical Center, Washington DC, Beiersdorf, Inc. – SP(H); Merz Aesthetics – C(OB); Miramar Labs – A(H); Sciton Inc. – I(OB); Solta Medical – I(OB); Ulthera – SP(H); Valeant Pharmaceuticals North America LLC – A(H); Zeltiq Aesthetics – A(Fees).

Tappero, Jordan W., MD, Senior Advisor for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta,GA, no financial relationships exist with commercial interests.

Tarbox, Michelle B., MD, Assistant Professor of Dermatology, Texas Tech University Health Sciences Center, Lubbock, TX, no financial relationships exist with commercial interests.

Tausk, Francisco A., MD, Professor of Dermatology and Psychiatry, University of Rochester, Rochester,NY, no financial relationships exist with commercial interests.

Taylor, Susan C., MD, Standing Faculty, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Allergan, Inc – I(Grants/Research Funding); Alphaeon – I(Grants/Research Funding); Beiersdorf, Inc. – A(H); Croma-Pharma GmbH Austria – I(Grants/Research Funding); Evolus, Inc. – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding).

Tebbey, Paul W., PhD, MBA,Paul W. Tebbey, Medical Affairs, Abbvie, North Chicago, IL, AbbVie – E(S), E(ST).

Teng, Joyce, MD, Clinical associate professor of Dermatology and Pediatrics, Stanford University, Palo Alto, CA, no financial relationships exist with commercial interests.

Tetzlaff, Michael, MD, PhD,Associate Professor, Department of Pathology, MD Anderson Cancer Center, Houston, TX, Galderma Research & Development, LLC – A(Fees); Myriad Genetics Inc – A(Fees); Seattle Genetics – C(Fees).

Thakuria, Manisha, MD, Instructor in Dermatology, Harvard Medical School, Dana Farber/BWH Cancer Center, Boston, MA, no financial relationships exist with commercial interests.

Tharp, Michael D., MD, Prof/Chmn Derm, Rush U Med Ctr, Chicago, IL, Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); BestDoctors – C(Fees); Boehringer Ingelheim – I(Grants/Research Funding); Chugai Pharma – I(Grants/Research Funding); GlaxoSmithKline – I(Grants/Research Funding); Kyowa Hakko USA – I(Grants/Research Funding); Leo Pharma Inc – I(Grants/Research Funding); Medical Information Network – F(S); Novartis Pharmaceuticals Corp. – C(H); Regeneron – I(Grants/Research Funding); Unilever Home & Personal Care USA – A(Grants/Research Funding); XOMA (US) LLC – I(Grants/Research Funding).

Thiboutot, Diane M., MD, Prof, Dept Derm, Penn State Hershey College of Medicine, Hershey, PA, Allergan, Inc. – A(H), C(Fees), I(Grants/Research Funding); Cassiopea SpA – C(Fees), I(Grants/Research Funding); Dermira – I(Grants/Research Funding); Galderma Labo-

ratories, L.P. – A(H), C(Fees), I(Grants/Research Funding); Mimetica Pty Limited – C(Fees), I(Grants/Research Funding); Novan – C(Fees), I(Grants/Research Funding); Novartis – C(Fees); Sebcaia, Inc – C(H).

Thiers, Bruce Harris, MD, Prof, Dept Derm and Derm Surg, Med U SC, Charleston, SC, Elsevier Inc. – O(H); Galderma Laboratories, L.P. – O(H); Pfizer Inc. – C(H); Valeant Pharmaceuticals North America LLC – C(H).

Thomas, Valencia D., MD, Associate Professor, M.D. Anderson Cancer Center, Houston, TX, Genentech, Inc. – A(H).

Thompson, Curtis T., MD, Clinical Professor, Depts of Biomedical Engineering, Pathology & Dermatology, OHSU, Portland, OR, no financial relationships exist with commercial interests.

Thornfeldt, Carl R., MD, Carl Thornfeldt,MD, FAAD,RSM at CT Derm, P.C., Fruitland, Idaho, CT Derm, PC – F(S); Episciences, Inc – F(S).

Tkaczyk, Eric Robert, MD, MS, PhD,Assistant Professor, Vanderbilt University, Nashville, Tennessee, Pierre Fabre Dermo Cosmetique France – SP(H).

Tlougan, Brook, MD, Assistant Clinical Professor of Dermatology, Columbia University & Physician, WESTMED Medical Group, no financial relationships exist with commercial interests.

Tollefson, Megha M., MD, Associate Professor of Dermatology and Pediatrics, Rochester, MN, no financial relationships exist with commercial interests.

Tom, Wynnis L., MD, Associate Clinical Professor, Univ. of California, San Diego/Rady Children's Hospital, San Diego, CA, Amgen – I(NC); Anacor Pharmaceuticals, Inc. – I(NC); Celgene Corporation – I(NC); GlaxoSmithKline – I(NC); Otsuka Pharmaceutical Co., Ltd. – I(NC); Regeneron – I(NC); Symbio – I(NC).

Tomecki, Kenneth J., MD, Dept Derm, Cleveland Clinic, Cleveland, OH, no financial relationships exist with commercial interests.

Tomic-Canic, Marjana, PhD,Professor of Dermatology, University of Miami Miller School of Medicine, Miami, FL, Molynlycke – A(H); Novartis – C(H); Organogenesis, Inc. – I(Grants/Research Funding).

Torgerson, Rochelle R., MD, PhD,Asst Prof Derm, Mayo Clinic, Rochester MN, no financial relationships exist with commercial interests.

Torres, Abel, MD, JD,Professor and Chairman, Dermatology, Loma Linda University School of Medicine, CA, American Academy of Dermatology – B(NC); Loma Linda University - LLFMG – B(NC).

Torres, Fernanda, MD, Private Practice, Rio de Janeiro, Brazil, no financial relationships exist with commercial interests.

Tosti, Antonella, MD, Professor , Department of Dermatology and Cutaneous Surgery, University of Miami Fl, Aclaris Therapeutics, Inc. – A(H); Anacor Pharmaceuticals, Inc. – A(H); DS Laboratories – C(Fees); Fotofinder – C(EQ); Incyte Corporation – C(H); Kurt Wolff GmbH & Co. KG – A(H); Kythera – A(H); Meiji Seika Pharma Co., Ltd – A(H); MSD – SP(H); Novartis – A(H); PharmaDerm – Speaker/Faculty Education(H); Pierre Fabre Dermatologie – C(H); Polichem SA – A(H); Procter & Gamble Company – A(H); Springer Science & Business Media – O(IP); Taylor & Francis – O(IP); topica – C(Fees); Valeant Pharmaceuticals International – C(Fees); Viamet Pharmaceuticals, Inc – A(H).

Tran, Thanh-Nga Trinh, MD, PhD,Instructor in Dermatology, Harvard Medical School, Boston, MA, no financial relationships exist with commercial interests.

Travelute, Christie, MD, Professor Dept Derm, Penn State Hershey Medical Center, Hershey, PA, no financial relationships exist with commercial interests.

Tremaine, Anne Marie, MD, Dermatologist and Cosmetic Surgeon, Skin Wellness Physicians, Naples Florida, no financial relationships exist with commercial interests.

Trevino, Julian J., MD, Professor and Chair, Dept of Dermatology, Wright State Univ, Dayton, OH, no financial relationships exist with commercial interests.

Trufant, Joshua W, MD, Assistant Professor, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, no financial relationships exist with commercial interests.

Tsao, Hensin, MD, PhD,Prof, Dept Derm, Harvard Med Sch, Mass Gen Hosp, Boston, MA, Lubax – A(H); Massachusetts General Hospital – E(S).

Tsao, Sandy Sharon, MD, Assistant Professor, Harvard Med School, Dept Derm, MA Gen Hosp, Boston, MA, no financial relationships exist with commercial interests.

Tschandl, Philipp, MD, Dermatology Resident, Medical University of Vienna, Vienna, Austria, no financial relationships exist with commercial interests.

Tsoukas, Maria M., MD, PhD,Associate Professor, Program Director, University of Illinois, Chicago, IL, American Society of Dermatologic Surgery – I(Grants/Research Funding); Biofrontera AG – A(H).

Tyler, Kelly, MD, Ohio State University, Division of Dermatology, Columbus, OH, no financial relationships exist with commercial interests.

Tyring, Stephen K., MD, PhD,Clinical Prof Dept

Derm, U Texas Hlth Sci Ctr, Houston, TX, Agenus Inc. – I(Grants/Research Funding); AiCuris GmbH & Co. KG – I(Grants/Research Funding); Genocea Biosciences – I(Grants/Research Funding); Merck & Co., Inc – I(Grants/Research Funding); Nycomed Amersham – I(Grants/Research Funding); Vical Incorporated – I(Grants/Research Funding).

U

Udey, Mark C., MD, PhD,Chief, Dermatology Branch, CCR, NCI, NIH, Bethesda, MD, no financial relationships exist with commercial interests.

Uitto, Jouni J., MD, PhD,Prof & Chmn, Dept Derm & Cut Biol, Thomas Jefferson Univ , Philadelphia, PA, no financial relationships exist with commercial interests.

V

Van Beek, Marta Jane, MD, MPH,Associate Prof, Dept of Dermatology, University of Iowa Hospitals & Clinics, Iowa City, IA, no financial relationships exist with commercial interests.

Van Voorhees, Abby S., MD, Professor and Chair, Department of Dermatology, Eastern Virginia Medical School, AbbVie – C(H); Celgene Corporation – A(H), C(H); Dermira – C(H); Merck & Co., Inc – A(H), O(OB); Novartis – A(H); Novartis Pharmaceuticals Corp. – A(H); Valeant Pharmaceuticals North America LLC – A(H).

Vandergriff, Travis W., MD, Assitant Professor, Department of Dermatology; UT Southwestern Medical Center; Dallas, Texas, no financial relationships exist with commercial interests.

Varghese, George, MD, Assistant Professor in Dermatology, Weill Cornell Medicine, New York, NY, no financial relationships exist with commercial interests.

Vashi, Neelam, MD, Assistant Professor of Dermatology, Boston University, Boston, MA, L'Oreal USA Inc. – C(H).

Vaughan-Jones, Samantha A., MD, Consultant Dermatologist, Ashford and St Peter's Foundation Trust, Chertsey. Surrey UK., no financial relationships exist with commercial interests.

Vermeer, Maarten H., MD, PhD,Prof dr MH Vermeer, Dept Dermatology, Leiden University Medical Center, Leiden, The Netherlands, Innate Pharma, S.A. – O(NC); Kyowa Hakko Kirin Pharma, Inc. – A(H).

Vidimos, Allison Therese, MD, RPh,Chmn, Dept Derm, Cleveland Clinic; Prof of Medicine, Case Western Reserve, Cleveland, OH, Genentech, Inc. – I(Grants/Research Funding).

Villasenor-Park, Jennifer, MD, PhD,Assistant Professor of Clinical Dermatology, University of Pennsylvania, Philadelphia, PA, no disclodure available at time of printing.

Vlahovic, Tracey C., DPM,Clinical Assoc Professor, Dept of Podiatric Medicine, Temple Univ School of Podiatric Med, Phila, PA, Pharmaderm – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – I(NC).

Vleugels, Ruth Ann, MD, Associate Professor, Harvard Medical School, Brigham and Women's Dermatology, Boston, MA, no financial relationships exist with commercial interests.

W

Wada, David Akio, MD, David Wada, M.D., Assistant Professor, Department of Dermatology University of Utah, SLC, UT, no financial relationships exist with commercial interests.

Waibel, Jill S., MD, Medical Director & Owner, Miami Dermatology & Laser Institute, Acelity – I(Grants/Research Funding); Alma Lasers – SP(H); Candela Corporation – SP(H); Cutera, Inc. – I(Grants/Research Funding); Harvest Technologies – I(Grants/Research Funding); Lumenis – I(H); Lutronics, Inc. – I(Grants/Research Funding); Michelson Diagnostics Ltd. – I(EQ); Sciton Inc. – I(Grants/Research Funding); Sebacia, Inc. – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – A(H); Zeltiq Aesthetics – SP(H).

Waldorf, Heidi A., MD, Assoc Clin Prof, Dept Derm, Icahn Sch Med, Mt Sinai, New York, NY, Aclaris Therapeutics, Inc. – A(H); Allergan, Inc. – A(H); Caudalie – SP(H); Dove/Unilever – A(H), C(H); Galderma USA – A(H); Kythera – A(H), I(-Fees), Speaker/Faculty Education(H); Lifes2Good – A(H); Merz Aesthetics – A(H), SP(H); Procter & Gamble Company – C(H); Revance Therapeutics, Inc. – A(H); Solta Medical – SP(H); Suneva Medical, Inc. – A(H), I(Fees); Valeant Pharmaceuticals International – A(H), SP(H).

Walker, Angela K., MD, , DIrect Dermatology – E(S), SH(SO); Science 37, Inc. – SH(SO).

Walker, Neal S., DO,Neal Walker, President and CEO of Aclaris Therapeutics, Malvern, PA, Aclaris Therapeutics Inc. – F(ST); Alexar Therapeutics, Inc. – F(ST); Allergan, Inc – Independent Contractor(OB); Sebacia, Inc. – B(ST); Vicept Therapeutics, Inc. – F(ST).

Waller, William L., MD, Clinical Assistant Professor, Tulane University, New Orleans, LA, Merck & Co., Inc – SH(ST).

Wanat, Karolyn, MD, Assistant Professor, Department of Dermatology and Pathology, University of Iowa, Iowa City, IA, no financial relationships exist with commercial interests.

Wang, Kevin C., MD, PhD,Assistant Professor of Dermatology, Stanford University School of Medicine, Stanford, CA, no financial relationships exist with commercial interests.

Wang, Steven Q., MD, Memorial Sloan Kettering Cancer Center, NY, Avon Products, Inc.

– A(H); L'Oreal USA Inc. – A(H).
Warren, Christine Baran, MD, MS,Staff, Department of Dermatology, Cleveland Clinic, Cleveland, OH, no financial relationships exist with commercial interests.
Warshaw, Erin M., MD, Professor Dermatology, U MN, Minneapolis, MN, no financial relationships exist with commercial interests.
Washenik, Ken, MD, PhD,Med Dir, Bosley Medical Group; Fac, NYU Dept Derm, New York, NY,N/A.
Webster, Guy F., MD, PhD,Jefferson Med Col, Philadelphia, PA, AbbVie – A(Fees); Anacor Pharmaceuticals, Inc. – A(Fees); Anterios Inc. – C(Fees); Cutanea Life Sciences – C(Fees); Dermira – C(Fees), SH(ST); Foamix – C(Fees); Galderma Laboratories, L.P. – C(Fees); Janssen Pharmaceuticals, Inc – C(Fees); OPKO Health, Inc – SH(NC); Ranbaxy Laboratories Limited – C(Fees); Sol-Gel Technologies – C(Fees); Valeant Pharmaceuticals International – C(Fees).
Weinberg, Harvey I., MD, Assistant Clinical Professor Department of Dermatology Columbia University NY NY, no financial relationships exist with commercial interests.
Weinkle, Susan H., MD, Affiliate Clin Prof, Dept Derm, Univ of South FL, Tampa, FL, Allergan, Inc – C(H), I(H); Allergan, Inc. – A(H), SP(H); Alphaeon – I(H); Derm Advance – I(NC), SH(NC); Ethicon, Inc. – A(H), C(H), SP(H); Galderma Laboratories, L.P. – C(H), SP(H); Kythera – A(H), C(H), I(H); Merz Aesthetics – A(H), C(H), SP(H); Procter & Gamble Company – C(H); TEOXANE Laboratories – I(H); Valeant Pharmaceuticals International – C(H).
Weinstein, Andrew Hart, MD, MPH,Partner, Boynton Beach SKIN. Voluntary Professor University of Miami, Miller School of Medicine, Castle Biosciences – A(H).
Weinstock, Martin A., MD, PhD,Professor of Dermatology and Epidemiology, Brown University/VA Med Ctr, Providence, RI, AbbVie – C(Fees); Castle Biosciences, Inc – C(Fees); Celgene Corporation – C(Fees).
Weintraub, Gil, MD, Resident, Harvard Combined Dermatology Training Program at Massachusetts General Hospital, Boston MA, no financial relationships exist with commercial interests.
Weiss, Eduardo Tomas, MD, Eduardo, Weiss, Hollywood, FL, AbbVie – SP(H); Allergan, Inc – SP(H); Galderma USA – SP(H).
Weiss, Jonathan S., MD, Adjunct Asst Prof of Derm, Emory U, Atlanta, GA, AbbVie – C(H); Allergan, Inc – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Celgene Corporation – C(H), I(Grants/Research Funding); Foamix – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding); Leo Pharma Inc – C(H); LEO Pharma, US – I(Grants/Research Funding); Moberg Pharma North America LLC – I(Grants/Research Funding); Neothetics – I(Grants/Research Funding); Novan – A(H); Perrigo Company – I(Grants/Research Funding); Promius Pharma, LLC – A(H), I(Grants/Research Funding); Sebcaia, Inc – C(Fees), I(Grants/Research Funding); Valeant Pharmaceuticals International – A(H), I(Grants/Research Funding); Xenoport, Inc – I(Grants/Research Funding).
Weiss, Robert A., MD, Clinical Assoc Prof, Dept Derm, University of Maryland, Baltimore, MD, Allergan, Inc – A(H), C(Fees), C(H); Allergan, Inc. – I(Grants/Research Funding); BTL Industries – I(Grants/Research Funding); Cutera, Inc. – Speaker/Faculty Education(Fees); Cynosure, Inc – A(Fees), I(Grants/Research Funding); Cynosure, Inc. – SP(Fees); Evolus, Inc. – I(Grants/Research Funding); Fibrocell Sciences – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding); Galderma USA – SP(H); Merz Aesthetics – A(H), I(Grants/Research Funding), SP(Fees); Merz Pharmaceuticals, LLC – C(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Sapheon, Inc. – I(Grants/Research Funding); Sebacia, Inc. – I(Grants/Research Funding); SkinCeauticals LLC – A(Fees); Syneron Candela – A(IP), I(Grants/Research Funding), SP(Fees); ThermiAesthetics – SP(H); Valeant Pharmaceuticals International – I(Grants/Research Funding); Zeltiq Aesthetics – I(Grants/Research Funding).
Welsh, Kathleen M., MD, California Pacific Medical Center, San Francisco,CA; Courtesy Staff, Allergan, Inc – A(H), SH(NC); Neothetics – SH(NC); Revance Therapeutics, Inc. – SH(NC); ThermiAesthetics – Speaker/Faculty Education(S); Valeant Pharmaceuticals International – SH(NC); Zeltiq Aesthetics – SH(NC), Speaker/Faculty Education(H).
Werth, Victoria P., MD, Prof Derm, U PA, Philadelphia, PA, Biogen – C(H), I(Grants/Research Funding); Celgene Corporation – C(H), I(Grants/Research Funding); Cipher Pharmaceuticals – C(H); Genentech, Inc. – C(H); Idera Pharmaceuticals, Inc. – C(H); Immune Pharmaceuticals – C(H); Immunotherapeutics – C(H); Janssen Pharmaceuticals, Inc – C(H); Kyowa Hakko Kirin Pharma, Inc. – C(H); Lilly ICOS LLC – C(H); Lupus Foundation of America – C(H); Mallinckrodt Pharmaceuticals – C(H); Medimmune – C(H); Novartis – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – C(H); Principia Biopharma Inc. – C(H); Resolve Therapeutics – C(H); Roche Laboratories – C(H);

Stiefel a GSK company – C(H); Syntimmune, Inc. – C(H); TG Therapeutics – C(H); UV Therapeutics – A(ST); XOMA (US) LLC – C(H).
West, Daniel A, MD, Assistant Professor, St. Louis University, Department of Dermatology, St. Louis, MO, no financial relationships exist with commercial interests.
Wetter, David A., MD, Professor of Dermatology, Mayo Clinic, Rochester, Minnesota, no financial relationships exist with commercial interests.
White, Kevin P., MD, Assoc. Professor, Dermatology, Dermatopathology, Oregon Health & Science University, Portland, OR, no financial relationships exist with commercial interests.
Whitfeld, Margot J., MD, Consultant Dermatologist, FACD MBBS DT&H St Vincent's Hospital, Sydney NSW Australia, no financial relationships exist with commercial interests.
Wickless, Heather Woodworth, MD, Assistant Professor of Dermatology, University of Texas Southwestern, Dallas, Texas, Actelion – I(Grants/Research Funding).
Willey, Andrea, MD, Surgical & Aesthetic Dermatology, Sacramento, CA, DUSA Pharmaceuticals, Inc – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – A(H).
Wilson, Morgan, MD, Asst Prof of Dermatology, Southern Illinois Univ. School of Medicine, Springfield, IL, no financial relationships exist with commercial interests.
Wine Lee, Lara, MD, Assistant Professor, Medical University of South Carolina, Charleston, SC, Scioderm – I(Grants/Research Funding).
Winter, Jonathan, MD, Clinical Assistant Professor, Rowan University SOM, Stratford, NJ, no financial relationships exist with commercial interests.
Winterfield, Laura S., MD, Assoc Prof, Medical University of South Carolina, Charleston, SC, no financial relationships exist with commercial interests.
Wisco, Oliver J., DO,Melanoma Specialist & Mohs Surgeon, Bend Memorial Clinic, Bend, OR, Clearpath Solutions Group – C(Fees); MiMedx Group, Inc – C(Fees), SH(ST).
Witman, Patricia M., MD, Chief, Dermatology, Nationwide Childrens Hospital, Assoc Prof Pediatrics, Ohio State, Columbus, OH, no financial relationships exist with commercial interests.
Wohltmann, Wendi E., MD, Program Director, SAUSHEC Dermatology Residency Program, San Antonio, TX, no financial relationships exist with commercial interests.
Wolf, Ronni, MD, Ronni Wolf MD, the Hebrew University and Hadassah, Israel, no financial relationships exist with commercial interests.
Wolfe, Christopher, MD, Resident Physician, Florida State University College of Medicine, Division of Dermatology, no financial relationships exist with commercial interests.
Wolverton, Stephen E., MD, Prof Clin Derm, Dept Derm, IN U Med Ctr, Indianapolis, IN, Elsevier Inc. – Independent Contractor(OB).
Wong, Michael K.K., MD, PhD,Professor of Medicine, MD Anderson Cancer Center, Houston, TX, EMD Serono – A(NC); Vali Nanomedical Inc. – F(ST).
Wood, Gary S., MD, Prof & Chmn, Dept Derm, U WI & VA, Madison, WI, Millennium Pharmaceuticals – A(H); Solgenix, Inc. – I(Grants/Research Funding).
Woodley, David T., MD, Prof & Emeritus Founding Chmn, Dept Derm, Keck Sch Med, USC, Los Angeles, CA, no financial relationships exist with commercial interests.
Wright, Natalie Ann, MD, Dallas, Texas, no financial relationships exist with commercial interests.
Wright, Teresa S., MD, Associate. Prof. of Dermatology and Pediatrics; LeBonheur Children's Hospital; Memphis, TN, no financial relationships exist with commercial interests.
Wu, Jashin J., MD, Director of Dermatology Research, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, AbbVie – C(Fees), I(Grants/Research Funding); Amgen – C(Fees), I(Grants/Research Funding); AstraZeneca – I(Grants/Research Funding); Boehringer Ingelheim – I(Grants/Research Funding); Celgene Corporation – C(Fees); Coherus Biosciences – I(Grants/Research Funding); Dermira – C(Fees), I(Grants/Research Funding); Eli Lilly and Company – C(Fees), I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Leo Pharma Inc – C(Fees); Merck & Co., Inc – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Pfizer Inc. – C(Fees), I(Grants/Research Funding); Regeneron – C(Fees), I(Grants/Research Funding); Sandoz, a Novartis company – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(Fees), I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – C(Fees).
Wu, Peggy, MD, Assistant Professor Dermatology, Beth Israel Deaconess Medical Center, Boston MA, no financial relationships exist with commercial interests.
Wysong, Ashley, MD, MS,Asst. Professor; Director of Mohs Surgery & Procedural Dermatology, Keck School of Medicine of USC, no financial relationships exist with commercial interests.

X

Xu, Yaohui Gloria, MD, Associate Professor,

Univ of Wisconsin School of Medicine and Public Health, Madison, WI, no financial relationships exist with commercial interests.

Y

Yag-Howard, Cyndi Jill, MD, Volunteer Faculty, University of South Florida College of Medicine, Private Practice Naples, FL, no financial relationships exist with commercial interests.

Yamauchi, Paul Steven, MD, PhD,Clinical Assistant Professor of Dermatology David Geffen School of Medicine at UCLA, Los Angeles, CA, AbbVie – C(H), SP(H); Amgen – A(H), C(H), I(Grants/Research Funding), SP(H); Celgene Corporation – C(H), I(Grants/Research Funding), SP(H); Dermira – A(H), I(Grants/Research Funding); Galderma USA – I(Grants/Research Funding), SP(H); Janssen-Ortho Inc. – C(H), I(Grants/Research Funding), SP(H); Leo Pharma Inc – I(Grants/Research Funding), SP(H); LEO Pharma, US – C(H); Lilly ICOS LLC – A(H), I(Grants/Research Funding); Medimmune – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding), SP(H); Pfizer Inc. – C(H), I(Grants/Research Funding); Regeneron – C(H), I(Grants/Research Funding); Sandoz, a Novartis company – I(Grants/Research Funding).

Yancey, Kim B., MD, Prof & Chmn, Dept Derm, UT Southwestern Med Ctr, Dallas, TX, Ashland, Inc. – C(H); UpToDate, Inc – O(H).

Yang, Fei-Shiuann Clarissa, MD, MD, Assistant Professor, Brigham and Women's Hospital, Boston, MA, Modernizing Medicine – A(SO).

Yasuda, Mariko R., MD, Mariko R. Yasuda Instructor in Dermatology, Massachusetts General Hospital, Boston, MA, no financial relationships exist with commercial interests.

Yee, Jackie, MD, Baker Plastic Surgery, Miami, FL, Allergan, Inc - AB(H), C(H), Speaker/Faculty Education(H), Galderma Laboratories, L.P. - AB(H), C(H), Speaker/Faculty Education(H), Medical Education Advocates, LLC - Speaker/Faculty Education(H) , Merz Aesthetics - AB(H), C(H), Speaker/Faculty Education(H), Paradigm Medical Communications, LLC - Speaker/Faculty Education(H), Revance Therapeutics, Inc. - AB(H), Sientra, Inc. - C(H), Valeant Pharmaceuticals North America LLC - AB(H), C(H), X-Medica - Speaker/Faculty Education(H).

Yeh, Iwei, MD, PhD,Assistant Professor, Dermatology and Pathology, University of California, San Francisco, no financial relationships exist with commercial interests.

Yoo, Simon S., MD, Associate Professor of Dermatology, Otolaryngology, and Surgery, Northwestern U, Chicago, IL, AbbVie – C(H); Genentech, Inc. – A(H), C(H).

Yosipovitch, Gil, MD, Prof Department of Dermatology, Director Miami Itch Center, University of Miami Medical School, Allergan, Inc – I(Grants/Research Funding); Anacor Pharmaceuticals, Inc. – C(H); Celgene Corporation – A(H); Chugai Pharmaceutical Co., Ltd – A(H); Creabilis, SA – A(H); dermira – A(H); Eli Lilly and Company – C(H); Estee Lauder – C(H); IntraDerm Pharmaceuticals – C(H); Johnson & Johnson Consumer Products Company – C(H); LEO Pharma, US – I(H); Novartis – C(H); OPKO Health, Inc – C(H); Pfizer Inc. – A(H); Sanofi/Regeneron – A(H); Stiefel a GSK company – I(Grants/Research Funding); Trevi Therapeutics – A(H); Velocity Pharma – A(H).

Yost, John, MD, Director, Nail Disorders Clinic; Clinical Assistant Professor; Stanford University; Palo Alto, CA, no financial relationships exist with commercial interests.

Young, Peter C., MD, Specialty Director, Central Medical Specialties, Atrius Health, no financial relationships exist with commercial interests.

Yu, Kenneth, MD, Senior Resident, PGY-3, University of Michigan Department of Dermatology, Ann Arbor, MI, no financial relationships exist with commercial interests.

Yu, Siegrid S., MD, Associate Professor, University of California, San Francisco, Department of Dermatology, no financial relationships exist with commercial interests.

Z

Zachary, Christopher B., MD, Prof & Chmn, Dept Derm, U CA, Irvine, CA, Almirall – I(EQ); Candela Corporation – I(EQ); Sciton Inc. – A(H); Solta Medical – A(H); Zeltiq Aesthetics – A(H).

Zaenglein, Andrea L., MD, Professor, Dermatology & Pediatrics, Penn State/Hershey Medical Center, Hershey, PA,Anacor Pharmaceuticals, Inc. - AB(H), Ranbaxy Laboratories Limited - C(H), Valeant Pharmaceuticals International - AB(H), Anacor Pharmaceuticals, Inc. – PI(Grants/Research Funding), Astellas Pharma US, Inc – PI(Grants/Research Funding), Ranbaxy Laboratories Limited – PI(Grants/Research Funding), Stiefel a GSK company – PI(Grants/Research Funding).

Zagari, Martin J., Amgen Inc., Vice President, Global Health Economics, no disclosure available at time of printing.

Zaiac, Martin N., MD, Greater Miami Skin & Laser, Miami, FL, no financial relationships exist with commercial interests.

Zakka, Labib, MD, Research Fellow, Brigham and Women's Hospital, Department of Dermatology, Boston MA, no financial relationships exist with commercial interests.

Zalaudek, Iris, MD, Dept Derm, Med U, Graz, Austria, Almirall – SP(H); Bristol-Myers Squibb – O(NC); Leo Pharma A/S – SP(H); Meda Pharmaceuticals Inc. – C(H).
Zeichner, Joshua, MD, Assistant Professor, Mount Sinai Hosptial, New York, NY, Allergan, Inc – A(H); Allergan, Inc. – SP(H); Anacor Pharmaceuticals, Inc. – A(H); Bayer Pharmaceuticals – Speaker/Faculty Education(H); Exelixis – C(H); Foamix – A(H); Galderma Laboratories, L.P. – A(H); Johnson & Johnson Consumer Products Company – C(H); La Roche-Posay Laboratorie Pharmaceutique – A(H); Leo Pharma Inc – A(H); Pharmaderm – A(H); Procter & Gamble Company – C(H); Promius Pharma, LLC – A(H); Ranbaxy Laboratories Limited – A(H); Valeant Pharmaceuticals International – A(H); Valeant Pharmaceuticals North America LLC – Speaker/Faculty Education(H).
Zeitouni, Nathalie C., MD, Professor of Dermatology University of Arizona, Section Leader UA Cancer Center, Phoenix, AZ, DUSA Pharmaceuticals, Inc – A(H); Genentech, Inc. – I(Grants/Research Funding).
Zelickson, Brian D., MD, Zel Skin and Laser Specialists, Associate Professor of Derm, University of MN, Allergan, Inc – I(Grants/Research Funding); Alma Lasers – O(IP); Candela Corporation – I(None Chosen), O(IP); Lumenis – I(Grants/Research Funding); MD Complete – F(ST); Medtronics – O(ST); Novellus – A(ST); Palomar Medical Technologies – I(Grants/Research Funding); Sciton Inc. – I(Grants/Research Funding); Syneron, Inc. – I(None Chosen); Ulthera – I(Grants/Research Funding); Zeltiq Aesthetics – I(Grants/Research Funding), SH(ST); Zift Medical – F(SO).
Zenker, Sabine, MD, MD, Dermatologist, Ludwig Maximilians University Munich, Germany, L'Oréal France – C(H); Merz Aesthetics – Speaker/Faculty Education(Fees); Sinclair Pharma – A(Fees).
Zhang, Alexandra Y., MD, Alexandra Zhang, MD. Department of Dermatology, MetroHealth Medical Center, CWRU, Cleveland, OH, Castle Biosciences – O(H).
Zheng, Qian, MD, PhD,AVP - Advanced Research Clinical Discovery, L'Oreal Research & Innovation, Clark, NJ, L'Oreal USA Inc. – E(S).
Zhou, Xiaolong Alan, MD, Clinical Instructor of Dermatology, Department of Dermatology, Northwestern University, Chicago, IL, no financial relationships exist with commercial interests.
Ziering, Thomas, MD, Medical Director:LGBTI Medicine; Summit Medical Group, no financial relationships exist with commercial interest.
Zippin, Jonathan, MD, PhD,Jonathan Zippin, Assistant Professor Department of Dermatology, Weill Cornell Medicine , New York NY, CEP Biotech – F(ST); Regeneron Pharmaceuticals, Inc. – E(S); Shade, Inc – A(SO).
Zitelli, John A., MD, Adj Clin Assoc Prof Dermatology, Otolaryngol, and Plastic Surg, U Pittsburgh Med Ctr, Pittsburgh, PA, no financial relationships exist with commercial interests.
Zwald, Fiona O'Reilly, MD, Dermatology Consultants, PC, Piedmont Transplant Institute, Atlanta, GA, no financial relationships exist with commercial interests.
Zwerner, Jeffrey P., MD, Assistant Professor of Medicine (Dermatology), Vanderbilt University, Nashville, TN, no financial relationships exist with commercial interests.

SAVE THE DATE
for future AAD meetings

AAD Annual Meetings
Registration opens around November

SAN DIEGO, CA
2018 AAD Annual Meeting • February 16 – 20

WASHINGTON, DC
2019 AAD Annual Meeting • March 1 – 5

DENVER, CO
2020 AAD Annual Meeting • March 20 – 24

SAN FRANCISCO, CA
2021 AAD Annual Meeting • March 19 – 23

AAD Summer Meetings
Registration opens around May

NEW YORK, NY
2017 AAD Summer Meeting • July 27 – 30

CHICAGO, IL
2018 AAD Summer Meeting • July 26 – 29

NEW YORK, NY
2019 AAD Summer Meeting • July 25 – 28

SEATTLE, WA
2020 AAD Summer Meeting • August 13 – 16



AAD.ORG/MEETINGS

BOOST THE VOLUME ON RETINOL

NEW

RETINOL + NAG COMPLEX

You've never experienced Retinol like this. Pure 0.5% Retinol in a time-released, microencapsulated formula maximizes potency and tolerability, while patented NeoGlucosamine® boosts the volumizing and firming effects of Retinol. **A better way to renew your skin.**

Visit booth #1539 for free samples.

FORMULATED BY WORLD LEADERS IN ANTIAGING SKIN CARE.

FOR MORE INFORMATION, CALL 800.628.9904.

Proprietary Complex:

- **SMOOTHES** fine lines, texture
- **DIMINISHES** dark spots
- **BUILDS** volume

PASSION FOR SKIN CARE.
PROVEN BY SCIENCE.

NeoStrata®

©2017 NeoStrata Company, Inc.